FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Costa-Ferro, ZSM
   de Oliveira, GN
   da Silva, DV
   Marinowic, DR
   Machado, DC
   Longo, BM
   da Costa, JC
AF Costa-Ferro, Zaquer Suzana Munhoz
   de Oliveira, Gutierre Neves
   da Silva, Daniele Vieira
   Marinowic, Daniel Rodrigo
   Machado, Denise Cantarelli
   Longo, Beatriz Monteiro
   da Costa, Jaderson Costa
TI Intravenous infusion of bone marrow mononuclear cells promotes
   functional recovery and improves impaired cognitive function via
   inhibition of Rho guanine nucleotide triphosphatases and inflammatory
   signals in a model of chronic epilepsy
SO BRAIN STRUCTURE & FUNCTION
LA English
DT Article
DE Chronic epilepsy; Bone marrow mononuclear cells; Memory; Exploratory
   behavior; Mossy fiber sprouting; Long&#8208; term potentiation;
   Inflammatory responses
ID LONG-TERM POTENTIATION; TEMPORAL-LOBE EPILEPSY; SPONTANEOUS RECURRENT
   SEIZURES; MESENCHYMAL STEM-CELLS; STATUS EPILEPTICUS; PILOCARPINE MODEL;
   RAT MODEL; FACTOR-I; MEMORY; TRANSPLANTATION
AB Temporal lobe epilepsy is the most common form of intractable epilepsy in adults. More than 30% of individuals with epilepsy have persistent seizures and have drug-resistant epilepsy. Based on our previous findings, treatment with bone marrow mononuclear cells (BMMC) could interfere with early and chronic phase epilepsy in rats and in clinical settings. In this pilocarpine-induced epilepsy model, animals were randomly assigned to two groups: control (Con) and epileptic pre-treatment (Ep-pre-t). The latter had status epilepticus (SE) induced through pilocarpine intraperitoneal injection. Later, seizure frequency was assessed using a video-monitoring system. Ep-pre-t was further divided into epileptic treated with saline (Ep-Veh) and epileptic treated with BMMC (Ep-BMMC) after an intravenous treatment with BMMC was done on day 22 after SE. Analysis of neurobehavioral parameters revealed that Ep-BMMC had significantly lower frequency of spontaneous recurrent seizures (SRS) in comparison to Ep-pre-t and Ep-Veh groups. Hippocampus-dependent spatial and non-spatial learning and memory were markedly impaired in epileptic rats, a deficit that was robustly recovered by treatment with BMMC. Moreover, long-term potentiation-induced synaptic remodeling present in epileptic rats was restored by BMMC. In addition, BMMC was able to reduce abnormal mossy fiber sprouting in the dentate gyrus. Molecular analysis in hippocampal tissue revealed that BMMC treatment down-regulates the release of inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and Allograft inflammatory factor-1 (AIF-1) as well as the Rho subfamily of small GTPases [Ras homolog gene family member A (RhoA) and Ras-related C3 botulinum toxin substrate 1 (Rac)]. Collectively, delayed BMMC treatment showed positive effects when intravenously infused into chronic epileptic rats.
C1 [Costa-Ferro, Zaquer Suzana Munhoz; de Oliveira, Gutierre Neves; da Silva, Daniele Vieira; Marinowic, Daniel Rodrigo; Machado, Denise Cantarelli; da Costa, Jaderson Costa] Pontifical Catholic Univ Rio Grande Sul PUCRS, Brain Inst Rio Grande Sul BraIns, Porto Alegre, RS, Brazil.
   [Longo, Beatriz Monteiro] Univ Fed Sao Paulo, UNIFESP, Dept Physiol, Lab Neurophysiol, Sao Paulo, SP, Brazil.
RP da Costa, JC (corresponding author), Pontifical Catholic Univ Rio Grande Sul PUCRS, Brain Inst Rio Grande Sul BraIns, Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul
   (FAPERGS)Foundation for Research Support of the State of Rio Grande do
   Sul (FAPERGS); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Pandurata Alimentos Ltda; CNPq (research productivity-PQ1A)National
   Council for Scientific and Technological Development (CNPq); CNPq
   (research productivity-1D)National Council for Scientific and
   Technological Development (CNPq); FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP); FAPERGSFoundation for Research Support of
   the State of Rio Grande do Sul (FAPERGS); Pontificia Universidade
   Catolica do Rio Grande do Sul (PUCRS)
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: This study
   was supported by Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq), Fundacao de Amparo a Pesquisa do Estado do Rio
   Grande do Sul (FAPERGS), Pontificia Universidade Catolica do Rio Grande
   do Sul (PUCRS), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP), and Pandurata Alimentos Ltda. The funding organizations played
   no role in the study design, conduct, data interpretation or article
   writing. Jaderson Costa da Costa is funded by the CNPq (research
   productivity-PQ1A). Beatriz Monteiro Longo is funded by CNPq (research
   productivity-1D) and FAPESP. Gutierre Neves de Oliveira is funded by
   FAPERGS.
CR Agadi S, 2015, STEM CELLS, V33, P2093, DOI 10.1002/stem.2029
   Anacker C, 2017, NAT REV NEUROSCI, V18, P335, DOI 10.1038/nrn.2017.45
   Arnous S, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt93
   Aronica E, 2012, GLIA, V60, P1258, DOI 10.1002/glia.22312
   Autieri MV, 1996, BIOCHEM BIOPH RES CO, V228, P29, DOI 10.1006/bbrc.1996.1612
   Bartolini E, 2019, EPILEPSY BEHAV, V97, P212, DOI 10.1016/j.yebeh.2019.05.036
   Behbahan IS, 2013, STEM CELLS, V31, P2313, DOI 10.1002/stem.1510
   BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273
   BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0
   Boison D, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00109
   Buckmaster PS, 2014, ADV EXP MED BIOL, V813, P161, DOI 10.1007/978-94-017-8914-1_13
   CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x
   CAVALHEIRO EA, 1987, DEV BRAIN RES, V37, P43, DOI 10.1016/0165-3806(87)90227-6
   Cavarsan CF, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01023
   Choi EK, 2017, REGULATION RHOA GTPA, DOI [10.1080/21541248.2017.1364831, DOI 10.1080/21541248.2017.1364831]
   Costa-Ferro ZSM, 2012, NEUROBIOL DIS, V46, P302, DOI 10.1016/j.nbd.2011.12.001
   Costa-Ferro ZSM, 2010, SEIZURE-EUR J EPILEP, V19, P84, DOI 10.1016/j.seizure.2009.12.003
   Council NR, 2011, GUIDE CARE USE LAB A, DOI [10.17226/12910, DOI 10.17226/12910]
   Covolan L, 2000, EPILEPSY RES, V39, P133, DOI 10.1016/S0920-1211(99)00119-9
   Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019
   DaCosta JC, 2018, J TISSUE ENG REGEN M, V12, pE648, DOI [10.1002/term.2456, 10.1002/term.2334]
   Dash PK, 2004, BIOCHEM BIOPH RES CO, V322, P893, DOI 10.1016/j.bbrc.2004.08.004
   de Oliveira DL, 2008, EPILEPSIA, V49, P842, DOI 10.1111/j.1528-1167.2007.01484.x
   de Vargas LD, 2017, BRAIN RES, V1670, P44, DOI 10.1016/j.brainres.2017.06.007
   de Vries EE, 2016, NEUROSCI BIOBEHAV R, V63, P177, DOI 10.1016/j.neubiorev.2016.02.007
   Fukurnura S, 2018, EPILEPSY RES, V141, P56, DOI 10.1016/j.eplepsyres.2018.02.008
   Furini CRG, 2014, BEHAV BRAIN RES, V271, P212, DOI 10.1016/j.bbr.2014.06.027
   Guerra G, 2018, CURR PHARM BIOTECHNO, V19, P700, DOI 10.2174/1389201019666181017161752
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103
   Harney SMJ, 2008, RHEUMATOLOGY, V47, P1761, DOI 10.1093/rheumatology/ken376
   Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476
   Herman JP, 1987, TRENDS NEUROSCI, V10, DOI [10.1016/0166-2236(87)90017-8, DOI 10.1016/0166-2236(87)90017-8]
   Hester MS, 2013, J NEUROSCI, V33, P8926, DOI 10.1523/JNEUROSCI.5161-12.2013
   Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67
   Hu JL, 2017, NEURAL REGEN RES, V12, P525, DOI 10.4103/1673-5374.205080
   IRIS FJM, 1993, NAT GENET, V3, P137, DOI 10.1038/ng0293-137
   Jensen FE, 2011, EPILEPSIA, V52, P1, DOI 10.1111/j.1528-1167.2010.02904.x
   Katche C, 2010, P NATL ACAD SCI USA, V107, P349, DOI 10.1073/pnas.0912931107
   Kim IH, 2014, ELIFE, V3, DOI 10.7554/eLife.02839
   Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498
   Leite JP, 2002, EPILEPSY RES, V50, P93, DOI 10.1016/S0920-1211(02)00072-4
   LEITE JP, 1990, NEUROSCI BIOBEHAV R, V14, P511, DOI 10.1016/S0149-7634(05)80076-4
   Lenck-Santini PP, 2008, J NEUROSCI, V28, P5053, DOI 10.1523/JNEUROSCI.5024-07.2008
   Li J, 2016, NEUROCHEM RES, V41, P836, DOI 10.1007/s11064-015-1759-y
   Liu YL, 2016, CURR BIOL, V26, P2351, DOI 10.1016/j.cub.2016.06.056
   Lynch M, 2000, EUR J NEUROSCI, V12, P2252, DOI 10.1046/j.1460-9568.2000.00117.x
   Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003
   Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870
   Malheiros JM, 2012, EPILEPSIA, V53, P1225, DOI 10.1111/j.1528-1167.2012.03521.x
   Mameniskiene R, 2006, EPILEPSY BEHAV, V8, P278, DOI 10.1016/j.yebeh.2005.11.003
   Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617
   Mazumder AG, 2017, J ETHNOPHARMACOL, V204, P8, DOI 10.1016/j.jep.2017.03.060
   Mello LE, 2009, ENCYCLOPEDIA OF BASIC EPILEPSY RESEARCH, VOLS 1-3, P1210
   MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x
   Milczarek O, 2018, STEM CELL TRANSL MED, V7, P20, DOI 10.1002/sctm.17-0041
   MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0
   Moser EI, 1998, SCIENCE, V281, P2038, DOI 10.1126/science.281.5385.2038
   Muller L, 2013, NEUROBIOL DIS, V54, P183, DOI 10.1016/j.nbd.2012.12.011
   Costa-Ferro ZSM, 2014, CYTOTECHNOLOGY, V66, P193, DOI 10.1007/s10616-013-9557-3
   Murakoshi H, 2011, NATURE, V472, P100, DOI 10.1038/nature09823
   Organization WOH, 2019, EP PUBL HLTH IMP
   Parent JM, 1997, J NEUROSCI, V17, P3727
   Park M, 2006, NEURON, V52, P817, DOI 10.1016/j.neuron.2006.09.040
   Pearson JN, 2014, EPILEPSY RES, V108, P1032, DOI 10.1016/j.eplepsyres.2014.04.003
   Pereira P, 2005, PHARMACOL RES, V52, P199, DOI 10.1016/j.phrs.2005.03.003
   Queiroz CMT, 2007, EUR J NEUROSCI, V25, P3071, DOI 10.1111/j.1460-9568.2007.05573.x
   RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0
   Ramey WL, 2013, CLIN NEUROL NEUROSUR, V115, P2411, DOI 10.1016/j.clineuro.2013.09.035
   Ravizza T, 2005, EPILEPSIA, V46, P113, DOI 10.1111/j.1528-1167.2005.01006.x
   Reid IC, 1997, SEIZURE, V6, P351, DOI 10.1016/S1059-1311(97)80034-9
   Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5
   Saneyoshi T, 2019, NEURON, V102, P1199, DOI 10.1016/j.neuron.2019.04.012
   Scharfman HE, 2016, NAT REV NEUROSCI, V17, P562, DOI 10.1038/nrn.2016.87
   Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3
   do Prado-Lima PAS, 2019, J PSYCHOPHARMACOL, V33, P632, DOI 10.1177/0269881119841562
   Sharma AK, 2009, TOXICOL PATHOL, V37, P776, DOI 10.1177/0192623309344202
   Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964
   Smolensky IV, 2019, BEHAV BRAIN RES, V372, DOI 10.1016/j.bbr.2019.112044
   Suarez LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048128
   SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303
   Tai XY, 2018, NEUROPATH APPL NEURO, V44, P70, DOI 10.1111/nan.12458
   Takai Y, 2001, PHYSIOL REV, V81, P153
   TAUCK DL, 1985, J NEUROSCI, V5, P1016
   Tim B, 2006, SYNAPTIC PLASTICITY
   Toni N, 1999, NATURE, V402, P421
   Leal MMT, 2014, NEUROCHEM RES, V39, P259, DOI 10.1007/s11064-013-1217-7
   TURSKI WA, 1984, BRAIN RES, V321, P237, DOI 10.1016/0006-8993(84)90177-X
   TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5
   Vahidy FS, 2016, STROKE, V47, P1632, DOI 10.1161/STROKEAHA.116.012701
   Venturin GT, 2011, LIFE SCI, V89, P229, DOI 10.1016/j.lfs.2011.06.006
   Vezzani A, 2013, EXP NEUROL, V244, P11, DOI 10.1016/j.expneurol.2011.09.033
   Wearick-Silva LE, 2019, INT J DEV NEUROSCI, V75, P13, DOI 10.1016/j.ijdevneu.2019.03.005
   Wiens KM, 2005, J NEUROSCI, V25, P10627, DOI 10.1523/JNEUROSCI.1947-05.2005
   Xiao-Lan Ai FY, 2018, J SO MED U, V38, P511
   Zanirati G, 2015, CNS NEUROSCI THER, V21, P463, DOI 10.1111/cns.12382
   Zhao YY, 2013, CELL IMMUNOL, V284, P75, DOI 10.1016/j.cellimm.2013.07.008
   Zhou CW, 2011, J NEUROSCI, V31, P18211, DOI 10.1523/JNEUROSCI.4838-11.2011
   Zhou JL, 2007, EUR J NEUROSCI, V25, P3667, DOI 10.1111/j.1460-9568.2007.05598.x
NR 99
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1863-2653
EI 1863-2661
J9 BRAIN STRUCT FUNCT
JI Brain Struct. Funct.
PD DEC
PY 2020
VL 225
IS 9
BP 2799
EP 2813
DI 10.1007/s00429-020-02159-7
EA OCT 2020
PG 15
WC Anatomy & Morphology; Neurosciences
SC Anatomy & Morphology; Neurosciences & Neurology
GA OT1YE
UT WOS:000585675500002
PM 33128125
DA 2020-12-08
ER

PT J
AU Azevedo, PN
   Zanirati, G
   Venturin, GT
   Schu, GG
   Duran-Carabali, LE
   Odorcyk, FK
   Soares, AV
   Laguna, GD
   Netto, CA
   Zimmer, ER
   da Costa, JC
   Greggio, S
AF Azevedo, Pamella Nunes
   Zanirati, Gabriele
   Venturin, Gianina Teribele
   Schu, Guilherme Garcia
   Duran-Carabali, Luz Elena
   Odorcyk, Felipe Kawa
   Soares, Andrey Vinicius
   Laguna, Gabriela de Oliveira
   Netto, Carlos Alexandre
   Zimmer, Eduardo Rigon
   da Costa, Jaderson Costa
   Greggio, Samuel
TI Long-term changes in metabolic brain network drive memory impairments in
   rats following neonatal hypoxia-ischemia
SO NEUROBIOLOGY OF LEARNING AND MEMORY
LA English
DT Article
DE Neuronal plasticity; microPET; F-18-FDG; Neonatal hypoxia ischemia;
   Metabolic brain network
ID INFLAMMATORY CYTOKINES; INJURY; STRATEGIES; OUTCOMES; CELLS; PET
AB Background and purpose: Hypoxia and cerebral ischemia (HI) events are capable of triggering important changes in brain metabolism, including glucose metabolism abnormalities, which may be related to the severity of the insult. Using positron emission microtomography (microPET) with [F-18]fluorodeoxyglucose (F-18-FDG), this study proposes to assess abnormalities of brain glucose metabolism in adult rats previously submitted to the neonatal HI model. We hypothesize that cerebral metabolic outcomes will be associated with cognitive deficits and magnitude of brain injury.
   Methods: Seven-day-old rats were subjected to an HI model, induced by permanent occlusion of the right common carotid artery and systemic hypoxia. F-18-FDG-microPET was used to assess regional and whole brain glucose metabolism in rats at 60 postnatal days (PND 60). An interregional cross-correlation matrix was utilized to construct metabolic brain networks (MBN). Rats were also subjected to the Morris Water Maze (MWM) to evaluate spatial memory and their brains were processed for volumetric evaluation.
   Results: Brain glucose metabolism changes were observed in adult rats after neonatal HI insult, limited to the right brain hemisphere. However, not all HI animals exhibited significant cerebral hypometabolism. Hippocampal glucose metabolism was used to stratify HI animals into HI hypometabolic (HI-h) and HI nonhypometabolic (HI non-h) groups. The HI-h group had drastic MBN disturbance, cognitive deficit, and brain tissue loss, concomitantly. Conversely, HI non-h rats had normal brain glucose metabolism and brain tissue preserved, but also presented MBN changes and spatial memory impairment. Furthermore, data showed that brain glucose metabolism correlated with cognitive deficits and brain volume outcomes.
   Conclusions: Our findings demonstrated that long-term changes in MBN drive memory impairments in adult rats subjected to neonatal hypoxic ischemia, using in vivo imaging microPET-FDG. The MBN analyses identified glucose metabolism abnormalities in HI non-h animals, which were not detected by conventional F-18-FDG standardized uptake value (SUVr) measurements. These animals exhibited a metabolic brain signature that may explain the cognitive deficit even with no identifiable brain damage.
C1 [Azevedo, Pamella Nunes; da Costa, Jaderson Costa] Pontifical Catholic Univ Rio Grande do Sul PUCRS, Grad Program Med & Hlth Sci, Sch Med, Porto Alegre, RS, Brazil.
   [Zanirati, Gabriele; Laguna, Gabriela de Oliveira; da Costa, Jaderson Costa] Pontifical Catholic Univ Rio Grande do Sul PUCRS, Grad Program Pediat & Child Hlth, Sch Med, Porto Alegre, RS, Brazil.
   [Azevedo, Pamella Nunes; Zanirati, Gabriele; da Costa, Jaderson Costa] Brain Inst BraIns Rio Grande do Sul, Lab Neurosci, Porto Alegre, RS, Brazil.
   [Venturin, Gianina Teribele; da Costa, Jaderson Costa; Greggio, Samuel] Brain Inst BraIns Rio Grande do Sul, Preclin Res Ctr, Porto Alegre, RS, Brazil.
   [Schu, Guilherme Garcia; Duran-Carabali, Luz Elena; Odorcyk, Felipe Kawa; Soares, Andrey Vinicius; Netto, Carlos Alexandre; Zimmer, Eduardo Rigon] Fed Univ Rio Grande do Sul UFRGS, Dept Biochem, Porto Alegre, RS, Brazil.
   [Zimmer, Eduardo Rigon] Fed Univ Rio Grande do Sul UFRGS, Dept Pharmacol, Porto Alegre, RS, Brazil.
   [Zimmer, Eduardo Rigon] Fed Univ Rio Grande do Sul UFRGS, Grad Program Biol Sci Biochem, Porto Alegre, RS, Brazil.
   [Zimmer, Eduardo Rigon] Fed Univ Rio Grande do Sul UFRGS, Grad Program Biol Sci Pharmacol & Therapeut, Porto Alegre, RS, Brazil.
RP Greggio, S (corresponding author), Pontifical Catholic Univ Rio Grande do Sul PUCRS, Preclin Res Ctr, Brain Inst Rio Grande do Sul BraIns, Ave Ipiranga 6690,Predio 63,Sala 140, BR-90610000 Porto Alegre, RS, Brazil.
EM samuel.greggio@pucrs.br
RI Zimmer, Eduardo R Rigon/I-2932-2015; Greggio, Samuel/E-1498-2013
OI Zimmer, Eduardo R Rigon/0000-0002-5349-0053; Greggio,
   Samuel/0000-0002-5187-0335
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil
   (CAPES)CAPES [001]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - Brazil (CNPq; Chamada Universal MCTI/CNPq)National Council
   for Scientific and Technological Development (CNPq) [01/2016,
   405470/2016-9]; CAPESCAPES
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brazil (CAPES; Finance Code 001), and by the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - Brazil
   (CNPq; Chamada Universal MCTI/CNPq No 01/2016, grant number
   405470/2016-9). Other resources were provided by PUCRS (Porto Alegre,
   Brazil), and Pandurata Alimentos Ltda (Sao Paulo, Brazil). P. N.
   Azevedo, and G. Zanirati are recipients of fellowships from CAPES. E. R.
   Zimmer, C. A. Netto, and J. C. DaCosta are CNPq researchers.
CR Alexander M, 2014, BEHAV BRAIN RES, V259, P85, DOI 10.1016/j.bbr.2013.10.038
   Aylward GP, 2014, J DEV BEHAV PEDIATR, V35, P394, DOI 10.1097/01.DBP.0000452240.39511.d4
   Balduini W, 2000, BRAIN RES, V859, P318, DOI 10.1016/S0006-8993(00)01997-1
   Batista CEA, 2007, PEDIATR NEUROL, V36, P330, DOI 10.1016/j.pediatrneurol.2007.01.004
   Biran V, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/858929
   Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107
   Brekke EMF, 2014, J CEREBR BLOOD F MET, V34, P724, DOI 10.1038/jcbfm.2014.8
   Choi H, 2014, NEUROIMAGE, V99, P226, DOI 10.1016/j.neuroimage.2014.05.039
   de Paula S, 2009, PEDIATR RES, V65, P631, DOI 10.1203/PDR.0b013e31819ed5c8
   Duran-Carabali LE, 2017, NEUROSCIENCE, V340, P291, DOI 10.1016/j.neuroscience.2016.10.068
   Fu YK, 2009, APPL RADIAT ISOTOPES, V67, P1743, DOI 10.1016/j.apradiso.2009.03.002
   Gao F, 2010, EUR J NUCL MED MOL I, V37, P954, DOI 10.1007/s00259-009-1342-3
   Greggio S, 2014, LIFE SCI, V96, P33, DOI 10.1016/j.lfs.2013.10.017
   Hyun H, 2011, BIOMATERIALS, V32, P306, DOI 10.1016/j.biomaterials.2010.08.116
   Johnston MV, 2011, LANCET NEUROL, V10, P372, DOI 10.1016/S1474-4422(11)70016-3
   Alles YCJ, 2010, BRAIN RES, V1356, P130, DOI 10.1016/j.brainres.2010.07.106
   Jung WB, 2016, NEUROIMAGE, V126, P140, DOI 10.1016/j.neuroimage.2015.11.032
   Kannan S, 2010, SEMIN PERINATOL, V34, P39, DOI 10.1053/j.semperi.2009.10.004
   Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010
   Levine Seymour, 1960, AM J PATHOLOGY
   Li JH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/507091
   Liu CL, 2004, NEUROSCIENCE, V127, P113, DOI 10.1016/j.neuroscience.2004.03.062
   Love C, 2005, RADIOGRAPHICS, V25, P1357, DOI 10.1148/rg.255045122
   Lubics A, 2005, BEHAV BRAIN RES, V157, P157, DOI 10.1016/j.bbr.2004.06.019
   Malisza KL, 1999, NMR BIOMED, V12, P31, DOI 10.1002/(SICI)1099-1492(199902)12:1<31::AID-NBM544>3.3.CO;2-D
   Matsui T, 2009, J NUCL MED, V50, P920, DOI 10.2967/jnumed.108.060103
   McKenna MC, 2015, NEUROCHEM RES, V40, P2527, DOI 10.1007/s11064-015-1600-7
   Millar LJ, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00078
   Netto CA, 2017, J NEUROSCI RES, V95, P409, DOI 10.1002/jnr.23828
   Odorcyk FK, 2018, J PERINAT MED, V46, P433, DOI 10.1515/jpm-2017-0070
   Pomykala KL, 2013, BRAIN IMAGING BEHAV, V7, P511, DOI 10.1007/s11682-013-9243-2
   Pooters T, 2016, BEHAV BRAIN RES, V298, P134, DOI 10.1016/j.bbr.2015.11.001
   RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206
   Rubinov M., 2010, NEUROIMAGE, DOI [10.1016/j.neuroimage.2009.10., DOI 10.1016/J.NEUROIMAGE.2009.10]
   Sanches E. F., 2015, NEUROSCIENCE
   Sanches EF, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00480
   Seo EH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053922
   Shah D, 2019, CEREB CORTEX, V29, P4519, DOI 10.1093/cercor/bhy329
   Shankaran S, 2012, CLIN PERINATOL, V39, P919, DOI 10.1016/j.clp.2012.09.008
   Shi Y, 2012, PEDIATR NEUROL, V46, P116, DOI 10.1016/j.pediatrneurol.2011.11.005
   Siegel JS, 2018, CORTEX, V101, P44, DOI 10.1016/j.cortex.2017.12.019
   Sizonenko SV, 2003, PEDIATR RES, V54, P263, DOI 10.1203/01.PDR.0000072517.01207.87
   Smith AL, 2015, DEV NEUROSCI-BASEL, V37, P440, DOI 10.1159/000375487
   Vaessen MJ, 2012, CEREB CORTEX, V22, P2139, DOI 10.1093/cercor/bhr298
   Vannucci R. C., 1988, STROKE, DOI [10.1161/01.STR.19.2., DOI 10.1161/01.STR.19.2]
   Vial F, 2004, MAGN RESON IMAGING, V22, P457, DOI 10.1016/j.mri.2004.01.036
   Wixey JA, 2011, J NEUROPATH EXP NEUR, V70, P23, DOI 10.1097/NEN.0b013e3182020b7b
   Zanirati G, 2018, EPILEPSIA, V59, P923, DOI 10.1111/epi.14057
   Zimmer ER, 2017, NAT NEUROSCI, V20, P393, DOI 10.1038/nn.4492
NR 49
TC 3
Z9 3
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1074-7427
EI 1095-9564
J9 NEUROBIOL LEARN MEM
JI Neurobiol. Learn. Mem.
PD MAY
PY 2020
VL 171
AR 107207
DI 10.1016/j.nlm.2020.107207
PG 11
WC Behavioral Sciences; Neurosciences; Psychology; Psychology,
   Multidisciplinary
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA LJ3SH
UT WOS:000530087400008
PM 32147586
DA 2020-12-08
ER

PT J
AU Marrone, LCP
   Martins, WA
   Ramos, SWMI
   Tomasi, GH
   Garcia, MS
   Marrone, BF
   Gadonski, G
   Poli-de-Figueiredo, CE
   da Costa, BEP
   Soder, RB
   Marrone, ACH
   da Costa, JC
AF Porcello Marrone, Luiz Carlos
   Martins, William Alves
   Monteiro Iranso Ramos, Sirlei Westernower
   Tomasi, Gustavo Henrique
   Garcia, Marcio Severo
   Marrone, Bianca Fontana
   Gadonski, Giovani
   Poli-de-Figueiredo, Carlos Eduardo
   Pinheiro da Costa, Bartira Ercilia
   Soder, Ricardo Bernardi
   Huf Marrone, Antonio Carlos
   da Costa, Jaderson Costa
TI Posterior reversible encephalopathy syndrome (PRES): Is DWI a prognosis
   factor?
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Article
DE Posterior reversible encephalopathy syndrome; PRES; DWI; Brain MRI
ID DIFFUSION; ANGIOGRAPHY; UTILITY
AB Introduction: Posterior reversible encephalopathy syndrome is a clinicoradiologic entity with typical MR imaging showing a white matter vasogenic edema predominantly affecting the occipital and parietal lobes of the brain. The aim of this article is evaluated the importance of DWI as a prognosis factor in patients with PRES.
   Materials and methods: We reviewed data from 70 patients with PRES (35 with restricted DWI and 35 with no DWI abnormalities), that were admitted to Hospital Sao Lucas-PUCRS. These two groups were evaluated in age, sex, previous diseases and past medical history, use of medications, the neurologic manifestations, the highest blood pressure during the neurologic presentation and the highest creatinine during the period of observation.
   Results: Evaluating 70 patients with PRES with a mean age of 25.4 years old (range from 2 to 74 years old; 55 female and 15 male) we identified 35 cases were brain MRI presents with restricted DWI. Restricted DWI was associated with higher mortality in 90 days (14.2% vs 0.0%; p: 0.027).
   Conclusions: Few articles present new data that will help clinicians in therapeutic decisions or that modify the knowledge of this syndrome. We suggested that restricted DWI is associated with a worst prognosis in PRES. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Porcello Marrone, Luiz Carlos] Lutheran Univ Canoas, Canoas, Brazil.
   [Porcello Marrone, Luiz Carlos] Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre, RS, Brazil.
   [Porcello Marrone, Luiz Carlos; Martins, William Alves; Monteiro Iranso Ramos, Sirlei Westernower; Tomasi, Gustavo Henrique; Garcia, Marcio Severo; Marrone, Bianca Fontana; Gadonski, Giovani; Poli-de-Figueiredo, Carlos Eduardo; Pinheiro da Costa, Bartira Ercilia; Soder, Ricardo Bernardi; Huf Marrone, Antonio Carlos; da Costa, Jaderson Costa] Hosp Sao Lucas PUCRS, Ave Ipiranga,6690 Sala 220, Porto Alegre, RS, Brazil.
   [Porcello Marrone, Luiz Carlos; Martins, William Alves; Monteiro Iranso Ramos, Sirlei Westernower; Tomasi, Gustavo Henrique; Garcia, Marcio Severo; Marrone, Bianca Fontana; Gadonski, Giovani; Poli-de-Figueiredo, Carlos Eduardo; Pinheiro da Costa, Bartira Ercilia; Soder, Ricardo Bernardi; Huf Marrone, Antonio Carlos; da Costa, Jaderson Costa] Brain Inst Brains, Ave Ipiranga 6690 Sala 220, Porto Alegre, RS, Brazil.
RP Marrone, LCP (corresponding author), Lutheran Univ Canoas, Canoas, Brazil.; Marrone, LCP (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre, RS, Brazil.; Marrone, LCP (corresponding author), Hosp Sao Lucas PUCRS, Ave Ipiranga,6690 Sala 220, Porto Alegre, RS, Brazil.; Marrone, LCP (corresponding author), Brain Inst Brains, Ave Ipiranga 6690 Sala 220, Porto Alegre, RS, Brazil.
EM Icpmarrone@gmail.com
CR Bartynski WS, 2008, AM J NEURORADIOL, V29, P924, DOI 10.3174/ajnr.A0960
   Bartynski WS, 2008, AM J NEURORADIOL, V29, P447, DOI 10.3174/ajnr.A0839
   Bartynski WS, 2006, AM J NEURORADIOL, V27, P2179
   Casey SO, 2000, AM J NEURORADIOL, V21, P1199
   Chen TY, 2017, J STROKE CEREBROVASC, V26, P1560, DOI 10.1016/j.jstrokecerebrovasdis.2017.02.033
   COLOSIMO C, 1985, NEURORADIOLOGY, V27, P313, DOI 10.1007/BF00339563
   Covarrubias DJ, 2002, AM J NEURORADIOL, V23, P1038
   Fugate JE, 2010, MAYO CLIN PROC, V85, P427, DOI 10.4065/mcp.2009.0590
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Hiremath SB, 2017, J NEURORADIOL
   Hiremath SB, 2017, J NEURORADIOLOGY, V44, P319, DOI 10.1016/j.neurad.2017.05.002
   Lamy C, 2004, J NEUROIMAGING, V14, P89, DOI 10.1177/1051228403258161
   Marrone LCP, 2016, J STROKE CEREBROVASC, V25, P1776, DOI 10.1016/j.jstrokecerebrovasdis.2016.03.042
   Marrone LCP, 2011, CASE REP ONCOL, V4, P82, DOI 10.1159/000324581
   Schwartz RB, 2000, RADIOLOGY, V217, P371, DOI 10.1148/radiology.217.2.r00nv44371
   Schwartz RB, 2002, NEUROLOGIST, V8, P22, DOI 10.1097/00127893-200201000-00003
   Wagih A, 2015, POL J RADIOL, V80, P210, DOI 10.12659/PJR.893460
NR 17
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-5868
EI 1532-2653
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD FEB
PY 2020
VL 72
BP 357
EP 359
DI 10.1016/j.jocn.2019.12.023
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA KR5NG
UT WOS:000517664500063
PM 31874813
DA 2020-12-08
ER

PT J
AU Marinowic, DR
   Majolo, F
   Zanirati, GG
   Plentz, I
   Neto, EP
   Palmini, ALF
   Machado, DC
   Da Costa, JC
AF Marinowic, Daniel Rodrigo
   Majolo, Fernanda
   Zanirati, Gabriele Goulart
   Plentz, Ismael
   Paglioli Neto, Eliseu
   Fernandes Palmini, Andre Luis
   Machado, Denise Cantarelli
   Da Costa, Jaderson Costa
TI Analysis of genes involved in cell proliferation, adhesion, and control
   of apoptosis during embryonic neurogenesis in Induced Pluripotent Stem
   Cells (iPSCs) from patients with Focal Cortical Dysplasia
SO BRAIN RESEARCH BULLETIN
LA English
DT Article
DE Focal cortical dysplasia; Cortical malformation; Epilepsy; iPSC;
   Embryonic neurodevelopment
ID BRAIN MALFORMATIONS; DEATH; PATHWAY; MTOR; INHIBITION; PIKE
AB Focal cortical dysplasia (FCD) is a malformation of cortical development which is strongly associated with drug-refractory epilepsy. Certain studies have demonstrated an increase in mTOR signaling in patients with FCD on the basis of observation of phosphorylated molecules. The aim of the present study was to verify the differences in genes involved in cell proliferation, adhesion, and control of apoptosis during embryonic neurogenesis in iPSCs derived from the Focal Cortical Dysplasia. Fibroblasts were obtained from the skin biopsies of patients with FCD (n = 2) and controls (n = 2). iPSCs were generated by exposing the fibroblasts to viral vectors that contained the Yamanaka factors (OCT4, SOX2, KLF4, and c-MYC genes) responsible for promoving cell reprogramation. The fibroblasts and iPSCs were tested during different phases of neurodifferentiation for migration capacity and expression of the genes involved in the PI3K pathway. Fibroblasts of patients with FCD migrated with greater intensity during the first two time points of analyses. iPSCs did not exhibit any difference in cell migration between the groups. Fibroblasts, brain tissue, and iPSCs of the patients with FCD exhibited a significant reduction in the relative expression values of 4EBP-1. During neurodevelopment, the iPSCs from patients with FCD exhibited a reduction in the expression of cIAP-1, cIAP-2, PI3K, beta-Catenin and 4EBP-1 gene. We suggest that the differences observed in the migration potential of adult cells and in the gene expression related to the fundamental processes involved in normal brain development during the neurodifferentiation process might be associated with cortical alteration in the patients with FCD.
C1 [Marinowic, Daniel Rodrigo; Majolo, Fernanda; Zanirati, Gabriele Goulart; Plentz, Ismael; Machado, Denise Cantarelli; Da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst Rio Grande do Sul BraIns, Porto Alegre, RS, Brazil.
   [Marinowic, Daniel Rodrigo; Majolo, Fernanda; Machado, Denise Cantarelli; Da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Grad Program Med & Hlth Sci, Porto Alegre, RS, Brazil.
   [Zanirati, Gabriele Goulart; Plentz, Ismael; Da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Grad Program Med Pediat & Child Hlth, Porto Alegre, RS, Brazil.
   [Paglioli Neto, Eliseu; Fernandes Palmini, Andre Luis; Da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Porto Alegre, RS, Brazil.
   [Paglioli Neto, Eliseu; Fernandes Palmini, Andre Luis] Pontificia Univ Catolica Rio Grande do Sul, Sao Lucas Hosp, Epilepsy Surg Program, Porto Alegre, RS, Brazil.
RP Da Costa, JC (corresponding author), Brain Inst Rio Grande do Sul BraIns, Jardim Bot, Av Ipiranga 6690,Bldg 63, BR-90610000 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Machado, Denise C/G-2852-2014; Majolo, Fernanda/S-5732-2018
OI Machado, Denise C/0000-0002-9371-5886; Majolo,
   Fernanda/0000-0002-7955-078X
FU Pontifical Catholic University of Rio Grande do Sul (PUCRS)
FX The authors thank Pontifical Catholic University of Rio Grande do Sul
   (PUCRS) for the support and scholarships for the authors.
CR Arai A, 2012, BRAIN RES, V1470, P89, DOI 10.1016/j.brainres.2012.06.009
   Avansini SH, 2018, ANN NEUROL, V83, P623, DOI 10.1002/ana.25187
   Buss RR, 2006, ANNU REV NEUROSCI, V29, P1, DOI 10.1146/annurev.neuro.29.051605.112800
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Chan CB, 2012, REV NEUROSCIENCE, V23, P153, DOI 10.1515/revneuro-2011-0066
   Cuesto G, 2011, J NEUROSCI, V31, P2721, DOI 10.1523/JNEUROSCI.4477-10.2011
   D'Gama AM, 2017, CELL REP, V21, P3754, DOI 10.1016/j.celrep.2017.11.106
   Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002
   Gross C, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00012
   Guerrini R, 2014, LANCET NEUROL, V13, P710, DOI 10.1016/S1474-4422(14)70040-7
   HAEGEL H, 1995, DEVELOPMENT, V121, P3529
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Hofsteen P, 2016, P NATL ACAD SCI USA, V113, P1002, DOI 10.1073/pnas.1523930113
   Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498
   Ichida JK, 2015, EMBO J, V34, P1456, DOI 10.15252/embj.201591267
   Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5
   Jansen LA, 2015, BRAIN, V138, P1613, DOI 10.1093/brain/awv045
   Jaworski J, 2005, J NEUROSCI, V25, P11300, DOI 10.1523/JNEUROSCI.2270-05.2005
   Kabat J., 2019, POLISH J RADIOL, V77, P35
   Kristiansen M, 2014, CELL DEATH DIFFER, V21, P1025, DOI 10.1038/cdd.2014.47
   Kuzniecky R, 2015, CURR OPIN NEUROL, V28, P151, DOI 10.1097/WCO.0000000000000175
   Lee CC, 2011, NEUROPHARMACOLOGY, V61, P867, DOI 10.1016/j.neuropharm.2011.06.003
   Liu Y, 2007, CELL BIOCHEM FUNCT, V25, P45, DOI 10.1002/cbf.1332
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Majolo F, 2018, INT J DEV NEUROSCI, V69, P112, DOI 10.1016/j.ijdevneu.2018.07.006
   Majolo F, 2019, NEUROSCIENCE, V408, P81, DOI 10.1016/j.neuroscience.2019.03.025
   Marinowic DR, 2017, MOL MED REP, V15, P2049, DOI 10.3892/mmr.2017.6264
   Nityanandam A, 2015, STEM CELLS DEV, V24, P1265, DOI 10.1089/scd.2015.0044
   OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321
   Palmini A, 2004, NEUROLOGY, V62, pS2, DOI 10.1212/01.WNL.0000114507.30388.7E
   Prayson RA, 2002, NEUROSURG CLIN N AM, V13, P17, DOI 10.1016/S1042-3680(02)80003-1
   Sandoe J, 2013, NAT NEUROSCI, V16, P780, DOI 10.1038/nn.3425
   Sarnat HB, 2014, PROG BRAIN RES, V213, P181, DOI 10.1016/B978-0-444-63326-2.00010-7
   Tang XL, 2008, NAT CELL BIOL, V10, P698, DOI 10.1038/ncb1732
   TAYLOR DC, 1971, J NEUROL NEUROSUR PS, V34, P369, DOI 10.1136/jnnp.34.4.369
   Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680
   Zhao TT, 2009, CELL DEATH DIFFER, V16, P244, DOI 10.1038/cdd.2008.146
   Zhou J, 2009, J NEUROSCI, V29, P1773, DOI 10.1523/JNEUROSCI.5685-08.2009
NR 38
TC 2
Z9 2
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
EI 1873-2747
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD FEB
PY 2020
VL 155
BP 112
EP 118
DI 10.1016/j.brainresbull.2019.11.016
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA KE7RI
UT WOS:000508748400012
PM 31816405
DA 2020-12-08
ER

PT J
AU Radaelli, G
   Nunes, ML
   Soder, RB
   de Oliveira, JM
   Bruzzo, FTK
   Neto, FK
   Leal-Conceicao, E
   Portuguez, MW
   da Costa, JC
AF Radaelli, Graciane
   Nunes, Magda Lahorgue
   Soder, Ricardo Bernardi
   de Oliveira, Julia Monteiro
   Bruzzo, Fernanda Thays Konat
   Neto, Felipe Kalil
   Leal-Conceicao, Eduardo
   Portuguez, Mirna Wetters
   da Costa, Jaderson Costa
TI Review of neuroimaging findings in congenital Zika virus syndrome and
   its relation to the time of infection
SO NEURORADIOLOGY JOURNAL
LA English
DT Review
DE Zika virus; microcephaly; tomography; magnetic resonance
ID OUTBREAK; FETUSES
AB Background Many original articles and case series have been published emphasizing the neuroimaging findings of congenital Zika virus (ZIKV) infection. The majority of these studies do not follow a neuroradiological methodology to describe malformations and brain abnormalities resulting from ZIKV infection. The cause-and-effect correlation between the gestational period of maternal infection and the severity of encephalic changes at birth has rarely been reported. A systematic literature review was conducted on the neuroimaging findings in children affected with microcephaly due to ZIKV. Methods PubMed, Cochrane Library and Web of Science were searched for full-text articles published up to July 2019. Duplicate entries were removed. Two independent reviewers performed a quality assessment of all the studies included. Results A total of 2214 publications were identified. Of these 2170 were excluded by analysis of titles and abstracts, resulting in the inclusion of only eight articles. Chi-square and Fisher's exact tests were performed with a 95% confidence interval to verify the statistically significant differences in the neuroradiological findings between the cases of ZIKV infection in the first or second trimester of gestation. The studies published so far have described image abnormalities at random, without utilizing any pre-established neuroradiological criteria, and imaging modalities with different sensitivity and accuracy have been used, which jeopardizes a reliable and adequate statistical analysis. Conclusions Neuroimaging abnormalities are much more prevalent and severe when the infection by ZIKV is contracted in the first or second trimester of pregnancy.
C1 [Radaelli, Graciane; Nunes, Magda Lahorgue; Soder, Ricardo Bernardi; de Oliveira, Julia Monteiro; Bruzzo, Fernanda Thays Konat; Neto, Felipe Kalil; Leal-Conceicao, Eduardo; Portuguez, Mirna Wetters; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst Rio Grande do Sul BraIns, Porto Alegre, RS, Brazil.
   [Nunes, Magda Lahorgue; da Costa, Jaderson Costa] CNPq, Brasilia, DF, Brazil.
   [Nunes, Magda Lahorgue; Soder, Ricardo Bernardi; Portuguez, Mirna Wetters; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Porto Alegre, RS, Brazil.
RP da Costa, JC (corresponding author), Brain Inst Rio Grande do Sul BraIns, Av Ipiranga 6690, BR-90610000 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515; Radaelli,
   Graciane/0000-0002-1208-362X
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: Our study was
   supported by the following grants: CNPq (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico) and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). J.C.C. and M.L.N.
   were funded by CNPq (bolsa de produtividade em pesquisa). J.C.C. and
   M.L.N. are researchers 1A and 1D, respectively, from CNPq, Brazil.
CR Aragao MFVV, 2017, AM J NEURORADIOL, V38, P1427, DOI 10.3174/ajnr.A5216
   Bale JF, 2009, CLIN PERINATOL, V36, P639, DOI 10.1016/j.clp.2009.06.005
   Carvalho MDCG, 2017, CLIN NEUROPHYSIOL, V128, P204, DOI 10.1016/j.clinph.2016.11.004
   da Silva NA, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012602
   de Oliveira WK, 2017, NEW ENGL J MED, V376, P1591, DOI 10.1056/NEJMc1608612
   de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
   de Oliveira-Szejnfeld PS, 2016, RADIOLOGY, V281, P203, DOI 10.1148/radiol.2016161584
   Desai SK, 2017, AM J STEM CELLS, V6, P13
   El Ghouzzi V, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.266
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Liang QM, 2016, CELL STEM CELL, V19, P663, DOI 10.1016/j.stem.2016.07.019
   Mehrjardi MZ, 2017, JPN J RADIOL, V35, P341, DOI 10.1007/s11604-017-0641-z
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Nunes ML, 2016, J PEDIAT-BRAZIL, V92, P230, DOI 10.1016/j.jped.2016.02.009
   Parra-Saavedra M, 2017, OBSTET GYNECOL, V130, P207, DOI 10.1097/AOG.0000000000002105
   Pires P, 2018, CHILD NERV SYST, V34, P957, DOI 10.1007/s00381-017-3682-9
   Pool KL, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8124
   Rothan HA, 2018, MOL NEUROBIOL, P1
   Paiva MHS, 2017, GENET MOL BIOL, V40, P597, DOI [10.1590/1678-4685-GMB-2016-0312, 10.1590/1678-4685-gmb-2016-0312]
   Van Der Linden V, 2016, MMWR MORB MORTAL WKL, V65
   Aragao MDV, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1901
   de Castro JDV, 2017, ARQ NEURO-PSIQUIAT, V75, P703, DOI [10.1590/0004-282X20170134, 10.1590/0004-282x20170134]
NR 22
TC 3
Z9 3
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1971-4009
EI 2385-1996
J9 NEURORADIOL J
JI Neuradiology J.
PD APR
PY 2020
VL 33
IS 2
BP 152
EP 157
AR UNSP 1971400919896264
DI 10.1177/1971400919896264
EA JAN 2020
PG 6
WC Neuroimaging
SC Neurosciences & Neurology
GA LA1RS
UT WOS:000506992500001
PM 31896285
DA 2020-12-08
ER

PT J
AU Luft, C
   Greggio, S
   Venturin, GT
   da Costa, MS
   da Costa, JC
   Donadio, MVF
AF Luft, Carolina
   Greggio, Samuel
   Venturin, Gianina Teribele
   da Costa, Mariana Severo
   da Costa, Jaderson Costa
   Fagundes Donadio, Marcio Vinicius
TI Sex differences in the effects of acute stress on cerebral glucose
   metabolism: A microPET study
SO BRAIN RESEARCH
LA English
DT Article
DE Stress; Restraint stress; F-18-FDG; microPET; Gender differences
ID CHRONIC RESTRAINT STRESS; PARAVENTRICULAR NUCLEUS; HIPPOCAMPAL
   NEUROGENESIS; IMMOBILIZATION STRESS; ESTROGEN; EXPRESSION; DISORDERS;
   RECEPTOR; BEHAVIOR; CORTEX
AB Stress has been considered as a risk factor for the development and aggravation of several diseases. The hypothalamic-pituitary-adrenal axis (HPA) is one of the main actors for the stress response and homeostasis maintenance. Positron emission tomography (PET) has been used to evaluate neuronal activity and to study brain regions that may be related to the HPA axis response. Since neuroimaging is an important tool in detecting neuroendocrine-related changes, we used fluorodeoxyglucose-18 (F-18-FDG) and positron emission microtomography (microPET) to evaluate sexual differences in the glucose brain metabolism after 10, 30 and 40 min of acute stress in Balb/c mice. We also investigated the effects of restraint stress in blood, liver and adrenal gland F-18-FDG biodistribution using a gamma counter. A decreased glucose uptake in the whole brain in both females and males was found. Additionally, there were time and sex-dependent alterations in the F-18-FDG uptake after restraint stress in specific brain regions, indicating that males could be more vulnerable to the short-term effects of acute stress. According to the gamma counter biodistribution, only females showed a significant decreased glucose uptake in the blood, liver and right adrenal after restraint stress. In addition, in comparisons between the sexes, males showed a decreased glucose uptake in the whole brain and in several brain regions compared to females. In conclusion, exposure to acute restraint stress resulted in significant decreased glucose metabolism in the brain, with particular effects in different regions and organs in a sex-specific manner.
C1 [Luft, Carolina; da Costa, Mariana Severo; Fagundes Donadio, Marcio Vinicius] Pontificia Univ Catolica Rio Grande Sul PUCRS, Infant Ctr, BR-90619900 Porto Alegre, RS, Brazil.
   [Greggio, Samuel; Venturin, Gianina Teribele; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande Sul PUCRS, Preclin Res Ctr, Brain Inst BraIns, BR-90619900 Porto Alegre, RS, Brazil.
RP Donadio, MVF (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Ctr Infant, Av Ipiranga 6690,2 Andar, BR-90610000 Porto Alegre, RS, Brazil.
EM mdonadio@pucrs.br
RI Donadio, Marcio Vinicius Fagundes/E-7702-2013; Greggio,
   Samuel/E-1498-2013; Donadio, Marcio/AAJ-5792-2020
OI Donadio, Marcio Vinicius Fagundes/0000-0001-8836-9109; Greggio,
   Samuel/0000-0002-5187-0335; Donadio, Marcio/0000-0001-8836-9109
FU CAPESCAPES [001]; CNPqNational Council for Scientific and Technological
   Development (CNPq); PUCRS
FX This research did not receive any specific grant from funding agencies
   in the public, commercial, or not-for-profit sectors. The authors thank
   CAPES (finance code 001), CNPq and PUCRS for the concession of
   scholarships.
CR Aschbacher K, 2014, PSYCHONEUROENDOCRINO, V46, P14, DOI 10.1016/j.psyneuen.2014.04.003
   Bangasser DA, 2014, FRONT NEUROENDOCRIN, V35, P303, DOI 10.1016/j.yfrne.2014.03.008
   Bicks LK, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01805
   Carda APP, 2015, STRESS, V18, P233, DOI 10.3109/10253890.2015.1014790
   CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244
   Chu XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep32935
   Collins PY, 2011, NATURE, V475, P27, DOI 10.1038/475027a
   Conrad CD, 2004, PHARMACOL BIOCHEM BE, V78, P569, DOI 10.1016/j.pbb.2004.04.025
   Davidson RJ, 2002, ANNU REV PSYCHOL, V53, P545, DOI 10.1146/annurev.psych.53.100901.135148
   Molina ME, 2010, WORLD J BIOL PSYCHIA, V11, P493, DOI 10.3109/15622970701472094
   FOY MR, 1987, BEHAV NEURAL BIOL, V48, P138, DOI 10.1016/S0163-1047(87)90664-9
   Furay AR, 2008, ENDOCRINOLOGY, V149, P5482, DOI 10.1210/en.2008-0642
   Gerrard B, 2017, NEUROSCIENCE, V359, P299, DOI 10.1016/j.neuroscience.2017.07.033
   Gianaros PJ, 2008, J NEUROSCI, V28, P990, DOI 10.1523/JNEUROSCI.3606-07.2008
   Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958
   Golub Y, 2011, J PSYCHIATR RES, V45, P650, DOI 10.1016/j.jpsychires.2010.10.014
   Hare BD, 2014, NEUROPSYCHOPHARMACOL, V39, P1262, DOI 10.1038/npp.2013.329
   Herman JP, 2016, COMPR PHYSIOL, V6, P603, DOI 10.1002/cphy.c150015
   Hillerer KM, 2013, HIPPOCAMPUS, V23, P476, DOI 10.1002/hipo.22107
   Hu H, 2010, NEUROSCIENCE, V169, P171, DOI 10.1016/j.neuroscience.2010.04.057
   HU Y, 2013, PLOS ONE, V8, DOI DOI 10.1371/JOURNAL.PONE.0063332
   Huang RR, 2015, INT J MOL MED, V35, P553, DOI 10.3892/ijmm.2014.2026
   Isgor C, 2003, NEUROSCIENCE, V121, P837, DOI 10.1016/S0306-4522(03)00561-X
   Ishunina TA, 1999, J CLIN ENDOCR METAB, V84, P4637, DOI 10.1210/jc.84.12.4637
   Iwasaki-Sekino A, 2009, PSYCHONEUROENDOCRINO, V34, P226, DOI 10.1016/j.psyneuen.2008.09.003
   Karisetty BC, 2017, BEHAV BRAIN RES, V318, P36, DOI 10.1016/j.bbr.2016.10.034
   Kern S, 2008, PSYCHONEUROENDOCRINO, V33, P517, DOI 10.1016/j.psyneuen.2008.01.010
   Khan N, 2011, Mymensingh Med J, V20, P332
   Kim EJ, 2015, LEARN MEMORY, V22, P411, DOI 10.1101/lm.037291.114
   Marik PE, 2013, CRIT CARE MED, V41, pE93, DOI 10.1097/CCM.0b013e318283d124
   McEwen BS, 2012, NEUROPHARMACOLOGY, V62, P3, DOI 10.1016/j.neuropharm.2011.07.014
   McEwen BS, 2005, METABOLISM, V54, P20, DOI 10.1016/j.metabol.2005.01.008
   Menard C, 2017, NAT NEUROSCI, V20, P1752, DOI 10.1038/s41593-017-0010-3
   Mirrione MM, 2006, SYNAPSE, V59, P119, DOI 10.1002/syn.20216
   Mitchner NA, 1998, ENDOCRINOLOGY, V139, P3976, DOI 10.1210/en.139.9.3976
   Vargas MHM, 2016, PHYSIOL BEHAV, V165, P358, DOI 10.1016/j.physbeh.2016.08.023
   O'Doherty DCM, 2015, PSYCHIAT RES-NEUROIM, V232, P1, DOI 10.1016/j.pscychresns.2015.01.002
   Olive I, 2018, HUM BRAIN MAPP, V39, P563, DOI 10.1002/hbm.23865
   Rachman IM, 1998, P NATL ACAD SCI USA, V95, P13941, DOI 10.1073/pnas.95.23.13941
   Rahman MM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29127
   Rui LY, 2014, COMPR PHYSIOL, V4, P177, DOI 10.1002/cphy.c130024
   Schutter DJLG, 2012, MED HYPOTHESES, V79, P779, DOI 10.1016/j.mehy.2012.08.027
   Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83
   Silva R.B.M., 2018, MOL NEUROBIOL
   Smith ME, 2005, HIPPOCAMPUS, V15, P798, DOI 10.1002/hipo.20102
   Sung KK, 2009, NEUROIMAGE, V44, P1074, DOI 10.1016/j.neuroimage.2008.09.032
   Thomas RM, 2007, J NEUROSCI, V27, P2734, DOI 10.1523/JNEUROSCI.3849-06.2007
   Trejter M, 2015, FOLIA HISTOCHEM CYTO, V53, P133, DOI 10.5603/FHC.a2015.0012
   Ueyama T, 2006, BRAIN RES, V1084, P67, DOI 10.1016/j.brainres.2006.02.008
   Van Laeken N, 2018, J NEURAL TRANSM, V125, P1381, DOI 10.1007/s00702-018-1899-8
   VANDENBERGHE G, 1991, J INHERIT METAB DIS, V14, P407, DOI 10.1007/BF01797914
   Viau V, 2005, ENDOCRINOLOGY, V146, P137, DOI 10.1210/en.2004-0846
   Walf AA, 2005, NEUROPSYCHOPHARMACOL, V30, P1598, DOI 10.1038/sj.npp.1300713
   Wei K, 2018, NEUROSCI LETT, V665, P104, DOI 10.1016/j.neulet.2017.11.047
   Zanirati G, 2018, EPILEPSIA, V59, P923, DOI 10.1111/epi.14057
   Zavala JK, 2011, PHYSIOL BEHAV, V104, P215, DOI 10.1016/j.physbeh.2011.03.022
NR 56
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD NOV 1
PY 2019
VL 1722
AR 146355
DI 10.1016/j.brainres.2019.146355
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA JF3QF
UT WOS:000491301400017
PM 31356782
DA 2020-12-08
ER

PT J
AU Bellaver, B
   Rocha, AS
   Souza, DG
   Leffa, DT
   De Bastiani, MA
   Schu, G
   Ferreira, PCL
   Venturin, GT
   Greggio, S
   Ribeiro, CT
   da Costa, JC
   Moreira, JCF
   Gelain, DP
   Torres, ILD
   Klamt, F
   Zimmer, ER
AF Bellaver, Bruna
   Rocha, Andreia S.
   Souza, Debora G.
   Leffa, Douglas T.
   De Bastiani, Marco Antonio
   Schu, Guilherme
   Ferreira, Pamela C. Lukasewicz
   Venturin, Gianina T.
   Greggio, Samuel
   Ribeiro, Camila T.
   da Costa, Jaderson C.
   Fonseca Moreira, Jose Claudio
   Gelain, Daniel P.
   Torres, Iraci Lucena da S.
   Klamt, Fabio
   Zimmer, Eduardo R.
TI Activated peripheral blood mononuclear cell mediators trigger astrocyte
   reactivity
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Astrocyte; Glucose; Glutamate; Energy metabolism; PBMC; Sepsis
ID COGNITIVE IMPAIRMENT; EXPRESSION; SEPSIS; PROTEIN; NEUROINFLAMMATION;
   PERFORMANCE; BRAIN
AB Sepsis is characterized by a severe and disseminated inflammation. In the central nervous system, sepsis promotes synaptic dysfunction and permanent cognitive impairment. Besides sepsis-induced neuronal dysfunction, glial cell response has been gaining considerable attention with microglial activation as a key player. By contrast, astrocytes' role during acute sepsis is still underexplored. Astrocytes are specialized immunocompetent cells involved in brain surveillance. In this context, the potential communication between the peripheral immune system and astrocytes during acute sepsis still remains unclear. We hypothesized that peripheral blood mononuclear cell (PBMC) mediators are able to affect the brain during an episode of acute sepsis. With this in mind, we first performed a data-driven transcriptome analysis of blood from septic patients to identify common features among independent clinical studies. Our findings evidenced pronounced impairment in energy-related signaling pathways in the blood of septic patients. Since astrocytes are key for brain energy homeostasis, we decided to investigate the communication between PBMC mediators and astrocytes in a rat model of acute sepsis, induced by cecal ligation and perforation (CLP). In the CLP animals, we identified widespread in vivo brain glucose hypometabolism. Ex vivo analyses demonstrated astrocyte reactivity along with reduced glutamate uptake capacity during sepsis. Also, by exposing cultured astrocytes to mediators released by PBMCs from CLP animals, we reproduced the energetic failure observed in vivo. Finally, by pharmacologically inhibiting phosphoinositide 3-kinase (PI3K), a central metabolic pathway downregulated in the blood of septic patients and reduced in the CLP rat brain, we mimicked the PBMC mediators effect on glutamate uptake but not on glucose metabolism. These results suggest that PBMC mediators are capable of directly mediating astrocyte reactivity and contribute to the brain energetic failure observed in acute sepsis. Moreover, the evidence of PI3K participation in this process indicates a potential target for therapeutic modulation.
C1 [Bellaver, Bruna; Rocha, Andreia S.; Souza, Debora G.; De Bastiani, Marco Antonio; Schu, Guilherme; Ribeiro, Camila T.; Fonseca Moreira, Jose Claudio; Gelain, Daniel P.; Klamt, Fabio; Zimmer, Eduardo R.] Univ Fed Rio Grande do Sul, Grad Program Biol Sci Biochem, Porto Alegre, RS, Brazil.
   [Leffa, Douglas T.; Torres, Iraci Lucena da S.] Univ Fed Rio Grande do Sul, Grad Program Med Med Sci, Porto Alegre, RS, Brazil.
   [Ferreira, Pamela C. Lukasewicz] Univ Fed Rio Grande do Sul, Grad Program Pharmaceut Sci, Porto Alegre, RS, Brazil.
   [Venturin, Gianina T.; Greggio, Samuel; da Costa, Jaderson C.] Brain Inst BraIns Rio Grande Sul, Preclin Imaging Ctr, Porto Alegre, RS, Brazil.
   [Fonseca Moreira, Jose Claudio; Gelain, Daniel P.] Univ Fed Rio Grande do Sul, Dept Biochem, Porto Alegre, RS, Brazil.
   [Torres, Iraci Lucena da S.; Zimmer, Eduardo R.] Univ Fed Rio Grande do Sul, Grad Program Biol Sci Pharmacol & Therapeut, Porto Alegre, RS, Brazil.
   [Klamt, Fabio] Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Lab Cellular Biochem, Porto Alegre, RS, Brazil.
   [Torres, Iraci Lucena da S.; Zimmer, Eduardo R.] Univ Fed Rio Grande do Sul, Dept Pharmacol, 2500 Ramiro Barcelos St, BR-90035003 Porto Alegre, RS, Brazil.
RP Zimmer, ER (corresponding author), Univ Fed Rio Grande do Sul, Dept Pharmacol, 2500 Ramiro Barcelos St, BR-90035003 Porto Alegre, RS, Brazil.
EM eduardo.zimmer@ufrgs.br
RI Ferreira, Pamela/AAH-2187-2019; Gelain, Daniel Pens/I-5144-2013; De
   Bastiani, Marco Antonio/AAD-8366-2019; Greggio, Samuel/E-1498-2013;
   Torres, Iraci L. S./G-6693-2012; Leffa, Douglas Teixeira/AAG-5822-2020;
   Zimmer, Eduardo R Rigon/I-2932-2015
OI Ferreira, Pamela/0000-0003-2134-9829; Gelain, Daniel
   Pens/0000-0001-5254-0509; Greggio, Samuel/0000-0002-5187-0335; Torres,
   Iraci L. S./0000-0002-3081-115X; Zimmer, Eduardo R
   Rigon/0000-0002-5349-0053; Silva da Rocha, Andreia/0000-0003-1567-3374;
   Teixeira Leffa, Douglas/0000-0002-4890-8451; Tiefensee Ribeiro,
   Camila/0000-0003-0876-119X; De Bastiani, Marco
   Antonio/0000-0003-3924-5278
FU CAPESCAPES [88881.141186/2017-01]; CNPqNational Council for Scientific
   and Technological Development (CNPq) [460172/2014-0]; PRONEX;
   FAPERGS/CNPqNational Council for Scientific and Technological
   Development (CNPq)Foundation for Research Support of the State of Rio
   Grande do Sul (FAPERGS) [16/2551-0000475-7]; Brazilian National
   Institute of Science and Technology in Excitotoxicity and
   Neuroprotection [465671/2014-4]; FAPERGS/MS/CNPq/SESRS- PPSUS
   [30786.434.24734.23112017]
FX ERZ receives financial support from CAPES [88881.141186/2017-01], CNPq
   [460172/2014-0], PRONEX, FAPERGS/CNPq [16/2551-0000475-7], Brazilian
   National Institute of Science and Technology in Excitotoxicity and
   Neuroprotection [465671/2014-4], FAPERGS/MS/CNPq/SESRS- PPSUS
   [30786.434.24734.23112017].
CR Anderson CM, 2000, GLIA, V32, P1
   Bellaver B., 2016, MOL NEUROBIOL
   Bellaver B, 2017, NEUROBIOL MOL
   Bellaver B, 2016, BBA-MOL BASIS DIS, V1862, P1827, DOI 10.1016/j.bbadis.2016.06.018
   Bergeron M, 2014, PHYS MED BIOL, V59, P661, DOI 10.1088/0031-9155/59/3/661
   Brahmachari S, 2006, J NEUROSCI, V26, P4930, DOI 10.1523/JNEUROSCI.5480-05.2006
   Calsavara AC, 2015, METAB BRAIN DIS, V30, P669, DOI 10.1007/s11011-014-9610-8
   Catarina AV, 2018, BRAIN RES, V1698, P54, DOI 10.1016/j.brainres.2018.06.024
   Cazalis MA, 2014, INTENS CARE MED EXP, V2, DOI 10.1186/s40635-014-0020-3
   Chou CH, 2017, ONCOTARGET, V8, P84300, DOI 10.18632/oncotarget.20899
   Clark IA, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0708-2
   Cunningham C, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0117-2
   Dolinay T, 2012, AM J RESP CRIT CARE, V185, P1225, DOI 10.1164/rccm.201201-0003OC
   Domise M, 2016, EXPERIENTIA SUPPL, V107, P153, DOI 10.1007/978-3-319-43589-3_7
   Gardener SL, 2016, J ALZHEIMERS DIS, V52, P661, DOI 10.3233/JAD-151084
   Godini R., 2018, NETWORK ANAL INFLAMM, V13
   Gorina R, 2009, GLIA, V57, P93, DOI 10.1002/glia.20738
   Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200
   Hato T, 2019, J CLIN INVEST, V129, P296, DOI 10.1172/JCI123284
   Horng S, 2017, J CLIN INVEST, V127, P3136, DOI 10.1172/JCI91301
   Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553
   Kyrkanides S, 2008, J NEUROIMMUNOL, V203, P50, DOI 10.1016/j.jneuroim.2008.06.024
   Lee I, 2014, BBA-MOL BASIS DIS, V1842, P1579, DOI 10.1016/j.bbadis.2014.05.031
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Michels Monique, 2015, Intensive Care Med Exp, V3, P30, DOI 10.1186/s40635-015-0066-x
   Murtagh F, 2014, J CLASSIF, V31, P274, DOI 10.1007/s00357-014-9161-z
   Nortley R, 2017, CURR OPIN NEUROBIOL, V47, P80, DOI 10.1016/j.conb.2017.09.012
   Pagani M, 2015, NEUROIMAGE-CLIN, V7, P34, DOI 10.1016/j.nicl.2014.11.007
   Pankla R, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r127
   Parnell GP, 2013, SHOCK, V40, P166, DOI 10.1097/SHK.0b013e31829ee604
   Pellegrina D., 2015, PLOS ONE, V10
   Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149
   Petronilho F, 2012, BRAIN BEHAV IMMUN, V26, P904, DOI 10.1016/j.bbi.2012.03.007
   Ransohoff RM, 2015, NEUROTHERAPEUTICS, V12, P896, DOI 10.1007/s13311-015-0385-3
   Richards MH, 2015, GLIA, V63, P441, DOI 10.1002/glia.22763
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003
   Semmler A, 2013, J NEUROL NEUROSUR PS, V84, P62, DOI 10.1136/jnnp-2012-302883
   Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38
   Shalova IN, 2015, IMMUNITY, V42, P484, DOI 10.1016/j.immuni.2015.02.001
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002
   Souza D. G., 2016, PURINERG SIGNAL
   Souza D. G., 2019, SEMINARS CELL DEV BI
   Souza DG, 2016, NEUROCHEM RES, V41, P1578, DOI 10.1007/s11064-016-1871-7
   Souza DG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060282
   Sutherland A, 2011, CRIT CARE, V15, DOI 10.1186/cc10274
   Tang BMP, 2009, CRIT CARE MED, V37, P882, DOI 10.1097/CCM.0b013e31819b52fd
   Venet F, 2017, HUM IMMUNOL, V78, P441, DOI 10.1016/j.humimm.2017.03.010
   Weise CM, 2018, NEUROIMAGE-CLIN, V20, P286, DOI 10.1016/j.nicl.2018.07.016
   Wrann CD, 2007, J IMMUNOL, V178, P5940, DOI 10.4049/jimmunol.178.9.5940
   Young GB, 2010, CRIT CARE, V14, DOI 10.1186/cc9010
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zanirati G, 2018, EPILEPSIA, V59, P923, DOI 10.1111/epi.14057
   Zhang X, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00152
   Ziaja M, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0383-y
   Zimmer E. R., 2017, FDG PET SIGNAL IS DR
NR 57
TC 3
Z9 3
U1 1
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD AUG
PY 2019
VL 80
BP 879
EP 888
DI 10.1016/j.bbi.2019.05.041
PG 10
WC Immunology; Neurosciences; Psychiatry
SC Immunology; Neurosciences & Neurology; Psychiatry
GA IM6LX
UT WOS:000478105500081
PM 31176000
DA 2020-12-08
ER

PT J
AU Dagnino, APA
   da Silva, RBM
   Chagastelles, PC
   Pereira, TCB
   Venturin, GT
   Greggio, S
   da Costa, JC
   Boge, MR
   Campos, MM
AF Aquistapase Dagnino, Ana Paula
   Madeira da Silva, Rodrigo Braccini
   Chagastelles, Pedro Cesar
   Brandao Pereira, Talita Carneiro
   Venturin, Gianina Teribele
   Greggio, Samuel
   da Costa, Jaderson Costa
   Boge, Mauricio Reis
   Campos, Maria Martha
TI Nociceptin/orphanin FQ receptor modulates painful and fatigue symptoms
   in a mouse model of fibromyalgia
SO PAIN
LA English
DT Article
DE Fibromyalgia; Reserpine; Nociceptin/orphanin FQ; Nociceptin/orphanin FQ
   receptor; UFP-101; SB-612111; Nociception; Fatigue
ID SYSTEM; ANTAGONIST; STRESS; PHARMACOLOGY; PEPTIDE; NOP; INVOLVEMENT;
   BEHAVIOR; ANXIETY; NEUROPEPTIDES
AB Generalized pain and fatigue are both hallmarks of fibromyalgia, a syndrome with an indefinite etiology. The treatment options for fibromyalgia are currently limited, probably because of its intricate pathophysiology. Thus, further basic and clinical research on this condition is currently needed. This study investigated the effects of nociceptin/orphanin FQ (N/OFQ) receptor (NOPr) ligands and the modulation of the NOP system in the preclinical mouse model of reserpine-induced fibromyalgia. The effects of administration of the natural agonist N/OFQ and the selective NOPr antagonists (UFP-101 and SB-612111) were evaluated in fibromyalgia-related symptoms in reserpine-treated mice. The expression of prepronociceptin/orphanin FQ and NOPr was assessed in central and peripheral sites at different time points after reserpine administration. Nociceptin/orphanin FQ displayed dual effects in the behavioral changes in the reserpine-elicited fibromyalgia model. The peptide NOPr antagonist UFP-101 produced analgesic and antifatigue effects, by preventing alterations in brain activity and skeletal muscle metabolism, secondary to fibromyalgia induction. The nonpeptide NOPr antagonist SB-612111 mirrored the favorable effects of UFP-101 in painful and fatigue alterations induced by reserpine. A time-related up-or downregulation of prepronociceptin/orphanin FQ and NOPr was observed in supraspinal, spinal, and peripheral sites of reserpine-treated mice. Our data shed new lights on the mechanisms underlying the fibromyalgia pathogenesis, supporting a role for N/OFQ-NOP receptor system in this syndrome.
C1 [Aquistapase Dagnino, Ana Paula; Brandao Pereira, Talita Carneiro; Boge, Mauricio Reis; Campos, Maria Martha] Pontificia Univ Catolica Rio Grande do Sul, Programa Posgrad Biol Celular & Mol, Escola Ciencias, Porto Alegre, RS, Brazil.
   [Aquistapase Dagnino, Ana Paula; Campos, Maria Martha] Pontificia Univ Catolica Rio Grande do Sul, Ctr Pesquisa Toxicol & Farmacol, Escola Ciencias Saude, Porto Alegre, RS, Brazil.
   [Madeira da Silva, Rodrigo Braccini; Chagastelles, Pedro Cesar; Boge, Mauricio Reis; Campos, Maria Martha] Pontificia Univ Catolica Rio Grande do Sul, Programa Posgrad Med & Ciencias Saude, Escola Med, Porto Alegre, RS, Brazil.
   [Brandao Pereira, Talita Carneiro; Boge, Mauricio Reis] Pontificia Univ Catolica Rio Grande do Sul, Lab Biol Genom & Mol, Escola Ciencias, Porto Alegre, RS, Brazil.
   [Venturin, Gianina Teribele; Greggio, Samuel; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Ctr Pesquisa Preclin, Inst Cerebro Rio Grande do Sul, Brain Inst BraIns, Porto Alegre, RS, Brazil.
   [Greggio, Samuel] Pontificia Univ Catolica Rio Grande do Sul, Curso Grad Biomed, Escola Ciencias Saude, Porto Alegre, RS, Brazil.
   [Campos, Maria Martha] Pontificia Univ Catolica Rio Grande do Sul, Escola Ciencias Saude, Programa Posgrad Odontol, Porto Alegre, RS, Brazil.
RP Campos, MM (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Escola Ciencias Saude, Ave Ipiranga 6681, BR-90619900 Porto Alegre, RS, Brazil.
EM maria.campos@pucrs.br
RI Silva, Rodrigo BM/O-7441-2017; Greggio, Samuel/E-1498-2013; Dagnino, Ana
   Paula/T-3518-2019; Bogo, Mauricio R/D-7537-2013
OI Silva, Rodrigo BM/0000-0001-6284-7387; Greggio,
   Samuel/0000-0002-5187-0335; Bogo, Mauricio R/0000-0002-5728-9576;
   Campos, Maria/0000-0001-7738-9892
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil
   (CAPES)CAPES [001]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Pontificia Universidade Catolica do Rio Grande do
   Sul (PUCRS); Financiadora de Estudos e Projetos (FINEP) research grant
   "Expansao da Infraestrutura Multiusuaria de Pesquisa na PUCRS
   (MULTIPUCRS)" (Brazil) [01.13.0292-00]; CAPESCAPES; PNPD/CAPES
   fellowship; National Research Council of Brazil (CNPq)National Council
   for Scientific and Technological Development (CNPq) [303842-2014-8,
   303776/2013-7]
FX The authors thank Mrs Janaina Pasetti Nunes for her valuable technical
   assistance in histological processing (Laboratory of Oral
   Pathology/PUCRS). The authors are grateful to Mrs. Moema Queiroz Vieira
   (Central Laboratory of Microscopy and Microanalysis; LabCEMM/PUCRS) for
   the technical assistance in transmission electron microscopy
   experiments. The authors also thank the staff of the Centre of
   Experimental Biological Models (CeMBE/PUCRS) for animal care. This study
   was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior-Brasil (CAPES) Finance Code 001, Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), and Pontificia
   Universidade Catolica do Rio Grande do Sul (PUCRS), in addition to a
   Financiadora de Estudos e Projetos (FINEP) research grant "Expansao da
   Infraestrutura Multiusuaria de Pesquisa na PUCRS (MULTIPUCRS)"
   #01.13.0292-00 (Brazil). A.P.A.D. is a PhD student receiving grants from
   CAPES and T.C.B.P is recipient of PNPD/CAPES fellowship. M.M.C. (CNPq,
   303842-2014-8) and M.R.B. (CNPq, 303776/2013-7) are Research Career
   Awardees of the National Research Council of Brazil (CNPq).
CR Agostini S, 2009, PAIN, V141, P292, DOI 10.1016/j.pain.2008.12.007
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS17, DOI 10.1111/bph.13878
   Anderberg UM, 1998, Z RHEUMATOL, V57, P77
   Arcuri L, 2017, ONCOTARGET, V8, P8995, DOI 10.18632/oncotarget.13710
   Arora V, 2013, J AFFECT DISORDERS, V151, P1041, DOI 10.1016/j.jad.2013.08.032
   Aydede M, 2018, PAIN, V159, P1176, DOI 10.1097/j.pain.0000000000001184
   Baraniuk JN, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-48
   Blasco-Serra A, 2015, PHYSIOL BEHAV, V151, P456, DOI 10.1016/j.physbeh.2015.07.033
   Bodera P, 2014, PHARMACOL REP, V66, P288, DOI 10.1016/j.pharep.2013.12.003
   Bonaterra GA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151116
   Brederson JD, 2011, CURR PHARM BIOTECHNO, V12, P1613, DOI 10.2174/138920111798357258
   Briscini L, 2002, EUR J PHARMACOL, V447, P59, DOI 10.1016/S0014-2999(02)01833-2
   Cabo-Meseguer A, 2017, MED CLIN-BARCELONA, V149, P441, DOI 10.1016/j.medcli.2017.06.008
   Calo G, 2002, BRIT J PHARMACOL, V136, P303, DOI 10.1038/sj.bjp.0704706
   Calo G, 2000, BRIT J PHARMACOL, V129, P1261, DOI 10.1038/sj.bjp.0703219
   Chen Y, 2006, J PERIPHER NERV SYST, V11, P232, DOI 10.1111/j.1529-8027.2006.0093.x
   Chiou LC, 2007, CURR DRUG TARGETS, V8, P117, DOI 10.2174/138945007779315605
   Clauw DJ, 2014, JAMA-J AM MED ASSOC, V311, P1547, DOI 10.1001/jama.2014.3266
   da Silveira NS, 2014, BIOL PHARM BULL, V37, P771, DOI 10.1248/bpb.b13-00832
   Deacon RMJ, 2013, JOVE-J VIS EXP, DOI 10.3791/2705
   DeSantana JM, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4402
   Devine DP, 2003, J NEUROENDOCRINOL, V15, P69, DOI 10.1046/j.1365-2826.2003.00868.x
   Fatima G, 2017, INT J RHEUM DIS, V20, P39, DOI 10.1111/1756-185X.12550
   Freitas RDS, 2016, J NUTR BIOCHEM, V27, P219, DOI 10.1016/j.jnutbio.2015.09.007
   Fulford AJ, 2015, VITAM HORM, V97, P267, DOI 10.1016/bs.vh.2014.12.012
   Garcia-Cazarin ML, 2011, JOVE-J VIS EXP, V49, P1
   Gavioli EC, 2004, N-S ARCH PHARMACOL, V369, P547, DOI 10.1007/s00210-004-0939-0
   Gavioli EC, 2003, EUR J NEUROSCI, V17, P1987, DOI 10.1046/j.1460-9568.2003.02603.x
   Gavioli EC, 2013, PHARMACOL THERAPEUT, V140, P10, DOI 10.1016/j.pharmthera.2013.05.008
   George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002
   Goldfarb Y, 2006, J NEUROIMMUNOL, V176, P76, DOI 10.1016/j.jneuroim.2006.04.008
   Granholm L, 2015, BRIT J PHARMACOL, V172, P606, DOI 10.1111/bph.12753
   Hernandez-Leon A, 2018, HORM BEHAV, V97, P39, DOI 10.1016/j.yhbeh.2017.10.011
   Holanda VAD, 2018, PSYCHOPHARMACOLOGY, V235, P3093, DOI 10.1007/s00213-018-5004-7
   Holtermann A, 2011, J ELECTROMYOGR KINES, V21, P519, DOI 10.1016/j.jelekin.2011.01.004
   Jang MU, 2011, ORAL DIS, V17, P187, DOI 10.1111/j.1601-0825.2010.01717.x
   Jorge LL, 2012, CURR PAIN HEADACHE R, V16, P388, DOI 10.1007/s11916-012-0284-9
   Karatay S, 2018, PAIN MED, V19, P615, DOI 10.1093/pm/pnx263
   Kiguchi N, 2016, ADV PHARMACOL, V75, P217, DOI 10.1016/bs.apha.2015.10.001
   Kilkenny C, 2010, J PHARMACOL PHARMACO, V1, P94, DOI 10.4103/0976-500X.72351
   Kiso T, 2018, EUR J PHARMACOL, V827, P117, DOI 10.1016/j.ejphar.2018.03.011
   Klein CP, 2014, NEUROPHARMACOLOGY, V86, P57, DOI 10.1016/j.neuropharm.2014.05.043
   Klein CP, 2016, PAIN RES TREAT, V2016, DOI 10.1155/2016/3191638
   Lambert DG, 2008, NAT REV DRUG DISCOV, V7, P694, DOI 10.1038/nrd2572
   Lima KG, 2018, TOXICOL IN VITRO, V48, P11, DOI 10.1016/j.tiv.2017.12.017
   Littlejohn G, 2018, SEMIN IMMUNOPATHOL, V40, P291, DOI 10.1007/s00281-018-0672-2
   Maciel IS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077227
   Marti M, 2013, BRIT J PHARMACOL, V168, P863, DOI 10.1111/j.1476-5381.2012.02219.x
   McGrath JC, 2015, BRIT J PHARMACOL, V172, P3189, DOI 10.1111/bph.12955
   Medeiros IU, 2015, PEPTIDES, V72, P95, DOI 10.1016/j.peptides.2015.05.006
   Micheli L, 2015, EUR J PHARMACOL, V754, P79, DOI 10.1016/j.ejphar.2015.02.020
   Mogil JS, 2001, PHARMACOL REV, V53, P381
   Murga I, 2017, MED CLIN-BARCELONA, V148, P511, DOI 10.1016/j.medcli.2017.01.034
   Nagakura Y, 2018, PHYSIOL BEHAV, V194, P505, DOI 10.1016/j.physbeh.2018.07.007
   Nagakura Y, 2009, PAIN, V146, P26, DOI 10.1016/j.pain.2009.05.024
   Nazzaro C, 2007, PEPTIDES, V28, P663, DOI 10.1016/j.peptides.2006.11.004
   Oezel L, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.248
   Ozawa A, 2018, BRIT J PHARMACOL, V175, P2662, DOI 10.1111/bph.14225
   Palmisano M, 2017, GENES BRAIN BEHAV, V16, P537, DOI 10.1111/gbb.12365
   Pernot F, 2010, J NEUROSCI RES, V88, P1000, DOI 10.1002/jnr.22282
   Reinscheid Rainer K., 2006, CNS & Neurological Disorders-Drug Targets, V5, P219, DOI 10.2174/187152706776359628
   Rizzi A, 2007, J PHARMACOL EXP THER, V321, P968, DOI 10.1124/jpet.106.116780
   Rizzi A, 2006, PAIN, V124, P100, DOI 10.1016/j.pain.2006.03.021
   Rodriguez-Pinto I, 2014, IMMUNOL LETT, V161, P200, DOI 10.1016/j.imlet.2014.01.009
   Schroder W, 2014, BRIT J PHARMACOL, V171, P3777, DOI 10.1111/bph.12744
   Shim JY, 2010, TOXICOL APPL PHARM, V242, P318, DOI 10.1016/j.taap.2009.11.005
   Silva RBM, 2018, MOL NEUROBIOL, V55, P9307, DOI 10.1007/s12035-018-1049-1
   Sleigh James N, 2016, BMC Res Notes, V9, P82, DOI 10.1186/s13104-016-1915-8
   Srikuea R, 2013, ARTHRITIS RHEUM-US, V65, P519, DOI 10.1002/art.37763
   Staud Roland, 2010, Curr Rheumatol Rep, V12, P448, DOI 10.1007/s11926-010-0134-x
   Takeuchi Y, 2007, NEUROPHARMACOLOGY, V53, P842, DOI 10.1016/j.neuropharm.2007.08.013
   Toll L, 2016, PHARMACOL REV, V68, P419, DOI 10.1124/pr.114.009209
   Totsch SK, 2017, MOL PAIN, V13, DOI 10.1177/1744806917724559
   Trevisan G, 2013, NEUROPHARMACOLOGY, V73, P261, DOI 10.1016/j.neuropharm.2013.06.011
   Tsai CY, 2018, J PAIN RES, V11, P2699, DOI 10.2147/JPR.S175259
   Tsilioni I, 2016, J PHARMACOL EXP THER, V356, P664, DOI 10.1124/jpet.115.230060
   Vincent A, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4395
   Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44
   Walker JR, 2002, NEUROPSYCHOPHARMACOL, V27, P203, DOI 10.1016/S0893-133X(02)00292-0
   Wang J, 2016, MOL MED REP, V13, P1861, DOI 10.3892/mmr.2015.4734
   Wells JA, 2017, SCI REP-UK, V7, DOI 10.1038/srep38325
   Witkin JM, 2014, PHARMACOL THERAPEUT, V141, P283, DOI 10.1016/j.pharmthera.2013.10.011
   Wolfe F, 2016, SEMIN ARTHRITIS RHEU, V46, P319, DOI 10.1016/j.semarthrit.2016.08.012
   Zanirati G, 2018, EPILEPSIA, V59, P923, DOI 10.1111/epi.14057
   Zaratin PF, 2004, J PHARMACOL EXP THER, V308, P454, DOI 10.1124/jpet.103.055848
   Zaveri N, 2003, LIFE SCI, V73, P663, DOI 10.1016/S0024-3205(03)00387-4
   Zaveri NT, 2016, J MED CHEM, V59, P7011, DOI 10.1021/acs.jmedchem.5b01499
NR 87
TC 5
Z9 5
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0304-3959
EI 1872-6623
J9 PAIN
JI Pain
PD JUN
PY 2019
VL 160
IS 6
BP 1383
EP 1401
DI 10.1097/j.pain.0000000000001513
PG 19
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA IQ5AF
UT WOS:000480762400014
PM 30720581
DA 2020-12-08
ER

PT J
AU Majolo, F
   Marinowic, DR
   Palmini, ALF
   DaCosta, JC
   Machado, DC
AF Majolo, Fernanda
   Marinowic, Daniel Rodrigo
   Fernandes Palmini, Andre Luis
   DaCosta, Jaderson Costa
   Machado, Denise Cantarelli
TI Migration and Synaptic Aspects of Neurons Derived from Human Induced
   Pluripotent Stem Cells from Patients with Focal Cortical Dysplasia II
SO NEUROSCIENCE
LA English
DT Article
DE focal cortical dysplasia type IIb; synaptic; migration; hiPSCs; neural
   differentiation
ID MESSENGER-RNA; BALLOON CELLS; EXPRESSION; DEATH; MECHANISMS; PATHWAY;
   MALFORMATIONS; MTOR; CLASSIFICATION; DYSMATURATION
AB Malformations of cortical development (MCDs) include many different Central Nervous System (CNS) disorders related to a complex process of cortex formation. In children with refractory epilepsy to drug treatment undergoing surgery, focal cortical dysplasia (FCD), one of the MCDs, is considered the most common structural brain lesion found. This study aimed to study the possible alterations in neural differentiation process of human induced pluripotent stem cells (hiPSCs) related to migration and synaptic aspects from fibroblasts of two individuals affected by FCD type IIb (45-year-old male and 12-year-old female) and normal individuals. At the days 14th, 22nd and 35th, hiPSCs were neural differentiated and analyzed. Using qRT-PCR approach, the expression of 9 genes associated with synaptic and neural migration were quantified. Diagnostic of both patients was consistent with FCD type IIb. Our results showed that in all processes and groups, individuals with dysplasia presented alterations in most part of the genes in relation to control individuals. According to our results, it is suggested that the different expressions are mainly involved in alterations of the expression of receptors and capture sites, timing, coupling of synaptic vesicles with the presynaptic membrane, regulation of ion channel and synaptic exocytosis, imbalance of the apoptosis process and abnormal microtubules that may also contribute to delays in synaptogenesis. Thus, brain formation with dysplasia is probably influenced by these genes studied. (C) 2019 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Majolo, Fernanda; Marinowic, Daniel Rodrigo; Fernandes Palmini, Andre Luis; DaCosta, Jaderson Costa; Machado, Denise Cantarelli] Med Sch, Brain Inst Rio Grande Brains, Av Ipiranga,6690 Bldg 63, BR-90610000 Porto Alegre, RS, Brazil.
   [Fernandes Palmini, Andre Luis] Epilepsy Surg Program PUCRS, Av Ipiranga,6690 Bldg 63, BR-90610000 Porto Alegre, RS, Brazil.
RP Machado, DC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Med Sch, Postgrad Program Med & Hlth Sci, Av Ipiranga,6690 Bldg 63, BR-90610000 Porto Alegre, RS, Brazil.
EM fernanda.majolo@acad.pucrs.br; daniel.marinowic@pucrs.br;
   andre.palmini@-pucrs.br; jcc@pucrs.br; dcm@pucrs.br
RI Machado, Denise C/G-2852-2014; Majolo, Fernanda/S-5732-2018
OI Machado, Denise C/0000-0002-9371-5886; Majolo,
   Fernanda/0000-0002-7955-078X
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brazil
   (CAPES)CAPES [001]
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brazil (CAPES) - Finance Code 001.
CR Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568
   Back SA, 2014, ANN NEUROL, V75, P469, DOI 10.1002/ana.24132
   BARTHOLOMA A, 1994, MECH DEVELOP, V48, P217, DOI 10.1016/0925-4773(94)90061-2
   Baybis M, 2004, ANN NEUROL, V56, P478, DOI 10.1002/ana.20211
   Blumcke I, 2011, EPILEPSIA, V52, P158, DOI 10.1111/j.1528-1167.2010.02777.x
   Buss RR, 2006, ANNU REV NEUROSCI, V29, P1, DOI 10.1146/annurev.neuro.29.051605.112800
   Castejon OJ., 2008, ASTRODATA MARACAIBO, P17
   Cepeda C, 2006, EPILEPSY BEHAV, V9, P219, DOI 10.1016/j.yebeh.2006.05.012
   Crino PB, 2001, NEUROLOGY, V56, P906, DOI 10.1212/WNL.56.7.906
   Crino PB, 2011, TRENDS MOL MED, V17, P734, DOI 10.1016/j.molmed.2011.07.008
   Gonzalez AM, 1996, PEDIATR RES, V39, P375, DOI 10.1203/00006450-199603000-00001
   Guerrini R., 2015, EPILEPTOLOGIE, V32, P129
   Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5
   Kabat J, 2012, POL J RADIOL, V77, P35, DOI 10.12659/PJR.882968
   Kriegstein AR, 2004, TRENDS NEUROSCI, V27, P392, DOI 10.1016/j.tins.2004.05.001
   Kristiansen M, 2014, CELL DEATH DIFFER, V21, P1025, DOI 10.1038/cdd.2014.47
   Kuzniecky R, 2015, CURR OPIN NEUROL, V28, P151, DOI 10.1097/WCO.0000000000000175
   Lee JH, 2012, NAT GENET, V44, P941, DOI 10.1038/ng.2329
   Li YY, 2017, J BIOL CHEM, V292, P19590, DOI 10.1074/jbc.M117.796383
   Ljungberg MC, 2006, ANN NEUROL, V60, P420, DOI 10.1002/ana.20949
   LOPES A. C. P., 1999, MEDICINA RIBEIRAO PR, V32, P167
   MAGLIOCCO AM, 1992, ARCH PATHOL LAB MED, V116, P181
   Majolo F, 2018, INT J DEV NEUROSCI, V69, P112, DOI 10.1016/j.ijdevneu.2018.07.006
   Marin-Valencia I, 2014, EPILEPSIA, V55, P970, DOI 10.1111/epi.12650
   Marinowic DR, 2017, MOL MED REP, V15, P2049, DOI 10.3892/mmr.2017.6264
   McClendon E, 2014, ANN NEUROL, V75, P508, DOI 10.1002/ana.24100
   Metin C, 2006, EUR J NEUROSCI, V23, P894, DOI 10.1111/j.1460-9568.2006.04630.x
   Najm IM, 2007, EPILEPSIA, V48, P21, DOI 10.1111/j.1528-1167.2007.01064.x
   OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321
   Palmini A, 2004, NEUROLOGY, V62, pS2, DOI 10.1212/01.WNL.0000114507.30388.7E
   Pang T, 2008, NEUROLOGIST, V14, P181, DOI 10.1097/NRL.0b013e31816606b9
   Parrini E, 2017, HUM MUTAT, V38, P216, DOI 10.1002/humu.23149
   Poduri A, 2013, SCIENCE, V341, P43, DOI 10.1126/science.1237758
   Rossini L, 2017, EPILEPSY RES, V129, P146, DOI 10.1016/j.eplepsyres.2016.12.002
   Rowland NC, 2012, J NEUROSURG, V116, P1035, DOI 10.3171/2012.1.JNS111105
   Sarnat H, 2012, FOLIA NEUROPATHOL, V50, P330, DOI 10.5114/fn.2012.32363
   Sarnat HB, 2015, BRAIN DEV-JPN, V37, P553, DOI 10.1016/j.braindev.2014.08.010
   Sarnat HB, 2015, PEDIATR NEUROL, V52, P473, DOI 10.1016/j.pediatrneurol.2015.01.020
   Sarnat HB, 2015, CELL TISSUE RES, V359, P279, DOI 10.1007/s00441-014-1988-4
   Sarnat HB, 2014, PROG BRAIN RES, V213, P181, DOI 10.1016/B978-0-444-63326-2.00010-7
   Sarnat HB, 2013, CLIN NEUROPATHOL, V32, P255, DOI 10.5414/NP300588
   Sarnat HB, 2010, J NEUROPATH EXP NEUR, V69, P234, DOI 10.1097/NEN.0b013e3181d0151f
   Sarnat HB., 1992, CEREBRAL DYSGENESES
   Sato R, 2010, ARCH BIOCHEM BIOPHYS, V501, P177, DOI 10.1016/j.abb.2010.06.004
   Schick V, 2007, EPILEPSIA, V48, P65, DOI 10.1111/j.1528-1167.2007.01291.x
   Shen Q, 2002, DEVELOPMENT, V129, P4843
   SHIMIZU C, 1995, EUR J BIOCHEM, V229, P239, DOI 10.1111/j.1432-1033.1995.0239l.x
   Song Shijie, 2008, V438, P123, DOI 10.1007/978-1-59745-133-8_11
   Takei N, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00028
   TAYLOR DC, 1971, J NEUROL NEUROSUR PS, V34, P369, DOI 10.1136/jnnp.34.4.369
   Uittenbogaard M, 2005, J NEUROCHEM, V92, P585, DOI 10.1111/j.1471-4159.2004.02886.x
   Uittenbogaard M, 2010, ASN NEURO, V2, DOI 10.1042/AN20100005
   Uittenbogaard M, 2010, J NEUROSCI RES, V88, P33, DOI 10.1002/jnr.22182
   WRIGHT LL, 1983, J NEUROCYTOL, V12, P727, DOI 10.1007/BF01258147
   Yasin SA, 2010, ACTA NEUROPATHOL, V120, P85, DOI 10.1007/s00401-010-0677-y
   Ying Z, 2005, EPILEPSIA, V46, P1716, DOI 10.1111/j.1528-1167.2005.00276.x
   Zhou X, 1996, HEARING RES, V93, P147, DOI 10.1016/0378-5955(95)00222-7
NR 57
TC 2
Z9 2
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD JUN 1
PY 2019
VL 408
BP 81
EP 90
DI 10.1016/j.neuroscience.2019.03.025
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA IB2QL
UT WOS:000470113700008
PM 30902678
DA 2020-12-08
ER

PT J
AU do Prado-Lima, PAS
   Onsten, GA
   de Oliveira, GN
   Brito, GC
   Ghilardi, IM
   de Souza, EV
   dos Santos, PG
   Salamoni, SD
   Machado, DC
   Duarte, MMF
   Barbisan, F
   da Cruz, IBM
   Costa-Ferro, ZSM
   daCosta, JC
AF Schmidt do Prado-Lima, Pedro Antonio
   Onsten, Guilherme Ary
   de Oliveira, Gutierre Neves
   Brito, Guilherme Camargo
   Ghilardi, Isadora Machado
   de Souza, Eduardo Vieira
   dos Santos, Paula Gabrielli
   Salamoni, Simone Denise
   Machado, Denise Cantarelli
   Frescura Duarte, Marta Medeiros
   Barbisan, Fernanda
   Manica da Cruz, Ivana Beatrice
   Munhoz Costa-Ferro, Zaquer Suzana
   daCosta, Jaderson Costa
TI The antidepressant effect of bone marrow mononuclear cell
   transplantation in chronic stress
SO JOURNAL OF PSYCHOPHARMACOLOGY
LA English
DT Article
DE Depression; bone marrow mononuclear cells; escitalopram; chronic stress
ID MAJOR DEPRESSIVE DISORDER; OXIDATIVE DAMAGE; INFLAMMATION; BRAIN;
   METAANALYSIS; CYTOKINE; DISEASE; PROTEIN; MODEL
AB Background: Inflammation could be a risk factor for the development of depression and change the outcome of this common chronic-recurrent mental disorder.
   Aims: This study aimed to investigate if bone marrow mononuclear cell (BMMC) transplantation is effective in restoring sucrose preference in rats subjected to chronic stress (CS), if it has an anti-inflammatory effect and is able to restore damaged DNA.
   Methods: The effect of BMMC transplantation was studied in a controlled protocol (compared with a control group and a selective serotonin reuptake inhibitor escitalopram group) involving sucrose preference in CS in rats. Measurements were taken of the amygdala, hippocampus, frontal cortex, and other brain areas, the spleen and blood pro-inflammatory cytokines, namely interleukin-1, interleukin-6, tumor necrosis factor-alpha, and interferon-gamma, as well as anti-inflammatory cytokine interleukin-10. Finally, 8-hydroxy-2'-deoxyguanosine (a DNA damage marker) was determined.
   Results: BMMC transplantation was as effective as escitalopram in restoring sucrose preference. It also had an anti-inflammatory effect and slightly improved damaged DNA after one week.
   Conclusions: These findings suggest administration of BMMC in rats subjected to CS restores sucrose preference, resolves inflammation in both the peripheral and central nervous system, as well as diminishes DNA damage. This effect was similar to that of escitalopram, which is effective in the treatment of depressive patients.
C1 [Schmidt do Prado-Lima, Pedro Antonio; Onsten, Guilherme Ary; de Oliveira, Gutierre Neves; Brito, Guilherme Camargo; Ghilardi, Isadora Machado; de Souza, Eduardo Vieira; dos Santos, Paula Gabrielli; Salamoni, Simone Denise; Machado, Denise Cantarelli; Munhoz Costa-Ferro, Zaquer Suzana; daCosta, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst BraIns, Porto Alegre, RS, Brazil.
   [Frescura Duarte, Marta Medeiros; Barbisan, Fernanda; Manica da Cruz, Ivana Beatrice] Univ Fed Santa Maria, Ctr Ciencias Saude, Lab Biogen, Santa Maria, RS, Brazil.
RP daCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Brain Inst, Ave Ipiranga 6690, Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI de Oliveira, Gutierre Neves/O-7380-2016; Barbisan, Fernanda/L-7854-2018;
   Costa-Ferro, Zaquer Suzana Munhoz/C-5875-2015; Barbisan,
   Fernanda/AAS-5551-2020; Brito, Guilherme/AAQ-9582-2020; da Cruz, Ivana
   BM/G-4329-2012; Oliveira, Gutierre N/F-5083-2017; Machado, Denise
   C/G-2852-2014
OI de Oliveira, Gutierre Neves/0000-0003-0472-2919; Costa-Ferro, Zaquer
   Suzana Munhoz/0000-0002-9120-8856; Barbisan,
   Fernanda/0000-0002-2960-7047; da Cruz, Ivana BM/0000-0003-3008-6899;
   Oliveira, Gutierre N/0000-0003-0472-2919; Machado, Denise
   C/0000-0002-9371-5886; Machado Ghilardi, Isadora/0000-0001-7094-4195;
   Brito, Guilherme/0000-0002-3421-0693
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do RS (FAPERGS);
   Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS);
   Universidade Federal de Santa Maria (UFSM); Pandurata Alimentos Ltda.;
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [PQ1A]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: This study
   was supported by Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq), Fundacao de Amparo a Pesquisa do Estado do RS
   (FAPERGS), Pontificia Universidade Catolica do Rio Grande do Sul
   (PUCRS), Universidade Federal de Santa Maria (UFSM), and Pandurata
   Alimentos Ltda. The funding organizations played no role in the design
   or conduct of the study, in data interpretation, or article writing.
   Jaderson Costa daCosta is funded by the CNPq (research productivity -
   PQ1A).
CR Baptista PPA, 2015, NEUROCHEM RES, V40, P1153, DOI 10.1007/s11064-015-1576-3
   Black CN, 2015, PSYCHONEUROENDOCRINO, V51, P164, DOI 10.1016/j.psyneuen.2014.09.025
   Borlongan CV, 2011, LEUKEMIA, V25, P1674, DOI 10.1038/leu.2011.167
   Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6
   Costa-Ferro ZSM, 2012, NEUROBIOL DIS, V46, P302, DOI 10.1016/j.nbd.2011.12.001
   Costa-Ferro ZSM, 2010, SEIZURE-EUR J EPILEP, V19, P84, DOI 10.1016/j.seizure.2009.12.003
   Souza BSD, 2012, CYTOTHERAPY, V14, P1011, DOI 10.3109/14653249.2012.684445
   Eyre H, 2012, PSYCHONEUROENDOCRINO, V37, P1397, DOI 10.1016/j.psyneuen.2012.03.019
   Forlenza MJ, 2006, PSYCHOSOM MED, V68, P1, DOI 10.1097/01.psy.0000195780.37277.2a
   Janakiraman U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146671
   Jayatissa MN, 2006, NEUROPSYCHOPHARMACOL, V31, P2395, DOI 10.1038/sj.npp.1301041
   Katon W, 2008, J GEN INTERN MED, V23, P1571, DOI 10.1007/s11606-008-0731-9
   Kohler CA, 2017, ACTA PSYCHIAT SCAND, V135, P373, DOI 10.1111/acps.12698
   Liu JK, 1996, FASEB J, V10, P1532
   Maluach Alfred M, 2017, Chronic Stress (Thousand Oaks), V1, DOI 10.1177/2470547017724744
   Martin HL, 2009, FASEB J, V23, P3263, DOI 10.1096/fj.08-125443
   Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5
   Moylan S, 2013, MOL PSYCHIATR, V18, P595, DOI 10.1038/mp.2012.33
   Nicholson A, 2006, EUR HEART J, V27, P2763, DOI 10.1093/eurheartj/ehl338
   Pierce JL, 2019, BONE, V118, P2, DOI 10.1016/j.bone.2018.05.019
   Rosenblat JD, 2014, PROG NEURO-PSYCHOPH, V53, P23, DOI 10.1016/j.pnpbp.2014.01.013
   Russo SJ, 2013, NAT REV NEUROSCI, V14, P609, DOI 10.1038/nrn3381
   Setiawan E, 2018, LANCET PSYCHIAT, V5, P339, DOI 10.1016/S2215-0366(18)30048-8
   Slavich GM, 2014, PSYCHOL BULL, V140, P774, DOI 10.1037/a0035302
   Leal MMT, 2014, NEUROCHEM RES, V39, P259, DOI 10.1007/s11064-013-1217-7
   Venturin GT, 2011, LIFE SCI, V89, P229, DOI 10.1016/j.lfs.2011.06.006
   Willner P, 2005, NEUROPSYCHOBIOLOGY, V52, P90, DOI 10.1159/000087097
   Woelfer M, 2019, NEUROSCIENCE, V403, P93, DOI 10.1016/j.neuroscience.2018.03.034
   World Health Organization (WHO), 2017, DEPR OTH COMM MENT D, P24
   Yao JK, 2006, DIS MARKERS, V22, P83, DOI 10.1155/2006/248387
   Zanirati G, 2015, CNS NEUROSCI THER, V21, P463, DOI 10.1111/cns.12382
   Zhou M, 2018, NEUROSCIENCE, V376, P24, DOI 10.1016/j.neuroscience.2018.02.010
NR 32
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-8811
EI 1461-7285
J9 J PSYCHOPHARMACOL
JI J. Psychopharmacol.
PD MAY
PY 2019
VL 33
IS 5
BP 632
EP 639
DI 10.1177/0269881119841562
PG 8
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA IC6XG
UT WOS:000471115200009
PM 31018809
DA 2020-12-08
ER

PT J
AU Silva, RBM
   Greggio, S
   Venturin, GT
   da Costa, JC
   Gomez, MV
   Campos, MM
AF Silva, Rodrigo B. M.
   Greggio, Samuel
   Venturin, Gianina T.
   da Costa, Jaderson C.
   Gomez, Marcus V.
   Campos, Maria M.
TI Beneficial Effects of the Calcium Channel Blocker CTK 01512-2 in a Mouse
   Model of Multiple Sclerosis
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE Multiple sclerosis; Neuroinflammation; CTK 01512-2; Calcium signaling;
   Ziconotide; Fingolimod
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SPIDER
   PHONEUTRIA-NIGRIVENTER; KININ B-1; PEPTIDE PH-ALPHA-1-BETA; COGNITIVE
   IMPAIRMENT; HEMORRHAGIC CYSTITIS; PAIN MODEL; MICE; NEUROINFLAMMATION;
   VENOM
AB Voltage-gated calcium channels (VGCCs) play a critical role in neuroinflammatory diseases, such as multiple sclerosis (MS). CTK 01512-2 is a recombinant version of the peptide Ph1 derived from the spider Phoneutria nigriventer, which inhibits N-type VGCC/TRPA1-mediated calcium influx. We investigated the effects of this molecule in the mouse model of experimental autoimmune encephalomyelitis (EAE). The effects of CTK 01512-2 were compared to those displayed by ziconotidea selective N-type VGCC blocker clinically used for chronic painand fingolimoda drug employed for MS treatment. The intrathecal (i.t.) treatment with CTK 01512-2 displayed beneficial effects, by preventing nociception, body weight loss, splenomegaly, MS-like clinical and neurological scores, impaired motor coordination, and memory deficits, with an efficacy comparable to that observed for ziconotide and fingolimod. This molecule displayed a favorable profile on EAE-induced neuroinflammatory changes, including inflammatory infiltrate, demyelination, pro-inflammatory cytokine production, glial activation, and glucose metabolism in the brain and spinal cord. The recovery of spatial memory, besides a reduction of serum leptin levels, allied to central and peripheral elevation of the anti-inflammatory cytokine IL-10, was solely modulated by CTK 01512-2, dosed intrathecally. The intravenous (i.v.) administration of CTK 01512-2 also reduced the EAE-elicited MS-like symptoms, similarly to that seen in animals that received fingolimod orally. Ziconotide lacked any significant effect when dosed by i.v. route. Our results indicate that CTK 01512-2 greatly improved the neuroinflammatory responses in a mouse model of MS, with a higher efficacy when compared to ziconotide, pointing out this molecule as a promising adjuvant for MS management.
C1 [Silva, Rodrigo B. M.; Campos, Maria M.] Pontificia Univ Catolica Rio Grande do Sul, Escola Med, Programa Posgrad Med & Ciencias Saude, BR-90619900 Porto Alegre, RS, Brazil.
   [Silva, Rodrigo B. M.; Campos, Maria M.] Pontificia Univ Catolica Rio Grande do Sul, Escola Ciencias Saude, Ctr Toxicol & Farmacol, Ave Ipiranga 6681, BR-90619900 Porto Alegre, RS, Brazil.
   [Greggio, Samuel; Venturin, Gianina T.; da Costa, Jaderson C.] Pontificia Univ Catolica Rio Grande do Sul, Ctr Pesquisa Preclin, Inst Cerebro Rio Grande do Sul, Brain Inst BraIns, BR-90610000 Porto Alegre, RS, Brazil.
   [Greggio, Samuel] Pontificia Univ Catolica Rio Grande do Sul, Escola Ciencias Saude, Curso Grad Biomed, BR-90619900 Porto Alegre, RS, Brazil.
   [Gomez, Marcus V.] Inst Ensino & Pesquisa Santa Casa Belo Horizonte, Nucleo Posgrad, BR-30150240 Belo Horizonte, MG, Brazil.
   [Campos, Maria M.] Pontificia Univ Catolica Rio Grande do Sul, Escola Ciencias Saude, Curso Grad Odontol, BR-90619900 Porto Alegre, RS, Brazil.
   [Campos, Maria M.] Pontificia Univ Catolica Rio Grande do Sul, Escola Ciencias Saude, Programa Posgrad Odontol, BR-90619900 Porto Alegre, RS, Brazil.
RP Campos, MM (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Escola Med, Programa Posgrad Med & Ciencias Saude, BR-90619900 Porto Alegre, RS, Brazil.; Campos, MM (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Escola Ciencias Saude, Ctr Toxicol & Farmacol, Ave Ipiranga 6681, BR-90619900 Porto Alegre, RS, Brazil.; Campos, MM (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Escola Ciencias Saude, Curso Grad Odontol, BR-90619900 Porto Alegre, RS, Brazil.; Campos, MM (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Escola Ciencias Saude, Programa Posgrad Odontol, BR-90619900 Porto Alegre, RS, Brazil.
EM camposmmartha@yahoo.com
RI Greggio, Samuel/E-1498-2013; Silva, Rodrigo BM/O-7441-2017; Campos,
   Maria Martha M/J-8829-2015
OI Greggio, Samuel/0000-0002-5187-0335; Silva, Rodrigo
   BM/0000-0001-6284-7387; Campos, Maria Martha M/0000-0002-1153-3633;
   Campos, Maria/0000-0001-7738-9892
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)-AUX-PE Toxinologia; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq) [303842-2014-8]; Pontificia
   Universidade Catolica do Rio Grande do Sul (PUCRS); Financiadora de
   Estudos e Projetos (FINEP), BrazilCiencia Tecnologia e Inovacao (FINEP)
   [01.11.0014-00]; CAPESCAPES
FX This work was supported by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES)-AUX-PE Toxinologia, Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), and Pontificia
   Universidade Catolica do Rio Grande do Sul (PUCRS), in addition to a
   Financiadora de Estudos e Projetos (FINEP) research grant "Implantacao,
   Modernizacao e Qualificacao de Estrutura de Pesquisa da PUCRS"
   (PUCRSINFRA) #01.11.0014-00, Brazil. Rodrigo B. M. Silva is a
   pharmacology PhD student receiving grants from CAPES. Maria M. Campos is
   a researcher career awardee of CNPq (303842-2014-8).
CR Baptista PPA, 2015, NEUROCHEM RES, V40, P1153, DOI 10.1007/s11064-015-1576-3
   Amor S, 2012, MULT SCLER RELAT DIS, V1, P111, DOI 10.1016/j.msard.2012.01.003
   Assini FL, 2009, BEHAV BRAIN RES, V204, P206, DOI 10.1016/j.bbr.2009.06.005
   Balasa RI, 2017, CNS NEUROL DISORD-DR, V16, P1018, DOI 10.2174/1871527316666170807130632
   Becher B, 2017, NAT REV IMMUNOL, V17, P49, DOI 10.1038/nri.2016.123
   Bergantin LB, 2016, EUR J PHARMACOL, V788, P255, DOI 10.1016/j.ejphar.2016.06.034
   Bhat S, 2012, PROG NEUROBIOL, V99, P1, DOI 10.1016/j.pneurobio.2012.06.001
   Bourinet E, 2017, NEUROPHARMACOLOGY, V127, P109, DOI 10.1016/j.neuropharm.2016.10.016
   Buck D, 2012, J NUCL MED, V53, P1269, DOI 10.2967/jnumed.111.102608
   Cassidy RM, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00104
   Chakroborty S, 2014, EUR J PHARMACOL, V739, P83, DOI 10.1016/j.ejphar.2013.11.012
   Chiaravalloti ND, 2008, LANCET NEUROL, V7, P1139, DOI 10.1016/S1474-4422(08)70259-X
   Dendrou CA, 2016, NAT REV NEUROL, V12, P685, DOI 10.1038/nrneurol.2016.171
   Diniz DM, 2014, PHARMACOL BIOCHEM BE, V126, P97, DOI 10.1016/j.pbb.2014.09.017
   Domingues HS, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00071
   Duggan PJ, 2015, TOXINS, V7, P4175, DOI 10.3390/toxins7104175
   Dutra RC, 2013, BRAIN BEHAV IMMUN, V33, P90, DOI 10.1016/j.bbi.2013.06.002
   Dutra RC, 2013, NEUROBIOL DIS, V54, P82, DOI 10.1016/j.nbd.2013.02.007
   Fairless R, 2014, CELL TISSUE RES, V357, P455, DOI 10.1007/s00441-013-1758-8
   Farjam M, 2015, J NEUROL SCI, V358, P22, DOI 10.1016/j.jns.2015.09.346
   Farrokhi M, 2016, IMMUNOL INVEST, V45, P328, DOI 10.3109/08820139.2016.1157811
   Felix R, 2006, NEUROMOL MED, V8, P307, DOI 10.1385/NMM:8:3:307
   Fernandes ES, 2005, BRIT J PHARMACOL, V146, P209, DOI 10.1038/sj.bjp.0706327
   Freitas RDS, 2016, J NUTR BIOCHEM, V27, P219, DOI 10.1016/j.jnutbio.2015.09.007
   Giovannoni G, 2016, MULT SCLER RELAT DIS, V9, pS5, DOI 10.1016/j.msard.2016.07.003
   Gomez MV, 2002, CELL MOL NEUROBIOL, V22, P579, DOI 10.1023/A:1021836403433
   Gong N, 2018, BRIT J PHARMACOL, V175, P2231, DOI 10.1111/bph.13930
   Hamalainen P, 2016, ACTA NEUROL SCAND, V134, P8, DOI 10.1111/ane.12650
   Hopp SC, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0262-3
   Hou HQ, 2016, INT IMMUNOPHARMACOL, V30, P171, DOI 10.1016/j.intimp.2015.11.024
   Huang BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091167
   Hutcheson J, 2015, CYTOKINE, V75, P272, DOI 10.1016/j.cyto.2015.04.004
   HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4
   Jones BL, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00116
   Kawachi I, 2017, J NEUROL NEUROSUR PS, V88, P137, DOI 10.1136/jnnp-2016-313300
   Lopez-Diego RS, 2008, NAT REV DRUG DISCOV, V7, P909, DOI 10.1038/nrd2358
   Luo C, 2017, NEUROPSYCH DIS TREAT, V13, P1661, DOI 10.2147/NDT.S140634
   Maciel IS, 2014, NEUROSCIENCE, V277, P794, DOI 10.1016/j.neuroscience.2014.07.065
   Mandolesi G, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2015.222
   Naylor C, 2016, TRENDS MOL MED, V22, P88, DOI 10.1016/j.molmed.2015.12.001
   Nicoletti NF, 2017, TOXICON, V129, P58, DOI 10.1016/j.toxicon.2017.02.001
   O'Connelln K, 2014, MULT SCLER RELAT DIS, V3, P678, DOI 10.1016/j.msard.2014.09.002
   Ochoa-Reparaz J, 2007, J IMMUNOL, V178, P1791, DOI 10.4049/jimmunol.178.3.1791
   Oliva-Moreno J, 2017, PHARMACOECONOMICS, V35, P331, DOI 10.1007/s40273-016-0468-y
   Olsson T, 2017, NAT REV NEUROL, V13, P25, DOI 10.1038/nrneurol.2016.187
   Palhares MR, 2017, LIFE SCI, V182, P122, DOI 10.1016/j.lfs.2017.06.018
   Payne C, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008427.pub3
   Perlman S, 2017, J NEUROIMMUNOL, V308, P6, DOI 10.1016/j.jneuroim.2017.01.001
   Pringos E, 2011, TOXINS, V3, P17, DOI 10.3390/toxins3010017
   Quancard J, 2012, CHEM BIOL, V19, P1142, DOI 10.1016/j.chembiol.2012.07.016
   Quintao NLM, 2008, J NEUROSCI, V28, P2856, DOI 10.1523/JNEUROSCI.4389-07.2008
   Radu CG, 2007, P NATL ACAD SCI USA, V104, P1937, DOI 10.1073/pnas.0610544104
   Rigo FK, 2013, CANCER SCI, V104, P1226, DOI 10.1111/cas.12209
   Rosa F, 2014, ANESTH ANALG, V119, P196, DOI 10.1213/ANE.0000000000000249
   Rynda A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008720
   Sama DM, 2013, AGEING RES REV, V12, P982, DOI 10.1016/j.arr.2013.05.008
   Schampel A, 2017, P NATL ACAD SCI USA, V114, pE3295, DOI 10.1073/pnas.1620052114
   Schwartz M, 2016, TRENDS IMMUNOL, V37, P668, DOI 10.1016/j.it.2016.08.001
   Silva RBM, 2015, BRIT J PHARMACOL, V172, P924, DOI 10.1111/bph.12966
   Simmons SB, 2013, TRENDS IMMUNOL, V34, P410, DOI 10.1016/j.it.2013.04.006
   Sinmaz N, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0678-4
   Thell K, 2016, P NATL ACAD SCI USA, V113, P3960, DOI 10.1073/pnas.1519960113
   Tian DH, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00168
   Tokuhara N, 2010, J BIOL CHEM, V285, P33294, DOI 10.1074/jbc.M109.089805
   Tonello R, 2017, BRIT J PHARMACOL, V174, P57, DOI 10.1111/bph.13652
   Tonello R, 2014, J PAIN, V15, P619, DOI 10.1016/j.jpain.2014.02.007
   Tsagareli MG, 2012, NEURAL REGEN RES, V7, P1029, DOI 10.3969/j.issn.1673-5374.2012.13.010
   Zamponi GW, 2016, NAT REV DRUG DISCOV, V15, P19, DOI 10.1038/nrd.2015.5
   Zhan CY, 2015, ADV DRUG DELIVER REV, V90, P101, DOI 10.1016/j.addr.2015.04.025
NR 69
TC 21
Z9 21
U1 3
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD DEC
PY 2018
VL 55
IS 12
BP 9307
EP 9327
DI 10.1007/s12035-018-1049-1
PG 21
WC Neurosciences
SC Neurosciences & Neurology
GA GY3VF
UT WOS:000448483400038
PM 29667130
DA 2020-12-08
ER

PT J
AU Catarina, AV
   Luft, C
   Greggio, S
   Venturin, GT
   Ferreira, F
   Marques, EP
   Rodrigues, L
   Wartchow, K
   Leite, MC
   Goncalves, CA
   Wyse, ATS
   Da Costa, JC
   De Oliveira, JR
   Branchini, G
   Nunes, FB
AF Catarina, Anderson V.
   Luft, Carolina
   Greggio, Samuel
   Venturin, Gianina T.
   Ferreira, Fernanda
   Marques, Eduardo P.
   Rodrigues, Leticia
   Wartchow, Krista
   Leite, Marina C.
   Goncalves, Carlos A.
   Wyse, Angela T. S.
   Da Costa, Jaderson C.
   De Oliveira, Jarbas R.
   Branchini, Gisele
   Nunes, Fernanda B.
TI Fructose-1,6-bisphosphate preserves glucose metabolism integrity and
   reduces reactive oxygen species in the brain during experimental sepsis
SO BRAIN RESEARCH
LA English
DT Article
DE Sepsis; Encephalopathy; Brain metabolism; Fructose-1,6-bisphosphate;
   Oxidative stress
ID NEURON-SPECIFIC ENOLASE; FRUCTOSE 1,6-DIPHOSPHATE; ALZHEIMERS-DISEASE;
   SEPTIC SHOCK; ENDOTHELIAL DYSFUNCTION; COGNITIVE IMPAIRMENT; SIGNALING
   PATHWAY; OXIDATIVE STRESS; UNITED-STATES; ACTIVATION
AB Sepsis is one of the main causes of hospitalization and mortality in Intensive Care Units. One of the first manifestations of sepsis is encephalopathy, reported in up to 70% of patients, being associated with higher mortality and morbidity. The factors that cause sepsis-associated encephalopathy (SAE) are still not well known, and may be multifactorial, as perfusion changes, neuroinflammation, oxidative stress and glycolytic metabolism alterations. Fructose-1,6-bisphosphate (FBP), a metabolite of the glycolytic route, has been reported as neuroprotective agent. The present study used an experimental sepsis model in C57BL/6 mice. We used in vivo brain imaging to evaluate glycolytic metabolism through microPET scans and the radiopharmaceutical (18) F-fluoro-2-deoxy-D-glucose (F-18-FDG). Brain images were obtained before and 12 h after the induction of sepsis in animals with and without FBP treatment. We also evaluated the treatment effects in the brain oxidative stress by measuring the production of reactive oxygen species (ROS), the activity of catalase (CAT) and glutathione peroxidase (GPx), and the levels of fluorescent marker 2'7'-dichlorofluorescein diacetate (DCF). There was a significant decrease in brain glucose metabolism due to experimental sepsis. A significant protective effect of FBP treatment was observed in the cerebral metabolic outcomes. FBP also modulated the production of ROS, evidenced by reduced CAT activity and lower levels of DCF. Our results suggest that FBP may be a possible candidate in the treatment of SAE. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Catarina, Anderson V.; Branchini, Gisele; Nunes, Fernanda B.] UFCSPA, Programa Posgrad Patol, BR-90050170 Porto Alegre, RS, Brazil.
   [Luft, Carolina; De Oliveira, Jarbas R.; Nunes, Fernanda B.] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Lab Biofis Celular & Inflamacao, Porto Alegre, RS, Brazil.
   [Greggio, Samuel; Venturin, Gianina T.; Da Costa, Jaderson C.] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Inst Cerebro Rio Grande do Sul, Brain Inst Brains, Ctr Pesquisa Preclin, Porto Alegre, RS, Brazil.
   [Ferreira, Fernanda; Marques, Eduardo P.; Wyse, Angela T. S.] Univ Fed Rio Grande do Sul, Dept Bioquim, Lab Neuroprotecao & Doencas Neurometab, Dept Bioquim, Porto Alegre, RS, Brazil.
   [Rodrigues, Leticia; Wartchow, Krista; Leite, Marina C.; Goncalves, Carlos A.] Univ Fed Rio Grande do Sul, Dept Bioquim, Lab Prot Ligante Calcio Sistema Nervoso Cent, Porto Alegre, RS, Brazil.
RP Catarina, AV (corresponding author), UFCSPA, Programa Posgrad Patol, BR-90050170 Porto Alegre, RS, Brazil.
EM anderson.catarina@acad.pucrs.br
RI Greggio, Samuel/E-1498-2013; Luft, Carolina/G-1340-2017; Wyse, Angela
   TS/K-6104-2013
OI Greggio, Samuel/0000-0002-5187-0335; Luft, Carolina/0000-0001-9044-0701;
   /0000-0002-1907-6051; Wyse, Angela TS/0000-0001-8769-1147
CR AIELLO LC, 1995, CURR ANTHROPOL, V36, P199, DOI 10.1086/204350
   Alva N, 2016, CURR MED CHEM, V23, P4396, DOI 10.2174/0929867323666161014144250
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Angus DC, 2011, JAMA-J AM MED ASSOC, V306, P2614, DOI 10.1001/jama.2011.1853
   Barbosa LF, 2006, QUIM NOVA, V29, P1352, DOI 10.1590/S0100-40422006000600034
   Berg RMG, 2011, J CEREBR BLOOD F MET, V31, P1532, DOI 10.1038/jcbfm.2011.48
   BICKLER PE, 1992, STROKE, V23, P1617, DOI 10.1161/01.STR.23.11.1617
   Boisrame-Helms J, 2013, CURR VASC PHARMACOL, V11, P150
   BONE RC, 1991, CHEST, V100, P802, DOI 10.1378/chest.100.3.802
   Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701
   Chadwick J, 1950, MED WORKS HIPPOCRATE
   Chavan SS, 2012, MOL MED, V18, P930, DOI 10.2119/molmed.2012.00195
   CHLOUVERAKIS C, 1968, METABOLISM, V17, P708, DOI 10.1016/0026-0495(68)90055-3
   Chu SJ, 2002, CRIT CARE MED, V30, P1605, DOI 10.1097/00003246-200207000-00034
   Cohen Jeffrey E, 2006, Heart Lung Circ, V15, P119, DOI 10.1016/j.hlc.2005.12.004
   Cunnane S, 2011, NUTRITION, V27, P3, DOI 10.1016/j.nut.2010.07.021
   Dal-Pizzol F, 2010, NEUROCHEM RES, V35, P1, DOI 10.1007/s11064-009-0043-4
   Danielski LG, 2018, MOL NEUROBIOL, V55, P5255, DOI 10.1007/s12035-017-0706-0
   Danielski LG, 2018, MOL NEUROBIOL, V55, P1045, DOI 10.1007/s12035-016-0356-7
   Dejager L, 2011, TRENDS MICROBIOL, V19, P198, DOI 10.1016/j.tim.2011.01.001
   DIDLAKE R, 1989, J SURG RES, V47, P220, DOI 10.1016/0022-4804(89)90111-X
   Ebersoldt M, 2007, INTENS CARE MED, V33, P941, DOI 10.1007/s00134-007-0622-2
   Fahlman CS, 2002, BRAIN RES, V958, P43, DOI 10.1016/S0006-8993(02)03433-9
   FARIAS LA, 1989, AM J MED SCI, V297, P294, DOI 10.1097/00000441-198905000-00005
   FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686
   Gardener SL, 2016, J ALZHEIMERS DIS, V52, P661, DOI 10.3233/JAD-151084
   Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje
   Guimaraes LSP, 2012, REV HCPA, V32, P503
   Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x
   Hernandez G, 2013, CURR VASC PHARMACOL, V11, P161
   Hertz L, 2018, J NEUROSCI RES, V96, P757, DOI 10.1002/jnr.24192
   Hoesel LM, 2006, IMMUNOL RES, V34, P133, DOI 10.1385/IR:34:2:133
   Huerta Patricio T, 2016, Mol Med, V22, P789, DOI 10.2119/molmed.2015.00201
   Iacobone Emanuele, 2009, Crit Care Med, V37, pS331, DOI 10.1097/CCM.0b013e3181b6ed58
   Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0
   KIRTLEY ME, 1977, MOL CELL BIOCHEM, V18, P141, DOI 10.1007/BF00280279
   Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004
   Kozlov AV, 2017, BBA-MOL BASIS DIS, V1863, P2627, DOI 10.1016/j.bbadis.2016.12.020
   LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012
   Leite MC, 2009, J NEUROSCI RES, V87, P2439, DOI 10.1002/jnr.22083
   Lima KG, 2018, TOXICOL IN VITRO, V48, P11, DOI 10.1016/j.tiv.2017.12.017
   Lin Ai-Ling, 2017, Curr Nutr Rep, V6, P41, DOI 10.1007/s13668-017-0187-9
   Liu S, 2018, NEUROIMAGE-CLIN, V17, P354, DOI 10.1016/j.nicl.2017.10.038
   Liu WL, 2017, FREE RADICAL BIO MED, V112, P174, DOI 10.1016/j.freeradbiomed.2017.07.024
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Messaris E, 2004, CRIT CARE MED, V32, P1764, DOI 10.1097/01.CCM.0000135744.30137.B4
   Nguyen D. N., 2014, BIOMED RES INT, V20, P712
   Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49
   Nunes FB, 2002, CRIT CARE MED, V30, P2069, DOI 10.1097/00003246-200209000-00020
   Osier W, 1892, PRINCIPLES PRACTICE
   Pasechnik I N, 2015, Khirurgiia (Mosk), P18, DOI 10.17116/hirurgia20151218-23
   Pedrazza L, 2014, INFLAMM RES, V63, P719, DOI 10.1007/s00011-014-0745-1
   Peters K, 2003, CARDIOVASC RES, V60, P49, DOI 10.1016/S0008-6363(03)00397-3
   Pfister D, 2008, CRIT CARE, V12, DOI 10.1186/cc6891
   Polito A, 2013, CRIT CARE, V17, DOI 10.1186/cc12899
   Quartin AA, 1997, JAMA-J AM MED ASSOC, V277, P1058, DOI 10.1001/jama.277.13.1058
   Reiman EM, 2001, P NATL ACAD SCI USA, V98, P3334, DOI 10.1073/pnas.061509598
   Ruokonen E, 2002, ANN MED, V34, P590, DOI 10.1080/078538902321117814
   Sales Júnior João Andrade L., 2006, Rev. bras. ter. intensiva, V18, P9, DOI 10.1590/S0103-507X2006000100003
   SCHINETTI ML, 1986, BIOCHEM PHARMACOL, V35, P1762, DOI 10.1016/0006-2952(86)90338-2
   Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38
   Sharshar T, 2014, INTENS CARE MED, V40, P484, DOI 10.1007/s00134-014-3214-y
   Silva E, 2004, CRIT CARE, V8, pR251, DOI 10.1186/cc2892
   Silva RBM, 2018, MOL NEUROBIOL, V55, P9307, DOI 10.1007/s12035-018-1049-1
   Silvestre F, 2014, NEUROTOX RES, V26, P382, DOI 10.1007/s12640-014-9475-y
   Sola A, 1996, BRAIN RES, V741, P294, DOI 10.1016/S0006-8993(96)00984-5
   Sola A, 2003, J LEUKOCYTE BIOL, V73, P74, DOI 10.1189/jlb.0602299
   Sonneville R, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-15
   Stranahan AM, 2012, J ALZHEIMERS DIS, V30, pS5, DOI 10.3233/JAD-2011-110899
   Su YJ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0336-2
   Suchyta MR, 2010, BRAIN IMAGING BEHAV, V4, P22, DOI 10.1007/s11682-009-9082-3
   Taccone F. S., 2010, CRIT CARE, V14, P28
   Taccone FS, 2013, CURR VASC PHARMACOL, V11, P170
   Taccone FS, 2010, NEUROCRIT CARE, V12, P35, DOI 10.1007/s12028-009-9289-6
   Takeuchi K, 1998, J THORAC CARDIOV SUR, V116, P335, DOI 10.1016/S0022-5223(98)70135-7
   Tsai MY, 2017, STAT MED, V36, P1319, DOI 10.1002/sim.7207
   Tsuruta R, 2016, J INTENSIVE CARE, V4, DOI 10.1186/s40560-016-0145-4
   Victor VM, 2004, INT IMMUNOPHARMACOL, V4, P327, DOI 10.1016/j.intimp.2004.01.020
   Wendel A, 1981, Methods Enzymol, V77, P325
   Widmann CN, 2014, LANCET NEUROL, V13, P630, DOI 10.1016/S1474-4422(14)70017-1
   Wilson JX, 2003, CAN J NEUROL SCI, V30, P98, DOI 10.1017/S031716710005335X
   Winterbourn CC, 2013, METHOD ENZYMOL, V528, P3, DOI 10.1016/B978-0-12-405881-1.00001-X
   Yao B, 2014, NEUROCHEM RES, V39, P1263, DOI 10.1007/s11064-014-1308-0
   Zanirati G, 2018, EPILEPSIA, V59, P923, DOI 10.1111/epi.14057
NR 84
TC 6
Z9 6
U1 1
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD NOV 1
PY 2018
VL 1698
BP 54
EP 61
DI 10.1016/j.brainres.2018.06.024
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA GW6YE
UT WOS:000447110200005
PM 29932894
DA 2020-12-08
ER

PT J
AU Majolo, F
   Marinowic, DR
   Machado, DC
   da Costa, JC
AF Majolo, F.
   Marinowic, D. R.
   Machado, D. C.
   da Costa, Jaderson Costa
TI Notch signaling in human iPS-derived neuronal progenitor lines from
   Focal Cortical Dysplasia patients
SO INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE
LA English
DT Article
DE Focal cortical dysplasia type II; Drug refractory; Induced puluripotent
   stem cell (iPSCs); Neurodifferenciation; Cortical malformation
ID REGULATE MAINTENANCE; SYNAPTIC PLASTICITY; SOMATIC MUTATIONS; CELLS;
   ACTIVATION; PATHWAY; MTOR; HES1; DIFFERENTIATION; CLASSIFICATION
AB Focal Cortical Dysplasia (FCD), a common type of Malformations of cortical development, may result from an early disturbance in the migration and final arrangement of the cortical architecture of immature neurons. FCD type II is now known to be due to a post-zygotic somatic mutation that involves the mTOR and AKT pathways. The aim of the present study was to investigate the possible differences in neurogenesis and neurodifferentiation of iPSCs (induced pluripotent stem cells) from fibroblasts of individuals affected by FCD type II (2) and normal individuals (2). iPSCs were generated from skin fibroblasts of FCD individuals and healthy individuals. The reprogramming was done through the fibroblasts exposure to viral vectors containing the OCT4, KLF4, SOX2, and c-MYC genes and the clones were characterized by immunohistochemistry. iPSCs were neurodifferentiated and analyzed at the 14th, 22nd and 35th days. We also analyzed the cerebral cortex tissue, fibroblasts and iPSCs cells from the individuals. Through qRT-PCR, the expression of 4 genes involved in Notch signaling process were quantified. In general, individuals with dysplasia presented increase and decrease in the relative quantification in the most genes analyzed compared to control individuals in all processes and study groups. We suggest that, during embryonic neurogenesis, the neural precursor cells of FCD type II individuals present increase and decrease in gene expression in the Notch signaling pathway causing cortical formation disorders and can be seen as a candidate for the developmental changes observed in the cerebral cortex of individuals with FCD type II. This altered gene expression may be related to brain formation with dysplasia.
C1 [Majolo, F.; Marinowic, D. R.; Machado, D. C.; da Costa, Jaderson Costa] Brain Inst Rio Grande do Sul BraIns, Porto Alegre, RS, Brazil.
RP Majolo, F (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Postgrad Program Med & Hlth Sci, BR-90610000 Porto Alegre, RS, Brazil.
EM femanda.majolo@acad.pucrs.br; dmarinowic@gmail.com; dcm@pucrs.br
RI Machado, Denise C/G-2852-2014; Majolo, Fernanda/S-5732-2018
OI Machado, Denise C/0000-0002-9371-5886; Majolo,
   Fernanda/0000-0002-7955-078X
FU CNPqNational Council for Scientific and Technological Development (CNPq)
FX We thank to CNPq for the support.
CR Bai G, 2007, DEV CELL, V13, P283, DOI 10.1016/j.devcel.2007.05.014
   Baybis M, 2004, ANN NEUROL, V56, P478, DOI 10.1002/ana.20211
   Blumcke I, 2011, EPILEPSIA, V52, P158, DOI 10.1111/j.1528-1167.2010.02777.x
   Breunig JJ, 2007, P NATL ACAD SCI USA, V104, P20558, DOI 10.1073/pnas.0710156104
   Cotter D, 1999, ACTA NEUROPATHOL, V98, P465, DOI 10.1007/s004010051111
   Crino PB, 2011, TRENDS MOL MED, V17, P734, DOI 10.1016/j.molmed.2011.07.008
   de Bivort BL, 2009, J NEUROGENET, V23, P395, DOI 10.3109/01677060902878481
   Hashimoto-Torii K, 2008, NEURON, V60, P273, DOI 10.1016/j.neuron.2008.09.026
   Imayoshi I, 2011, MOL NEUROBIOL, V44, P7, DOI 10.1007/s12035-011-8186-0
   Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0
   Kobayashi T, 2010, GENES CELLS, V15, P689, DOI 10.1111/j.1365-2443.2010.01413.x
   Kubetzko FBB, 2004, CARCINOGENESIS, V25, P1839, DOI 10.1093/carcin/bgh190
   Lathia JD, 2008, J NEUROCHEM, V107, P1471, DOI 10.1111/j.1471-4159.2008.05715.x
   Lee JH, 2012, NAT GENET, V44, P941, DOI 10.1038/ng.2329
   Lim JS, 2015, NAT MED, V21, P395, DOI 10.1038/nm.3824
   Ljungberg MC, 2006, ANN NEUROL, V60, P420, DOI 10.1002/ana.20949
   Marinowic DR, 2017, MOL MED REP, V15, P2049, DOI 10.3892/mmr.2017.6264
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Palmini A, 2004, NEUROLOGY, V62, pS2, DOI 10.1212/01.WNL.0000114507.30388.7E
   Pascual-Castroviejo I, 2012, NEUROLOGIA, V27, P472, DOI 10.1016/j.nrl.2011.10.012
   Pfeffer PL, 1998, DEVELOPMENT, V125, P3063
   Poduri A, 2013, SCIENCE, V341, P43, DOI 10.1126/science.1237758
   Poduri A, 2012, NEURON, V74, P41, DOI 10.1016/j.neuron.2012.03.010
   Rowland NC, 2012, J NEUROSURG, V116, P1035, DOI 10.3171/2012.1.JNS111105
   Sakamoto M, 2003, J BIOL CHEM, V278, P44808, DOI 10.1074/jbc.M300448200
   Sarnat H. B., 2015, TXB AND ATLAS
   Sato R, 2010, ARCH BIOCHEM BIOPHYS, V501, P177, DOI 10.1016/j.abb.2010.06.004
   Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5
   Schick V, 2007, EPILEPSIA, V48, P65, DOI 10.1111/j.1528-1167.2007.01291.x
   Shimojo H, 2008, NEURON, V58, P52, DOI 10.1016/j.neuron.2008.02.014
   Sisodiya SM, 2004, LANCET NEUROL, V3, P29, DOI 10.1016/S1474-4422(03)00620-3
   Takei N., 2014, FRONT MOL NEUROSCI, V7, DOI [10.3389/fnmo1.2014, DOI 10.3389/FNMO1.2014]
   Whitford KL, 2002, ANNU REV NEUROSCI, V25, P127, DOI 10.1146/annurev.neuro.25.112701.142932
   Whitford KL, 2002, NEURON, V33, P47, DOI 10.1016/S0896-6273(01)00566-9
   Wu ZQ, 2017, CEREB CORTEX, V27, P1369, DOI 10.1093/cercor/bhv318
   Zhang SB, 2014, NEOPLASIA, V16, P158, DOI 10.1593/neo.131870
NR 36
TC 3
Z9 3
U1 2
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0736-5748
EI 1873-474X
J9 INT J DEV NEUROSCI
JI Int. J. Dev. Neurosci.
PD OCT
PY 2018
VL 69
BP 112
EP 118
DI 10.1016/j.ijdevneu.2018.07.006
PG 7
WC Developmental Biology; Neurosciences
SC Developmental Biology; Neurosciences & Neurology
GA GT6VT
UT WOS:000444659700014
PM 30048676
DA 2020-12-08
ER

PT J
AU Andrade, MA
   Borelli, WV
   Araujo, AS
   Matushita, CS
   Hartmann, LM
   da Silva, AM
   da Costa, JC
AF Andrade, M. A.
   Borelli, W. V.
   Araujo, A. S.
   Matushita, C. S.
   Hartmann, L. M.
   Marques da Silva, A.
   da Costa, J. C.
TI Evaluation of Different Methods for SUVR Calculations to Classify
   Subjects in [C-11]PiB PET Imaging
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Meeting Abstract
CT 31st Annual Congress of the European-Association-of-Nuclear-Medicine
   (EANM)
CY OCT 13-17, 2018
CL Dusseldorf, GERMANY
SP European Assoc Nucl Med
C1 [Andrade, M. A.; Borelli, W. V.; Araujo, A. S.; Marques da Silva, A.; da Costa, J. C.] Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre, RS, Brazil.
   [Andrade, M. A.; Borelli, W. V.; Matushita, C. S.; Hartmann, L. M.; Marques da Silva, A.; da Costa, J. C.] Brain Inst Rio Grande Sul, Porto Alegre, RS, Brazil.
RI Borelli, Wyllians Vendramini/F-5585-2016; Borelli, Wyllians
   Vendramini/AAA-8410-2019; Borelli, Wyllians Vendramini/ABA-2075-2020
OI Borelli, Wyllians Vendramini/0000-0001-9282-0601; Borelli, Wyllians
   Vendramini/0000-0001-9282-0601; Borelli, Wyllians
   Vendramini/0000-0001-9282-0601
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1619-7070
EI 1619-7089
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD OCT
PY 2018
VL 45
SU 1
MA EP-0990
BP S705
EP S705
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA GZ3DB
UT WOS:000449266206196
DA 2020-12-08
ER

PT J
AU Radaelli, G
   Santos, FD
   Borelli, WV
   Pisani, L
   Nunes, ML
   Scorza, FA
   da Costa, JC
AF Radaelli, Graciane
   Santos, Francisco de Souza
   Borelli, Wyllians Vendramini
   Pisani, Leonardo
   Nunes, Magda Lahorgue
   Scorza, Fulvio Alexandre
   da Costa, Jaderson Costa
TI Causes of mortality in early infantile epileptic encephalopathy: A
   systematic review
SO EPILEPSY & BEHAVIOR
LA English
DT Review
DE Ohtahara syndrome; Early infantile epileptic syndrome; Suppression
   burst; Epilepsy
ID SUDDEN UNEXPECTED DEATH; SUPPRESSION-BURST; OHTAHARA SYNDROME;
   MUTATIONS; SPECTRUM
AB Introduction: Early infantile epileptic encephalopathy syndrome (EIEE), also known as Ohtahara syndrome, is an age-dependent epileptic encephalopathy syndrome defined by clinical features and electroencephalographic findings. Epileptic disorders with refractory seizures beginning in the neonatal period and/or early infancy have a potential risk of premature mortality, including sudden death. We aimed to identify the causes of death in EIEE and conducted a literature survey of fatal outcomes.
   Methods: We performed a literature search in MEDLINE, EMBASE, and Web of Science for data from inception until September 2017. The terms "death sudden," "unexplained death," "SUDEP," " lethal," and "fatal" and the medical subject heading terms " epileptic encephalopathy," "mortality," " death," " sudden infant death syndrome," and "human" were used in the search strategy. The EIEE case report studies reporting mortality were included.
   Results: The search yielded 1360 articles. After screening for titles and abstracts and removing duplicate entries, full texts of 15 articles were reviewed. After reading full texts, 11 articles met the inclusion criteria (9 articles in English and 2 in Japanese, dated from 1976 to 2015). The review comprised 38 unique cases of EIEE, 17 of which had death as an outcome. In all cases, the suppression-burst pattern on electroencephalographies (EEGs) was common. Most cases (55%) involved male infants. The mean (standard deviation [SD]) age at onset of seizure was 19.6 +/- 33 days. The mean (SD) age at death was 12.9 +/- 14.1 months. Most infants (58.8%) survived less than one year. The cause of death was described only in eight (47%) patients; the cause was pneumonia/respiratory illness or sudden unexpected death in epilepsy (SUDEP).
   Discussion: The results show EIEE as a severe disease associated with a premature mortality, evidenced by a very young age at death. Increasing interest in the detection of new molecular bases of EIEE is leading us to a better understanding of this severe disease, but well-reported data are lacking to clarify EIEE-related causes of death. (c) 2018 Elsevier Inc. All rights reserved.
C1 [Radaelli, Graciane] Fed Univ Sao Paulo UNIFESP, Paulista Sch Med, Sao Paulo, Brazil.
   [Radaelli, Graciane; Santos, Francisco de Souza; Borelli, Wyllians Vendramini; Pisani, Leonardo; Nunes, Magda Lahorgue; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst Rio Grande do Sul BraIns, Porto Alegre, RS, Brazil.
   [Scorza, Fulvio Alexandre] Univ Fed Sao Paulo, Dept Neurol & Neurosurg, Lab Neurosci, Sao Paulo, SP, Brazil.
   [Nunes, Magda Lahorgue; Scorza, Fulvio Alexandre; da Costa, Jaderson Costa] CNPq, Brasilia, DF, Brazil.
RP da Costa, JC (corresponding author), Brain Inst Rio Grande do Sul BraIns, Av Ipiranga 6690, BR-90610000 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Borelli, Wyllians Vendramini/AAA-8410-2019; Borelli, Wyllians
   Vendramini/F-5585-2016; Scorza, Fulvio/C-7048-2013; Borelli, Wyllians
   Vendramini/ABA-2075-2020
OI Borelli, Wyllians Vendramini/0000-0001-9282-0601; Borelli, Wyllians
   Vendramini/0000-0001-9282-0601; Scorza, Fulvio/0000-0002-0694-8674;
   Borelli, Wyllians Vendramini/0000-0001-9282-0601; de Souza Santos,
   Francisco/0000-0001-8208-1438
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); CNPq (Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico)National Council
   for Scientific and Technological Development (CNPq); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES;
   FAPESP/CNPq/MCT (Instituto Nacional de Neurociencia
   Translacional)National Council for Scientific and Technological
   Development (CNPq)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)
FX Our study was supported by the following grants: FAPESP (Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo); CNPq (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and FAPESP/CNPq/MCT
   (Instituto Nacional de Neurociencia Translacional).
CR Absoud M, 2010, DEV MED CHILD NEUROL, V52, P305, DOI 10.1111/j.1469-8749.2009.03470.x
   AICARDI J, 1992, CURR OPIN NEUROL NEU, V5, P344
   Al K, 1982, EARLY INFANTILE EPIL
   Asher YJT, 2012, EUR J MED GENET, V55, P299, DOI 10.1016/j.ejmg.2012.04.002
   Beal Md JC, 2012, EARLY ONSET EPILEPTI, DOI [10.1016/j.pediatrneurol.2012.06.002, DOI 10.1016/J.PEDIATRNEUROL.2012.06.002]
   CLARKE M, 1987, DEV MED CHILD NEUROL, V29, P520
   Kato M, 2007, AM J HUM GENET, V81, P361, DOI 10.1086/518903
   Kong WJ, 2015, EPILEPSIA, V56, P431, DOI 10.1111/epi.12925
   Korff CM, 2012, EUR J PAEDIATR NEURO, V16, P753, DOI 10.1016/j.ejpn.2012.05.009
   Larsen J, 2015, NEUROLOGY, V84, P480, DOI 10.1212/WNL.0000000000001211
   Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
   Mastrangelo M, 2015, PEDIATR NEUROL, V53, P119, DOI 10.1016/j.pediatrneurol.2015.04.001
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Nascimento FA, 2017, EPILEPSY BEHAV, V73, P119, DOI 10.1016/j.yebeh.2017.05.013
   Nashef L, 2012, EPILEPSIA, V53, P227, DOI 10.1111/j.1528-1167.2011.03358.x
   OHTAHARA S, 1987, BRAIN DEV-JPN, V9, P371, DOI 10.1016/S0387-7604(87)80110-9
   Ohtahara S, 2003, J CLIN NEUROPHYSIOL, V20, P398, DOI 10.1097/00004691-200311000-00003
   Ohtahara S, 1976, NO TO HATTATSU TOKYO, V8, P270, DOI [10.11251/ojjscn1969.8.270, DOI 10.11251/OJJSCN1969.8.270]
   Quan L, 2001, FORENSIC SCI INT, V124, P62, DOI 10.1016/S0379-0738(01)00568-0
   Robain O, 1992, EARLY EPILEPTIC ENDE, P162
   Cazorla MR, 2010, BRAIN DEV-JPN, V32, P673, DOI 10.1016/j.braindev.2009.08.007
   Saitsu H, 2008, NAT GENET, V40, P782, DOI 10.1038/ng.150
   Saitsu H, 2014, J HUM GENET, V59, P687, DOI 10.1038/jhg.2014.91
   Saneto RP, 2007, J CHILD NEUROL, V22, P631, DOI 10.1177/0883073807303220
   Shmuely S, 2016, EPILEPSY BEHAV, V64, P69, DOI 10.1016/j.yebeh.2016.09.007
   Sillanpaa M, 2010, LONG TERM MORTALITY, P26
   Vaher U, 2014, J CHILD NEUROL, V29, pNP202, DOI 10.1177/0883073813511300
NR 27
TC 4
Z9 4
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD AUG
PY 2018
VL 85
BP 32
EP 36
DI 10.1016/j.yebeh.2018.05.015
PG 5
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA GN4BD
UT WOS:000438956900007
PM 29906699
DA 2020-12-08
ER

PT J
AU Majolo, F
   Marinowic, DR
   Machado, DC
   Da Costa, JC
AF Majolo, Fernanda
   Marinowic, Daniel Rodrigo
   Machado, Denise Cantarelli
   Da Costa, Jaderson Costa
TI MTOR pathway in focal cortical dysplasia type 2: What do we know?
SO EPILEPSY & BEHAVIOR
LA English
DT Review
DE Drug-resistant epilepsy; Molecular and cellular biology; Pubmed
ID TUBEROUS SCLEROSIS COMPLEX; PLURIPOTENT STEM-CELLS; MAMMALIAN TARGET;
   INTRACTABLE EPILEPSY; REFRACTORY EPILEPSY; SOMATIC MUTATIONS; DYSMORPHIC
   NEURONS; RAPAMYCIN PATHWAY; BALLOON CELLS; ACTIVATION
AB Focal cortical dysplasia (FCD) is the most commonly encountered developmental malformation that causes refractory epilepsy. Focal cortical dysplasia type 2 is one of the most usual neuropathological findings in tissues resected therapeutically from patients with drug-resistant epilepsy. Unlike other types of FCD, it is characterized by laminar disorganization and dysplastic neurons, which compromise the organization of the six histologically known layers in the cortex; the morphology and/or cell location can also be altered. A comprehensive review about the pathogenesis of this disease is important because of the necessity to update the results reported over the past years. Here, we present an updated review through Pubmed about the mammalian target of rapamycin (MTOR) pathway in FCD type 2. A wide variety of aspects was covered in 44 articles related to molecular and cellular biology, including experiments in animal and human models. The first publications appeared in 2004, but there is still a lack of studies specifically for one type of FCD. With the advancement of techniques and greater access to molecular and cellular experiments, such as induced pluripotent stem cells (iPSCs) and organoids, it is believed that the trend is increasing the number of publications contributing to the achievement of new discoveries. (c) 2018 Elsevier Inc. All rights reserved.
C1 Brain Inst Rio Grande do Sul BraIns, Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Postgrad Program Med & Hlth Sci, Porto Alegre, RS, Brazil.
RP Majolo, F (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Postgrad Program Med & Hlth Sci, BR-90610000 Porto Alegre, RS, Brazil.
EM fernanda.majolo@acad.pucrs.br
RI Majolo, Fernanda/S-5732-2018; Machado, Denise C/G-2852-2014
OI Majolo, Fernanda/0000-0002-7955-078X; Machado, Denise
   C/0000-0002-9371-5886
FU CAPES-BrazilCAPES; Pontificia Universidade Catolica do Rio Grande do Sul
   (PUCRS)
FX The authors are grateful to CAPES-Brazil and the Pontificia Universidade
   Catolica do Rio Grande do Sul (PUCRS) for the scholarships for the first
   and second authors.
CR Alcantara D, 2017, BRAIN, V140, P2610, DOI 10.1093/brain/awx203
   Avansini SH, 2018, ANN NEUROL, V83, P623, DOI 10.1002/ana.25187
   Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5
   Blackmon K, 2015, CEREB CORTEX, V25, P2854, DOI 10.1093/cercor/bhu080
   Blumcke I, 2011, EPILEPSIA, V52, P158, DOI 10.1111/j.1528-1167.2010.02777.x
   Blumcke I, 2009, EPILEPTIC DISORD, V11, P181, DOI 10.1684/epd.2009.0261
   Boer K, 2010, EPILEPSY RES, V91, P84, DOI 10.1016/j.eplepsyres.2010.06.015
   Buccoliero AM, 2016, CLIN NEUROPATHOL, V35, P295, DOI 10.5414/NP300936
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Conti V, 2015, CLIN GENET, V88, P241, DOI 10.1111/cge.12476
   D'Gama AM, 2015, ANN NEUROL, V77, P720, DOI 10.1002/ana.24357
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Fatehullah A, 2016, NAT CELL BIOL, V18, P246, DOI 10.1038/ncb3312
   Grajkowska W, 2008, FOLIA NEUROPATHOL, V46, P43
   Hanai S, 2017, AM J PATHOL, V187, P1177, DOI 10.1016/j.ajpath.2017.01.015
   Hsieh LS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11753
   Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498
   Huch M, 2015, DEVELOPMENT, V142, P3113, DOI 10.1242/dev.118570
   Iffland PH, 2018, NEUROBIOL DIS, V114, P184, DOI 10.1016/j.nbd.2018.02.013
   Iyer A, 2014, BRAIN PATHOL, V24, P1, DOI 10.1111/bpa.12060
   Iyer A, 2010, EPILEPSIA, V51, P1763, DOI 10.1111/j.1528-1167.2010.02547.x
   Jansen LA, 2015, BRAIN, V138, P1613, DOI 10.1093/brain/awv045
   Kabat J, 2012, POL J RADIOL, V77, P35, DOI 10.12659/PJR.882968
   Kadoshima T, 2013, P NATL ACAD SCI USA, V110, P20284, DOI 10.1073/pnas.1315710110
   Kakkar A, 2017, NEUROL INDIA, V65, P1076, DOI 10.4103/neuroindia.NI_207_17
   Krueger DA, 2013, CURR TREAT OPTION NE, V15, P618, DOI 10.1007/s11940-013-0249-2
   Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517
   Lee Sang Kun, 2013, J Epilepsy Res, V3, P43, DOI 10.14581/jer.13009
   Leventer RJ, 2015, NEUROLOGY, V84, P2029, DOI 10.1212/WNL.0000000000001594
   Lim JS, 2017, AM J HUM GENET, V100, P454, DOI 10.1016/j.ajhg.2017.01.030
   Lim JS, 2015, NAT MED, V21, P395, DOI 10.1038/nm.3824
   Lin Kun, 2013, Zhonghua Bing Li Xue Za Zhi, V42, P311, DOI 10.3760/cma.j.issn.0529-5807.2013.05.005
   Lin YX, 2015, GENET MOL RES, V14, P9994, DOI 10.4238/2015.August.21.5
   Lin YX, 2015, EPILEPSY RES, V112, P137, DOI 10.1016/j.eplepsyres.2015.02.002
   Liu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-71
   Liu JYW, 2016, ANN NEUROL, V80, P882, DOI 10.1002/ana.24803
   Ljungberg MC, 2006, ANN NEUROL, V60, P420, DOI 10.1002/ana.20949
   Mariani J, 2012, P NATL ACAD SCI USA, V109, P12770, DOI 10.1073/pnas.1202944109
   Marinowic DR, 2017, MOL MED REP, V15, P2049, DOI 10.3892/mmr.2017.6264
   Marsan E, 2016, NEUROBIOL DIS, V89, P180, DOI 10.1016/j.nbd.2016.02.010
   Miles L, 2013, J NEUROPATH EXP NEUR, V72, P884, DOI 10.1097/NEN.0b013e3182a38d88
   Mirzaa GM, 2016, JAMA NEUROL, V73, P836, DOI 10.1001/jamaneurol.2016.0363
   Miyata H, 2004, ANN NEUROL, V56, P510, DOI 10.1002/ana.20234
   Moller RS, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000118
   Muhlebner A, 2016, J NEURODEV DISORD, V8, DOI 10.1186/s11689-016-9142-0
   Nakashima M, 2015, ANN NEUROL, V78, P375, DOI 10.1002/ana.24444
   Ni Hai-chun, 2012, Chinese Journal of Pathology, V41, P391, DOI 10.3760/cma.j.issn.0529-5807.2012.06.007
   Passier R, 2016, CELL STEM CELL, V18, P309, DOI [10.1016/j.stem.2016.02.011, 10.1016/j.stem.2016.02.013]
   Patil VV, 2016, NEUROPATHOLOGY, V36, P146, DOI 10.1111/neup.12242
   Rossini L, 2017, EPILEPSY RES, V129, P146, DOI 10.1016/j.eplepsyres.2016.12.002
   Rossini L, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-45
   Scerri T, 2015, ANN CLIN TRANSL NEUR, V2, P575, DOI 10.1002/acn3.191
   Schick V, 2007, BRAIN PATHOL, V17, P165, DOI 10.1111/j.1750-3639.2007.00059.x
   Scholl T, 2017, BRAIN PATHOL, V27, P770, DOI 10.1111/bpa.12452
   Sim JC, 2016, ANN NEUROL, V79, P132, DOI 10.1002/ana.24502
   Sisodiyo SM, 2009, LANCET NEUROL, V8, P830, DOI 10.1016/S1474-4422(09)70201-7
   Spreafico R, 2012, HDB CLIN NEUROLOGY, V108, P536
   Suzuki IK, 2015, DEVELOPMENT, V142, P3138, DOI 10.1242/dev.120568
   TAYLOR DC, 1971, J NEUROL NEUROSUR PS, V34, P369, DOI 10.1136/jnnp.34.4.369
   Tenney JR, 2014, EPILEPSIA, V55, P1415, DOI 10.1111/epi.12731
   Terrone G, 2016, EUR J HUM GENET, V24, P1359, DOI 10.1038/ejhg.2016.7
   Thom M, 2018, BRAIN PATHOL, V28, P155, DOI 10.1111/bpa.12555
   van Scheppingen J, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0662-z
   Wiegand G, 2013, EUR J PAEDIATR NEURO, P17
   Willems L, 2012, CURR ONCOL REP, V14, P129, DOI 10.1007/s11912-012-0227-y
   Yao K, 2016, ONCOTARGET, V7, P76415, DOI 10.18632/oncotarget.13001
   Yasin SA, 2013, ACTA NEUROPATHOL, V126, P207, DOI 10.1007/s00401-013-1135-4
   Yin XL, 2016, CELL STEM CELL, V18, P25, DOI 10.1016/j.stem.2015.12.005
   Zhou J, 2009, J NEUROSCI, V29, P1773, DOI 10.1523/JNEUROSCI.5685-08.2009
NR 69
TC 3
Z9 3
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD AUG
PY 2018
VL 85
BP 157
EP 163
DI 10.1016/j.yebeh.2018.05.014
PG 7
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA GN4BD
UT WOS:000438956900024
PM 29945038
DA 2020-12-08
ER

PT J
AU Zanirati, G
   Azevedo, PN
   Venturin, GT
   Greggio, S
   Alcara, AM
   Zimmer, ER
   Feltes, PK
   DaCosta, JC
AF Zanirati, Gabriele
   Azevedo, Pamella Nunes
   Venturin, Gianina Teribele
   Greggio, Samuel
   Alcara, Allan Marinho
   Zimmer, Eduardo R.
   Feltes, Paula Kopschina
   DaCosta, Jaderson Costa
TI Depression comorbidity in epileptic rats is related to brain glucose
   hypometabolism and hypersynchronicity in the metabolic network
   architecture
SO EPILEPSIA
LA English
DT Article
DE depressive-like behavior; epilepsy; microPET; neuroimage; pilocarpine
ID POSITRON-EMISSION-TOMOGRAPHY; TEMPORAL-LOBE EPILEPSY; SPONTANEOUS
   RECURRENT SEIZURES; MAJOR DEPRESSION; MOUSE MODEL; PET; SYNCHRONIZATION;
   TRANSPLANTATION; EPILEPTOGENESIS; CONNECTIVITY
AB ObjectiveTemporal lobe epilepsy (TLE) is one of the most common types of epilepsy syndromes in the world. Depression is an important comorbidity of epilepsy, which has been reported in patients with TLE and in different experimental models of epilepsy. However, there is no established consensus on which brain regions are associated with the manifestation of depression in epilepsy. Here, we investigated the alterations in cerebral glucose metabolism and the metabolic network in the pilocarpine-induced rat model of epilepsy and correlated it with depressive behavior during the chronic phase of epilepsy.
   MethodsFluorodeoxyglucose (F-18-FDG) was used to investigate the cerebral metabolism, and a cross-correlation matrix was used to examine the metabolic network in chronically epileptic rats using micro-positron emission tomography (microPET) imaging. An experimental model of epilepsy was induced by pilocarpine injection (320 mg/kg, ip). Forced swim test (FST), sucrose preference test (SPT), and eating-related depression test (ERDT) were used to evaluate depression-like behavior.
   ResultsOur results show an association between epilepsy and depression comorbidity based on changes in both cerebral glucose metabolism and the functional metabolic network. In addition, we have identified a significant correlation between brain glucose hypometabolism and depressive-like behavior in chronically epileptic rats. Furthermore, we found that the epileptic depressed group presents a hypersynchronous brain metabolic network in relation to the epileptic nondepressed group.
   SignificanceThis study revealed relevant alterations in glucose metabolism and the metabolic network among the brain regions of interest for both epilepsy and depression pathologies. Thus it seems that depression in epileptic animals is associated with a more diffuse hypometabolism and altered metabolic network architecture and plays an important role in chronic epilepsy.
C1 [Zanirati, Gabriele; Azevedo, Pamella Nunes; Venturin, Gianina Teribele; Greggio, Samuel; Alcara, Allan Marinho; Zimmer, Eduardo R.; Feltes, Paula Kopschina; DaCosta, Jaderson Costa] Pontifical Catholic Univ Rio Grande Sul PUCRS, Brain Inst Rio Grande Sul BraIns, Porto Alegre, RS, Brazil.
   [Zimmer, Eduardo R.] Fed Univ Rio Grande Sul UFRGS, Dept Biochem, Porto Alegre, RS, Brazil.
   [Zimmer, Eduardo R.] Fed Univ Rio Grande Sul UFRGS, Dept Pharmacol, Porto Alegre, RS, Brazil.
RP DaCosta, JC (corresponding author), Pontifical Catholic Univ Rio Grande Sul PUCRS, Brain Inst Rio Grande Sul BraIns, Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Zimmer, Eduardo R Rigon/I-2932-2015; Greggio, Samuel/E-1498-2013;
   Feltes, Paula Kopschina/AAB-9529-2020
OI Zimmer, Eduardo R Rigon/0000-0002-5349-0053; Greggio,
   Samuel/0000-0002-5187-0335; Feltes, Paula Kopschina/0000-0002-5189-6236;
   Zanirati, Gabriele/0000-0002-1986-973X
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Pandurata Alimentos Ltd; Coordenacao de Aperfeicoamento Pessoal
   de Nivel Superior (CAPES)CAPES
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   Pandurata Alimentos Ltd; Coordenacao de Aperfeicoamento Pessoal de Nivel
   Superior (CAPES)
CR Akman CI, 2010, EPILEPSY BEHAV, V17, P373, DOI 10.1016/j.yebeh.2009.12.007
   Baptista PPA, 2015, NEUROCHEM RES, V40, P1153, DOI 10.1007/s11064-015-1576-3
   Bertoglio D, 2017, BRAIN BEHAV IMMUN, V61, P69, DOI 10.1016/j.bbi.2016.12.015
   Blumenfeld H, 2004, CEREB CORTEX, V14, P892, DOI 10.1093/cercor/bhh048
   Choi H, 2015, ELIFE, V4, DOI [10.7554/eLife.11571, 10.7554/eLife.11571.001]
   Choi H, 2014, NEUROIMAGE, V99, P226, DOI 10.1016/j.neuroimage.2014.05.039
   CHUGANI HT, 1993, PEDIATR NEUROL, V9, P10, DOI 10.1016/0887-8994(93)90003-U
   CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408
   Costa-Ferro ZSM, 2012, NEUROBIOL DIS, V46, P302, DOI 10.1016/j.nbd.2011.12.001
   Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x
   Epps SA, 2012, NEUROPSYCHOPHARMACOL, V37, P2756, DOI 10.1038/npp.2012.141
   Fang L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166049
   Fitzgerald PB, 2008, HUM BRAIN MAPP, V29, P683, DOI 10.1002/hbm.20426
   Goffin K, 2009, EXP NEUROL, V217, P205, DOI 10.1016/j.expneurol.2009.02.008
   Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020
   Guo Y, 2009, NEUROSCIENCE, V162, P972, DOI 10.1016/j.neuroscience.2009.05.041
   Holthoff VA, 2004, ACTA PSYCHIAT SCAND, V110, P184, DOI 10.1111/j.1600-0447.2004.00351.x
   Jiruska P, 2013, J PHYSIOL-LONDON, V591, P787, DOI 10.1113/jphysiol.2012.239590
   Jupp B., 2007, NEUROL ASIA S1, V12, P51
   Jupp B, 2012, EPILEPSIA, V53, P1233, DOI 10.1111/j.1528-1167.2012.03525.x
   Kanner AM, 2002, NEUROLOGY, V58, pS27, DOI 10.1212/WNL.58.8_suppl_5.S27
   Khalid A, 2014, NEUROIMAGE, V101, P351, DOI 10.1016/j.neuroimage.2014.07.040
   Mazarati A, 2008, BRAIN, V131, P2071, DOI 10.1093/brain/awn117
   Mazarati AM, 2010, NEUROBIOL DIS, V37, P461, DOI 10.1016/j.nbd.2009.11.001
   Mirrione MM, 2006, SYNAPSE, V59, P119, DOI 10.1002/syn.20216
   Morgan VL, 2011, EPILEPSIA, V52, P1741, DOI 10.1111/j.1528-1167.2011.03196.x
   Mormann F, 2000, PHYSICA D, V144, P358, DOI 10.1016/S0167-2789(00)00087-7
   Parente A, 2016, J NUCL MED, V57, P785, DOI 10.2967/jnumed.115.165019
   PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723
   Pineda E, 2010, EPILEPSIA, V51, P110, DOI 10.1111/j.1528-1167.2010.02623.x
   PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0
   RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0
   Schindler K, 2007, BRAIN, V130, P65, DOI 10.1093/brain/awl304
   Su L, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0321-9
   Theodore WH, 2004, EPILEPSIA, V45, P276, DOI 10.1111/j.0013-9580.2004.51803.x
   Upadhya Dinesh, 2016, Curr Protoc Stem Cell Biol, V38, DOI 10.1002/cpsc.9
   Venturin GT, 2011, LIFE SCI, V89, P229, DOI 10.1016/j.lfs.2011.06.006
   Zanirati G, 2015, CNS NEUROSCI THER, V21, P463, DOI 10.1111/cns.12382
   Zhang L, 2015, INT J MED SCI, V12, P288, DOI 10.7150/ijms.10527
   Zimmer ER, 2017, NAT NEUROSCI, V20, P393, DOI 10.1038/nn.4492
NR 40
TC 12
Z9 12
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD MAY
PY 2018
VL 59
IS 5
BP 923
EP 934
DI 10.1111/epi.14057
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA GE8QB
UT WOS:000431495200006
PM 29600825
OA Bronze
DA 2020-12-08
ER

PT J
AU DaCosta, JC
   Portuguez, MW
   Marinowic, DR
   Schilling, LP
   Torres, CM
   DaCosta, DI
   Carrion, MJM
   Raupp, EF
   Machado, DC
   Soder, RB
   Lardi, SL
   Garicochea, B
AF DaCosta, Jaderson C.
   Portuguez, Mirna W.
   Marinowic, Daniel R.
   Schilling, Lucas P.
   Torres, Carolina M.
   DaCosta, Danielle I.
   Carrion, Maria Julia M.
   Raupp, Eduardo F.
   Machado, Denise C.
   Soder, Ricardo B.
   Lardi, Silvia L.
   Garicochea, Bernardo
TI Safety and seizure control in patients with mesial temporal lobe
   epilepsy treated with regional superselective intra-arterial injection
   of autologous bone marrow mononuclear cells
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE bone marrow; mononuclear cells; hippocampal sclerosis; memory deficit;
   refractory epilepsy; superselective intra-arterial injection; stem cells
ID SPONTANEOUS RECURRENT SEIZURES; INDUCED STATUS EPILEPTICUS; NEONATAL
   HYPOXIA-ISCHEMIA; CORD BLOOD-CELLS; STEM-CELLS; RAT MODEL; HIPPOCAMPAL
   SCLEROSIS; MYOCARDIAL-INFARCTION; NATURAL-HISTORY; NEURONAL LOSS
AB Temporal lobe epilepsy (TLE) is a highly prevalent syndrome among people with epilepsy, and is usually refractory to drug treatment. Structural and physiological changes, such as hippocampal sclerosis, are often present in TLE patients. The objective of this study is to evaluate the feasibility and safety of intra-arterial infusion of autologous bone marrow mononuclear cells (BMMC) in adults with medically refractory mesial TLE (MTLE) and unilateral hippocampal sclerosis (HS). We enrolled 20 patients who had been diagnosed with MTLE-HS and were refractory to medical treatment. All patients underwent a neurological evaluation, magnetic resonance imaging with hippocampal volumetry, video-electroencephalography (EEG) with ictal recording, and a neuropsychological test battery focusing on verbal and nonverbal memory domains. After bone marrow aspiration and subsequent cell preparation, the BMMC were infused by selective posterior cerebral artery catheterization. Patients were followed for 6months. Safety of the procedure, seizure frequency, neuropsychological evaluation, EEG variables, routine brain magnetic resonance imaging and hippocampal volumetry were considered measurements of outcome. Any serious intercurrent clinical event or adverse effects related to the procedure were reported. No additional lesions and no significant hippocampal volumetric changes were observed. EEG recordings showed a decrease in theta activity and spike density. At 6months, eight patients (40%) were seizure free. A significant increase in the memory scores over time was observed. The BMMC autologous transplant for the treatment of temporal lobe epilepsy is feasible and safe. The seizure control achieved in this novel study supports the therapeutic potential of stem cell transplants in MTLE-HS patients. Copyright (c) 2016 John Wiley & Sons, Ltd.
C1 [DaCosta, Jaderson C.; Portuguez, Mirna W.; Marinowic, Daniel R.; Schilling, Lucas P.; DaCosta, Danielle I.; Soder, Ricardo B.] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst Rio Grande Sul BraIns, Porto Alegre, RS, Brazil.
   [DaCosta, Jaderson C.; Portuguez, Mirna W.; Marinowic, Daniel R.; Machado, Denise C.] Pontificia Univ Catolica Rio Grande do Sul, Biomed Res Inst, Porto Alegre, RS, Brazil.
   [DaCosta, Jaderson C.; Portuguez, Mirna W.; Schilling, Lucas P.; DaCosta, Danielle I.; Carrion, Maria Julia M.; Machado, Denise C.; Garicochea, Bernardo] Pontificia Univ Catolica Rio Grande do Sul, Postgrad Program Med & Hlth Sci, Porto Alegre, RS, Brazil.
   [DaCosta, Jaderson C.; Portuguez, Mirna W.; Machado, Denise C.; Soder, Ricardo B.; Lardi, Silvia L.; Garicochea, Bernardo] Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Porto Alegre, RS, Brazil.
   [DaCosta, Jaderson C.; Portuguez, Mirna W.; Schilling, Lucas P.; Torres, Carolina M.; DaCosta, Danielle I.; Garicochea, Bernardo] Pontificia Univ Catolica Rio Grande do Sul, Sao Lucas Hosp, Porto Alegre, RS, Brazil.
   [Garicochea, Bernardo] Hosp Sirio Libanes, Teaching & Res Oncol Ctr, Sao Paulo, SP, Brazil.
RP DaCosta, JC (corresponding author), Inst Cerebro Rio Grande Sul InsCer, Av Ipiranga 6690,Predio 63, BR-90610000 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Portuguez, Mirna/A-9362-2018; Machado, Denise C/G-2852-2014
OI Portuguez, Mirna/0000-0003-4068-6249; Machado, Denise
   C/0000-0002-9371-5886
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES
FX J.C. DaCosta is a researcher at Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq). S.L. Lardi was awarded a scientific
   initiation scholarship (CNPq) during her undergraduate studies. M.J.M.
   Carrion and D.I. DaCosta were the recipients of scholarships from
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and
   some of the data were used to fulfil requirements for their MSc and PhD
   degrees, respectively. The authors wish to thank Maria Dal Pozzo,
   Ricardo Vaz Breda and Daniela Abreu de Souza for technical assistance,
   Nurma Pereira for assistance with subject recruitment and Professor
   Mario Wagner for the statistics assistance. The authors also thank
   Professor J.W.S. Sander for a critical reading of the manuscript and to
   Samuel Greggio for help in reviewing the text. Our grateful thanks go to
   all of the neurologists who referred patients to this study.
CR Abdanipour A, 2011, NEUROL RES, V33, P625, DOI 10.1179/1743132810Y.0000000018
   Angeli FS, 2012, INT J CARDIOL, V158, P449, DOI 10.1016/j.ijcard.2012.04.136
   Baraban SC, 2009, P NATL ACAD SCI USA, V106, P15472, DOI 10.1073/pnas.0900141106
   Bartsch T, 2007, CLIN RES CARDIOL, V96, P891, DOI 10.1007/s00392-007-0569-x
   Beghi E, 2005, EPILEPSIA, V46, P1698, DOI 10.1111/j.1528-1167.2005.00273_1.x
   Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1
   Berg AT, 2008, CURR OPIN NEUROL, V21, P173, DOI 10.1097/WCO.0b013e3282f36ccd
   Bovolenta R, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-81
   Brassel F, 1996, NEURORADIOLOGY, V38, P417
   Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009
   Cammalleri M, 2011, EUR J NEUROSCI, V33, P482, DOI 10.1111/j.1460-9568.2010.07529.x
   Chu K, 2004, BRAIN RES, V1023, P213, DOI 10.1016/j.brainres.2004.07.045
   Costa-Ferro ZSM, 2012, NEUROBIOL DIS, V46, P302, DOI 10.1016/j.nbd.2011.12.001
   Costa-Ferro ZSM, 2010, SEIZURE-EUR J EPILEP, V19, P84, DOI 10.1016/j.seizure.2009.12.003
   Alves-de-Moraes LBDE, 2013, BEHAV BRAIN RES, V248, P32, DOI 10.1016/j.bbr.2013.03.042
   de Paula S, 2012, NEUROSCIENCE, V210, P431, DOI 10.1016/j.neuroscience.2012.03.009
   de Paula S, 2010, J PEDIAT-BRAZIL, V86, P451, DOI [10.2223/JPED.2035, 10.1590/S0021-75572010000600003]
   de Paula S, 2009, PEDIATR RES, V65, P631, DOI 10.1203/PDR.0b013e31819ed5c8
   Demartini DR, 2014, J PROTEOMICS, V104, P24, DOI 10.1016/j.jprot.2014.04.014
   Duveau V, 2010, EUR J NEUROSCI, V32, P89, DOI 10.1111/j.1460-9568.2010.07272.x
   Ferrazoli EG, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-97
   Friedrich MAG, 2012, CELL TRANSPLANT, V21, pS13, DOI 10.3727/096368912X612512
   Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7
   Gonzalez-Perez Oscar, 2010, J Stem Cells, V5, P23, DOI jsc.2010.5.1.23
   Greggio S, 2014, LIFE SCI, V96, P33, DOI 10.1016/j.lfs.2013.10.017
   Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098
   Harroud Adil, 2012, Epilepsy Res Treat, V2012, P201651, DOI 10.1155/2012/201651
   Hartman NW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015856
   Hemb M, 2013, J NEUROL NEUROSUR PS, V84, P800, DOI 10.1136/jnnp-2012-304038
   Henchcliffe C, 2011, PROG NEUROBIOL, V95, P601, DOI 10.1016/j.pneurobio.2011.09.002
   Hogan RE, 2001, ARCH NEUROL-CHICAGO, V58, P1484, DOI 10.1001/archneur.58.9.1484
   Jeong HK, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-28
   Jing M, 2009, BRAIN RES, V1295, P203, DOI 10.1016/j.brainres.2009.07.079
   Kaminski Elisa Lettnin, 2013, Coluna/Columna, V12, P274, DOI 10.1590/S1808-18512013000400001
   Kim J, 2010, INT J DEV NEUROSCI, V28, P227, DOI 10.1016/j.ijdevneu.2010.02.003
   Kwan P, 2004, J NEUROL NEUROSUR PS, V75, P1376, DOI 10.1136/jnnp.2004.045690
   Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503
   Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x
   Leblond AL, 2009, STEM CELLS CLONING, V2, P11, DOI 10.2147/SCCAA.S6210
   Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525
   Long Q, 2012, NEUROSCIENCE, V212, P214, DOI 10.1016/j.neuroscience.2012.04.002
   Long QF, 2013, BRAIN RES, V1532, P1, DOI 10.1016/j.brainres.2013.07.020
   Longo B, 2010, EPILEPSIA, V51, P1628, DOI 10.1111/j.1528-1167.2010.02570.x
   Maisano X, 2009, NEUROTHERAPEUTICS, V6, P263, DOI 10.1016/j.nurt.2009.01.011
   Marchi N, 2012, EPILEPSIA, V53, P1877, DOI 10.1111/j.1528-1167.2012.03637.x
   Mayhall EA, 2004, CURR OPIN CELL BIOL, V16, P713, DOI 10.1016/j.ceb.2004.09.007
   McIntosh AM, 2001, EPILEPSIA, V42, P1288, DOI 10.1046/j.1528-1157.2001.02001.x
   McIntosh AM, 2004, BRAIN, V127, P2018, DOI 10.1093/brain/awh221
   McIntosh AM, 2006, NEUROLOGY, V67, P1671, DOI 10.1212/01.wnl.0000242735.24539.33
   Nicoletti JN, 2010, EPILEPSY BEHAV, V19, P272, DOI 10.1016/j.yebeh.2010.07.011
   Paglioli E, 2006, J NEUROSURG, V104, P70, DOI 10.3171/jns.2006.104.1.70
   Paglioli E, 2004, EPILEPSIA, V45, P1383, DOI 10.1111/j.0013-9580.2004.22204.x
   Pruessner JC, 2000, CEREB CORTEX, V10, P433, DOI 10.1093/cercor/10.4.433
   Quigg M, 1997, EPILEPSY RES, V27, P101, DOI 10.1016/S0920-1211(97)01026-7
   Riquelme PA, 2008, PHILOS T R SOC B, V363, P123, DOI 10.1098/rstb.2006.2016
   Roper SN, 2013, EXP NEUROL, V244, P59, DOI 10.1016/j.expneurol.2012.01.004
   Schueller PO, 2007, INT J CARDIOL, V119, P398, DOI 10.1016/j.ijcard.2006.07.169
   Shen H, 2010, INT J NEUROSCI, V120, P647, DOI 10.3109/00207454.2010.509526
   Shindo A, 2010, NEUROL MED-CHIR, V50, P98, DOI 10.2176/nmc.50.98
   Shu XM, 2011, CELL BIOCHEM BIOPHYS, V61, P367, DOI 10.1007/s12013-011-9219-z
   Silani V, 2004, CURR NEUROVASC RES, V1, P283, DOI 10.2174/1567202043362243
   Silani V, 2004, LANCET, V364, P200, DOI 10.1016/S0140-6736(04)16634-8
   Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003
   Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160
   Stabell KE, 2004, EPILEPSIA, V45, P817, DOI 10.1111/j.0013-9580.2004.59903.x
   Strauer BE, 2005, J AM COLL CARDIOL, V46, P1651, DOI 10.1016/j.jacc.2005.01.069
   Thom M, 2005, BRAIN, V128, P1344, DOI 10.1093/brain/awh475
   Tonini C, 2004, EPILEPSY RES, V62, P75, DOI 10.1016/j.eplepsyres.2004.08.006
   Leal MMT, 2014, NEUROCHEM RES, V39, P259, DOI 10.1007/s11064-013-1217-7
   Ullal GR, 2007, NEUROCHEM INT, V50, P866, DOI 10.1016/j.neuint.2007.02.009
   Venturin GT, 2011, LIFE SCI, V89, P229, DOI 10.1016/j.lfs.2011.06.006
   Waldau B, 2010, STEM CELLS, V28, P1153, DOI 10.1002/stem.446
   Wieser HG, 2004, EPILEPSIA, V45, P32
   Zanirati G, 2015, CNS NEUROSCI THER, V21, P463, DOI 10.1111/cns.12382
NR 74
TC 2
Z9 3
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1932-6254
EI 1932-7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD FEB
PY 2018
VL 12
IS 2
BP E648
EP E656
DI 10.1002/term.2456
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA FW3CY
UT WOS:000425184900002
PM 27688159
DA 2020-12-08
ER

PT J
AU Escouto, DC
   Gadonski, G
   Porcello-Marrone, L
   da Costa, JC
   Paludo, N
   do Amaral, RR
   da Costa, BEP
   Poli-de-Figueiredo, CE
AF Escouto, Daniele Cristovao
   Gadonski, Giovani
   Porcello-Marrone, Luiz
   da Costa, Jaderson Costa
   Paludo, Nathalia
   do Amaral, Rayssa Ruszkowski
   Pinheiro da Costa, Bartira Ercilia
   Poli-de-Figueiredo, Carlos Eduardo
TI Using the Reduced Uterine Perfusion Pressure model of preeclampsia to
   study the blood brain barrier permeability
SO SCIENTIA MEDICA
LA English
DT Article
DE animal models; blood-brain barrier; preeclampsia; eclampsia; toxemia of
   pregnancy; hypertension; posterior leukoencephalopathy syndrome;
   pregnancy complications
ID RATS; PREGNANCY; INCREASES; ECLAMPSIA
AB AIMS: To use the Reduced Uterine Perfusion Pressure (RUPP) model for preeclampsia to describe and evaluate the blood brain barrier permeability in pregnant rats.
   METHODS: Forty-one pregnant Wistar rats were divided into different intervention groups between 13 to 15 days of gestation: PregnantControl (PC; n=12), Reduced Uterine Perfusion Pressure (RUPP; n=15), Invasive Blood Pressure-Control (IBP; n=7) and Reduced Uterine Perfusion Pressure and Invasive Blood Pressure (RUPP-IBP; n=7). The 14 rats of groups IBP and RUPP-IBP had their mean arterial pressure measured at day 21. All animals were then sacrificed, administered Evans Blue dye through the tail vein and perfused with paraformaldehyde 4%. Brains were removed and evaluated by a blinded pathologist. Results are presented as means and standard errors. Comparisons between the groups were performed using Student's t-test for continuous variables and Fisher's exact test for categorical variables. Statistical significance was set as a p value less than 0.05.
   RESULTS: Mean arterial pressure averaged 85.4 +/- 2.2 mmHg in the IPB group and 102.5 +/- 8.3 mmHg in the RUPP-IPB group (p=0.002). Among all the RUPP rats (RUPP and RUPP-IBP groups), 82% had a positive staining with Evans Blue dye for at least one of the brain hemispheres, while none of the pregnant control rats (PC and IBP groups) had brain staining (p< 0.001).
   CONCLUSIONS: In this study, altered permeability of the blood brain barrier was successfully reproduced in pregnant rats exposed to the RUPP protocol. Therefore, we concluded that the RUPP model is a valid surrogate to study blood brain barrier abnormalities.
C1 [Escouto, Daniele Cristovao; Pinheiro da Costa, Bartira Ercilia] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Programa Posgrad Med & Ciencias Saude, Porto Alegre, RS, Brazil.
   [Escouto, Daniele Cristovao; Gadonski, Giovani; Paludo, Nathalia; do Amaral, Rayssa Ruszkowski; Pinheiro da Costa, Bartira Ercilia; Poli-de-Figueiredo, Carlos Eduardo] Pontificia Univ Catolica Rio Grande do Sul, Escola Med, Lab Nefrol, Porto Alegre, RS, Brazil.
   [Gadonski, Giovani; Porcello-Marrone, Luiz] Uniao Brasileira Educ & Assistencia, Inst Cerebro Rio Grande do Sul, Porto Alegre, RS, Brazil.
RP Escouto, DC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Lab Nefrol, Ave Ipiranga 6690,2 Andar, BR-90610000 Porto Alegre, RS, Brazil.
EM daniele.escouto@acad.pucrs.br
RI de Figueiredo, Carlos E Poli/A-2027-2013; da Costa, Bartira E
   Pinheiro/E-4183-2013
OI de Figueiredo, Carlos E Poli/0000-0002-7333-8884; da Costa, Bartira E
   Pinheiro/0000-0001-8015-3952
FU Brazilian Coordination for Improvement of Higher Education Personnel
   (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -
   CAPES)CAPES
FX This study received financial support from the Brazilian Coordination
   for Improvement of Higher Education Personnel (Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - CAPES).
CR Abalos E, 2014, BJOG-INT J OBSTET GY, V121, P14, DOI 10.1111/1471-0528.12629
   Abalos E, 2013, EUR J OBSTET GYN R B, V170, P1, DOI 10.1016/j.ejogrb.2013.05.005
   Alexander BT, 2001, HYPERTENSION, V37, P1191, DOI 10.1161/01.HYP.37.4.1191
   Amburgey OA, 2010, HYPERTENSION, V56, P1003, DOI 10.1161/HYPERTENSIONAHA.110.158931
   Auer L M, 1978, Acta Neurochir Suppl (Wien), V27, P1
   Brennan L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162487
   Brewer J, 2013, AM J OBSTET GYNECOL, V208, pe1, DOI DOI 10.1016/J.AJ0G.2013.02.015
   Cardoso LM, 2005, BRAZ J MED BIOL RES, V38, P205, DOI 10.1590/S0100-879X2005000200008
   Cipolla MJ, 2007, HYPERTENSION, V50, P14, DOI 10.1161/HYPERTENSIONAHA.106.079442
   Cornelius Denise C, 2016, American journal of physiology. Regulatory, integrative and comparative physiology, V311, pR1192, DOI 10.1152/ajpregu.00117.2016
   Gadonski G, 2006, HYPERTENSION, V48, P711, DOI 10.1161/01.HYP.0000238442.33463.94
   Gage Gregory J, 2012, J Vis Exp, DOI 10.3791/3564
   Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Karumanchi SA, 2008, CURR HYPERTENS REP, V10, P305, DOI 10.1007/s11906-008-0057-3
   Li J, 2012, AM J PHYSIOL-HEART C, V303, pH1, DOI 10.1152/ajpheart.00117.2012
   McCarthy FP, 2011, PLACENTA, V32, P413, DOI 10.1016/j.placenta.2011.03.010
   NIENARTOWICZ A, 1989, J DEV PHYSIOL, V12, P101
   Marrone LCP, 2014, J STROKE CEREBROVASC, V23, P2075, DOI 10.1016/j.jstrokecerebrovasdis.2014.03.012
   Spradley FT, 2016, HYPERTENSION, V67, P740, DOI 10.1161/HYPERTENSIONAHA.115.06783
NR 20
TC 0
Z9 0
U1 0
U2 1
PU EDITORA PUCRS
PI PORTO ALEGRE
PA AVENIDA IPIRANGA 6681, PREDIO 33, PORTO ALEGRE, RS 90619-900, BRAZIL
SN 1806-5562
EI 1980-6108
J9 SCI MED
JI Sci. Med.
PY 2018
VL 28
IS 2
AR 29631
DI 10.15448/1980-6108.2018.2.29631
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA GN1VW
UT WOS:000438783600007
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Freitas, AM
   Portuguez, MW
   Russomano, T
   de Freitas, M
   Silvello, SLD
   da Costa, JC
AF Freitas, Angela M.
   Portuguez, Mirna Wetters
   Russomano, Thais
   de Freitas, Marcos
   da Silva Silvello, Silvio Luis
   da Costa, Jaderson Costa
TI Effects of an alternating work shift on air traffic controllers and the
   relationship with excessive daytime sleepiness and stress
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE disorders of excessive somnolence; workload; physiological stress;
   psychological stress
ID PERFORMANCE; SCALE; NIGHT; RISK
AB Objective: To evaluate symptoms of stress and excessive daytime sleepiness (EDS) in air traffic control (ATC) officers in Brazil. Methods: Fifty-two ATC officers participated, based at three air traffic control units, identified as A, B and C. Stress symptoms were assessed using the Lipp Inventory of Stress Symptoms for Adults, and EDS by the Epworth Sleepiness Scale. Results: The sample mean age was 37 years, 76.9% of whom were male. Excessive daytime sleepiness was identified in 25% of the ATC officers, with 84.6% of these based at air traffic control unit A, which has greater air traffic flow, operating a 24-hour alternating work shift schedule. A total of 16% of the ATC officers had stress symptoms, and of these, 62% showed a predominance of physical symptoms. Conclusion: The high percentage of ATC officers with EDS identified in group A may be related to chronodisruption due to night work and alternating shifts.
C1 [Freitas, Angela M.; Portuguez, Mirna Wetters; da Costa, Jaderson Costa] Pontificia Univ Rio Grande Sul, Programa Posgrad Med & Ciencias Saude, Porto Alegre, RS, Brazil.
   [Portuguez, Mirna Wetters; da Costa, Jaderson Costa] Pontificia Univ Rio Grande Sul, Inst Cerebro Rio Grande Sul, Porto Alegre, RS, Brazil.
   [Russomano, Thais] Kings Coll London, Ctr Human & Aerosp Physiol Sci, Fac Life Sci & Med, Grad Program Space Physiol & Hlth, London, England.
   [de Freitas, Marcos; da Silva Silvello, Silvio Luis] Empresa Brasileira Infraestruct Aeroportuaria, NASU, SRSU, Gestao Reg Navegacao Aerea, Porto Alegre, RS, Brazil.
RP Freitas, AM (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro Rio Grande Sul, Ave Ipiranga,6690 Predio 63, BR-90610000 Porto Alegre, RS, Brazil.
EM mirna@pucrs.br
RI Portuguez, Mirna/A-9362-2018; Russomano, Thais/K-2973-2015
OI Portuguez, Mirna/0000-0003-4068-6249; Russomano,
   Thais/0000-0002-1633-4449
FU Brain Institute, PUCRS
FX Special thanks to the Brain Institute, PUCRS, for their continued
   support in the development of this research.
CR Ashkenazi IE, 1997, CHRONOBIOL INT, V14, P99, DOI 10.3109/07420529709001148
   Belyavin AJ, 2004, AVIAT SPACE ENVIR MD, V75, pA93
   Bertolazi AN, 2009, J BRAS PNEUMOL, V35, P877, DOI 10.1590/S1806-37132009000900009
   Connor J, 2002, BRIT MED J, V324, P1125, DOI 10.1136/bmj.324.7346.1125
   Drake CL, 2004, SLEEP, V27, P1453, DOI 10.1093/sleep/27.8.1453
   Erren TC, 2009, J PINEAL RES, V46, P245, DOI 10.1111/j.1600-079X.2009.00665.x
   Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x
   Lapolli FR, 2009, P 2009 BRAZ S AER EN
   Lipp ME, 2000, MANUAL INVENTARIO SI, P23
   Loura J., 2013, INT J TRENDS BUS ADM, V2, P189
   Maier R., 2011, J PSYCHOL ED RES, V19, P52
   McWhirter Dewey, 2007, Psychiatry (Edgmont), V4, P26
   Ministerio da Defesa (BR), 2014, ICA6316 BR DECEA, P19
   Ministerio da Defesa (BR), 2013, ICA6316 BR DECEA, P18
   Ministerio da Defesa (BR), 2015, GER TRAF AER
   Ministerio da Educacao (BR), 2015, EIX TECN MIL
   Monk TH, 1996, APPL ERGON, V27, P17, DOI 10.1016/0003-6870(95)00048-8
   Moreira S. B., 1999, RELATORIOS PESQUISAS
   Noce F., 2010, THESIS
   Perrow C., 2011, NORMAL ACCIDENTS LIV
   Reinberg AE, 1996, PATHOL BIOL, V44, P487
   Reinberg A, 2008, CHRONOBIOL INT, V25, P625, DOI 10.1080/07420520802256101
   Reinberg A, 2015, CHRONOBIOL INT, V32, P1005, DOI 10.3109/07420528.2015.1053911
   Ribas Valdenilson Ribeiro, 2011, Dement. neuropsychol., V5, P209, DOI 10.1590/S1980-57642011DN05030009
   Stores G, 2007, J NEUROL NEUROSUR PS, V78, P1293, DOI 10.1136/jnnp.2006.111179
   Touitou Y, 2017, LIFE SCI, V173, P94, DOI 10.1016/j.lfs.2017.02.008
   U. S. Department of Transportation, 2015, TIT DOC VIS
   Word Heath Organization (WHO), 2011, NON TRADITIONAL REF
NR 28
TC 3
Z9 4
U1 0
U2 5
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD OCT
PY 2017
VL 75
IS 10
BP 711
EP 717
DI 10.1590/0004-282X20170123
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA FN4VF
UT WOS:000416004100007
PM 29166462
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU de Vargas, LD
   Goncalves, R
   Lara, MVS
   Costa-Ferro, ZSM
   Salamoni, SD
   Domingues, MF
   Piovesan, AR
   de Assis, DR
   Vinade, L
   Corrado, AP
   Alves-Do-Prado, W
   Correia-de-Sa, P
   da Costa, JC
   Izquierdo, I
   Dal Belo, CA
   Mello-Carpes, PB
AF de Vargas, Liane da Silva
   Goncalves, Rithiele
   Lara, Marcus Vinicius S.
   Costa-Ferro, Zaquer S. M.
   Salamoni, Simone Denise
   Domingues, Michelle Flores
   Piovesan, Angela Regina
   de Assis, Denis Reis
   Vinade, Lucia
   Corrado, Alexandre P.
   Alves-Do-Prado, Wilson
   Correia-de-Sa, Paulo
   da Costa, Jaderson Costa
   Izquierdo, Ivan
   Dal Belo, Chariston A.
   Mello-Carpes, Pamela B.
TI Methylprednisolone as a memory enhancer in rats: Effects on aversive
   memory, long-term potentiation and calcium influx
SO BRAIN RESEARCH
LA English
DT Article
DE Inhibitory avoidance; Aversive memory; Glucocorticoids; Long-term
   potentiation
ID CHANNEL SUBUNIT EXPRESSION; ACUTE STRESS; GLUCOCORTICOIDS; RECEPTORS;
   MODULATION; CORTICOSTEROIDS; TRANSMISSION; PREDNISOLONE; ACTIVATION;
   IMPAIRMENT
AB It is well recognized that stress or glucocorticoids hormones treatment can modulate memory performance in both directions, either impairing or enhancing it. Despite the high number of studies aiming at explaining the effects of glucocorticoids on memory, this has not yet been completely elucidated. Here, we demonstrate that a low daily dose of methylprednisolone (MP, 5 mg/kg, i.p.) administered for 10-days favors aversive memory persistence in adult rats, without any effect on the exploring behavior, locomotor activity, anxiety levels and pain perception. Enhanced performance on the inhibitory avoidance task was correlated with long-term potentiation (LTP), a phenomenon that was strengthen in hippocampal slices of rats injected with MP (5 mg/kg) during 10 days. Additionally, in vitro incubation with MP (30-300 mu M) concentration-dependently increased intracellular [Ca2+) in cultured hippocampal neurons depolarized by KCl (35 mM). In conclusion, a low daily dose of MP for 10 days may promote aversive memory persistence in rats. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Mello-Carpes, Pamela B.] Fed Univ Pampa, Physiol Res Grp, Uruguaiana, RS, Brazil.
   [Piovesan, Angela Regina; Corrado, Alexandre P.; da Costa, Jaderson Costa; Mello-Carpes, Pamela B.] Brain Inst Rio Grande, Lab Neuroscience, InsCer, PUCRS, Porto Alegre, RS, Brazil.
   [Salamoni, Simone Denise; Alves-Do-Prado, Wilson; Dal Belo, Chariston A.] Fed Univ Pampa, Lab Neurobiol & Toxinol, Lanetox, Sao Gabriel, RS, Brazil.
   [Salamoni, Simone Denise; Domingues, Michelle Flores; Corrado, Alexandre P.; Alves-Do-Prado, Wilson; Izquierdo, Ivan] Univ Sao Paulo, Dept Pharmacol, FMRP, Ribeirao Preto, SP, Brazil.
   [Salamoni, Simone Denise; Correia-de-Sa, Paulo; Dal Belo, Chariston A.] Univ Estadual Maringa, Dept Pharmacol & Therapeut, Maringa, PR, Brazil.
   [Costa-Ferro, Zaquer S. M.; Domingues, Michelle Flores; de Assis, Denis Reis; Correia-de-Sa, Paulo] Univ Porto, Inst Ciencias Biomed Abel Salazar, Porto, Portugal.
   [Costa-Ferro, Zaquer S. M.; Domingues, Michelle Flores; Vinade, Lucia; Alves-Do-Prado, Wilson] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst Rio Grande, Ctr Memory, InsCer, Porto Alegre, RS, Brazil.
   [Vinade, Lucia; da Costa, Jaderson Costa; Izquierdo, Ivan] Univ Fed Rio Grande, Grad Program Cell & Mol Biol, Ctr Biotechnol, Porto Alegre, RS, Brazil.
RP Mello-Carpes, PB (corresponding author), Fed Univ Pampa, Physiol Res Grp, Uruguaiana, RS, Brazil.
EM pamelacarpes@unipampa.edu.br
RI Mello-Carpes, Pamela/AAM-7404-2020; Correia-de-Sa, Paulo/AAG-5901-2019;
   Mello-Carpes, Pamela Billig/O-2118-2017; Vargas, Liane/AAM-4071-2020;
   Costa-Ferro, Zaquer Suzana Munhoz/C-5875-2015; Salamoni,
   Simone/C-4126-2015; Correia-De-Sa, P./F-1079-2015
OI Mello-Carpes, Pamela/0000-0002-9008-2091; Correia-de-Sa,
   Paulo/0000-0002-6114-9189; Mello-Carpes, Pamela
   Billig/0000-0002-9008-2091; Costa-Ferro, Zaquer Suzana
   Munhoz/0000-0002-9120-8856; Correia-De-Sa, P./0000-0002-6114-9189;
   Vinade, Lucia/0000-0001-5373-6351; Salamoni, Simone
   Denise/0000-0003-4329-710X; Izquierdo, Ivan/0000-0002-7208-0869; Reis de
   Assis, Denis/0000-0002-2984-0279
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES/Brazil)CAPES; Federal University of Pampa/Brazil;
   CAPES/BrazilCAPES; CNPq/BrazilNational Council for Scientific and
   Technological Development (CNPq); CNpqNational Council for Scientific
   and Technological Development (CNPq); Fundacao para a Ciencia e a
   Tecnologia (FCT)Portuguese Foundation for Science and Technology
   [UID/BIM/4308/2016]; University of Porto/ Banco Santander Totta/Portugal
FX This work was supported by research grants from the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES/Brazil), and from
   the Federal University of Pampa/Brazil granted to PBMC, II, CDB and LV.
   LSV was supported by CAPES/Brazil. RG was supported by CNPq/Brazil. II
   was supported by CNpq. PCS was supported by Fundacao para a Ciencia e a
   Tecnologia (FCT, project UID/BIM/4308/2016) and, by University of Porto/
   Banco Santander Totta/Portugal.
CR Ahmed T, 2006, J NEUROSCI, V26, P3951, DOI 10.1523/JNEUROSCI.4901-05.2006
   Bast T, 2014, NEUROPEDIATRICS, V45, P378, DOI 10.1055/s-0034-1387817
   Belanoff JK, 2001, AM J PSYCHIAT, V158, P1612, DOI 10.1176/appi.ajp.158.10.1612
   Belanoff JK, 2001, J CLIN PSYCHOPHARM, V21, P516, DOI 10.1097/00004714-200110000-00009
   Bisaz R, 2009, NEUROBIOL LEARN MEM, V91, P333, DOI 10.1016/j.nlm.2008.11.003
   BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0
   Bonini JS, 2006, HORM BEHAV, V50, P308, DOI 10.1016/j.yhbeh.2006.03.016
   Brown ES, 2004, J AFFECT DISORDERS, V83, P277, DOI 10.1016/j.jad.2004.07.001
   Brunner R, 2005, NEUROLOGY, V64, P335, DOI 10.1212/01.WNL.0000149523.35039.4C
   Buss C, 2004, PSYCHONEUROENDOCRINO, V29, P1093, DOI 10.1016/j.psyneuen.2003.09.006
   Chameau P, 2007, J NEUROPHYSIOL, V97, P5, DOI 10.1152/jn.00821.2006
   Chen S, 2011, NEUROREPORT, V22, P660, DOI 10.1097/WNR.0b013e32834a282a
   Dal Belo CA, 2002, MUSCLE NERVE, V26, P37, DOI 10.1002/mus.10132
   de Kloet ER, 1999, TRENDS NEUROSCI, V22, P422, DOI 10.1016/S0166-2236(99)01438-1
   de Quervain DJF, 2003, EUR J NEUROSCI, V17, P1296, DOI 10.1046/j.1460-9568.2003.02542.x
   de Quervain DJF, 2009, FRONT NEUROENDOCRIN, V30, P358, DOI 10.1016/j.yfrne.2009.03.002
   DIAMOND DM, 1992, HIPPOCAMPUS, V2, P421, DOI 10.1002/hipo.450020409
   Dozmorov M, 2006, NEUROSCI RES, V55, P182, DOI 10.1016/j.neures.2006.03.001
   Gan J, 2011, BRIT J PHARMACOL, V163, P984, DOI 10.1111/j.1476-5381.2011.01293.x
   GOLD PE, 1986, BEHAV NEURAL BIOL, V46, P87, DOI 10.1016/S0163-1047(86)90927-1
   Goosens KA, 2011, CURR OPIN NEUROBIOL, V21, P460, DOI 10.1016/j.conb.2011.04.003
   Hidalgo C, 2016, PHYSIOLOGY, V31, P201, DOI 10.1152/physiol.00038.2015
   Izquierdo I, 2008, AN ACAD BRAS CIENC, V80, P115, DOI 10.1590/S0001-37652008000100007
   Joels M, 2006, TRENDS PHARMACOL SCI, V27, P244, DOI 10.1016/j.tips.2006.03.007
   Joels M, 2012, PHARMACOL REV, V64, P901, DOI 10.1124/pr.112.005892
   Joels M, 2011, TRENDS COGN SCI, V15, P280, DOI 10.1016/j.tics.2011.04.004
   Kajiyama Y, 2010, PROG NEURO-PSYCHOPH, V34, P159, DOI 10.1016/j.pnpbp.2009.10.018
   Karst H, 2005, P NATL ACAD SCI USA, V102, P19204, DOI 10.1073/pnas.0507572102
   Karst H, 2002, EUR J NEUROSCI, V16, P1083, DOI 10.1046/j.1460-9568.2002.02172.x
   Kinali M, 2002, NEUROMUSCULAR DISORD, V12, pS169, DOI 10.1016/S0960-8966(02)00097-4
   Krugers HJ, 2005, HIPPOCAMPUS, V15, P697, DOI 10.1002/hipo.20092
   Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009
   Maggio N, 2007, J NEUROSCI, V27, P5757, DOI 10.1523/JNEUROSCI.0155-07.2007
   McGaugh JL, 2015, ANNU REV PSYCHOL, V66, P1, DOI 10.1146/annurev-psych-010814-014954
   McGaugh JL, 2009, PSYCHOPHARMACOLOGY, V202, P3, DOI 10.1007/s00213-008-1285-6
   McGaugh JL, 2002, CURR OPIN NEUROBIOL, V12, P205, DOI 10.1016/S0959-4388(02)00306-9
   McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248
   Nicolaides NC, 2010, STEROIDS, V75, P1, DOI 10.1016/j.steroids.2009.09.002
   Odermatt A, 2008, BIOCHEM PHARMACOL, V76, P1184, DOI 10.1016/j.bcp.2008.07.019
   Oliveira L, 2015, NEUROPHARMACOLOGY, V89, P64, DOI 10.1016/j.neuropharm.2014.09.004
   Payne JD, 2007, LEARN MEMORY, V14, P861, DOI 10.1101/lm.743507
   PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7
   Rashidy-Pour A, 2009, BEHAV BRAIN RES, V203, P76, DOI 10.1016/j.bbr.2009.04.018
   Revest JM, 2005, NAT NEUROSCI, V8, P664, DOI 10.1038/nn1441
   Roozendaal B, 1999, P NATL ACAD SCI USA, V96, P11642, DOI 10.1073/pnas.96.20.11642
   Rossato JI, 2009, SCIENCE, V325, P1017, DOI 10.1126/science.1172545
   SAITO S, 2016, SCI REP UK, V6
   Sandi C, 2011, TRENDS NEUROSCI, V34, P165, DOI 10.1016/j.tins.2011.01.006
   Sarabdjitsingh RA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145858
   Segev A, 2016, NEUROPSYCHOPHARMACOL, V41, P1066, DOI 10.1038/npp.2015.238
   Stahn C, 2008, NAT CLIN PRACT RHEUM, V4, P525, DOI 10.1038/ncprheum0898
   Stepan J, 2012, FRONT NEURAL CIRCUIT, V6, DOI 10.3389/fncir.2012.00064
   Suwanjang W, 2013, CELL CALCIUM, V53, P256, DOI 10.1016/j.ceca.2012.12.006
   Tauheed N, 2014, SAUDI J ANAESTH, V8, P51, DOI 10.4103/1658-354X.125937
   TJOLSEN A, 1989, J NEUROSCI METH, V26, P259, DOI 10.1016/0165-0270(89)90124-6
   Vogel Susanne, 2016, NPJ Sci Learn, V1, P16011, DOI 10.1038/npjscilearn.2016.11
   Whitehead G, 2013, BRAIN, V136, P3753, DOI 10.1093/brain/awt293
   Wiegert O, 2005, NEUROSCIENCE, V135, P403, DOI 10.1016/j.neuroscience.2005.05.039
   Zhang BL, 2011, BRAIN RES, V1382, P165, DOI 10.1016/j.brainres.2011.01.065
   Zucker RS, 1999, CURR OPIN NEUROBIOL, V9, P305, DOI 10.1016/S0959-4388(99)80045-2
NR 60
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD SEP 1
PY 2017
VL 1670
BP 44
EP 51
DI 10.1016/j.brainres.2017.06.007
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA FD6VM
UT WOS:000407666000006
PM 28606783
OA Bronze
DA 2020-12-08
ER

PT J
AU da Silva, CC
   Azevedo, BN
   Machado, DC
   Zimmer, ER
   Martins, LAM
   da Costa, JC
AF da Silva, Caroline Calice
   Azevedo, Barbara Nunes
   Machado, Denise Cantarelli
   Zimmer, Eduardo R.
   Meira Martins, Leo Anderson
   da Costa, Jaderson Costa
TI Dissociation between dopaminergic response and motor behavior following
   intrastriatal, but not intravenous, transplant of bone marrow
   mononuclear stem cells in a mouse model of Parkinson's disease
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE Parkinson's disease; Mouse; Stem cell; Intravenous; Intrastriatal; Motor
   behavior
ID BLOOD-BRAIN-BARRIER; SUBSTANTIA-NIGRA; ACTIVATED MICROGLIA;
   CAUDATE-NUCLEUS; ANIMAL-MODEL; IN-VIVO; NEURONS; 6-HYDROXYDOPAMINE;
   NEUROINFLAMMATION; DEGENERATION
AB Parkinson's disease is characterized by the progressive loss of dopaminergic neurons from the substantia nigra, a process that leads to a dopamine deficiency in the striatum. This deficiency is responsible for the development of motor symptoms, including resting tremor, bradykinesia, rigidity and postural instability. Based on the observation of substantial neuronal death, alternatives to Parkinson's disease treatment have been studied, including cell-based therapies. The present study aimed to assess the therapeutic potential of intravenous and intrastriatal transplant of bone marrow mononuclear cells in a mouse model of Parkinson's disease. Animals underwent stereotaxic surgery and received an injection of 6-hydroxydopamine into their medial forebrain bundle. Three weeks later, mice were injected with bone marrow mononuclear cells or saline through the caudal vein or directly into their right striatum. Motor function was assessed using the rotarod and apomorphine-induced rotation tests. Our results showed that intrastriatal bone marrow mononuclear cells, but not intravenous, have a short-term therapeutic effect on dopaminergic response in this mice model of parkinsonism assessed by the apomorphine-induced rotation test. This phenomenon was not identified on the rotarod test, showing dissociation between dopaminergic response and motor behavior. Further experiments are needed to elucidate the precise mechanisms involved in these effects.(C) 2017 Elsevier B.V. All rights reserved.
C1 [da Silva, Caroline Calice; Machado, Denise Cantarelli; da Costa, Jaderson Costa] Pontifical Catholic Univ Rio Grande Do Sul PUCRS, Postgrad Program Med & Hlth Sci, BR-90619900 Porto Alegre, RS, Brazil.
   [da Silva, Caroline Calice; Azevedo, Barbara Nunes; da Costa, Jaderson Costa] Pontifical Catholic Univ Rio Grande Do Sul PUCRS, Inst Biomed Res, Lab Neurosci & Cellular Signaling, BR-90619900 Porto Alegre, RS, Brazil.
   [da Silva, Caroline Calice; Azevedo, Barbara Nunes; da Costa, Jaderson Costa] Pontifical Catholic Univ Rio Grande Do Sul PUCRS, Brain Inst Rio Grande Do Sul Bralns, BR-90619900 Porto Alegre, RS, Brazil.
   [Machado, Denise Cantarelli] Pontifical Catholic Univ Rio Grande Do Sul PUCRS, Inst Biomed Res, Lab Mol & Cellular Biol, BR-90619900 Porto Alegre, RS, Brazil.
   [Zimmer, Eduardo R.; Meira Martins, Leo Anderson] Fed Univ Rio Grande Do Sul UFRGS, Inst Basic Hlth Sci ICBS, Dept Biochem, BR-90035003 Porto Alegre, RS, Brazil.
   [da Silva, Caroline Calice] IMED, Sch Med, BR-99070220 Passo Fundo, RS, Brazil.
RP da Costa, JC (corresponding author), Pontifical Catholic Univ Rio Grande Do Sul PUCRS, Brain Inst Rio Grande Do Sul Bralns, Av Ipiranga,6690,Predio 63,2o Andar, BR-90619900 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Martins, Leo/R-7147-2016; da Silva, Caroline Calice/AAQ-1413-2020;
   Machado, Denise C/G-2852-2014; Zimmer, Eduardo R Rigon/I-2932-2015
OI da Silva, Caroline Calice/0000-0003-3239-000X; Machado, Denise
   C/0000-0002-9371-5886; Zimmer, Eduardo R Rigon/0000-0002-5349-0053
FU Coordenagao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES);
   Secretaria de Ciencias e Tecnologia do Estado do RS and Pandurata Ltda,
   Brazil
FX We would like to thank the Laboratorio de Biologia Molecular e Celular
   from PUCRS for the support in PCR and flow cytometry techniques, as well
   as Dr. Gianina Venturin and Dr. Samuel Greggio for proof reading the
   article. This work was supported by grants from Coordenagao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Secretaria de
   Ciencias e Tecnologia do Estado do RS and Pandurata Ltda, Brazil.
CR Bahat-Stroomza M, 2009, J MOL NEUROSCI, V39, P199, DOI 10.1007/s12031-008-9166-3
   Bandopadhyay R, 2010, TRENDS MOL MED, V16, P27, DOI 10.1016/j.molmed.2009.11.004
   Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870
   Bartels AL, 2008, PARKINSONISM RELAT D, V14, P505, DOI 10.1016/j.parkreldis.2007.11.007
   Blandini F, 2010, CELL TRANSPLANT, V19, P203, DOI 10.3727/096368909X479839
   Bove J, 2012, NEUROSCIENCE, V211, P51, DOI 10.1016/j.neuroscience.2011.10.057
   Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198
   Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2
   Capitelli CS, 2014, INT J MED SCI, V11, P1049, DOI 10.7150/ijms.8182
   Carvey PM, 2005, EUR J NEUROSCI, V22, P1158, DOI 10.1111/j.1460-9568.2005.04281.x
   Chao YX, 2009, J NEUROIMMUNOL, V216, P39, DOI 10.1016/j.jneuroim.2009.09.003
   Cho BP, 2006, GLIA, V53, P92, DOI 10.1002/glia.20265
   Cicchetti F, 2002, EUR J NEUROSCI, V15, P991, DOI 10.1046/j.1460-9568.2002.01938.x
   Costa-Ferro ZSM, 2012, NEUROBIOL DIS, V46, P302, DOI 10.1016/j.nbd.2011.12.001
   Costa-Ferro ZSM, 2010, SEIZURE-EUR J EPILEP, V19, P84, DOI 10.1016/j.seizure.2009.12.003
   Danielyan L, 2011, REJUV RES, V14, P3, DOI 10.1089/rej.2010.1130
   de Paula S, 2012, NEUROSCIENCE, V210, P431, DOI 10.1016/j.neuroscience.2012.03.009
   Delcroix GJR, 2011, BIOMATERIALS, V32, P1560, DOI 10.1016/j.biomaterials.2010.10.041
   dos Santos AD, 2010, BRAIN RES, V1306, P149, DOI 10.1016/j.brainres.2009.09.094
   Fahn Stanley, 2004, NeuroRx, V1, P139, DOI 10.1602/neurorx.1.1.139
   FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202
   Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002
   Grunblatt E, 2000, ANN NY ACAD SCI, V899, P262
   Hauser RA, 1999, ARCH NEUROL-CHICAGO, V56, P179, DOI 10.1001/archneur.56.2.179
   Hefti F., BRAIN RES, V195
   Hellmann MA, 2006, NEUROSCI LETT, V395, P124, DOI 10.1016/j.neulet.2005.10.097
   Iancu R, 2005, BEHAV BRAIN RES, V162, P1, DOI 10.1016/j.bbr.2005.02.023
   Isacson O, 2004, NEURON, V43, P165, DOI 10.1016/j.neuron.2004.07.007
   Kefalopoulou Z, 2014, JAMA NEUROL, V71, P83, DOI 10.1001/jamaneurol.2013.4749
   Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900
   Kim YJ, 2009, GLIA, V57, P13, DOI 10.1002/glia.20731
   Kortekaas R, 2005, ANN NEUROL, V57, P176, DOI 10.1002/ana.20369
   Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X
   Leist M, 2008, ALTEX-ALTERN TIEREXP, V25, P163
   Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9
   Limousin P, 2008, NEUROTHERAPEUTICS, V5, P309, DOI 10.1016/j.nurt.2008.01.006
   LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529
   MADRAZO I, 1988, NEW ENGL J MED, V318, P51
   MADRAZO I, 1990, ARCH NEUROL-CHICAGO, V47, P1281, DOI 10.1001/archneur.1990.00530120025005
   Marchi N., EPILEPSIA, V53
   Marchi N, 2014, TRENDS NEUROSCI, V37, P55, DOI 10.1016/j.tins.2013.11.002
   MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285
   Meissner A, 2007, NAT BIOTECHNOL, V25, P1177, DOI 10.1038/nbt1335
   Minguell JJ, 2000, BRAZ J MED BIOL RES, V33, P881, DOI 10.1590/S0100-879X2000000800003
   Na SJ, 2010, NEUROCHEM RES, V35, P761, DOI 10.1007/s11064-010-0133-3
   Nilsson A, 2009, MOL CELL PROTEOMICS, V8, P1094, DOI 10.1074/mcp.M800454-MCP200
   Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X
   Parish CL, 2008, J CLIN INVEST, V118, P149, DOI 10.1172/JCI32273
   Paxinos G., 2003, MOUSE BRAIN STEREOTA
   Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3
   Piccini P, 1999, NAT NEUROSCI, V2, P1137, DOI 10.1038/16060
   SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201
   UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P69
   Venturin GT, 2011, LIFE SCI, V89, P229, DOI 10.1016/j.lfs.2011.06.006
   Wang FF, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-52
   Wang H.Q., ANTIOXID REDOX SIGNA, V9
   Webber DJ, 2007, REGEN MED, V2, P929, DOI 10.2217/17460751.2.6.929
   Wei P, 2007, NEUROSCI LETT, V419, P49, DOI 10.1016/j.neulet.2007.03.046
   Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8
   Zanirati G, 2015, CNS NEUROSCI THER, V21, P463, DOI 10.1111/cns.12382
   Zhang X, 2008, P NATL ACAD SCI USA, V105, P2163, DOI 10.1073/pnas.0711839105
   Zhang ZQ, 2008, IN VITRO CELL DEV-AN, V44, P169, DOI 10.1007/s11626-008-9093-1
NR 62
TC 2
Z9 2
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD MAY 1
PY 2017
VL 324
BP 30
EP 40
DI 10.1016/j.bbr.2017.02.005
PG 11
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA EP9JY
UT WOS:000397691100004
PM 28167338
DA 2020-12-08
ER

PT J
AU da Silva, AMM
   Narciso, LDL
   Schuck, PN
   Dartora, CM
   Alves, IL
   Matushita, CS
   da Costa, JC
   Becker, J
AF Marques da Silva, A. M.
   Narciso, L. D. L.
   Schuck, P. N.
   Dartora, C. M.
   Alves, I. L.
   Matushita, C. S.
   da Costa, J. C.
   Becker, J.
TI Semiquantification of [C-11]-(R)-PK11195 PET imaging in juxtacortical
   and periventricular regions in multiple sclerosis
SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
LA English
DT Meeting Abstract
CT 28th International Symposium on Cerebral Blood Flow, Metabolism and
   Function / 13th International Conference on Quantification of Brain
   Function with PET
CY APR 01-04, 2017
CL Int Soc Cerebral Blood Flow & Metab, Berlin, GERMANY
SP MCI Deutschland GmbH
HO Int Soc Cerebral Blood Flow & Metab
C1 [Marques da Silva, A. M.; Schuck, P. N.] Pontificia Univ Catolica Rio Grande do Sul, Sch Phys, Porto Alegre, RS, Brazil.
   [Narciso, L. D. L.; Dartora, C. M.] Pontificia Univ Catolica Rio Grande do Sul, Sch Engn, Porto Alegre, RS, Brazil.
   [Alves, I. L.] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, Groningen, Netherlands.
   [Matushita, C. S.; da Costa, J. C.; Becker, J.] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst Rio Grande do Sul, Porto Alegre, RS, Brazil.
RI Becker, Jefferson/G-6417-2012; Dartora, Caroline/O-5257-2017
OI Dartora, Caroline/0000-0003-1357-3230
CR Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366
   Schmidt P, 2012, NEUROIMAGE, V59, P3774, DOI 10.1016/j.neuroimage.2011.11.032
NR 2
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0271-678X
EI 1559-7016
J9 J CEREBR BLOOD F MET
JI J. Cereb. Blood Flow Metab.
PD APR
PY 2017
VL 37
SU 1
MA PS02-073
BP 213
EP 214
PG 2
WC Endocrinology & Metabolism; Hematology; Neurosciences
SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology
GA ET3DM
UT WOS:000400157400312
DA 2020-12-08
ER

PT J
AU Marinowic, DR
   Majolo, F
   Sebben, AD
   Da Silva, VD
   Lopes, TG
   Paglioli, E
   Palmini, A
   Machado, DC
   Da Costa, JC
AF Marinowic, Daniel Rodrigo
   Majolo, Fernanda
   Sebben, Alessandra Deise
   Da Silva, Vinicius Duval
   Lopes, Tiago Giuliani
   Paglioli, Eliseu
   Palmini, Andre
   Machado, Denise Cantarelli
   Da Costa, Jaderson Costa
TI Induced pluripotent stem cells from patients with focal cortical
   dysplasia and refractory epilepsy
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE focal cortical dysplasia; refractory epilepsy; induced; pluripotent stem
   cells; cellular model
ID FAMILIAL ALZHEIMERS-DISEASE; HUMAN BRAIN; NEURONAL DIFFERENTIATION;
   GENETIC CORRECTION; CEREBRAL-CORTEX; MUTATIONS CAUSE; SENDAI-VIRUS;
   MODEL; IPSCS; MALFORMATIONS
AB Focal cortical dysplasia (FCD) is caused by numerous alterations, which can be divided into abnormalities of the cortical architecture and cytological variations; however, the exact etiology of FCD remains unknown. The generation of induced pluripotent stem cells (iPSCs) from the cells of patients with neurological diseases, and their subsequent tissue-specific differentiation, serves as an invaluable source for testing and studying the initial development and subsequent progression of diseases associated with the central nervous system. A total of 2 patients demonstrating seizures refractory to drug treatment, characterized as FCD Type IIb, were enrolled in the present study. Fibroblasts were isolated from residual skin fragments obtained from surgical treatment and from brain samples obtained during surgical resection. iPSCs were generated following exposure of fibroblasts to viral vectors containing POU class 5 homeobox 1 (OCT4), sex determining region Y-box 2 (SOX2), Kruppel-like factor 4 and c-MYC genes, and were characterized by immunohistochemical staining for the pluripotent markers homeobox protein NANOG, SOX2, OCT4, TRA1-60 and TRA1-81. The brain samples were tested with antibodies against protein kinase B (AKT), phosphorylated-AKT, mechanistic target of rapamycin (mTOR) and phosphorylated-mTOR. Analysis of the AKT/mTOR pathway revealed a statistically significant difference between the cerebral tissues of the two patients, which were of different ages (45 and 12 years old). Clones with the morphological features of embryonic cells were detected on the 13th day and were characterized following three subcultures. The positive staining characteristics of the embryonic cells confirmed the successful generation of iPSCs derived from the patients' fibroblasts. Therefore, the present study presents a method to obtain a useful cellular source that may help to understand embryonic brain development associated with FCD.
C1 [Marinowic, Daniel Rodrigo; Sebben, Alessandra Deise; Machado, Denise Cantarelli; Da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst Rio Grande do Sul BraIns, 6690 Ave Ipiranga, BR-90610000 Porto Alegre, RS, Brazil.
   [Marinowic, Daniel Rodrigo; Majolo, Fernanda; Sebben, Alessandra Deise; Machado, Denise Cantarelli] Pontificia Univ Catolica Rio Grande do Sul, Inst Biomed Res, BR-90610000 Porto Alegre, RS, Brazil.
   [Da Silva, Vinicius Duval; Lopes, Tiago Giuliani; Machado, Denise Cantarelli] Pontificia Univ Catolica Rio Grande do Sul, Lab Pathol Anat, BR-90610000 Porto Alegre, RS, Brazil.
   [Da Silva, Vinicius Duval; Palmini, Andre; Da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Postgrad Program Med & Hlth Sci, BR-90610000 Porto Alegre, RS, Brazil.
   [Paglioli, Eliseu; Palmini, Andre] Pontificia Univ Catolica Rio Grande do Sul, Epilepsy Surg Program, BR-90610000 Porto Alegre, RS, Brazil.
RP Da Costa, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Brain Inst Rio Grande do Sul BraIns, 6690 Ave Ipiranga, BR-90610000 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Majolo, Fernanda/S-5732-2018; Machado, Denise C/G-2852-2014
OI Majolo, Fernanda/0000-0002-7955-078X; Machado, Denise
   C/0000-0002-9371-5886
FU National Council for Scientific and Technological DevelopmentNational
   Council for Scientific and Technological Development (CNPq)
   [457384/2013-1]; Coordination of improvement of Higher Level Personnel
   [380095/2014-9]
FX The authors would like to thank the National Council for Scientific and
   Technological Development (grant no. 457384/2013-1) and the Coordination
   of improvement of Higher Level Personnel (grant no 380095/2014-9) for
   their financial support.
CR Andrews PW, 2009, STEM CELL REV REP, V5, P301, DOI 10.1007/s12015-009-9085-x
   Arai A, 2012, BRAIN RES, V1470, P89, DOI 10.1016/j.brainres.2012.06.009
   Asprer JST, 2015, STEM CELL REV REP, V11, P357, DOI 10.1007/s12015-014-9580-6
   Blumcke I, 2011, EPILEPSIA, V52, P158, DOI 10.1111/j.1528-1167.2010.02777.x
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Chung CY, 2013, SCIENCE, V342, P983, DOI 10.1126/science.1245296
   Devlin AC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6999
   Djuric U, 2015, NEUROBIOL DIS, V76, P37, DOI 10.1016/j.nbd.2015.01.001
   Doers ME, 2014, STEM CELLS DEV, V23, P1777, DOI 10.1089/scd.2014.0030
   Dolmetsch R, 2011, CELL, V145, P831, DOI 10.1016/j.cell.2011.05.034
   Dragunow M, 2008, NAT REV DRUG DISCOV, V7, P659, DOI 10.1038/nrd2617
   Duan LS, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-3
   FRIES KM, 1994, CLIN IMMUNOL IMMUNOP, V72, P283, DOI 10.1006/clin.1994.1144
   Fusaki N, 2009, P JPN ACAD B-PHYS, V85, P348, DOI 10.2183/pjab.85.348
   Guerrini R, 2008, TRENDS NEUROSCI, V31, P154, DOI 10.1016/j.tins.2007.12.004
   Guerrini R, 2014, LANCET NEUROL, V13, P710, DOI 10.1016/S1474-4422(14)70040-7
   Guo X, 2013, J CLIN INVEST, V123, P5371, DOI 10.1172/JCI70911
   Hossini AM, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1262-5
   Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498
   Ichida JK, 2015, EMBO J, V34, P1456, DOI 10.15252/embj.201591267
   Israel MA, 2012, NATURE, V482, P216, DOI 10.1038/nature10821
   Jansen LA, 2015, BRAIN, V138, P1613, DOI 10.1093/brain/awv045
   Jiao J, 2013, HUM MOL GENET, V22, P4241, DOI 10.1093/hmg/ddt275
   Johnson TE, 2008, EXP GERONTOL, V43, P1, DOI 10.1016/j.exger.2007.09.008
   Kabat J, 2012, POL J RADIOL, V77, P35, DOI 10.12659/PJR.882968
   Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980
   Kiskinis E, 2014, CELL STEM CELL, V14, P781, DOI 10.1016/j.stem.2014.03.004
   Kuzniecky R, 2015, CURR OPIN NEUROL, V28, P151, DOI 10.1097/WCO.0000000000000175
   Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517
   Lee G, 2009, NATURE, V461, P402, DOI 10.1038/nature08320
   Lee P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2824
   Li HO, 2000, J VIROL, V74, P6564, DOI 10.1128/JVI.74.14.6564-6569.2000
   Livide G, 2015, EUR J HUM GENET, V23, P195, DOI 10.1038/ejhg.2014.81
   Luo YM, 2012, TOHOKU J EXP MED, V226, P151, DOI 10.1620/tjem.226.151
   Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016
   Marinowic DR, 2015, IN VITRO CELL DEV-AN, V51, P26, DOI 10.1007/s11626-014-9804-8
   Mekhoubad S, 2012, CELL STEM CELL, V10, P595, DOI 10.1016/j.stem.2012.02.014
   O' Neill C, 2013, EXP GERONTOL, V48, P647, DOI 10.1016/j.exger.2013.02.025
   Palmini A, 2004, NEUROLOGY, V62, pS2, DOI 10.1212/01.WNL.0000114507.30388.7E
   Parent JM, 2015, NAT NEUROSCI, V18, P360, DOI 10.1038/nn.3944
   Paulsen BD, 2012, CELL TRANSPLANT, V21, P1547, DOI 10.3727/096368911X600957
   Prayson RA, 2002, NEUROSURG CLIN N AM, V13, P17, DOI 10.1016/S1042-3680(02)80003-1
   Reinhardt P, 2013, CELL STEM CELL, V12, P354, DOI 10.1016/j.stem.2013.01.008
   Robicsek O, 2013, MOL PSYCHIATR, V18, P1067, DOI 10.1038/mp.2013.67
   Sanders LH, 2014, NEUROBIOL DIS, V62, P381, DOI 10.1016/j.nbd.2013.10.013
   Sareen D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007529
   Song B, 2012, STEM CELL RES, V8, P259, DOI 10.1016/j.scr.2011.12.001
   Takahashi K, 2007, NAT PROTOC, V2, P3081, DOI 10.1038/nprot.2007.418
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   TAYLOR DC, 1971, J NEUROL NEUROSUR PS, V34, P369, DOI 10.1136/jnnp.34.4.369
   Tiscornia G, 2013, HUM MOL GENET, V22, P633, DOI 10.1093/hmg/dds471
   Wainger BJ, 2014, CELL REP, V7, P1, DOI 10.1016/j.celrep.2014.03.019
   Williams EC, 2014, HUM MOL GENET, V23, P2968, DOI 10.1093/hmg/ddu008
   Yagi T, 2011, HUM MOL GENET, V20, P4530, DOI 10.1093/hmg/ddr394
   Yao YW, 2015, ELIFE, V4, DOI 10.7554/eLife.05449
   Yoon KJ, 2014, CELL STEM CELL, V15, P79, DOI 10.1016/j.stem.2014.05.003
   Zhou J, 2009, J NEUROSCI, V29, P1773, DOI 10.1523/JNEUROSCI.5685-08.2009
NR 58
TC 9
Z9 9
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD APR
PY 2017
VL 15
IS 4
BP 2049
EP 2056
DI 10.3892/mmr.2017.6264
PG 8
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA EP2HE
UT WOS:000397203200076
PM 28260047
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Paglioli, E
   Martins, WA
   Azambuja, N
   Portuguez, M
   Frigeri, TM
   Pinos, L
   Saute, R
   Salles, C
   Hoefel, JR
   Soder, RB
   da Costa, JC
   Hemb, M
   Theys, T
   Palmini, A
AF Paglioli, Eliseu
   Martins, William Alves
   Azambuja, Ney
   Portuguez, Mirna
   Frigeri, Thomas More
   Pinos, Larissa
   Saute, Ricardo
   Salles, Cora
   Hoefel, Joao Rubiao
   Soder, Ricardo Bernardi
   da Costa, Jaderson Costa
   Hemb, Marta
   Theys, Tom
   Palmini, Andre
TI Selective posterior callosotomy for drop attacks A new approach sparing
   prefrontal connectivity
SO NEUROLOGY
LA English
DT Article
ID TERM-FOLLOW-UP; CORPUS CALLOSOTOMY; INTRACTABLE EPILEPSY;
   PEDIATRIC-PATIENTS; SEIZURE OUTCOMES; CALLOSAL SECTION; ANTERIOR;
   CHILDREN; STIMULATION; DIVISION
AB Objective: To evaluate a novel approach to control epileptic drop attacks through a selective posterior callosotomy, sparing all prefrontal interconnectivity.
   Methods: Thirty-six patients with refractory drop attacks had selective posterior callosotomy and prospective follow-up for >4 years. Falls, episodes of aggressive behavior, and IQ were quantified. Autonomy in activities of daily living, axial tonus, and speech generated a functional score ranging from 0 to 13. Subjective effect on patient well-being and caregiver burden was also assessed.
   Results: Median monthly frequency of drop attacks decreased from 150 to 0.5. Thirty patients (83%) achieved either complete or >90% control of the falls. Need for constant supervision decreased from 90% to 36% of patients. All had estimated IQ below 85. Median functional score increased from 7 to 10 (p = 0.03). No patient had decrease in speech fluency or hemiparesis. Caregivers rated the effect of the procedure as excellent in 40% and as having greatly improved functioning in another 50%. Clinical, EEG, imaging, and cognitive variables did not correlate with outcome.
   Conclusions: This cohort study with objective outcome assessment suggests that selective posterior callosotomy is safe and effective to control drop attacks, with functional and behavioral gains in patients with intellectual disability. Results are comparable to historical series of total callosotomy and suggest that anterior callosal fibers may be spared.
   Classification of evidence: This study provides Class III evidence that selective posterior callosotomy reduces falls in patients with epileptic drop attacks.
C1 [Paglioli, Eliseu; Martins, William Alves; Azambuja, Ney; Portuguez, Mirna; Frigeri, Thomas More; da Costa, Jaderson Costa; Hemb, Marta; Palmini, Andre] Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre Epilepsy Surg Program, Neurol & Neurosurg Serv, Hosp Sao Lucas, Porto Alegre, RS, Brazil.
   [Portuguez, Mirna; Soder, Ricardo Bernardi; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Inst Brain, Porto Alegre, RS, Brazil.
   [Paglioli, Eliseu; Azambuja, Ney; Portuguez, Mirna; Pinos, Larissa; Saute, Ricardo; Salles, Cora; Hoefel, Joao Rubiao; Soder, Ricardo Bernardi; da Costa, Jaderson Costa; Hemb, Marta; Palmini, Andre] Pontificia Univ Catolica Rio Grande do Sul, Fac Med, Porto Alegre, RS, Brazil.
   [Theys, Tom] Univ Ziekenhuizen Leuven, Dept Neurosurg, Leuven, Belgium.
RP Palmini, A (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre Epilepsy Surg Program, Neurol & Neurosurg Serv, Hosp Sao Lucas, Porto Alegre, RS, Brazil.; Palmini, A (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Fac Med, Porto Alegre, RS, Brazil.
EM andre.palmini@pucrs.br
RI Portuguez, Mirna/A-9362-2018; Theys, Tom/AAG-4536-2019
OI Portuguez, Mirna/0000-0003-4068-6249; Theys, Tom/0000-0001-7595-3234
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); NovartisNovartis; AbbottAbbott Laboratories; UCBUCB Pharma SA;
   Janssen-CilagJohnson & Johnson USAJanssen Biotech Inc; Eli LillyEli
   Lilly
FX E. Paglioli, W. Martins, N. Azambuja, M. Portuguez, T. Frigeri, L.
   Pinos, R. Saute, C. Salles, J. Hoefel, R. Soder, J. da Costa, M. Hemb,
   and T. Theys report no disclosures relevant to the manuscript. A.
   Palmini holds a grant from CNPq and has received funds from Novartis,
   Abbott, UCB, Janssen-Cilag, and Eli Lilly as board member, invited
   speaker, for development of educational material, and to cover
   meeting/travel expenses unrelated to the present study. Go to
   Neurology.org for full disclosures.
CR Aboitiz F., 1992, SCIENCE, V598, P143
   Bower RS, 2013, NEUROSURGERY, V73, P993, DOI 10.1227/NEU.0000000000000161
   Devinsky O, 2003, EPILEPSY BEHAV, V4, P607, DOI 10.1016/j.yebeh.2003.08.029
   GAZZANIGA MS, 1962, P NATL ACAD SCI USA, V48, P1765, DOI 10.1073/pnas.48.10.1765
   GAZZANIGA MS, 1975, NEUROLOGY, V25, P10, DOI 10.1212/WNL.25.1.10
   Gazzaniga MS., 2015, TALES 2 SIDES BRAIN
   Geshwind N., 1965, BRAIN, V88, P237
   Graham D, 2016, EPILEPSIA, V57, P1053, DOI 10.1111/epi.13408
   Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044
   Jalilian L, 2010, J NEUROSURG-PEDIATR, V6, P257, DOI 10.3171/2010.5.PEDS1029
   Jea A, 2008, CHILD NERV SYST, V24, P685, DOI 10.1007/s00381-008-0626-4
   LUDERS HO, 1995, ADV NEUROL, V67, P115
   Machado VH, 2011, EPILEPSIA, V52, P1303, DOI 10.1111/j.1528-1167.2011.03075.x
   Maillard L, 2014, CLIN NEUROPHYSIOL, V125, P2344, DOI 10.1016/j.clinph.2014.03.023
   Naets W, 2015, BRAIN STRUCT FUNCT
   OGUNI H, 1991, ANN NEUROL, V30, P357, DOI 10.1002/ana.410300307
   Pinard JM, 1999, EPILEPSIA, V40, P1727, DOI 10.1111/j.1528-1157.1999.tb01590.x
   Rathore C, 2007, BRAIN DEV-JPN, V29, P577, DOI 10.1016/j.braindev.2007.03.008
   REUTENS DC, 1993, EPILEPSIA, V34, P904, DOI 10.1111/j.1528-1157.1993.tb02110.x
   Rolston JD, 2015, EPILEPSY BEHAV, V51, P13, DOI 10.1016/j.yebeh.2015.06.001
   Shim KW, 2008, J NEUROSURG-PEDIATR, V2, P29, DOI 10.3171/PED/2008/2/7/029
   SIDTIS JJ, 1981, SCIENCE, V212, P344, DOI 10.1126/science.6782673
   SPENCER SS, 1988, EPILEPSIA, V29, pS85, DOI 10.1111/j.1528-1157.1988.tb05802.x
   SPENCER SS, 1993, EPILEPSIA, V34, P561, DOI 10.1111/j.1528-1157.1993.tb02596.x
   SPENCER SS, 1988, NEUROLOGY, V38, P19, DOI 10.1212/WNL.38.1.19
   Stigsdotter-Broman L, 2014, EPILEPSIA, V55, P316, DOI 10.1111/epi.12488
   Sunaga S, 2009, SEIZURE-EUR J EPILEP, V18, P124, DOI 10.1016/j.seizure.2008.08.001
   Tanriverdi T, 2009, J NEUROSURG, V110, P332, DOI 10.3171/2008.3.17570
   Turanli G, 2006, CHILD NERV SYST, V22, P1322, DOI 10.1007/s00381-006-0045-3
   Van Wagenen WP, 1940, ARCH NEURO PSYCHIATR, V44, P740, DOI 10.1001/archneurpsyc.1940.02280100042004
   Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501
   WILSON DH, 1978, NEUROLOGY, V28, P649, DOI 10.1212/WNL.28.7.649
   Yang PF, 2014, EPILEPSY BEHAV, V36, P47, DOI 10.1016/j.yebeh.2014.04.019
   Zarei M, 2006, J ANAT, V209, P311, DOI 10.1111/j.1469-7580.2006.00615.x
NR 34
TC 13
Z9 13
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD NOV 8
PY 2016
VL 87
IS 19
BP 1968
EP 1974
DI 10.1212/WNL.0000000000003307
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA EI1JP
UT WOS:000392233600007
PM 27733569
DA 2020-12-08
ER

PT J
AU Venturin, GT
   Greggio, S
   Zanirati, G
   Marinowic, DR
   de Oliveira, IM
   Henriques, JAP
   DaCosta, JC
AF Venturin, Gianina Teribele
   Greggio, Samuel
   Zanirati, Gabriele
   Marinowic, Daniel Rodrigo
   de Oliveira, Iuri Marques
   Pegas Henriques, Joao Antonio
   DaCosta, Jaderson Costa
TI Transplantation of bone marrow mononuclear cells prolongs survival,
   delays disease onset and progression and mitigates neuronal loss in
   pre-symptomatic, but not symptomatic ALS mice
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Amyotrophic lateral sclerosis; Cell therapy; SOD1 mice
ID AMYOTROPHIC-LATERAL-SCLEROSIS; MESENCHYMAL STROMAL CELLS; TRANSGENIC
   MOUSE MODEL; NEURAL STEM-CELLS; SPINAL-CORD; FOCAL TRANSPLANTATION;
   MOTOR-NEURONS; MUTANT SOD1; RAT MODEL; BRAIN
AB Cell-based therapy provides a novel strategy to restore lost neurons or modulate the degenerating microenvironment in amyotrophic lateral sclerosis (ALS). This study verified the therapeutic potential of bone marrow mononuclear cells (BMMCs) in SOD1(G93A) mice. BMMCs were obtained from enhanced green fluorescent protein (EGFP) transgenic C57BL/6 mice ((BMMCs)-B-EGFP) or from SOD1(G93A) transgenic mice ((BMMCs)-B-mSOD1) and given to mice at the pre-symptomatic or late symptomatic stage. Survival, body weight and motor performance data were recorded. DNA integrity was evaluated using the alkaline comet assay. The spinal cords were collected to assess motoneuron preservation and cell migration. (BMMCs)-B-EGFP and (BMMCs)-B-mSOD1 transplantation to pre-symptomatic SOD1(G93A) mice prolonged survival and delayed disease progression. The effects were more significant for the (BMMC)-B-EGFP-transplanted mice. In late symptomatic mice, (BMMCs)-B-EGFP promoted a discrete increase in survival, without other clinical improvements. DNA from (BMMCs)-B-EGFP and (BMMCs)-B-mSOD1 was found in the spinal cords of transplanted animals. DNA damage was not modified by BMMCs in any of the studied groups. Despite positive behavioral effects observed in our study, the limited results we observed for late transplanted mice call for caution before clinical application of BMMCs in ALS. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Venturin, Gianina Teribele; Greggio, Samuel; DaCosta, Jaderson Costa] Inst Cerebro Rio Grande Sul, Brain Inst Brains, Ctr Pesquisa Preclin, Porto Alegre, RS, Brazil.
   [Venturin, Gianina Teribele; Greggio, Samuel; Zanirati, Gabriele; DaCosta, Jaderson Costa] Pontificia Univ Catolica Rio Grande Sul PUCRS, Brain Inst Brains, Inst Cerebro Rio Grande Sul, Lab Neurociencias, Porto Alegre, RS, Brazil.
   [Marinowic, Daniel Rodrigo] Pontificia Univ Catolica Rio Grande Sul PUCRS, Brain Inst Brains, Inst Cerebro Rio Grande Sul, Lab Terapia Celular, Porto Alegre, RS, Brazil.
   [de Oliveira, Iuri Marques; Pegas Henriques, Joao Antonio] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Biofis, Porto Alegre, RS, Brazil.
RP DaCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande Sul PUCRS, Brain Inst Brains, Inst Cerebro InsCer, Jardim Bot, Ave Ipiranga 6690,Predio 60,2 Andar,Sala 07, BR-90610000 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Greggio, Samuel/E-1498-2013; de Olveira, Iuri/AAV-2953-2020
OI Greggio, Samuel/0000-0002-5187-0335; Zanirati,
   Gabriele/0000-0002-1986-973X; Teribele Venturin,
   Gianina/0000-0001-7696-8219
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Pandurata SA; Coordenacao de Aperfeicoamento Pessoal de Nivel
   Superior (CAPES)CAPES; CNPq (Brazil)National Council for Scientific and
   Technological Development (CNPq)
FX This work was supported by research grants from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) and Pandurata SA. J.C.
   DaCosta and J.A.P. Henriques are CNPq researchers. G.T. Venturin, S.
   Greggio, I.M. de Oliveira and G. Zanirati were recipients of fellowships
   from Coordenacao de Aperfeicoamento Pessoal de Nivel Superior (CAPES) or
   CNPq (Brazil). The authors would like to thank Dr. Jefferson Becker and
   Dr. Denise Cantarelli Machado for their support. The authors have no
   conflicts of interest to disclose.
CR Bigini P, 2011, REJUV RES, V14, P623, DOI 10.1089/rej.2011.1197
   Boido M, 2014, CYTOTHERAPY, V16, P1059, DOI 10.1016/j.jcyt.2014.02.003
   Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511
   Boucherie C, 2009, J NEUROSCI RES, V87, P2034, DOI 10.1002/jnr.22038
   Cabanes C, 2007, NEUROBIOL DIS, V26, P408, DOI 10.1016/j.nbd.2007.01.008
   Cho GW, 2010, STEM CELLS DEV, V19, P1035, DOI 10.1089/scd.2009.0453
   Choi CI, 2013, CELL TRANSPLANT, V22, P855, DOI 10.3727/096368912X637019
   Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071
   Corti S, 2004, BRAIN, V127, P2518, DOI 10.1093/brain/awh273
   Corti S, 2007, BRAIN, V130, P1289, DOI 10.1093/brain/awm043
   Corti S, 2010, HUM MOL GENET, V19, P3782, DOI 10.1093/hmg/ddq293
   Ende N, 2000, LIFE SCI, V67, P53, DOI 10.1016/S0024-3205(00)00602-0
   Forostyak S, 2011, CYTOTHERAPY, V13, P1036, DOI 10.3109/14653249.2011.592521
   Garbuzova-Davis S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001205
   Garbuzova-Davis S, 2012, BRAIN RES, V1469, P114, DOI 10.1016/j.brainres.2012.05.056
   Garbuzova-Davis S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031254
   Garbuzova-Davis S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002494
   Greggio S, 2011, NEUROBIOL DIS, V44, P152, DOI 10.1016/j.nbd.2011.06.018
   Gubert F, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0293-4
   GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258
   Kim H, 2010, NEUROSCI LETT, V468, P190, DOI 10.1016/j.neulet.2009.10.074
   Knippenberg S, 2012, NEURODEGENER DIS, V9, P107, DOI 10.1159/000331327
   Knippenberg S, 2010, BEHAV BRAIN RES, V213, P82, DOI 10.1016/j.bbr.2010.04.042
   Koh SH, 2012, EXP NEUROL, V233, P472, DOI 10.1016/j.expneurol.2011.11.021
   Kondo T, 2014, STEM CELL REP, V3, P242, DOI 10.1016/j.stemcr.2014.05.017
   Lepore AC, 2008, NAT NEUROSCI, V11, P1294, DOI 10.1038/nn.2210
   Lindvall O, 2012, CELL STEM CELL, V10, P660, DOI [10.1016/j.stem.2012.04.004, 10.1016/j.stem.2012.01.009]
   Liu D, 2007, NEUROSCIENCE, V146, P255, DOI 10.1016/j.neuroscience.2007.01.028
   Ludolph AC, 2010, AMYOTROPH LATERAL SC, V11, P38, DOI 10.3109/17482960903545334
   Mitrecic D, 2010, CELL TRANSPLANT, V19, P537, DOI 10.3727/096368910X498269
   Nicaise C, 2011, NEUROPATH APPL NEURO, V37, P179, DOI 10.1111/j.1365-2990.2010.01124.x
   Nicaise C, 2009, BRAIN RES, V1301, P152, DOI 10.1016/j.brainres.2009.09.018
   Ohnishi S, 2009, BRAIN RES, V1296, P216, DOI 10.1016/j.brainres.2009.08.012
   Pastor D, 2012, STEM CELL REV REP, V8, P445, DOI 10.1007/s12015-011-9295-x
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   Suzuki M, 2008, TRENDS NEUROSCI, V31, P192, DOI 10.1016/j.tins.2008.01.006
   Suzuki M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000689
   Terashima T, 2014, J NEUROSCI RES, V92, P856, DOI 10.1002/jnr.23368
   Thomsen GM, 2014, EXP NEUROL, V262, P127, DOI 10.1016/j.expneurol.2014.02.021
   Turner BJ, 2008, PROG NEUROBIOL, V85, P94, DOI 10.1016/j.pneurobio.2008.01.001
   Uccelli A, 2012, MOL MED, V18, P794, DOI 10.2119/molmed.2011.00498
   Venturin GT, 2011, LIFE SCI, V89, P229, DOI 10.1016/j.lfs.2011.06.006
   Xu LY, 2006, TRANSPLANTATION, V82, P865, DOI 10.1097/01.tp.0000235532.00920.7a
   Yamanaka K, 2008, P NATL ACAD SCI USA, V105, P7594, DOI 10.1073/pnas.0802556105
   Zhao CP, 2007, CYTOTHERAPY, V9, P414, DOI 10.1080/14653240701376413
   Zhong ZH, 2008, NAT NEUROSCI, V11, P420, DOI 10.1038/nn2073
NR 46
TC 3
Z9 3
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD OCT 28
PY 2016
VL 633
BP 182
EP 188
DI 10.1016/j.neulet.2016.09.030
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA EA8BY
UT WOS:000386861500028
PM 27666978
OA Bronze
DA 2020-12-08
ER

PT J
AU Battel, L
   Kieling, RR
   Kieling, C
   Anes, M
   Aurich, NK
   da Costa, JC
   Rohde, LA
   Franco, AR
AF Battel, Lucas
   Kieling, Renata R.
   Kieling, Christian
   Anes, Mauricio
   Aurich, Nathassia Kadletz
   da Costa, Jaderson Costa
   Rohde, Luis Augusto
   Franco, Alexandre Rosa
TI Intrinsic Brain Connectivity Following Long-Term Treatment with
   Methylphenidate in Children with Attention-Deficit/Hyperactivity
   Disorder
SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
LA English
DT Article
ID DEFICIT HYPERACTIVITY DISORDER; STIMULANT MEDICATION; DOPAMINE; YOUTH;
   ADHD; FMRI; UNDERACTIVATION; INTERFERENCE; ADOLESCENTS; GUIDELINES
AB Introduction: Although widely used for the treatment of attention-deficit/hyperactivity disorder (ADHD) across the life span, the effects of methylphenidate (MPH) on the brain are not completely understood. Functional neuroimaging techniques may help increase knowledge about the mechanisms of MPH action.
   Objective: To evaluate changes in functional connectivity patterns of the default mode network (DMN) in children with ADHD following long-term treatment with MPH.
   Methods: Twenty-three right-handed treatment-naive boys with ADHD underwent a protocol of intrinsic functional connectivity before and after 6 months of treatment with MPH. Functional connectivity was analyzed using a region of interest (ROI) approach and independent component analysis (ICA).
   Results: ROI analyses showed no significant changes in connectivity between regions of the DMN following treatment, with a relatively small increase in the anterior-posterior connectivity of the network. ICA revealed a significant increase in connectivity between the left putamen and the DMN (p < 0.001, corrected). There was a correlation between the reduction of symptoms and the increased connectivity between the putamen and the DMN after treatment (rho = -0.65, p = 0.017).
   Conclusion: Dysfunctions in cortical-subcortical circuits have often been associated with the pathophysiology of ADHD. Our findings suggest that effective treatment with MPH in children with ADHD may affect brain functioning by increasing connectivity between the DMN and subcortical nuclei.
C1 [Battel, Lucas; Kieling, Renata R.; Kieling, Christian; Anes, Mauricio; Rohde, Luis Augusto] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Dept Psychiat, Rua Ramiro Barcelos 2530-400N, BR-90035009 Porto Alegre, RS, Brazil.
   [Anes, Mauricio; da Costa, Jaderson Costa; Franco, Alexandre Rosa] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst InsCer, Porto Alegre, RS, Brazil.
   [Aurich, Nathassia Kadletz; Rohde, Luis Augusto] Natl Inst Dev Psychiat Children & Adolescents, Porto Alegre, RS, Brazil.
   [Franco, Alexandre Rosa] Pontificia Univ Catolica Rio Grande do Sul, Sch Engn, Porto Alegre, RS, Brazil.
RP Kieling, C (corresponding author), Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Dept Psychiat, Rua Ramiro Barcelos 2530-400N, BR-90035009 Porto Alegre, RS, Brazil.
EM ckieling@ufrgs.br
RI Kieling, Christian/U-3905-2019; Rohde, Luis Augusto P/A-6426-2008; Rosa
   Franco, Alexandre/D-1706-2015; KIELING, RENATA/F-7351-2012
OI Kieling, Christian/0000-0001-7691-4149; Rohde, Luis Augusto
   P/0000-0002-4552-4188; Rosa Franco, Alexandre/0000-0002-1552-1090;
   KIELING, RENATA/0000-0001-6407-324X
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado do Rio Grande do
   Sul (FAPERGS)Foundation for Research Support of the State of Rio Grande
   do Sul (FAPERGS)
FX Drs. C. Kieling, J.C. da Costa, L.A. Rohde, and A.R. Franco receive
   research grants from CNPq, Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES), and Fundacao de Amparo a Pesquisa do Estado do
   Rio Grande do Sul (FAPERGS).
CR An L, 2013, NEUROPSYCHOPHARMACOL, V38, P1287, DOI 10.1038/npp.2013.27
   Atkinson M, 2010, ARCH DIS CHILDHOOD-E, V95, P24, DOI 10.1136/adc.2009.175943
   Bamford NS, 2004, J NEUROSCI, V24, P9541, DOI 10.1523/JNEUROSCI.2891-04.2004
   Bamford NS, 2004, NEURON, V42, P653, DOI 10.1016/S0896-6273(04)00265-X
   BARKLEY RA, 1990, PEDIATRICS, V86, P184
   Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634
   Beckmann CF, 2012, NEUROIMAGE, V62, P891, DOI 10.1016/j.neuroimage.2012.02.020
   Bolea-Alamanac B, 2014, J PSYCHOPHARMACOL, V28, P179, DOI 10.1177/0269881113519509
   Bordin IA, 2013, CAD SAUDE PUBLICA, V29, P13, DOI 10.1590/S0102-311X2013000100004
   Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048
   Chen G, 2013, NEUROIMAGE, V73, P176, DOI 10.1016/j.neuroimage.2013.01.047
   Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014
   Czerniak SM, 2013, HARVARD REV PSYCHIAT, V21, P151, DOI 10.1097/HRP.0b013e318293749e
   Fair DA, 2010, BIOL PSYCHIAT, V68, P1084, DOI 10.1016/j.biopsych.2010.07.003
   Findling RL, 2008, CLIN THER, V30, P942, DOI 10.1016/j.clinthera.2008.05.006
   Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102
   Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021
   Kelly C, 2012, TRENDS COGN SCI, V16, P181, DOI 10.1016/j.tics.2012.02.001
   Kieling C, 2008, CHILD ADOL PSYCH CL, V17, P285, DOI 10.1016/j.chc.2007.11.012
   Kieling C, 2010, AM J PSYCHIAT, V167, P14, DOI 10.1176/appi.ajp.2009.09060796
   Kiyatkin EA, 1996, J NEUROPHYSIOL, V75, P142
   Mattos Paulo, 2006, Rev. psiquiatr. Rio Gd. Sul, V28, P290, DOI 10.1590/S0101-81082006000300008
   Pliszka SR, 2007, J CHILD ADOL PSYCHOP, V17, P356, DOI 10.1089/cap.2006.0081
   Polanczyk GV, 2014, INT J EPIDEMIOL, V43, P434, DOI 10.1093/ije/dyt261
   Posner J, 2011, PSYCHIAT RES-NEUROIM, V193, P151, DOI 10.1016/j.pscychresns.2011.02.005
   Querne L, 2014, J ATTEN DISORD, DOI [10.1177/1087054713517542, DOI 10.1177/1087054713517542.]
   Rappley MD, 2005, NEW ENGL J MED, V352, P165, DOI 10.1056/NEJMcp032387
   Reitan RM, 1992, TRAIL MAKING TEST MA
   Rieppi R, 2002, J AM ACAD CHILD PSY, V41, P269, DOI 10.1097/00004583-200203000-00006
   Rosa-Neto P, 2005, NEUROIMAGE, V25, P868, DOI 10.1016/j.neuroimage.2004.11.031
   Rubia K, 2014, BIOL PSYCHIAT, V76, P616, DOI 10.1016/j.biopsych.2013.10.016
   Rubia K, 2011, BIOL PSYCHIAT, V70, P255, DOI 10.1016/j.biopsych.2011.04.018
   Rubia K, 2011, NEUROPSYCHOPHARMACOL, V36, P1575, DOI 10.1038/npp.2011.30
   Rubia K, 2009, NEUROPHARMACOLOGY, V57, P640, DOI 10.1016/j.neuropharm.2009.08.013
   Rubia K, 2009, PHILOS T R SOC B, V364, P1919, DOI 10.1098/rstb.2009.0014
   SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228
   Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051
   Staff M.H.S, 2000, CONNERS CONTINUOUS P, P1
   Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651
   Supekar K, 2010, NEUROIMAGE, V52, P290, DOI 10.1016/j.neuroimage.2010.04.009
   SWANSON JM, 1991, J LEARN DISABIL, V24, P219, DOI 10.1177/002221949102400406
   Taylor E, 2004, EUR CHILD ADOLES PSY, V13, P7, DOI 10.1007/s00787-004-1002-x
   Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044
   Volkow N D, 2002, J Atten Disord, V6 Suppl 1, pS31
   Volkow N D, 2001, J Neurosci, V21, pRC121
   Volkow ND, 2005, BIOL PSYCHIAT, V57, P1410, DOI 10.1016/j.biopsych.2004.11.006
   Volkow ND, 2002, SYNAPSE, V43, P181, DOI 10.1002/syn.10038
   Volkow ND, 1998, AM J PSYCHIAT, V155, P1325, DOI 10.1176/ajp.155.10.1325
   VOLKOW ND, 1995, ARCH GEN PSYCHIAT, V52, P456
   Volkow ND, 2007, ARCH GEN PSYCHIAT, V64, P932, DOI 10.1001/archpsyc.64.8.932
   WESCHLER D, 1991, WECHSLER INTELLIGENC
   Wolraich M, 2011, PEDIATRICS, V128, P1007, DOI 10.1542/peds.2011-2654
NR 52
TC 5
Z9 5
U1 1
U2 15
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5463
EI 1557-8992
J9 J CHILD ADOL PSYCHOP
JI J. Child Adolesc. Psychopharmacol.
PD AUG
PY 2016
VL 26
IS 6
BP 555
EP +
DI 10.1089/cap.2015.0221
PG 8
WC Pediatrics; Pharmacology & Pharmacy; Psychiatry
SC Pediatrics; Pharmacology & Pharmacy; Psychiatry
GA DU6FA
UT WOS:000382308300009
PM 27027427
DA 2020-12-08
ER

PT J
AU Scorza, FA
   Cavalheiro, EA
   da Costa, JC
AF Scorza, Fulvio A.
   Cavalheiro, Esper A.
   da Costa, Jaderson Costa
TI Sudden cardiac death in epilepsy disappoints, but epileptologists keep
   faith
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Review
DE epilepsy; death, sudden
ID MULTIPLE SOURCE SURVEILLANCE; UNEXPECTED DEATH; REFRACTORY EPILEPSY;
   UNEXPLAINED DEATH; RISK-FACTORS; PREVENTION; SUDEP; EPIDEMIOLOGY;
   CONVERGENCE; MECHANISMS
AB Sudden unexpected death in epilepsy (SUDEP) is the most common cause of death in people with intractable epilepsy. Probably, optimization of seizure control will prevent some of these deaths. Briefly, we integrated in this paper some data about the epidemiology, risk factors, etiology, and preventative measures in the management of SUDEP.
C1 [Scorza, Fulvio A.; Cavalheiro, Esper A.] Univ Fed Sao Paulo, Escola Paulista Med, Disciplina Neurociencia, Dept Neurol Neurocirurgia, Sao Paulo, SP, Brazil.
   [da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Porto, Brazil.
   [da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro Rio Grande Sul, Serv Neurol, Porto, Brazil.
RP Scorza, FA (corresponding author), Rua Pedro Toledo,669-10 Andar, BR-04039032 Sao Paulo, SP, Brazil.
EM scorza.nexp@epm.br
RI Cavalheiro, Esper/N-3985-2019; Scorza, Fulvio/C-7048-2013; Cavalheiro,
   Esper A/F-4325-2014; Cavalheiro, Esper A/I-3084-2016; Scorza, Carla
   Alessandra/C-4199-2013
OI Cavalheiro, Esper/0000-0002-0854-3582; Scorza,
   Fulvio/0000-0002-0694-8674; Cavalheiro, Esper A/0000-0002-0854-3582;
   Cavalheiro, Esper A/0000-0002-0854-3582; Scorza, Carla
   Alessandra/0000-0001-7810-4748
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); CNPq (Conselho
   National de Desenvolvimento Cientifico e Tecnologico); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), CEPID/FAPESP;
   FAPESP/PRONEXFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); FAPESP/CNPq/MCT (Instituto Nacional de Neurociencia
   Translational)
FX This study has been supported by the following grants: FAPESP (Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo); CNPq (Conselho National de
   Desenvolvimento Cientifico e Tecnologico); Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), CEPID/FAPESP;
   FAPESP/PRONEX and FAPESP/CNPq/MCT (Instituto Nacional de Neurociencia
   Translational).
CR Abhilash S P, 2014, Indian Heart J, V66 Suppl 1, pS4, DOI 10.1016/j.ihj.2014.01.002
   Alters K, 2015, BMC NEUROL, V15, P245, DOI [10.1186/s12883-015-0494-y, DOI 10.1186/S12883-015-0494-Y]
   Banerjee PN, 2009, EPILEPSY RES, V85, P31, DOI 10.1016/j.eplepsyres.2009.03.003
   Bottiger BW, 2014, INTENS CARE MED, V40, P907, DOI 10.1007/s00134-014-3319-3
   Byrne R, 2008, EUR HEART J, V29, P1418, DOI 10.1093/eurheartj/ehn155
   Chugh SS, 2004, J AM COLL CARDIOL, V44, P1268, DOI 10.1016/j.jacc.2004.06.029
   Deo R, 2012, CIRCULATION, V125, P620, DOI 10.1161/CIRCULATIONAHA.111.023838
   Devinsky O, 2011, NEW ENGL J MED, V365, P1801, DOI 10.1056/NEJMra1010481
   deVreedeSwagemakers JJM, 1997, J AM COLL CARDIOL, V30, P1500, DOI 10.1016/S0735-1097(97)00355-0
   Donner EJ, 2001, NEUROLOGY, V57, P430, DOI 10.1212/WNL.57.3.430
   Duncan JS, 2006, LANCET, V367, P1087, DOI 10.1016/S0140-6736(06)68477-8
   Engelstein ED, 1998, HEART ARTERIES VEINS, P1081
   Fishman GI, 2010, CIRCULATION, V122, P2335, DOI 10.1161/CIRCULATIONAHA.110.976092
   Forsgren I, 2005, EUR J NEUROL, V12, P54, DOI 10.1111/j.1468-1331.2005.01191.x
   Goldman AM, 2016, EPILEPSIA, V57, P17, DOI 10.1111/epi.13232
   Goldman AM, 2015, CURR OPIN NEUROL, V28, P166, DOI 10.1097/WCO.0000000000000184
   Goldman AM, 2011, SUDDEN UNEXPECTED DE
   Grasner JT, 2013, BEST PRACT RES-CLIN, V27, P293, DOI 10.1016/j.bpa.2013.07.008
   Hesdorffer DC, 2013, CNS DRUGS, V27, P113, DOI 10.1007/s40263-012-0006-1
   Hesdorffer DC, 2011, EPILEPSIA, V52, P1150, DOI 10.1111/j.1528-1167.2010.02952.x
   Hua W, 2009, J AM COLL CARDIOL, V54, P1110, DOI 10.1016/j.jacc.2009.06.016
   Jansen K, 2010, SEIZURE-EUR J EPILEP, V19, P455, DOI 10.1016/j.seizure.2010.07.008
   Jehi Lara, 2010, Cleve Clin J Med, V77 Suppl 3, pS51, DOI 10.3949/ccjm.77.s3.09
   Lamberts RJ, 2012, EPILEPSIA, V53, P253, DOI 10.1111/j.1528-1167.2011.03360.x
   Langan Y, 2000, J NEUROL NEUROSUR PS, V68, P211, DOI 10.1136/jnnp.68.2.211
   Laxer KD, 2014, EPILEPSY BEHAV, V37, P59, DOI 10.1016/j.yebeh.2014.05.031
   Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667
   Massey CA, 2014, NAT REV NEUROL, V10, P271, DOI 10.1038/nrneurol.2014.64
   Mirchandani S, 2003, INT J CARDIOL, V90, P41, DOI 10.1016/S0167-5273(02)00517-X
   Moshe SL, 2015, LANCET, V385, P884, DOI 10.1016/S0140-6736(14)60456-6
   Myerburg RJ, 1997, HEART DIS TXB CARDIO, P742
   Nashef L, 1997, EPILEPSIA, V38, pS6, DOI 10.1111/j.1528-1157.1997.tb06130.x
   Nashef L, 2009, NEUROL CLIN, V27, P1063, DOI 10.1016/j.ncl.2009.08.003
   Nei M, 2010, CURR NEUROL NEUROSCI, V10, P319, DOI 10.1007/s11910-010-0116-4
   Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423
   Novak JL, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00252
   Priori Silvia G, 2014, Indian Heart J, V66 Suppl 1, pS58, DOI 10.1016/j.ihj.2013.11.004
   Schuele Stephan U, 2007, Cleve Clin J Med, V74 Suppl 1, pS121
   Scorza FA, 2008, NEPHROL DIAL TRANSPL, V23, P1775, DOI 10.1093/ndt/gfn017
   Scorza FA, 2010, EPILEPSY BEHAV, V18, P137, DOI 10.1016/j.yebeh.2010.04.046
   Scorza FA, 2009, EPILEPSY BEHAV, V14, P707, DOI 10.1016/j.yebeh.2009.01.009
   Scorza FA, 2011, CLINICS, V66, P65, DOI 10.1590/S1807-59322011001300008
   Scorza FA, 2009, J BRAS PNEUMOL, V35, P613, DOI 10.1590/S1806-37132009000600015
   So EL, 2000, EPILEPSIA, V41, P1494, DOI 10.1111/j.1528-1157.2000.tb00128.x
   Stollberger C, 2004, EPILEPSY RES, V59, P51, DOI 10.1016/j.eplepsyres.2004.03.008
   Surges R, 2009, NAT REV NEUROL, V5, P492, DOI 10.1038/nrneurol.2009.118
   Tigaran S, 2003, NEUROLOGY, V60, P492, DOI 10.1212/01.WNL.0000042090.13247.48
   Tomson T, 2008, LANCET NEUROL, V7, P1021, DOI 10.1016/S1474-4422(08)70202-3
   Tomson T, 2016, EPILEPSIA, V57, P4, DOI 10.1111/epi.13234
   Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334
NR 50
TC 9
Z9 9
U1 0
U2 0
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUL
PY 2016
VL 74
IS 7
BP 570
EP 573
DI 10.1590/0004-282X20160086
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DT4KI
UT WOS:000381448200010
PM 27487377
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Marrone, LCP
   Martins, WA
   Borges, MT
   Rossi, BC
   Brunelli, JPF
   Vedana, VM
   Missima, N
   Soder, RB
   Marrone, ACH
   da Costa, JC
AF Porcello Marrone, Luiz Carlos
   Martins, William Alves
   Borges, Magno Tauceda
   Rossi, Bruna Carvalho
   Farina Brunelli, Joao Pedro
   Vedana, Viviane Maria
   Missima, Nathalia
   Soder, Ricardo Bernardi
   Huf Marrone, Antonio Carlos
   da Costa, Jaderson Costa
TI Posterior Reversible Encephalopathy Syndrome: Clinical Differences in
   Patients with Exclusive Involvement of Posterior Circulation Compared to
   Anterior or Global Involvement
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Posterior reversible encephalopathy syndrome; PRES; cerebral
   autoregulation; cerebral edema; blood pressure
ID IMAGING PATTERNS; SPECTRUM
AB Introduction: Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiologic syndrome not yet fully understood and characterized by transient neurologic symptoms in addition to typical radiological findings. There are only a few articles that describe the clinical differences between patients with PRES that involve carotid and vertebrobasilar circulations. Our study aims to further evaluate the differences between predominantly anterior and posterior circulation PRES. Methods: We review 54 patients who had received the diagnosis of PRES from 2009 to 2015. The patients were divided into 2 groups: (1) exclusively in posterior zones; and (2) anterior plus posterior zones or exclusively anterior zones. Several clinical characteristics were evaluated, including the following: age, sex, previous diseases, the neurologic manifestations, the highest blood pressure in the first 48 hours of presentation, highest creatinine level during symptoms, and the neuroimaging alterations in brain magnetic resonance imaging. Results: Mean age at diagnosis was 28.5 years old (9 men and 45 women) and mean systolic blood pressure among patients with lesions only in posterior zones was 162.1 mmHg compared to 179.2 mmHg in the anterior circulation. The most common symptoms in the 2 groups were headache and visual disturbances. Discussion: PRES may have several radiological features. A higher blood pressure seems to be 1 of the factors responsible for developing widespread PRES, with involvement of carotid vascular territory. This clinical-radiological difference probably occurs because of the larger number of autonomic receptors in the carotid artery in comparison to the vertebralbasilar system. (C) 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.
C1 Pontificia Univ Catolica Rio Grande Sul PUCRS, Hosp Sao Lucas, Dept Neurol, Porto Alegre, RS, Brazil.
   [Porcello Marrone, Luiz Carlos] Pontificia Univ Catolica Rio Grande Sul PUCRS, Inst Cerebro Inscer, Ave Ipiranga 6690,Sala 220, BR-90610000 Porto Alegre, RS, Brazil.
RP Marrone, LCP (corresponding author), Pontificia Univ Catolica Rio Grande Sul PUCRS, Inst Cerebro Inscer, Ave Ipiranga 6690,Sala 220, BR-90610000 Porto Alegre, RS, Brazil.; Marrone, LCP (corresponding author), Pontificia Univ Catolica Rio Grande Sul PUCRS, Hosp Sao Lucas, Ave Ipiranga 6690,Sala 220, BR-90610000 Porto Alegre, RS, Brazil.
EM lcpmarrone@gmail.com
OI Marrone, Luiz Carlos/0000-0002-8071-813X
CR Bartynski WS, 2008, AM J NEURORADIOL, V29, P1036, DOI 10.3174/ajnr.A0928
   Bartynski WS, 2007, AM J NEURORADIOL, V28, P1320, DOI 10.3174/ajnr.A0549
   Brewer J, 2013, AM J OBSTET GYNECOL, V208, pe1, DOI DOI 10.1016/J.AJ0G.2013.02.015
   Casey SO, 2000, AM J NEURORADIOL, V21, P1199
   Cipolla MJ, 2009, PERIVASCULAR INNERVA
   Cruz RJ, 2012, AM J TRANSPLANT, V12, P2228, DOI 10.1111/j.1600-6143.2012.04048.x
   DUNCAN R, 1989, J NEUROL NEUROSUR PS, V52, P899, DOI 10.1136/jnnp.52.7.899
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Kastrup O, 2015, CLIN NEURORADIOL, V25, P161, DOI 10.1007/s00062-014-0293-7
   Lamy C, 2004, J NEUROIMAGING, V14, P89, DOI 10.1177/1051228403258161
   Legriel S, 2011, ANN UPD INTENS CARE, P631
   Liman TG, 2012, J NEUROL, V259, P155, DOI 10.1007/s00415-011-6152-4
   Marrone Luis, 2012, Rev Bras Reumatol, V52, P804
   NAG S, 1977, LAB INVEST, V36, P150
   Marrone LCP, 2014, J STROKE CEREBROVASC, V23, P2075, DOI 10.1016/j.jstrokecerebrovasdis.2014.03.012
   Marrone LCP, 2014, NEUROL INT, V6, P11, DOI 10.4081/ni.2014.5376
   Marrone LCP, 2013, CASE REP ONCOL MED, DOI 10.1155/2013/306983
   Marrone LCP, 2011, CASE REP ONCOL, V4, P82, DOI 10.1159/000324581
   Port JD, 1998, RADIOGRAPHICS, V18, P353, DOI 10.1148/radiographics.18.2.9536483
   STRANDGAARD S, 1984, STROKE, V15, P413, DOI 10.1161/01.STR.15.3.413
   Sukumaran S, 2010, BONE MARROW TRANSPL, V45, P779, DOI 10.1038/bmt.2009.211
   TRUWIT CL, 1991, AM J NEURORADIOL, V12, P651
NR 22
TC 6
Z9 8
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD JUL
PY 2016
VL 25
IS 7
BP 1776
EP 1780
DI 10.1016/j.jstrokecerebrovasdis.2016.03.042
PG 5
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA DO7ZW
UT WOS:000378002800031
PM 27103268
DA 2020-12-08
ER

PT J
AU Martins, WA
   Marrone, LCP
   Soder, RB
   da Costa, JC
AF Martins, William Alves
   Porcello Marrone, Luiz Carlos
   Soder, Ricardo Bernardi
   da Costa, Jaderson Costa
TI Hypertrophic olivary degeneration: unveiling the triangle of
   Guillain-Mollaret
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Editorial Material
C1 [Martins, William Alves; Porcello Marrone, Luiz Carlos; Soder, Ricardo Bernardi; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Dept Neurol, Porto Alegre, RS, Brazil.
   [da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Fac Med, Dept Med Interna, Porto Alegre, RS, Brazil.
   [Porcello Marrone, Luiz Carlos; Soder, Ricardo Bernardi; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro, Porto Alegre, RS, Brazil.
RP Martins, WA (corresponding author), Hosp Sao Lucas PUCRS, Dept Neurol, Ave Ipiranga 6690-220, BR-00610000 Porto Alegre, RS, Brazil.
EM walvesm.br@gmail.com
OI Marrone, Luiz Carlos/0000-0002-8071-813X
CR Guillain GC, 1931, REV NEUROL, V2, P545
   Martins WA, 2016, CLIN NEURORADIOL, V26, P99, DOI 10.1007/s00062-015-0384-0
   Siebert E, 2013, NEUROL SCI, V34, P1829, DOI 10.1007/s10072-013-1309-9
NR 3
TC 2
Z9 2
U1 0
U2 1
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD MAY
PY 2016
VL 74
IS 5
BP 426
EP 427
DI 10.1590/0004-282X20160049
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA DN3WT
UT WOS:000376995500013
PM 27191241
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Zanirati, G
   Azevedo, PN
   Marinowic, DR
   Rodrigues, F
   Dias, ACD
   Venturin, GT
   Greggio, S
   Simao, F
   DaCosta, JC
AF Zanirati, Gabriele
   Azevedo, Pamella Nunes
   Marinowic, Daniel Rodrigo
   Rodrigues, Felipe
   de Oliveira Dias, Ana Christina
   Venturin, Gianina Teribele
   Greggio, Samuel
   Simao, Fabricio
   DaCosta, Jaderson Costa
TI Transplantation of Bone Marrow Mononuclear Cells Modulates Hippocampal
   Expression of Growth Factors in Chronically Epileptic Animals
SO CNS NEUROSCIENCE & THERAPEUTICS
LA English
DT Article
DE Epilepsy; Neurotrophic factors; Pilocarpine; Stem cells
ID SPONTANEOUS RECURRENT SEIZURES; NEUROTROPHIC FACTORS; MOUSE HIPPOCAMPUS;
   DENTATE GYRUS; UP-REGULATION; STEM-CELLS; RAT MODEL; BRAIN; BDNF;
   NEUROGENESIS
AB AimsIn previous studies, transplantation of bone marrow mononuclear cells (BMMCs) in epileptic animals has been found to be neuroprotective. However, the mechanism by which the BMMCs act remains unclear. We hypothesize that BMMCs may provide neuroprotection to the epileptic brain through trophic support. To test our hypothesis, we studied the temporal expression of neurotrophins after BMMC transplantation in the epileptic rat hippocampus.
   MethodsChronically epileptic rats were intravenously transplanted with 1x10(7) BMMCs isolated from GFP transgenic mice. Expression levels of BDNF, GDNF, NGF, VEGF, and TGF-1, and their receptors, were evaluated by ELISA and/or qRT-PCR analysis.
   ResultsOur data revealed increased protein expression of BDNF, GDNF, NGF, and VEGF and reduced levels of TGF-1 in the hippocampus of transplanted epileptic animals. Additionally, an increase in the mRNA expression of BDNF, GDNF, and VEGF, a reduction in TGF-1, and a decrease in mRNA levels of the TrkA and TGFR-1 receptors were also observed.
   ConclusionThe gain provided by transplanted BMMCs in the epileptic brain may be related to the ability of these cells in modulating the network of neurotrophins and angiogenic signals.
C1 [Zanirati, Gabriele; Azevedo, Pamella Nunes; Marinowic, Daniel Rodrigo; Rodrigues, Felipe; Simao, Fabricio; DaCosta, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro Rio Grande do Sul InsCer, Lab Neurociencias & Sinalizacao Celular, Posgrad Med & Ciencias Saude,Inst Pesquisas Biomo, BR-90619900 Porto Alegre, RS, Brazil.
   [de Oliveira Dias, Ana Christina] Pontificia Univ Catolica Rio Grande do Sul, Quatro G Pesquisa & Desenvolvimento Ltda, BR-90619900 Porto Alegre, RS, Brazil.
   [Venturin, Gianina Teribele; Greggio, Samuel; DaCosta, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro Rio Grande do Sul InsCer, Ctr Pesquisa Pre Clin, BR-90619900 Porto Alegre, RS, Brazil.
RP DaCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro Rio Grande do Sul InsCer, Lab Neurociencias & Sinalizacao Celular, Ave Ipiranga 6690,Predio 63,Sala 205, BR-90619900 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Greggio, Samuel/E-1498-2013; Simao, Fabricio/A-4621-2013
OI Greggio, Samuel/0000-0002-5187-0335; Simao,
   Fabricio/0000-0002-6229-7618; Teribele Venturin,
   Gianina/0000-0001-7696-8219; Zanirati, Gabriele/0000-0002-1986-973X
FU Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul
   (FAPERGS)Foundation for Research Support of the State of Rio Grande do
   Sul (FAPERGS) [PQG-11/1546-1, ARD- 11/1678-0]; Pandurata Ltda;
   Coordenacao de Aperfeicoamento Pessoal de Nivel Superior (CAPES)CAPES
FX This work was supported by research grants from the Fundacao de Amparo a
   Pesquisa do Estado do Rio Grande do Sul (FAPERGS; PQG-11/1546-1 to J.C.
   DaCosta., ARD- 11/1678-0 to F. Simao) and Pandurata Ltda. G. Zanirati
   and P. Azevedo are the recipient of scholarship from Coordenacao de
   Aperfeicoamento Pessoal de Nivel Superior (CAPES). J.C. DaCosta is a
   researcher of the Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq). We acknowledge Dr. Denise Cantarelli Machado for her
   support in bone marrow mononuclear cell processing.
CR Abdanipour A, 2011, NEUROL RES, V33, P625, DOI 10.1179/1743132810Y.0000000018
   Aronica E, 2000, EUR J NEUROSCI, V12, P2333, DOI 10.1046/j.1460-9568.2000.00131.x
   Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063
   Binder DK, 2001, TRENDS NEUROSCI, V24, P47, DOI 10.1016/S0166-2236(00)01682-9
   Bovolenta R, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-81
   Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009
   Cammalleri M, 2011, EUR J NEUROSCI, V33, P482, DOI 10.1111/j.1460-9568.2010.07529.x
   Carpentino JE, 2008, J NEUROSCI RES, V86, P512, DOI 10.1002/jnr.21514
   Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334
   Chu K, 2004, BRAIN RES, V1023, P213, DOI 10.1016/j.brainres.2004.07.045
   Costa-Ferro ZSM, 2012, NEUROBIOL DIS, V46, P302, DOI 10.1016/j.nbd.2011.12.001
   Costa-Ferro ZSM, 2010, SEIZURE-EUR J EPILEP, V19, P84, DOI 10.1016/j.seizure.2009.12.003
   Dudek FE, 2007, PROG BRAIN RES, V163, P755, DOI 10.1016/S0079-6123(07)63041-6
   Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x
   Guttinger M, 2005, EPILEPSIA, V46, P1162, DOI 10.1111/j.1528-1167.2005.61804.x
   Hawryluk GWJ, 2012, STEM CELLS DEV, V21, P2222, DOI 10.1089/scd.2011.0596
   HEFTI F, 1986, ANN NEUROL, V20, P275, DOI 10.1002/ana.410200302
   HOLTZMAN DM, 1995, J NEUROSCI, V15, P7062
   Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317
   Jankowsky JL, 2001, PROG NEUROBIOL, V63, P125, DOI 10.1016/S0301-0082(00)00022-8
   Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499
   Jing M, 2009, BRAIN RES, V1295, P203, DOI 10.1016/j.brainres.2009.07.079
   Kanter-Schlifke I, 2007, MOL THER, V15, P1106, DOI 10.1038/sj.mt.6300148
   Kobayashi T, 2006, STROKE, V37, P2361, DOI 10.1161/01.STR.0000236025.44089.e1
   Kolomeyer AM, 2011, INVEST OPHTH VIS SCI, V52, P5963, DOI 10.1167/iovs.10-6440
   Koyama R, 2005, NEUROSCIENTIST, V11, P282, DOI 10.1177/1073858405278266
   Krasnova IN, 2013, NEUROBIOL DIS, V58, P132, DOI 10.1016/j.nbd.2013.05.009
   KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108
   Li SL, 2002, EXP NEUROL, V178, P49, DOI 10.1006/exnr.2002.8036
   Li TF, 2009, EPILEPSY RES, V84, P238, DOI 10.1016/j.eplepsyres.2009.01.002
   LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X
   Loscher W, 2002, TRENDS PHARMACOL SCI, V23, P113, DOI 10.1016/S0165-6147(00)01974-X
   Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922
   Maisano X, 2012, J NEUROSCI, V32, P46, DOI 10.1523/JNEUROSCI.2683-11.2012
   Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001
   Nanobashvili A, 2000, P NATL ACAD SCI USA, V97, P12312, DOI 10.1073/pnas.97.22.12312
   Nicoletti JN, 2010, EPILEPSY BEHAV, V19, P272, DOI 10.1016/j.yebeh.2010.07.011
   Paradiso B, 2009, P NATL ACAD SCI USA, V106, P7191, DOI 10.1073/pnas.0810710106
   Plata-Salaman CR, 2000, MOL BRAIN RES, V75, P248, DOI 10.1016/S0169-328X(99)00306-X
   RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0
   Sheedlo HJ, 1998, J ANAT, V193, P223, DOI 10.1046/j.1469-7580.1998.19320223.x
   Shibuya M, 2013, J BIOCHEM, V153, P13, DOI 10.1093/jb/mvs136
   Simonato M, 2006, TRENDS PHARMACOL SCI, V27, P631, DOI 10.1016/j.tips.2006.10.002
   Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217
   Leal MMT, 2014, NEUROCHEM RES, V39, P259, DOI 10.1007/s11064-013-1217-7
   TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5
   Van Kanegan MJ, 2009, MOL CELL BIOL, V29, P662, DOI 10.1128/MCB.01242-08
   Venturin GT, 2011, LIFE SCI, V89, P229, DOI 10.1016/j.lfs.2011.06.006
   Waldau B, 2010, STEM CELLS, V28, P1153, DOI 10.1002/stem.446
NR 49
TC 10
Z9 10
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-5930
EI 1755-5949
J9 CNS NEUROSCI THER
JI CNS Neurosci. Ther.
PD MAY
PY 2015
VL 21
IS 5
BP 463
EP 471
DI 10.1111/cns.12382
PG 9
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA CG4DH
UT WOS:000353232200009
PM 25645708
OA Green Published
DA 2020-12-08
ER

PT J
AU Falavigna, A
   da Costa, JC
AF Falavigna, Asdrubal
   da Costa, Jaderson Costa
TI Mesenchymal Autologous Stem Cells
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cell transplantation; Clinical translations; Mesenchymal stem cells;
   Neuronal differentiation; Spinal cord injury
ID MARROW STROMAL CELLS; SPINAL-CORD-INJURY; HUMAN BONE-MARROW; TRAUMATIC
   BRAIN-INJURY; PROMOTE FUNCTIONAL RECOVERY; MYELIN-ASSOCIATED
   GLYCOPROTEIN; CEREBRAL-ISCHEMIA MODEL; CHRONIC PARAPLEGIC RATS; HUMAN
   ADIPOSE-TISSUE; IN-VIVO
AB The use of cell-based therapies for spinal cord injuries has recently gained prominence as a potential therapy or component of a combination strategy. Experimental and clinical studies have been performed using mesenchymal stem cell therapy to treat spinal cord injuries with encouraging results. However, there have been reports on the adverse effects of these stem cell-based therapies, especially in the context of tumor modulation. This article surveys the literature relevant to the potential of mesenchymal autologous stem cells for spinal cord injuries and their clinical implications.
C1 [Falavigna, Asdrubal] Univ Caxias do Sul, Sch Med, Dept Neurosurg, Caxias Do Sul, Brazil.
   [da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Neurol Serv, Porto Alegre, RS, Brazil.
   [da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro, Porto Alegre, RS, Brazil.
RP Falavigna, A (corresponding author), Univ Caxias do Sul, Sch Med, Dept Neurosurg, Caxias Do Sul, Brazil.
EM asdrubalmd@gmail.com
RI Falavigna, Asdrubal/H-5123-2012
OI Falavigna, Asdrubal/0000-0002-0016-3198
CR Abrams MB, 2009, RESTOR NEUROL NEUROS, V27, P307, DOI 10.3233/RNN-2009-0480
   Alexanian AR, 2011, NEUROREHAB NEURAL RE, V25, P873, DOI 10.1177/1545968311416823
   Alexanian AR, 2010, REGEN MED, V5, P891, DOI 10.2217/RME.10.67
   Angelopoulou M, 2003, EXP HEMATOL, V31, P413, DOI 10.1016/S0301-472X(03)00042-0
   Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045
   Azari MF, 2006, J NEUROPATH EXP NEUR, V65, P914, DOI 10.1097/01.jnen.0000235855.77716.25
   Azari MF, 2010, CURR NEUROPHARMACOL, V8, P316, DOI 10.2174/157015910793358204
   Bakshi A, 2006, J NEUROTRAUM, V23, P55, DOI 10.1089/neu.2006.23.55
   Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501
   Barnabe-Heider F, 2008, CELL STEM CELL, V3, P16, DOI 10.1016/j.stem.2008.06.011
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Benn SC, 2004, NAT REV NEUROSCI, V5, P686, DOI 10.1038/nrn1477
   Bhanot Y, 2011, BRIT J NEUROSURG, V25, P516, DOI 10.3109/02688697.2010.550658
   Bonfield TL, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-51
   Bonner JF, 2011, J NEUROSCI, V31, P4675, DOI 10.1523/JNEUROSCI.4130-10.2011
   Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F
   Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754
   Cao QL, 2005, J NEUROSCI, V25, P6947, DOI 10.1523/JNEUROSCI.1065-05.2005
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471-4914(01)02016-0
   Caplan AI, 2008, CELL STEM CELL, V3, P229, DOI 10.1016/j.stem.2008.08.008
   Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197
   Chapel A, 2003, J GENE MED, V5, P1028, DOI 10.1002/jgm.452
   Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D
   Chen LY, 2009, SCI CHINA SER C, V52, P622, DOI 10.1007/s11427-009-0092-6
   Chernykh ER, 2006, B EXP BIOL MED+, V141, P117, DOI 10.1007/s10517-006-0109-0
   Chidgey AP, 2008, NATURE, V453, P330, DOI 10.1038/nature07041
   Cho KJ, 2005, STEM CELLS, V23, P383, DOI 10.1634/stemcells.2004-0251
   Cizkova D, 2006, CELL MOL NEUROBIOL, V26, P1167, DOI 10.1007/s10571-006-9093-1
   Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097
   Corti S, 2002, J NEUROSCI RES, V70, P721, DOI 10.1002/jnr.10455
   Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Croft AP, 2006, STEM CELLS, V24, P1841, DOI 10.1634/stemcells.2005-0609
   Dasari VR, 2008, NEUROCHEM RES, V33, P134, DOI 10.1007/s11064-007-9426-6
   Dasari VR, 2007, NEUROCHEM RES, V32, P2080, DOI 10.1007/s11064-007-9368-z
   Dasari VR, 2007, J NEUROTRAUM, V24, P391, DOI 10.1089/neu.2006.0142
   Dasari VR, 2008, NEUROBIOL DIS, V32, P486, DOI 10.1016/j.nbd.2008.09.005
   Delorme B, 2006, REGEN MED, V1, P497, DOI 10.2217/17460751.1.4.497
   Delorme B, 2010, STEM CELLS DEV, V19, P853, DOI 10.1089/scd.2009.0267
   Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370
   Deng YB, 2006, CYTOTHERAPY, V8, P210, DOI 10.1080/14653240600760808
   Deng YB, 2005, CHINESE MED J-PEKING, V118, P1533
   Deumens R, 2008, MOL NEUROBIOL, V37, P52, DOI 10.1007/s12035-008-8016-1
   DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303
   Dezawa M, 2005, CURR MOL MED, V5, P723, DOI 10.2174/156652405774641070
   Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935
   DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365-2141.1999.01715.x
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Erceg S, 2009, STEM CELLS, V27, P78, DOI 10.1634/stemcells.2008-0543
   Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305
   Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014
   Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473
   Fluckiger AC, 2003, M S-MED SCI, V19, P699, DOI 10.1051/medsci/20031967699
   FRIEDENS.AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83
   Gerdoni E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Gluckman E, 1997, NEW ENGL J MED, V337, P373, DOI 10.1056/NEJM199708073370602
   Grill R, 1997, J NEUROSCI, V17, P5560
   Gronthos S, 2001, BONE, V28, P174, DOI 10.1016/S8756-3282(00)00424-5
   Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033
   Guillaume DJ, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E2
   Han IS, 2003, MOL CELLS, V15, P176
   Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-12
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756-3282(92)90364-3
   HAYNESWORTH SE, 1992, BONE, V13, P69, DOI 10.1016/8756-3282(92)90363-2
   Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307
   Hill CE, 2001, EXP NEUROL, V171, P153, DOI 10.1006/exnr.2001.7734
   Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976
   Hirouchi Masaaki, 2002, Nihon Yakurigaku Zasshi, V120, P107
   Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299
   Horita Y, 2006, J NEUROSCI RES, V84, P1495, DOI 10.1002/jnr.21056
   Horwitz EM, 2008, CYTOTHERAPY, V10, P771, DOI 10.1080/14653240802618085
   Hu SL, 2010, CRIT CARE MED, V38, P2181, DOI 10.1097/CCM.0b013e3181f17c0e
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Jackson WM, 2010, EXPERT OPIN BIOL TH, V10, P505, DOI 10.1517/14712591003610606
   Janjanin S, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2459
   Javazon EH, 2004, EXP HEMATOL, V32, P414, DOI 10.1016/j.exphem.2004.02.004
   Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Jones EA, 2004, ARTHRITIS RHEUM-US, V50, P817, DOI 10.1002/art.20203
   Ju SH, 2010, INVEST RADIOL, V45, P625, DOI 10.1097/RLI.0b013e3181ed55f4
   Jung DI, 2009, J NEUROL SCI, V285, P67, DOI 10.1016/j.jns.2009.05.027
   Kang SK, 2006, STEM CELLS DEV, V15, P583, DOI 10.1089/scd.2006.15.583
   Karaoz E, 2012, TURK NEUROSURG, V22, P207, DOI 10.5137/1019-5149.JTN.5412-11.1
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kassis I, 2008, ARCH NEUROL-CHICAGO, V65, P753, DOI 10.1001/archneur.65.6.753
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342
   Kim DH, 2004, J KOREAN MED SCI, V19, P113, DOI 10.3346/jkms.2004.19.1.113
   Kim SU, 2004, NEUROPATHOLOGY, V24, P159, DOI 10.1111/j.1440-1789.2004.00552.x
   Kishk NA, 2010, NEUROREHAB NEURAL RE, V24, P702, DOI 10.1177/1545968310369801
   Klein-Nulend J, 2005, PATHOL BIOL, V53, P576, DOI 10.1016/j.patbio.2004.12.005
   Koc ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650
   KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105
   Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608
   Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711
   KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794
   Kucerova L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-129
   Kurozumi K, 2004, MOL THER, V9, P189, DOI 10.1016/j.ymthe.2003.10.012
   Kurtova AV, 2009, BLOOD, V114, P4441, DOI 10.1182/blood-2009-07-233718
   Kwon BK, 2007, SPINE, V32, P1164, DOI 10.1097/BRS.0b013e318053ec35
   Kwon BK, 2010, SPINE, V35, pS263, DOI 10.1097/BRS.0b013e3181f3286d
   LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557
   Lazarus HM, 2005, BIOL BLOOD MARROW TR, V11, P389, DOI 10.1016/j.bbmt.2005.02.001
   Lazennec G, 2008, STEM CELLS, V26, P1387, DOI 10.1634/stemcells.2007-1006
   Le Blanc K, 2005, BIOL BLOOD MARROW TR, V11, P321, DOI 10.1016/j.bbmt.2005.01.005
   LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X
   Lee MW, 2005, INT J HEMATOL, V81, P126, DOI 10.1532/IJH97.A10404
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670
   Lee PH, 2008, CLIN PHARMACOL THER, V83, P723, DOI 10.1038/sj.clpt.6100386
   Lennon DP, 1996, IN VITRO CELL DEV-AN, V32, P602
   Li JY, 2008, TRENDS NEUROSCI, V31, P146, DOI 10.1016/j.tins.2007.12.001
   Li L, 2011, J CELL PHYSIOL, V226, P1860, DOI 10.1002/jcp.22511
   Lin YM, 2006, CHINESE MED J-PEKING, V119, P905, DOI 10.1097/00029330-200606010-00005
   Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031
   Liu CF, 2006, NEOPLASIA, V8, P716, DOI 10.1593/neo.06253
   Liu H, 2006, BRAIN, V129, P2734, DOI 10.1093/brain/awl207
   Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126
   Liu Y, 2002, EXP NEUROL, V178, P150, DOI 10.1006/exnr.2002.7977
   Liu ZW, 2007, BRAIN RES, V1149, P172, DOI 10.1016/j.brainres.2007.02.047
   Lopez-Gonzalez R, 2009, CELL TRANSPLANT, V18, P1171, DOI 10.3727/096368909X12483162197123
   Lu LL, 2006, HAEMATOLOGICA, V91, P1017
   Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018
   Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148
   Ma YL, 2006, STEM CELLS, V24, P315, DOI 10.1634/stemcells.2005-0046
   Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50
   Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C
   Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA
   Malgieri A, 2010, INT J CLIN EXP MED, V3, P248
   McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007-1122
   Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779
   MINAIRE P, 1984, CALCIFIED TISSUE INT, V36, P338, DOI 10.1007/BF02405340
   Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943
   Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005-0403
   Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197
   Mueller SM, 2001, J CELL BIOCHEM, V82, P583, DOI 10.1002/jcb.1174
   Naghdi M, 2009, CYTOTHERAPY, V11, P137, DOI 10.1080/14653240802716582
   Nakagami H, 2005, ARTERIOSCL THROM VAS, V25, P2542, DOI 10.1161/01.ATV.0000190701.92007.6d
   Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055
   Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147
   Newman MB, 2008, NEUROTHERAPEUTICS, V5, P237, DOI 10.1016/j.nurt.2008.02.004
   Nishida S, 1999, J BONE MINER METAB, V17, P171, DOI 10.1007/s007740050081
   Nomura T, 2005, NEUROSCIENCE, V136, P161, DOI 10.1016/j.neuroscience.2005.06.062
   Nori S, 2011, P NATL ACAD SCI USA, V108, P16825, DOI 10.1073/pnas.1108077108
   O'Donoghue K, 2004, LANCET, V364, P179, DOI 10.1016/S0140-6736(04)16631-2
   O'Malley J, 2009, CURR OPIN BIOTECH, V20, P516, DOI 10.1016/j.copbio.2009.09.005
   Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021
   Onda T, 2008, J CEREBR BLOOD F MET, V28, P329, DOI 10.1038/sj.jcbfm.9600527
   Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100
   Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104
   Osaka M, 2010, BRAIN RES, V1343, P226, DOI 10.1016/j.brainres.2010.05.011
   Pal R, 2009, CYTOTHERAPY, V11, P897, DOI 10.3109/14653240903253857
   Park JH, 2012, NEUROSURGERY, V70, P1238, DOI 10.1227/NEU.0b013e31824387f9
   Park WB, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-119
   Parr AM, 2008, SURG NEUROL, V70, P600, DOI 10.1016/j.surneu.2007.09.043
   Patel SA, 2010, J IMMUNOL, V184, P5885, DOI 10.4049/jimmunol.0903143
   Paul C, 2009, SPINE, V34, P328, DOI 10.1097/BRS.0b013e31819403ce
   Pevsner-Fischer M, 2011, STEM CELL REV REP, V7, P560, DOI 10.1007/s12015-011-9229-7
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637
   Phinney DG, 2006, STEM CELLS DEV, V15, P437, DOI 10.1089/scd.2006.15.437
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Potian JA, 2003, J IMMUNOL, V171, P3426, DOI 10.4049/jimmunol.171.7.3426
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Proia RL, 2004, J CLIN INVEST, V113, P1108, DOI 10.1172/JCI200421476
   Qian LC, 2004, BIOMATERIALS, V25, P1331, DOI 10.1016/j.biomaterials.2003.08.013
   Qu RJ, 2007, NEUROPATHOLOGY, V27, P355, DOI 10.1111/j.1440-1789.2007.00792.x
   Ra JC, 2011, STEM CELLS DEV, V20, P1297, DOI 10.1089/scd.2010.0466
   Ramasamy R, 2007, LEUKEMIA, V21, P304, DOI 10.1038/sj.leu.2404489
   Ramer MS, 2000, SPINAL CORD, V38, P449, DOI 10.1038/sj.sc.3101055
   Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1
   Reiser J, 2005, EXPERT OPIN BIOL TH, V5, P1571, DOI 10.1517/14712598.5.12.1571
   Ripa RS, 2007, CIRCULATION, V116, pI24, DOI 10.1161/CIRCULATIONAHA.106.678649
   Romanov YA, 2003, STEM CELLS, V21, P105, DOI 10.1634/stemcells.21-1-105
   Ronaghi M, 2010, STEM CELLS, V28, P93, DOI 10.1002/stem.253
   Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2
   Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194
   Rubio D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001398
   Sadat S, 2007, BIOCHEM BIOPH RES CO, V363, P674, DOI 10.1016/j.bbrc.2007.09.058
   Sah DWY, 1997, NAT BIOTECHNOL, V15, P574, DOI 10.1038/nbt0697-574
   Saito F, 2008, J TRAUMA, V64, P53, DOI 10.1097/TA.0b013e31815b847d
   Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389
   Sasaki M, 2006, GLIA, V53, P352, DOI 10.1002/glia.20285
   Sasaki M, 2009, J NEUROSCI, V29, P14932, DOI 10.1523/JNEUROSCI.2769-09.2009
   Satake K, 2004, SPINE, V29, P1971, DOI 10.1097/01.brs.0000138273.02820.0a
   Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004
   Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840
   Seki T, 2010, CELL STEM CELL, V7, P11, DOI 10.1016/j.stem.2010.06.003
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530
   Sensebe L, 2010, VOX SANG, V98, P93, DOI 10.1111/j.1423-0410.2009.01227.x
   Shih YRV, 2009, CELL PROLIFERAT, V42, P461, DOI 10.1111/j.1365-2184.2009.00614.x
   Shinagawa K, 2010, INT J CANCER, V127, P2323, DOI 10.1002/ijc.25440
   Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271
   Spaeth E, 2008, GENE THER, V15, P730, DOI 10.1038/gt.2008.39
   Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Sun Y, 2007, CHINESE MED J-PEKING, V120, P771, DOI 10.1097/00029330-200705010-00007
   Sykova E, 2006, CELL MOL NEUROBIOL, V26, P1113, DOI 10.1007/s10571-006-9007-2
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takeuchi M, 2007, IN VITRO CELL DEV-AN, V43, P129, DOI 10.1007/s11626-007-9021-9
   Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955
   Timper K, 2006, BIOCHEM BIOPH RES CO, V341, P1135, DOI 10.1016/j.bbrc.2006.01.072
   Tokumine J, 2003, J NEUROSCI RES, V74, P552, DOI 10.1002/jnr.10760
   Tolar J, 2007, STEM CELLS, V25, P371, DOI 10.1634/stemcells.2005-0620
   Tome M, 2009, STEM CELLS, V27, P2196, DOI 10.1002/stem.130
   Tondreau T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-166
   Toyama K, 2009, EXP NEUROL, V216, P47, DOI 10.1016/j.expneurol.2008.11.010
   Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007
   Ukai R, 2007, J NEUROTRAUM, V24, P508, DOI 10.1089/neu.2006.0161
   Vallieres L, 2003, J NEUROSCI, V23, P5197
   Vaquero J, 2006, NEUROSCI LETT, V398, P129, DOI 10.1016/j.neulet.2005.12.072
   Veeravalli KK, 2009, NEUROBIOL DIS, V36, P200, DOI 10.1016/j.nbd.2009.07.012
   Vianello F, 2010, HAEMATOL-HEMATOL J, V95, P1081, DOI 10.3324/haematol.2009.017178
   Wagner W, 2006, EXP HEMATOL, V34, P536, DOI 10.1016/j.exphem.2006.01.002
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wang XF, 2010, LEUKEMIA RES, V34, P1325, DOI 10.1016/j.leukres.2010.05.006
   Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008-0333
   Wei ZH, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-141
   Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053
   Wislet-Gendebien S, 2005, STEM CELLS, V23, P392, DOI 10.1634/stemcells.2004-0149
   Wong RSY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/459510
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.3.CO;2-3
   Wright KT, 2008, SPINAL CORD, V46, P811, DOI 10.1038/sc.2008.77
   Wright KT, 2007, BIOCHEM BIOPH RES CO, V354, P559, DOI 10.1016/j.bbrc.2007.01.013
   Wu KH, 2007, J CELL BIOCHEM, V100, P608, DOI 10.1002/jcb.21078
   Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739
   Zeng R, 2011, SPINE, V36, P997, DOI 10.1097/BRS.0b013e3181eab764
   Zhang H, 2005, AM J PHYSIOL-HEART C, V289, pH2089, DOI 10.1152/ajpheart.00019.2005
   Zhang J, 2006, J NEUROSCI RES, V84, P587, DOI 10.1002/jnr.20962
   Zhukareva V, 2010, CYTOKINE, V50, P317, DOI 10.1016/j.cyto.2010.01.004
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
   Zuk PA, 2010, MOL BIOL CELL, V21, P1783, DOI 10.1091/mbc.E09-07-0589
   Zurita M, 2004, NEUROREPORT, V15, P1105, DOI 10.1097/00001756-200405190-00004
   Zurita M, 2006, NEUROSCI LETT, V402, P51, DOI 10.1016/j.neulet.2006.03.069
NR 243
TC 2
Z9 2
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2015
VL 83
IS 2
BP 236
EP 250
DI 10.1016/j.wneu.2013.02.026
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA CF4CT
UT WOS:000352496900026
PM 23402865
DA 2020-12-08
ER

PT J
AU Marinowic, DR
   Domingues, MF
   Machado, DC
   DaCosta, JC
AF Marinowic, D. R.
   Domingues, M. F.
   Machado, D. C.
   DaCosta, J. C.
TI The expression of pluripotency genes and neuronal markers after
   neurodifferentiation in fibroblasts co-cultured with human umbilical
   cord blood mononuclear cells
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
LA English
DT Article
DE Umbilical cord blood; Fibroblast; Co-cultivation; Neurodifferentiation;
   Redifferentiation
ID MESENCHYMAL STEM-CELLS; STROMAL CELLS; BONE-MARROW; SOMATIC-CELLS; MOUSE
   EMBRYOS; DIFFERENTIATION; INHIBITION; HYBRIDIZATION; PROLIFERATION;
   INFLAMMATION
AB Human umbilical cord blood is an attractive source of stem cells; however, it has a heterogeneous cell population with few mesenchymal stem cells. Cell reprogramming induced by different methodologies can confer pluripotency to differentiated adult cells. The objective of this study was to evaluate the reprogramming of fibroblasts and their subsequent neural differentiation after co-culture with umbilical cord blood mononuclear cells. Cells were obtained from four human umbilical cords. The mononuclear cells were cultured for 7 d and subsequently co-cultured with mouse fibroblast NIH-3T3 cells for 6 d. The pluripotency of the cells was evaluated by RT-PCR using primers specific for pluripotency marker genes. The pluripotency was also confirmed by adipogenic and osteogenic differentiation. Neural differentiation of the reprogrammed cells was evaluated by immunofluorescence. All co-cultured cells showed adipogenic and osteogenic differentiation capacity. After co-cultivation, cells expressed the pluripotency gene KLF4. Statistically significant differences in cell area, diameter, optical density, and fractal dimension were observed by confocal microscopy in the neurally differentiated cells. Contact in the form of co-cultivation of fibroblasts with umbilical cord blood mononuclear fraction for 6 d promoted the reprogramming of these cells, allowing the later induction of neural differentiation.
C1 [Marinowic, D. R.; Domingues, M. F.; Machado, D. C.] Pontificia Univ Catolica Rio Grande do Sul, Biomed Res Inst, BR-90610000 Porto Alegre, RS, Brazil.
   [Marinowic, D. R.; Domingues, M. F.; DaCosta, J. C.] Pontificia Univ Catolica Rio Grande do Sul, Inst Brain, BR-90610000 Porto Alegre, RS, Brazil.
   [Marinowic, D. R.; Domingues, M. F.; DaCosta, J. C.] Pontificia Univ Catolica Rio Grande do Sul, Cellular Therapy Ctr, BR-90610000 Porto Alegre, RS, Brazil.
RP DaCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Inst Brain, BR-90610000 Porto Alegre, RS, Brazil.
EM dmarinowic@gmail.com; michidomingues@hotmail.com; dcm@pucrs.br;
   jcc@pucrs.br
RI DaCosta, Jaderson/C-4968-2015; Machado, Denise C/G-2852-2014
OI DaCosta, Jaderson/0000-0001-6776-1515; Machado, Denise
   C/0000-0002-9371-5886
FU CNPQ-Counsel of Technological and Scientific Development (Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico), Brazil;
   CCB-Cryogenesis Brazil Center (Centro de Criogenia Brasil), Brazil
FX CNPQ-Counsel of Technological and Scientific Development (Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico), Brazil;
   CCB-Cryogenesis Brazil Center (Centro de Criogenia Brasil), Brazil.
CR Al-Nbaheen M, 2012, STEM CELL REV
   Ariel A, 2007, TRENDS IMMUNOL, V28, P176, DOI 10.1016/j.it.2007.02.007
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582-4934.2004.tb00320.x
   Bieback Karen, 2010, World J Stem Cells, V2, P81, DOI 10.4252/wjsc.v2.i4.81
   Bocelli-Tyndall C, 2006, J CELL PHYSIOL, V209, P732, DOI 10.1002/jcp.20789
   Bourillot PY, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-125
   Bourillot PY, 2009, STEM CELLS, V27, P1760, DOI 10.1002/stem.110
   Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   CARRINO D, 1977, P NATL ACAD SCI USA, V74, P3874, DOI 10.1073/pnas.74.9.3874
   Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447
   Desmouliere A, 2003, LAB INVEST, V83, P1689, DOI 10.1097/01.LAB.0000101911.53973.90
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Eldering JA, 2004, BIOLOGICALS, V32, P183, DOI 10.1016/j.biologicals.2004.08.005
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   FRIES KM, 1994, CLIN IMMUNOL IMMUNOP, V72, P283, DOI 10.1006/clin.1994.1144
   Haniffa MA, 2007, J IMMUNOL, V179, P1595, DOI 10.4049/jimmunol.179.3.1595
   Haniffa MA, 2009, HAEMATOL-HEMATOL J, V94, P258, DOI 10.3324/haematol.13699
   Hardy RR, 2004, IMMUNOL REV, V197, P60, DOI 10.1111/j.0105-2896.2004.0100.x
   Jiang JM, 2008, NAT CELL BIOL, V10, P353, DOI 10.1038/ncb1698
   Jones S, 2007, J IMMUNOL, V179, P2824, DOI 10.4049/jimmunol.179.5.2824
   Kobylka P, 1998, TRANSPLANTATION, V65, P1275, DOI 10.1097/00007890-199805150-00024
   KORN JH, 1981, CELL IMMUNOL, V63, P374, DOI 10.1016/0008-8749(81)90016-2
   LE JM, 1987, J IMMUNOL, V139, P3330
   Mareschi K, 2001, HAEMATOLOGICA, V86, P1099
   MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Momin EN, 2010, CURR STEM CELL RES T, V5, P326
   Phinney DG, 1999, J CELL BIOCHEM, V72, P570
   Rossi DJ, 2005, P NATL ACAD SCI USA, V102, P9194, DOI 10.1073/pnas.0503280102
   Sarkhosh K, 2003, WOUND REPAIR REGEN, VII, P337
   Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev
   Song Shijie, 2008, V438, P123, DOI 10.1007/978-1-59745-133-8_11
   Steinberg S, 2005, J MED GENET, V42, P38, DOI 10.1136/jmg.2004.023556
   Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Volokhov DV, 2008, APPL ENVIRON MICROB, V74, P5383, DOI 10.1128/AEM.00720-08
   Wagner J, 2009, CURR OPIN BIOTECH, V20, P531, DOI 10.1016/j.copbio.2009.08.009
   Wang H, 2004, APPL ENVIRON MICROB, V70, P1483, DOI 10.1128/AEM.70.3.1483-1486.2004
   Wilkins A, 2009, STEM CELL RES, V3, P63, DOI 10.1016/j.scr.2009.02.006
   Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0
NR 42
TC 3
Z9 4
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-2690
EI 1543-706X
J9 IN VITRO CELL DEV-AN
JI In Vitro Cell. Dev. Biol.-Anim.
PD JAN
PY 2015
VL 51
IS 1
BP 26
EP 35
DI 10.1007/s11626-014-9804-8
PG 10
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA CA6AF
UT WOS:000348989700005
PM 25134818
DA 2020-12-08
ER

PT J
AU Hemb, M
   Paglioli, E
   Dubeau, F
   Andermann, F
   Olivier, A
   da Costa, JC
   Martins, WA
   Nunes, ML
   Palmini, A
AF Hemb, Marta
   Paglioli, Eliseu
   Dubeau, Francois
   Andermann, Frederick
   Olivier, Andre
   da Costa, Jaderson C.
   Martins, William A.
   Nunes, Magda L.
   Palmini, Andre
TI "Mirror EPC" Epilepsia partialis continua shifting sides after rolandic
   resection in dysplasia
SO NEUROLOGY
LA English
DT Article
ID CORTICAL DYSPLASIA; STATUS EPILEPTICUS; MECHANISMS
AB Background: Epilepsia partialis continua (EPC) is a life-threatening condition often caused by focal cortical dysplasia (FCD). Resection of the motor cortex is contemplated in the hope that the trade-off between a severe motor deficit and complete seizure control justifies the procedure.
   Methods: Report of 3 patients with EPC due to histologically confirmed FCD, who underwent resection of the motor cortex under acute electrocorticography.
   Results: All had re-emergence of medically intractable EPC in the other side of the body after rolandic resection. Two patients died and the third continues with refractory attacks.
   Conclusion: In some instances, EPC due to FCD may shift sides and re-emerge in the contralateral, previously asymptomatic, hemibody. Amechanism of disinhibition by surgery of a suppressed contralateral and homologous epileptogenic zone is speculated.
C1 [Hemb, Marta; da Costa, Jaderson C.; Martins, William A.; Nunes, Magda L.; Palmini, Andre] Pontificia Univ Catolica Rio Grande do Sul, Serv Neurol, Porto Alegre, RS, Brazil.
   [Paglioli, Eliseu] Pontificia Univ Catolica Rio Grande do Sul, Neurosurg Serv, Porto Alegre, RS, Brazil.
   [Hemb, Marta; Paglioli, Eliseu; da Costa, Jaderson C.; Palmini, Andre] Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre Epilepsy Surg Program, Porto Alegre, RS, Brazil.
   [Martins, William A.; Nunes, Magda L.; Palmini, Andre] Pontificia Univ Catolica Rio Grande do Sul, Dept Internal Med, Div Neurol, Porto Alegre, RS, Brazil.
   [Paglioli, Eliseu] Pontificia Univ Catolica Rio Grande do Sul, Dept Surg, Porto Alegre, RS, Brazil.
   [da Costa, Jaderson C.; Nunes, Magda L.] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst InsCer, Porto Alegre, RS, Brazil.
   [Dubeau, Francois; Andermann, Frederick; Olivier, Andre] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada.
RP Hemb, M (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Serv Neurol, Porto Alegre, RS, Brazil.
EM martahemb@hotmail.com
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515; Martins,
   William/0000-0002-8752-5760
FU CAPESCAPES [EDITAL MEC/CAPES MCT/CNPQ/CINEPE 001/2010 PNPD];
   CIHRCanadian Institutes of Health Research (CIHR) [MOP10189, MOP38079]
FX M. Hemb receives research support from CAPES (EDITAL MEC/CAPES
   MCT/CNPQ/CINEPE 001/2010 PNPD). E. Paglioli reports no disclosures
   relevant to the manuscript. F. Dubeau receives research support from
   CIHR MOP10189 and MOP38079. F. Andermann, A. Olivier, J. Costa da Costa,
   W. Martins, and M. Nunes report no disclosures relevant to the
   manuscript. A. Palmini has received honoraria for speaking and
   participation in advisory boards from Novartis, Abbott, Eli Lilly, and
   Janssen-Cilag. Go to Neurology.org for full disclosures.
CR Avoli M, 2001, EPILEPSIA, V42, P2, DOI 10.1046/j.1528-1157.2001.042suppl.3002.x
   DESBIENS R, 1993, ARCH NEUROL-CHICAGO, V50, P695, DOI 10.1001/archneur.1993.00540070015007
   Fauser S, 2009, BRAIN, V132, P2079, DOI 10.1093/brain/awp145
   Guerrini R, 2009, EPILEPSIA, V50, P7, DOI 10.1111/j.1528-1167.2009.02356.x
   Iffland PH, 2013, NEUROBIOL DIS, V59, P206, DOI 10.1016/j.nbd.2013.07.006
   Jahan R, 1997, PEDIATR NEUROL, V17, P344, DOI 10.1016/S0887-8994(97)00091-X
   Kometani H, 2010, BRAIN DEV-JPN, V32, P412, DOI 10.1016/j.braindev.2009.03.003
   Najm IM, 2007, EPILEPSIA, V48, P21, DOI 10.1111/j.1528-1167.2007.01064.x
   PALMINI A, 1995, ANN NEUROL, V37, P476, DOI 10.1002/ana.410370410
   Palmini A, 2010, EPILEPSIA, V51, P23, DOI 10.1111/j.1528-1167.2009.02437.x
   Takei H, 2010, NEUROPATHOLOGY, V30, P381, DOI 10.1111/j.1440-1789.2009.01079.x
NR 11
TC 4
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD OCT 14
PY 2014
VL 83
IS 16
BP 1439
EP 1443
DI 10.1212/WNL.0000000000000878
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA AT3RD
UT WOS:000344850500012
PM 25217055
OA Green Published
DA 2020-12-08
ER

PT J
AU Marrone, LCP
   Gadonski, G
   Laguna, GD
   Poli-de-Figueiredo, CE
   da Costa, BEP
   Lopes, MFT
   Brunelli, JPF
   Diogo, LP
   Marrone, ACH
   Da Costa, JC
AF Porcello Marrone, Luiz Carlos
   Gadonski, Giovani
   Laguna, Gabriela de Oliveira
   Poli-de-Figueiredo, Carlos Eduardo
   Pinheiro da Costa, Bartira Ercilia
   Torres Lopes, Maria Francisca
   Farina Brunelli, Joao Pedro
   Diogo, Luciano Passamani
   Huf Marrone, Antonio Carlos
   Da Costa, Jaderson Costa
TI Blood-Brain Barrier Breakdown in Reduced Uterine Perfusion Pressure: A
   Possible Model of Posterior Reversible Encephalopathy Syndrome
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Posterior reversible encephalopathy syndrome; blood-brain barrier;
   experimental model; reduction of uterine blood pressure; hypertension
ID HYPERTENSIVE ENCEPHALOPATHY; PREGNANCY; RATS
AB Background: Posterior reversible encephalopathy syndrome (PRES) is a clinical entity characterized by headaches, altered mental status, seizures, and visual disturbances and is associated with white matter vasogenic edema. There are no experimental models to study PRES brain changes. Methods: Twenty-eight pregnant Wistar rats were divided into 4 groups of 7: (1) pregnant-control; (2) reduced uterine perfusion pressure (RUPP); (3) invasive blood pressure (IBP); and (4) reduced uterine perfusion pressure plus invasive blood pressure (RUPP-IBP). The RUPP and RUPP-IBP groups were submitted to a reduction of uterine perfusion pressure at pregnancy days 13 to 15. The invasive mean arterial pressure of the IBP and RUPP-IBP groups was measured on day 20. The blood-brain barriers (BBBs) of all groups were analyzed using 2% Evans Blue dye on day 21. Results: RUPP rats had higher blood pressures and increased BBB permeability to Evans Blue dye compared with the control animals. Brain staining occurred in 11 of 14 RUPP rats and in none of the control groups (P < .0001). Conclusions: The physiopathology of PRES remains unclear. Here, we described the use of RUPP rats as a potential model to better comprehend this syndrome.
C1 [Porcello Marrone, Luiz Carlos; Gadonski, Giovani; Laguna, Gabriela de Oliveira; Poli-de-Figueiredo, Carlos Eduardo; Pinheiro da Costa, Bartira Ercilia; Farina Brunelli, Joao Pedro; Diogo, Luciano Passamani; Huf Marrone, Antonio Carlos; Da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande Sul PUCRS, Hosp Sao Lucas, Neurol Serv, BR-90610000 Porto Alegre, RS, Brazil.
   [Porcello Marrone, Luiz Carlos; Laguna, Gabriela de Oliveira; Farina Brunelli, Joao Pedro; Diogo, Luciano Passamani; Huf Marrone, Antonio Carlos; Da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande Sul PUCRS, Inst Cerebro Rio Grande Sul, BR-90610000 Porto Alegre, RS, Brazil.
   [Torres Lopes, Maria Francisca] Hosp Moinhos Vento, Pathol Serv Anatpat, Porto Alegre, RS, Brazil.
RP Marrone, LCP (corresponding author), Pontificia Univ Catolica Rio Grande Sul PUCRS, Hosp Sao Lucas, Ave Ipiranga 6690,Sala 220, BR-90610000 Porto Alegre, RS, Brazil.
EM lcpmarrone@gmail.com
RI de Figueiredo, Carlos E Poli/A-2027-2013; DaCosta, Jaderson/C-4968-2015;
   Diogo, Luciano P/Q-5942-2016; da Costa, Bartira E Pinheiro/E-4183-2013;
   Diogo, L P/N-2762-2013
OI de Figueiredo, Carlos E Poli/0000-0002-7333-8884; DaCosta,
   Jaderson/0000-0001-6776-1515; da Costa, Bartira E
   Pinheiro/0000-0001-8015-3952; Diogo, L P/0000-0001-6304-2767; Marrone,
   Luiz Carlos/0000-0002-8071-813X
CR Alexander BT, 1999, HYPERTENSION, V34, P368
   Auer L M, 1978, Acta Neurochir Suppl (Wien), V27, P1
   Aukes AM, 2008, REPROD SCI, V15, P411, DOI 10.1177/1933719107314067
   Bartynski WS, 2008, AM J NEURORADIOL, V29, P924, DOI 10.3174/ajnr.A0960
   Bartynski WS, 2008, AM J NEURORADIOL, V29, P447, DOI 10.3174/ajnr.A0839
   Bartynski WS, 2006, AM J NEURORADIOL, V27, P2179
   Brewer J, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.02.015
   Cardoso LM, 2005, BRAZ J MED BIOL RES, V38, P205, DOI 10.1590/S0100-879X2005000200008
   Cipolla MJ, 2012, HYPERTENSION, V60, P705, DOI 10.1161/HYPERTENSIONAHA.112.198952
   Costa JC, 1972, ARQUIVOS NEUROPSIQUI, V30, P1
   Crews JK, 2000, HYPERTENSION, V35, P367, DOI 10.1161/01.HYP.35.1.367
   Eder DJ, 1987, CLIN EXP HYPER HYPER, V6, P431, DOI DOI 10.3109/10641958709023492
   Gadonski G, 2006, HYPERTENSION, V48, P711, DOI 10.1161/01.HYP.0000238442.33463.94
   Gilbert J, 2007, AM J HYPERTENS, V20, P686, DOI 10.1016/j.amjhyper.2006.12.016
   Gokce M, 2006, NEUROCRIT CARE, V4, P133, DOI 10.1385/NCC:4:2:133
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Lamy C, 2004, J NEUROIMAGING, V14, P89, DOI 10.1177/1051228403258161
   Li J, 2012, AM J PHYSIOL-HEART C, V303, pH1, DOI 10.1152/ajpheart.00117.2012
   NIENARTOWICZ A, 1989, J DEV PHYSIOL, V12, P101
   Onder AM, 2007, PEDIATR NEPHROL, V22, P1921, DOI 10.1007/s00467-007-0578-z
   Marrone LCP, 2011, CASE REP ONCOL, V4, P82, DOI 10.1159/000324581
   Schwartz RB, 2002, NEUROLOGIST, V8, P22, DOI 10.1097/00127893-200201000-00003
NR 22
TC 16
Z9 17
U1 1
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD SEP
PY 2014
VL 23
IS 8
BP 2075
EP 2079
DI 10.1016/j.jstrokecerebrovasdis.2014.03.012
PG 5
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA AO6TQ
UT WOS:000341484900023
PM 25113078
DA 2020-12-08
ER

PT J
AU Demartini, DR
   Schilling, LP
   da Costa, JC
   Carlini, CR
AF Demartini, Diogo Ribeiro
   Schilling, Lucas Porcello
   da Costa, Jaderson Costa
   Carlini, Celia Regina
TI Alzheimer's and Parkinson's diseases: An environmental proteomic point
   of view
SO JOURNAL OF PROTEOMICS
LA English
DT Review
DE Alzheimer's; Parkinson's; Biomarkers; Environmental factors;
   Neurodegenerative diseases; Mass spectrometry
ID MILD COGNITIVE IMPAIRMENT; MASS-SPECTROMETRY; CEREBROSPINAL-FLUID;
   RISK-FACTORS; NATIONAL INSTITUTE; NEURODEGENERATIVE DISEASES;
   ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; OCCUPATIONAL-EXPOSURE;
   PROTEIN EXPRESSION
AB Alzheimer's and Parkinson's diseases are severe neurodegenerative conditions triggered by complex biochemical routes. Many groups are currently pursuing the search for valuable biomarkers to either perform early diagnostic or to follow the disease's progress. Several studies have reported relevant findings regarding environmental issues and the progression of such diseases. Here the etiology and mechanisms of these diseases are briefly reviewed. Approaches that might reveal candidate biomarkers and environmental stressors associated to the diseases were analyzed under a proteomic perspective. This article is part of a Special Issue entitled: Environmental and structural proteomics. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Demartini, Diogo Ribeiro; Carlini, Celia Regina] Univ Fed Rio Grande do Sul, Ctr Biotechnol, BR-91501970 Porto Alegre, RS, Brazil.
   [Schilling, Lucas Porcello; da Costa, Jaderson Costa; Carlini, Celia Regina] Pontifical Catholic Univ Rio Grande do Sul PUCRS, Brain Inst Rio Grande do Sul, BR-90610000 Porto Alegre, RS, Brazil.
RP Demartini, DR (corresponding author), Univ Fed Rio Grande do Sul, Ctr Biotechnol, Av Bento Goncalves 9500,Predio 43431,Sala 214, BR-91501970 Porto Alegre, RS, Brazil.
EM diogord@terra.com.br; jcc@pucrs.br
RI DaCosta, Jaderson/C-4968-2015; da Silva Carlini, Celia Regina
   Ribeiro/H-4017-2011; DEMARTINI, DIOGO/F-6029-2013
OI DaCosta, Jaderson/0000-0001-6776-1515; da Silva Carlini, Celia Regina
   Ribeiro/0000-0002-7027-2445; DEMARTINI, DIOGO/0000-0001-5294-3666
FU Conselho Nacional de Desenvoluimento Cientifico e Tecno logic (CNPq,
   Ministry of Science and Technology-Universal [47.5908/2012-0];
   Coordenactio de Apeifeigoamento de Pessoal de Nivel Superior (CAPES,
   Ministry of Education- ToxinologiaCAPES [63/2010, 1205/2011]; Fundacao
   de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS,
   PRONEX)Foundation for Research Support of the State of Rio Grande do Sul
   (FAPERGS) [10/0014-2]
FX The authors would like to express their gratitude to the editors of the
   special issue for the invitation and acceptance of the proposed subject.
   The authors are grateful to the Brazilian funding agencies Conselho
   Nacional de Desenvoluimento Cientifico e Tecno logic (CNPq, Ministry of
   Science and Technology-Universal 2012, # 47.5908/2012-0), Coordenactio
   de Apeifeigoamento de Pessoal de Nivel Superior (CAPES, Ministry of
   Education- Toxinologia number 63/2010, # 1205/2011), and Fundacao de
   Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS, PRONEX, #
   10/0014-2).
CR Aarsland D, 2010, BRAIN PATHOL, V20, P633, DOI 10.1111/j.1750-3639.2009.00369.x
   Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008
   Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989
   Bakulski KM, 2012, CURR ALZHEIMER RES, V9, P563
   Baldi I, 2003, AM J EPIDEMIOL, V157, P409, DOI 10.1093/aje/kwf216
   Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9
   Basha MR, 2005, J NEUROSCI, V25, P823, DOI 10.1523/JNEUROSCI.4335-04.2005
   Bemay B, 2009, MOL CELL PROTEOMICS, V8, P946
   Benninghoff AD, 2007, TOXICOL SCI, V95, P1, DOI 10.1093/toxsci/kfl157
   Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2
   Bjornstad A, 2006, J TOXICOL ENV HEAL A, V69, P77, DOI 10.1080/15287390500259277
   Blennow K, 2013, MED CLIN N AM, V97, P369, DOI 10.1016/j.mcna.2012.12.012
   Bocca B, 2004, SPECTROCHIM ACTA B, V59, P559, DOI 10.1016/j.sab.2004.02.007
   Booij BB, 2011, J ALZHEIMERS DIS, V23, P109, DOI 10.3233/JAD-2010-101518
   Borroni B, 2006, EUR J PHARMACOL, V545, P73, DOI 10.1016/j.ejphar.2006.06.023
   Braconi D, 2011, J PROTEOMICS, V74, P2324, DOI 10.1016/j.jprot.2011.06.029
   Brocchieri L, 2004, P NATL ACAD SCI USA, V101, P8257, DOI 10.1073/pnas.0402797101
   Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381
   Buter TC, 2008, NEUROLOGY, V70, P1017, DOI 10.1212/01.wnl.0000306632.43729.24
   Butterfield DA, 2012, ANTIOXID REDOX SIGN, V17, P1610, DOI 10.1089/ars.2011.4109
   Cannon JR, 2009, NEUROBIOL DIS, V34, P279, DOI 10.1016/j.nbd.2009.01.016
   Chen HM, 2011, CLIN BIOCHEM, V44, P377, DOI 10.1016/j.clinbiochem.2011.01.002
   Cheng Lesley, 2013, Frontiers in Genetics, V4, P150, DOI 10.3389/fgene.2013.00150
   Chin MH, 2008, J PROTEOME RES, V7, P666, DOI 10.1021/pr070546l
   Cipriani G, 2011, NEUROL SCI, V32, P275, DOI 10.1007/s10072-010-0454-7
   Colasanti T, 2010, AUTOIMMUN REV, V9, P807, DOI 10.1016/j.autrev.2010.07.008
   Company R, 2012, SCI TOTAL ENVIRON, V437, P413, DOI 10.1016/j.scitotenv.2012.07.089
   Constantinescu R, 2010, PARKINSONISM RELAT D, V16, P545, DOI 10.1016/j.parkreldis.2010.06.011
   da Costa Andreia Gomes, 2011, Acta Med Port, V24 Suppl 4, P761
   Dahm R, 2006, CURR BIOL, V16, pR906, DOI 10.1016/j.cub.2006.09.056
   De Iuliis A, 2005, CLIN CHIM ACTA, V357, P202, DOI 10.1016/j.cccn.2005.03.028
   de Lau LML, 2006, LANCET NEUROL, V5, P525, DOI 10.1016/S1474-4422(06)70471-9
   DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953
   Di Domenico F, 2011, J PROTEOMICS, V74, P1091, DOI 10.1016/j.jprot.2011.03.033
   Di Domenico F, 2010, BRAIN RES, V1333, P72, DOI 10.1016/j.brainres.2010.03.085
   Di Paolo G, 2011, NAT REV NEUROSCI, V12, P284, DOI 10.1038/nrn3012
   Dinis-Oliveira RJ, 2006, NEUROTOXICOLOGY, V27, P1110, DOI 10.1016/j.neuro.2006.05.012
   Doecke JD, 2012, ARCH NEUROL-CHICAGO, V69, P1318, DOI 10.1001/archneurol.2012.1282
   Dowd WW, 2012, INTEGR COMP BIOL, V52, P705, DOI 10.1093/icb/ics093
   Dowling VA, 2006, PROTEOMICS, V6, P5597, DOI 10.1002/pmic.200600274
   Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3
   Dubois B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474-4422(10)70223-4
   Fehlbaum-Beurdeley P, 2012, J ALZHEIMERS DIS, V32, P169, DOI 10.3233/JAD-2012-120637
   FLATEN TP, 1990, ENVIRON GEOCHEM HLTH, V12, P152, DOI 10.1007/BF01734064
   Fountoulakis M, 2006, ELECTROPHORESIS, V27, P1556, DOI 10.1002/elps.200500738
   Fuller BF, 2010, J MOL NEUROSCI, V41, P165, DOI 10.1007/s12031-009-9316-2
   Gauthier E, 2001, ENVIRON RES, V86, P37, DOI 10.1006/enrs.2001.4254
   Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5
   Geekiyanage H, 2012, EXP NEUROL, V235, P491, DOI 10.1016/j.expneurol.2011.11.026
   Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33
   Genius J, 2012, EUR ARCH PSY CLIN N, V262, pS71, DOI 10.1007/s00406-012-0362-3
   Gilman S, 2008, NEUROLOGY, V71, P670, DOI 10.1212/01.wnl.0000324625.00404.15
   Goldman SM, 2014, ANNU REV PHARMACOL, V54, P141, DOI 10.1146/annurev-pharmtox-011613-135937
   Gonzalez-Fernandez M, 2009, BIOCHIMIE, V91, P1311, DOI 10.1016/j.biochi.2009.07.006
   Gorell JM, 1999, NEUROTOXICOLOGY, V20, P239
   Gotelli NJ, 2012, TRENDS ECOL EVOL, V27, P436, DOI 10.1016/j.tree.2012.03.001
   Grant WB, 2002, J ALZHEIMERS DIS, V4, P179, DOI 10.3233/JAD-2002-4308
   Guan X, 2013, NEUROSCIENCE, V236, P262, DOI 10.1016/j.neuroscience.2013.01.039
   Harezlak J, 2008, J PROTEOME RES, V7, P217, DOI 10.1021/pr070491n
   Hashimoto M, 2012, J CELL MOL MED, V16, P1686, DOI 10.1111/j.1582-4934.2011.01441.x
   Hayden KM, 2010, NEUROLOGY, V74, P1524, DOI 10.1212/WNL.0b013e3181dd4423
   Henriksen K, 2014, ALZHEIMERS DEMENT, V10, P115, DOI 10.1016/j.jalz.2013.01.013
   Henry MS, 2013, INT J GERIATR PSYCH, V28, P331, DOI 10.1002/gps.3829
   Hornykiewicz O, 2006, J NEURAL TRANSM-SUPP, P9
   Horvath J, 2013, PARKINSONISM RELAT D, V19, P864, DOI 10.1016/j.parkreldis.2013.05.010
   Hu WT, 2012, NEUROLOGY, V79, P897, DOI 10.1212/WNL.0b013e318266fa70
   Hughes AJ, 2002, BRAIN, V125, P861, DOI 10.1093/brain/awf080
   Irvine GB, 2008, MOL MED, V14, P451, DOI 10.2119/2007-00100.Irvine
   Jin JH, 2005, MOL BRAIN RES, V134, P119, DOI 10.1016/j.molbrainres.2004.10.003
   Johansen KK, 2010, PARKINSONISM RELAT D, V16, P307, DOI 10.1016/j.parkreldis.2010.02.015
   Jones CE, 2004, J BIOL CHEM, V279, P32018, DOI 10.1074/jbc.M403467200
   Kang JH, 2013, CLIN CHEM, V59, P903, DOI 10.1373/clinchem.2013.202937
   Kempster PA, 2010, BRAIN, V133, P1755, DOI 10.1093/brain/awq059
   Kuter K, 2010, NEUROCHEM RES, V35, P1121, DOI 10.1007/s11064-010-0163-x
   Le Couteur DG, 1999, BIOMED PHARMACOTHER, V53, P122, DOI 10.1016/S0753-3322(99)80077-8
   Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583
   Lista S, 2013, PROG NEUROBIOL, V101, P18, DOI 10.1016/j.pneurobio.2012.06.006
   Llano DA, 2013, ALZ DIS ASSOC DIS, V27, P233, DOI 10.1097/WAD.0b013e31826d597a
   Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983
   Ma QF, 2006, PEPTIDES, V27, P841, DOI 10.1016/j.peptides.2005.09.002
   Martyniuk CJ, 2010, TOXICOL SCI, V117, P190, DOI 10.1093/toxsci/kfq192
   Matusch A, 2010, J AM SOC MASS SPECTR, V21, P161, DOI 10.1016/j.jasms.2009.09.022
   McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507
   McGhee DJM, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-35
   McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005
   Montes-Nieto R, 2007, PROTEOMICS, V7, P4376, DOI 10.1002/pmic.200700409
   Nee L E, 1991, Clin Auton Res, V1, P9, DOI 10.1007/BF01826052
   Orme RP, 2010, J NEUROSCI METH, V191, P75, DOI 10.1016/j.jneumeth.2010.06.009
   Ozcelik D, 2009, BIOL TRACE ELEM RES, V127, P45, DOI 10.1007/s12011-008-8219-3
   Pal R, 2013, MOL NEUROBIOL, P1
   Parnetti L, 2013, NAT REV NEUROL, V9, P131, DOI 10.1038/nrneurol.2013.10
   Pedriali A, 2013, DRUG TEST ANAL, V5, P646, DOI 10.1002/dta.1409
   Priyadarshi A, 2001, ENVIRON RES, V86, P122, DOI 10.1006/enrs.2001.4264
   Ray S, 2007, NAT MED, V13, P1359, DOI 10.1038/nm1653
   Reed TT, 2009, BRAIN RES, V1274, P66, DOI 10.1016/j.brainres.2009.04.009
   Respondek G, 2013, MOVEMENT DISORD, V28, P504, DOI 10.1002/mds.25327
   Rosa-Neto P, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt223
   Rye PD, 2011, J ALZHEIMERS DIS, V23, P121, DOI 10.3233/JAD-2010-101521
   Schapira AHV, 2013, CURR OPIN NEUROL, V26, P395, DOI 10.1097/WCO.0b013e3283633741
   Sharma S, 2013, NEUROCHEM INT, V63, P201, DOI 10.1016/j.neuint.2013.06.005
   Shcherbatykh I, 2007, J ALZHEIMERS DIS, V11, P191
   Shi M, 2009, NEUROBIOL DIS, V35, P157, DOI 10.1016/j.nbd.2008.09.004
   Simon R, 2012, MOL CELL PROTEOMICS, V11, P1389, DOI 10.1074/mcp.M112.018861
   Soares HD, 2012, ARCH NEUROL-CHICAGO, V69, P1310, DOI 10.1001/archneurol.2012.1070
   Song F, 2009, BRAIN RES REV, V61, P69, DOI 10.1016/j.brainresrev.2009.05.003
   Sultana R, 2006, NEUROBIOL DIS, V22, P76, DOI 10.1016/j.nbd.2005.10.004
   Sultana R, 2013, FREE RADICAL BIO MED, V65, P595, DOI 10.1016/j.freeradbiomed.2013.08.001
   Thies W, 2013, ALZHEIMERS DEMENT, V9, P208, DOI 10.1016/j.jalz.2013.02.003
   Tsuruoka M, 2013, ELECTROPHORESIS, V34, P2865, DOI 10.1002/elps.201300019
   Tyas SL, 2001, INT J EPIDEMIOL, V30, P590, DOI 10.1093/ije/30.3.590
   Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2
   Van Laar VS, 2008, NEUROBIOL DIS, V29, P477, DOI 10.1016/j.nbd.2007.11.007
   Verity MA, 1999, NEUROTOXICOLOGY, V20, P489
   Villemagne VL, 2013, LANCET NEUROL, V12, P357, DOI 10.1016/S1474-4422(13)70044-9
   Vineis P, 2013, ENVIRON MOL MUTAGEN, V54, P461, DOI 10.1002/em.21764
   Wang L, 2013, ADV INTELL SYST, V181, P181
   Wang M, 2013, PLOS ONE, P8
   Waragai M, 2006, BIOCHEM BIOPH RES CO, V345, P967, DOI 10.1016/j.bbrc.2006.05.011
   Williams-Gray CH, 2007, BRAIN, V130, P1787, DOI 10.1093/brain/awm111
   Witholt R, 2000, NEUROTOXICOL TERATOL, V22, P851, DOI 10.1016/S0892-0362(00)00108-2
   Zatta P, 2003, BRAIN RES BULL, V62, P15, DOI 10.1016/S0361-9230(03)00182-5
   Zhang CG, 2010, NEUROCHEM RES, V35, P1487, DOI 10.1007/s11064-010-0218-z
   Zhang J, 2013, ACTA NEUROPATHOL, V126, P671, DOI 10.1007/s00401-013-1121-x
   Zhang KL, 2012, PROTEOMICS, V12, P1261, DOI 10.1002/pmic.201200010
   Zurbig P, 2012, ELECTROPHORESIS, V33, P3617, DOI 10.1002/elps.201200360
NR 127
TC 7
Z9 7
U1 0
U2 36
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1874-3919
EI 1876-7737
J9 J PROTEOMICS
JI J. Proteomics
PD JUN 2
PY 2014
VL 104
SI SI
BP 24
EP 36
DI 10.1016/j.jprot.2014.04.014
PG 13
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA AJ7LL
UT WOS:000337878100003
PM 24751585
DA 2020-12-08
ER

PT J
AU Nunes, ML
   Khan, RL
   Gomes, I
   Booij, L
   da Costa, JC
AF Nunes, Magda Lahorgue
   Khan, Richard Lester
   Gomes Filho, Irenio
   Booij, Linda
   da Costa, Jaderson Costa
TI Maturational changes of neonatal electroencephalogram: A comparison
   between intra uterine and extra uterine development
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE Prematurity; Neonatal EEG; Bioletrogenesis; Neurological outcome; Sleep
ID PRETERM INFANTS; PREMATURE-INFANTS; GESTATIONAL-AGE; PROGNOSTIC VALUE;
   EEG PATTERNS; SHARP WAVES; FOLLOW-UP; FULL-TERM; SLEEP; NEWBORNS
AB Objectives: To evaluate electroencephalogram (EEG) patterns in very low birth weight premature newborns when reaching term-to-term neonates, thereby comparing extra uterine to intra uterine development.
   Methods: EEG recordings were obtained between 2 and 14 days of life in 47 preterm (<37 weeks) very low birth weight (<= 1500 g) newborns and repeated when reaching term age (38-42 weeks) in a subsample (n = 22). EEG recordings were also obtained in term newborns. Clinical evaluation was performed at birth and at 6 and 12 months.
   Results: Relative to the first EEG, preterm newborns showed a reduction in delta brushes and interburst intervals and increased interhemispheric synchrony, suggesting an improvement in EEG maturation. Further organization in sleep patterns, like a reduction in total sleep time and phase shifts, were also observed. However, when reaching term, preterm newborns still had less mature EEG patterns, phase shifts and transitional sleep than matched controls. Background abnormalities and dysmaturity in preterm newborns during the first EEG predicted adverse neurological outcome later on.
   Conclusions: EEG patterns in preterm very low birth weight newborns might be influenced by extra uterine development. Specific EEG abnormalities are related to increased risk of neurological disorders.
   Significance: Extra uterine development of very low birth weight delays the acquisition of maturational EEG patterns. (C) 2013 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Nunes, Magda Lahorgue; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Sch Med, Porto Alegre, RS, Brazil.
   [Khan, Richard Lester] Hosp Sao Lucas PUCRS, Clin Neurophysiol Lab, BR-90610000 Porto Alegre, RS, Brazil.
   [Gomes Filho, Irenio] Inst Gerontol PUCRS, Porto Alegre, RS, Brazil.
   [Booij, Linda] Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada.
   [Booij, Linda] Univ Montreal, St Justine Hosp, Res Ctr, Montreal, PQ H3C 3J7, Canada.
RP Nunes, ML (corresponding author), Hosp Sao Lucas PUCRS, Div Neurol, Av Ipiranga 6690 220, BR-90610000 Porto Alegre, RS, Brazil.
EM nunes@pucrs.br
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
FU CNPq-Brazil (Universal ); CNPq-BrazilNational Council for Scientific and
   Technological Development (CNPq)
FX We acknowledge Julia R. Kampff MD and the staff of NICU for their
   support and help with patient selection. Part of this study was
   supported by a Grant from CNPq-Brazil (Universal 2008), and by a PQ
   Grant from CNPq-Brazil awarded to Magda Nunes, MD. The authors thank
   Lyndall Schumann, M.Sc for proofreading the manuscript.
CR Allen MC, 2008, CURR OPIN NEUROL, V21, P123, DOI 10.1097/WCO.0b013e3282f88bb4
   Andre M, 2010, NEUROPHYSIOL CLIN, V40, P59, DOI 10.1016/j.neucli.2010.02.002
   Bertelle V, 2005, EARLY HUM DEV, V81, P595, DOI 10.1016/j.earlhumdev.2005.01.008
   Borsini W, 1990, Riv Neurol, V60, P234
   Calciolari G, 2011, J MATERN-FETAL NEO M, V24, P12, DOI 10.3109/14767058.2011.607563
   Conde JRC, 2004, CLIN NEUROPHYSIOL, V115, P2479, DOI 10.1016/j.clinph.2004.05.028
   Curzi-Dascalova L., 2000, LUNG BIOL HEALTH DIS, P3
   CURZIDASCALOVA L, 1993, PEDIATR RES, V34, P624, DOI 10.1203/00006450-199311000-00013
   De Weerd AW, 1999, ELECTROENCEPH CL S52, p[149, 52]]
   De Weerd AW, 1999, ELECTROENCEPH CL S52, P159
   DREYFUSBRISAC C, 1962, BIOL NEONATORUM, V4, P154
   FRANKENBURG WK, 1992, PEDIATRICS, V89, P91
   HAHN JS, 1989, ELECTROEN CLIN NEURO, V73, P410, DOI 10.1016/0013-4694(89)90090-4
   Hayakawa F, 1997, BRAIN DEV-JPN, V19, P122, DOI 10.1016/S0387-7604(96)00491-3
   Khan RL, 2008, J CHILD NEUROL, V23, P144, DOI 10.1177/0883073807308711
   Le Bihannic A, 2012, ARCH DIS CHILD-FETAL, V97, pF106, DOI 10.1136/adc.2010.204735
   LOMBROSO CT, 1985, PEDIATRICS, V76, P52
   LOMBROSO CT, 1979, ELECTROEN CLIN NEURO, V46, P460, DOI 10.1016/0013-4694(79)90147-0
   Lombroso CT, 1987, ELECTROENCEPHALOGRAP, P725
   MARRET S, 1992, ARCH DIS CHILD, V67, P948, DOI 10.1136/adc.67.7.948
   Marret S, 1997, ELECTROEN CLIN NEURO, V102, P178, DOI 10.1016/S0013-4694(96)95655-6
   MONOD N, 1972, ELECTROEN CLIN NEURO, V32, P529, DOI 10.1016/0013-4694(72)90063-6
   NOLTE R, 1978, DEV MED CHILD NEUROL, V20, P167
   Nunes ML, 2010, SLEEP MED, V11, P665, DOI 10.1016/j.sleep.2009.10.009
   NUNES ML, 1995, ARQ NEURO-PSIQUIAT, V53, P625, DOI 10.1590/S0004-282X1995000400013
   Nunes ML, 1997, ELECTROEN CLIN NEURO, V102, P186, DOI 10.1016/S0013-4694(96)95191-7
   Oliveira AJ, 2000, CLIN NEUROPHYSIOL, V111, P1646, DOI 10.1016/S1388-2457(00)00380-1
   Scher MS, 2008, SLEEP MED, V9, P615, DOI 10.1016/j.sleep.2007.08.014
   Scher MS, 2011, PEDIATR RES, V70, P524, DOI 10.1203/PDR.0b013e31822f24af
   SCHER MS, 1987, PEDIATR NEUROL, V3, P256, DOI 10.1016/0887-8994(87)90064-6
   Selton D, 2000, CLIN NEUROPHYSIOL, V111, P2116, DOI 10.1016/S1388-2457(00)00440-5
   Selton D, 2010, CLIN NEUROPHYSIOL, V121, P818, DOI 10.1016/j.clinph.2009.11.006
   Shah DK, 2010, PEDIATR RES, V67, P102, DOI 10.1203/PDR.0b013e3181bf5914
   Shany E, 2011, J CHILD NEUROL, V26, P341, DOI 10.1177/0883073810384866
   THARP BR, 1989, NEUROPEDIATRICS, V20, P64, DOI 10.1055/s-2008-1071267
   Tich SNT, 2007, NEUROPHYSIOL CLIN, V37, P325, DOI 10.1016/j.neucli.2007.10.001
   Vecchierini MF, 2007, NEUROPHYSIOL CLIN, V37, P311, DOI 10.1016/j.neucli.2007.10.008
   Vecchierini MF, 2003, BRAIN DEV-JPN, V25, P330, DOI 10.1016/S0387-7604(03)00007-X
   Weisman O, 2011, PEDIATRICS, V128, P706, DOI 10.1542/peds.2011-0047
   West CR, 2011, ARCH DIS CHILD-FETAL, V96, pF108, DOI 10.1136/adc.2009.180539
NR 40
TC 17
Z9 17
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1388-2457
EI 1872-8952
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD JUN
PY 2014
VL 125
IS 6
BP 1121
EP 1128
DI 10.1016/j.clinph.2013.10.049
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AH1UR
UT WOS:000335907200008
PM 24315811
DA 2020-12-08
ER

PT J
AU Greggio, S
   de Paula, S
   Azevedo, PN
   Venturin, GT
   DaCosta, JC
AF Greggio, Samuel
   de Paula, Simone
   Azevedo, Pamella Nunes
   Venturin, Gianina Teribele
   DaCosta, Jaderson Costa
TI Intra-arterial transplantation of human, umbilical cord blood
   mononuclear cells in neonatal hypoxic-ischemic rats
SO LIFE SCIENCES
LA English
DT Article
DE Neonatal hypoxia-ischemia; Human umbilical cord blood mononuclear cells;
   Intra-arterial transplantation; Rodent model; Memory; Motor function;
   Brain lesion
ID FOCAL CEREBRAL-ISCHEMIA; NEURAL PROGENITOR CELLS; MESENCHYMAL
   STEM-CELLS; BRAIN-INJURY; DELIVERY; STROKE; RECOVERY; BEHAVIOR;
   NEUROPROTECTION; BIODISTRIBUTION
AB Based on preclinical findings, cellular therapy has become a promising therapeutic approach for neonatal hypoxiaischemia (HI). However, before translation into the clinical setting, new and effective routes of cell. delivery must be determined. Intra-arterial (IA) delivery is an attractive route of cellular administration but has never been used in neonatal HI rats. Aims: In this study, we investigated the feasibility of IA transplantation of human umbilical cord blood (HUCB) mononuclear cells for the treatment of long-term behavior dysfunction and brain lesion after neonatal HI. Main methods: Seven-day-old rats were subjected to a HI model and the animals received HUCB mononuclear cells into the left common carotid artery 24 h after HI insult. Key findings: At 9 weeks post-HI, intra-arterially transplanted HUCB mononuclear cells significantly improved learning and long-term spatial memory impairments when evaluated by the Morris water maze paradigm. There was no effect of neonatal HI insult or IA procedure on body weight and on motor coordination and balance when evaluated by the accelerating rotarod test. Cellular transplantation by the IA route did not restore neonatal HI-induced brain damage according to stereological volume assessment. Furthermore, HUCB mononuclear cells were tracked in the injured brain and peripheral organs of HI transplanted-rats by nested polymerase chain reaction analysis at different time points. Significance: Our findings contribute to the translational knowledge of cell based-therapy in neonatal HI and demonstrate for the first time that IA transplantation into rat pups is a feasible route for cellular delivery and prevents long-term cognitive deficits induced by experimental neonatal HI. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Greggio, Samuel; Venturin, Gianina Teribele] Pontificia Univ Catolica Rio Grande Sul PUCRS, Inst Cerebro Rio Grande InsCer, Ctr Pesquisa Preclin, BR-90619900 Porto Alegre, RS, Brazil.
   [Greggio, Samuel; de Paula, Simone; DaCosta, Jaderson Costa] Pontificia Univ Catolica Rio Grande Sul PUCRS, Inst Pesquisas Biomed, Lab Neurociencias & Sinalizacao Celular, Programa Posgrad Pediat & Saude Crianca, BR-90619900 Porto Alegre, RS, Brazil.
   [Azevedo, Pamella Nunes; Venturin, Gianina Teribele] Pontificia Univ Catolica Rio Grande Sul PUCRS, Inst Pesquisas Biomed, Lab Neurociencias & Sinalizacao Celular, Programa Posgrad Med & Ciencias Saude, BR-90619900 Porto Alegre, RS, Brazil.
RP DaCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande Sul PUCRS, Inst Cerebro Rio Grande InsCer, Lab Neurociencias & Sinalizacao Celular, Av Ipiranga 6690,Predio 63,Sala 205, BR-90619900 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI DaCosta, Jaderson/C-4968-2015; Greggio, Samuel/E-1498-2013
OI DaCosta, Jaderson/0000-0001-6776-1515; Greggio,
   Samuel/0000-0002-5187-0335; Teribele Venturin,
   Gianina/0000-0001-7696-8219
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Pontificia Universidade Catolica do Rio Grande do Sul
   (PUCRS); Hemo Cord Clinica Medica Sociedade Simples Ltda; Pandurata
   Ltda; CAPESCAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq)
FX This research was supported by grants from Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Pontificia
   Universidade Catolica do Rio Grande do Sul (PUCRS), Hemo Cord Clinica
   Medica Sociedade Simples Ltda and Pandurata Ltda. Greggio S., Venturin
   G.T. and Azevedo P. are the recipients of scholarships from CAPES and
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq).
   DaCosta J.C. is a researcher at CNPq. The authors would like to thank
   Prof. Ivan Izquierdo, Prof. Martin Cammarota and Prof. Denise Cantarelli
   Machado for providing an excellent research facility for our study at
   Centro de Memoria (PUCRS) and Laboratorio de Biologia Celular e
   Molecular (PUCRS). We thank Prof. Renato Machado Fiori and Prof.
   Humberto Holmer Fiori for their assistance in the discussion of the
   manuscript. We also would like to thank Ms. Barbara Nunes Azevedo for
   helping in the brain volume analysis, Mr. Daniel Rodrigo Marinowic and
   Mr. Fagner Heldt for technical support in the HUCB cell processing and
   nested-PCR analysis.
CR Anderson J, 2008, NEW ENGL J MED, V359, pE18, DOI 10.1056/NEJMvcm0800666
   Andres RH, 2011, STROKE, V42, P2923, DOI 10.1161/STROKEAHA.110.606368
   Balduini W, 2000, BRAIN RES, V859, P318, DOI 10.1016/S0006-8993(00)01997-1
   da Fonseca LMB, 2010, EXP NEUROL, V221, P122, DOI 10.1016/j.expneurol.2009.10.010
   Berenstein A, 1997, NEUROSURGERY, V41, P846, DOI 10.1097/00006123-199710000-00014
   Borlongan CV, 2011, PEDIATR RES, V70, P3, DOI 10.1203/PDR.0b013e31821d0d00
   Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7
   Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198
   Chua JY, 2011, J CEREBR BLOOD F MET, V31, P1263, DOI 10.1038/jcbfm.2010.213
   Chung DJ, 2009, J NEUROSCI RES, V87, P3554, DOI 10.1002/jnr.22162
   Daadi MM, 2010, STROKE, V41, P516, DOI 10.1161/STROKEAHA.109.573691
   de Paula S, 2012, NEUROSCIENCE, V210, P431, DOI 10.1016/j.neuroscience.2012.03.009
   de Paula S, 2010, J PEDIAT-BRAZIL, V86, P451, DOI [10.2223/JPED.2035, 10.1590/S0021-75572010000600003]
   de Paula S, 2009, PEDIATR RES, V65, P631, DOI 10.1203/PDR.0b013e31819ed5c8
   Donega V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051253
   Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253
   Friedrich MAG, 2012, CELL TRANSPLANT, V21, pS13, DOI 10.3727/096368912X612512
   Greggio S, 2011, NEUROBIOL DIS, V44, P152, DOI 10.1016/j.nbd.2011.06.018
   Gutierrez-Fernandez M, 2011, NEUROSCIENCE, V175, P394, DOI 10.1016/j.neuroscience.2010.11.054
   Guzman R, 2008, STROKE, V39, P1300, DOI 10.1161/STROKEAHA.107.500470
   Johnston MV, 2011, LANCET NEUROL, V10, P372, DOI 10.1016/S1474-4422(11)70016-3
   Alles YCJ, 2010, BRAIN RES, V1356, P130, DOI 10.1016/j.brainres.2010.07.106
   Kamiya N, 2008, LIFE SCI, V83, P433, DOI 10.1016/j.lfs.2008.07.018
   Lappalainen RS, 2008, NEUROSCI LETT, V440, P246, DOI 10.1016/j.neulet.2008.05.090
   Lee JA, 2010, PEDIATR RES, V67, P42, DOI 10.1203/PDR.0b013e3181bf594b
   Li L, 2010, J CEREBR BLOOD F MET, V30, P653, DOI 10.1038/jcbfm.2009.238
   Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666
   Liao Y, 2013, BONE MARROW TRANSPL, V48, P890, DOI 10.1038/bmt.2012.169
   Lubics A, 2005, BEHAV BRAIN RES, V157, P157, DOI 10.1016/j.bbr.2004.06.019
   Lundberg J, 2012, CELL TRANSPLANT, V21, P333, DOI 10.3727/096368911X576036
   Ma J, 2007, NEUROCHEM INT, V51, P57, DOI 10.1016/j.neuint.2007.04.012
   Misra V, 2012, STEM CELLS DEV, V21, P1007, DOI 10.1089/scd.2011.0612
   Mitkari B, 2013, EXP NEUROL, V239, P158, DOI 10.1016/j.expneurol.2012.09.018
   Ohta T, 2006, NEUROSURGERY, V59, P679, DOI 10.1227/01.NEU.0000229058.08706.88
   Osanai T, 2012, NEUROSURGERY, V70, P435, DOI 10.1227/NEU.0b013e318230a795
   Pendharkar AV, 2010, STROKE, V41, P2064, DOI 10.1161/STROKEAHA.109.575993
   Pimentel-Coelho PM, 2012, PEDIATR RES, V71, P464, DOI 10.1038/pr.2011.59
   RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206
   Rojas JJ, 2013, EXP NEUROL, V241, P25, DOI 10.1016/j.expneurol.2012.11.026
   Rosenkranz K, 2012, CELL TISSUE RES, V348, P429, DOI 10.1007/s00441-012-1401-0
   Shankaran S, 2012, CLIN PERINATOL, V39, P919, DOI 10.1016/j.clp.2012.09.008
   Vasconcelos-dos-Santos A, 2012, STEM CELL RES, V9, P1, DOI 10.1016/j.scr.2012.02.002
   Venturin GT, 2011, LIFE SCI, V89, P229, DOI 10.1016/j.lfs.2011.06.006
   Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047
   Yasuhara T, 2006, REV NEUROSCIENCE, V17, P215
   Yasuhara T, 2010, J CELL MOL MED, V14, P914, DOI 10.1111/j.1582-4934.2008.00671.x
   Zhang L, 2012, BRAIN RES, V1489, P104, DOI 10.1016/j.brainres.2012.10.017
NR 47
TC 20
Z9 23
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD FEB 6
PY 2014
VL 96
IS 1-2
BP 33
EP 39
DI 10.1016/j.lfs.2013.10.017
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 302LW
UT WOS:000330607000005
PM 24177600
DA 2020-12-08
ER

PT J
AU Pereira, AA
   Pereira, AG
   Pereira, NA
   Lima, LC
   da Costa, JC
   Kraemer, JL
   Portuguez, MW
AF Pereira-Filho, Arthur A.
   Pereira, Adriana G.
   Pereira-Filho, Nelson A.
   Lima, Leonardo C.
   da Costa, Jaderson Costa
   Kraemer, Jorge L.
   Portuguez, Mirna W.
TI Long-Term Behavioral and Cognitive Outcomes Following Clipping for
   Incidental Unruptured Intracranial Aneurysms
SO NEUROPSYCHOLOGY
LA English
DT Article
DE intracranial aneurysm; microsurgery; cognition; behavior
ID TYPE-2 DIABETES-MELLITUS; NEUROPSYCHOLOGICAL EVALUATION; SURGICAL
   REPAIR; NATURAL-HISTORY; SURGERY; HYPERTENSION; IMPACT
AB Objective: Recent advances in neuroimaging techniques have resulted in more frequent detection of unruptured intracranial aneurysms. Regardless of the method employed, most interventions to treat lesions have low morbidity and mortality rates. Recently, some studies have suggested that changes in cognitive status are one complication of microsurgical treatments. However, no study to date has performed any behavioral analysis. Moreover, cognitive assessment beyond 12 months after surgical intervention is missing. The current study sought to evaluate the long-term impact of clipping on the behavioral and cognitive functions of patients with unruptured intracranial aneurysms. Method: A within-subjects prospective clinical trial was performed to evaluate 40 patients who underwent microsurgical clipping for incidental unruptured intracranial aneurysms. The participants underwent a full neuropsychological evaluation during the preoperative period, at 3 months after surgery and at 3 years after surgery. Paired Student's t tests and an ANOVA, followed by a Bonferroni post hoc test, were used to examine group differences. Results: The cognitive and behavioral test performance of the patients did not deteriorate during either the short or the long term following intervention. Moreover, the patients' clinical and demographic characteristics did not predict behavioral or cognitive changes, and neither the surgical approach nor the topography, multiplicity, or size of the aneurysms affected the results. Conclusions: In either the short or the long term following clipping for patients with incidental unruptured intracranial aneurysms, behavioral and cognitive functions had no significant change from baseline. The intervention demonstrated high efficacy and was associated with a low morbidity rate.
C1 [Pereira-Filho, Arthur A.; Pereira, Adriana G.; da Costa, Jaderson Costa; Portuguez, Mirna W.] Pontificia Univ Catolica Rio Grande do Sul, Inst Brain, Porto Alegre, RS, Brazil.
   [Pereira-Filho, Arthur A.; Pereira-Filho, Nelson A.; Kraemer, Jorge L.] Moinhos de Vento Hosp, Dept Neurosurg, Porto Alegre, RS, Brazil.
   [Lima, Leonardo C.; Kraemer, Jorge L.] Santa Casa Hosp Complex, Neurosurg Dept, Porto Alegre, RS, Brazil.
RP Pereira, AA (corresponding author), Rua Costa 30-605, BR-90110270 Porto Alegre, RS, Brazil.
EM arthurpereirafilho@gmail.com
RI Portuguez, Mirna/A-9362-2018; DaCosta, Jaderson/C-4968-2015
OI Portuguez, Mirna/0000-0003-4068-6249; DaCosta,
   Jaderson/0000-0001-6776-1515
CR Borsutzky S, 2010, NEUROPSYCHOLOGIA, V48, P2811, DOI 10.1016/j.neuropsychologia.2010.05.023
   Chan A, 2002, EUR NEUROL, V47, P37, DOI 10.1159/000047945
   Cohen J., 1988, STAT POWER ANAL BEHA
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Frazer D, 2007, NEUROSURGERY, V60, P434, DOI 10.1227/01.NEU.0000255335.72662.25
   Fukunaga A, 1999, SURG NEUROL, V51, P132, DOI 10.1016/S0090-3019(98)00090-1
   Fukunaga A, 2002, NEUROL MED-CHIR, V42, P419, DOI 10.2176/nmc.42.419
   Grace J., 2001, FRSBE FRONTAL SYSTEM
   Hassing LB, 2004, AGE AGEING, V33, P355, DOI 10.1093/ageing/afh100
   Haug T, 2009, NEUROSURGERY, V64, P412, DOI 10.1227/01.NEU.0000338952.13880.4E
   Hillis AE, 2000, J NEUROL NEUROSUR PS, V69, P608, DOI 10.1136/jnnp.69.5.608
   Hutter BO, 1999, ACT NEUR S, V72, P157
   Kaplan E., 1983, BOSTON NAMING TEST
   Kubo Y, 2010, WORLD NEUROSURG, V73, P350, DOI 10.1016/j.wneu.2010.01.001
   Martinaud O, 2009, EUR J NEUROL, V16, P595, DOI 10.1111/j.1468-1331.2009.02546.x
   Molyneux Andrew, 2002, J Stroke Cerebrovasc Dis, V11, P304, DOI 10.1053/jscd.2002.130390
   Ohue S, 2003, SURG NEUROL, V59, P269, DOI 10.1016/S0090-3019(03)00043-0
   Otawara Y, 2005, STROKE, V36, P142, DOI 10.1161/01.STR.0000149925.36914.4e
   Pereira AA, 2010, ARQ NEURO-PSIQUIAT, V68, P770, DOI 10.1590/S0004-282X2010000500018
   Rasmussen PA, 2004, STROKE, V35, P232, DOI 10.1161/01.STR.0000107769.23095.FE
   Seibert Brad, 2011, Front Neurol, V2, P45, DOI 10.3389/fneur.2011.00045
   Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651
   Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4
   Tuffiash E, 2003, STROKE, V34, P2195, DOI 10.1161/01.STR.0000087787.38080.B8
   van den Berg E, 2009, BBA-MOL BASIS DIS, V1792, P470, DOI 10.1016/j.bbadis.2008.09.004
   Wang JZ, 2011, BRAIN RES, V1408, P41, DOI 10.1016/j.brainres.2011.05.060
   Wechsler D., 1997, WECHSLER MEMORY SCAL
   Wechsler D., 1997, WECHSLER ADULT INTEL
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   Zipfel Gregory J, 2004, Neurosurg Focus, V17, pE2
NR 31
TC 0
Z9 0
U1 0
U2 5
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0894-4105
EI 1931-1559
J9 NEUROPSYCHOLOGY
JI Neuropsychology
PD JAN
PY 2014
VL 28
IS 1
BP 75
EP 83
DI 10.1037/neu0000010
PG 9
WC Psychology, Clinical; Neurosciences; Psychology
SC Psychology; Neurosciences & Neurology
GA 281RO
UT WOS:000329118900008
PM 24245927
DA 2020-12-08
ER

PT J
AU Kieling, RR
   Kieling, C
   Da Costa, JC
   Franco, AR
AF Kieling, R. R.
   Kieling, C.
   Da Costa, J. C.
   Franco, A. R.
TI Head motion in children with ADHD: how it affects connectivity results
   in neuroimaging studies
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Meeting Abstract
CT 21st Annual Meeting of the Israel-Society-for-Neuroscience / 1st
   Binational Australian-Israeli Meeting on Neuroscience
CY DEC 15-15, 2012
CL Eilat, ISRAEL
SP Israel Soc Neuroscience
C1 [Kieling, R. R.] Pontificia Univ Catolica Rio Grande do Sul, Neurosci Program, Porto Alegre, RS, Brazil.
   [Kieling, C.] Univ Fed Rio Grande do Sul, Dept Psychiat, BR-90046900 Porto Alegre, RS, Brazil.
   [Da Costa, J. C.; Franco, A. R.] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst, Porto Alegre, RS, Brazil.
   [Franco, A. R.] Pontificia Univ Catolica Rio Grande do Sul, Elect Engn Dept, Porto Alegre, RS, Brazil.
RI Franco, Alexandre Rosa/D-1706-2015
OI Franco, Alexandre Rosa/0000-0002-1552-1090
NR 0
TC 0
Z9 0
U1 0
U2 3
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD NOV
PY 2013
VL 51
SU 1
BP S41
EP S41
PG 1
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA AC9DF
UT WOS:000332833800098
DA 2020-12-08
ER

PT J
AU Rodrigues, FS
   Souza, MA
   Magni, DV
   Ferreira, APO
   Mota, BC
   Cardoso, AM
   Paim, M
   Xavier, LL
   Ferreira, J
   Schetinger, MRC
   Da Costa, JC
   Royes, LFF
   Fighera, MR
AF Rodrigues, Fernanda S.
   Souza, Mauren A.
   Magni, Danieli V.
   Ferreira, Ana Paula O.
   Mota, Bibiana C.
   Cardoso, Andreia M.
   Paim, Mariana
   Xavier, Leder L.
   Ferreira, Juliano
   Schetinger, Maria Rosa C.
   Da Costa, Jaderson C.
   Royes, Luiz Fernando F.
   Fighera, Michele R.
TI N-Acetylcysteine Prevents Spatial Memory Impairment Induced by Chronic
   Early Postnatal Glutaric Acid and Lipopolysaccharide in Rat Pups
SO PLOS ONE
LA English
DT Article
ID COA DEHYDROGENASE-DEFICIENCY; NITRIC-OXIDE SYNTHASES; NA+-K+-ATPASE;
   NA+,K+-ATPASE ACTIVITY; OXIDATIVE STRESS; ALZHEIMER-DISEASE; REDOX
   STATE; COGNITIVE DEFICITS; DORSAL-HIPPOCAMPUS; HYDROGEN-PEROXIDE
AB Background and Aims: Glutaric aciduria type I (GA-I) is characterized by accumulation of glutaric acid (GA) and neurological symptoms, such as cognitive impairment. Although this disease is related to oxidative stress and inflammation, it is not known whether these processes facilitate the memory impairment. Our objective was to investigate the performance of rat pups chronically injected with GA and lipopolysaccharide (LPS) in spatial memory test, antioxidant defenses, cytokines levels, Na+, K+-ATPase activity, and hippocampal volume. We also evaluated the effect of N-acetylcysteine (NAC) on theses markers.
   Methods: Rat pups were injected with GA (5umol g of body weight-1, subcutaneously; twice per day; from 5th to 28th day of life), and were supplemented with NAC (150mg/kg/day; intragastric gavage; for the same period). LPS (2mg/kg; E. coli 055 B5) or vehicle (saline 0.9%) was injected intraperitoneally, once per day, from 25th to 28th day of life. Oxidative stress and inflammatory biomarkers as well as hippocampal volume were assessed.
   Results: GA caused spatial learning deficit in the Barnes maze and LPS potentiated this effect. GA and LPS increased TNF-alpha and IL-1 beta levels. The co-administration of these compounds potentiated the increase of IL-1 beta levels but not TNF-alpha levels in the hippocampus. GA and LPS increased TBARS (thiobarbituric acid-reactive substance) content, reduced antioxidant defenses and inhibited Na+, K+-ATPase activity. GA and LPS co-administration did not have additive effect on oxidative stress markers and Na+, K+ pump. The hippocampal volume did not change after GA or LPS administration. NAC protected against impairment of spatial learning and increase of cytokines levels. NAC Also protected against inhibition of Na+, K+-ATPase activity and oxidative markers.
   Conclusions: These results suggest that inflammatory and oxidative markers may underlie at least in part of the neuropathology of GA-I in this model. Thus, NAC could represent a possible adjuvant therapy in treatment of children with GA-I.
C1 [Rodrigues, Fernanda S.; Souza, Mauren A.; Ferreira, Ana Paula O.; Mota, Bibiana C.; Fighera, Michele R.] Univ Fed Santa Maria, Dept Neuropsiquiatria, Ctr Ciencias Saude, BR-97119900 Santa Maria, RS, Brazil.
   [Rodrigues, Fernanda S.; Souza, Mauren A.; Ferreira, Ana Paula O.; Mota, Bibiana C.; Cardoso, Andreia M.; Ferreira, Juliano; Schetinger, Maria Rosa C.; Royes, Luiz Fernando F.; Fighera, Michele R.] Univ Fed Santa Maria, Ctr Ciencias Nat & Exatas, Programa Posgrad Ciencias Biol Bioquim Toxicol, BR-97119900 Santa Maria, RS, Brazil.
   [Da Costa, Jaderson C.] Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Lab Neurociencias, Porto Alegre, RS, Brazil.
   [Da Costa, Jaderson C.] Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro, Porto Alegre, RS, Brazil.
   [Paim, Mariana; Xavier, Leder L.] Pontificia Univ Catolica Rio Grande do Sul, Fac Biociencias, Dept Ciencias Fisiol, Porto Alegre, RS, Brazil.
   [Rodrigues, Fernanda S.; Souza, Mauren A.; Ferreira, Ana Paula O.; Mota, Bibiana C.; Royes, Luiz Fernando F.; Fighera, Michele R.] Univ Fed Santa Maria, Lab Bioquim Exercicio BIOEX, Dept Metodos & Tecn Desportivas, Ctr Educ Fis & Desportos, BR-97119900 Santa Maria, RS, Brazil.
   [Royes, Luiz Fernando F.; Fighera, Michele R.] Univ Fed Santa Maria, Dept Fisiol & Farmacol, Programa Posgrad Farmacol, Ctr Ciencias Saude, BR-97119900 Santa Maria, RS, Brazil.
   [Magni, Danieli V.] Univ Reg Integrada Alto Uruguai & Missoes, Santiago, RS, Brazil.
RP Fighera, MR (corresponding author), Univ Fed Santa Maria, Dept Neuropsiquiatria, Ctr Ciencias Saude, BR-97119900 Santa Maria, RS, Brazil.
EM mrfighera@yahoo.com.br
RI Schetinger, Maria Rosa Chitolina/I-7658-2019; Souza, Mauren/A-7990-2015;
   Fighera, Michele R/J-9576-2014; royes, luiz/T-3581-2019; DaCosta,
   Jaderson/C-4968-2015; Xavier, Leder/G-4540-2014; Ferreira,
   Juliano/A-9803-2013
OI DaCosta, Jaderson/0000-0001-6776-1515; Xavier,
   Leder/0000-0002-7213-4935; Ferreira, Juliano/0000-0002-9562-0602; royes,
   luiz/0000-0003-4045-4827; Chitolina Schetinger, Maria
   Rosa/0000-0002-5240-8935
FU FAPERGS / CNPQNational Council for Scientific and Technological
   Development (CNPq)Foundation for Research Support of the State of Rio
   Grande do Sul (FAPERGS) [Pronem: 11/2082-4]
FX The present work was supported by FAPERGS / CNPQ (grants: Pronem:
   11/2082-4). The funders had the role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579
   Barrientos RM, 2002, BEHAV BRAIN RES, V134, P291, DOI 10.1016/S0166-4328(02)00043-8
   BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1
   Beauchamp MH, 2009, J INHERIT METAB DIS, V32, pS207, DOI 10.1007/s10545-009-1167-z
   Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490
   Bilbo SD, 2005, BEHAV NEUROSCI, V119, P293, DOI 10.1037/0735-7044.119.1.293
   Block ML, 2007, BIOCHEM SOC T, V35, P1127, DOI 10.1042/BST0351127
   Boneh A, 2008, MOL GENET METAB, V94, P287, DOI 10.1016/j.ymgme.2008.03.005
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Burton BK, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.6.e69
   Casadesus G, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-2
   Crack PJ, 2006, J NEURAL TRANSM, V113, P645, DOI 10.1007/s00702-005-0352-y
   DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518
   de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528
   de Paula S, 2009, PEDIATR RES, V65, P631, DOI 10.1203/PDR.0b013e31819ed5c8
   dos Reis EA, 2002, BRAIN RES, V951, P151, DOI 10.1016/S0006-8993(02)03077-9
   Dringen R, 1999, J NEUROCHEM, V72, P2523, DOI 10.1046/j.1471-4159.1999.0722523.x
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6
   Eriksson C, 2000, CYTOKINE, V12, P423, DOI 10.1006/cyto.1999.0582
   Fan Y, 2008, NEUROIMAGE, V41, P277, DOI 10.1016/j.neuroimage.2008.02.043
   Farooqui T., 2011, PARKINSONS DIS, P247
   Ferreira GD, 2005, NEUROCHEM RES, V30, P1123, DOI 10.1007/s11064-005-7711-9
   Ferreira GD, 2008, BEHAV BRAIN RES, V187, P411, DOI 10.1016/j.bbr.2007.10.003
   Fighera MR, 2006, NEUROBIOL DIS, V22, P611, DOI 10.1016/j.nbd.2006.01.002
   File SE, 1996, PHARMACOL BIOCHEM BE, V54, P123, DOI 10.1016/0091-3057(95)02108-6
   Fiske CH, 1927, SCIENCE, V65, P401, DOI 10.1126/science.65.1686.401
   Forshammar J, 2011, J BIOL CHEM, V286, P31586, DOI 10.1074/jbc.M111.247767
   Frantseva MV, 2000, EUR J NEUROSCI, V12, P1431, DOI 10.1046/j.1460-9568.2000.00016.x
   Funk CBR, 2005, BRAIN, V128, P711, DOI 10.1093/brain/awh401
   Goncalves JF, 2012, FOOD CHEM TOXICOL, V50, P3709, DOI 10.1016/j.fct.2012.07.016
   Goncalves JF, 2010, CHEM-BIOL INTERACT, V186, P53, DOI 10.1016/j.cbi.2010.04.011
   GOODMAN SI, 1987, ENZYME, V38, P76, DOI 10.1159/000469193
   Goodman SI, 2001, PRENATAL DIAG, V21, P1167, DOI 10.1002/pd.201
   GOODMAN SI, 1977, J PEDIATR-US, V90, P746, DOI 10.1016/S0022-3476(77)81240-7
   GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611
   GUNDERSEN RW, 1987, DEV BIOL, V121, P423, DOI 10.1016/0012-1606(87)90179-5
   Hao LY, 2010, NEUROSCIENCE, V166, P763, DOI 10.1016/j.neuroscience.2010.01.006
   Harting I, 2009, BRAIN, V132, P1764, DOI 10.1093/brain/awp112
   Hein AM, 2007, NEUROSCIENCE, V150, P754, DOI 10.1016/j.neuroscience.2007.10.003
   Hellstrom IC, 2005, HIPPOCAMPUS, V15, P656, DOI 10.1002/hipo.20086
   Hemmens B, 1998, METH MOL B, V100, P1
   HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2
   Ikeda T, 2005, AM J OBSTET GYNECOL, V192, P719, DOI 10.1016/j.ajog.2004.12.048
   Ikegaya Y, 2003, SYNAPSE, V47, P54, DOI 10.1002/syn.10154
   Alles YCJ, 2010, BRAIN RES, V1356, P130, DOI 10.1016/j.brainres.2010.07.106
   Kierdorf K, 2010, RESULTS PROBL CELL D, V51, P173, DOI 10.1007/400_2008_15
   Kolker S, 2006, BRAIN, V129, pE54, DOI 10.1093/brain/awl137
   Koeller DM, 2002, HUM MOL GENET, V11, P347, DOI 10.1093/hmg/11.4.347
   Kolker S, 1999, J INHERIT METAB DIS, V22, P259
   Kolker S, 2002, J NEUROSCI RES, V68, P424, DOI 10.1002/jnr.10187
   Kreydiyyeh SI, 2004, PFLUG ARCH EUR J PHY, V448, P231, DOI 10.1007/s00424-004-1242-0
   Kreydiyyeh SI, 2004, CYTOKINE, V26, P1, DOI 10.1016/j.cyto.2003.11.014
   Kulkens S, 2005, NEUROLOGY, V64, P2142, DOI 10.1212/01.WNL.0000167428.12417.B2
   LEES GJ, 1993, NEUROSCIENCE, V54, P287, DOI 10.1016/0306-4522(93)90254-D
   Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013
   Lima TTF, 1998, BRAIN RES, V802, P55, DOI 10.1016/S0006-8993(98)00563-0
   Liu SH, 1997, NEUROSCI LETT, V234, P166, DOI 10.1016/S0304-3940(97)00686-1
   Lundborg C, 2011, J NEUROCHEM, V119, P686, DOI 10.1111/j.1471-4159.2011.07465.x
   Maeda Shigeru, 2008, Neuropsychiatr Dis Treat, V4, P663
   Magni DV, 2007, BRAIN RES, V1185, P336, DOI 10.1016/j.brainres.2007.09.023
   Magni DV, 2011, EPILEPSY RES, V93, P138, DOI 10.1016/j.eplepsyres.2010.11.007
   Magni DV, 2009, INT J DEV NEUROSCI, V27, P65, DOI 10.1016/j.ijdevneu.2008.09.004
   Martinovich GG, 2005, EUR BIOPHYS J BIOPHY, V34, P937, DOI 10.1007/s00249-005-0470-3
   Matsumoto Y, 2001, EUR J PHARMACOL, V430, P283, DOI 10.1016/S0014-2999(01)01374-7
   MISRA HP, 1972, J BIOL CHEM, V247, P6960
   Mukhopadhyay C, 2008, J POSTGRAD MED, V54, P35, DOI 10.4103/0022-3859.39189
   Muriel P, 2000, NITRIC OXIDE-BIOL CH, V4, P333, DOI 10.1006/niox.2000.0285
   NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6
   NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4
   Nguyen KT, 1998, J NEUROSCI, V18, P2239
   Nishi A, 1999, J NEUROCHEM, V73, P1492, DOI 10.1046/j.1471-4159.1999.0731492.x
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Olcese JM, 2009, J PINEAL RES, V47, P82, DOI 10.1111/j.1600-079X.2009.00692.x
   Oliveira MS, 2009, J NEUROCHEM, V109, P416, DOI 10.1111/j.1471-4159.2009.05961.x
   Olivera-Bravo S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020831
   Patil Neela, 2004, Indian J Pediatr, V71, P948
   PERRELLA O, 1992, J NEUROL, V239, P387
   Pugh CR, 1998, BRAIN BEHAV IMMUN, V12, P212, DOI 10.1006/brbi.1998.0524
   PUTTFARCKEN PS, 1993, BRAIN RES, V624, P223, DOI 10.1016/0006-8993(93)90081-W
   Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467
   Rosales-Corral S, 2004, J NEUROIMMUNOL, V150, P20, DOI 10.1016/j.jneuroim.2004.01.005
   Rosales-Corral S, 2010, ANTIOXID REDOX SIGN, V13, P193, DOI 10.1089/ars.2009.2629
   Sauer SW, 2006, J NEUROCHEM, V97, P899, DOI 10.1111/j.1471-4159.2006.03813.x
   Scaini G, 2012, BEHAV BRAIN RES, V231, P92, DOI 10.1016/j.bbr.2012.03.004
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Schmidt C, 2007, J AM SOC NEPHROL, V18, P1072, DOI 10.1681/ASN.2006050454
   Seminotti B, 2012, MOL GENET METAB, V106, P31, DOI 10.1016/j.ymgme.2012.03.002
   Sparkman NL, 2005, PHYSIOL BEHAV, V85, P278, DOI 10.1016/j.physbeh.2005.04.015
   Strauss KA, 2003, AM J MED GENET C, V121C, P38, DOI 10.1002/ajmg.c.20007
   Strauss KA, 2003, AM J MED GENET C, V121C, P53, DOI 10.1002/ajmg.c.20008
   Strauss KA, 2007, BRAIN, V130, P1905, DOI 10.1093/brain/awm058
   Ullrich K, 1999, J INHERIT METAB DIS, V22, P392, DOI 10.1023/A:1005595921323
   Victor VM, 2003, FREE RADICAL RES, V37, P919, DOI 10.1080/1071576031000148727
   Viviani B, 2003, J NEUROSCI, V23, P8692
   WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482
   Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052
   Yang MJ, 2003, ACTA CRYSTALLOGR D, V59, P146, DOI 10.1107/S0907444902018024
   Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015
   Zhan H, 2004, NEUROL RES, V26, P35, DOI 10.1179/016164104773026507
   Zhang XY, 2007, JPN J OPHTHALMOL, V51, P14, DOI 10.1007/s10384-006-0382-5
   Zinnanti WJ, 2007, J CLIN INVEST, V117, P3258, DOI 10.1172/JCI31617
NR 101
TC 16
Z9 16
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2013
VL 8
IS 10
AR e78332
DI 10.1371/journal.pone.0078332
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 241FR
UT WOS:000326152300049
PM 24205200
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Marrone, LC
   Marrone, BF
   Neto, FK
   Costa, FC
   Thome, GG
   Aramburu, MB
   Schilling, LP
   Pascoal, TA
   Gadonski, G
   Huf Marrone, AC
   da Costa, JC
AF Porcello Marrone, Luiz Carlos
   Marrone, Bianca Fontana
   Kalil Neto, Felipe
   Costa, Francisco Cosme
   Thome, Gustavo Gomes
   Aramburu, Martin Brandolt
   Schilling, Lucas Porcello
   Pascoal, Tharick Ali
   Gadonski, Giovani
   Huf Marrone, Antonio Carlos
   da Costa, Jaderson Costa
TI Posterior Reversible Encephalopathy Syndrome Following a Scorpion Sting
SO JOURNAL OF NEUROIMAGING
LA English
DT Article
DE Posterior reversible encephalopathy syndrome (PRES); scorpion sting;
   seizure; brain MRI; cerebral autoregulation; oedema; Tityus bahiensis
ID HYPERTENSIVE ENCEPHALOPATHY
AB Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiologic entity not yet understood, that is present with transient neurologic symptoms and particular radiological findings. The most common imaging pattern in PRES is the presence of edema in the white matter of the posterior portions of both cerebral hemispheres. The cause of PRES is unclear. We report a case of 13-year-old male who was stung by a scorpion and developed a severe headche, visual disturbance, and seizures and had the diagnosis of PRES with a good outcome. Numerous factors can trigger this syndrome, most commonly: acute elevation of blood pressure, abnormal renal function, and immunosuppressive therapy. There are many cases described showing the relationship between PRES and eclampsia, transplantation, neoplasia and chemotherapy treatment, systemic infections, renal disease acute, or chronic. However, this is the first case of PRES following a scorpion sting.
C1 [Porcello Marrone, Luiz Carlos; Marrone, Bianca Fontana; Kalil Neto, Felipe; Costa, Francisco Cosme; Thome, Gustavo Gomes; Aramburu, Martin Brandolt; Schilling, Lucas Porcello; Pascoal, Tharick Ali; Gadonski, Giovani; Huf Marrone, Antonio Carlos; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Inst Cerebro, Dept Neurol, BR-90610000 Porto Alegre, RS, Brazil.
RP Marrone, LCP (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Inst Cerebro Rio Grande Sul, Ave Ipiranga 6690 Room 220, BR-90610000 Porto Alegre, RS, Brazil.
EM lcpmarrone@gmail.com
RI Pascoal, Tharick/N-2352-2019; DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515; Pascoal,
   Tharick/0000-0001-9057-8014; Marrone, Luiz Carlos/0000-0002-8071-813X
FU Grants-in-Aid for Scientific ResearchMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)Japan Society for the
   Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [21591171] Funding Source: KAKEN
CR Auer L M, 1978, Acta Neurochir Suppl (Wien), V27, P1
   Bartynski WS, 2008, AM J NEURORADIOL, V29, P447, DOI 10.3174/ajnr.A0839
   Bartynski WS, 2006, AM J NEURORADIOL, V27, P2179
   Casey SO, 2000, AM J NEURORADIOL, V21, P1199
   Dube Simmi, 2011, J Indian Med Assoc, V109, P194
   Feske SK, 2011, SEMIN NEUROL, V31, P202, DOI 10.1055/s-0031-1277990
   Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803
   Lamy C, 2004, J NEUROIMAGING, V14, P89, DOI 10.1177/1051228403258161
   Loh H H, 2012, Med J Malaysia, V67, P133
   Lourenco GA, 2002, TOXICON, V40, P149, DOI 10.1016/S0041-0101(01)00202-1
   Petricevich VL, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/903295
   Marrone LCP, 2011, CASE REP ONCOL, V4, P82, DOI 10.1159/000324581
   Prendini L, 2005, CLADISTICS, V21, P446, DOI 10.1111/j.1096-0031.2005.00073.x
   Schwartz RB, 2000, RADIOLOGY, V217, P371, DOI 10.1148/radiology.217.2.r00nv44371
   Schwartz RB, 2002, NEUROLOGIST, V8, P22, DOI 10.1097/00127893-200201000-00003
NR 15
TC 9
Z9 9
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1051-2284
EI 1552-6569
J9 J NEUROIMAGING
JI J. Neuroimaging
PD OCT
PY 2013
VL 23
IS 4
BP 535
EP 536
DI 10.1111/jon.12017
PG 2
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 269XM
UT WOS:000328277200014
PM 23551823
DA 2020-12-08
ER

PT J
AU Hemb, M
   Palmini, A
   Paglioli, E
   Paglioli, EB
   da Costa, JC
   Azambuja, N
   Portuguez, M
   Viuniski, V
   Booij, L
   Nunes, ML
AF Hemb, Marta
   Palmini, Andre
   Paglioli, Eliseu
   Paglioli, Eduardo Beck
   da Costa, Jaderson Costa
   Azambuja, Ney
   Portuguez, Mirna
   Viuniski, Verena
   Booij, Linda
   Nunes, Magda Lahorgue
TI An 18-year follow-up of seizure outcome after surgery for temporal lobe
   epilepsy and hippocampal sclerosis
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID FOCAL CORTICAL DYSPLASIAS; ANTIEPILEPTIC DRUGS; SURGICAL-TREATMENT; DUAL
   PATHOLOGY; PREDICTORS; LOBECTOMY; RECURRENCE; CLASSIFICATION; PATTERNS;
   TRIAL
AB Objectives To evaluate the very long-term clinical outcome of surgery for mesial temporal lobe epilepsy and unilateral hippocampal sclerosis (MTLE/HS) without atypical features. The impact of surgical technique and postoperative reduction of medication on this outcome was investigated.
   Design Prospective longitudinal cohort follow-up study for up to 18 years.
   Setting Epilepsy surgery centre in a university hospital.
   Patients 108 patients who underwent unilateral MTLE/HS.
   Intervention Surgery for MTLE/HS.
   Main outcome measure Engel classification (I). Clinical evaluations were based on systematic interviews in person or by phone. Kaplan-Maier survival curves estimated the probability of remaining seizure free. The impact of medication management in the postoperative outcome was analysed using Cox regression.
   Results The probability of remaining completely seizure-free at 12 and 18 years after MTLE/HS surgery was 65% and 62%, respectively. The risk of having any recurrence was 22% during the first 24 months and increased 1.4% per year afterwards. Type of surgical technique (selective amygdalohippocampectomy vs anterior temporal lobectomy) did not impact on outcome. Remaining on antiepileptic drugs and history of generalised clonic seizure diminished the probability of remaining seizure free.
   Conclusions MTLE/HS surgery is able to keep patients seizure free for almost up to two decades. Removal of the neocortex besides the mesial portion of the temporal lobe does not lead to better chances of seizure control. These findings are applicable to the typical unilateral MTLE/HS syndrome and cannot be generalised for all types of TLE. Future longitudinal randomised controlled studies are needed to replicate these findings.
C1 [Hemb, Marta; Palmini, Andre] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Hosp Sao Lucas, Serv Neurol, Severe Epilepsies Outpatient Clin, Porto Alegre, RS, Brazil.
   [Hemb, Marta; Palmini, Andre; Paglioli, Eliseu; Paglioli, Eduardo Beck; da Costa, Jaderson Costa; Azambuja, Ney; Portuguez, Mirna] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Hosp Sao Lucas, Porto Alegre Epilepsy Surg Program, Neurol Serv, Porto Alegre, RS, Brazil.
   [Hemb, Marta; Palmini, Andre; Paglioli, Eliseu; Paglioli, Eduardo Beck; da Costa, Jaderson Costa; Azambuja, Ney; Portuguez, Mirna] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Hosp Sao Lucas, Porto Alegre Epilepsy Surg Program, Neurosurg Serv, Porto Alegre, RS, Brazil.
   [Palmini, Andre; da Costa, Jaderson Costa; Portuguez, Mirna; Viuniski, Verena; Nunes, Magda Lahorgue] Pontificia Univ Catolica Rio Grande do Sul, Fac Med, Dept Internal Med Neurol, BR-90610000 Porto Alegre, RS, Brazil.
   [Palmini, Andre; da Costa, Jaderson Costa; Portuguez, Mirna; Nunes, Magda Lahorgue] Pontificia Univ Catolica Rio Grande do Sul, Brain Inst InsCer, BR-90610000 Porto Alegre, RS, Brazil.
   [Paglioli, Eduardo Beck; da Costa, Jaderson Costa; Azambuja, Ney] Pontificia Univ Catolica Rio Grande do Sul, Fac Med, Dept Surg, BR-90610000 Porto Alegre, RS, Brazil.
   [Booij, Linda] St Justine Hosp, Res Ctr, Porto Alegre, RS, Brazil.
   [Booij, Linda] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada.
   [Booij, Linda] McGill Univ, Dept Psychiat, Montreal, PQ, Canada.
RP Palmini, A (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Serv Neurol, Av Ipiranga 6690 220, BR-90610000 Porto Alegre, RS, Brazil.
EM apalmini@uol.com.br
RI Portuguez, Mirna/A-9362-2018
OI Portuguez, Mirna/0000-0003-4068-6249
FU Fonds de recherchedu Quebec-SanteFonds de la Recherche en Sante du
   Quebec; CAPESCAPES [00000.058723/2010]; CNPQNational Council for
   Scientific and Technological Development (CNPq); NovartisNovartis;
   AbbottAbbott Laboratories; Janssenn-Cilag; Eli-LillyEli Lilly;
   CAPESCAPES; PNPD programme
FX We thank our colleagues of the Severe Epilepsies Outpatient Clinics,
   including all neurology and neurosurgery residents from these last two
   decades for helping to take care of the patients included here. We
   particularly thank Dr Carolina Torres and Dr Jose Victor Martinez for
   helping out with preceptorship in the Clinic. Finally, we were blessed
   by the opportunity to develop honest doctor-patient and doctor-family
   relationships, which provided an exquisite degree of cooperation when
   collecting outcome data over the years. We cannot thank these people
   enough for their goodwill. We also thank Dr Renata Kieling for extremely
   useful suggestions. Linda Booij, PhD is supported by a career award from
   the Fonds de recherchedu Quebec-Sante. None of these funding agencies
   played a role in the design, data collection, management, analysis,
   interpretation of the data; and preparation, review or approval of the
   manuscript.; The study was supported by a grant from CAPES:
   00000.058723/2010.; AP, MD, PhD: holds a grant from CNPQ; receives funds
   from Novartis, Abbott, Janssenn-Cilag and Eli-Lilly as board member;
   invited speaker for the development of educational presentations, for
   manuscript preparation and to cover meeting/travel expenses unrelated to
   the present study. MH, MD, PhD: has a grant pending from CAPES, PNPD
   programme. The other authors report no other competing interests.
CR Aull-Watschinger S, 2008, EPILEPSIA, V49, P1308, DOI 10.1111/j.1528-1167.2008.01732.x
   Blumcke I, 2011, LANCET NEUROL, V10, P26, DOI 10.1016/S1474-4422(10)70225-8
   de Tisi J, 2011, LANCET, V378, P1388, DOI 10.1016/S0140-6736(11)60890-8
   Engel Jerome Jr., 1993, P609
   Engel J, 2012, JAMA-J AM MED ASSOC, V307, P922, DOI 10.1001/jama.2012.220
   Englot DJ, 2012, NEUROLOGY, V78, P1200, DOI 10.1212/WNL.0b013e318250d7ea
   Fong JS, 2011, EPILEPSIA, V52, P1393, DOI 10.1111/j.1528-1167.2011.03091.x
   Janszky J, 2005, BRAIN, V128, P395, DOI 10.1093/brain/awh358
   Jeha LE, 2006, NEUROLOGY, V66, P1938, DOI 10.1212/01.wnl.0000219810.71010.9b
   Jehi LE, 2010, J NEUROSURG, V113, P1186, DOI 10.3171/2010.8.JNS10180
   Kieling RR, 2012, JAMA-J AM MED ASSOC, V307, P2483, DOI 10.1001/jama.2012.4985
   KIELING RR, 2012, JAMA-J AM MED ASSOC, V307, P4
   Kim DW, 2010, EPILEPSIA, V51, P1429, DOI 10.1111/j.1528-1167.2009.02403.x
   McIntosh AM, 2001, EPILEPSIA, V42, P1288, DOI 10.1046/j.1528-1157.2001.02001.x
   McIntosh AM, 2004, BRAIN, V127, P2018, DOI 10.1093/brain/awh221
   McIntosh AM, 2006, NEUROLOGY, V67, P1671, DOI 10.1212/01.wnl.0000242735.24539.33
   Mohammed HS, 2012, EPILEPSIA, V53, P712, DOI 10.1111/j.1528-1167.2011.03398.x
   Chacon LM, 2009, SEIZURE-EUR J EPILEP, V18, P593, DOI 10.1016/j.seizure.2009.06.008
   Niemeyer P., 1958, TEMPORAL LOBE EPILEP, P461
   Paglioli E, 2006, J NEUROSURG, V104, P70, DOI 10.3171/jns.2006.104.1.70
   Paglioli E, 2004, EPILEPSIA, V45, P1383, DOI 10.1111/j.0013-9580.2004.22204.x
   Palmini A, 2011, CAUSES EPILEPSY COMM, P413
   Palmini A, 2011, EPILEPSIA, V52, P189, DOI 10.1111/j.1528-1167.2010.02923.x
   Pimentel J, 2012, EPILEPSY RES, V100, P55, DOI 10.1016/j.eplepsyres.2012.01.010
   Ramesha KN, 2011, EPILEPSIA, V52, P917, DOI 10.1111/j.1528-1167.2010.02891.x
   Sagher O, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2011.12.FOCUS11342
   Schijns OEMG, 2011, NEUROSURGERY, V68, P98, DOI 10.1227/NEU.0b013e3181fc60ff
   Schramm J, 2008, EPILEPSIA, V49, P1296, DOI 10.1111/j.1528-1167.2008.01604.x
   Tassi L, 2009, EPILEPTIC DISORD, V11, P281, DOI 10.1684/epd.2009.0279
   Tellez-Zenteno JF, 2005, BRAIN, V128, P1188, DOI 10.1093/brain/awh449
   Tellez-Zenteno JF, 2007, BRAIN, V130, P334, DOI 10.1093/brain/awl316
   Tellez-Zenteno JF, 2010, EPILEPSY RES, V89, P310, DOI 10.1016/j.eplepsyres.2010.02.007
   Thom M, 2010, ANN NEUROL, V68, P424, DOI 10.1002/ana.22142
   Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501
   Wiebe S, 2012, NAT REV NEUROL, V8, P123, DOI 10.1038/nrneurol.2012.9
NR 35
TC 43
Z9 46
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 1468-330X
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD JUL
PY 2013
VL 84
IS 7
BP 800
EP 805
DI 10.1136/jnnp-2012-304038
PG 6
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 160HB
UT WOS:000320108200018
PM 23408065
DA 2020-12-08
ER

PT J
AU Palmini, A
   Neto, EP
   Camargo, D
   Pascoal, TA
   Filho, J
   Torres, C
   Hemb, M
   da Costa, JC
   Paglioli, E
AF Palmini, A.
   Paglioli Neto, E.
   Camargo, D.
   Pascoal, T. A.
   Filho, Jr.
   Torres, C.
   Hemb, M.
   da Costa, J. C.
   Paglioli, E.
TI SURGERY FOR EXTRATEMPORAL FOCAL CORTICAL DYSPLASIA FOLLOWING A
   NON-INVASIVE PRESURGICAL PROTOCOL: THE PORTO ALEGRE SERIES
SO EPILEPSIA
LA English
DT Meeting Abstract
CT 30th International Epilepsy Congress
CY JUN 23-27, 2013
CL Montreal, CANADA
SP Int Bur Epilepsy (IBE), Int League Against Epilepsy (ILAE)
C1 [Palmini, A.; Paglioli Neto, E.; Camargo, D.; Torres, C.; Hemb, M.; da Costa, J. C.; Paglioli, E.] Pontificia Univ Catolica Rio Grande Sul PUCRS, Hosp Sao Lucas, Porto Alegre Epilepsy Surg Program, Dept Neurol, Porto Alegre, RS, Brazil.
   [Palmini, A.; Paglioli Neto, E.; Camargo, D.; Torres, C.; Hemb, M.; da Costa, J. C.; Paglioli, E.] Pontificia Univ Catolica Rio Grande Sul PUCRS, Hosp Sao Lucas, Porto Alegre Epilepsy Surg Program, Dept Neurosurg, Porto Alegre, RS, Brazil.
   [Pascoal, T. A.] Pontificia Univ Catolica Rio Grande Sul PUCRS, Neurol Serv, Porto Alegre, RS, Brazil.
   [Filho, Jr.] Pontificia Univ Catolica Rio Grande Sul PUCRS, Radiol Serv, Porto Alegre, RS, Brazil.
RI Pascoal, Tharick/N-2352-2019
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD JUN
PY 2013
VL 54
SU 3
SI SI
BP 288
EP 288
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 165GS
UT WOS:000320472001215
DA 2020-12-08
ER

PT J
AU Marrone, LCP
   Diogo, LP
   de Oliveira, FM
   Trentin, S
   Scalco, RS
   de Almeida, AG
   Gutierres, LDV
   Marrone, ACH
   da Costa, JC
AF Porcello Marrone, Luiz Carlos
   Diogo, Luciano Passamani
   de Oliveira, Faberson Mocelin
   Trentin, Sheila
   Scalco, Renata Siciliani
   de Almeida, Andrea Garcia
   Vega Gutierres, Luis del Carmo
   Huf Marrone, Antonio Carlos
   da Costa, Jaderson Costa
TI Risk Factors among Stroke Subtypes in Brazil
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Stroke in Brazil; Trial of Org 10172 in Acute Stroke Treatment
   classification; stroke risk factors
ID ISCHEMIC-STROKE; CEREBRAL INFARCTION; PREVALENCE; EPIDEMIOLOGY; TRIAL
AB Stroke is a leading cause of mortality and disability in Brazil. Among the risk factors for cerebrovascular disease, some have more influence than others in certain stroke subtypes. Little data are available in the literature on the prevalence of stroke subtypes in Latin America. We analyzed data from 688 patients with acute ischemic stroke (52.3% women; mean age, 65.7 years) who were enrolled in a stroke data bank. Standardized data assessment and stroke subtype classification were used. The most common stroke subtype was large-artery atherosclerosis (n = 223; 32.4%), followed by cardioembolism (n = 195; 28.3%), and microangiopathy (n = 127; 18.5%). Stroke risk factors differ among stroke subtypes. The population of South America is ethnically diverse, and few previous studies have describe the distribution of risk factors among stroke subtypes in this population. In this study, the most important risk factors were hypertension and dyslipidemia.
C1 [Porcello Marrone, Luiz Carlos; de Almeida, Andrea Garcia; Vega Gutierres, Luis del Carmo] Pontificiae Univ Catolica Rio Grande Sul PUCRS, Sao Lucas Hosp, Dept Neurol, Inst Cerebro INSCER, BR-90440002 Porto Alegre, RS, Brazil.
   [Diogo, Luciano Passamani] PUCRS Sch Med, Dept Internal Med, Porto Alegre, RS, Brazil.
   [Huf Marrone, Antonio Carlos] PUCRS Sch Med, Dept Neurol, Inst Brain, Porto Alegre, RS, Brazil.
   [da Costa, Jaderson Costa] Pontificiae Univ Catolica Rio Grande Sul PUCRS, PUCRS Sch Med, Dept Neurol, BR-90440002 Porto Alegre, RS, Brazil.
RP Marrone, LCP (corresponding author), Pontificiae Univ Catolica Rio Grande Sul PUCRS, Sao Lucas Hosp, Dept Neurol, Inst Cerebro INSCER, Rua Coronel Bordini 300-1204, BR-90440002 Porto Alegre, RS, Brazil.
EM lcpmarrone@gmail.com
RI Scalco, Renata/B-5648-2013; Diogo, L P/N-2762-2013; DaCosta,
   Jaderson/C-4968-2015; Diogo, Luciano P/Q-5942-2016
OI Scalco, Renata/0000-0002-5400-562X; Diogo, L P/0000-0001-6304-2767;
   DaCosta, Jaderson/0000-0001-6776-1515; Reis,
   AlessanRSS/0000-0001-8486-7469; Marrone, Luiz Carlos/0000-0002-8071-813X
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Arboix A, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-9
   BILLER J, 2004, NEUROLOGY CLIN PRACT, P1197
   BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U
   DELBRUTTO OH, 1993, STROKE, V24, P1833, DOI 10.1161/01.STR.24.12.1833
   Diaz V, 2001, REV MED CHILE, V129, P161
   Grau AJ, 2001, STROKE, V32, P2559, DOI 10.1161/hs1101.098524
   Hassaballa H, 2001, NEUROLOGY, V57, P691, DOI 10.1212/WNL.57.4.691
   Jackson C, 2005, STROKE, V36, P891, DOI 10.1161/01.STR.0000157949.34986.30
   JAILLARD AS, 1995, STROKE, V26, P562, DOI 10.1161/01.STR.26.4.562
   Moreno VP, 2008, VER NEUROL, V46, P593
   Nogales-Gaete J, 2000, REV MED CHILE, V128, P1227
   Osseby G-V, 2008, J NEUROL NEUROSUR PS, V12, P1344
   Pena I, 2001, ACTA NEUROL COLOMB, V17, P304
   Pradilla G, 1995, ACTA NEUROL COLOMB, V11, P129
   SACCO RL, 1995, NEUROLOGY, V45, P659, DOI 10.1212/WNL.45.4.659
   Saposnik G, 2003, STROKE, V34, P2103, DOI 10.1161/01.STR.0000088063.74250.DB
   Saposnik G, 2000, STROKE, V31, P2385, DOI 10.1161/01.STR.31.10.2385
   Schulz UGR, 2003, STROKE, V34, P2050, DOI 10.1161/01.STR.0000079818.08343.8C
   Uribe CS, 1997, REV NEUROLOGIA, V25, P1008
NR 20
TC 18
Z9 20
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD JAN
PY 2013
VL 22
IS 1
BP 32
EP 35
DI 10.1016/j.jstrokecerebrovasdis.2011.05.022
PG 4
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 056YP
UT WOS:000312528600006
PM 22078780
DA 2020-12-08
ER

PT J
AU Marrone, LCP
   Marrone, ACH
   Gadonski, G
   Diogo, LP
   Poli-de-Figueiredo, CE
   da Costa, JC
AF Marrone, L. C. P.
   Marrone, A. C. H.
   Gadonski, G.
   Diogo, L. P.
   Poli-de-Figueiredo, C. E.
   da Costa, J. C.
TI Posterior reversible encephalopathy syndrome (PRES): description of 25
   cases
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
CT 16th Congress of the European-Federation-of-Neurological-Societies
   (EFNS)
CY SEP 08-11, 2012
CL Stockholm, SWEDEN
SP European Federat Neurol Soc (EFNS)
C1 [Marrone, L. C. P.; Marrone, A. C. H.; Gadonski, G.; Diogo, L. P.; Poli-de-Figueiredo, C. E.; da Costa, J. C.] Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre, RS, Brazil.
RI de Figueiredo, Carlos E Poli/A-2027-2013; Diogo, L P/N-2762-2013; Diogo,
   Luciano P/Q-5942-2016
OI de Figueiredo, Carlos E Poli/0000-0002-7333-8884; Diogo, L
   P/0000-0001-6304-2767; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD SEP
PY 2012
VL 19
SU 1
SI SI
BP 411
EP 411
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 014FD
UT WOS:000309359702193
DA 2020-12-08
ER

PT J
AU Crestani, D
   Hemb, M
   Severino, RF
   Palmini, A
   Paglioli, E
   Paglioli, E
   Da Costa, JC
   Portuguez, M
   Azambuja, N
   Nunes, M
AF Crestani, D.
   Hemb, M.
   Severino, R. F.
   Palmini, A.
   Paglioli, E.
   Paglioli, E.
   Da Costa, J. Costa
   Portuguez, M.
   Azambuja, N.
   Nunes, M.
TI EVOLUTION UP TO 18 YEARS AFTER SURGERY FOR TEMPORAL EPILEPSY WITH
   HIPPOCAMPAL SCLEROSIS: IMPACT OF TECHNIQUE, MEDICATION MANAGEMENT AND
   PRESURGICAL VARIABLES
SO EPILEPSIA
LA English
DT Meeting Abstract
CT 10th European Congress on Epileptology
CY SEP 30-OCT 04, 2012
CL London, ENGLAND
C1 [Crestani, D.; Hemb, M.; Severino, R. F.; Palmini, A.; Paglioli, E.; Paglioli, E.; Da Costa, J. Costa; Portuguez, M.; Azambuja, N.; Nunes, M.] Hosp Sao Lucas, Porto Alegre, RS, Brazil.
RI Portuguez, Mirna/A-9362-2018
OI Portuguez, Mirna/0000-0003-4068-6249
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD SEP
PY 2012
VL 53
SU 5
SI SI
BP 109
EP 109
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 007GD
UT WOS:000308875900372
DA 2020-12-08
ER

PT J
AU Costa-Ferro, ZSM
   Souza, BSF
   Leal, MMT
   Kaneto, CM
   Azevedo, CM
   da Silva, IC
   Soares, MBP
   Ribeiro-dos-Santos, R
   DaCosta, JC
AF Costa-Ferro, Zaquer S. M.
   Souza, Bruno S. F.
   Leal, Marcos M. T.
   Kaneto, Carla Martins
   Azevedo, Carine Machado
   da Silva, Igor Campos
   Soares, Milena B. P.
   Ribeiro-dos-Santos, Ricardo
   DaCosta, Jaderson C.
TI Transplantation of bone marrow mononuclear cells decreases seizure
   incidence, mitigates neuronal loss and modulates pro-inflammatory
   cytokine production in epileptic rats
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Temporal lobe epilepsy; Bone marrow mononuclear cells; Seizure
   frequency; Neuronal loss; Cytokines; Pilocarpine
ID TEMPORAL-LOBE EPILEPSY; HEMATOPOIETIC CYTOKINES; CEREBRAL INFARCTION;
   THERAPEUTIC WINDOW; SUBACUTE PHASE; BRAIN-INJURY; EXPRESSION;
   PILOCARPINE; ASTROCYTES; GLUTAMATE
AB Approximately 30% of patients with mesial temporal lobe epilepsy do not respond to treatment with antiepileptic drugs. We have previously shown that transplantation of mononuclear bone marrow cells (BMC) has an anticonvulsant effect in acute epilepsy. Here, we used pilocarpine to induce epilepsy in rats and studied the effects of BMC injected intravenously either at the onset of seizures or after 10 months of recurrent seizures. BMC effectively decreased seizure frequency and duration. In addition, decreased levels of proinflammatory cytokines (TNF-alpha, IL-1 beta and IL-6) and increased levels of anti-inflammatory cytokine (IL-10) were observed in the brain and serum of BMC-treated rats. Transplants performed at seizure-onset protected against pilocarpine-induced neuronal loss and gliosis and stimulated the proliferation of new neurons in epileptic rats. Our data demonstrate that BMC transplantation has potent therapeutic effects and could be a potential therapy for clinically intractable epilepsies. (C) 2012 Elsevier Inc. All rights reserved.a
C1 [Costa-Ferro, Zaquer S. M.; DaCosta, Jaderson C.] Pontificia Univ Catolica Rio Grande Sul PUCRS, Inst Cerebro, BR-90610000 Porto Alegre, RS, Brazil.
   [Costa-Ferro, Zaquer S. M.; DaCosta, Jaderson C.] Pontificia Univ Catolica Rio Grande Sul PUCRS, Inst Pesquisas Biomed, BR-90610000 Porto Alegre, RS, Brazil.
   [Costa-Ferro, Zaquer S. M.; Souza, Bruno S. F.; Leal, Marcos M. T.; Kaneto, Carla Martins; Azevedo, Carine Machado; da Silva, Igor Campos; Soares, Milena B. P.; Ribeiro-dos-Santos, Ricardo] Hosp Sao Rafael, Ctr Biotecnol & Terapia Celular, Salvador, BA, Brazil.
   [Souza, Bruno S. F.; Soares, Milena B. P.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil.
   [da Silva, Igor Campos] Hosp Sao Rafael, Serv Anat Patol & Citopatol, Salvador, BA, Brazil.
RP DaCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande Sul PUCRS, Inst Cerebro, Av Ipiranga 6690, BR-90610000 Porto Alegre, RS, Brazil.
EM samuelgreggio@yahoo.com
RI Costa-Ferro, Zaquer Suzana Munhoz/C-5875-2015
OI Costa-Ferro, Zaquer Suzana Munhoz/0000-0002-9120-8856; Soares,
   Milena/0000-0001-7549-2992
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Instituto de Pesquisa
   Biomedica (IPB); Instituto do Cerebro (InsCer) da Pontificia
   Universidade Catolica do Rio Grande do Sul (PUCRS); Centro de
   Biotecnologia e Terapia Celular do Hospital Sao Rafael, Salvador-BA
   (CBTC-BA); FAPESB; FINEPCiencia Tecnologia e Inovacao (FINEP)
FX This work was supported by the Brazilian National Research Council
   (CNPq), Instituto de Pesquisa Biomedica (IPB) and Instituto do Cerebro
   (InsCer) da Pontificia Universidade Catolica do Rio Grande do Sul
   (PUCRS), Centro de Biotecnologia e Terapia Celular do Hospital Sao
   Rafael, Salvador-BA (CBTC-BA), FAPESB and FINEP. The authors would like
   to thank Juliana Vasconcelos for assistance with ELISA experiments.
CR ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210
   Akassoglou K, 1997, J IMMUNOL, V158, P438
   Aronica E, 2000, EUR J NEUROSCI, V12, P2333, DOI 10.1046/j.1460-9568.2000.00131.x
   Baker AH, 2007, P NATL ACAD SCI USA, V104, P3597, DOI 10.1073/pnas.0611112104
   Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063
   Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490
   Bovolenta R, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-81
   Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775
   Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198
   CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061
   Cavalheiro EA, 2006, MODELS OF SEIZURES AND EPILEPSY, P433, DOI 10.1016/B978-012088554-1/50037-2
   Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6
   CLIFFORD DB, 1987, NEUROSCIENCE, V23, P953, DOI 10.1016/0306-4522(87)90171-0
   Costa-Ferro ZSM, 2010, SEIZURE-EUR J EPILEP, V19, P84, DOI 10.1016/j.seizure.2009.12.003
   Crain BJ, 2005, J NEUROL SCI, V233, P121, DOI 10.1016/j.jns.2005.03.017
   Dharmasaroja P, 2009, J CLIN NEUROSCI, V16, P12, DOI 10.1016/j.jocn.2008.05.006
   dos Santos AD, 2010, BRAIN RES, V1306, P149, DOI 10.1016/j.brainres.2009.09.094
   Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080
   Eid T, 2008, EPILEPSIA, V49, P42, DOI 10.1111/j.1528-1167.2008.01492.x
   Engel J, 1996, EPILEPSY RES, V26, P141, DOI 10.1016/S0920-1211(96)00043-5
   Engel J, 2001, NEUROSCIENTIST, V7, P340, DOI 10.1177/107385840100700410
   Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x
   Franklin K.B.J., 1997, MOUSE BRAIN STEREOTA
   Giraidi-Guimaraes A, 2009, BRAIN RES, V1266, P108, DOI 10.1016/j.brainres.2009.01.062
   Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3
   Hu DZ, 2004, CHINESE MED J-PEKING, V117, P1576
   Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084
   JANECZKO K, 1994, FOLIA HISTOCHEM CYTO, V32, P239
   Kamiya N, 2008, LIFE SCI, V83, P433, DOI 10.1016/j.lfs.2008.07.018
   Kanter-Schlifke I, 2007, MOL THER, V15, P1106, DOI 10.1038/sj.mt.6300148
   Kawada H, 2006, CIRCULATION, V113, P701, DOI 10.1161/CIRCULATIONAHA.105.563668
   Li G, 2011, SEIZURE-EUR J EPILEP, V20, P249, DOI 10.1016/j.seizure.2010.12.005
   Liu N, 2009, CELL MOL IMMUNOL, V6, P207, DOI 10.1038/cmi.2009.28
   Mathern GW, 1996, EPILEPSY RES, V26, P151, DOI 10.1016/S0920-1211(96)00052-6
   MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x
   Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459
   Morita Y, 2007, NEUROSCI RES, V58, P356, DOI 10.1016/j.neures.2007.04.006
   Parent JM, 1997, J NEUROSCI, V17, P3727
   RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P269, DOI 10.1016/0013-4694(72)90176-9
   Rijkers K, 2009, EXP NEUROL, V216, P258, DOI 10.1016/j.expneurol.2008.12.014
   SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5
   Takahashi M, 2006, AM J PHYSIOL-HEART C, V291, pH886, DOI 10.1152/ajpheart.00142.2006
   TURSKI L, 1987, POL J PHARMACOL PHAR, V39, P545
   Venturin GT, 2011, LIFE SCI, V89, P229, DOI 10.1016/j.lfs.2011.06.006
   Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x
   Vezzani A, 2008, BRAIN BEHAV IMMUN, V22, P797, DOI 10.1016/j.bbi.2008.03.009
   Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178
   Vilcek Jan, 1998, P1
   Walker PA, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/369578
   Wieser HG, 2004, EPILEPSIA, V45, P32
   Ye ZC, 1996, NEUROREPORT, V7, P2181, DOI 10.1097/00001756-199609020-00025
   Zacharek A, 2010, STROKE, V41, P524, DOI 10.1161/STROKEAHA.109.568881
NR 52
TC 33
Z9 35
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
EI 1095-953X
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD MAY
PY 2012
VL 46
IS 2
BP 302
EP 313
DI 10.1016/j.nbd.2011.12.001
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 937BC
UT WOS:000303633000008
PM 22198377
OA Green Published
DA 2020-12-08
ER

PT J
AU Saueressig, F
   Xavier, LL
   Bagatini, PB
   Nique, PS
   DaCosta, JC
   Gomes, I
   Cherubini, K
AF Saueressig, Frederico
   Xavier, Leder L.
   Bagatini, Pamela B.
   Nique, Pamela S.
   DaCosta, Jaderson C.
   Gomes, Irenio
   Cherubini, Karen
TI Morphofunctional analysis of sciatic nerve and motor performance of rats
   after cryotherapy with liquid nitrogen
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID NON-SERRATED CLAMP; CRUSH INJURY; MORPHOLOGICAL ASSESSMENT;
   FUNCTIONAL-EVALUATION; MUSCLE REINNERVATION; NEUROPATHIC PAIN;
   REGENERATION; LESIONS; RECOVERY; MANAGEMENT
AB Objective. This work evaluated sciatic nerve regeneration after cryotherapy.
   Study design. Rats underwent surgical access of the sciatic nerve and subsequent cryotherapy, crush lesion, or no manipulation. Walking-track, electroneuromyographic, and histomorphometric analyses were performed at 15, 30, and 70 postoperative days.
   Results. At 15 days, the crush and cryotherapy groups showed significant morphofunctional impairment. At 30 days, functional loss was significant in the walking-track, but at 70 days, there were no significant differences between the groups. Amplitude was near zero for the crush group at 15 and 30 days and zero for the cryotherapy group. Measurement of latency was not possible in the latter group. Crush and cryotherapy groups showed greater amounts of myelinated fibers (by 30 days), with axonal diameter and width of the myelin sheath being less than in control group.
   Conclusions. Sciatic nerve lesion by application of liquid nitrogen is classified as axonotmesis, which is reversible. (Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:319-326)
C1 [Saueressig, Frederico; Cherubini, Karen] Pontificia Univ Catolica Rio Grande do Sul, Coll Dent, Porto Alegre, RS, Brazil.
   [Xavier, Leder L.; Bagatini, Pamela B.; Nique, Pamela S.] Pontificia Univ Catolica Rio Grande do Sul, Lab Biol Celular & Tecidual, Porto Alegre, RS, Brazil.
   [DaCosta, Jaderson C.; Gomes, Irenio] Pontificia Univ Catolica Rio Grande do Sul, Serv Neurol, Porto Alegre, RS, Brazil.
RP Cherubini, K (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Serv Estomatol, Hosp Sao Lucas, Av Ipiranga,6690 Sala 231, Porto Alegre, RS, Brazil.
EM karen.cherubini@pucrs.br
RI Xavier, Leder/G-4540-2014; DaCosta, Jaderson/C-4968-2015; Cherubini,
   Karen/K-2572-2015
OI Xavier, Leder/0000-0002-7213-4935; DaCosta,
   Jaderson/0000-0001-6776-1515; Cherubini, Karen/0000-0003-0913-477X
CR BAIN JR, 1989, PLAST RECONSTR SURG, V83, P129, DOI 10.1097/00006534-198901000-00024
   BEAZLEY RM, 1974, J SURG RES, V16, P231, DOI 10.1016/0022-4804(74)90036-5
   BRIDGE PM, 1994, EXP NEUROL, V127, P284, DOI 10.1006/exnr.1994.1104
   Burnett Mark G, 2004, Neurosurg Focus, V16, pE1, DOI 10.3171/foc.2004.16.5.2
   CARMIGNOTO G, 1983, NEUROSCIENCE, V8, P393, DOI 10.1016/0306-4522(83)90187-2
   CONACHER ID, 1986, LANCET, V1, P277
   Defrin R, 1996, BRAIN RES, V711, P241, DOI 10.1016/0006-8993(95)01481-0
   DELEO JA, 1994, PAIN, V56, P9, DOI 10.1016/0304-3959(94)90145-7
   DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5
   Ferris A, 1999, P INT GEOSC REM SENS, P1
   Fraher J, 1998, J ANAT, V193, P195, DOI 10.1046/j.1469-7580.1998.19320195.x
   GORIO A, 1983, NEUROSCIENCE, V8, P403, DOI 10.1016/0306-4522(83)90188-4
   HARE GMT, 1992, PLAST RECONSTR SURG, V89, P251, DOI 10.1097/00006534-199202000-00009
   Hupp JR, 2005, CONT ORAL MAXILLOFAC, P53
   Ilha J, 2008, NEUROREHAB NEURAL RE, V22, P355, DOI 10.1177/1545968307313502
   Kanaya F, 1996, PLAST RECONSTR SURG, V98, P1264, DOI 10.1097/00006534-199612000-00023
   Kauppila T, 1998, NEUROSCI BIOBEHAV R, V23, P111, DOI 10.1016/S0149-7634(98)00038-4
   KERNS JM, 1991, PAIN, V47, P31, DOI 10.1016/0304-3959(91)90008-L
   Kumar V, 2008, ROBBINS BASIC PATHOL, P937
   Luis AL, 2007, J NEUROSCI METH, V163, P92, DOI 10.1016/j.jneumeth.2007.02.017
   Minamoto VB, 2007, FISIOTER MOV, V20, P63
   Myers RR, 1996, J NEUROL SCI, V139, P28, DOI 10.1016/0022-510X(96)00038-X
   Oliveira EF, 2001, J RECONSTR MICROSURG, V17, P69, DOI 10.1055/s-2001-12691
   Oliveira LS, 2008, REV NEUROLOGIA, V47, P11
   ORR IA, 1981, BMJ-BRIT MED J, V283, P945, DOI 10.1136/bmj.283.6297.945
   Ozay R, 2007, SURG NEUROL, V68, P615, DOI 10.1016/j.surneu.2006.12.054
   POGREL MA, 1993, J ORAL MAXIL SURG, V51, P269
   Pogrel MA, 1996, ORAL SURG ORAL MED O, V81, P396, DOI 10.1016/S1079-2104(96)80014-X
   SALMASSY DA, 1995, J ORAL MAXIL SURG, V53, P784, DOI 10.1016/0278-2391(95)90333-X
   Santos AB, 2002, MORPHOLOGICAL ANAL E
   Santos T.S., 2007, REV NEUROCI, V15, P120
   Schmidt BL, 2004, J ORAL MAXIL SURG, V62, P1183, DOI 10.1016/j.joms.2004.03.012
   Schmidt BL, 2001, J ORAL MAXIL SURG, V59, P720, DOI 10.1053/joms.2001.24278
   Takeda SYM, 2008, REV NEUROLOGIA, V47, P185, DOI 10.33588/rn.4704.2008030
   Varejao ASP, 2004, J NEUROTRAUM, V21, P1652, DOI 10.1089/0897715042441738
   Varejao ASP, 2001, J NEUROSCI METH, V108, P1, DOI 10.1016/S0165-0270(01)00378-8
   Verdu E, 2000, J PERIPHER NERV SYST, V5, P191, DOI 10.1046/j.1529-8027.2000.00026.x
   WAGNER R, 1995, PHYSIOL BEHAV, V58, P37, DOI 10.1016/0031-9384(95)00037-J
   Wolthers M, 2005, MICROSURG, V25, P508, DOI 10.1002/micr.20156
   Zuniga JR, 1998, J ORAL MAXIL SURG, V56, P2, DOI 10.1016/S0278-2391(98)90904-1
NR 40
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2212-4403
EI 1528-395X
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD MAR
PY 2012
VL 113
IS 3
BP 319
EP 326
DI 10.1016/j.tripleo.2011.03.023
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 899BC
UT WOS:000300785900015
PM 22676823
DA 2020-12-08
ER

PT J
AU Greggio, S
   de Paula, S
   de Oliveira, IM
   Trindade, C
   Rosa, RM
   Henriques, JAP
   DaCosta, JC
AF Greggio, Samuel
   de Paula, Simone
   de Oliveira, Iuri M.
   Trindade, Cristiano
   Rosa, Renato M.
   Henriques, Joao A. P.
   DaCosta, Jaderson C.
TI NAP prevents acute cerebral oxidative stress and protects against
   long-term brain injury and cognitive impairment in a model of neonatal
   hypoxia-ischemia
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Perinatal hypoxia-ischemia; NAP; Neuroprotection; Rat model; Oxidative
   stress; Memory; Brain lesion
ID INDUCED LEARNING-DEFICITS; POLYADP-RIBOSYLATION; PEPTIDES PREVENT;
   FREE-RADICALS; MOUSE MODEL; DNA-DAMAGE; MICE; RAT; DIFFERENTIATION;
   PEROXIDATION
AB Hypoxia-ischemia (HI) is a common cause of neonatal brain damage with lifelong morbidities in which current therapies are limited. In this study, we investigated the effect of neuropeptide NAP (NAPVSIPQ) on early cerebral oxidative stress, long-term neurological function and brain injury after neonatal HI. Seven-day-old rat pups were subjected to an HI model by applying a unilateral carotid artery occlusion and systemic hypoxia. The animals were randomly assigned to groups receiving an intraperitoneal injection of NAP (3 mu g/g) or vehicle immediately (0 h) and 24 h after HI. Brain DNA damage, lipid peroxidation and reduced glutathione (GSH) content were determined 24 h after the last NAP injection. Cognitive impairment was assessed on postnatal day 60 using the spatial version of the Morris water maze learning task. Next, the animals were euthanized to assess the cerebral hemispheric volume using the Cavalieri principle associated with the counting point method. We observed that NAP prevented the acute HI-induced DNA and lipid membrane damage and also recovered the GSH levels in the injured hemisphere of the HI rat pups. Further, NAP was able to prevent impairments in learning and long-term spatial memory and to significantly reduce brain damage up to 7 weeks following the neonatal HI injury. Our findings demonstrate that NAP confers potent neuroprotection from acute brain oxidative stress, long-term cognitive impairment and brain lesions induced by neonatal HI through, at least in part, the modulation of the glutathione-mediated antioxidant system. (C) 2011 Elsevier Inc. All rights reserved.
C1 [DaCosta, Jaderson C.] Pontificia Univ Catolica Rio Grande do Sul, Lab Neurociencias, Inst Pesquisas Biomed, Programa Posgrad Pediat & Saude Crianca, BR-90619900 Porto Alegre, RS, Brazil.
   [Greggio, Samuel; de Paula, Simone; DaCosta, Jaderson C.] Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro, Lab Neurociencias, BR-90619900 Porto Alegre, RS, Brazil.
   [de Oliveira, Iuri M.; Trindade, Cristiano; Henriques, Joao A. P.] Univ Fed Rio Grande do Sul, Dept Biofis, Inst Biociencias, Porto Alegre, RS, Brazil.
   [Rosa, Renato M.] Univ Luterana Brasil ULBRA, Lab Genet Toxicol, Canoas, RS, Brazil.
   [Rosa, Renato M.] Univ Luterana Brasil ULBRA, Programa Posgrad Genet & Toxicol Aplicada, Canoas, RS, Brazil.
RP DaCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Lab Neurociencias, Inst Pesquisas Biomed, Programa Posgrad Pediat & Saude Crianca, Ave Ipiranga 6690,Predio 60,2 Andar,Sala 07, BR-90619900 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Greggio, Samuel/E-1498-2013; DaCosta, Jaderson/C-4968-2015; Trindade,
   Cristiano/AAF-4226-2019; de Olveira, Iuri/AAV-2953-2020; marques de
   oliveira, Iuri/L-7585-2015
OI Greggio, Samuel/0000-0002-5187-0335; DaCosta,
   Jaderson/0000-0001-6776-1515; Trindade, Cristiano/0000-0002-6128-5025;
   de Paula, Simone/0000-0003-3198-2695
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS);
   Pandurata Ltda; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES)CAPES
FX This work was supported by research grants from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Pontificia Universidade
   Catolica do Rio Grande do Sul (PUCRS) and Pandurata Ltda. J.C. DaCosta
   and J.A.P. Henriques are researchers of the CNPq. S. de Paula and I.M.
   de Oliveria are recipients of fellowships from Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). S. Greggio and C.
   Trindade are recipients of scholarships from CNPq. The authors would
   like to thank professors Ivan Izquierdo and Martin Cammarota for
   providing excellent research facility for our study at Centro de Memoria
   (Instituto do Cerebro, PUCRS).
CR Akerboom T P, 1981, Methods Enzymol, V77, P373
   Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005
   Ashur-Fabian O, 2001, NEUROSCI LETT, V307, P167, DOI 10.1016/S0304-3940(01)01954-1
   Bagenholm R, 1997, BRAIN RES, V773, P132, DOI 10.1016/S0006-8993(97)00776-2
   Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x
   Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57
   Brenneman DE, 2004, J PHARMACOL EXP THER, V309, P1190, DOI 10.1124/jpet.103.063891
   Buonocore G, 2001, BIOL NEONATE, V79, P180
   Burlinson B, 2007, MUTAT RES-GEN TOX EN, V627, P31, DOI 10.1016/j.mrgentox.2006.08.011
   Busciglio J, 2007, CURR PHARM DESIGN, V13, P1091, DOI 10.2174/138161207780618957
   Cai JM, 2009, BRAIN RES, V1256, P129, DOI 10.1016/j.brainres.2008.11.048
   Chen SZ, 2008, P NATL ACAD SCI USA, V105, P19962, DOI 10.1073/pnas.0807758105
   Dafre AL, 2003, NEUROSCI LETT, V345, P65, DOI 10.1016/S0304-3940(03)00510-X
   de Paula S, 2009, PEDIATR RES, V65, P631, DOI 10.1203/PDR.0b013e31819ed5c8
   Ferriero DM, 2001, DEV NEUROSCI-BASEL, V23, P198, DOI 10.1159/000046143
   Goldberg S, 2009, J NEUROCHEM, V111, P72, DOI 10.1111/j.1471-4159.2009.06296.x
   Gozes I, 2004, J MOL NEUROSCI, V24, P67, DOI 10.1385/JMN:24:1:067
   Gozes I, 2002, J MOL NEUROSCI, V19, P167, DOI 10.1007/s12031-002-0028-0
   Gozes I, 2005, CNS DRUG REV, V11, P353
   Greggio S, 2009, NEUROBIOL DIS, V36, P435, DOI 10.1016/j.nbd.2009.08.008
   GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x
   Incerti M, 2011, OBSTET GYNECOL, V117, P354, DOI 10.1097/AOG.0b013e3182051ca5
   Incerti M, 2010, OBSTET GYNECOL, V115, P350, DOI 10.1097/AOG.0b013e3181cb59da
   Alles YCJ, 2010, BRAIN RES, V1356, P130, DOI 10.1016/j.brainres.2010.07.106
   Kumar A, 2008, PEDIATRICS, V122, pE722, DOI 10.1542/peds.2008-0269
   Kumral A, 2006, BRAIN RES, V1115, P169, DOI 10.1016/j.brainres.2006.07.114
   Lafemina MJ, 2006, PEDIATR RES, V59, P680, DOI 10.1203/01.pdr.0000214891.35363.6a
   Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Nadin SB, 2001, J HISTOCHEM CYTOCHEM, V49, P1183, DOI 10.1177/002215540104900912
   Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x
   Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6
   Pascual M, 2007, J NEUROCHEM, V103, P557, DOI 10.1111/j.1471-4159.2007.04761.x
   Perlman JM, 2006, CLIN THER, V28, P1353, DOI 10.1016/j.clinthera.2006.09.005
   RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206
   Rotstein M, 2006, J PHARMACOL EXP THER, V319, P332, DOI 10.1124/jpet.106.106898
   Salgo MG, 1996, ARCH BIOCHEM BIOPHYS, V333, P482, DOI 10.1006/abbi.1996.0418
   Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x
   Schmidt H, 1996, PEDIATR RES, V40, P15, DOI 10.1203/00006450-199607000-00003
   Sheldon RA, 2007, PEDIATR RES, V61, P666, DOI 10.1203/pdr.0b013e318053664c
   Shi Y, 2000, PEDIATRICS, V106, P1447, DOI 10.1542/peds.106.6.1447
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Sokolowska P, 2011, NEUROSCIENCE, V173, P156, DOI 10.1016/j.neuroscience.2010.10.074
   Spong CY, 2001, J PHARMACOL EXP THER, V297, P774
   Steingart RA, 2006, MOL CELL ENDOCRINOL, V252, P148, DOI 10.1016/j.mce.2006.03.029
   Steingart RA, 2000, J MOL NEUROSCI, V15, P137, DOI 10.1385/JMN:15:3:137
   Takizawa Y, 2009, PEDIATR RES, V65, P636, DOI 10.1203/PDR.0b013e3181a16a9f
   Toso L, 2006, AM J OBSTET GYNECOL, V194, P1153, DOI 10.1016/j.ajog.2005.12.023
   Toso L, 2006, AM J OBSTET GYNECOL, V194, P681, DOI 10.1016/j.ajog.2006.01.003
   Toso L, 2007, AM J OBSTET GYNECOL, V196, P259, DOI 10.1016/j.ajog.2007.01.015
   Toso L, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.05.049
   Venturin GT, 2011, LIFE SCI, V89, P229, DOI 10.1016/j.lfs.2011.06.006
   Vink J, 2005, AM J OBSTET GYNECOL, V193, P825, DOI 10.1016/j.ajog.2005.02.101
   Vink J, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2009.01.052
   Visochek L, 2005, J NEUROSCI, V25, P7420, DOI 10.1523/JNEUROSCI.0333-05.2005
   VOLPE JJ, 2008, HYPOXIC ISCHEMIC ENC, P400
   Vulih-Shultzman I, 2007, J PHARMACOL EXP THER, V323, P438, DOI 10.1124/jpet.107.129551
   WEIS SN, 2011, INT J DEV NEUROSCI
   Zaltzman R, 2004, J MOL NEUROSCI, V24, P181, DOI 10.1385/JMN:24:2:181
   Zhu CL, 2000, J NEUROCHEM, V75, P819, DOI 10.1046/j.1471-4159.2000.0750819.x
NR 60
TC 20
Z9 23
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
EI 1095-953X
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD OCT
PY 2011
VL 44
IS 1
BP 152
EP 159
DI 10.1016/j.nbd.2011.06.018
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 811HO
UT WOS:000294197700016
PM 21757007
DA 2020-12-08
ER

PT J
AU Venturin, GT
   Greggio, S
   Marinowic, DR
   Zanirati, G
   Cammarota, M
   Machado, DC
   DaCosta, JC
AF Venturin, Gianina Teribele
   Greggio, Samuel
   Marinowic, Daniel Rodrigo
   Zanirati, Gabriele
   Cammarota, Martin
   Machado, Denise Cantarelli
   DaCosta, Jaderson Costa
TI Bone marrow mononuclear cells reduce seizure frequency and improve
   cognitive outcome in chronic epileptic rats
SO LIFE SCIENCES
LA English
DT Article
DE Temporal lobe epilepsy; Seizures; Bone marrow stem cells; Cognition
ID TEMPORAL-LOBE EPILEPSY; SPONTANEOUS RECURRENT SEIZURES; PILOCARPINE
   MODEL; SPATIAL MEMORY; ANIMAL-MODELS; STEM-CELLS; ADULT MICE; BRAIN;
   HIPPOCAMPUS; TRANSPLANTATION
AB Aims: Epilepsy affects 0.5-1% of the world's population, and approximately a third of these patients are refractory to current medication. Given their ability to proliferate, differentiate and regenerate tissues, stem cells could restore neural circuits lost during the course of the disease and reestablish the physiological excitability of neurons. This study verified the therapeutic potential of bone marrow mononuclear cells (BMMCs) on seizure control and cognitive impairment caused by experimentally induced epilepsy.
   Main methods: Status epilepticus (SE) was induced by lithium-pilocarpine injection and controlled with diazepam 90 min after SE onset. Lithium-pilocarpine-treated rats were intravenously transplanted 22 days after SE with BMMCs obtained from enhanced green fluorescent protein (eGFP) transgenic C57BL/6 mice. Control epileptic animals were given an equivalent volume of saline or fibroblast injections. Animals were video-monitored for the presence of spontaneous recurrent seizures prior to and following the cell administration procedure. In addition, rats underwent cognitive evaluation using a Morris water maze.
   Key findings: Our data show that BMMCs reduced the frequency of seizures and improved the learning and long-term spatial memory impairments of epileptic rats. EGFP-positive cells were detected in the brains of transplanted animals by PCR analysis.
   Significance: The positive behavioral effects observed in our study indicate that BMMCs could represent a promising therapeutic option in the management of chronic temporal lobe epilepsy. (C) 2011 Elsevier Inc. All rights reserved.
C1 [DaCosta, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Lab Neurociencias, Inst Cerebro, BR-90619900 Porto Alegre, RS, Brazil.
   [Venturin, Gianina Teribele; Greggio, Samuel; Zanirati, Gabriele; DaCosta, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Lab Neurociencias, Inst Pesquisas Biomed, BR-90619900 Porto Alegre, RS, Brazil.
   [Venturin, Gianina Teribele] Univ Fed Rio Grande do Sul, Programa Posgrad Neurociencias, Porto Alegre, RS, Brazil.
   [Marinowic, Daniel Rodrigo; Machado, Denise Cantarelli] Pontificia Univ Catolica Rio Grande do Sul, Lab Terapia Celular, Inst Pesquisas Biomed, BR-90619900 Porto Alegre, RS, Brazil.
   [Cammarota, Martin] Pontificia Univ Catolica Rio Grande do Sul, Ctr Memoria, Inst Pesquisas Biomed, BR-90619900 Porto Alegre, RS, Brazil.
RP DaCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Lab Neurociencias, Inst Cerebro, Ave Ipiranga 6690,Jardim Botan,Predio 60,2 Andar, BR-90619900 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Greggio, Samuel/E-1498-2013; Machado, Denise C/G-2852-2014; DaCosta,
   Jaderson/C-4968-2015; Neurociencia, Inct/I-1011-2013
OI Greggio, Samuel/0000-0002-5187-0335; Machado, Denise
   C/0000-0002-9371-5886; DaCosta, Jaderson/0000-0001-6776-1515; Cammarota,
   Martin/0000-0001-9741-5074; Teribele Venturin,
   Gianina/0000-0001-7696-8219; Zanirati, Gabriele/0000-0002-1986-973X
FU National Council of Scientific and Technological Development (CNPq)
   through the Department of Science and Technology of the Ministry of
   Health (Decit - Ministerio da Saude), Pandurata SANational Council for
   Scientific and Technological Development (CNPq); Gama e Souza; Parana
   University Foundation (FUNPAR); Coordination for the Improvement of
   Higher Education Personnel (CAPES)CAPES; CNPq (Brazil)National Council
   for Scientific and Technological Development (CNPq)
FX This work was supported by research grants from the National Council of
   Scientific and Technological Development (CNPq) through the Department
   of Science and Technology of the Ministry of Health (Decit - Ministerio
   da Saude), Pandurata SA, Gama e Souza and the Parana University
   Foundation (FUNPAR). J.C. da Costa, M. Cammarota and D.C. Machado are
   researchers of the CNPq. G.T. Venturin and S. Greggio are recipients of
   PhD degree fellowships from Coordination for the Improvement of Higher
   Education Personnel (CAPES) and CNPq (Brazil). The authors wish to thank
   professors Ricardo Ribeiro Santos and Milena Soares, who provided the
   eGFP transgenic mice, and the helpful assistance of Simone Denise
   Salamoni and Daniela Souza de Abreu.
CR Arida RM, 1999, EPILEPSY RES, V34, P99, DOI 10.1016/S0920-1211(98)00092-8
   BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7
   Blumcke I, 1996, ACTA NEUROPATHOL, V92, P576, DOI 10.1007/s004010050564
   Blumcke I, 1999, EPILEPSY RES, V36, P205, DOI 10.1016/S0920-1211(99)00052-2
   Bonini JS, 2007, NEUROSCIENCE, V147, P37, DOI 10.1016/j.neuroscience.2007.04.013
   Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7
   Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775
   Carpentino JE, 2008, J NEUROSCI RES, V86, P512, DOI 10.1002/jnr.21514
   CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x
   Chu K, 2004, BRAIN RES, V1023, P213, DOI 10.1016/j.brainres.2004.07.045
   Chu K, 2008, EPILEPSIA, V49, P1723, DOI 10.1111/j.1528-1167.2008.01644.x
   Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3
   Costa-Ferro ZSM, 2010, SEIZURE-EUR J EPILEP, V19, P84, DOI 10.1016/j.seizure.2009.12.003
   Detour J, 2005, EPILEPSIA, V46, P499, DOI 10.1111/j.0013-9580.2005.38704.x
   Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080
   Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x
   Eves EM, 2001, J NEUROSCI, V21, P4996, DOI 10.1523/JNEUROSCI.21-14-04996.2001
   Gernert M, 2002, EXP NEUROL, V176, P183, DOI 10.1006/exnr.2002.7914
   GREGGIO B, 2011, NEUROBIOL DIS, DOI DOI 10.1016/J.NBD.2011.06.018
   Hattiangady B, 2004, NEUROBIOL DIS, V17, P473, DOI 10.1016/j.nbd.2004.08.008
   Hattiangady B, 2008, EXP NEUROL, V212, P468, DOI 10.1016/j.expneurol.2008.04.040
   Hermann BP, 2002, PROG BRAIN RES, V135, P429
   Hermann BP, 2006, ANN NEUROL, V60, P80, DOI 10.1002/ana.20872
   Huber A, 2001, P NATL ACAD SCI USA, V98, P7611, DOI 10.1073/pnas.131102898
   Jing M, 2009, BRAIN RES, V1295, P203, DOI 10.1016/j.brainres.2009.07.079
   Kanter-Schlifke I, 2007, MOL THER, V15, P1106, DOI 10.1038/sj.mt.6300148
   Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361
   Li L, 2009, STROKE, V40, P936, DOI 10.1161/STROKEAHA.108.527713
   Li TF, 2009, EPILEPSY RES, V84, P238, DOI 10.1016/j.eplepsyres.2009.01.002
   Loscher W, 2002, TRENDS PHARMACOL SCI, V23, P113, DOI 10.1016/S0165-6147(00)01974-X
   Louboutin JP, 2011, FASEB J, V25, P737, DOI 10.1096/fj.10-161851
   Maurer MH, 2008, CURR MED CHEM, V15, P1407, DOI 10.2174/092986708784567671
   Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779
   Minnerup J, 2008, STROKE, V39, P1855, DOI 10.1161/STROKEAHA.107.506816
   MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4
   Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105
   Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X
   Oyegbile TO, 2006, EPILEPSIA, V47, P143, DOI 10.1111/j.1528-1167.2006.00380.x
   Oyegbile TO, 2004, NEUROLOGY, V62, P1736, DOI 10.1212/01.WNL.0000125186.04867.34
   Park DH, 2009, STEM CELLS DEV, V18, P693, DOI 10.1089/scd.2009.0008
   Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889
   RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0
   Rao MS, 2006, NEUROBIOL DIS, V21, P276, DOI 10.1016/j.nbd.2005.07.009
   Ruschenschmidt T, 2005, EPILEPSIA, V46, P174, DOI 10.1111/j.1528-1167.2005.01028.x
   Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433
   Schwarting S, 2008, STROKE, V39, P2867, DOI 10.1161/STROKEAHA.108.513978
   Shen H, 2010, INT J NEUROSCI, V120, P647, DOI 10.3109/00207454.2010.509526
   Shetty AK, 2003, J NEUROCHEM, V87, P147, DOI 10.1046/j.1471-4159.2003.01979.x
   Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730
   TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5
   Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x
   Yasuhara T, 2010, J CELL MOL MED, V14, P914, DOI 10.1111/j.1582-4934.2008.00671.x
   Zaman V, 2000, EXP NEUROL, V161, P535, DOI 10.1006/exnr.1999.7304
NR 53
TC 32
Z9 33
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD AUG 15
PY 2011
VL 89
IS 7-8
BP 229
EP 234
DI 10.1016/j.lfs.2011.06.006
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 806MD
UT WOS:000293811100003
PM 21718708
DA 2020-12-08
ER

PT J
AU de Oliveira, FP
   da Costa, JC
   Marroni, SP
   da Silva, AMM
   Barreiro, SH
   Maeda, FK
   Portuguez, MW
AF de Oliveira, Fabio Pascotto
   da Costa, Jaderson Costa
   Marroni, Sabine Possa
   Marques da Silva, Ana Maria
   Barreiro, Sthefanie Hansen
   Maeda, Fabio Kunihiro
   Portuguez, Mirna Wetters
TI Primary progressive aphasia patients evaluated using diffusion tensor
   imaging and voxel based volumetry-preliminary results
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE anomia; primary progressive aphasia; DTI; tractography; arcuate
   fasciculus; language
ID ANATOMO-FUNCTIONAL CONNECTIVITY; TRACTOGRAPHY; LANGUAGE; IMPAIRMENT;
   INTEGRITY; PATHWAYS; INSIGHTS; MILD
AB There are individuals who have a progressive language deficit without presenting cognitive deficits in other areas. One of the diseases related to this presentation is primary progressive aphasia (PPA). Objective: Identify by means of diffusion tensor imaging (DTI) and measurements of cortical volume, brain areas that lead to dysphasia when presenting signs of impaired connectivity or reduced volume. Method: Four patients with PPA were evaluated using DTI, and measurements of cortical volumes in temporal areas. These patients were compared with two normal volunteers. Results: There is a trend to a difference in the number and volume of related fibers between control group and patients with PPA. Comparing cortical volumes in temporal areas between groups yielded a trend to a smaller volume in PPA patients. Conclusion: Patients with PPA have a trend to impairment in cortical and subcortical levels regarding relevant areas.
C1 [de Oliveira, Fabio Pascotto] HUSM, Santa Maria, RS, Brazil.
   [da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Director Brain Inst, Porto Alegre, RS, Brazil.
   [Marroni, Sabine Possa] Pontificia Univ Catolica Rio Grande do Sul, Unit Neuropsychol Hosp Sao Lucas, Porto Alegre, RS, Brazil.
   [Marques da Silva, Ana Maria] Pontificia Univ Catolica Rio Grande do Sul, Sch Phys, Porto Alegre, RS, Brazil.
   [Barreiro, Sthefanie Hansen; Maeda, Fabio Kunihiro] Pontificia Univ Catolica Rio Grande do Sul, NIMed, Porto Alegre, RS, Brazil.
RP de Oliveira, FP (corresponding author), Av Fernando Ferrari 1067, BR-97050801 Santa Maria, RS, Brazil.
EM fpascotto@hotmail.com
RI Portuguez, Mirna/A-9362-2018; DaCosta, Jaderson/C-4968-2015; da Silva,
   Ana Maria Marques/G-8197-2014
OI Portuguez, Mirna/0000-0003-4068-6249; DaCosta,
   Jaderson/0000-0001-6776-1515; da Silva, Ana Maria
   Marques/0000-0002-5924-6852
CR Aoki Shigeki, 2005, Radiat Med, V23, P195
   Ben Shalom D, 2008, NEUROSCIENTIST, V14, P119, DOI 10.1177/1073858407305726
   Catani M, 2005, ANN NEUROL, V57, P8, DOI 10.1002/ana.20319
   Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004
   Ciccarelli O, 2006, BRAIN, V129, P1859, DOI 10.1093/brain/awl100
   Ciccarelli O, 2008, LANCET NEUROL, V7, P715, DOI 10.1016/S1474-4422(08)70163-7
   Duffau H, 2002, BRAIN, V125, P199, DOI 10.1093/brain/awf016
   Duffau H, 2005, BRAIN, V128, P797, DOI 10.1093/brain/awh423
   Duffau H, 2008, NEUROPSYCHOLOGIA, V46, P927, DOI 10.1016/j.neuropsychologia.2007.10.025
   Gorno-Tempini ML, 2004, ANN NEUROL, V55, P335, DOI 10.1002/ana.10825
   Hickok G, 2007, NAT REV NEUROSCI, V8, P393, DOI 10.1038/nrn2113
   Ingles JL, 2007, CORTEX, V43, P558, DOI 10.1016/S0010-9452(08)70250-8
   Johansen-Berg H, 2006, CURR OPIN NEUROL, V19, P379, DOI 10.1097/01.wco.0000236618.82086.01
   Lindenberg R, 2010, NEUROLOGY, V74, P280, DOI 10.1212/WNL.0b013e3181ccc6d9
   Mesulam MM, 2007, ALZ DIS ASSOC DIS, V21, pS8, DOI 10.1097/WAD.0b013e31815bf7e1
   Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765
   Price CJ, 2000, J ANAT, V197, P335, DOI 10.1046/j.1469-7580.2000.19730335.x
   Rogalski EJ, 2009, BEHAV NEUROL, V21, P51, DOI [10.1155/2009/408037, 10.3233/BEN-2009-0235]
   Rogalski E, 2007, CURR NEUROL NEUROSCI, V7, P388, DOI 10.1007/s11910-007-0060-0
   Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213
   Saur D, 2008, P NATL ACAD SCI USA, V105, P18035, DOI 10.1073/pnas.0805234105
   Tae WS, 2008, NEURORADIOLOGY, V50, P569, DOI 10.1007/s00234-008-0383-9
   Valdes-Hernandesbn P, 2006, IBASPM TOOLBOX AUTOM
NR 23
TC 5
Z9 5
U1 1
U2 2
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 2011
VL 69
IS 3
BP 446
EP 451
DI 10.1590/S0004-282X2011000400007
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 783WR
UT WOS:000292115600007
PM 21755119
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Becker, J
   da Silva, IG
   da Silva, HF
   Schuch, A
   Ramos, FLD
   Ghisolfi, ES
   Lara, DR
   da Costa, JC
AF Becker, Jefferson
   da Silva Filho, Irenio Gomes
   da Silva Filho, Helio Fernandes
   Schuch, Alice
   de Paula Ramos, Fernanda Lia
   Ghisolfi, Eduardo Soerensen
   Lara, Diogo Rizzato
   da Costa, Jaderson Costa
TI Pattern of P50 suppression deficit in patients with epilepsy and
   individuals with schizophrenia
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE epilepsy; P50 auditory evoked potential; schizophrenia; sensory filter
ID AUDITORY-EVOKED POTENTIALS; MACHADO-JOSEPH-DISEASE; TRAUMATIC
   BRAIN-INJURY; TEMPORAL VARIABILITY; HIPPOCAMPAL; RESPONSES; SURGERY
AB Objective: To identify P50 suppression in patients with epilepsy, to investigate the effect of seizure control on P50 suppression, and to compare epilepsy patients with individuals with schizophrenia and healthy volunteers. Method: P50 evoked potential parameters and P50 suppression were studied crossectionally in patients with uncontrolled or controlled epilepsy, in individuals with schizophrenia and in healthy volunteers. Results: Individuals with schizophrenia had significantly smaller conditioning stimulus (Si) amplitude, and patients with epilepsy had larger test stimulus (S2) amplitude. Mean S2/S1 ratio was 0.71+/-0.33 for patients with uncontrolled epilepsy; 0.68+/-0.36 for patients with controlled epilepsy; 0.96+/-0.47 for individuals with schizophrenia, and 0.42+/-0.24 for healthy volunteers. Conclusion: The sensory filter of patients with epilepsy is altered, and this alteration is not associated with seizure control. Also, it works differently from the sensory filter of individuals with schizophrenia.
C1 [Becker, Jefferson; da Silva Filho, Irenio Gomes; da Silva Filho, Helio Fernandes; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Neurol Serv, Hosp Sao Lucas, Porto Alegre, RS, Brazil.
   [Lara, Diogo Rizzato] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Psychiat Serv, Porto Alegre, RS, Brazil.
   [da Silva Filho, Irenio Gomes; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Fac Med, Dept Internal Med, Porto Alegre, RS, Brazil.
   [Schuch, Alice; de Paula Ramos, Fernanda Lia; Ghisolfi, Eduardo Soerensen; Lara, Diogo Rizzato] Pontificia Univ Catolica Rio Grande do Sul, Dept Biochem, Fac Biociencias, Porto Alegre, RS, Brazil.
RP Becker, J (corresponding author), Rua Ely Costa 60, BR-90480110 Porto Alegre, RS, Brazil.
EM jeffersonbecker@hotmail.com
RI Becker, Jefferson/G-6417-2012; DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR Ambrosini A, 2001, NEUROSCI LETT, V306, P132, DOI 10.1016/S0304-3940(01)01871-7
   Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77
   Arciniegas DB, 2001, J NEUROPSYCH CLIN N, V13, P213, DOI 10.1176/appi.neuropsych.13.2.213
   Becker J, 2004, CLIN NEUROPHYSIOL, V115, P396, DOI 10.1016/j.clinph.2003.09.018
   Boutros NN, 2006, J NEUROPSYCH CLIN N, V18, P409, DOI 10.1176/appi.neuropsych.18.3.409
   Boutros NN, 1999, BIOL PSYCHIAT, V45, P917, DOI 10.1016/S0006-3223(98)00253-4
   Etchebehere ECSC, 2001, ARCH NEUROL-CHICAGO, V58, P1257, DOI 10.1001/archneur.58.8.1257
   Fein G, 1996, BIOL PSYCHIAT, V39, P955, DOI 10.1016/0006-3223(95)00299-5
   FEIN G, 1994, ELECTROEN CLIN NEURO, V92, P536, DOI 10.1016/0168-5597(94)90138-4
   Freedman R, 1996, ARCH GEN PSYCHIAT, V53, P1114
   Ghisolfi ES, 2004, CLIN NEUROPHYSIOL, V115, P2231, DOI 10.1016/j.clinph.2004.04.025
   Ghisolfi ES, 2004, INT J PSYCHOPHYSIOL, V51, P209, DOI 10.1016/j.ijpsycho.2003.09.002
   Ghisolfi ES, 2002, NEUROPSYCHOPHARMACOL, V27, P629
   Grunwald T, 2003, BIOL PSYCHIAT, V53, P511, DOI 10.1016/S0006-3223(02)01673-6
   Hetrick WP, 1996, BIOL PSYCHIAT, V39, P51, DOI 10.1016/0006-3223(95)00067-4
   Jin Y, 1997, PSYCHIAT RES, V70, P71, DOI 10.1016/S0165-1781(97)03091-6
   Jin Y, 1998, BIOL PSYCHIAT, V43, P873, DOI 10.1016/S0006-3223(98)00115-2
   Kurthen M, 2007, PSYCHIAT RES-NEUROIM, V155, P121, DOI 10.1016/j.pscychresns.2006.10.003
   NAGAMOTO HT, 1991, SCHIZOPHR RES, V4, P31, DOI 10.1016/0920-9964(91)90007-E
   Patrick G, 1999, BIOL PSYCHIAT, V45, P1307, DOI 10.1016/S0006-3223(98)00155-3
   Patterson JV, 2000, ARCH GEN PSYCHIAT, V57, P57, DOI 10.1001/archpsyc.57.1.57
   Pirker S, 2003, J NEUROPATH EXP NEUR, V62, P820, DOI 10.1093/jnen/62.8.820
   Rosburg T, 2008, CLIN NEUROPHYSIOL, V119, P1310, DOI 10.1016/j.clinph.2008.02.007
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   SIEGEL C, 1984, ARCH GEN PSYCHIAT, V41, P607
   Tregellas JR, 2009, AM J PSYCHIAT, V166, P354, DOI 10.1176/appi.ajp.2008.08030411
   Uc EY, 2003, J NEUROL SCI, V212, P1, DOI 10.1016/S0022-510X(03)00082-0
   WEATE SJ, 1995, CLIN ELECTROENCEPHAL, V26, P214, DOI 10.1177/155005949502600407
   Weiland BJ, 2008, NEUROIMAGE, V42, P827, DOI 10.1016/j.neuroimage.2008.05.042
   Zimmerman RS, 2003, MAYO CLIN PROC, V78, P109, DOI 10.4065/78.1.109
NR 30
TC 4
Z9 4
U1 0
U2 4
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 2011
VL 69
IS 3
BP 460
EP 465
DI 10.1590/S0004-282X2011000400010
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 783WR
UT WOS:000292115600010
PM 21755122
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Pereira, AG
   Portuguez, MW
   da Costa, DI
   Azambuja, LS
   Marroni, SP
   da Costa, JC
   Pereira, AA
AF Pereira, Adriana Gutterres
   Portuguez, Mirna Wetters
   da Costa, Danielle Irigoyen
   Azambuja, Luciana Schermann
   Marroni, Sabine Possa
   da Costa, Jaderson Costa
   Pereira-Filho, Arthur Azambuja
TI Route Learning Performance: Is it a Hippocampus Function?
SO COGNITIVE AND BEHAVIORAL NEUROLOGY
LA English
DT Article
DE memory; epilepsy; selective amygdalo-hippocampectomy
ID HUMAN NAVIGATION; SEX-DIFFERENCES; MEMORY; ACTIVATION; LONDON
AB Introduction: In temporal lobe epilepsy (TLE), about 30% of the patients do not achieve adequate pharmacologic control of refractory crises, and surgery becomes an alternative. In ablative interventions, neuropsychologic testing of memory is a crucial step. However, evaluations of the right hippocampal functions have not been consistent.
   Aim: To assess the hippocampal function in remote orientation and visuospatial memory in patients with refractory temporal epilepsy.
   Methods: A controlled study of patients with left (LTLE) or right (RTLE) TLE. The subjects were submitted to a neuropsychologic evaluation through the Route Learning Test and the Childhood Home Test in the preoperative period. The statistical analysis was performed using the Kruskal-Wallis, analysis of variance, chi(2), and Mann-Whitney U tests.
   Results: There was no significant difference in performance in the remote visuospatial memory (as measured by the Childhood Home Test) across the groups (LTLE, RTLE, and control). Concerning the spatial orientation memory, however, there was a significant difference between the LTLE and controls as compared with the RTLE group (P < 0.001), the latter showing a poorer performance.
   Conclusions: The study suggests that spatial orientation memory relies on the integrity of the right hippocampus. Nevertheless, further studies are necessary to confirm this hypothesis.
C1 [Pereira, Adriana Gutterres; Portuguez, Mirna Wetters; da Costa, Danielle Irigoyen; Azambuja, Luciana Schermann; Marroni, Sabine Possa; da Costa, Jaderson Costa; Pereira-Filho, Arthur Azambuja] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Programa Pos Grad, Fac Med, Porto Alegre, RS, Brazil.
   [Pereira, Adriana Gutterres; Portuguez, Mirna Wetters; da Costa, Danielle Irigoyen; Azambuja, Luciana Schermann; Marroni, Sabine Possa; da Costa, Jaderson Costa] Pontificia Univ Rio Grande do Sul PUCRS, Hosp Sao Lucas, Porto Alegre, RS, Brazil.
   [da Costa, Danielle Irigoyen] Fac Serra Gaucha FSG, Caxias Do Sul, Brazil.
   [Azambuja, Luciana Schermann] Univ Luterana Brasil ULBRA, Canoas, Brazil.
   [da Costa, Jaderson Costa] Inst Cerebro INSCER, Porto Alegre, RS, Brazil.
   [Pereira-Filho, Arthur Azambuja] Hosp Moinhos Vento, Dept Neurol & Neurosurg, Porto Alegre, RS, Brazil.
   Pontificia Univ Rio Grande do Sul PUCRS, Hosp Sao Lucas HSL, Serv Neurol, BR-90610000 Porto Alegre, RS, Brazil.
RP Pereira, AG (corresponding author), Rua Anita Garibaldi 2120-619, Porto Alegre, RS, Brazil.
EM adrianapereira@pop.com.br
RI Portuguez, Mirna/A-9362-2018; DaCosta, Jaderson/C-4968-2015
OI Portuguez, Mirna/0000-0003-4068-6249; DaCosta,
   Jaderson/0000-0001-6776-1515
CR Andreano JM, 2009, LEARN MEMORY, V16, P248, DOI 10.1101/lm.918309
   Badgaiyan RD, 2002, NEUROIMAGE, V17, P393, DOI 10.1006/nimg.2002.1219
   Barr W, 2004, EPILEPSY BEHAV, V5, P175, DOI 10.1016/j.yebeh.2003.12.010
   BARRASH J, 1993, J CLIN EXP NEUROPSYC, V15, P66
   Barrash J, 2000, NEUROPSYCHOLOGIA, V38, P820, DOI 10.1016/S0028-3932(99)00131-1
   BARRASH J, 1996, J INT NEUROPSYCH SOC, V2, P69
   BEAR MF, 2001, LINGUAGEM ATENCAO NE
   Bohbot VD, 1998, NEUROPSYCHOLOGIA, V36, P1217, DOI 10.1016/S0028-3932(97)00161-9
   Cherrier MM, 2001, NEUROPSY NEUROPSY BE, V14, P159
   Chiaravalloti ND, 2004, BRAIN COGNITION, V54, P35, DOI 10.1016/S0278-2626(03)00257-4
   DALACORTE A, 2002, THESIS PONTIFICIA U
   DERENZI E, 1977, J NEUROL NEUROSUR PS, V40, P498, DOI 10.1136/jnnp.40.5.498
   Giovagnoli AR, 1999, EPILEPSIA, V40, P904, DOI 10.1111/j.1528-1157.1999.tb00797.x
   Gron G, 2000, NAT NEUROSCI, V3, P404
   Harness A, 2008, PSYCHOL REP, V103, P214, DOI 10.2466/PR0.103.1.214-218
   Herlitz A, 1997, MEM COGNITION, V25, P801, DOI 10.3758/BF03211324
   Hollup SA, 2001, J NEUROSCI, V21, P1635
   Iaria G, 2007, EUR J NEUROSCI, V25, P890, DOI 10.1111/j.1460-9568.2007.05371.x
   KANDEL ER, 2000, COGNICAO E O CORTEX
   KANDEL ER, 2003, MEMORIA MENTE MOL
   Lee Andy C. H., 2000, Critical Reviews in Neurobiology, V14, P165
   Lewin C, 2001, NEUROPSYCHOLOGY, V15, P165, DOI 10.1037//0894-4105.15.2.165
   Lopes-Cendes Iscia, 2000, EPILEPSIA
   Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921
   Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255
   Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597
   Maguire EA, 1997, J NEUROSCI, V17, P7103
   Maguire EA, 2006, BRAIN, V129, P2894, DOI 10.1093/brain/awl286
   McCarthy RA, 1996, J NEUROL NEUROSUR PS, V60, P318, DOI 10.1136/jnnp.60.3.318
   Moscovitch M, 2006, CURR OPIN NEUROBIOL, V16, P179, DOI 10.1016/j.conb.2006.03.013
   Moser EI, 2001, CURR OPIN NEUROBIOL, V11, P745, DOI 10.1016/S0959-4388(01)00279-3
   OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1
   OKEEFE J, 2003, BRAIN, V124, P2476
   OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4
   Oliveira M. S., 1999, FIGURAS COMPLEXAS RE
   PORTUGUEZ MW, 1998, FUNDAMENTOS NEUROBIO, V2, P939
   Pouzet B, 2002, BEHAV BRAIN RES, V133, P279, DOI 10.1016/S0166-4328(02)00007-4
   Ranganath C, 2003, NEUROPSYCHOLOGIA, V41, P378, DOI 10.1016/S0028-3932(02)00169-0
   Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286
   Rosenbaum RS, 2005, J COGNITIVE NEUROSCI, V17, P446, DOI 10.1162/0898929053279496
   Teng E, 1999, NATURE, V400, P675
   WECHSLER D, 1999, WECHSLER MEMORY SCAL, P3
   WECHSLER D, 2002, TESTE INTELIGENCIA A
   Yue XM, 2007, NEUROREPORT, V18, P525, DOI 10.1097/WNR.0b013e328091c1f9
NR 44
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1543-3633
EI 1543-3641
J9 COGN BEHAV NEUROL
JI Cogn. Behav. Neurol.
PD MAR
PY 2011
VL 24
IS 1
BP 4
EP 10
DI 10.1097/WNN.0b013e318218c3d6
PG 7
WC Behavioral Sciences; Clinical Neurology
SC Behavioral Sciences; Neurosciences & Neurology
GA 749IJ
UT WOS:000289458200002
PM 21487258
DA 2020-12-08
ER

PT J
AU Cesar-Tognoli, LMM
   Salamoni, SD
   Tavares, AA
   Elias, CF
   Da Costa, JC
   Bittencourt, JC
   Palma, MS
AF Cesar-Tognoli, Lilian M. M.
   Salamoni, Simone D.
   Tavares, Andrea A.
   Elias, Carol F.
   Da Costa, Jaderson C.
   Bittencourt, Jackson C.
   Palma, Mario S.
TI Effects of Spider Venom Toxin PWTX-I (6-Hydroxytrypargine) on the
   Central Nervous System of Rats
SO TOXINS
LA English
DT Article
DE 6-hydroxytrypargine; fos protein; immunohistochemistry; hypothalamus;
   hippocampus; epilepsy; NMDA; neurotoxicity
ID TETRAHYDRO-BETA-CARBOLINE; OXIDASE INHIBITORY-ACTIVITIES; C-FOS; HARMAN
   1-METHYL-BETA-CARBOLINE; CHEMICAL-CHARACTERIZATION; EPILEPTIFORM
   ACTIVITY; ALKALOID-TOXIN; NEURONS; BINDING; BENZODIAZEPINE
AB The 6-hydroxytrypargine (6-HT) is an alkaloidal toxin of the group of tetrahydro-beta-carbolines (TH beta C) isolated from the venom of the colonial spider Parawixia bistriata. These alkaloids are reversible inhibitors of the monoamine-oxidase enzyme (MAO), with hallucinogenic, tremorigenic and anxiolytic properties. The toxin 6-HT was the first TH beta C chemically reported in the venom of spiders; however, it was not functionally well characterized up to now. The action of 6-HT was investigated by intracerebroventricular (i.c.v.) and intravenous (i.v.) applications of the toxin in adult male Wistar rats, followed by the monitoring of the expression of fos-protein, combined with the use of double labeling immunehistochemistry protocols for the detection of some nervous receptors and enzymes related to the metabolism of neurotransmitters in the central nervous system (CNS). We also investigated the epileptiform activity in presence of this toxin. The assays were carried out in normal hippocampal neurons and also in a model of chronic epilepsy obtained by the use of neurons incubated in free-magnesium artificial cerebro-spinal fluid (ACSF). Trypargine, a well known TH beta C toxin, was used as standard compound for comparative purposes. Fos-immunoreactive cells (fos-ir) were observed in hypothalamic and thalamic areas, while the double-labeling identified nervous receptors of the sub-types rGlu2/3 and NMR1, and orexinergic neurons. The 6-HT was administrated by perfusion and ejection in "brain slices" of hippocampus, inducing epileptic activity after its administration; the toxin was not able to block the epileptogenic crisis observed in the chronic model of the epilepsy, suggesting that 6-HT did not block the overactive GluRs responsible for this epileptic activity.
C1 [Cesar-Tognoli, Lilian M. M.; Palma, Mario S.] Sao Paulo State Univ UNESP, Inst Biosci, CEIS, Dept Biol,Lab Struct Biol & Zoochem, BR-13506900 Rio Claro, SP, Brazil.
   [Salamoni, Simone D.; Tavares, Andrea A.; Da Costa, Jaderson C.] Pontif Catholic Univ Rio Grande Sul PUCRS, Inst Biomed Res, Neurosci Lab, BR-90619900 Porto Alegre, RS, Brazil.
   [Elias, Carol F.; Bittencourt, Jackson C.] Univ Sao Paulo, Inst Biomed Sci, Lab Chem Neuroanat, Dept Anat, BR-05508900 Sao Paulo, Brazil.
   [Salamoni, Simone D.; Tavares, Andrea A.; Da Costa, Jaderson C.] Pontif Catholic Univ Rio Grande Sul PUCRS, Brain Inst InsCer, BR-90619900 Porto Alegre, RS, Brazil.
RP Palma, MS (corresponding author), Sao Paulo State Univ UNESP, Inst Biosci, CEIS, Dept Biol,Lab Struct Biol & Zoochem, BR-13506900 Rio Claro, SP, Brazil.
EM lmmctognoli@gmail.com; salamoni@pucrs.br; almalencar@ig.com.br;
   carol.elias@utsouthwestern.edu; jcc@pucrs.br; jcbitten@icb.usp.br;
   mspalma@rc.unesp.br
RI Bittencourt, Jackson/I-9187-2014; Palma, Mario/N-3903-2019; Salamoni,
   Simone/C-4126-2015; DaCosta, Jaderson/C-4968-2015; Palma, Mario
   Sergio/E-7800-2012
OI Bittencourt, Jackson/0000-0002-8908-6474; DaCosta,
   Jaderson/0000-0001-6776-1515; Palma, Mario Sergio/0000-0002-7363-8211;
   Elias, Carol F/0000-0001-9878-9203; Salamoni, Simone
   Denise/0000-0003-4329-710X
FU Sao Paulo State Research Foundation (FAPESP, BIOprospecTA program)
   [04/07942-2, 06/57122-7]
FX This work was supported by a grant from the Sao Paulo State Research
   Foundation (FAPESP, BIOprospecTA program 04/07942-2; 06/57122-7);
   L.M.M.C.T. was a Ph.D. student fellows from the CAPES. M.S.P., J.C.B.,
   C.F.E. and J.C.C. are researching for CNPq. We also wish to thank to
   Fernanda Noal Carlesso, Michele Franzen Pedroso, Raquel Mattos de
   Oliveira and Ricardo Vaz Breda for helping in the laboratory
   electrophysiological techniques and Jose Amaro Martins and Fernanda de
   Borba Cunha for helping in the carefulness with the animals.
CR Adell A, 1996, NEUROPHARMACOLOGY, V35, P1101, DOI 10.1016/S0028-3908(96)00043-3
   AIRAKSINEN MM, 1987, PHARMACOL TOXICOL, V60, P5, DOI 10.1111/j.1600-0773.1987.tb01711.x
   AIRAKSINEN MM, 1980, MED BIOL, V58, P341
   AKIZAWA T, 1982, BIOMED RES-TOKYO, V3, P232
   Ali SF, 1999, MOL BRAIN RES, V74, P237, DOI 10.1016/S0169-328X(99)00283-1
   Babb TL, 1996, EPILEPSY RES, V26, P193, DOI 10.1016/S0920-1211(96)00053-8
   BACK G, 1977, PHARMACOLOGY, V15, P127, DOI 10.1159/000136672
   BARKER SA, 1981, BIOCHEM PHARMACOL, V30, P9, DOI 10.1016/0006-2952(81)90278-1
   BASHIR ZI, 1997, NEUROSCIENCE LABFAX, P13
   BERNARD C, 1995, EPILEPSY RES, V21, P95, DOI 10.1016/0920-1211(95)00017-5
   Carmona C, 2000, J PHOTOCH PHOTOBIO A, V135, P171, DOI 10.1016/S1010-6030(00)00294-X
   Cesar LMM, 2005, TOXICON, V46, P786, DOI 10.1016/j.toxicon.2005.08.005
   Cesar LMM, 2005, HELV CHIM ACTA, V88, P796, DOI 10.1002/hlca.200590056
   Escoubas P, 2000, BIOCHIMIE, V82, P893, DOI 10.1016/S0300-9084(00)01166-4
   GERFEN CR, 1984, BRAIN RES, V290, P219, DOI 10.1016/0006-8993(84)90940-5
   Glennon RA, 2000, DRUG ALCOHOL DEPEN, V60, P121, DOI 10.1016/S0376-8716(99)00148-9
   Hagiwara K., 1991, AGELENA OPULENTA PEP, V1, P351
   Harikai N, 2003, BRAIN RES BULL, V61, P617, DOI 10.1016/j.brainresbull.2003.07.001
   Herraiz T, 2006, J CHROMATOGR A, V1120, P237, DOI 10.1016/j.chroma.2005.12.009
   Hoover NG, 2004, PEDIATRICS, V114, pE128, DOI 10.1542/peds.114.1.e128
   Husbands SM, 2001, DRUG ALCOHOL DEPEN, V64, P203, DOI 10.1016/S0376-8716(01)00123-5
   Jensen MS, 1996, J PHYSIOL-LONDON, V492, P199, DOI 10.1113/jphysiol.1996.sp021301
   King GF, 2008, CHANNELS, V2, P100, DOI 10.4161/chan.2.2.6022
   King GF, 2007, TOXICON, V49, P513, DOI 10.1016/j.toxicon.2006.11.012
   Kobelt P, 2004, BRAIN RES PROTOC, V13, P45, DOI 10.1016/j.brainresprot.2004.01.003
   KOHR G, 1994, NEUROSCIENCE, V62, P975, DOI 10.1016/0306-4522(94)90336-0
   KRAUSE W, 1990, ARZNEIMITTEL-FORSCH, V40-1, P522
   LEINO M, 1984, ACTA PHARMACOL TOX, V54, P361
   Lino-De-Oliveira C, 2001, BRAIN RES BULL, V55, P747, DOI 10.1016/S0361-9230(01)00566-4
   LUTES J, 1988, NEUROPHARMACOLOGY, V27, P849, DOI 10.1016/0028-3908(88)90102-5
   Marques MR, 2005, CHEM BIODIVERS, V2, P525, DOI 10.1002/cbdv.200590034
   Martin L, 2003, J PHARMACEUT BIOMED, V32, P991, DOI 10.1016/S0731-7085(03)00201-2
   MCCORMICK KD, 1993, J CHEM ECOL, V19, P2411, DOI 10.1007/BF00979674
   MCILWAIN H, 1953, BIOCHEM J, V53, P412, DOI 10.1042/bj0530412
   MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225
   MULLER WE, 1981, PHARMACOL BIOCHEM BE, V14, P693, DOI 10.1016/0091-3057(81)90133-7
   MYERS RD, 1981, J PHYSIOLOGY PARIS, V77, P505
   NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206
   *NAT AC SCI, 1996, GUID CAR US LAB AN
   NISTICO G, 1987, EUR J PHARMACOL, V142, P121, DOI 10.1016/0014-2999(87)90660-1
   Pahkla R, 1996, PHARMACOL RES, V34, P73, DOI 10.1006/phrs.1996.0066
   Palma MS, 2005, TOXIN REV, V24, P209, DOI 10.1081/TXR-200057857
   Peyron C, 1998, J NEUROSCI, V18, P9996
   Prince D A, 1986, Adv Neurol, V44, P275
   QUISTAD GB, 1993, TOXICON, V31, P920, DOI 10.1016/0041-0101(93)90229-C
   ROBERTSON HA, 1980, EUR J PHARMACOL, V67, P129, DOI 10.1016/0014-2999(80)90020-5
   ROMMELSPACHER H, 1985, EUR J PHARMACOL, V109, P363, DOI 10.1016/0014-2999(85)90397-8
   ROMMELSPACHER H, 1994, EUR J PHARMACOL, V252, P51, DOI 10.1016/0014-2999(94)90574-6
   SAANO V, 1982, ACTA PHARMACOL TOX, V51, P300
   Saidemberg DM, 2009, TOXICON, V54, P717, DOI 10.1016/j.toxicon.2009.05.027
   Salamoni SD, 2005, BRAIN RES, V1048, P170, DOI 10.1016/j.brainres.2005.04.060
   SEYAMA I, 1985, JPN J PHYSIOL, V35, P367, DOI 10.2170/jjphysiol.35.367
   SHIMIZU M, 1982, CHEM PHARM BULL, V30, P909
   SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1
   Singewald N, 2003, BIOL PSYCHIAT, V53, P275, DOI 10.1016/S0006-3223(02)01574-3
   Sita LV, 2003, BRAIN RES, V970, P232, DOI 10.1016/S0006-8993(03)02345-X
   Solis-Maldonado C, 2003, INT IMMUNOPHARMACOL, V3, P1261, DOI 10.1016/S1567-5769(03)00080-8
   Stone T.W., 1995, NEUROPHAMACOLOGY
   Taggi AE, 2004, J AM CHEM SOC, V126, P10364, DOI 10.1021/ja047416n
   TRAUB RD, 1994, J PHYSIOL-LONDON, V478, P379, DOI 10.1113/jphysiol.1994.sp020259
   Ucar G, 2005, TOXICON, V45, P43, DOI 10.1016/j.toxicon.2004.09.009
   Windle WF, 1943, STAIN TECHNOL, V18, P77, DOI 10.3109/10520294309105794
   Yamada M, 2004, NEUROTOXICOLOGY, V25, P215, DOI 10.1016/S0161-813X(03)00097-4
   Yildiz A, 2006, EMERG MED J, V23, DOI 10.1136/emj.2005.030007
NR 64
TC 5
Z9 7
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6651
J9 TOXINS
JI Toxins
PD FEB
PY 2011
VL 3
IS 2
BP 142
EP 162
DI 10.3390/toxins3020142
PG 21
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA 994ZJ
UT WOS:000307974700003
PM 22069702
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Almeida, ACG
   Scorza, FA
   Rodrigues, AM
   Arida, RM
   Carlesso, FN
   Batista, AG
   Duarte, MA
   DaCosta, JC
AF Almeida, Antonio-Carlos G.
   Scorza, Fulvio A.
   Rodrigues, Antonio M.
   Arida, Ricardo M.
   Carlesso, Fernanda N.
   Batista, Aline G.
   Duarte, Mario A.
   DaCosta, Jaderson C.
TI Combined effect of bumetanide, bromide, and GABAergic agonists: An
   alternative treatment for intractable seizures
SO EPILEPSY & BEHAVIOR
LA English
DT Letter
ID EPILEPSY; EPILEPTOGENESIS; TRANSPORTERS; MECHANISMS; PATTERNS; CHANNEL;
   GABA
C1 [Almeida, Antonio-Carlos G.; Rodrigues, Antonio M.; Duarte, Mario A.] Univ Fed Sao Joao del Rei, Lab Neurociencia Expt & Computac, Programa Inst Bioengn, Sao Joao Del Rei, Brazil.
   [Scorza, Fulvio A.; Batista, Aline G.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Expt Neurol, Sao Paulo, Brazil.
   [Arida, Ricardo M.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Fisiol, Sao Paulo, Brazil.
   [Carlesso, Fernanda N.; DaCosta, Jaderson C.] Pontificia Univ Catolica Rio Grande do Su, Inst Cerebro, Porto Alegre, RS, Brazil.
RP Almeida, ACG (corresponding author), Univ Fed Sao Joao del Rei, Lab Neurociencia Expt & Computac, Programa Inst Bioengn, Pr Dom Helvecio 74, BR-36301170 Sao Joao del Rei, MG, Brazil.
EM acga@ufsj.edu.br
RI ALMEIDA, ANTONIO-CARLOS G/B-8028-2008; Rodrigues, Eduardo
   Buchele/C-6852-2015; Rodrigues, Antonio M/D-3953-2012; Arida, Ricardo
   M/E-2667-2013; Arida, Ricardo Mario/P-7408-2016; Neurociencia,
   Inct/I-1011-2013; Scorza, Fulvio/C-7048-2013; DaCosta,
   Jaderson/C-4968-2015
OI ALMEIDA, ANTONIO-CARLOS G/0000-0003-4893-338X; Rodrigues, Antonio
   M/0000-0002-2678-9180; Arida, Ricardo M/0000-0002-0908-3274; Arida,
   Ricardo Mario/0000-0002-7771-6133; Scorza, Fulvio/0000-0002-0694-8674;
   DaCosta, Jaderson/0000-0001-6776-1515
CR AHMAD S, 1976, BRIT J CLIN PHARMACO, V3, P621, DOI 10.1111/j.1365-2125.1976.tb04885.x
   Aronica E, 2007, NEUROSCIENCE, V145, P185, DOI 10.1016/j.neuroscience.2006.11.041
   Avoli M, 2005, PROG NEUROBIOL, V77, P166, DOI 10.1016/j.pneurobio.2005.09.006
   Ben-Ari Y, 2002, NAT REV NEUROSCI, V3, P728, DOI 10.1038/nrn920
   Cepeda C, 2006, EPILEPSY BEHAV, V9, P219, DOI 10.1016/j.yebeh.2006.05.012
   de Almeida ACG, 2008, EPILEPSIA, V49, P1908, DOI 10.1111/j.1528-1167.2008.01686.x
   de Boer HM, 2008, EPILEPSY BEHAV, V12, P540, DOI 10.1016/j.yebeh.2007.12.019
   Duncan JS, 2006, LANCET, V367, P1087, DOI 10.1016/S0140-6736(06)68477-8
   ERNST JP, 1988, BRAIN DEV-JPN, V10, P385, DOI 10.1016/S0387-7604(88)80098-6
   FRANCIOLINI F, 1987, J GEN PHYSIOL, V90, P453, DOI 10.1085/jgp.90.4.453
   GAGNON K, 2007, CELL PHYSIOL BIOCHEM, P121
   GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0
   Halatchev V N, 2000, Folia Med (Plovdiv), V42, P17
   Hochman DW, 2000, J NEUROPHYSIOL, V83, P406
   Hoffmann EK, 1995, INT REV CYTOL, V161, P173
   JOYNT RJ, 1974, AM J DIS CHILD, V128, P362, DOI 10.1001/archpedi.1974.02110280092012
   Kahle Kristopher T, 2008, Epilepsy Curr, V8, P51, DOI 10.1111/j.1535-7511.2008.00235.x
   KAILA K, 1994, PROG NEUROBIOL, V42, P489, DOI 10.1016/0301-0082(94)90049-3
   Korinthenberg R, 2007, J CHILD NEUROL, V22, P414, DOI 10.1177/0883073807302758
   Kwan P, 2004, J NEUROL NEUROSUR PS, V75, P1376, DOI 10.1136/jnnp.2004.045690
   Maa E, 2007, EPILEPSIA, V48, P330
   Meierkord H, 2000, N-S ARCH PHARMACOL, V361, P25, DOI 10.1007/s002109900162
   Owens DF, 2002, NEURON, V36, P989, DOI 10.1016/S0896-6273(02)01136-4
   Pathak HR, 2007, J NEUROSCI, V27, P14012, DOI 10.1523/JNEUROSCI.4390-07.2007
   Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7
   Sander JW, 2003, CURR OPIN NEUROL, V16, P165, DOI 10.1097/00019052-200304000-00008
   SANDER JWAS, 1993, EPILEPSIA, V34, P1007, DOI 10.1111/j.1528-1157.1993.tb02126.x
   Santos DOC, 2009, PHYS BIOL, V6, DOI 10.1088/1478-3975/6/4/046019
   Schwartzkroin PA, 1998, EPILEPSY RES, V32, pVII
   Staley Kevin J, 2006, Epilepsy Curr, V6, P124, DOI 10.1111/j.1535-7511.2006.00119.x
   Steinhoff B J, 1992, J Hist Neurosci, V1, P119
   SUZUKI S, 1994, EPILEPSY RES, V19, P89, DOI 10.1016/0920-1211(94)90019-1
   Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x
   WOODY RC, 1990, J CHILD NEUROL, V5, P65, DOI 10.1177/088307389000500116
NR 34
TC 2
Z9 2
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD JAN
PY 2011
VL 20
IS 1
BP 148
EP 150
DI 10.1016/j.yebeh.2010.10.030
PG 3
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA 721DG
UT WOS:000287331300031
PM 21167788
OA Green Published
DA 2020-12-08
ER

PT J
AU de Almeida, AG
   Nunes, ML
   Palmini, ALF
   da Costa, JC
AF de Almeida, Andrea Garcia
   Nunes, Magda Lahorgue
   Fernandes Palmini, Andre Luis
   da Costa, Jaderson Costa
TI Incidence of SUDEP in a cohort of patients with refractory epilepsy The
   role of surgery and lesion localization
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE SUDEP; refractory epilepsy; epilepsy surgery; extratemporal epilepsy
ID SUDDEN UNEXPECTED DEATH; HEART-RATE-VARIABILITY; RISK-FACTORS;
   UNEXPLAINED DEATH; MORTALITY; SEIZURES
AB Objective: The aim of this study was to verify incidence and characteristics of sudden unexpected death in patients (SUDEP) with refractory epilepsy and its relation to previous surgery and lesion localization. Method: A cross sectional study was carried out in a cohort of 550 patients with refractory epilepsy followed up by the Epilepsy Surgery Program of the University Hospital of PUCRS, Porto Alegre, Brazil, between January, 1992 and July, 2002. Patients were allocated in two groups (operated and non operated). Seizure type, distribution of interictal spikes and MRI findings were correlated with the SUDEP outcome. Results: The estimated incidence of probable SUDEP amounted to 29: 1000 individuals. Probable SUDEP occurred in 1.2% of the 166 patients of the non operated group and in 3.7% of the 384 patients who were operated (OR=3.02, 95% CI 0.69-13.16) (p=0.11). Comparing patients who died to patients alive in the operated group a significant difference was observed concerning the following variables: SUDEP patients had a predominance of generalized seizures (p=0.002), extratemporal lesion on MRI (p<0.001) and epileptiform activity over extratemporal regions (p=0.001). Conclusion: In surgically treated patients with refractory epilepsy, an extratemporal location of the lesion and of the epileptiform discharges significantly correlated to SUDEP. Thus it is possible that in those patients; the underlying disease may play a role in the pathogenesis of SUDEP.
C1 [Nunes, Magda Lahorgue] Pontificia Univ Catolica Rio Grande do Sul, Sao Lucas Hosp, Div Neurol, Epilepsy Surg Program, BR-90610000 Porto Alegre, RS, Brazil.
   [Nunes, Magda Lahorgue; Fernandes Palmini, Andre Luis; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Sch Med, BR-90610000 Porto Alegre, RS, Brazil.
RP Nunes, ML (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Sao Lucas Hosp, Div Neurol, Epilepsy Surg Program, Av Ipiranga 6690-220, BR-90610000 Porto Alegre, RS, Brazil.
EM nunes@pucrs.br
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515; Reis,
   AlessanRSS/0000-0001-8486-7469
CR DASHEIFF RM, 1991, J CLIN NEUROPHYSIOL, V8, P216, DOI 10.1097/00004691-199104000-00010
   Drake M E, 1993, Seizure, V2, P63, DOI 10.1016/S1059-1311(05)80104-9
   EARNEST MP, 1992, EPILEPSIA, V33, P310, DOI 10.1111/j.1528-1157.1992.tb02321.x
   Elsharkawy AE, 2008, NEUROSURGERY, V63, P516, DOI 10.1227/01.NEU.0000324732.36396.E9
   Engel J, 2006, EPILEPSIA, V47, P1558, DOI 10.1111/j.1528-1167.2006.00215.x
   Engel Jerome Jr., 1993, P609
   Ferri R, 2002, J SLEEP RES, V11, P153, DOI 10.1046/j.1365-2869.2002.00283.x
   Hennessy MJ, 1999, NEUROLOGY, V53, P1276, DOI 10.1212/WNL.53.6.1276
   HIRSCH CS, 1971, NEUROLOGY, V21, P682, DOI 10.1212/WNL.21.7.682
   Johnston Ann, 2007, Expert Rev Neurother, V7, P1751, DOI 10.1586/14737175.7.12.1751
   Kloster R, 1999, J NEUROL NEUROSUR PS, V67, P439, DOI 10.1136/jnnp.67.4.439
   Langan Y, 2000, SEIZURE-EUR J EPILEP, V9, P179, DOI 10.1053/seiz.2000.0388
   LEESTMA JE, 1984, EPILEPSIA, V25, P84, DOI 10.1111/j.1528-1157.1984.tb04159.x
   LEESTMA JE, 1989, ANN NEUROL, V26, P195, DOI 10.1002/ana.410260203
   Mohanraj R, 2006, LANCET NEUROL, V5, P481, DOI 10.1016/S1474-4422(06)70448-3
   Monte CPJA, 2007, SEIZURE-EUR J EPILEP, V16, P1, DOI 10.1016/j.seizure.2006.10.002
   Nashef L, 1996, J NEUROL NEUROSUR PS, V60, P297, DOI 10.1136/jnnp.60.3.297
   Nashef L, 1998, J NEUROL NEUROSUR PS, V64, P349, DOI 10.1136/jnnp.64.3.349
   Nashef L, 1997, EPILEPSIA, V38, pS6, DOI 10.1111/j.1528-1157.1997.tb06130.x
   Nashef L, 2007, EPILEPSIA, V48, P859, DOI 10.1111/j.1528-1167.2007.01082.x
   Nilsson L, 1999, LANCET, V353, P888, DOI 10.1016/S0140-6736(98)05114-9
   Schuele SU, 2007, NEUROLOGY, V69, P434, DOI 10.1212/01.wnl.0000266595.77885.7f
   SCHWENDER LA, 1986, AM J FOREN MED PATH, V7, P283, DOI 10.1097/00000433-198612000-00003
   Sperling MR, 1999, ANN NEUROL, V46, P45, DOI 10.1002/1531-8249(199907)46:1<45::AID-ANA8>3.0.CO;2-I
   Stollberger C, 2004, EPILEPSY RES, V59, P51, DOI 10.1016/j.eplepsyres.2004.03.008
   Tavernor SJ, 1996, SEIZURE, V5, P79, DOI 10.1016/S1059-1311(96)80067-7
   Timmings P L, 1993, Seizure, V2, P287, DOI 10.1016/S1059-1311(05)80142-6
   Tomson T, 1998, EPILEPSY RES, V30, P77, DOI 10.1016/S0920-1211(97)00094-6
   Tomson T, 2005, EPILEPSIA, V46, P54, DOI 10.1111/j.1528-1167.2005.00411.x
   Tomson T, 2008, LANCET NEUROL, V7, P1021, DOI 10.1016/S1474-4422(08)70202-3
   Walczak TS, 2001, NEUROLOGY, V56, P519, DOI 10.1212/WNL.56.4.519
   Wannamaker BB, 1990, EPILEPSY SUDDEN DEAT, P27
NR 32
TC 8
Z9 8
U1 0
U2 2
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD DEC
PY 2010
VL 68
IS 6
BP 898
EP 902
DI 10.1590/S0004-282X2010000600013
PG 5
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 707WA
UT WOS:000286319900013
PM 21243249
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU de Paula, S
   Greggio, S
   DaCosta, JC
AF de Paula, Simone
   Greggio, Samuel
   DaCosta, Jaderson Costa
TI Use of stem cells in perinatal asphyxia: from bench to bedside
SO JORNAL DE PEDIATRIA
LA English
DT Review
ID HYPOXIC-ISCHEMIC ENCEPHALOPATHY; CORD BLOOD-CELLS; MARROW
   MONONUCLEAR-CELLS; FOCAL CEREBRAL-ISCHEMIA; FACTOR-SECRETING CELLS;
   BONE-MARROW; BRAIN-INJURY; STROMAL CELLS; PROGENITOR CELLS; NEUROLOGICAL
   DISORDERS
AB Objectives: To present recent scientific evidence on the effects of stem cell transplantation in animal models of neonatal hypoxic-ischemic brain injury and address the translational relevance of cell therapy for clinical application in this context.
   Sources: The PubMed and Scopus databases were used to select articles. The selection criterion was the specificity of articles regarding the subject studied, preferably articles published from 2000 onward. We also reviewed classic articles from previous years that were applicable to this review.
   Summary of the findings: Stem cells from different exogenous sources may exhibit neuroprotective properties in experimental models of neonatal hypoxia-ischemia. In most animal experiments, the morphological and functional benefits observed were independent of neural differentiation, suggesting associated mechanisms of action, such as the release of trophic factors and inflammatory modulation.
   Conclusions: Based on the experimental studies analyzed, cell therapy may become a promising therapeutic approach in the treatment of children with hypoxic-ischemic encephalopathy. However, further studies are warranted to elucidate potential mechanisms of action of these cells and to define safe and effective clinical strategies.
C1 [DaCosta, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, InsCer, Lab Neurociencias, BR-90619900 Porto Alegre, RS, Brazil.
   [DaCosta, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Fac Med, BR-90619900 Porto Alegre, RS, Brazil.
   [de Paula, Simone; Greggio, Samuel] Pontificia Univ Catolica Rio Grande do Sul, Programa Posgrad Saude Crianca, BR-90619900 Porto Alegre, RS, Brazil.
RP DaCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, InsCer, Lab Neurociencias, Ave Ipiranga 6690,Predio 60,2 Andar,Sale 07 Jardi, BR-90619900 Porto Alegre, RS, Brazil.
RI DaCosta, Jaderson/C-4968-2015; Greggio, Samuel/E-1498-2013
OI DaCosta, Jaderson/0000-0001-6776-1515; Greggio,
   Samuel/0000-0002-5187-0335; de Paula, Simone/0000-0003-3198-2695
CR Alexanian AR, 2008, STEM CELLS DEV, V17, P1123, DOI 10.1089/scd.2007.0212
   da Fonseca LMB, 2010, EXP NEUROL, V221, P122, DOI 10.1016/j.expneurol.2009.10.010
   Barnabe GF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005222
   Bliss T, 2007, STROKE, V38, P817, DOI 10.1161/01.STR.0000247888.25985.62
   Borlongan CV, 2009, STROKE, V40, pS146, DOI 10.1161/STROKEAHA.108.533091
   Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7
   Borlongan CV, 2005, BRAIN RES, V1048, P116, DOI 10.1016/j.brainres.2005.04.087
   Boucherie C, 2009, J NEUROSCI RES, V87, P1509, DOI 10.1002/jnr.21970
   Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775
   Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198
   Burns TC, 2009, J COMP NEUROL, V515, P125, DOI 10.1002/cne.22038
   Carroll JE, 2008, CNS NEUROL DISORD-DR, V7, P361, DOI 10.2174/187152708786441812
   Chen JR, 2008, J ANAT, V213, P249, DOI 10.1111/j.1469-7580.2008.00948.x
   Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D
   Correa PL, 2007, CLIN NUCL MED, V32, P839, DOI 10.1097/RLU.0b013e318156b980
   Costa-Ferro ZSM, 2010, SEIZURE-EUR J EPILEP, V19, P84, DOI 10.1016/j.seizure.2009.12.003
   Crook JM, 2008, J CELL BIOCHEM, V105, P1361, DOI 10.1002/jcb.21967
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Daadi MM, 2010, STROKE, V41, P516, DOI 10.1161/STROKEAHA.109.573691
   Dayer AG, 2007, BRAIN, V130, P2962, DOI 10.1093/brain/awm200
   de Paula S, 2009, PEDIATR RES, V65, P631, DOI 10.1203/PDR.0b013e31819ed5c8
   DEPAULA D, 2010, THESIS PONTIFICIA U
   Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dunnett Stephen B, 2004, NeuroRx, V1, P394, DOI 10.1602/neurorx.1.4.394
   Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080
   Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100
   Elsayed MH, 1996, EXP NEUROL, V137, P127, DOI 10.1006/exnr.1996.0013
   Fernandes KJL, 2006, EXP NEUROL, V201, P32, DOI 10.1016/j.expneurol.2006.03.018
   Guzman R, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E14
   Haas S, 2005, CURR OPIN NEUROL, V18, P59, DOI 10.1097/00019052-200502000-00012
   Harris DT, 2008, STEM CELL REV, V4, P269, DOI 10.1007/s12015-008-9039-8
   Hess DC, 2008, CELL PROLIFERAT, V41, P94, DOI 10.1111/j.1365-2184.2008.00486.x
   Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102
   Janowski M, 2010, STEM CELLS DEV, V19, P5, DOI 10.1089/scd.2009.0271
   Jansen EM, 1997, EXP NEUROL, V147, P487, DOI 10.1006/exnr.1997.6596
   Jenny B, 2009, STEM CELLS, V27, P1309, DOI 10.1002/stem.46
   Katsuragi S, 2005, AM J OBSTET GYNECOL, V192, P1028, DOI 10.1016/j.ajog.2005.01.014
   Katsuragi S, 2005, AM J OBSTET GYNECOL, V192, P1137, DOI 10.1016/j.ajog.2004.10.619
   Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900
   Koda M, 2005, NEUROREPORT, V16, P1763, DOI 10.1097/01.wnr.0000183329.05994.d7
   Kornblum HI, 2007, STROKE, V38, P810, DOI 10.1161/01.STR.0000255757.12198.0f
   Lean MEJ, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a863
   Lee JA, 2010, PEDIATR RES, V67, P42, DOI 10.1203/PDR.0b013e3181bf594b
   Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525
   Li L, 2010, J CEREBR BLOOD F MET, V30, P653, DOI 10.1038/jcbfm.2009.238
   Liu ZW, 2010, J CEREBR BLOOD F MET, V30, P1288, DOI 10.1038/jcbfm.2010.8
   Ma J, 2007, NEUROCHEM INT, V51, P57, DOI 10.1016/j.neuint.2007.04.012
   Meier C, 2006, PEDIATR RES, V59, P244, DOI 10.1203/01.pdr.0000197309.08852.f5
   Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779
   Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100
   Muller FJ, 2006, NAT REV NEUROSCI, V7, P75, DOI 10.1038/nrn1829
   Ong J, 2005, PEDIATR RES, V58, P600, DOI 10.1203/01.PDR.0000179381.86809.02
   Orive G, 2009, NAT REV NEUROSCI, V10, P682, DOI 10.1038/nrn2685
   Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751
   Park KI, 2006, EXP NEUROL, V199, P156, DOI 10.1016/j.expneurol.2006.04.002
   Park KI, 2006, EXP NEUROL, V199, P179, DOI 10.1016/j.expneurol.2006.03.016
   Perlman JM, 2006, PEDIATRICS, V117, pS28, DOI 10.1542/peds.2005-0620E
   Phinney DG, 2005, CURR PHARM DESIGN, V11, P1255, DOI 10.2174/1381612053507495
   Pimentel-Coelho PM, 2010, STEM CELLS DEV, V19, P351, DOI 10.1089/scd.2009.0049
   Plane JM, 2004, NEUROBIOL DIS, V16, P585, DOI 10.1016/j.nbd.2004.04.003
   Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889
   Procianoy R S, 2001, J Pediatr (Rio J), V77 Suppl 1, pS63
   Rice CM, 2004, LANCET, V364, P193, DOI 10.1016/S0140-6736(04)16633-6
   Sahni R, 2008, CLIN PERINATOL, V35, P717, DOI 10.1016/j.clp.2008.07.016
   Sanberg PR, 2005, ANN NY ACAD SCI, V1049, P67, DOI 10.1196/annals.1334.008
   Santner-Nanan B, 2005, AUST NZ J OBSTET GYN, V45, P102, DOI 10.1111/j.1479-828X.2005.00362.x
   Sato Y, 2008, REPROD SCI, V15, P613, DOI 10.1177/1933719108317299
   Schwartz M, 2003, J CEREBR BLOOD F MET, V23, P385, DOI 10.1097/01.WCB.0000061881.75234.5E
   Senior K, 2001, LANCET, V358, P817, DOI 10.1016/S0140-6736(05)71790-6
   Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092
   Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311
   SOUZA FM, 2003, THESIS FUNDACAO O CR
   van Velthoven CTJ, 2010, BRAIN BEHAV IMMUN, V24, P387, DOI 10.1016/j.bbi.2009.10.017
   Vannucci RC, 2000, AM J PERINAT, V17, P113, DOI 10.1055/s-2000-9293
   Vannucci SJ, 2004, J EXP BIOL, V207, P3149, DOI 10.1242/jeb.01064
   Vendrame M, 2005, STEM CELLS DEV, V14, P595, DOI 10.1089/scd.2005.14.595
   Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047
   Wechsler L, 2009, STROKE, V40, P510, DOI 10.1161/STROKEAHA.108.526863
   Wislet-Gendebien S, 2005, BRAIN RES BULL, V68, P95, DOI 10.1016/j.brainresbull.2005.08.016
   Xia GZ, 2010, J PERINAT MED, V38, P215, DOI [10.1515/JPM.2010.021, 10.1515/jpm.2010.021]
   YASUHARA T, 2009, J CELL MOL MED  0204
   Yasuhara T, 2008, J CEREBR BLOOD F MET, V28, P1804, DOI 10.1038/jcbfm.2008.68
   Yasuhara T, 2006, CELL TRANSPLANT, V15, P231, DOI 10.3727/000000006783982034
   Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456
   Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460
   Zheng T, 2006, BRAIN RES, V1112, P99, DOI 10.1016/j.brainres.2006.07.014
NR 87
TC 10
Z9 13
U1 0
U2 6
PU SOC BRASIL PEDIATRIA
PI RIO DE JANEIRO, RJ
PA RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401-01, BRAZIL
SN 0021-7557
EI 1678-4782
J9 J PEDIAT-BRAZIL
JI J. Pediatr.
PD NOV-DEC
PY 2010
VL 86
IS 6
BP 451
EP 464
DI 10.2223/JPED.2035
PG 14
WC Pediatrics
SC Pediatrics
GA 710CH
UT WOS:000286488000003
PM 21140037
OA Bronze
DA 2020-12-08
ER

PT J
AU Alles, YCJ
   Greggio, S
   Alles, RM
   Azevedo, PN
   Xavier, LL
   DaCosta, JC
AF Juarez Alles, Yanet Chong
   Greggio, Samuel
   Alles, Raul Miguel
   Azevedo, Pamella Nunes
   Xavier, Leder Leal
   DaCosta, Jarderson Costa
TI A novel preclinical rodent model of collagenase-induced germinal
   matrix/intraventricular hemorrhage
SO BRAIN RESEARCH
LA English
DT Article
DE Animal model; Germinal matrix hemorrhage-intraventricular hemorrhage;
   Neurobehavioral testing; Brain injury; Rat; Collagenase
ID INTRACEREBRAL HEMORRHAGE; INTRAVENTRICULAR HEMORRHAGE; CRANIAL
   ULTRASOUND; PRETERM INFANTS; ANIMAL-MODELS; RAT; BLOOD; BIRTH; MATRIX;
   AGE
AB Germinal matrix/intraventricular hemorrhage (GMH/IVH) is a complication that arises in premature infants associated with neurological sequelae. Greater understanding of GMH/IVH is needed to develop therapies, a goal that depends on the existence of appropriate animal models. Towards this goal, we aimed to develop a rodent model of GMH/IVH based on collagenase-induced hemorrhage that exhibits histological and neurological consequences similar to that seen in patients. Male 6-day-old rats were placed on a warming pad and anesthetized with halothane/nitrous oxide delivered by face mask. Uni- or bilateral periventricular injections of 2-mu l collagenase (2.0 U) were performed freehand with a needle inserted percutaneously. Sham rats were infused with saline. Early neonatal development, long-term motor and cognitive performances and alterations in brain volume were assessed. Collagenase-based GMH/IVH negatively affected ambulation, surface righting and negative geotaxis outcomes more evidently in bilaterally infused rats, which also presented an early decrease in brain volume, as assessed by the Cavalieri method. In adult animals, a unilateral collagenase infusion produced no significant alteration on forepaw preference. Only bilaterally infused rats presented an impairment of object recognition memory and locomotor deficit. Nevertheless, histological evaluation also demonstrated a persistent brain volume reduction in bilaterally infused rats. Our study provides a pioneering animal model of collagenase-based GMH/IVH, which can be used to evaluate preventive strategies and potential therapeutic interventions for this disorder. (C) 2010 Elsevier B.V. All rights reserved.
C1 [DaCosta, Jarderson Costa] Pontificia Univ Catolica Rio Grande Sul PUCRS, Lab Neurociencias, Inst Cerebro, BR-90619900 Porto Alegre, RS, Brazil.
   [Juarez Alles, Yanet Chong; Greggio, Samuel; Alles, Raul Miguel; Azevedo, Pamella Nunes; DaCosta, Jarderson Costa] Pontificia Univ Catolica Rio Grande Sul PUCRS, Lab Neurociencias, Inst Pesquisas Biomed, BR-90619900 Porto Alegre, RS, Brazil.
   [Xavier, Leder Leal] Pontificia Univ Catolica Rio Grande do Sul, Fac Biociencias, Dept Ciencias Morfofisol, Lab Biol Celular & Tecidual, Porto Alegre, RS, Brazil.
RP DaCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande Sul PUCRS, Lab Neurociencias, Inst Cerebro, Ave Ipiranga 6690,Jardim Bot,Predio 60,2 Andar,Sa, BR-90619900 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI DaCosta, Jaderson/C-4968-2015; Greggio, Samuel/E-1498-2013; Xavier,
   Leder/G-4540-2014
OI DaCosta, Jaderson/0000-0001-6776-1515; Greggio,
   Samuel/0000-0002-5187-0335; Xavier, Leder/0000-0002-7213-4935
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Pandurata Ltda.; Pontificia Universidade Catolica do Rio
   Grande do Sul (PUCRS); CAPESCAPES
FX This work was supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Pandurata Ltda. and Pontificia
   Universidade Catolica do Rio Grande do Sul (PUCRS). Y. C. J. Alles was a
   recipient of a Master's scholarship from CAPES.
CR ALLEN MC, 1989, PEDIATRICS, V83, P498
   ALTMAN J, 1975, ANIM BEHAV, V23, P896, DOI 10.1016/0003-3472(75)90114-1
   Andaluz N, 2002, NEUROSURG CLIN N AM, V13, P385, DOI 10.1016/S1042-3680(02)00006-2
   Balasubramaniam J, 2006, EXP NEUROL, V197, P122, DOI 10.1016/j.expneurol.2005.09.010
   Balasubramaniam J, 2006, J CHILD NEUROL, V21, P365, DOI 10.1177/08830738060210050201
   Ballabh P, 2010, PEDIATR RES, V67, P1, DOI 10.1203/PDR.0b013e3181c1b176
   Bassan H, 2007, PEDIATRICS, V120, P785, DOI 10.1542/peds.2007-0211
   Berger R, 1997, EUR J OBSTET GYN R B, V75, P191, DOI 10.1016/S0301-2115(97)00135-8
   Cherian SS, 2003, J NEUROPATH EXP NEUR, V62, P292, DOI 10.1093/jnen/62.3.292
   Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296
   de Paula S, 2009, PEDIATR RES, V65, P631, DOI 10.1203/PDR.0b013e31819ed5c8
   DelBigio MR, 1996, STROKE, V27, P2312, DOI 10.1161/01.STR.27.12.2312
   DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7
   ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X
   GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x
   Haut SR, 2004, LANCET NEUROL, V3, P608, DOI 10.1016/S1474-4422(04)00881-6
   James ML, 2008, NEUROCRIT CARE, V9, P139, DOI 10.1007/s12028-007-9030-2
   Juliet PAR, 2009, J NEUROCHEM, V109, P1285, DOI 10.1111/j.1471-4159.2009.06060.x
   KELLEY AE, 1993, TECHNIQUES BEHAV NEU, V10, P499
   Luu TM, 2009, PEDIATRICS, V123, P1037, DOI 10.1542/peds.2008-1162
   MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548
   Maitre NL, 2009, PEDIATRICS, V124, pE1153, DOI 10.1542/peds.2009-0953
   Matsushita K, 2000, J CEREBR BLOOD F MET, V20, P396, DOI 10.1097/00004647-200002000-00022
   PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0
   PHILIP AGS, 1989, PEDIATRICS, V84, P797
   PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249
   Quester R, 1997, J NEUROSCI METH, V75, P81, DOI 10.1016/S0165-0270(97)00050-2
   ROMIJN HJ, 1991, EARLY HUM DEV, V26, P61, DOI 10.1016/0378-3782(91)90044-4
   ROSENBERG GA, 1993, NEUROSCI LETT, V160, P117, DOI 10.1016/0304-3940(93)90927-D
   ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801
   Roze E, 2009, PEDIATRICS, V123, P1493, DOI 10.1542/peds.2008-1919
   Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8
   Vasileiadis GT, 2004, PEDIATRICS, V114, pE367, DOI 10.1542/peds.2004-0500
   Volpe J. J., 2000, NEUROLOGY NEWBORN, P428
   Xue Mengzhou, 2003, J Stroke Cerebrovasc Dis, V12, P152, DOI 10.1016/S1052-3057(03)00036-3
   Xue MZ, 2003, J NEUROPATH EXP NEUR, V62, P1154, DOI 10.1093/jnen/62.11.1154
NR 36
TC 24
Z9 24
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD OCT 14
PY 2010
VL 1356
BP 130
EP 138
DI 10.1016/j.brainres.2010.07.106
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 670AW
UT WOS:000283393200013
PM 20692236
DA 2020-12-08
ER

PT J
AU Nunes, ML
   da Costa, JC
AF Nunes, Magda Lahorgue
   da Costa, Jaderson Costa
TI Sleep and epilepsy in neonates
SO SLEEP MEDICINE
LA English
DT Review
DE Sleep; Neonates; Preterm newborn; Neonatal seizures; Neonatal EEG;
   Epilepsy
ID ELECTROGRAPHIC SEIZURES; PREMATURE-INFANTS; NORMAL EEG; BURST
   SUPPRESSION; SHARP TRANSIENTS; PROGNOSTIC VALUE; DEVELOPING BRAIN; ICTAL
   ACTIVITY; RISK-FACTORS; PRETERM
AB Background and objective: In clinical practice, the association between sleep and epilepsy has been increasingly observed in adults and during childhood. The aim of this article is to verify the relationship between sleep and epilepsy in the neonatal period in order to identify evidence and mechanisms to explain how epilepsy or neonatal seizures might disrupt sleep and how sleep might influence seizure occurrence and epilepsy during this age span.
   Methods: Literature review with search of PubMed database using the key words neonatal seizures and sleep.
   Results and conclusion: The complex processes of cortical maturation are closely related to the regulation of sleep-wakefulness cycles. Sleep regulation in the context of neonatal seizures is frequently abnormal, and these alterations may be a result of the maladaptative plasticity of neuronal networks. Furthermore, in this situation altered connectivity might also be associated with other expressions of neurological dysfunction such as cognitive and behavioral problems. EEG background abnormalities and higher frequency of discharges are often associated with disrupted sleep organization. The outcome of newborns with seizures where sleep organization is undifferentiated seems to be more unfavorable. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Nunes, Magda Lahorgue; da Costa, Jaderson Costa] Hosp Sao Lucas PUCRS, Clin Neurophysiol Lab, Div Neurol, Sch Med, BR-90610000 Porto Alegre, RS, Brazil.
RP Nunes, ML (corresponding author), Hosp Sao Lucas PUCRS, Clin Neurophysiol Lab, Div Neurol, Sch Med, Av Ipiranga 6690 220, BR-90610000 Porto Alegre, RS, Brazil.
EM nunes@pucrs.br
RI Neurociencia, Inct/I-1011-2013; DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR AICARDI J, 1978, REV EEG NEUROPHYSIOL, V8, P99, DOI 10.1016/S0370-4475(78)80124-5
   Aicardi J, 2005, EPILEPTIC SYNDROMES, P39
   Biagioni E, 2007, CLIN NEUROPHYSIOL, V118, P53, DOI 10.1016/j.clinph.2006.09.018
   Biagioni E, 1998, Eur J Paediatr Neurol, V2, P117, DOI 10.1016/S1090-3798(98)80027-5
   Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403
   CAVAZUTTI GB, 1978, CLIN PEDIATR, V60, P239
   CLANCY RR, 1991, EPILEPSIA, V32, P69, DOI 10.1111/j.1528-1157.1991.tb05614.x
   Curzi-Dascalova L., 2000, LUNG BIOL HEALTH DIS, P3
   Curzi-Dascalova L., 1996, MANUAL METHODS RECOR
   CURZIDASCALOVA L, 1988, DEV PSYCHOBIOL, V21, P431, DOI 10.1002/dev.420210503
   CURZIDASCALOVA L, 1993, PEDIATR RES, V34, P624, DOI 10.1203/00006450-199311000-00013
   Da Silva LFG, 2004, PEDIATR NEUROL, V30, P271, DOI 10.1016/j.pediatrneurol.2003.09.015
   DACOSTA JC, 1991, JLBE, V4, P17
   Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528-1157.2001.10401.x
   FENICHEL GM, 1980, ANN NEUROL, V7, P577, DOI 10.1002/ana.410070612
   da Silva LFG, 2006, PEDIATR NEUROL, V34, P360, DOI 10.1016/j.pediatrneurol.2005.10.011
   Garcia-Rill E, 2008, SLEEP, V31, P673, DOI 10.1093/sleep/31.5.673
   GUILLEMINAULT C, 1987, SLEEP ITS DISORDERS, P195
   Hedberg TG, 2003, INT J DEV NEUROSCI, V21, P95, DOI 10.1016/S0736-5748(02)00125-9
   HIRSCH E, 1993, ANN NEUROL, V34, P835, DOI 10.1002/ana.410340613
   HOLMES GL, 1986, J CLIN NEUROPHYSIOL, V3, P209, DOI 10.1097/00004691-198607000-00002
   Jensen FE, 1999, EPILEPSIA, V40, pS51, DOI 10.1111/j.1528-1157.1999.tb00879.x
   JOUVET M, 1986, CONFRONTATIONS PSYCH, V27, P153
   Khan RL, 2008, J CHILD NEUROL, V23, P144, DOI 10.1177/0883073807308711
   Laroia N, 1998, EPILEPSIA, V39, P545, DOI 10.1111/j.1528-1157.1998.tb01418.x
   LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0
   Lombroso CT, 1996, BRAIN DEV-JPN, V18, P1, DOI 10.1016/S0387-7604(96)90001-7
   Lombroso CT, 1987, ELECTROENCEPHALOGRAP, P725
   McBride MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506
   MCMILLEN IC, 1991, PEDIATR RES, V29, P381, DOI 10.1203/00006450-199104000-00010
   MIRMIRAN M, 1990, EARLY HUM DEV, V23, P139, DOI 10.1016/0378-3782(90)90137-8
   MIZRAHI EM, 1987, NEUROLOGY, V37, P1837, DOI 10.1212/WNL.37.12.1837
   Mizrahi EM, 1999, EPILEPSIA, V40, pS42, DOI 10.1111/j.1528-1157.1999.tb00878.x
   Mizrahi EM, 1998, DIAGNOSIS MANAGEMENT
   Monod N, 1973, Rev Electroencephalogr Neurophysiol Clin, V3, P87, DOI 10.1016/S0370-4475(73)80028-0
   Nunes ML, 2006, CURR PEDIATR REV, V2, P315, DOI 10.2174/157339606778699662
   Nunes ML, 2008, ARQ NEURO-PSIQUIAT, V66, P168, DOI 10.1590/S0004-282X2008000200005
   Nunes ML, 2005, ARQ NEURO-PSIQUIAT, V63, P14, DOI 10.1590/S0004-282X2005000100003
   Nunes ML, 2003, ARQ NEURO-PSIQUIAT, V61, P574, DOI 10.1590/S0004-282X2003000400009
   Nunes ML, 1997, ELECTROEN CLIN NEURO, V102, P186, DOI 10.1016/S0013-4694(96)95191-7
   Nunes ML, 2000, CLIN NEUROPHYSIOL, V111, P305, DOI 10.1016/S1388-2457(99)00234-5
   NUNES ML, 2003, MANUAL EEG POLISSONO
   Ohtahara S, 1978, ASIAN MED J, V21, P499
   Oliveira AJ, 2000, CLIN NEUROPHYSIOL, V111, pS74, DOI 10.1016/S1388-2457(00)00405-3
   Oliveira AJ, 2000, CLIN NEUROPHYSIOL, V111, P1646, DOI 10.1016/S1388-2457(00)00380-1
   PAINTER MJ, 1986, PEDIATR CLIN N AM, V33, P91
   PARMELEE AH, 1964, J PEDIATR-US, V65, P576, DOI 10.1016/S0022-3476(64)80291-2
   Patrizi S, 2003, BRAIN DEV-JPN, V25, P427, DOI 10.1016/S0387-7604(03)00031-7
   PLOUIN P, 2005, EPILEPTIC SYNDROMES, P3
   PRECHTL HFR, 1988, FETAL NEONATAL NEURO, P35
   PURPURA DP, 1972, SLEEP MATURING NERVO, P3
   RETT A., 1964, WIENER KLIN WOCHEWSCH, V76, P609
   ROFFWARG HP, 1966, SCIENCE, V152, P604, DOI 10.1126/science.152.3722.604
   ROSE AL, 1970, PEDIATRICS, V45, P404
   ROSEN CL, 2000, LUNG BIOL HEALTH DIS, V147, P181
   Scher MS, 2008, SLEEP MED, V9, P615, DOI 10.1016/j.sleep.2007.08.014
   Scher MS, 2006, EPILEPSY RES, V70, pS41, DOI 10.1016/j.eplepsyres.2005.11.020
   SCHER MS, 1993, PEDIATRICS, V91, P128
   SCHER MS, 2001, EPILEPSY SLEEP PHYSL, P101
   SCHER MS, 2000, LUNG BIOL HEALTH DIS, V147, P39
   Schmutzler KMRS, 2005, CLIN NEUROPHYSIOL, V116, P1520, DOI 10.1016/j.clinph.2005.02.024
   Selton D, 2000, CLIN NEUROPHYSIOL, V111, P2116, DOI 10.1016/S1388-2457(00)00440-5
   SINGH B, 1993, EPILEPSIA, V34, P901, DOI 10.1111/j.1528-1157.1993.tb02109.x
   SPITZER AR, 1986, PEDIATR CLIN N AM, V33, P561
   SPREAFICO R, 1993, EPILEPSIA, V34, P800, DOI 10.1111/j.1528-1157.1993.tb02093.x
   Staudt M, 2004, ANN NEUROL, V56, P854, DOI 10.1002/ana.20297
   TORRES F, 1985, J CLIN NEUROPHYSIOL, V2, P89, DOI 10.1097/00004691-198504000-00001
   Vecchierini MF, 2007, NEUROPHYSIOL CLIN, V37, P311, DOI 10.1016/j.neucli.2007.10.008
   Veliskova J, 1996, EUR J PHARMACOL, V309, P167
   VOLPE J, 1973, NEW ENGL J MED, V289, P413, DOI 10.1056/NEJM197308232890807
   WATANABE K, 1982, PEDIATRICS, V70, P87
   WATANABE K, 1982, AM J DIS CHILD, V136, P980, DOI 10.1001/archpedi.1982.03970470024006
   WILLIS J, 1980, DEV MED CHILD NEUROL, V22, P214
NR 73
TC 6
Z9 7
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1389-9457
EI 1878-5506
J9 SLEEP MED
JI Sleep Med.
PD AUG
PY 2010
VL 11
IS 7
SI SI
BP 665
EP 673
DI 10.1016/j.sleep.2009.10.009
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 638RV
UT WOS:000280914500011
PM 20620106
DA 2020-12-08
ER

PT J
AU Carrion, MJ
   Costa, DI
   Schilling, LP
   Torres, CM
   Marinovic, D
   Garicochea, B
   Raupp, EF
   Machado, DC
   Portuguez, MW
   da Costa, JC
AF Carrion, M. J.
   Costa, D. I.
   Schilling, L. P.
   Torres, C. M.
   Marinovic, D.
   Garicochea, B.
   Raupp, E. F.
   Machado, D. C.
   Portuguez, M. W.
   da Costa, J. C.
TI Bone marrow mononuclear stem cells transplant as treatment of refractory
   temporal lobe epilepsy
SO JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
CT 20th Meeting of the European-Neurological-Society
CY JUN 19-23, 2010
CL Berlin, GERMANY
SP European Neurol Soc
C1 [Carrion, M. J.; Costa, D. I.; Schilling, L. P.; Torres, C. M.; Marinovic, D.; Garicochea, B.; Raupp, E. F.; Machado, D. C.; Portuguez, M. W.; da Costa, J. C.] Pontifical Catholic Univ Rio Grande, Porto Alegre, RS, Brazil.
RI Portuguez, Mirna/A-9362-2018; Machado, Denise C/G-2852-2014
OI Portuguez, Mirna/0000-0003-4068-6249; Machado, Denise
   C/0000-0002-9371-5886
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
J9 J NEUROL
JI J. Neurol.
PD JUN
PY 2010
VL 257
SU 1
MA P544
BP S178
EP S179
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 600AH
UT WOS:000277955200521
DA 2020-12-08
ER

PT J
AU Scalco, RS
   Marrone, LC
   Posenato, N
   Fighera, MR
   Palmini, AL
   Almeida, AG
   da Costa, JC
AF Scalco, R. S.
   Marrone, L. C.
   Posenato, N.
   Fighera, M. R.
   Palmini, A. L.
   Almeida, A. G.
   da Costa, J. C.
TI Kluver-Bucy syndrome following cardiac arrest: a case report
SO JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
CT 20th Meeting of the European-Neurological-Society
CY JUN 19-23, 2010
CL Berlin, GERMANY
SP European Neurol Soc
C1 [Scalco, R. S.; Marrone, L. C.; Posenato, N.; Fighera, M. R.; Palmini, A. L.; Almeida, A. G.; da Costa, J. C.] Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre, RS, Brazil.
RI Scalco, Renata/B-5648-2013; Fighera, Michele R/J-9576-2014
OI Scalco, Renata/0000-0002-5400-562X; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
J9 J NEUROL
JI J. Neurol.
PD JUN
PY 2010
VL 257
SU 1
MA P183
BP S58
EP S59
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 600AH
UT WOS:000277955200160
DA 2020-12-08
ER

PT J
AU Costa-Ferro, ZSM
   Vitola, AS
   Pedroso, MF
   Cunha, FB
   Xavier, LL
   Machado, DC
   Soares, MBP
   Ribeiro-dos-Santos, R
   daCosta, JC
AF Costa-Ferro, Zaquer S. M.
   Vitola, Affonso S.
   Pedroso, Michele F.
   Cunha, Fernanda B.
   Xavier, Leder L.
   Machado, Denise C.
   Soares, Milena B. P.
   Ribeiro-dos-Santos, Ricardo
   daCosta, Jaderson C.
TI Prevention of seizures and reorganization of hippocampal functions by
   transplantation of bone marrow cells in the acute phase of experimental
   epilepsy
SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
LA English
DT Article
DE Bone marrow cells; Epilepsy; Temporal lobe; Experimental status
   epilepticus; Neuronal loss
ID TEMPORAL-LOBE EPILEPSY; SPONTANEOUS RECURRENT SEIZURES; LONG-LASTING
   POTENTIATION; LITHIUM-PILOCARPINE; STEM-CELLS; SYNAPTIC-TRANSMISSION;
   MICROGLIAL RESPONSE; TERM POTENTIATION; PROGENITOR CELLS; STROMAL CELLS
AB In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by pilocarpine in rats. BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction Of Status epilepticus (SE). Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale. All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC Source. Over the long-term chronic phase ( 120 days after transplantation), only 25% of BMC-treated epileptic animals had seizures, but with a lower frequency and do ration compared to the epileptic control group. The density of hippocampal neurons in the brains of animals treated with BMCs was markedly preserved. At hippocampal Schaeffer collateral-CA1 synapses, long-term potentiation was preserved in BMC-transplanted rats compared to epileptic Controls. The donor-derived GFP(+) cells were rarely found in the brains of transplanted epileptic rats. In conclusion, treatment with BMCs can prevent the development of chronic seizures, reduce neuronal loss, and influence the reorganization of the hippocampal neuronal network. (C) 2010 Published by Elsevier Ltd on behalf of British Epilepsy Association.
C1 [Costa-Ferro, Zaquer S. M.; Vitola, Affonso S.; Pedroso, Michele F.; Cunha, Fernanda B.; Machado, Denise C.; daCosta, Jaderson C.] Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro, BR-90610000 Porto Alegre, RS, Brazil.
   [Costa-Ferro, Zaquer S. M.; Vitola, Affonso S.; Pedroso, Michele F.; Cunha, Fernanda B.; daCosta, Jaderson C.] Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Lab Neurociencias, BR-90610000 Porto Alegre, RS, Brazil.
   [Costa-Ferro, Zaquer S. M.; daCosta, Jaderson C.] Univ Fed Rio Grande do Sul, Dept Fisiol, Inst Ciencias Basicas Saude, Porto Alegre, RS, Brazil.
   [Costa-Ferro, Zaquer S. M.; Soares, Milena B. P.; Ribeiro-dos-Santos, Ricardo] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Lab Engn Tecidual & Imunofarmacol, Salvador, BA, Brazil.
   [Machado, Denise C.] Pontificia Univ Catolica Rio Grande do Sul, Ctr Terapia Celular, Inst Pesquisas Biomed, BR-90610000 Porto Alegre, RS, Brazil.
   [Xavier, Leder L.] Pontificia Univ Catolica Rio Grande do Sul, Fac Biociencias, Dept Ciencias Fisiol, BR-90610000 Porto Alegre, RS, Brazil.
   [Soares, Milena B. P.; Ribeiro-dos-Santos, Ricardo] Hosp Sao Rafael, Ctr Biotecnol & Terapia Celular, Salvador, BA, Brazil.
RP daCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro, Av Ipiranga 6690, BR-90610000 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Costa-Ferro, Zaquer Suzana Munhoz/C-5875-2015; DaCosta,
   Jaderson/C-4968-2015; Xavier, Leder/G-4540-2014; Machado, Denise
   C/G-2852-2014
OI Costa-Ferro, Zaquer Suzana Munhoz/0000-0002-9120-8856; DaCosta,
   Jaderson/0000-0001-6776-1515; Xavier, Leder/0000-0002-7213-4935;
   Machado, Denise C/0000-0002-9371-5886; Soares,
   Milena/0000-0001-7549-2992
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao da Universidade Federal do Parana (FUNPAR):
   Financiadora de Estudos e Projetos (FINEP)Ciencia Tecnologia e Inovacao
   (FINEP); Pandurata Ltda: Instituto de Pesquisas Biomedicas (IPB/PUCRS);
   Programa de Pos-Graduacao em Ciencias Biologicas: Fisiologia da
   Universidade Federal do Rio Grande do Sul (UFRGS)
FX The authors thank Elisalva T. Guimaraes for flow cytometric analysis.
   This work was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Fundacao da Universidade Federal do
   Parana (FUNPAR): Financiadora de Estudos e Projetos (FINEP), Pandurata
   Ltda: Instituto de Pesquisas Biomedicas (IPB/PUCRS), and Programa de
   Pos-Graduacao em Ciencias Biologicas: Fisiologia da Universidade Federal
   do Rio Grande do Sul (UFRGS).
CR Akiyama Y, 2002, GLIA, V39, P229, DOI 10.1002/glia.10102
   Alvares LD, 2006, BRAIN RES, V1075, P60, DOI 10.1016/j.brainres.2005.11.101
   Amaral David G., 1995, P443
   ANDERSEN P, 1980, J PHYSIOL-LONDON, V302, P463
   ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L
   Baker AH, 2007, P NATL ACAD SCI USA, V104, P3597, DOI 10.1073/pnas.0611112104
   BEREZOVSKAYA O, 1995, INT J DEV NEUROSCI, V13, P285, DOI 10.1016/0736-5748(95)00013-7
   BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273
   Bonilla S, 2005, NEUROSCIENCE, V133, P85, DOI 10.1016/j.neuroscience.2005.02.019
   Bonilla S, 2002, EUR J NEUROSCI, V15, P575, DOI 10.1046/j.1460-9568.2002.01895.x
   Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198
   Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691
   Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6
   Chu K, 2004, BRAIN RES, V1023, P213, DOI 10.1016/j.brainres.2004.07.045
   CLIFFORD DB, 1987, NEUROSCIENCE, V23, P953, DOI 10.1016/0306-4522(87)90171-0
   CLUSMANN H, 1994, NEUROSCIENCE, V61, P805, DOI 10.1016/0306-4522(94)90403-0
   Crain BJ, 2005, J NEUROL SCI, V233, P121, DOI 10.1016/j.jns.2005.03.017
   Dalbem A, 2005, BRAIN RES, V1047, P148, DOI 10.1016/j.brainres.2005.04.030
   DENG YB, 2009, NEUROL IN PRESS  MAY, DOI DOI 10.1179/174313209X414434
   DEVASCONCELOS DA, 2009, BRAIN RES, V1306, P149
   Engel J, 2002, PROG BRAIN RES, V135, P509
   Engel J, 2001, NEUROSCIENTIST, V7, P340, DOI 10.1177/107385840100700410
   Engel Jerome Jr, 2004, Suppl Clin Neurophysiol, V57, P392
   Giraidi-Guimaraes A, 2009, BRAIN RES, V1266, P108, DOI 10.1016/j.brainres.2009.01.062
   GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x
   Hu DZ, 2004, CHINESE MED J-PEKING, V117, P1576
   Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084
   Izquierdo I, 2008, AN ACAD BRAS CIENC, V80, P115, DOI 10.1590/S0001-37652008000100007
   Kamiya N, 2008, LIFE SCI, V83, P433, DOI 10.1016/j.lfs.2008.07.018
   Krampera M, 2006, BONE, V39, P678, DOI 10.1016/j.bone.2006.04.020
   Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2
   LEITE JP, 1995, EPILEPSY RES, V20, P93, DOI 10.1016/0920-1211(94)00070-D
   Leite JP, 2002, EPILEPSY RES, V50, P93, DOI 10.1016/S0920-1211(02)00072-4
   Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048
   Liu N, 2009, CELL MOL IMMUNOL, V6, P207, DOI 10.1038/cmi.2009.28
   MCNAMARA JO, 1994, J NEUROSCI, V14, P3413
   Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779
   Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100
   Mezey E, 2007, REGEN MED, V2, P37, DOI 10.2217/17460751.2.1.37
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Paglioli E, 2006, J NEUROSURG, V104, P70, DOI 10.3171/jns.2006.104.1.70
   Paglioli E, 2004, EPILEPSIA, V45, P1383, DOI 10.1111/j.0013-9580.2004.22204.x
   Parent JM, 1997, CURR OPIN NEUROL, V10, P103, DOI 10.1097/00019052-199704000-00006
   Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757
   Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix
   Priel MR, 1996, EPILEPSY RES, V26, P115, DOI 10.1016/S0920-1211(96)00047-2
   RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P269, DOI 10.1016/0013-4694(72)90176-9
   Roch C, 2002, EPILEPSIA, V43, P1129, DOI 10.1046/j.1528-1157.2002.17802.x
   Roch C, 2002, EPILEPSIA, V43, P325, DOI 10.1046/j.1528-1157.2002.11301.x
   Rodrigues AL, 2004, BRAIN RES, V1002, P94, DOI 10.1016/j.brainres.2003.12.020
   Sasaki M, 2001, GLIA, V35, P26, DOI 10.1002/glia.1067
   Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182
   Shetty AK, 2007, STEM CELLS, V25, P2396, DOI 10.1634/stemcells.2007-0313
   Shyu WC, 2006, FRONT BIOSCI-LANDMRK, V11, P899, DOI 10.2741/1846
   Soares MBP, 2004, AM J PATHOL, V164, P441, DOI 10.1016/S0002-9440(10)63134-3
   STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x
   Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3
   Zhou WB, 1998, BRAIN RES, V788, P202, DOI 10.1016/S0006-8993(97)01539-4
NR 58
TC 34
Z9 35
U1 0
U2 11
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 1059-1311
EI 1532-2688
J9 SEIZURE-EUR J EPILEP
JI Seizure
PD MAR
PY 2010
VL 19
IS 2
BP 84
EP 92
DI 10.1016/j.seizure.2009.12.003
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 569GK
UT WOS:000275584400004
PM 20080419
OA Green Published
DA 2020-12-08
ER

PT J
AU Carrion, MJM
   Nunes, ML
   Martinez, JVL
   Portuguez, MW
   da Costa, JC
AF Machline Carrion, Maria Julia
   Nunes, Magda Lahorgue
   Longo Martinez, Jose Victor
   Portuguez, Mirna Wetters
   da Costa, Jaderson Costa
TI Evaluation of sleep quality in patients with refractory seizures who
   undergo epilepsy surgery
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Sleep; Epilepsy; Epilepsy surgery; Refractory epilepsy
ID TEMPORAL-LOBE EPILEPSY; EXCESSIVE DAYTIME SLEEPINESS; CHILDREN;
   DISTURBANCE; HABITS; SCALE
AB The aim of the study was to evaluate excessive daytime sleepiness and subjective sleep quality in patients who undergo epilepsy surgery for treatment of refractory partial seizures. Forty-eight patients were enrolled in this research study. All of them were evaluated 2 days before and 3 months after the surgery. Two questionnaires were used to assess daytime sleepiness (Epworth Sleepiness Scale [ESS]) and sleep quality (Pittsburgh Sleep Quality Index [PSQI]). Global PSQI was high (mean = 5.65 SD = 3.71) before the surgical procedure (P < 0.001). PSQI evaluation revealed higher and statistically significant Scores in three components as well as in the global score, when analyzed by predominance of daytime or nocturnal seizures. ESS and PSQI scores were also analyzed by gender, antiepileptic drug class, age, and seizure frequency, with no significant differences. We concluded that patients with partial recurrent seizures of temporal origin have poor subjective sleep quality that improves significantly after epilepsy surgery. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Machline Carrion, Maria Julia] Pontificia Univ Catolica Rio Grande do Sul, Div Neurol, Hosp Sao Lucas, BR-90610000 Porto Alegre, Brazil.
   [Nunes, Magda Lahorgue; Portuguez, Mirna Wetters; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Dept Internal Med Neurol, BR-90610000 Porto Alegre, Brazil.
   [Longo Martinez, Jose Victor; Portuguez, Mirna Wetters; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Div Neurol, Epilepsy Surg Programme, BR-90610000 Porto Alegre, Brazil.
RP Nunes, ML (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Div Neurol, Hosp Sao Lucas, Av Ipiranga 6690 220, BR-90610000 Porto Alegre, Brazil.
EM nunes@pucrs.br
RI Portuguez, Mirna/A-9362-2018; DaCosta, Jaderson/C-4968-2015;
   Neurociencia, Inct/I-1011-2013
OI Portuguez, Mirna/0000-0003-4068-6249; DaCosta,
   Jaderson/0000-0001-6776-1515; 
FU CNPq-BrazilNational Council for Scientific and Technological Development
   (CNPq)
FX M.L.N. is supported by a grant from CNPq-Brazil.
CR ALMEIDA CA, 2003, ARQ NEURO-PSIQUIAT, V61, P979
   Batista BHB, 2007, EPILEPSY BEHAV, V11, P60, DOI 10.1016/j.yebeh.2007.03.016
   Bazil Carl W., 2000, Current Opinion in Neurology, V13, P171, DOI 10.1097/00019052-200004000-00010
   Bazil CW, 2003, EPILEPSY BEHAV, V4, pS39, DOI 10.1016/j.yebeh.2003.07.005
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Ceolim M F, 2000, Sleep Res Online, V3, P87
   Crespel A, 2000, CLIN NEUROPHYSIOL, V111, pS54, DOI 10.1016/S1388-2457(00)00402-8
   Crespel A, 1998, EPILEPSIA, V39, P150, DOI 10.1111/j.1528-1157.1998.tb01352.x
   de Weerd A, 2004, EPILEPSIA, V45, P1397, DOI 10.1111/j.0013-9580.2004.46703.x
   ENGEL J, 1993, SURG TREATMENT EPILE, P102
   Foldvary N, 2001, EPILEPSIA, V42, P1569, DOI 10.1046/j.1528-1157.2001.46100.x
   Fong SYY, 2005, J PSYCHOSOM RES, V58, P55, DOI 10.1016/j.jpsychores.2004.05.004
   Gigli GL, 1997, EPILEPSIA, V38, P696, DOI 10.1111/j.1528-1157.1997.tb01239.x
   JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
   Legros B, 2003, SLEEP MED, V4, P51, DOI 10.1016/S1389-9457(02)00217-4
   Nunes ML, 2003, J CHILD NEUROL, V18, P763
   Olson LG, 1998, J SLEEP RES, V7, P248, DOI 10.1046/j.1365-2869.1998.00123.x
   Paglioli E, 2004, EPILEPSIA, V45, P1383, DOI 10.1111/j.0013-9580.2004.22204.x
   Souza JC, 2005, ARQ NEURO-PSIQUIAT, V63, P925, DOI 10.1590/S0004-282X2005000600004
   Terra-Bustamante VC, 2005, SEIZURE-EUR J EPILEP, V14, P274, DOI 10.1016/j.seizure.2005.03.003
   Vignatelli L, 2006, EPILEPSIA, V47, P73, DOI 10.1111/j.1528-1167.2006.00882.x
   Xu X, 2006, EPILEPSIA, V47, P1176, DOI 10.1111/j.1528-1167.2006.00591.x
NR 22
TC 23
Z9 24
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD JAN
PY 2010
VL 17
IS 1
BP 120
EP 123
DI 10.1016/j.yebeh.2009.11.008
PG 4
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA 546UF
UT WOS:000273837700018
PM 20004148
DA 2020-12-08
ER

PT J
AU Greggio, S
   Rosa, RM
   Dolganov, A
   de Oliveira, IM
   Menegat, FD
   Henriques, JAP
   DaCosta, JC
AF Greggio, Samuel
   Rosa, Renato M.
   Dolganov, Alexandre
   de Oliveira, Iuri M.
   Menegat, Fernanda D.
   Henriques, Joao A. P.
   DaCosta, Jaderson C.
TI NAP prevents hippocampal oxidative damage in neonatal rats subjected to
   hypoxia-induced seizures
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Developing hippocampus; Oxidative stress; Hypoxia-induced seizures;
   Rodent model; NAP; Neuroprotection
ID NEAR-INFRARED SPECTROSCOPY; VASOACTIVE-INTESTINAL-PEPTIDE;
   NEUROPROTECTIVE PROTEIN ADNP; INDUCED STATUS EPILEPTICUS; DNA-DAMAGE;
   LIPID-PEROXIDATION; PERINATAL HYPOXIA; IMMATURE BRAIN; IN-VIVO;
   POSTHYPOXIC REOXYGENATION
AB Neonatal seizures in which hypoxic-ischemic encephalopathy is the main triggering etiology have a challenging diagnosis and limited efficacy of treatment. NAP (NAPVSIPQ) has shown extensive neuroprotective and antioxidant capacity in vitro and in vivo. To evaluate its neuroprotective role in the context of seizures associated with perinatal hypoxia, we assessed the integrity of DNA and lipid membranes as well as the redox status in the hippocampus of 10-day-old rats exposed to hypoxia-induced seizures (HS) with and without NAP treatment. Rats were exposed to transient global hypoxia (12 min exposure to 5-7% 02 was able to induce electrographic seizures) or room air with subsequent intraperitoneal NAP (0.03, 0.3 or 3 mu g/g) or vehicle administration. Results showed elevated DNA damage immediately after the insult until 72 h post-HS, while oxidized bases were only detected 3, 6 and 24 h later. In addition, thiobarbituric acid reactive species peaked at 6 h in parallel with decreased levels of reduced glutathione between 3 and 72 h post-HS insult. Our findings expand on the knowledge about the time course of HS-induced oxidative damage and demonstrate for the first time that a single NAP injection dose-dependently prevents HS-induced oxidative damage to DNA and lipid membranes, in correlation with modulation of the glutathione system. Hence, NAP may represent a promising therapeutic strategy for avoiding HS-induced oxidative damage. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Greggio, Samuel; Dolganov, Alexandre; DaCosta, Jaderson C.] Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro, Lab Neurociencias, Porto Alegre, RS, Brazil.
   [Greggio, Samuel; Dolganov, Alexandre; DaCosta, Jaderson C.] Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Porto Alegre, RS, Brazil.
   [Rosa, Renato M.; Henriques, Joao A. P.] Univ Luterana Brasil, Lab Genet Toxicol, Canoas, RS, Brazil.
   [Rosa, Renato M.; Henriques, Joao A. P.] Univ Luterana Brasil, Programa Posgrad Genet & Toxicol Aplicada, Canoas, RS, Brazil.
   [de Oliveira, Iuri M.; Menegat, Fernanda D.; Henriques, Joao A. P.] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Biofis, BR-90049 Porto Alegre, RS, Brazil.
RP DaCosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Inst Cerebro, Lab Neurociencias, Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI de Olveira, Iuri/AAV-2953-2020; DaCosta, Jaderson/C-4968-2015; Greggio,
   Samuel/E-1498-2013; marques de oliveira, Iuri/L-7585-2015
OI DaCosta, Jaderson/0000-0001-6776-1515; Greggio,
   Samuel/0000-0002-5187-0335; 
FU Brazilian Agencies Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do Rio Grande do Sul
   (FAPERGS)Foundation for Research Support of the State of Rio Grande do
   Sul (FAPERGS); Pontificia Universidade Catolica do Rio Grande do Sul
   (PUCRS)
FX We thank to Prof. Martin Cammarota for the critical review of the
   manuscript. This work was supported by grants from the Brazilian
   Agencies Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq), Fundacao de Amparo a Pesquisa do Rio Grande do Sul (FAPERGS),
   Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS) and
   GENOTOX-Genotoxicity Laboratory-Royal Institute. S. Greggio was a
   recipient of a Master's scholarship from CNPq.
CR Akerboom T P, 1981, Methods Enzymol, V77, P373
   Ashur-Fabian O, 2001, NEUROSCI LETT, V307, P167, DOI 10.1016/S0304-3940(01)01954-1
   Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x
   Ben-Ari Y, 2006, LANCET NEUROL, V5, P1055, DOI 10.1016/S1474-4422(06)70626-3
   Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57
   Bittigau P, 2002, P NATL ACAD SCI USA, V99, P15089, DOI 10.1073/pnas.222550499
   BRUCE AJ, 1995, FREE RADICAL BIO MED, V18, P993, DOI 10.1016/0891-5849(94)00218-9
   Buonocore G, 2000, PEDIATR RES, V47, P221, DOI 10.1203/00006450-200002000-00012
   Burlinson B, 2007, MUTAT RES-GEN TOX EN, V627, P31, DOI 10.1016/j.mrgentox.2006.08.011
   Busciglio J, 2007, CURR PHARM DESIGN, V13, P1091, DOI 10.2174/138161207780618957
   Chen WF, 2006, EPILEPSIA, V47, P288, DOI 10.1111/j.1528-1167.2006.00420.x
   Chen Y, 2003, PHYS MED BIOL, V48, P417, DOI 10.1088/0031-9155/48/4/301
   Chien Jen-Chung, 2007, J Chin Med Assoc, V70, P47
   Collins AR, 2009, MUTAT RES-REV MUTAT, V681, P24, DOI 10.1016/j.mrrev.2007.10.002
   CONNELL J, 1989, ARCH DIS CHILD-FETAL, V64, P459, DOI 10.1136/adc.64.4_Spec_No.459
   Curristin SM, 2002, P NATL ACAD SCI USA, V99, P15729, DOI 10.1073/pnas.232568799
   Dal-Pizzol F, 2000, NEUROSCI LETT, V291, P179, DOI 10.1016/S0304-3940(00)01409-9
   David JC, 2000, MOL REPROD DEV, V57, P153, DOI 10.1002/1098-2795(200010)57:2<153::AID-MRD6>3.0.CO;2-7
   Divinski I, 2006, J NEUROCHEM, V98, P973, DOI 10.1111/j.1471-4159.2006.03936.x
   Dizdaroglu M, 2005, MUTAT RES-FUND MOL M, V591, P45, DOI 10.1016/j.mrfmmm.2005.01.033
   Englander EW, 1999, J NEUROSCI RES, V58, P262, DOI 10.1002/(SICI)1097-4547(19991015)58:2<262::AID-JNR6>3.3.CO;2-N
   Fortini P, 2003, MUTAT RES-FUND MOL M, V531, P127, DOI 10.1016/j.mrfmmm.2003.07.004
   Franceschini MA, 2007, PEDIATR RES, V61, P546, DOI 10.1203/pdr.0b013e318045be99
   Freitas RM, 2005, FEBS J, V272, P1307, DOI 10.1111/j.1742-4658.2004.04537.x
   Fujikawa K, 2000, J RADIAT RES, V41, P113, DOI 10.1269/jrr.41.113
   GAZES I, 2007, PHARMACOL THERAPEUT, V114, P146
   Gozes I, 2004, J MOL NEUROSCI, V24, P67, DOI 10.1385/JMN:24:1:067
   Gozes I, 2005, CNS DRUG REV, V11, P353
   Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x
   HAUSER WA, 1994, EPILEPSIA, V35, pS1, DOI 10.1111/j.1528-1157.1994.tb05932.x
   Haut SR, 2004, LANCET NEUROL, V3, P608, DOI 10.1016/S1474-4422(04)00881-6
   Holmes GL, 2002, NEUROREPORT, V13, pA3, DOI 10.1097/00001756-200201210-00002
   Jensen FE, 1995, ITAL J NEUROL SCI, V16, P59, DOI 10.1007/BF02229075
   Koh S, 2004, EPILEPSIA, V45, P569, DOI 10.1111/j.0013-9580.2004.69103.x
   Koh S, 2001, ANN NEUROL, V50, P366, DOI 10.1002/ana.1122
   KRETZSCHMAR M, 1990, PHYSIOL BOHEMOSLOV, V39, P257
   Kumral A, 2006, BRAIN RES, V1115, P169, DOI 10.1016/j.brainres.2006.07.114
   Lafemina MJ, 2006, PEDIATR RES, V59, P680, DOI 10.1203/01.pdr.0000214891.35363.6a
   Lan J, 2000, J NEUROCHEM, V74, P302, DOI 10.1046/j.1471-4159.2000.0740302.x
   Lee HM, 2008, FREE RADICAL BIO MED, V44, P807, DOI 10.1016/j.freeradbiomed.2007.11.005
   Lee HM, 2002, J NEUROCHEM, V80, P928, DOI 10.1046/j.0022-3042.2002.00774.x
   Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7
   Liang LP, 2006, FREE RADICAL BIO MED, V40, P316, DOI 10.1016/j.freeradbiomed.2005.08.026
   Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mikati MA, 2003, EPILEPSIA, V44, P282, DOI 10.1046/j.1528-1157.2003.22502.x
   Mishra OP, 2006, BRAIN RES, V1101, P20, DOI 10.1016/j.brainres.2006.05.021
   Mishra OP, 2000, NEUROCHEM RES, V25, P1559, DOI 10.1023/A:1026610301978
   Morimoto BH, 2009, CHIM OGGI, V27, P16
   Mueller SG, 2001, NEUROLOGY, V57, P1422, DOI 10.1212/WNL.57.8.1422
   Nadin SB, 2001, J HISTOCHEM CYTOCHEM, V49, P1183, DOI 10.1177/002215540104900912
   Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6
   Parker J, 2007, NEUROSCI LETT, V412, P273, DOI 10.1016/j.neulet.2006.11.021
   Patel M, 2003, NEUROSCIENCE, V118, P431, DOI 10.1016/S0306-4522(02)00979-X
   Patel M, 2008, J NEUROCHEM, V104, P264, DOI 10.1111/j.1471-4159.2007.04974.x
   REUTER A, 1992, EXP TOXICOL PATHOL, V44, P339, DOI 10.1016/S0940-2993(11)80224-1
   Rotstein M, 2006, J PHARMACOL EXP THER, V319, P332, DOI 10.1124/jpet.106.106898
   Salgo MG, 1996, ARCH BIOCHEM BIOPHYS, V333, P482, DOI 10.1006/abbi.1996.0418
   Sanchez RM, 2001, EPILEPSIA, V42, P577, DOI 10.1046/j.1528-1157.2001.12000.x
   Sankar R, 2005, NEUROLOGY, V64, P776, DOI 10.1212/01.WNL.0000157320.78071.6D
   Santos NF, 2000, EPILEPSIA, V41, pS57, DOI 10.1111/j.1528-1157.2000.tb01558.x
   Sheth R D, 1999, J Perinatol, V19, P40, DOI 10.1038/sj.jp.7200107
   Shin EJ, 2008, NEUROCHEM INT, V52, P1134, DOI 10.1016/j.neuint.2007.12.003
   Shiryaev N, 2009, NEUROBIOL DIS, V34, P381, DOI 10.1016/j.nbd.2009.02.011
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Spong CY, 2001, J PHARMACOL EXP THER, V297, P774
   Steingart RA, 2006, MOL CELL ENDOCRINOL, V252, P148, DOI 10.1016/j.mce.2006.03.029
   Steingart RA, 2000, J MOL NEUROSCI, V15, P137, DOI 10.1385/JMN:15:3:137
   Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543
   Visochek L, 2005, J NEUROSCI, V25, P7420, DOI 10.1523/JNEUROSCI.0333-05.2005
   Volpe J., 2001, NEUROLOGY NEWBORN
   VONSIEBENTHAL K, 1992, BRAIN DEV-JPN, V14, P135
   Wallin C, 2000, DEV BRAIN RES, V125, P51, DOI 10.1016/S0165-3806(00)00112-7
   WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025
   Zemlyak I, 2009, EUR J PHARMACOL, V618, P9, DOI 10.1016/j.ejphar.2009.07.013
NR 75
TC 16
Z9 16
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
EI 1095-953X
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD DEC
PY 2009
VL 36
IS 3
BP 435
EP 444
DI 10.1016/j.nbd.2009.08.008
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 518KE
UT WOS:000271689400004
PM 19703564
DA 2020-12-08
ER

PT J
AU dos Santos, EF
   Busanello, ENB
   Miglioranza, A
   Zanatta, A
   Barchak, AG
   Vargas, CR
   Saute, J
   Rosa, C
   Carrion, MJ
   Camargo, D
   Dalbem, A
   da Costa, JC
   Miguel, SRPD
   Rieder, CRD
   Wajner, M
AF dos Santos, Eliseu Felippe
   Brandt Busanello, Estela Natacha
   Miglioranza, Anelise
   Zanatta, Angela
   Barchak, Alethea Gatto
   Vargas, Carmen Regla
   Saute, Jonas
   Rosa, Charles
   Carrion, Maria Julia
   Camargo, Daiane
   Dalbem, Andre
   da Costa, Jaderson Costa
   Pinto de Sousa Miguel, Sandro Rene
   de Mello Rieder, Carlos Roberto
   Wajner, Moacir
TI Evidence that folic acid deficiency is a major determinant of
   hyperhomocysteinemia in ParkinsonCs disease
SO METABOLIC BRAIN DISEASE
LA English
DT Article
DE Parkinson's disease; Hyperhomocysteinemia; Folic acid; Vitamin B-12;
   Smoking; Alcohol consumption; L-DOPA
ID PLASMA HOMOCYSTEINE LEVELS; MTHFR C677T GENOTYPE; LEVODOPA-TREATED
   PATIENTS; FOLATE-DEFICIENCY; RISK-FACTORS; VITAMIN-B-12; METABOLISM;
   DIETARY; SMOKING; NEURONS
AB In the present work we measured blood levels of total homocysteine ((t)Hcy), vitamin B-12 and folic acid in patients with ParkinsonCs disease (PD) and in age-matched controls and searched for possible associations between these levels with smoking, alcohol consumption, L-DOPA treatment and disease duration in PD patients. We initially observed that plasma (t)Hcy levels were increased by around 30 % in patients affected by PD compared to controls. Linear correlation, multiple regression and comparative analyses revealed that the major determinant of the increased plasma concentrations of (t)Hcy in PD patients was folic acid deficiency, whereas in controls (t)Hcy levels were mainly determined by plasma vitamin B-12 concentrations. We also observed that alcohol consumption, gender and L-DOPA treatment did not significantly alter plasma (t)Hcy, folic acid and vitamin B-12 levels in parkinsonians. Furthermore, disease duration was positively associated with (t)Hcy levels and smoking was linked with a deficit of folic acid in PD patients. Considering the potential synergistic deleterious effects of Hcy increase and folate deficiency on the central nervous system, we postulate that folic acid should be supplemented to patients affected by PD in order to normalize blood Hcy and folate levels, therefore potentially avoiding these risk factors for neurologic deterioration in this disorder.
C1 [Zanatta, Angela; Wajner, Moacir] Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Dept Bioquim, BR-90035003 Porto Alegre, RS, Brazil.
   [dos Santos, Eliseu Felippe; Wajner, Moacir] Univ Luterana Brasil, Canoas, RS, Brazil.
   [Brandt Busanello, Estela Natacha; Miglioranza, Anelise; Barchak, Alethea Gatto; Vargas, Carmen Regla; Wajner, Moacir] Hosp Clin Porto Alegre, Serv Genet Med, Porto Alegre, RS, Brazil.
   [Vargas, Carmen Regla] Univ Fed Rio Grande do Sul, PPGCF, Dept Anal, Fac Farm, Porto Alegre, RS, Brazil.
   [Saute, Jonas; Pinto de Sousa Miguel, Sandro Rene; de Mello Rieder, Carlos Roberto] Hosp Clin Porto Alegre, Serv Neurol, Porto Alegre, RS, Brazil.
   [Rosa, Charles; Carrion, Maria Julia; Camargo, Daiane; Dalbem, Andre; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Serv Neurol, Porto Alegre, RS, Brazil.
RP Wajner, M (corresponding author), Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Dept Bioquim, Rua Ramiro Barcelos 2600 Anexo, BR-90035003 Porto Alegre, RS, Brazil.
EM mwajner@ufrgs.br
RI Wajner, Moacir/K-8763-2015; Vargas, Carmen/W-9939-2019; Inagemp,
   Inct/J-9451-2013; Saute, Jonas Alex Morales/F-6635-2015; Carrion, Julia
   Machline/AAC-6988-2020; Busanello, Estela N B/D-2287-2014; DaCosta,
   Jaderson/C-4968-2015; Rieder, Carlos Roberto M/O-6600-2018
OI Wajner, Moacir/0000-0001-6372-1807; Saute, Jonas Alex
   Morales/0000-0003-1141-6573; Carrion, Julia
   Machline/0000-0003-1840-4372; DaCosta, Jaderson/0000-0001-6776-1515;
   Rieder, Carlos Roberto M/0000-0003-2950-7211; Busanello,
   Estela/0000-0002-6125-3285
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERGSFoundation for Research Support of the State of Rio
   Grande do Sul (FAPERGS); PRONEX; FINEPCiencia Tecnologia e Inovacao
   (FINEP); Rede Instituto Brasileiro de Neurociencia (IBN-Net)
   [01.06.0842-00]
FX We are grateful by the financial support of CNPq, FAPERGS, PRONEX and
   the FINEP research grant Rede Instituto Brasileiro de Neurociencia
   (IBN-Net) # 01.06.0842-00.
CR Aarsland D, 2001, NEUROLOGY, V56, P730, DOI 10.1212/WNL.56.6.730
   Barak AJ, 2001, ALCOHOL, V25, P77, DOI 10.1016/S0741-8329(01)00168-9
   Bazzano LA, 2003, ANN INTERN MED, V138, P891, DOI 10.7326/0003-4819-138-11-200306030-00010
   Beulens JWJ, 2005, ALCOHOL CLIN EXP RES, V29, P739, DOI 10.1097/01.ALC.0000163507.76773.1A
   BLADINI F, 2001, CLIN CHEM, V47, P1102
   BLASCO C, 2005, ALCOHOL CLIN EXP RES, V29, P739
   Bleich S, 2000, NEUROREPORT, V11, P2749, DOI 10.1097/00001756-200008210-00028
   Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290
   Bottiglieri T, 1996, NUTR REV, V54, P382, DOI 10.1111/j.1753-4887.1996.tb03851.x
   Castro R, 2006, J INHERIT METAB DIS, V29, P3, DOI 10.1007/s10545-006-0106-5
   Chern CL, 2001, BIOMED PHARMACOTHER, V55, P434, DOI 10.1016/S0753-3322(01)00095-6
   Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449
   De Bree A, 2002, PHARMACOL REV, V54, P599, DOI 10.1124/pr.54.4.599
   de Lau LML, 2005, ANN NEUROL, V57, P927, DOI 10.1002/ana.20509
   de Silva HA, 2000, CURR OPIN GENET DEV, V10, P292
   deRijk MC, 1997, ARCH NEUROL-CHICAGO, V54, P762, DOI 10.1001/archneur.1997.00550180070015
   Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1422, DOI 10.1001/archneur.57.10.1422
   Duan W, 2002, J NEUROCHEM, V80, P101, DOI 10.1046/j.0022-3042.2001.00676.x
   Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P
   Fowler JS, 1996, NATURE, V379, P733, DOI 10.1038/379733a0
   GRIEVE A, 1992, J NEUROSCI RES, V32, P60, DOI 10.1002/jnr.490320108
   Hancock DB, 2007, ARCH NEUROL-CHICAGO, V64, P576, DOI 10.1001/archneur.64.4.576
   Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9
   Hassin-Baer S, 2006, CLIN NEUROPHARMACOL, V29, P305, DOI 10.1097/01.WNF.0000236763.16032.60
   HERBERT V, 1962, J CLIN INVEST, V41, P1263, DOI 10.1172/JCI104589
   HULTBERG B, 1993, ALCOHOL CLIN EXP RES, V17, P687, DOI 10.1111/j.1530-0277.1993.tb00820.x
   Isobe C, 2005, LIFE SCI, V77, P1836, DOI 10.1016/j.lfs.2005.02.014
   Jacques PF, 2001, AM J CLIN NUTR, V73, P613
   JANSSON B, 1985, ANN NEUROL, V17, P505, DOI 10.1002/ana.410170514
   Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S
   Jenner P, 1998, MOVEMENT DISORD, V13, P24
   Kado DM, 2005, AM J MED, V118, P161, DOI 10.1016/j.amjmed.2004.08.019
   KIRCH DG, 1988, CELL MOL NEUROBIOL, V8, P285, DOI 10.1007/BF00711170
   Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002
   Kuhn W, 2001, NEUROLOGY, V56, P281
   Kuhn W, 1998, EUR NEUROL, V40, P225, DOI 10.1159/000007984
   Lamberti P, 2005, EUR J NEUROL, V12, P365, DOI 10.1111/j.1468-1331.2004.00973.x
   Langston JW, 1998, ANN NEUROL, V44, pS45, DOI 10.1002/ana.410440707
   Lazarewicz JW, 2003, NEUROCHEM RES, V28, P259, DOI 10.1023/A:1022329317218
   Lipton SA, 1997, P NATL ACAD SCI USA, V94, P5923, DOI 10.1073/pnas.94.11.5923
   Magera MJ, 1999, CLIN CHEM, V45, P1517
   MARSDEN CD, 1994, J NEUROL NEUROSUR PS, V57, P672, DOI 10.1136/jnnp.57.6.672
   Mooijaart SP, 2005, AM J CLIN NUTR, V82, P866
   Muller T, 2003, J NEUROL NEUROSUR PS, V74, P549, DOI 10.1136/jnnp.74.4.549
   Muller T, 1999, LANCET, V354, P126, DOI 10.1016/S0140-6736(99)01660-8
   O'Suilleabhain PE, 2004, ARCH NEUROL-CHICAGO, V61, P865, DOI 10.1001/archneur.61.6.865
   Obeid R, 2006, FEBS LETT, V580, P2994, DOI 10.1016/j.febslet.2006.04.088
   Quik M, 2004, TRENDS NEUROSCI, V27, P561, DOI 10.1016/j.tins.2004.06.008
   Religa D, 2006, NEUROSCI LETT, V404, P56, DOI 10.1016/j.neulet.2006.05.040
   Rogers JD, 2003, ARCH NEUROL-CHICAGO, V60, P59, DOI 10.1001/archneur.60.1.59
   Sachdev PS, 2005, PROG NEURO-PSYCHOPH, V29, P1152, DOI 10.1016/j.pnpbp.2005.06.026
   Sachdev PS, 2002, NEUROLOGY, V58, P1539, DOI 10.1212/WNL.58.10.1539
   Saw SM, 2001, AM J CLIN NUTR, V73, P232
   SCOTT JM, 1981, LANCET, V2, P337
   Selhub J, 2006, J NUTR, V136, p1726S, DOI 10.1093/jn/136.6.1726S
   Siniscalchi A, 2006, NUTR NEUROSCI, V9, P11, DOI 10.1080/10284150600583446
   Streck EL, 2003, NEUROCHEM INT, V43, P597, DOI 10.1016/S0197-0186(02)00230-9
   Streck EL, 2002, METAB BRAIN DIS, V17, P83, DOI 10.1023/A:1015594111778
   Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489
   Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.0.CO;2-#
   Todorovic Z, 2006, J NEUROL SCI, V248, P56, DOI 10.1016/j.jns.2006.05.040
   Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012
   van der Gaag MS, 2000, LANCET, V355, P1522, DOI 10.1016/S0140-6736(00)02172-3
   WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9
   Yasui K, 2000, NEUROLOGY, V55, P437, DOI 10.1212/WNL.55.3.437
   Zoccolella S, 2005, CLIN CHEM LAB MED, V43, P1107, DOI 10.1515/CCLM.2005.193
NR 66
TC 37
Z9 37
U1 0
U2 3
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-7490
EI 1573-7365
J9 METAB BRAIN DIS
JI Metab. Brain Dis.
PD JUN
PY 2009
VL 24
IS 2
BP 257
EP 269
DI 10.1007/s11011-009-9139-4
PG 13
WC Endocrinology & Metabolism; Neurosciences
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 446AN
UT WOS:000266092700002
PM 19294496
DA 2020-12-08
ER

PT J
AU de Paula, S
   Vitola, AS
   Greggio, S
   de Paula, D
   Mello, PB
   Lubianca, JM
   Xavier, LL
   Fiori, HH
   Dacosta, JC
AF de Paula, Simone
   Vitola, Affonso Santos
   Greggio, Samuel
   de Paula, Davi
   Mello, Pamela Billig
   Lubianca, Jeremiah Mistrello
   Xavier, Leder Leal
   Fiori, Humberto Holmer
   Dacosta, Jaderson Costa
TI Hemispheric Brain Injury and Behavioral Deficits Induced by Severe
   Neonatal Hypoxia-Ischemia in Rats Are Not Attenuated by Intravenous
   Administration of Human Umbilical Cord Blood Cells
SO PEDIATRIC RESEARCH
LA English
DT Article
ID STEM-CELLS; PROGENITOR CELLS; STROKE; DAMAGE; MODEL; GRAFTS;
   TRANSPLANTATION; ENCEPHALOPATHY; SENSORIMOTOR; SURVIVAL
AB Neonatal hypoxia-ischemia (HI) is an important cause of mortality and morbidity in infants. Human umbilical cord blood (HUCB) is a potential source of cellular therapy in perinatology. We investigated the effects of HUCB cells on spatial memory, motor performance, and brain morphologic changes in neonate rats submitted to HI. Seven-day-old rats underwent right carotid artery occlusion followed by exposure to 8% O-2 inhalation for 2 h. Twenty-four hours after HI, rats received either saline solution or HUCB cells i.v. After 3 wk, rats were assessed using a Morris Water Maze and four motor tests. Subsequently, rats were killed for histologic, immunohistochemical, and polymerase chain reaction (PCR) analyses. HI rats showed significant spatial memory deficits and a volumetric decrease in the hemisphere ipsilateral to arterial occlusion. These deficits and decreases were not significantly attenuated by the injection of HUCB cells. Moreover, immunofluorescence and PCR analysis revealed few HUCB cell, located in rat brain. Intravenous administration of HUCB cells requires optimization to achieve improved therapeutic outcomes in neonatal hypoxic-ischemic injury. (Pediatr Res 65: 631-635, 2009)
C1 [Dacosta, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Lab Neurociencias, BR-90610000 Porto Alegre, RS, Brazil.
   [Mello, Pamela Billig] Pontificia Univ Catolica Rio Grande do Sul, Ctr Memoria, BR-90610000 Porto Alegre, RS, Brazil.
   [Lubianca, Jeremiah Mistrello] Pontificia Univ Catolica Rio Grande do Sul, Ctr Terapia Celular, BR-90610000 Porto Alegre, RS, Brazil.
   [Fiori, Humberto Holmer] Pontificia Univ Catolica Rio Grande do Sul, Dept Pediat, BR-90610000 Porto Alegre, RS, Brazil.
RP Dacosta, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Lab Neurociencias, Av Ipiranga 6690-220, BR-90610000 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Mello-Carpes, Pamela Billig/O-2118-2017; Xavier, Leder/G-4540-2014;
   DaCosta, Jaderson/C-4968-2015; Greggio, Samuel/E-1498-2013;
   Mello-Carpes, Pamela/AAM-7404-2020
OI Mello-Carpes, Pamela Billig/0000-0002-9008-2091; Xavier,
   Leder/0000-0002-7213-4935; DaCosta, Jaderson/0000-0001-6776-1515;
   Greggio, Samuel/0000-0002-5187-0335; Mello-Carpes,
   Pamela/0000-0002-9008-2091; de Paula, Simone/0000-0003-3198-2695
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FUNPAR; Pandurata
FX supported by grants from CNPq, FUNPAR, and Pandurata.
CR AVENDANO C, 1995, BRAIN RES, V673, P83, DOI 10.1016/0006-8993(94)01407-9
   Bliss T, 2007, STROKE, V38, P817, DOI 10.1161/01.STR.0000247888.25985.62
   Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7
   Borlongan CV, 2005, BRAIN RES, V1048, P116, DOI 10.1016/j.brainres.2005.04.087
   Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367
   Chen N, 2005, STEM CELLS, V23, P1560, DOI 10.1634/stemcells.2004-0284
   Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002
   Golan H, 2006, DEVELOPMENTAL SCI, V9, P338, DOI 10.1111/j.1467-7687.2006.00498.x
   Grinnemo KH, 2004, J THORAC CARDIOV SUR, V127, P1293, DOI 10.1016/j.jtcvs.2003.07.037
   Guzman R, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E14
   Irons H, 2004, CELL TRANSPLANT, V13, P283, DOI 10.3727/000000004783983990
   Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002
   Lu DY, 2002, CELL TRANSPLANT, V11, P275
   Lubics A, 2005, BEHAV BRAIN RES, V157, P157, DOI 10.1016/j.bbr.2004.06.019
   Ma J, 2007, NEUROCHEM INT, V51, P57, DOI 10.1016/j.neuint.2007.04.012
   Makinen S, 2006, BRAIN RES, V1123, P207, DOI 10.1016/j.brainres.2006.09.056
   Meier C, 2006, PEDIATR RES, V59, P244, DOI 10.1203/01.pdr.0000197309.08852.f5
   Neumann H, 2006, J CLIN INVEST, V116, P2857, DOI 10.1172/JCI30230
   RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206
   Rodrigues AL, 2004, BRAIN RES, V1002, P94, DOI 10.1016/j.brainres.2003.12.020
   Rossato JI, 2007, LEARN MEMORY, V14, P36, DOI 10.1101/lm.422607
   Saito T, 2002, ANN THORAC SURG, V74, P19, DOI 10.1016/S0003-4975(02)03591-9
   Sanberg PR, 2005, ANN NY ACAD SCI, V1049, P67, DOI 10.1196/annals.1334.008
   Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8
   SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111
   Vannucci RC, 2000, AM J PERINAT, V17, P113, DOI 10.1055/s-2000-9293
   Vannucci RC, 2005, DEV NEUROSCI-BASEL, V27, P81, DOI 10.1159/000085978
   Vendrame M, 2004, STROKE, V35, P2390, DOI 10.1161/01.STR.0000141681.06735.9b
   Vendrame M, 2005, STEM CELLS DEV, V14, P595, DOI 10.1089/scd.2005.14.595
   Wennersten A, 2006, EXP NEUROL, V199, P339, DOI 10.1016/j.expneurol.2005.12.035
   Willing AE, 2003, J NEUROSCI RES, V73, P296, DOI 10.1002/jnr.10659
   Yager JY, 2006, BEHAV BRAIN RES, V173, P171, DOI 10.1016/j.bbr.2006.06.019
   Yasuhara T, 2008, J CEREBR BLOOD F MET, V28, P1804, DOI 10.1038/jcbfm.2008.68
   Yasuhara T, 2006, CELL TRANSPLANT, V15, P231, DOI 10.3727/000000006783982034
   Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853
NR 35
TC 55
Z9 59
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD JUN
PY 2009
VL 65
IS 6
BP 631
EP 635
DI 10.1203/PDR.0b013e31819ed5c8
PG 5
WC Pediatrics
SC Pediatrics
GA 448OL
UT WOS:000266271800007
PM 19430381
OA Bronze
DA 2020-12-08
ER

PT J
AU Sanchez, G
   Alvares, LD
   Oberholzer, MV
   Genro, B
   Quillfeldt, J
   da Costa, JC
   Cervenansky, C
   Jerusalinsky, D
   Kornisiuk, E
AF Sanchez, Gonzalo
   Alvares, Lucas de Oliveira
   Victoria Oberholzer, Maria
   Genro, Bruna
   Quillfeldt, Jorge
   da Costa, Jaderson Costa
   Cervenansky, Carlos
   Jerusalinsky, Diana
   Kornisiuk, Edgar
TI M-4 Muscarinic Receptors Are Involved in Modulation of Neurotransmission
   at Synapses of Schaffer Collaterals on CA1 Hippocampal Neurons in Rats
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Article
DE muscarinic acetylcholine receptor; CA1 synapses; long-term potentiation;
   rat hippocampus; muscarinic toxin 3
ID LONG-TERM POTENTIATION; METHYL-D-ASPARTATE; SYNAPTIC PLASTICITY;
   ACETYLCHOLINE; MEMORY; TRANSMISSION; ENHANCEMENT; SUBTYPES; TOXINS;
   ACTIVATION
AB All five subtypes of muscarinic acetylcholine receptors (mAChR; M-1-M-5) are expressed in the hippocampus, where they are involved both in cognitive functions and in synaptic plasticity, such as long-term potentiation (LTP). Muscarinic toxins (MTs) are small proteins from mamba snake venoms that display exquisite discrimination between mAChRs. MT1 acts as an agonist at M, and an antagonist at M-4 receptors, with similar affinities for both. MT3, the most selective antagonist available for M-4 receptors, infused into the CA1 region immediately after training caused amnesia in the rat, indicating the participation of M-4 receptors in memory consolidation. Our goal was to investigate the participation of M-4 receptor in neurotransmission at the hippocampal Schaffer collaterals-CA1 synapses. Two different preparations were used: 1) field potential recordings in freshly prepared rat hippocampal slices with high-frequency stimulation to induce potentiation and 2) whole-cell voltage clamp in cultured hippocampal organotypic slices with paired stimuli. In preparation 1, a dose of MT3 that was previously shown to cause amnesia blocked LTP; the nonselective antagonist scopolamine blocked LTP without affecting basal transmission, although it was depressed with higher concentration. In preparation 2, basal transmission was decreased and LTP induction was prevented by an MT3 concentration that would bind mainly to M-4 receptors. Although M, receptors appeared to modulate transmission positively at these excitatory synapses, M, activation concomitant with M-4 blockade (by MT1) only allowed a brief, short-term potentiation. Accordingly, M-4 blockade by MT3 strongly supports a permissive role of M-4 receptors and suggests their necessary participation in synaptic plasticity at these synapses. (C) 2008 Wiley-Liss, Inc.
C1 [Sanchez, Gonzalo; Victoria Oberholzer, Maria; Jerusalinsky, Diana; Kornisiuk, Edgar] Univ Buenos Aires, Fac Med, Inst Biol Celular & Neurociencias, Lab Neuroplasticidad & Neurotoxinas, RA-1121 Buenos Aires, DF, Argentina.
   [Sanchez, Gonzalo; Victoria Oberholzer, Maria; Jerusalinsky, Diana; Kornisiuk, Edgar] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina.
   [Alvares, Lucas de Oliveira; Genro, Bruna; Quillfeldt, Jorge] Univ Fed Rio Grande do Sul, Inst Biociencias, Dep Biofis, Lab Psicobiol & Neurocomputacao, BR-90049 Porto Alegre, RS, Brazil.
   [Alvares, Lucas de Oliveira; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Lab Neurociencias, Porto Alegre, RS, Brazil.
   [Cervenansky, Carlos] Inst Pasteur, Montevideo, Uruguay.
   [Cervenansky, Carlos] IIBCE, Montevideo, Uruguay.
RP Kornisiuk, E (corresponding author), Univ Buenos Aires, Fac Med, Inst Biol Celular & Neurociencias, Lab Neuroplasticidad & Neurotoxinas, 2155 Paraguay St,2nd Floor, RA-1121 Buenos Aires, DF, Argentina.
EM eko_rni@yahoo.com.ar
RI Sanchez, Gonzalo/B-6437-2013; Sanchez, Gonzalo/AAB-4566-2019;
   Quillfeldt, Jorge/I-8010-2014; DaCosta, Jaderson/C-4968-2015
OI Sanchez, Gonzalo/0000-0003-4415-1866; Quillfeldt,
   Jorge/0000-0002-6731-558X; DaCosta, Jaderson/0000-0001-6776-1515; De
   Oliveira Alvares, Lucas/0000-0002-0472-903X
CR Adem A, 1997, LIFE SCI, V60, P1069, DOI 10.1016/S0024-3205(97)00049-0
   ALEXANDER SPH, 2000, TIPS RECEPTOR ION CH, V11, P6
   Anagnostaras SG, 2003, NAT NEUROSCI, V6, P51, DOI 10.1038/nn992
   Atzori M, 2005, NEUROSCIENCE, V134, P1153, DOI 10.1016/j.neuroscience.2005.05.005
   Auerbach JM, 1996, J PHYSIOL-LONDON, V492, P479, DOI 10.1113/jphysiol.1996.sp021323
   BARATTI CM, 1993, BEHAV NEURAL BIOL, V60, P69, DOI 10.1016/0163-1047(93)90742-Z
   Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6
   BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051
   BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273
   BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Bradley KN, 2000, PHARMACOL THERAPEUT, V85, P87, DOI 10.1016/S0163-7258(99)00064-9
   Cobb SR, 2005, J PHYSIOL-LONDON, V562, P81, DOI 10.1113/jphysiol.2004.076539
   Descarries L, 1997, PROG NEUROBIOL, V53, P603, DOI 10.1016/S0301-0082(97)00050-6
   Felder CC, 2001, LIFE SCI, V68, P2605, DOI 10.1016/S0024-3205(01)01059-1
   de Sevilla DF, 2008, J NEUROSCI, V28, P1469, DOI 10.1523/JNEUROSCI.2723-07.2008
   Ferreira AR, 2003, PHARMACOL BIOCHEM BE, V74, P411
   FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D
   Gomeza J, 1999, P NATL ACAD SCI USA, V96, P10483, DOI 10.1073/pnas.96.18.10483
   HALLIWELL JV, 1990, PROG BRAIN RES, V84, P255
   Herrera-Morales W, 2007, EUR J NEUROSCI, V25, P1581, DOI 10.1111/j.1460-9568.2007.05391.x
   HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0
   Jakubik J, 1997, MOL PHARMACOL, V52, P172
   JERUSALINSKY D, 1995, TOXICON, V33, P389, DOI 10.1016/0041-0101(94)00103-F
   Jerusalinsky D, 2000, TOXICON, V38, P747, DOI 10.1016/S0041-0101(99)00196-8
   JERUSALINSKY D, 1994, TRENDS PHARMACOL SCI, V15, P424, DOI 10.1016/0165-6147(94)90092-2
   Jerusalinsky D, 1998, NEUROREPORT, V9, P1407, DOI 10.1097/00001756-199805110-00029
   Jerusalinsky D, 1997, NEUROCHEM RES, V22, P507, DOI 10.1023/A:1027376230898
   JERUSALINSKY D, 1992, NEUROCHEM INT, V20, P237, DOI 10.1016/0197-0186(92)90173-O
   Kornisiuk E, 2001, J NEUROCHEM, V78, P183
   KORNISIUK E, 1995, CORRIGENDUM TOXICON, V33, P111
   Leung LS, 2003, J NEUROSCI, V23, P9297
   LEVEY AI, 1995, J NEUROSCI, V15, P4077
   Li S, 2007, NEUROSCIENCE, V144, P754, DOI 10.1016/j.neuroscience.2006.10.001
   Lynch G, 2007, NEUROPHARMACOLOGY, V52, P12, DOI 10.1016/j.neuropharm.2006.07.027
   MARKRAM H, 1990, NEUROSCI LETT, V113, P62, DOI 10.1016/0304-3940(90)90495-U
   Max S. I., 1993, Society for Neuroscience Abstracts, V19, P462
   Miyakawa T, 2001, J NEUROSCI, V21, P5239, DOI 10.1523/JNEUROSCI.21-14-05239.2001
   Olianas MC, 1996, BRIT J PHARMACOL, V118, P283, DOI 10.1111/j.1476-5381.1996.tb15400.x
   QUIRION R, 1995, J NEUROSCI, V15, P1455
   Rouse ST, 1999, LIFE SCI, V64, P501, DOI 10.1016/S0024-3205(98)00594-3
   Rowe WB, 2003, BEHAV BRAIN RES, V145, P171, DOI 10.1016/S0166-4328(03)00116-5
   SALAMONI SD, 2005, ANTIEPILEPTIC EFFECT
   Santiago MP, 2001, BRAIN RES, V894, P12, DOI 10.1016/S0006-8993(00)03170-X
   Seeger T, 2004, J NEUROSCI, V24, P10117, DOI 10.1523/JNEUROSCI.3581-04.2004
   Shinoe T, 2005, J NEUROSCI, V25, P11194, DOI 10.1523/JNEUROSCI.2338-05.2005
   Shirey JK, 2008, NAT CHEM BIOL, V4, P42, DOI 10.1038/nchembio.2007.55
   Sim JA, 1996, EUR J NEUROSCI, V8, P880, DOI 10.1111/j.1460-9568.1996.tb01575.x
   SOKOLOV MV, 1995, BRAIN RES, V672, P281, DOI 10.1016/0006-8993(94)01376-S
   STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M
   Tai C, 2006, J NEUROSCI, V26, P6249, DOI 10.1523/JNEUROSCI.1009-06.2006
   VILARO MT, 1993, PROG BRAIN RES, V98, P95
   Volpicelli LA, 2004, PROG BRAIN RES, V145, P59, DOI 10.1016/S0079-6123(03)45003-6
   Yajeya J, 2000, SYNAPSE, V38, P151, DOI 10.1002/1098-2396(200011)38:2<151::AID-SYN6>3.3.CO;2-B
   Ye L, 2001, NEUROSCI LETT, V300, P145, DOI 10.1016/S0304-3940(01)01573-7
   Zhang WL, 2002, J NEUROSCI, V22, P1709, DOI 10.1523/JNEUROSCI.22-05-01709.2002
NR 56
TC 20
Z9 20
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0360-4012
EI 1097-4547
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD FEB 15
PY 2009
VL 87
IS 3
BP 691
EP 700
DI 10.1002/jnr.21876
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 404YX
UT WOS:000263190100012
PM 18816796
DA 2020-12-08
ER

PT J
AU Braga-Silva, J
   Gehlen, D
   Padoin, AV
   Machado, DC
   Garicochea, B
   Da Costa, JC
AF Braga-Silva, J.
   Gehlen, D.
   Padoin, A. V.
   Machado, D. C.
   Garicochea, B.
   Da Costa, J. Costa
TI Can local supply of bone marrow mononuclear cells improve the outcome
   from late tubular repair of human median and ulnar nerves?
SO JOURNAL OF HAND SURGERY-EUROPEAN VOLUME
LA English
DT Article
DE nerve regeneration; mesenchymal stem cells transplantation;
   transplantation; autologous; microsurgery; treatment outcome
ID HUMAN FOREARM; REGENERATION; TUBES; GAP
AB The purpose of this non-randomised retrospective study was to compare nerve regeneration after reconnection with silicone tubes with two different strategies. A total of 44 patients with injured median or ulnar nerves in the forearm were surgically treated. In one group of patients, a silicone tube alone was placed in the nerve gap. In a second group, the silicone tube was filled with autologous bone marrow mononuclear cells obtained by aspiration from the iliac crest. Motor function, sensation and the effect of pain on function were assessed I year after surgery. The tubes filled with bone marrow cells showed better recovery than the empty tubes. The use of bone marrow mononuclear cells in addition to tube re-connection may promote better nerve regeneration than conventional tubular repair.
C1 [Braga-Silva, J.] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Serv Hand Surg & Reconstruct Microsurg, Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Biomed Res Inst, Porto Alegre, RS, Brazil.
RP Braga-Silva, J (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Serv Hand Surg & Reconstruct Microsurg, Porto Alegre, RS, Brazil.
EM jeffmao@terra.com.br
RI Padoin, Alexandre V/M-7660-2013; DaCosta, Jaderson/C-4968-2015; Machado,
   Denise C/G-2852-2014; Silva, Jefferson L Braga/D-8429-2013
OI Padoin, Alexandre V/0000-0002-9754-4818; DaCosta,
   Jaderson/0000-0001-6776-1515; Machado, Denise C/0000-0002-9371-5886;
   Silva, Jefferson L Braga/0000-0002-4827-9253
CR Braga-Silva J, 1999, J HAND SURG-BRIT EUR, V24B, P703, DOI 10.1054/jhsb.1999.0276
   CHANSON L, 1976, REV CHIRURG ORTHOPED, V63, P153
   COLIN W, 1984, J DENT RES, V63, P987, DOI 10.1177/00220345840630071601
   Dahlin L, 2001, J HAND SURG-BRIT EUR, V26, P393, DOI 10.1054/jhsb.2001.0561
   DEMEDINACELI L, 1991, J HAND SURG-BRIT EUR, V16B, P499, DOI 10.1016/0266-7681(91)90103-U
   FIELDS RD, 1989, PROG NEUROBIOL, V33, P87, DOI 10.1016/0301-0082(89)90036-1
   Lundborg G, 1997, J HAND SURG-AM, V22A, P99, DOI 10.1016/S0363-5023(05)80188-1
   LUNDBORG G, 1982, J NEUROPATH EXP NEUR, V41, P412, DOI 10.1097/00005072-198207000-00004
   Lundborg G, 2004, J HAND SURG-BRIT EUR, V29B, P100, DOI 10.1016/j.jhsb.2003.09.018
   LUNDBORG G, 1994, J HAND SURG-BRIT EUR, V19B, P273, DOI 10.1016/0266-7681(94)90068-X
   Murakami T, 2003, BRAIN RES, V974, P17, DOI 10.1016/S0006-8993(03)02539-3
   Rosberg HE, 2005, J HAND SURG-BRIT EUR, V30B, P35, DOI 10.1016/j.jhsb.2004.09.003
   ROSEN B, 1994, J HAND SURG-BRIT EUR, V19B, P452, DOI 10.1016/0266-7681(94)90209-7
   Tohill M, 2004, BIOTECHNOL APPL BIOC, V40, P17, DOI 10.1042/BA20030173
NR 14
TC 14
Z9 17
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1753-1934
EI 2043-6289
J9 J HAND SURG-EUR VOL
JI J. Hand Surg.-Eur. Vol.
PD AUG
PY 2008
VL 33E
IS 4
BP 488
EP 493
DI 10.1177/1753193408090401
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 345RK
UT WOS:000259013900016
PM 18687837
DA 2020-12-08
ER

PT J
AU Nunes, ML
   Martins, MP
   Barea, BM
   Wainberg, RC
   da Costa, JC
AF Nunes, Magda Lahorgue
   Martins, Maurer Pereira
   Barea, Bianca Menke
   Wainberg, Ricardo C.
   da Costa, Jaderson Costa
TI Neurological outcome of newborns with neonatal seizures. a cohort study
   in a tertiary university hospital
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE neonatal seizures; follow up; epilepsy; neonatal EEG; preterm newborn
ID RISK-FACTORS; EPILEPSY; CONVULSIONS
AB Objective: To describe the neurological outcome of newborns with seizures. Method: Cohort study with newborns prospectively followed. Perinatal characteristics and etiological screening were related to outcome in a regression model. Results: During the study 3659 newborns were admitted and 2.7% were diagnosed as having seizures. Hypoxic ischemic encephalopathy (51%) was the etiology more frequently associated to seizures and also to postneonatal epilepsy (53%). In the follow up 25 died during the acute neonatal illness and 9 during the first years of life, 19 were diagnosed as having post neonatal epilepsy, 35 had developmental delay and 11 an association among this two comorbidities. A significant association between abnormal postnatal EEG and neuroimaging to developmental delay (p=0.014, p=0.026) was observed. The group of newborns that had seizures presented an increased risk of developing epilepsy compared to newborns from the same cohort without seizures (19.3/100 vs. 1.8/100, p < 0.001). Conclusion: In this study neonatal seizures predominated in term newborns with perinatal asphyxia an elevated perinatal mortality and post neonatal morbidity was observed.The follow up showed an increased risk for developing postnatal epilepsy and developmental delay.
C1 Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Div Neurol, Sch Med,Neurodev Outpatient Clin, BR-9061000 Porto Alegre, RS, Brazil.
RP Nunes, ML (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Div Neurol, Sch Med,Neurodev Outpatient Clin, Avenide Ipiranga 6690 Room 220, BR-9061000 Porto Alegre, RS, Brazil.
EM nunes@pucrs.br
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x
   Arpino C, 2001, J CHILD NEUROL, V16, P651, DOI 10.1177/088307380101600905
   BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9
   BERGMAN I, 1983, ANN NEUROL, V14, P642, DOI 10.1002/ana.410140607
   BERNES SM, 1994, PEDIATR CLIN N AM, V41, P1069
   CAPURRO H, 1978, J PEDIATR-US, V93, P120, DOI 10.1016/S0022-3476(78)80621-0
   CLANCY RR, 1991, EPILEPSIA, V32, P69, DOI 10.1111/j.1528-1157.1991.tb05614.x
   CURATOLO P, 1995, DEV MED CHILD NEUROL, V37, P776
   Da Silva LFG, 2004, PEDIATR NEUROL, V30, P271, DOI 10.1016/j.pediatrneurol.2003.09.015
   DENNIS J, 1978, DEV MED CHILD NEUROL, V20, P143
   ERIKSSON M, 1979, ACTA PAEDIATR SCAND, V68, P807
   FRANKENBURG WK, 1992, PEDIATRICS, V89, P91
   Holanda MRR, 2006, ARQ NEURO-PSIQUIAT, V64, P45, DOI 10.1590/S0004-282X2006000100010
   KEEN JH, 1973, ARCH DIS CHILD, V48, P542, DOI 10.1136/adc.48.7.542
   LANSKA MJ, 1995, NEUROLOGY, V45, P724, DOI 10.1212/WNL.45.4.724
   LEGIDO A, 1991, PEDIATRICS, V88, P583
   LOMBROSO CT, 1990, J CLIN NEUROPHYSIOL, V7, P380, DOI 10.1097/00004691-199007000-00005
   Lombroso CT, 1996, BRAIN DEV-JPN, V18, P1, DOI 10.1016/S0387-7604(96)90001-7
   LOMBROSO CT, 1983, STATUS EPILEPTICUS, P101
   LOMBROSO CT, 1996, EPILEPSIA S3, V37, pS5
   LOMBROSO CT, 1994, ELECTROENCEPHALOGRAP, P803
   MELLITS ED, 1982, PEDIATRICS, V70, P177
   Mizrahi EM, 1998, DIAGNOSIS MANAGEMENT
   Nunes ML, 2006, CURR PEDIATR REV, V2, P315, DOI 10.2174/157339606778699662
   NUNES ML, 2002, SEMIOLOGIA NEUROLOGI, P597
   NUNES ML, 2003, MANUAL EEG POLISSONO
   Ronen GM, 1999, J PEDIATR-US, V134, P71, DOI 10.1016/S0022-3476(99)70374-4
   SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829
   SCHER MS, 1989, PEDIATR CLIN N AM, V36, P281
   Scher MS, 1997, CLIN PERINATOL, V24, P735
   Tekgul H, 2006, PEDIATRICS, V117, P1270, DOI 10.1542/peds.2005-1178
   VOLPE J J, 1977, Clinics in Perinatology, V4, P43
   VOLPE JJ, 2000, NEUROLOGY NEWBORN
   WATANABE K, 1982, ADV EPILEPTOL, P77
NR 34
TC 25
Z9 28
U1 0
U2 1
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 2008
VL 66
IS 2A
BP 168
EP 174
DI 10.1590/S0004-282X2008000200005
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 309UI
UT WOS:000256485300005
PM 18545776
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU da Fontoura, DR
   Ranco, DDM
   Anes, M
   da Costa, JC
   Portuguezs, MW
AF da Fontoura, Denise Ren
   Ranco, Daniel de Moraes
   Anes, Mauricio
   da Costa, Jaderson Costa
   Portuguezs, Mirna Wetters
TI Language brain dominance in patients with refractory temporal lobe
   epilepsy - A comparative study between functional magnetic resonance
   imaging and dichotic listening test
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE dichotic listening test; functional magnetic resonance imaging;
   refractory temporal lobe epilepsy; brain dominance; language
ID LATERALIZATION; PERFORMANCE; MRI; REPRESENTATION; ACTIVATION; CHILDREN
AB Purpose: To identify brain dominance for language functions with DLT and correlate these results with those obtained from fMRI in patients suffering from intractable temporal lobe epilepsy. Method: This study reports on 13 patients who underwent pre-surgical epileptic evaluation between April and October 2004 at the Epilepsy Surgery Program, Hospital Sao Lucas, PUCKS. In DLT, dominance was assessed through a consonant-vowel task, whereas in fMRI patients performed a verb generation task. Results: Our results identified a correlation between the fMRI lateralization index and the DLT ear predominance index and reply difference index (r=0.6, p=0.02; Pearson Correlation Coefficient), showing positive correlation between results obtained from fMRI and DLT. Conclusion: DLT was found to significantly correlate with fMRI. These findings indicate that DLT (a non-invasive procedure) could be a useful tool to evaluate language brain dominance in pre-surgical epileptic patients as it is cheaper to perform than fMRI.
C1 Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Serv Neurol, Programa Cirurg Epilepsia, Porto Alegre, RS, Brazil.
   [da Fontoura, Denise Ren] Univ Nova Lisboa, Fac Med, P-1200 Lisbon, Portugal.
   [Ranco, Daniel de Moraes] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
   [Anes, Mauricio] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
   [da Fontoura, Denise Ren; da Costa, Jaderson Costa; Portuguezs, Mirna Wetters] Pontificia Univ Catolica Rio Grande do Sul, Fac Med, Porto Alegre, RS, Brazil.
RP da Fontoura, DR (corresponding author), Rua Dr Prudente Moraes 349, BR-91330170 Porto Alegre, RS, Brazil.
EM denisefontoura@sapo.pt
RI Anes, Mauricio/O-4264-2014; DaCosta, Jaderson/C-4968-2015
OI Anes, Mauricio/0000-0003-0624-1932; DaCosta,
   Jaderson/0000-0001-6776-1515
CR Adcock JE, 2003, NEUROIMAGE, V18, P423, DOI 10.1016/S1053-8119(02)00013-7
   Benson RR, 1999, NEUROLOGY, V52, P798, DOI 10.1212/WNL.52.4.798
   Bethmann A, 2007, BRAIN RES, V1133, P145, DOI 10.1016/j.brainres.2006.11.057
   Binder JR, 1996, NEUROLOGY, V46, P978, DOI 10.1212/WNL.46.4.978
   CANCERCUKIERT AR, 1995, EPILEPSIA S, V4, P129
   CANERCUKIERT AR, 2002, TRATAMENTO CLIN CIRU, P189
   CENDES F, 2000, EPILEPSIA, P201
   Chugani HT, 1996, BRAIN DEV-JPN, V18, P347, DOI 10.1016/0387-7604(96)00032-0
   COSTA JC, 1998, FUNDAMENTOS NEUROBIO, V2, P817
   Deblaere K, 2002, NEURORADIOLOGY, V44, P667, DOI 10.1007/s00234-002-0800-4
   DUCHOWNY M, 1996, ANN NEUROL, V40, P3
   Fernandes MA, 2006, BRAIN LANG, V96, P106, DOI 10.1016/j.bandl.2005.06.006
   GEFFEN G, 1981, NEUROPSYCHOLOGIA, V19, P413, DOI 10.1016/0028-3932(81)90071-3
   Hugdahl K, 1997, ARCH NEUROL-CHICAGO, V54, P1494, DOI 10.1001/archneur.1997.00550240046011
   Janszky J, 2003, BRAIN, V126, P2043, DOI 10.1093/brain/awg193
   Knecht S, 2004, BRAIN, V127, P1217, DOI 10.1093/brain/awh202
   LENT R, 2001, CEM BIHOES NEURONIOS
   Loring DW, 1999, NEUROLOGY, V53, P260, DOI 10.1212/WNL.53.2.260
   Lurito JT, 2001, NEUROIMAG CLIN N AM, V11, P355
   Ortiz Karin Zazo, 2002, Sao Paulo Med. J., V120, P185, DOI 10.1590/S1516-31802002000600006
   PALMINI A, 1998, FUNDAMENTOS NEUROBIO, V2, P857
   PORTUGUEZ M. W., 2002, SEMIOLOGIA NEUROLOGI
   PORTUGUEZ MW, 2000, EPILEPSIA, P119
   Risse GL, 1997, BRAIN COGNITION, V33, P118, DOI 10.1006/brcg.1997.0887
   Rutten GJM, 2002, NEUROIMAGE, V17, P447, DOI 10.1006/nimg.2002.1196
   Sabbah P, 2003, NEUROIMAGE, V18, P460, DOI 10.1016/S1053-8119(03)00025-9
   SANTOS F, 2001, THESIS PONTIFICIA U
   Springer JA, 1999, BRAIN, V122, P2033, DOI 10.1093/brain/122.11.2033
   STRAUSS E, 1987, NEUROPSYCHOLOGIA, V25, P747, DOI 10.1016/0028-3932(87)90112-6
   TEDESCO ML, 1997, PROCESSAMENTO AUDITI, P139
   YACUBIAN EMT, 1998, FUNDAMENTOS NEUROBIO, V2, P807
   ZATORRE RJ, 1989, NEUROPSYCHOLOGIA, V27, P1207, DOI 10.1016/0028-3932(89)90033-X
NR 32
TC 8
Z9 9
U1 0
U2 8
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD MAR
PY 2008
VL 66
IS 1
BP 34
EP 39
DI 10.1590/S0004-282X2008000100009
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 282PQ
UT WOS:000254580100009
PM 18392411
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Khan, RL
   Nunes, ML
   da Silva, LFG
   da Costa, JC
AF Khan, Richard Lester
   Nunes, Magda Lahorgue
   Garcias da Silva, Luis Fernando
   da Costa, Jaderson Costa
TI Predictive value of sequential electroencephalogram (EEG) in neonates
   with seizures and its relation to neurological outcome
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE neonatal EEG; outcome; neonatal seizures; epilepsy; west syndrome
ID PROGNOSTIC VALUE; FULL-TERM; ELECTROGRAPHIC SEIZURES; PREMATURE-INFANTS;
   PRETERM; RISK; ENCEPHALOPATHY; PATTERNS; EPILEPSY; BIRTH
AB The aim of this study was to evaluate the relationship of sequential neonatal electroencephalography (EEG) and neurological outcome in neonates with seizures to identify polysomnographic features predictive of outcome. Sequential EEGs recordings of 58 neonates that belonged to 2 historical cohorts of newborns with seizures from the same neonatal intensive care unit and who had follow-up at the Neurodevelopment Clinic of the Hospital Sao Lucas, Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS) in Porto Alegre, Brazil, were analyzed and classified into 4 groups: normal-normal, abnormal-normal, abnormal-abnormal, normal-abnormal. In patients with more than 2 recordings, during the neonatal period, the first EEG was compared with the following more abnormal. A total of 58 pairs of 2 sequential EEGs were analyzed. Considering the first EEG, a statistically significant difference was observed between the relationship of the result of this exam, if it was abnormal, with developmental delay (P = .030) and postnatal death (P = .030). Abnormal background activity was also related to neurodevelopment delay (P = .041). EEG sequences abnormal-abnormal and normal-abnormal significantly correlated to the outcome epilepsy (P = .015). Abnormal sequential background activity was associated with neurodevelopment delay (P = .006) and epilepsy (P = .041). The burst suppression pattern when present in any EEG correlated with epilepsy (P = .013) and postnatal death (P = .034). Sequential abnormal background patterns in the first and second EEG increased the risk for epilepsy (relative risk [RR] = 1.8; 95% confidence interval [CI] 1.03-3.0) and neurodevelopment delay (RR = 2.20; 95% CI 1.3-3.0). Abnormal background activity only in the second electroencephalogram increased the risk for neurodevelopment delay (RR = 2.20; 95% CI = 1.3-3.0). All the neonates (n = 33) with seizures related to probable hypoxic ischemic encephalopathy had abnormalities in the first EEG (P = .030). Postnatal epilepsy was diagnosed in 24 infants (41.4%). Five (20.8%) presented West syndrome, 7 (29.2%) focal symptomatic epilepsy, 6 (25%) generalized symptomatic epilepsy, 2 (8.3%) early myoclonic encephalopathy, 1 (4.2%) early infantile epileptic encephalopathy, and in 3, the epileptic syndrome was undefined (12.5%). All infants (n = 5) with West syndrome had some degree of neurodevelopment delay. In conclusion, our findings suggest that sequential EEG in neonates with seizures has more predictive value to estimate the outcomes of neurodevelopment delay, epilepsy, and postnatal death than a single EEG recording. The abnormal background activity in even 1 EEG of the sequential recordings was more significant to determine neurological outcome than abnormal ictal activity or abnormalities in the organization of sleep state.
C1 [Khan, Richard Lester; Nunes, Magda Lahorgue; Garcias da Silva, Luis Fernando; da Costa, Jaderson Costa] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Div Neurol, Sch Med, BR-90610000 Porto Alegre, RS, Brazil.
RP Nunes, ML (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Div Neurol, Sch Med, Av Ipiranga 6690,Cj220, BR-90610000 Porto Alegre, RS, Brazil.
EM nunes@pucrs.br
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR ABROMS IF, 1971, P ROY SOC MED, V64, P471, DOI 10.1177/003591577106400505
   ANDRE M, 1988, NEUROPEDIATRICS, V19, P201, DOI 10.1055/s-2008-1052446
   [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x
   BERRATT S, 2000, ARCH PEDIAT ADOLESC, V154, P411
   Bye A, 1995, J PAEDIATR CHILD H, V31, P503, DOI 10.1111/j.1440-1754.1995.tb00872.x
   CLANCY RR, 1991, EPILEPSIA, V32, P69, DOI 10.1111/j.1528-1157.1991.tb05614.x
   CONNELL J, 1989, ARCH DIS CHILD-FETAL, V64, P452, DOI 10.1136/adc.64.4_Spec_No.452
   Curzi-Dascalova L., 1996, MANUAL METHODS RECOR
   Da Silva LFG, 2004, PEDIATR NEUROL, V30, P271, DOI 10.1016/j.pediatrneurol.2003.09.015
   DREYFUSBRISAC C, 1972, HEREDIATRY CONGENITA, V38, P52
   ELLISON PH, 1981, J PEDIATR-US, V99, P455, DOI 10.1016/S0022-3476(81)80348-4
   Hankins GDV, 2003, OBSTET GYNECOL, V102, P628, DOI 10.1016/S0029-7844(03)00574-X
   HOLDEN KR, 1982, PEDIATRICS, V70, P165
   HOLMES GL, 1993, J CLIN NEUROPHYSIOL, V10, P323, DOI 10.1097/00004691-199307000-00008
   HUGHES JR, 1989, CLIN ELECTROENCEPHAL, V20, P228, DOI 10.1177/155005948902000410
   Jensen FE, 2006, CURR OPIN PEDIATR, V18, P628, DOI 10.1097/MOP.0b013e328010c536
   Kellaway P, 1983, Adv Neurol, V34, P93
   Laroia N, 1998, EPILEPSIA, V39, P545, DOI 10.1111/j.1528-1157.1998.tb01418.x
   LEGIDO A, 1991, PEDIATRICS, V88, P583
   Lombroso C T, 1983, Adv Neurol, V34, P101
   LOMBROSO CT, 1985, J CLIN NEUROPHYSIOL, V2, P105, DOI 10.1097/00004691-198504000-00002
   Lombroso CT, 1993, ELECTROENCEPHALOGRAP, P803
   McBride MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506
   Menache CC, 2002, PEDIATR NEUROL, V27, P93, DOI 10.1016/S0887-8994(02)00396-X
   MIZRAHI EM, 1987, NEUROLOGY, V37, P1837, DOI 10.1212/WNL.37.12.1837
   MONOD N, 1972, ELECTROEN CLIN NEURO, V32, P529, DOI 10.1016/0013-4694(72)90063-6
   NELSON KB, 1991, AM J DIS CHILD, V145, P1325, DOI 10.1001/archpedi.1991.02160110117034
   Nunes ML, 2005, ARQ NEURO-PSIQUIAT, V63, P14, DOI 10.1590/S0004-282X2005000100003
   NUNES ML, 1995, ARQ NEURO-PSIQUIAT, V53, P625, DOI 10.1590/S0004-282X1995000400013
   Nunes ML, 1997, ELECTROEN CLIN NEURO, V102, P186, DOI 10.1016/S0013-4694(96)95191-7
   Nunes ML, 2000, CLIN NEUROPHYSIOL, V111, P305, DOI 10.1016/S1388-2457(99)00234-5
   NUNES ML, 1994, JLBE, V7, P27
   NUNES ML, 2003, MANUAL EEG POLISSONO
   Oliveira AJ, 2000, CLIN NEUROPHYSIOL, V111, pS74, DOI 10.1016/S1388-2457(00)00405-3
   Oliveira AJ, 2000, CLIN NEUROPHYSIOL, V111, P1646, DOI 10.1016/S1388-2457(00)00380-1
   PAINTER MJ, 1986, PEDIATR CLIN N AM, V33, P91
   ROSE AL, 1970, PEDIATRICS, V45, P404
   ROWE JC, 1985, ELECTROEN CLIN NEURO, V60, P183, DOI 10.1016/0013-4694(85)90030-6
   Sand N, 2005, PEDIATRICS, V116, P174, DOI 10.1542/peds.2004-1809
   SCHER MS, 1993, PEDIATRICS, V91, P128
   SEHER MS, 2001, TREATMENT EPILEPSY P, P577
   Tekgul H, 2006, PEDIATRICS, V117, P1270, DOI 10.1542/peds.2005-1178
   ter Horst H, 2004, PEDIATR RES, V55, P1026, DOI 10.1203/01.pdr.0000127019.52562.8c
   TIBBLES JAR, 1965, PEDIATRICS, V35, P778
   Volpe JJ, 2001, NEUROLOGY NEWBORN, P178
NR 45
TC 39
Z9 40
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD FEB
PY 2008
VL 23
IS 2
BP 144
EP 150
DI 10.1177/0883073807308711
PG 7
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 275FK
UT WOS:000254057100002
PM 18160554
DA 2020-12-08
ER

PT J
AU Souza, VA
   Palmini, AL
   Paglioli-Neto, E
   Pereira, AM
   Carrion, MJ
   Martinez, JL
   Hoefel, JR
   Nunes, RM
   Torres, CM
   Portuguez, MW
   Paglioli, E
   Azambuja, NV
   da Costa, JC
AF Souza, Victor A.
   Palmini, A. L.
   Paglioli-Neto, E.
   Pereira, A. M.
   Carrion, M. J.
   Martinez, J. L.
   Hoefel, J. R.
   Nunes, Rafael M.
   Torres, C. M.
   Portuguez, M. W.
   Paglioli, E.
   Azambuja, N. V.
   da Costa, J. C.
TI MOTOR OUTCOME OF FOCAL RESECTIVE SURGERY IN PATIENTS WITH CONGENITAL
   HEMIPARESIS AND EXTENSIVE DESTRUCTIVE LESIONS: EFFECTS OF DIFFERENT
   RESECTION STRATEGIES
SO EPILEPSIA
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the American-Epilepsy-Society
CY DEC 05-09, 2008
CL Seattle, WA
SP Amer Epilepsy Soc
C1 [Souza, Victor A.; Palmini, A. L.; Paglioli-Neto, E.; Pereira, A. M.; Carrion, M. J.; Martinez, J. L.; Hoefel, J. R.; Nunes, Rafael M.; Torres, C. M.; Portuguez, M. W.; Paglioli, E.; Azambuja, N. V.; da Costa, J. C.] Pontificia Univ Catolica Rio Grande do Sul, Epilepsia Hosp Sao Lucas, Programa Cirurgia, Porto Alegre, RS, Brazil.
RI Portuguez, Mirna/A-9362-2018
OI Portuguez, Mirna/0000-0003-4068-6249
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PY 2008
VL 49
BP 306
EP 306
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 363ZS
UT WOS:000260306600732
DA 2020-12-08
ER

PT J
AU Izquierdo, LA
   Barros, DM
   da Costa, JC
   Furini, C
   Zinn, C
   Carnmarota, M
   Bevilaqua, LR
   Izquierdo, I
AF Izquierdo, Luciana A.
   Barros, Daniela M.
   da Costa, Jaderson Costa
   Furini, Cristiane
   Zinn, Carolina
   Carnmarota, Martin
   Bevilaqua, Lia R.
   Izquierdo, Ivan
TI A link between role of two prefrontal areas in immediate memory and in
   long-term memory consolidation
SO NEUROBIOLOGY OF LEARNING AND MEMORY
LA English
DT Article
DE prefrontal cortex in immediate memory; Prefrontal cortex in long-term
   memory; Dorsolateral prefrontal cortex; Medial prefrontal. cortex; AMPA
   receptors; Dopamine receptors; GABA receptors
ID MEDIAL TEMPORAL-LOBE; WORKING-MEMORY; DIFFERENTIAL INVOLVEMENT;
   INHIBITORY AVOIDANCE; FEAR EXTINCTION; CORTEX; AMYGDALA; MECHANISMS;
   RATS; INFORMATION
AB The dorsolateral and medial prefrontal cortex are critical for immediate memory processing. The possibility has been raised that those two areas may also contribute to long-term memory formation. Here, we studied the role of specific receptors in dorsolateral and medial prefrontal cortex in immediate and in long-term memory formation of one-trial inhibitory avoidance. Four different specific receptor ligands were infused into these two areas: the dopamine D1 receptor antagonist, SCH23390, the GABA(A) receptor agonist, muscimol, the AMPA glutamatergic receptor antagonist, ciano-nitro-quinoxaline-dione (CNQX), and the NMDA glutamatergic receptor antagonist, aminophosphonovaleric acid (AP5). In all cases the doses used had been previously shown to affect immediate or long-term memory. In the experiments on immediate memory the drugs were given 5 min before training and the animals were tested 3 s post-training. These animals were then also tested 24 h later for long-term memory. The effect of the treatments on long-term memory was studied by their infusion 0, 90, 180 or 270 min post-training, testing the animals 24 h after training. Immediate memory was inhibited by SCH23390, muscimol and CNQX, but not by AP5, given into any of the two subregions. Long-term memory formation was inhibited by SCH23390, muscimol and CNQX, but not by AP5, given pre-training or 0, 90 or 180 but not 270 min post-training into the dorsolateral region; or 90 but not 0 or 180 min post-training into the medial region. Thus, there is a time- and receptor-dependent correlation in the two areas between their role in immediate and in long-term memory processing. Both roles require intact glutamate AMPA and dopamine D1 receptors, are inhibited by GABAergic synapses, and are unaffected by AP5. In the dorsolateral prefrontal cortex the link between immediate and long-term memory appears to be direct; in the medial area the link suffers a 90 min delay. (C) 2007 Elsevier Inc. All rights reserved.
C1 Pontificia Univ Catolica Rio Grande do Sul, Ctr Mem, Inst Pesquisas Biol, BR-90610000 Porto Alegre, RS, Brazil.
RP Izquierdo, I (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Ctr Mem, Inst Pesquisas Biol, Av Ipiranga 6690 2nd Floor, BR-90610000 Porto Alegre, RS, Brazil.
EM izquier@terra.com.br
RI FURINI, CRISTIANE R. G./AAB-7773-2019; Zinn, Carolina/G-8186-2016;
   DaCosta, Jaderson/C-4968-2015
OI FURINI, CRISTIANE R. G./0000-0003-1609-7727; DaCosta,
   Jaderson/0000-0001-6776-1515; Izquierdo, Ivan/0000-0002-7208-0869;
   Cammarota, Martin/0000-0001-9741-5074
CR AKIRAV I, 2006, CEREBRAL CORTEX
   Bailey KR, 2004, CEREB CORTEX, V14, P974, DOI 10.1093/cercor/bhh058
   Bernabeu R, 1997, P NATL ACAD SCI USA, V94, P7041, DOI 10.1073/pnas.94.13.7041
   Blumenfeld RS, 2006, J NEUROSCI, V26, P916, DOI 10.1523/JNEUROSCI.2353-05.2006
   Christoff K, 2003, BEHAV NEUROSCI, V117, P1161, DOI 10.1037/0735-7044.117.6.1161
   EBBINGHAUS H, 1885, UBER DAS GEDACHTNISS
   Fuster JM, 2001, NEURON, V30, P319, DOI 10.1016/S0896-6273(01)00285-9
   GOLDMANRAKIC PS, 1991, AM PSYCHOP, P1
   HYMAN BT, 1990, NEUROLOGY, V40, P1721, DOI 10.1212/WNL.40.11.1721
   Izquierdo I, 1998, NATURE, V393, P635, DOI 10.1038/31371
   Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799
   IZQUIERDO I, 1985, BEHAV NEURAL BIOL, V43, P260, DOI 10.1016/S0163-1047(85)91606-1
   Izquierdo I, 1998, BEHAV PHARMACOL, V9, P421
   Izquierdo I, 2000, BEHAV PHARMACOL, V11, P517, DOI 10.1097/00008877-200011000-00001
   Izquierdo I, 2006, TRENDS NEUROSCI, V29, P496, DOI 10.1016/j.tins.2006.07.005
   Jackson ME, 2006, EUR J NEUROSCI, V24, P1702, DOI 10.1111/j.1460-9568.2006.05054.x
   Jacobsen CF, 1936, COMP PSYCHOL, V13, P1, DOI DOI 10.1001/ARCHNEURPSYC.1935.02250150108009
   Kalisch R, 2006, J NEUROSCI, V26, P9503, DOI 10.1523/JNEUROSCI.2021-06.2006
   KIM M, 1992, BRAIN RES, V585, P35, DOI 10.1016/0006-8993(92)91188-K
   Lebron K, 2004, LEARN MEMORY, V11, P544, DOI 10.1101/lm.78604
   LIANG KC, 1966, CHINESE J PHYSL, V39, P155
   Malin EL, 2006, P NATL ACAD SCI USA, V103, P1959, DOI 10.1073/pnas.0510890103
   MCGAUGH JL, 1966, SCIENCE, V153, P1351, DOI 10.1126/science.153.3742.1351
   MCGAUGH JL, 1973, ANNU REV PHARMACOL, V13, P217
   Milad MR, 2002, NATURE, V420, P70, DOI 10.1038/nature01138
   MILAD MR, 2007, BIOL PSYCHIAT
   Phelps EA, 2006, ANNU REV PSYCHOL, V57, P27, DOI 10.1146/annurev.psych.56.091103.070234
   Phelps EA, 2004, NEURON, V43, P897, DOI 10.1016/j.neuron.2004.08.042
   Quirk GJ, 2003, J NEUROSCI, V23, P8800, DOI 10.1523/jneurosci.23-25-08800.2003
   Ranganath C, 2005, J COGNITIVE NEUROSCI, V17, P994, DOI 10.1162/0898929054475118
   Ruchkin DS, 2003, BEHAV BRAIN SCI, V26, P709, DOI 10.1017/S0140525X03000165
   Runyan JD, 2005, LEARN MEMORY, V12, P232, DOI 10.1101/lm.92405
   Runyan JD, 2004, NEUROBIOL LEARN MEM, V82, P65, DOI 10.1016/j.nlm.2004.04.006
   Rypma B, 2003, COGNITIVE BRAIN RES, V16, P162, DOI 10.1016/S0926-6410(02)00247-1
   Sakai K, 2003, REV NEUROSCIENCE, V14, P241
   Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178
   SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111
   Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001
   Tronel S, 2004, LEARN MEMORY, V11, P453, DOI 10.1101/lm.74504
   Xiang JZ, 2004, NEURON, V42, P817, DOI 10.1016/j.neuron.2004.05.013
NR 40
TC 37
Z9 38
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1074-7427
EI 1095-9564
J9 NEUROBIOL LEARN MEM
JI Neurobiol. Learn. Mem.
PD SEP
PY 2007
VL 88
IS 2
BP 160
EP 166
DI 10.1016/j.nlm.2007.04.014
PG 7
WC Behavioral Sciences; Neurosciences; Psychology; Psychology,
   Multidisciplinary
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 208VQ
UT WOS:000249347700002
PM 17562373
DA 2020-12-08
ER

PT J
AU Tuon, L
   Portuguez-, M
   Lzquierdo, I
   da Costa, JC
AF Tuon, Lisiane
   Portuguez-, Mirna
   Lzquierdo, Ivan
   da Costa, Jaderson Costa
TI A new spatial orientation memory test: Evaluation in patients with mild
   Alzheimer's disease and in patients with operated and unoperated mesial
   temporal lobe epilepsy
SO EUROPEAN JOURNAL OF PSYCHIATRY
LA English
DT Article
ID PLACE CELLS; HIPPOCAMPUS; IMPAIRMENT
AB Background and objectives: Spatial orientation and spatial learning depend on the medial temporal lobe. A new test of spatial memory in humans is described, and applied to patients with Alzheimer's disease (AD), with presumable damage of that region, and to patients with unilateral mesial temporal sclerosis (MTS) submitted or not to treatment by selective surgical amygdala-hippocampectomy (SAH).
   Methods: Subjects were asked to go to each of four objects hanging from the wall of a room: a cylinder, a square, a ball and a triangle (trial 1). In trial 2 they repeated this blindfolded; all figures except the cylinder were removed; once the subjects reached the cylinder they had to say what figures should be at the left, right and back. In trial 3, all figures were withdrawn and the subjects, again blindfolded, were instructed first to go to the front, right, left and back, and then to go to the former positions occupied by the cylinder, the ball, the square and the triangle.
   Results: Experiment 1 studied 10 patients with mild AD and 10 controls matched by age, gender and schooling. Performance was 46% lower in AD patients relative to controls (p < 0.001). Experiment 2 studied 23 patients with NITS, 20 patients submitted to SAH, and 23 healthy volunteers with similar levels of age, gender and schooling. No differences in performance among these three groups were observed.
   Conclusions: The test distinguished performance deficits of AD patients relative to controls, but not among NITS and STH patients and controls.
C1 Lisiane Tuon & Ivan Izquierdo Ctr Mem, IPB, BR-90610000 Porto Alegre, RS, Brazil.
   Univ Extremo Sul Catarinense, Criciuma, SC, Brazil.
   Pontificia Univ Catolica Rio Grade Sul, Inst Pesquisas Biomed, BR-90610 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grade Sul, Ctr Mem, BR-90610 Porto Alegre, RS, Brazil.
RP Tuon, L (corresponding author), Lisiane Tuon & Ivan Izquierdo Ctr Mem, IPB, Av Ipiranga 6690,2 Andar, BR-90610000 Porto Alegre, RS, Brazil.
EM ivan.izquierdo@pucrs.br
RI DaCosta, Jaderson/C-4968-2015; Portuguez, Mirna/A-9362-2018
OI DaCosta, Jaderson/0000-0001-6776-1515; Portuguez,
   Mirna/0000-0003-4068-6249; Izquierdo, Ivan/0000-0002-7208-0869
CR Abrahams S, 1999, BRAIN COGNITION, V41, P39, DOI 10.1006/brcg.1999.1095
   Alessio A, 2004, EPILEPSY BEHAV, V5, P22, DOI 10.1016/j.yebeh.2003.10.010
   ARRIAGADA PV, 1992, NEUROLOGY, V42, P1681, DOI 10.1212/WNL.42.9.1681
   Braak H, 1998, J NEURAL TRANSM-SUPP, P127
   Burgess N, 2005, HIPPOCAMPUS, V15, P149, DOI 10.1002/hipo.20058
   CARAMELLIP, 2000, REV ASSOC MED BRAS, V46, P301
   Carroll B T, 2001, CNS Spectr, V6, P329
   Corkin S, 2002, NAT REV NEUROSCI, V3, P153, DOI 10.1038/nrn726
   COSTA JC, 2000, SEMIOLOGIA NEUROLOGI, P373
   della Rocchetta AI, 2004, NEUROPSYCHOLOGY, V18, P15, DOI 10.1037/0894-4105.18.1.15
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Hamilton DA, 2002, BEHAV BRAIN RES, V129, P159, DOI 10.1016/S0166-4328(01)00343-6
   Hollup SA, 2001, EUR J NEUROSCI, V13, P1197, DOI 10.1046/j.0953-816x.2001.01487.x
   Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799
   Izquierdo I, 2000, BEHAV PHARMACOL, V11, P517, DOI 10.1097/00008877-200011000-00001
   MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a
   MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0
   Moser EI, 2001, CURR OPIN NEUROBIOL, V11, P745, DOI 10.1016/S0959-4388(01)00279-3
   Nakazawa K, 2004, NAT REV NEUROSCI, V5, P361, DOI 10.1038/nrn1385
   NITRINI R, 1995, DEMENCIA, P90
   O'Keefe J, 2005, HIPPOCAMPUS, V15, P853, DOI 10.1002/hipo.20115
   OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1
   OKEEFE JA, 1979, EXP NEUROL, V51, P78
   Soltys K, 2005, NEUROREPORT, V16, P1677, DOI 10.1097/01.wnr.0000181582.95764.79
   Steinvorth S, 2005, NEUROPSYCHOLOGIA, V43, P479, DOI 10.1016/j.neuropsychologia.2005.01.001
   Stepankova K, 2004, NEUROPSYCHOLOGIA, V42, P1017, DOI 10.1016/j.neuropsychologia.2004.01.002
   SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x
   WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517
NR 28
TC 1
Z9 1
U1 0
U2 2
PU EUROPEAN JOURNAL OF PSYCHIATRY
PI ZARAGOZA
PA FAC MED, DEPT PSYCHIATRY PROF A LOBO, DOMINGO MIRAL S-N, 50009 ZARAGOZA,
   SPAIN
SN 0213-6163
J9 EUR J PSYCHIAT
JI Eur. J. Psychiat.
PD APR-JUN
PY 2007
VL 21
IS 2
BP 134
EP 142
PG 9
WC Psychiatry
SC Psychiatry
GA 205DD
UT WOS:000249092500005
OA Other Gold, Bronze
DA 2020-12-08
ER

PT J
AU Branco, DM
   Suarez, RO
   Whalen, S
   O'Shea, JP
   Nelson, AP
   da Costa, JC
   Golby, AJ
AF Branco, Daniel M.
   Suarez, Ralph O.
   Whalen, Stephen
   O'Shea, James P.
   Nelson, Aaron P.
   da Costa, Jaderson C.
   Golby, Alexandra J.
TI Functional MRI of memory in the hippocampus: Laterality indices may be
   more meaningful if calculated from whole voxel distributions
SO NEUROIMAGE
LA English
DT Article
DE memory; MTL; fMRI; epilepsy; neurosurgery
ID MEDIAL TEMPORAL-LOBE; LANGUAGE DOMINANCE; WADA TEST; FMRI; EPILEPSY;
   ACTIVATION; RETRIEVAL; INJECTION; CORTEX
AB Lateralization of memory by functional MRI (fMRI) may be helpful for surgical planning related to the medial temporal lobe (MTL). Most fMRI memory studies have calculated lateralization indices (LI) in the MTL from suprathreshold voxels only, but the selection of threshold remains highly arbitrary. We hypothesized that LIs could be reliably extracted from the distribution of voxels encompassing all positive T statistical values, each weighted by their own statistical significance. We also hypothesized that patient LIs that are two or more standard deviations (SD) away from the control group mean LI may be more clinically relevant than LIs that are not compared to control group. Thirteen healthy subjects had memory fMRI, and five epilepsy patients had both fMRI and the intracarotid amobarbital procedure (IAP). The fMRI task consisted of encoding patterns, scenes, and words. We found that normal subjects' LIs extracted from whole weighted statistical distributions tended to lateralize to the left for words, to the right for patterns, and intermediately for scenes, consistent with previous research. Weighted LIs were less variable than those calculated from suprathreshold voxels only. Using this approach, all patients had fMRI memory lateralizations consistent with IAP results. The weighted LIs provided a more clear-cut distinction of patients from the normal group (in terms of SDs from the group mean) than the suprathreshold voxel count approach. Our results suggest that using weighted distributions can be a useful strategy for assessing memory lateralization by fMRI in the MTL. (c) 2006 Elsevier Inc. All rights reserved.
C1 Harvard Univ, Dept Neurosurg, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   Harvard Univ, Dept Radiol, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   Harvard Univ, Dept Neurol, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
   Pontificia Univ Catolica Rio de Janeiro, Inst Pesquisas Biomed, Lab Neurociencias, Porto Alegre, RS, Brazil.
RP Golby, AJ (corresponding author), Harvard Univ, Dept Neurosurg, Brigham & Womens Hosp, Sch Med, 75 Francis St, Boston, MA 02115 USA.
EM agolby@bwh.harvard.edu
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
FU NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [K08NS048063, K08NS048063, K08NS048063, K08NS048063, K08NS048063]
   Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS
   048063-02, K08 NS048063] Funding Source: Medline
CR Adcock JE, 2003, NEUROIMAGE, V18, P423, DOI 10.1016/S1053-8119(02)00013-7
   Akanuma N, 2003, SEIZURE-EUR J EPILEP, V12, P346, DOI 10.1016/S1059-1311(02)00323-0
   Bellgowan PSF, 1998, NEUROLOGY, V51, P479, DOI 10.1212/WNL.51.2.479
   Benson RR, 1999, NEUROLOGY, V52, P798, DOI 10.1212/WNL.52.4.798
   Binder JR, 1996, NEUROLOGY, V46, P978, DOI 10.1212/WNL.46.4.978
   Buckner RL, 2001, J COGNITIVE NEUROSCI, V13, P406, DOI 10.1162/08989290151137430
   Cohen MS, 1999, JMRI-J MAGN RESON IM, V10, P33, DOI 10.1002/(SICI)1522-2586(199907)10:1<33::AID-JMRI5>3.0.CO;2-N
   Deblaere K, 2002, NEURORADIOLOGY, V44, P667, DOI 10.1007/s00234-002-0800-4
   Desmond JE, 1995, BRAIN, V118, P1411, DOI 10.1093/brain/118.6.1411
   Detre JA, 1998, NEUROLOGY, V50, P926, DOI 10.1212/WNL.50.4.926
   DION JE, 1987, STROKE, V18, P997, DOI 10.1161/01.STR.18.6.997
   Dolan RJ, 1999, HIPPOCAMPUS, V9, P25, DOI 10.1002/(SICI)1098-1063(1999)9:1<25::AID-HIPO3>3.3.CO;2-W
   Dupont S, 2000, BRAIN, V123, P1722, DOI 10.1093/brain/123.8.1722
   Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213
   Friston KJ, 1998, NEUROIMAGE, V7, P30, DOI 10.1006/nimg.1997.0306
   Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264
   Glover GH, 1998, MAGN RESON MED, V39, P361, DOI 10.1002/mrm.1910390305
   Glover GH, 2001, MAGNET RESON MED, V46, P515, DOI 10.1002/mrm.1222
   Golby AJ, 2002, EPILEPSIA, V43, P855, DOI 10.1046/j.1528-1157.2002.20501.x
   Golby AJ, 2001, BRAIN, V124, P1841, DOI 10.1093/brain/124.9.1841
   JACK CR, 1989, MAYO CLIN PROC, V64, P965, DOI 10.1016/S0025-6196(12)61225-7
   Jokeit H, 2001, NEUROLOGY, V57, P1786, DOI 10.1212/WNL.57.10.1786
   Kelley WM, 1998, NEURON, V20, P927, DOI 10.1016/S0896-6273(00)80474-2
   Killgore WDS, 1999, SEIZURE-EUR J EPILEP, V8, P450, DOI 10.1053/seiz.1999.0339
   Kirchhoff BA, 2000, J NEUROSCI, V20, P6173, DOI 10.1523/JNEUROSCI.20-16-06173.2000
   Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1
   Maldjian JA, 2004, NEUROIMAGE, V21, P450, DOI 10.1016/j.neuroimage.2003.09.032
   Martin JN, 1999, COMMUN THEOR, V9, P1, DOI 10.1111/j.1468-2885.1999.tb00160.x
   Milner B., 1962, T AM NEUROL ASSOC, V87, P224
   Nagata S, 2001, AM J NEURORADIOL, V22, P985
   Powell HWR, 2005, NEUROIMAGE, V27, P231, DOI 10.1016/j.neuroimage.2005.04.033
   Richardson MP, 2003, NEUROIMAGE, V20, pS112, DOI 10.1016/j.neuroimage.2003.09.008
   Rutten GJM, 2002, NEUROIMAGE, V17, P447, DOI 10.1006/nimg.2002.1196
   Sabbah P, 2003, NEUROIMAGE, V18, P460, DOI 10.1016/S1053-8119(03)00025-9
   Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K
   SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11
   Simkins-Bullock J, 2000, NEUROPSYCHOL REV, V10, P41, DOI 10.1023/A:1009044630227
   Springer JA, 1999, BRAIN, V122, P2033, DOI 10.1093/brain/122.11.2033
   SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195
   STEM CE, 1996, P NATL ACAD SCI USA, V93, P8660
   WADA J, 1960, J NEUROSURG, V17, P266, DOI 10.3171/jns.1960.17.2.0266
NR 41
TC 50
Z9 50
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD AUG 15
PY 2006
VL 32
IS 2
BP 592
EP 602
DI 10.1016/j.neuroimage.2006.04.201
PG 11
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 074YO
UT WOS:000239848700013
PM 16777435
DA 2020-12-08
ER

PT J
AU Franca, MC
   Calcagnotto, ME
   da Costa, JC
   Lopes-Cendes, I
AF Franca, Marcondes C., Jr.
   Calcagnotto, Maria E.
   da Costa, Jaderson C.
   Lopes-Cendes, Iscia
TI Spinocerebellar ataxia types 2 and 3 segregating simultaneously in a
   single family
SO MOVEMENT DISORDERS
LA English
DT Article
DE SCA2; SCA3; Machado-Joseph disease; genetic testing
ID MACHADO-JOSEPH-DISEASE; FREQUENCY; MUTATIONS; DIAGNOSIS; (CAG)(N); SCA2
AB Spinocerebellar ataxia (SCA) types 2 and 3 are autosomal-dominant neurodegenerative disorders caused by mutations in two different genes. We identified mutations for SCA2 and SCA3 segregating simultaneously in a single Brazilian family. The index patient had SCA2, whereas her two second-degree cousins had SCA3. Disease was more rapidly progressive in the SCA2 patient, who presented severe brainstem and pancerebellar atrophy, as opposed to the two SCA3 patients, who had only mild cerebellar vermian atrophy. In such situations, molecular confirmation of all patients may avoid misdiagnosis of SCA subtypes and eventual errors in predictive testing of unaffected family members. (C) 2006 Movement Disorder Society.
C1 Univ Estadual Campinas, UNICAMP, Fac Ciencias Med, Dept Med Genet, BR-13084971 Campinas, SP, Brazil.
   Univ Estadual Campinas, UNICAMP, Dept Neurol, BR-13084971 Campinas, SP, Brazil.
   Pontificia Univ Catolica, Dept Neurol, Porto Alegre, RS, Brazil.
RP Lopes-Cendes, I (corresponding author), Univ Estadual Campinas, UNICAMP, Fac Ciencias Med, Dept Med Genet, BR-13084971 Campinas, SP, Brazil.
EM icendes@unicamp.br
RI CALCAGNOTTO, MARIA ELISA/AAU-7718-2020; calcagnotto, maria
   elisa/B-1645-2013; DaCosta, Jaderson/C-4968-2015; Lopes-Cendes,
   Iscia/B-9416-2013
OI CALCAGNOTTO, MARIA ELISA/0000-0001-8196-0596; calcagnotto, maria
   elisa/0000-0001-8196-0596; DaCosta, Jaderson/0000-0001-6776-1515;
   Lopes-Cendes, Iscia/0000-0002-6221-6822
CR Etchebehere ECSC, 2001, ARCH NEUROL-CHICAGO, V58, P1257, DOI 10.1001/archneur.58.8.1257
   Giunti P, 1998, BRAIN, V121, P459, DOI 10.1093/brain/121.3.459
   Jardim LB, 2001, ARCH NEUROL-CHICAGO, V58, P899, DOI 10.1001/archneur.58.6.899
   Klockgether T, 1998, BRAIN, V121, P1687, DOI 10.1093/brain/121.9.1687
   LopesCendes I, 1996, ARCH NEUROL-CHICAGO, V53, P1168, DOI 10.1001/archneur.1996.00550110120020
   LopesCendes I, 1997, ARQ NEURO-PSIQUIAT, V55, P519, DOI 10.1590/S0004-282X1997000400001
   Maciel P, 2001, ARCH NEUROL-CHICAGO, V58, P1821, DOI 10.1001/archneur.58.11.1821
   Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9
   Silveira I, 1996, NEUROLOGY, V46, P214, DOI 10.1212/WNL.46.1.214
   Silveira I, 2002, ARCH NEUROL-CHICAGO, V59, P623, DOI 10.1001/archneur.59.4.623
NR 10
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JUL
PY 2006
VL 21
IS 7
BP 1051
EP 1053
DI 10.1002/mds.20893
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA 067EW
UT WOS:000239285600031
PM 16628604
DA 2020-12-08
ER

PT J
AU Tuon, L
   Portuguez, M
   da Costa, JC
AF Tuon, Lisiane
   Portuguez, Mirna
   Costa da Costa, Jaderson
TI Spatial orientation memory: evaluation in patents with Alzheimer disease
   and temporal lobe epilepsy
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA Portuguese
DT Article
DE memory; spatial orientation; epilepsy; mesial temporal sclerosis;
   selective amygdala hippocampectomy
ID PLACE CELLS; HIPPOCAMPAL; SCLEROSIS
AB Experimental studies have identified pyramidal cells in hippocampus in rats with participation in the spatial orientation memory (SOM), which are named location cells. This study had the purpose to adapt a test based in these experiments in order to check the performance of SOM and the participation of hippocampus into SOM in patients with mesial temporal sclerosis (MTS). The research was divided into two studies: the first one the test was adapted, and in order to check its capacity to investigate the deficits of SOM, it has applied in groups of 10 (ten) subjects, one group with patients that have Alzheimer disease and the other one with healthy elderly (p < 0.001). The second study has evaluated the participation of hippocampus into SOM in 43 patients (23 with mesial temporal sclerosis (MTS) and 20 submitted to selective amygdala hippocampectomy (SAH)) and 23 healthy volunteers with p < 0,05 between MTS and SAH and between controled and SAH. It was shown that the test of SOM is suitable to evaluate deficits, but it seems the SOM is not a specific function of human hippocampus.
C1 PUCRS, Area Concentracao Neurociencias, Porto Alegre, RS, Brazil.
   PUCRS, FAMED, Fac Med, Disciplina Neurol,Dept Med Interna, Porto Alegre, RS, Brazil.
RP Tuon, L (corresponding author), Ave Univ 1105, BR-88806000 Criciuma, SC, Brazil.
EM lisiane@contato.net
RI Portuguez, Mirna/A-9362-2018; DaCosta, Jaderson/C-4968-2015
OI Portuguez, Mirna/0000-0003-4068-6249; DaCosta,
   Jaderson/0000-0001-6776-1515
CR Abrahams S, 1999, BRAIN COGNITION, V41, P39, DOI 10.1006/brcg.1999.1095
   Alessio A, 2004, EPILEPSY BEHAV, V5, P22, DOI 10.1016/j.yebeh.2003.10.010
   BEAR MF, 2001, SISTEMAS MEMORIA NEU, P761
   CARMELLI P, 2000, REV ASSOC MED BRAS, V46, P301
   COSTA JC, 2000, SEMIOLOGIA NEUROLOGI, P373
   COSTA JC, 1998, FUNDAMENTOS NEUROBIO, V2, P149
   della Rocchetta AI, 2004, NEUROPSYCHOLOGY, V18, P15, DOI 10.1037/0894-4105.18.1.15
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   GUERREIRO CAM, 2000, EPILEPSIA, P113
   Hayman RMA, 2003, EUR J NEUROSCI, V18, P2825, DOI 10.1111/j.1460-9568.2003.03035.x
   Hollup SA, 2001, EUR J NEUROSCI, V13, P1197, DOI 10.1046/j.0953-816x.2001.01487.x
   MAGUIRE EA, 1997, NEUROSCIENCE, V17, P18
   MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a
   Moser EI, 2001, CURR OPIN NEUROBIOL, V11, P745, DOI 10.1016/S0959-4388(01)00279-3
   NITRINI R, 1995, DEMENCIA, P90
   OKEEFE JA, 1979, EXP NEUROL, V51, P78
   Stepankova K, 2004, NEUROPSYCHOLOGIA, V42, P1017, DOI 10.1016/j.neuropsychologia.2004.01.002
   SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x
NR 18
TC 0
Z9 0
U1 0
U2 3
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 2006
VL 64
IS 2B
BP 490
EP 495
DI 10.1590/S0004-282X2006000300026
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 068QW
UT WOS:000239390500026
PM 16917625
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Alvares, LD
   Genro, BP
   Breda, RV
   Pedroso, MF
   Da Costa, JC
   Quillfeldt, JA
AF Alvares, LD
   Genro, BP
   Breda, RV
   Pedroso, MF
   Da Costa, JC
   Quillfeldt, JA
TI AM251, a selective antagonist of the CB1 receptor, inhibits the
   induction of long-term potentiation and induces retrograde amnesia in
   rats
SO BRAIN RESEARCH
LA English
DT Article
DE memory; LTP; AM251; CB1 cannabinoid receptor; hippocampus
ID CANNABINOID RECEPTORS; SPATIAL MEMORY; HABITUATION TASK; RADIAL MAZE;
   BRAIN; SR141716A; ENDOCANNABINOIDS; CONSOLIDATION; HIPPOCAMPUS;
   PLASTICITY
AB Long-term potentiation (LTP) has a long history as putative mechanism of memory formation, specially in the hippocampus, a structure essential for memory formation. Endocannabinoids are one of the endogenous systems that modulate this plasticity event: the activation of hippocampal CBI receptors may inhibit local GABA release. Here, we have studied both (1) the role of the selective CB1 antagonist AM251 upon LTP induction in a hippocampal slice preparation, and (2) the effect of its intrahippocampal administration in the step-down inhibitory avoidance (IA) and the open field habituation tasks (OF). Standard extracellular electrophysiology techniques were used to record field excitatory postsynaptic potentials from the dendritic region of CA1 neurons in response to a high frequency stimulation of Schaffer's collaterals; a micropipette ejected 0.2 mu M of AM251 (in DMSO/PBS) 2 min before the stimulus: LTP was induced and lasted more than 30 min in the control, but not in the AM251-treated group. Immediately after training, either in IA (footshock, 0.5 mA) or OF, animals received a bilateral infusion of 0.55 or 5.5 ng/side of AM251 or its vehicle in the CA1 region, and test was performed 24 h later. AM2S1 has caused a significative decrease in the test step-down latency when compared to the control group, but no differences were detected in the OF task, including the number of crossings, i.e., there were no motor effects. The LTP supression could be caused by AM251 acting over GABAergic interneurons that modulate the LTP-bearing glutamatergic neurons. Endocanabinoids would then be the natural dis-inhibitors of local plasticity in the dorsal hippocampus, and the amnestic action of AM251 would be due to a disruption of this endogenous modulatory system. (c) 2005 Elsevier B.V. All rights reserved.
C1 Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Biofis, Lab Psicobiol & Neurocomputacao, BR-91501970 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Lab Neurociencias, Porto Alegre, RS, Brazil.
   Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Programa PosGraduacao Neurociencias, Porto Alegre, RS, Brazil.
RP Quillfeldt, JA (corresponding author), Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Biofis, Lab Psicobiol & Neurocomputacao, Av Bento Goncalves,9500,Predio 43422,Room 208, BR-91501970 Porto Alegre, RS, Brazil.
EM quillfe@ufrgs.br
RI Quillfeldt, Jorge/I-8010-2014; DaCosta, Jaderson/C-4968-2015
OI Quillfeldt, Jorge/0000-0002-6731-558X; DaCosta,
   Jaderson/0000-0001-6776-1515; De Oliveira Alvares,
   Lucas/0000-0002-0472-903X
CR ALGER BE, 1995, TRENDS NEUROSCI, V18, P333, DOI 10.1016/0166-2236(95)93923-L
   Alvares LD, 2005, NEUROBIOL LEARN MEM, V83, P119, DOI 10.1016/j.nlm.2004.10.002
   Ameri A, 1999, PROG NEUROBIOL, V58, P315, DOI 10.1016/S0301-0082(98)00087-2
   BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0
   Bohme GA, 2000, NEUROSCIENCE, V95, P5
   Breivogel CS, 2001, MOL PHARMACOL, V60, P155
   Cahill L, 1998, TRENDS NEUROSCI, V21, P294, DOI 10.1016/S0166-2236(97)01214-9
   Carlson G, 2002, NAT NEUROSCI, V5, P723, DOI 10.1038/nn879
   Chevaleyre V, 2003, NEURON, V38, P461, DOI 10.1016/S0896-6273(03)00235-6
   COLLINS DR, 1995, BRIT J PHARMACOL, V115, P869, DOI 10.1111/j.1476-5381.1995.tb15889.x
   Dalbem A, 2005, BRAIN RES, V1047, P148, DOI 10.1016/j.brainres.2005.04.030
   DASILVA GE, 2002, BIOL PSYCHIAT, V26, P321
   Davies SN, 2002, NEUROPHARMACOLOGY, V42, P993, DOI 10.1016/S0028-3908(02)00060-6
   Egashira N, 2002, BRAIN RES, V952, P239, DOI 10.1016/S0006-8993(02)03247-X
   Frankland PW, 2005, NAT REV NEUROSCI, V6, P119, DOI 10.1038/nrn1607
   Gatley SJ, 1996, EUR J PHARMACOL, V307, P331, DOI 10.1016/0014-2999(96)00279-8
   Hajos N, 2001, NEUROSCIENCE, V106, P1, DOI 10.1016/S0306-4522(01)00287-1
   Hajos N, 2002, NEUROPHARMACOLOGY, V43, P503, DOI 10.1016/S0028-3908(02)00157-0
   Hampson RE, 1999, LIFE SCI, V65, P715, DOI 10.1016/S0024-3205(99)00294-5
   HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991
   Hernandez-Tristan R, 2000, J PHYSIOL BIOCHEM, V56, P17, DOI 10.1007/BF03179772
   Hohmann AG, 2005, NATURE, V435, P1108, DOI 10.1038/nature03658
   IZQUIERDO I, 1995, NEUROBIOL LEARN MEM, V63, P19, DOI 10.1006/nlme.1995.1002
   IZQUIERDO I, 1992, BEHAV NEURAL BIOL, V58, P16, DOI 10.1016/0163-1047(92)90847-W
   Katona I, 1999, J NEUROSCI, V19, P4544
   Kreitzer AC, 2001, J NEUROSCI, V21, part. no.
   Lamprecht R, 2004, NAT REV NEUROSCI, V5, P45, DOI 10.1038/nrn1301
   Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6
   LICHTMAN AH, 1995, PSYCHOPHARMACOLOGY, V119, P282, DOI 10.1007/BF02246292
   Lichtman AH, 2000, EUR J PHARMACOL, V404, P175, DOI 10.1016/S0014-2999(00)00615-4
   MACKIE K, 1995, J NEUROSCI, V15, P6552
   Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839
   MCGAUGH JL, 1966, SCIENCE, V153, P1351, DOI 10.1126/science.153.3742.1351
   Ohno-Shosaku T, 2001, NEURON, V29, P729, DOI 10.1016/S0896-6273(01)00247-1
   Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix
   PERTWEE RG, 2002, ESSENT FATTY ACIDS, V66, P101
   ROSAT R, 1992, BRAZ J MED BIOL RES, V25, P267
   Salamoni SD, 2005, BRAIN RES, V1048, P170, DOI 10.1016/j.brainres.2005.04.060
   Savinainen JR, 2003, BRIT J PHARMACOL, V140, P1451, DOI 10.1038/sj.bjp.0705577
   SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195
   Takahashi RN, 2005, NEUROSCI LETT, V380, P270, DOI 10.1016/j.neulet.2005.01.049
   Terranova JP, 1996, PSYCHOPHARMACOLOGY, V126, P165, DOI 10.1007/BF02246352
   TERRANOVA JP, 1995, N-S ARCH PHARMACOL, V352, P576, DOI 10.1007/BF00169393
   Wilson RI, 2001, NATURE, V410, P588, DOI 10.1038/35069076
   Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545
   Wolff MC, 2003, EUR J PHARMACOL, V477, P213, DOI 10.1016/j.ejphar.2003.08.025
NR 46
TC 59
Z9 60
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD FEB 23
PY 2006
VL 1075
BP 60
EP 67
DI 10.1016/j.brainres.2005.11.101
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 029LS
UT WOS:000236564700007
PM 16464439
DA 2020-12-08
ER

PT J
AU Paglioli, E
   Palmini, A
   Portuguez, M
   Paglioli, E
   Azambuja, N
   Da Costa, JC
   Da Silva, HF
   Martinez, JV
   Hoeffel, JR
AF Paglioli, E
   Palmini, A
   Portuguez, M
   Paglioli, E
   Azambuja, N
   Da Costa, JC
   Da Silva, HF
   Martinez, JV
   Hoeffel, JR
TI Seizure and memory outcome following temporal lobe surgery: selective
   compared with nonselective approaches for hippocampal sclerosis
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE temporal lobe epilepsy; epilepsy surgery; amygdalohippocampectomy;
   anterior temporal lobectomy; memory outcome; survival analysis
ID EPILEPSY; AMYGDALOHIPPOCAMPECTOMY; LOBECTOMY; PATHOLOGY; RESECTION;
   ELECTROCORTICOGRAPHY; DEPTH; MRI; ELECTROENCEPHALOGRAPHY; EXPERIENCE
AB Object. The aim of this study was to compare seizure and memory outcome in patients with medically refractory mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) treated using an anterior temporal lobectomy (ATL) or a selective amygdalohippocampectomy (SA).
   Methods. Surgical Outcome data were prospectively collected for 2 to I I years in 161 consecutive patients with MTLE/HS. Eighty patients underwent an ATL and 8 1 an SA. Seizure control achieved with each technique was compared using the Engel classification scheme. Postoperative memory testing was performed in 86 patients (53%). At the last follow up, 72% of the patients who had undergone an ATL (mean follow up 6.7 years) and 71% of those who had undergone an SA (mean follow up 4.5 years) were seizure free (Engle Class IA). Estimated survival in patients in Engel Classes I. IA, and 1 and 11 combined did not differ between the two surgical techniques. Preoperatively, 58% of the patients had verbal memory scores one standard deviation (SD) below the normal mean. One third of the patients with preoperative scores in the normal range worsened after surgery, although this outcome was not related to the Surgical technique. In contrast, one third of those whose preoperative scores were less than -1 SD experienced improvement after surgery. Nine (18%) of the 50 patients whose left side had been surgically treated improved their verbal memory scores by more than one SD. Seven (78%) of these nine underwent an SA (p = 0.05).
   Conclusions. Both ATL and SA can lead to similar favorable seizure control in patients with MTLE/HS. Preliminary data suggest that postoperative verbal memory scores may improve in patients Who undergo selective resection of a sclerotic hippocampus in the dominant temporal lobe.
C1 PUCRS, Hosp Sao Lucas, Porto Alegre Epilepsy Surg Program, BR-90610000 Porto Alegre, RS, Brazil.
RP Paglioli, E (corresponding author), PUCRS, Hosp Sao Lucas, Porto Alegre Epilepsy Surg Program, Room 220,Avenida Ipiranga 6690, BR-90610000 Porto Alegre, RS, Brazil.
EM epaglioli@hotmail.com
RI Portuguez, Mirna/A-9362-2018; DaCosta, Jaderson/C-4968-2015
OI Portuguez, Mirna/0000-0003-4068-6249; DaCosta,
   Jaderson/0000-0001-6776-1515
CR Alarcon G, 1997, BRAIN, V120, P2259, DOI 10.1093/brain/120.12.2259
   Arruda F, 1996, ANN NEUROL, V40, P446, DOI 10.1002/ana.410400314
   Barbosa-Coutinho LM, 1999, ARQ NEURO-PSIQUIAT, V57, P405, DOI 10.1590/S0004-282X1999000300011
   BERKOVIC SF, 1995, NEUROLOGY, V45, P1358, DOI 10.1212/WNL.45.7.1358
   Bernasconi N, 2001, NEUROLOGY, V56, P1335, DOI 10.1212/WNL.56.10.1335
   Bernasconi N, 2000, ANN NY ACAD SCI, V911, P495
   Briellmann RS, 2002, NEUROLOGY, V58, P265, DOI 10.1212/WNL.58.2.265
   Bronen RA, 1997, AM J ROENTGENOL, V169, P875, DOI 10.2214/ajr.169.3.9275915
   Brown MW, 2001, NAT REV NEUROSCI, V2, P51, DOI 10.1038/35049064
   CASCINO GD, 1995, EPILEPSIA, V36, P692, DOI 10.1111/j.1528-1157.1995.tb01048.x
   CASCINO GD, 1995, EPILEPSIA, V36, P230, DOI 10.1111/j.1528-1157.1995.tb00989.x
   Cendes F, 1997, ANN NEUROL, V42, P737, DOI 10.1002/ana.410420510
   Clusmann H, 2002, J NEUROSURG, V97, P1131, DOI 10.3171/jns.2002.97.5.1131
   Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008
   Engel Jerome Jr., 1993, P609
   FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604
   Gleissner U, 2002, EPILEPSIA, V43, P87, DOI 10.1046/j.1528-1157.2002.24101.x
   Gleissner U, 2004, EPILEPSIA, V45, P960, DOI 10.1111/j.0013-9580.2004.42203.x
   HIRSCH LJ, 1991, ANN NEUROL, V30, P340, DOI 10.1002/ana.410300305
   JACKSON GD, 1993, NEUROLOGY, V43, P1793, DOI 10.1212/WNL.43.9.1793
   JACKSON GD, 1990, NEUROLOGY, V40, P1869, DOI 10.1212/WNL.40.12.1869
   Jones-Gotman M, 1987, SURGICAL TREATMENT E, P68
   Kier EL, 2004, AM J NEURORADIOL, V25, P677
   Lee TMC, 2002, EPILEPSIA, V43, P283, DOI 10.1046/j.1528-1157.2002.09901.x
   Lezak M. D., 1983, NEUROPSYCHOLOGICAL A
   Mackenzie RA, 1997, J CLIN NEUROSCI, V4, P152, DOI 10.1016/S0967-5868(97)90064-3
   MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105
   MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P175, DOI 10.1016/0028-3932(68)90017-1
   Niemeyer P., 1958, TEMPORAL LOBE EPILEP, P461
   OJEMANN G, 1989, J NEUROSURG, V71, P316, DOI 10.3171/jns.1989.71.3.0316
   Paglioli E, 2004, EPILEPSIA, V45, P1383, DOI 10.1111/j.0013-9580.2004.22204.x
   PALMINI A, 1992, NEUROLOGY, V42, P801, DOI 10.1212/WNL.42.4.801
   PALMINI A, 2004, HAND CLIN N, V3, P61
   Palmini ALF, 2001, EPILEPSY SURG, P675
   RASMUSSEN T, 1991, CAN J NEUROL SCI, V18, P601
   SALANOVA V, 1994, ARCH NEUROL-CHICAGO, V51, P1008, DOI 10.1001/archneur.1994.00540220054014
   Schaller C, 2002, NEUROSURGERY, V51, P971, DOI 10.1097/00006123-200210000-00022
   Schmidt D, 2004, EPILEPSIA, V45, P179, DOI 10.1111/j.0013-9580.2004.37803.x
   Schwartz TH, 1997, NEUROSURGERY, V40, P302, DOI 10.1097/00006123-199702000-00014
   SPENCER DD, 1992, EPILEPSY SURGERY, P533
   SPENCER SS, 1987, EPILEPSIA, V28, P479, DOI 10.1111/j.1528-1157.1987.tb03676.x
   Sperling MR, 1996, JAMA-J AM MED ASSOC, V276, P470, DOI 10.1001/jama.276.6.470
   Wechsler DA, 1987, WECHSLER MEMORY SCAL
   Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501
   Wieser HG, 2003, J NEUROSURG, V98, P751, DOI 10.3171/jns.2003.98.4.0751
   WILLIAMSON PD, 1993, ANN NEUROL, V34, P781, DOI 10.1002/ana.410340605
   WYLER AR, 1995, NEUROSURGERY, V37, P982, DOI 10.1227/00006123-199511000-00019
   Yasargil M G, 1985, Adv Tech Stand Neurosurg, V12, P93
NR 48
TC 110
Z9 117
U1 0
U2 4
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD JAN
PY 2006
VL 104
IS 1
BP 70
EP 78
DI 10.3171/jns.2006.104.1.70
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 001OX
UT WOS:000234547300012
PM 16509149
DA 2020-12-08
ER

PT J
AU Salamoni, SD
   da Costa, JC
   Palma, MS
   Konno, K
   Nihei, K
   Azambuja, NA
   Neto, EP
   Venturin, GT
   Tavares, AA
   de Abreu, DS
   Breda, RV
AF Salamoni, SD
   da Costa, JC
   Palma, MS
   Konno, K
   Nihei, K
   Azambuja, NA
   Neto, EP
   Venturin, GT
   Tavares, AA
   de Abreu, DS
   Breda, RV
TI The antiepileptic activity of JSTX-3 is mediated by N-methyl-D-aspartate
   receptors in human hippocampal neurons
SO NEUROREPORT
LA English
DT Article
DE epilepsy; hippocampus; JSTX-3; N-methyl-D-aspartate receptors
ID SPIDER TOXIN; AMPA
AB We analyzed the effect of the acylpolyaminetoxin JSTX-3 on the epileptogenic discharges induced by perfusion of human hippocampal slices with artificial cerebrospinal fluid lacking Mg2+ or N-methyl-D-aspartate. Hippocampi were surgically removed from patients with refractory medial temporal lobe epilepsy, sliced in the surgical room and taken to the laboratory immersed in normal artificial cerebrospinal fluid. Epileptiform activity was induced by perfusion with Mg2+-free artificial cerebrospinal fluid or by iontophoretically applied N-methyl-D-aspartate and intracellular and field recordings of CAI neurons were performed. The ictal-like discharges induced by Mg2+-free artificial cerebrospinal fluid and N-methyl-D-aspartate were blocked by incubation with JSTX-3. This effect was similar to that obtained with the N-methyl-D-aspartate receptor antagonist DL(-)2-amino-5 phosphonovaleric acid. Our findings suggest that in human hippocampal neurons, the antiepileptic effect of JSTX-3 is mediated by its action on N-methyl-D-aspartate receptor.
C1 Pontificia Univ Catolica Rio Grande do Sul, Neurosci Lab, Biomed Res Inst, BR-90610000 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Epilepsy Surg Program, BR-90610000 Porto Alegre, RS, Brazil.
   State Univ Sao Paulo, Dept Biol, Biosci Inst, Ctr Social Insects Study, Sao Paulo, Brazil.
   Fdn Res Support State Sao Paulo, Butantan Inst, Sao Paulo, Brazil.
   Fdn Res Support State Sao Paulo, Ctr Appl Toxicol, Ctr Res Innovat & Diffus, Sao Paulo, Brazil.
RP da Costa, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Lab Neurociencias, Inst Pesquisas Biomed, Av Ipiranga N 6690,2 Andar, BR-90610000 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI DaCosta, Jaderson/C-4968-2015; Palma, Mario/N-3903-2019; Palma, Mario
   Sergio/E-7800-2012; Salamoni, Simone/C-4126-2015
OI DaCosta, Jaderson/0000-0001-6776-1515; Palma, Mario
   Sergio/0000-0002-7363-8211; Teribele Venturin,
   Gianina/0000-0001-7696-8219; Salamoni, Simone
   Denise/0000-0003-4329-710X; Konno, Katsuhiro/0000-0002-1949-1845
CR ALNOORI S, 1998, FUNDAMENTOS NEUROBIO, P43
   ANDERSON WW, 1986, BRAIN RES, V398, P215, DOI 10.1016/0006-8993(86)91274-6
   Babb TL, 1996, EPILEPSY RES, V26, P193, DOI 10.1016/S0920-1211(96)00053-8
   BLASCHKE M, 1993, P NATL ACAD SCI USA, V90, P6528, DOI 10.1073/pnas.90.14.6528
   CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x
   DINGLEDINE R, 1994, MOL CELLULAR MED ASP, P367
   Engel J, 1996, EPILEPSY RES, V26, P141, DOI 10.1016/S0920-1211(96)00043-5
   HAUSER WA, 2001, EPILEPSY SURG, P55
   Henderson Graeme, 1993, V116, P89
   HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335
   KAWAI N, 1982, BRAIN RES, V247, P169, DOI 10.1016/0006-8993(82)91044-7
   Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503
   Mathern GW, 1997, BRAIN, V120, P1937, DOI 10.1093/brain/120.11.1937
   MCCORMICK KD, 1993, J CHEM ECOL, V19, P2411, DOI 10.1007/BF00979674
   MCILWAIN H, 1953, BIOCHEM J, V53, P412, DOI 10.1042/bj0530412
   MIYATA H, 1992, BRAIN RES, V581, P101, DOI 10.1016/0006-8993(92)90348-D
   NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206
   Niemeyer P., 1958, TEMPORAL LOBE EPILEP, P461
   Nihei K, 2002, BIOORG MED CHEM LETT, V12, P299, DOI 10.1016/S0960-894X(01)00733-8
   PRIESTLEY T, 1989, BRIT J PHARMACOL, V97, P1315, DOI 10.1111/j.1476-5381.1989.tb12594.x
   PRINCE DA, 1981, BRAIN RES, V210, P323, DOI 10.1016/0006-8993(81)90905-7
   SAITO M, 1985, BRAIN RES, V346, P397, DOI 10.1016/0006-8993(85)90878-9
   Salamoni SD, 2005, BRAIN RES, V1048, P170, DOI 10.1016/j.brainres.2005.04.060
   Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433
   TRAUB RD, 1994, J PHYSIOL-LONDON, V478, P379, DOI 10.1113/jphysiol.1994.sp020259
NR 25
TC 6
Z9 7
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4965
EI 1473-558X
J9 NEUROREPORT
JI Neuroreport
PD NOV 7
PY 2005
VL 16
IS 16
BP 1869
EP 1873
DI 10.1097/01.wnr.0000185012.98821.2b
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 984BO
UT WOS:000233277700030
PM 16237345
DA 2020-12-08
ER

PT J
AU Palmini, A
   Halasz, P
   Scheffer, IE
   Takahashi, Y
   Jimenez, AP
   Dubeau, F
   Andermann, F
   Paglioli-Neto, E
   da Costa, JC
   Rosenow, F
   Fritsch, B
AF Palmini, A
   Halasz, P
   Scheffer, IE
   Takahashi, Y
   Jimenez, AP
   Dubeau, F
   Andermann, F
   Paglioli-Neto, E
   da Costa, JC
   Rosenow, F
   Fritsch, B
TI Reflex seizures in patients with malformations of cortical development
   and refractory epilepsy
SO EPILEPSIA
LA English
DT Article
DE reflex seizures; malformations of cortical development; high degrees of
   epileptogenicity
ID NEURONAL MIGRATION DISORDERS; INTRINSIC EPILEPTOGENICITY; INTRACTABLE
   EPILEPSY; PARTIALIS CONTINUA; STATUS VERRUCOSUS; LOBE EPILEPSY;
   DYSPLASIA; EEG; DISCHARGES; MICROGYRIA
AB Purpose: Malformations of cortical development (MCDs) are usually highly epileptogenic, and their hyperexcitability could facilitate the occurrence of reflex seizures. We sought to characterize reflex seizures in patients with MCDs and refractory epilepsy.
   Methods: Clinical, electrographic, and neuroimaging data were reviewed in eight patients with MCDs who had reflex seizures reproduced during presurgical evaluation.
   Results: All eight patients had both reflex and spontaneous seizures. In six, however, drop attacks or axial myoclonic seizures occurred only upon specific sensory stimulation. Reflex seizures were induced by more than one type of stimulus in most patients, but anatomofunctional correlations could usually be invoked. Six patients had significant intellectual impairment. Surgical resection controlled seizures in two patients.
   Conclusions: Reflex seizures in patients with MCDs may be medically refractory and may often manifest as drop attacks or axial myoclonus. Surgical resection of focal lesions can bring reflex seizures under control. Putative mechanisms related to the relatively low frequency of reflex seizures in MCDs are discussed.
C1 Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Neurol Serv, Porto Alegre Epilepsy Surg Program, BR-90610000 Porto Alegre, RS, Brazil.
   Epilepsy Ctr, Natl Inst Psychiat & Neurol, Budapest, Hungary.
   Univ Melbourne, Austin Hosp, Melbourne, Vic, Australia.
   Monash Med Ctr, Melbourne, Vic, Australia.
   Gifu Prefectural Hosp, Dept Pediat, Gifu, Japan.
   Hosp Nino Jesus, Dept Pediat, Madrid, Spain.
   McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Hosp & Inst, Montreal, PQ, Canada.
   Philips Univ, Dept Neurol, Interdisciplinary Epilepsy Ctr, Marburg, Germany.
RP Palmini, A (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Neurol Serv, Porto Alegre Epilepsy Surg Program, Ave Ipiranga,6690, BR-90610000 Porto Alegre, RS, Brazil.
EM apalmini@uol.com.br
RI Scheffer, Ingrid E/G-1668-2013; DaCosta, Jaderson/C-4968-2015
OI Scheffer, Ingrid E/0000-0002-2311-2174; DaCosta,
   Jaderson/0000-0001-6776-1515; Fritsch, Brita/0000-0003-4884-9049;
   Takahashi, Yukitoshi/0000-0002-1922-8967
CR ANDERMANN F, 1992, BRAIN DEV-JPN, V14, P338, DOI 10.1016/S0387-7604(12)80155-0
   Avoli M, 1999, ANN NEUROL, V46, P816, DOI 10.1002/1531-8249(199912)46:6<816::AID-ANA3>3.0.CO;2-O
   Bartolomei F, 2004, EPILEPSY RES, V61, P89, DOI 10.1016/j.eplepsyres.2004.06.006
   Bartolomei F, 2001, CLIN NEUROPHYSIOL, V112, P1746, DOI 10.1016/S1388-2457(01)00591-0
   Biraben A, 1999, EPILEPSIA, V40, P655, DOI 10.1111/j.1528-1157.1999.tb05570.x
   Canevini MP, 2001, EPILEPTIC DISORD, V3, P143
   Colacitti C, 1998, EPILEPSY RES, V32, P49, DOI 10.1016/S0920-1211(98)00039-4
   DACOSTA CJ, 1996, EPILIPSIA, V37, P37
   Deonna T, 1998, Adv Neurol, V75, P193
   DESBIENS R, 1993, ARCH NEUROL-CHICAGO, V50, P695, DOI 10.1001/archneur.1993.00540070015007
   Dubeau F, 1998, ELECTROEN CLIN NEURO, P77
   DVORAK K, 1978, ACTA NEUROPATHOL, V44, P121
   FERRER I, 1993, EXP BRAIN RES, V94, P261
   Gambardella A, 1996, ELECTROEN CLIN NEURO, V98, P243, DOI 10.1016/0013-4694(95)00266-9
   GUERRINI R, 1995, EPILEPSIA, V36, P883, DOI 10.1111/j.1528-1157.1995.tb01631.x
   Hablitz JJ, 1998, EPILEPSY RES, V32, P75, DOI 10.1016/S0920-1211(98)00041-2
   Hannan AJ, 1999, BRAIN, V122, P219, DOI 10.1093/brain/122.2.219
   Hennessy MJ, 2000, EPILEPSIA, V41, P59, DOI 10.1111/j.1528-1157.2000.tb01506.x
   Innocenti GM, 2001, ANN NEUROL, V50, P672, DOI 10.1002/ana.1262
   Inoue Y., 1994, EPILEPTIC SEIZURES S, P81
   Ioos C, 2000, J CHILD NEUROL, V15, P125, DOI 10.1177/088307380001500211
   Jacobs KM, 1999, J NEUROPHYSIOL, V81, P159
   Janszky J, 2003, ANN NEUROL, V53, P759, DOI 10.1002/ana.10545
   KASTELEIJNNOLST TD, 1989, ACTA NEUROL SCA S125, V80, P1
   Koutroumanidis M, 2001, EPILEPSIA, V42, P686, DOI 10.1046/j.1528-1157.2001.32700.x
   KUZNIECKY R, 1993, J CHILD NEUROL, V8, P386, DOI 10.1177/088307389300800419
   KUZNIECKY R, 1995, DEV MED CHILD NEUROL, V37, P159
   Librizzi L, 2003, ANN NEUROL, V53, P382, DOI 10.1002/ana.10471
   Manford MRA, 1996, J NEUROL NEUROSUR PS, V61, P151, DOI 10.1136/jnnp.61.2.151
   Martinez O, 2001, NEUROLOGY, V56, P121, DOI 10.1212/WNL.56.1.121
   MOLYNEUX PD, 1997, J NEUROL NEUROSUR PS, V20, P137
   Morioka T, 1999, EPILEPSY RES, V33, P177, DOI 10.1016/S0920-1211(98)00096-5
   Naquet Robert Gustave, 1998, V75, P15
   Nishio S, 1999, NEUROPATH APPL NEURO, V25, P188
   OBrien TJ, 1996, EPILEPSIA, V37, P694, DOI 10.1111/j.1528-1157.1996.tb00636.x
   Palmini A, 2002, NEUROSURG CLIN N AM, V13, P1, DOI 10.1016/S1042-3680(02)80002-X
   PALMINI A, 1991, ANN NEUROL, V30, P741, DOI 10.1002/ana.410300602
   PALMINI A, 1995, ANN NEUROL, V37, P476, DOI 10.1002/ana.410370410
   PALMINI A, 1997, EPILEPSIA S3, V38, P31
   PALMINI A, 1997, EPILEPSIA, V38, P5
   Palmini Andre, 2000, Current Opinion in Neurology, V13, P183, DOI 10.1097/00019052-200004000-00012
   Panayiotopoulos C. P., 1996, P355
   PANAYIOTOPOULOS CP, 1989, BRAIN, V112, P1039, DOI 10.1093/brain/112.4.1039
   PAZZAGLIA P, 1985, NEUROLOGY, V35, P1725, DOI 10.1212/WNL.35.12.1725
   Racine R, 1975, Can J Neurol Sci, V2, P395
   Rosenow M, 1998, EPILEPSIA, V39, P850, DOI 10.1111/j.1528-1157.1998.tb01179.x
   Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256
   Serles W, 1999, EPILEPSIA, V40, P1031, DOI 10.1111/j.1528-1157.1999.tb00813.x
   SILVA LF, 1995, EPILEPSIA, V36, P148
   Sisodiya SM, 2000, BRAIN, V123, P1075, DOI 10.1093/brain/123.6.1075
   Spreafico R, 1998, EPILEPSY RES, V32, P34, DOI 10.1016/S0920-1211(98)00038-2
   Spreafico R, 2000, EPILEPSIA, V41, pS168, DOI 10.1111/j.1528-1157.2000.tb01576.x
   Tassi L, 2002, BRAIN, V125, P1719, DOI 10.1093/brain/awf175
   TASSINARI CA, 1997, EPILEPSY COMPREHENSI, P605
   Vignal J P, 1998, Adv Neurol, V75, P207
   Wendling F, 2003, BRAIN, V126, P1449, DOI 10.1093/brain/awg144
   Wieser H G, 1998, Adv Neurol, V75, P69
   WOLF P, 1986, J NEUROL NEUROSUR PS, V49, P1386, DOI 10.1136/jnnp.49.12.1386
   Ying Z, 2002, NEUROSURG CLIN N AM, V13, P27, DOI 10.1016/S1042-3680(02)80004-3
   Zifkin BG, 2000, EPILEPTIC DISORD, V2, P129
NR 60
TC 22
Z9 23
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD AUG
PY 2005
VL 46
IS 8
BP 1224
EP 1234
DI 10.1111/j.1528-1167.2005.52904.x
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 949DI
UT WOS:000230764700009
PM 16060932
DA 2020-12-08
ER

PT J
AU Schmutzler, KMRS
   Nunes, ML
   da Costa, JC
AF Schmutzler, KMRS
   Nunes, ML
   da Costa, JC
TI The relationship between ictal activity and sleep stages in the newborn
   EEG
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE ictal activity; sleep; REM sleep; NREM sleep; newborn EEG; neonatal
   seizures
ID NEONATAL SEIZURES; ELECTROGRAPHIC SEIZURES; PREMATURE-INFANTS;
   REM-SLEEP; MATURATION; EPILEPSY; RISK; AGE; PRETERM; BRAIN
AB Objective: To verify the relationship of ictal activity and sleep organization (REM/NREM stages) in the neonatal EEG.
   Methods: A retrospective study was developed with 41 high-risk newborns, with clinical history suggestive of seizures and ictal activity identified by the EEG. In each EEG, sleep organization and number/duration of sleep stages were determined. Sleep stages (REM, NREM) were scored following behavior and EEG activity. When it was impossible to recognize stages the epoch was classified as unrecognizable sleep stages (UNSS). Ictal activity was classified according to morphology and correlated with sleep epochs. Density of ictal activity was calculated as the duration of the discharge divided by the duration of the sleep epoch.
   Results: Unrecognizable sleep stages were observed in 21 EEGs (51.2%). Comparing NREM X REM states there was a significant predominance of ictal activity in REM sleep (P=0.01). Duration of discharges was longer on REM epochs; however, differences were not significant. Considering the type of discharges there was a predominance of monomorphic rhythmic discharges in all sleep epochs.
   Conclusions: In this sample, epileptogenic activity occurred more frequently in UNSS, where sleep organization was already disrupted. When it was possible to recognize sleep stages, ictal activity was more frequently during REM sleep.
   Significance: This study speculates the relationship between sleep organization and ictal activity and raises the hypothesis that the expression of ictal activity in relation to sleep stages (REM/NREM) may have age-dependent mechanisms in the developing brain. (c) 2005 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
C1 PUCRS, Div Neurol, Sch Med, Porto Alegre, RS, Brazil.
   Hosp Sao Lucas PUCRS, Clin Neurophysiol Lab, Porto Alegre, RS, Brazil.
RP Nunes, ML (corresponding author), Hosp Sao Lucas PUCRS, Div Neurol, Av Ipiranga 6690-220, BR-90610000 Porto Alegre, RS, Brazil.
EM nunes@pucrs.br
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR Anders T, 1971, MANUAL STANDARDIZED
   BANCAUD J, 1981, EPILEPSIA, V22, P489, DOI 10.1111/j.1528-1157.1981.tb06159.x
   CURZI-DASCALOVA L, 1992, Neurophysiologie Clinique, V22, P151, DOI 10.1016/S0987-7053(05)80751-8
   CURZIDASCALOVA L, 1977, REV EEG NEUROPHYSIOL, V7, P316, DOI 10.1016/S0370-4475(77)80010-5
   CURZIDASCALOVA L, 1993, PEDIATR RES, V34, P624, DOI 10.1203/00006450-199311000-00013
   CURZIDASCALOVA L, 1981, REV ELECTROENCEPHALO, V1191, P1
   Da Silva LFG, 2004, PEDIATR NEUROL, V30, P271, DOI 10.1016/j.pediatrneurol.2003.09.015
   Douglass LM, 2002, J CHILD NEUROL, V17, P403, DOI 10.1177/088307380201700601
   KANDEL ER, 2000, PRINCIPLES NEURAL SC, P936
   Kohyama J, 1996, J NEUROL SCI, V143, P150, DOI 10.1016/S0022-510X(96)00209-2
   Lamblin MD, 1999, NEUROPHYSIOL CLIN, V29, P123, DOI 10.1016/S0987-7053(99)80051-3
   Laroia N, 1998, EPILEPSIA, V39, P545, DOI 10.1111/j.1528-1157.1998.tb01418.x
   LOMBROSO CT, 1979, ELECTROEN CLIN NEURO, V46, P460, DOI 10.1016/0013-4694(79)90147-0
   Lombroso CT, 1996, BRAIN DEV-JPN, V18, P1, DOI 10.1016/S0387-7604(96)90001-7
   Lombroso CT, 1993, ELECTROENCEPHALOGRAP, P803
   McBride MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506
   Menache CC, 2002, PEDIATR NEUROL, V27, P93, DOI 10.1016/S0887-8994(02)00396-X
   MIZRAHI EM, 1998, DIAGNOSIS MANAGEMENT, P15
   Moshe S L, 1987, Epilepsia, V28 Suppl 1, pS3, DOI 10.1111/j.1528-1157.1987.tb05753.x
   Moshe SL, 2000, NEUROLOGY, V55, pS15
   MOSHE SL, 1997, TREATMENT EPILEPSY P, P139
   NUNES ML, 1997, ELECTROENCEPHALOGR C, V102, P191
   NUNES ML, 1994, JLBE, V7, P27
   Oliveira AJ, 2000, CLIN NEUROPHYSIOL, V111, pS74, DOI 10.1016/S1388-2457(00)00405-3
   Oliveira AJ, 2000, CLIN NEUROPHYSIOL, V111, P1646, DOI 10.1016/S1388-2457(00)00380-1
   PARMELEE AH, 1968, ELECTROEN CLIN NEURO, V24, P319, DOI 10.1016/0013-4694(68)90193-4
   Patrizi S, 2003, BRAIN DEV-JPN, V25, P427, DOI 10.1016/S0387-7604(03)00031-7
   SAMMARITANO M, 1991, NEUROLOGY, V41, P290, DOI 10.1212/WNL.41.2_Part_1.290
   SCHER MS, 1993, PEDIATRICS, V91, P128
   Scher MS, 2002, EPILEPTIC DISORD, V4, P139
   SCHER MS, 1999, ELECTROENCEPHALOGRAP, P936
   SHEWMON DA, 1990, J CLIN NEUROPHYSIOL, V7, P315, DOI 10.1097/00004691-199007000-00003
   SHOULDERS K, 1996, J NEW ENERGY, V1, P3
   Shouse MN, 2000, CLIN NEUROPHYSIOL, V111, pS9, DOI 10.1016/S1388-2457(00)00397-7
   STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588
   Veliskova J, 1996, EUR J PHARMACOL, V309, P167
   VINING EPG, 1990, EPILEPSIA, V31, pS30, DOI 10.1111/j.1528-1157.1990.tb05857.x
NR 37
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1388-2457
EI 1872-8952
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD JUL
PY 2005
VL 116
IS 7
BP 1520
EP 1532
DI 10.1016/j.clinph.2005.02.024
PG 13
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 942QL
UT WOS:000230296800006
PM 15953557
DA 2020-12-08
ER

PT J
AU Salamoni, SD
   da Costa, JC
   Palma, MS
   Konno, K
   Nihei, K
   Tavares, AA
   de Abreu, DS
   Venturin, GT
   Cunha, FD
   de Oliveira, RM
   Breda, RV
AF Salamoni, SD
   da Costa, JC
   Palma, MS
   Konno, K
   Nihei, K
   Tavares, AA
   de Abreu, DS
   Venturin, GT
   Cunha, FD
   de Oliveira, RM
   Breda, RV
TI Antiepileptic effect of acylpolyaminetoxin JSTX-3 on rat hippocampal CA1
   neurons in vitro
SO BRAIN RESEARCH
LA English
DT Article
DE JSTX-3; pilocarpine; epilepsy; NMDA; hippocampus
ID SPIDER TOXIN; EPILEPTIFORM ACTIVITY; PILOCARPINE; AMPA; EXPRESSION;
   RECEPTORS; SEIZURE; MODEL
AB The Joro spider toxin (JSTX-3), derived from Nephila clavata, has been found to block glutamate excitatory activity. Epilepsy has been studied in vitro, mostly on rat hippocampus, through brain slices techniques. The aim of this study is to verify the effect of the JSTX-3 on the epileptiform activity induced by magnesium-free medium in rat CA1 hippocampal neurons. Experiments were performed on hippocampus slices of control and pilocarpine-treated Wistar rats, prepared and maintained in vitro. Epileptiform activity was induced through omission of magnesium from the artificial cerebrospinal fluid (0-Mg2+ ACSF) superfusate and iontophoretic application of N-methyl-D-aspartate (NMDA). Intracellular recordings were obtained from CA] pyramidal neurons both of control and epileptic rats. Passive membrane properties were analyzed before and after perfusion with the 0-Mg2+ ACSF and the application of toxin JSTX-3. During the ictal-like activity, the toxin JSTX-3 was applied by pressure ejection, abolishing this activity. This effect was completely reversed during the washout period 2. when the slices were formerly perfused with artificial cerebrospinal fluid (ACSF) and again with 0-Mg2+ ACSF. Our results suggest that the toxin JSTX-3 is a potent blocker of induced epileptiform activity. (c) 2005 Elsevier B.V. All rights reserved.
C1 Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Lab Neurociencias, Porto Alegre, RS, Brazil.
   UNESP, Inst Biociencias, Dept Biol, CEIS,Lab Biol Estrutural, Rio Claro, SP, Brazil.
   Inst Butantan, Sao Paulo, SP, Brazil.
RP da Costa, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Inst Pesquisas Biomed, Lab Neurociencias, Av Ipiranga 6690, BR-90610000 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI Palma, Mario/N-3903-2019; Salamoni, Simone/C-4126-2015; DaCosta,
   Jaderson/C-4968-2015; Cunha, Fernando Q/M-3090-2014; Palma, Mario
   Sergio/E-7800-2012
OI DaCosta, Jaderson/0000-0001-6776-1515; Palma, Mario
   Sergio/0000-0002-7363-8211; Konno, Katsuhiro/0000-0002-1949-1845;
   Salamoni, Simone Denise/0000-0003-4329-710X; Teribele Venturin,
   Gianina/0000-0001-7696-8219
CR AIDLEY DJ, 1996, ION CHANNELS MOL ACT, P225
   ALNOORI S, 1998, FUNDAMENTOS NEUROBIO, V1, P43
   ANDERSON WW, 1986, BRAIN RES, V398, P215, DOI 10.1016/0006-8993(86)91274-6
   Babb TL, 1996, EPILEPSY RES, V26, P193, DOI 10.1016/S0920-1211(96)00053-8
   BASHIR ZI, 1997, NEUROSCIENCE LABFAX, P13
   BERNARD C, 1995, EPILEPSY RES, V21, P95, DOI 10.1016/0920-1211(95)00017-5
   BLASCHKE M, 1993, P NATL ACAD SCI USA, V90, P6528, DOI 10.1073/pnas.90.14.6528
   CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x
   Chen J, 2005, NEUROSCI LETT, V375, P192, DOI 10.1016/j.neulet.2004.11.008
   Costa MS, 2004, NEUROSCI LETT, V356, P41, DOI 10.1016/j.neulet.2003.11.019
   Dingledine R., 1984, BRAIN SLICES
   Dingledine Raymond, 1994, P367
   Freitas RM, 2004, NEUROSCI LETT, V365, P102, DOI 10.1016/j.neulet.2004.04.060
   GRIGOR'EV V V, 1989, Byulleten' Eksperimental'noi Biologii i Meditsiny, V108, P299
   HASHIMOTO Y, 1987, TETRAHEDRON LETT, V28, P3511, DOI 10.1016/S0040-4039(00)96340-8
   HAUSER WA, 2001, EPILEPSY SURG, P55
   HENDERSON G, 1993, ELECTROPHYSIOLOGY PR, P89
   HERLITZE S, 1993, NEURON, V10, P1131, DOI 10.1016/0896-6273(93)90061-U
   Hille B., 1984, IONIC CHANNELS EXCIT
   HIMI T, 1990, J NEURAL TRANSM, V80, P29
   HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335
   KAWAI N, 1982, BRAIN RES, V247, P169, DOI 10.1016/0006-8993(82)91044-7
   KOHLING R, SPONTANEOUS SHARP WA
   Kral T, 2003, SYNAPSE, V47, P278, DOI 10.1002/syn.10178
   Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503
   Mathern GW, 1997, BRAIN, V120, P1937, DOI 10.1093/brain/120.11.1937
   MCCORMICK KD, 1993, J CHEM ECOL, V19, P2411, DOI 10.1007/BF00979674
   MELLMWAIN H, 1953, BIOCHEM J, V53, P412
   MIYATA H, 1992, BRAIN RES, V581, P101, DOI 10.1016/0006-8993(92)90348-D
   NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206
   Nihei K, 2002, BIOORG MED CHEM LETT, V12, P299, DOI 10.1016/S0960-894X(01)00733-8
   Palma Mario Sergio, 1997, Natural Toxins, V5, P47, DOI 10.1002/(SICI)(1997)5:2<47::AID-NT1>3.0.CO;2-X
   PRIESTLEY T, 1989, BRIT J PHARMACOL, V97, P1315, DOI 10.1111/j.1476-5381.1989.tb12594.x
   Prince D A, 1986, Adv Neurol, V44, P275
   RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0
   Raza M, 2004, P NATL ACAD SCI USA, V101, P17522, DOI 10.1073/pnas.0408155101
   SAITO M, 1985, BRAIN RES, V346, P397, DOI 10.1016/0006-8993(85)90878-9
   Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433
   Scorza CA, 2005, NEUROSCI RES, V51, P285, DOI 10.1016/j.neures.2004.12.002
   Smolders I, 1997, BRIT J PHARMACOL, V121, P1171, DOI 10.1038/sj.bjp.0701231
   TRAUB RD, 1994, J PHYSIOL-LONDON, V478, P379, DOI 10.1113/jphysiol.1994.sp020259
NR 41
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD JUN 28
PY 2005
VL 1048
IS 1-2
BP 170
EP 176
DI 10.1016/j.brainres.2005.04.060
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 942CD
UT WOS:000230259600020
PM 15913572
DA 2020-12-08
ER

PT J
AU Dalbem, A
   Silveira, CV
   Pedroso, MF
   Breda, RV
   Baes, CV
   Bartmann, AP
   da Costa, JC
AF Dalbem, A
   Silveira, CV
   Pedroso, MF
   Breda, RV
   Baes, CV
   Bartmann, AP
   da Costa, JC
TI Altered distribution of striatal activity-dependent synaptic plasticity
   in the 3-nitropropionic acid model of Huntington's disease
SO BRAIN RESEARCH
LA English
DT Article
DE long-term potentiation; long-term depression; synaptic plasticity;
   corticostriatal slices; 3-nitropropionic acid; Huntington's disease
ID LONG-TERM POTENTIATION; MITOCHONDRIAL COMPLEX II; MUSCARINIC RECEPTORS;
   CORTICOSTRIATAL SYNAPSES; SUCCINATE-DEHYDROGENASE; RAT NEOSTRIATUM;
   VISUAL-CORTEX; IN-VIVO; ACTIVATION; DEPRESSION
AB Huntington's disease (HD) is a neurodegenerative disorder characterized by involuntary choreiform movements, neuropsychiatric, disturbances and cognitive decline. The hyperkinetic phenomenology has commonly been attributed to a disturbance of the basal ganglia function, mainly the neostriatum, but its pathophysiology mechanisms remain unclear. Activity-dependent long-term changes in synaptic efficacy, such as long-term potentiation (LTP) and long-term depression (LTD), are widely considered to be the cellular models for acquisition and storage of information in neuronal networks. Both LTP and LTD have been described at the corticostriatal pathway and they might be probably involved not only in physiological motor behavior processing but also in disease states affecting that pathway. Systemic injection of 3-nitropropionic acid (3-NP) induces excitotoxic striatal lesions and abnormal movements in rodents, resembling those seen in HD. We examined synaptic plasticity in dorsolateral striatum slices prepared from both control and 3-NP-treated rats by recording extracellular field potentials. Our results reinforce the idea that both forms of activity-dependent synaptic plasticity can be recorded at the dorsolateral region of striatum by the same stimulating protocol in control rats and suggest that 3-NP-induced striatal lesions may be associated with suppression of LTD expression in the sensorimotor striatum. (c) 2005 Elsevier B.V All rights reserved.
C1 Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Neurosci Lab, Inst Pesquisas Biomed,Biomed Res Inst, Porto Alegre, RS, Brazil.
RP da Costa, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Neurosci Lab, Inst Pesquisas Biomed,Biomed Res Inst, Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI DaCosta, Jaderson/C-4968-2015; Baes, Cristiane/AAB-9331-2020
OI DaCosta, Jaderson/0000-0001-6776-1515; Baes,
   Cristiane/0000-0001-5361-9091
CR Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X
   ALSTON TA, 1977, P NATL ACAD SCI USA, V74, P3767, DOI 10.1073/pnas.74.9.3767
   BEAL MF, 1993, J NEUROCHEM, V61, P1147, DOI 10.1111/j.1471-4159.1993.tb03633.x
   BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202
   BEAL MF, 1993, J NEUROSCI, V13, P4181
   BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0
   BORLONGAN CV, 1995, BRAIN RES BULL, V36, P549, DOI 10.1016/0361-9230(94)00242-S
   Calabresi P, 1998, EUR J NEUROSCI, V10, P3020, DOI 10.1046/j.1460-9568.1998.00348.x
   Calabresi P, 2001, J NEUROSCI, V21, P5110, DOI 10.1523/JNEUROSCI.21-14-05110.2001
   CALABRESI P, 1992, NEUROSCI LETT, V142, P95, DOI 10.1016/0304-3940(92)90628-K
   Calabresi P, 1999, NEUROPHARMACOLOGY, V38, P323, DOI 10.1016/S0028-3908(98)00199-3
   CALABRESI P, 1992, J NEUROSCI, V12, P4224
   CALABRESI P, 1992, EUR J NEUROSCI, V4, P929, DOI 10.1111/j.1460-9568.1992.tb00119.x
   Castro-Alamancos MA, 1999, J NEUROSCI, V19, P9090, DOI 10.1523/JNEUROSCI.19-20-09090.1999
   Charpier S, 1997, P NATL ACAD SCI USA, V94, P7036, DOI 10.1073/pnas.94.13.7036
   COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4
   COLES CJ, 1979, J BIOL CHEM, V254, P5161
   Deshpande SB, 1997, EXP NEUROL, V145, P38, DOI 10.1006/exnr.1997.6457
   FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U
   Fukuda A, 1998, NEUROSCIENCE, V87, P497, DOI 10.1016/S0306-4522(98)00139-0
   Guyot MC, 1997, NEUROSCIENCE, V79, P45, DOI 10.1016/S0306-4522(96)00602-1
   HASSEL B, 1995, J NEUROCHEM, V65, P1184
   He FS, 1995, NEUROLOGY, V45, P2178, DOI 10.1212/WNL.45.12.2178
   Holland LL, 1998, J NEUROSCI, V18, P887
   Huang CC, 2001, REV NEUROSCIENCE, V12, P51
   HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729
   Izaki Y, 2003, NEUROSCI LETT, V345, P69, DOI 10.1016/S0304-3940(03)00492-0
   Kim GW, 2000, J CEREBR BLOOD F MET, V20, P119, DOI 10.1097/00004647-200001000-00016
   Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0
   LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0
   Lee WT, 2002, NEUROSCIENCE, V113, P699, DOI 10.1016/S0306-4522(02)00177-X
   LOVINGER DM, 1993, J NEUROPHYSIOL, V70, P1937
   MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E
   MARTIN JB, 1986, NEW ENGL J MED, V315, P1267
   MISGELD U, 1980, EXP BRAIN RES, V39, P401
   Nishino H, 1996, J CHEM NEUROANAT, V10, P209, DOI 10.1016/0891-0618(96)00134-2
   O'Dell T J, 1994, Learn Mem, V1, P129
   Palfi S, 2000, MOVEMENT DISORD, V15, P524, DOI 10.1002/1531-8257(200005)15:3<524::AID-MDS1016>3.0.CO;2-F
   Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884
   Partridge JG, 2000, J NEUROPHYSIOL, V84, P1422
   Philpot BD, 2003, J NEUROSCI, V23, P5583
   Picconi B, 2003, NAT NEUROSCI, V6, P501, DOI 10.1038/nn1040
   QUARY S, 2000, NEUROSCIENCE, V97, P521
   Saulle E, 2004, MOL CELL NEUROSCI, V25, P9, DOI 10.1016/j.mcn.2003.09.013
   Smith R, 2001, NEUROSCIENCE, V106, P95, DOI 10.1016/S0306-4522(01)00260-3
   Spencer JP, 2000, EXP BRAIN RES, V135, P497, DOI 10.1007/s002210000523
   Steele PM, 1999, J NEUROPHYSIOL, V81, P1559
   Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E
   Villar FD, 1999, NEUROSCIENCE, V90, P1031, DOI 10.1016/S0306-4522(98)00504-1
   Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369
   WALSH JP, 1993, NEUROSCIENCE, V57, P241, DOI 10.1016/0306-4522(93)90059-O
   WULLNER U, 1994, J NEUROCHEM, V63, P1772
NR 52
TC 24
Z9 24
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD JUN 21
PY 2005
VL 1047
IS 2
BP 148
EP 158
DI 10.1016/j.brainres.2005.04.030
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 939MH
UT WOS:000230076500003
PM 15901483
DA 2020-12-08
ER

PT J
AU Nunes, ML
   Giraldes, MM
   Pinho, AP
   da Costa, JC
AF Nunes, ML
   Giraldes, MM
   Pinho, AP
   da Costa, JC
TI Prognostic value of non-reactive burst suppression EEG pattern
   associated to early neonatal seizures
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE neonatal EEG; neonatal seizures; burst-suppression pattern; neonatal
   epileptic syndromes
ID FULL-TERM; MYOCLONIC ENCEPHALOPATHY; ELECTROGRAPHIC SEIZURES; PRETERM;
   INFANTS; ELECTROENCEPHALOGRAPHY; EPILEPSY; NEWBORN; RISK
AB Seizures are the most frequent neurological event in newborns and clinical data suggest that etiology is the dominant factor in long term outcome. However, there are consistent background EEG abnormalities associated to neonatal seizures that are usually related to unfavorable outcome as the burst-suppression pattern. Objective: The objective of this study was to correlate clinical and EEG features associated to long-term outcome of newborns with non-reactive burst-suppression (BS) EEG. Method: Newborns included in the study were selected from our database and had conceptional age (at the time of first EEG) > 37 weeks, EEG recordings with non-reactive BS available for review and clinical follow up. Results: 12 newborns met inclusion criteria, 50% had seizures in the first day of life. Seizures became refractory to treatment in all of them. In 50% the etiology of seizures was considered cryptogenic, 33% had inborn errors of metabolism and 17% had clinical history and neuroimage suggestive of hypoxic-ischemic encephalopathy. The follow-up showed that 7/12 infants deceased, 3 during the first year of life, and one in the neonatal period. All the survivors had severe developmental delay and multifocal neurological impairment. 92% developed refractory epilepsy, 58% were latter diagnosed with West syndrome. Conclusion: The non-reactive BS pattern may appear related to many neonatal neurological disorders and is associated,with early and refractory neonatal seizures. it is clearly associated with elevated morbidity and mortality and to the development of post-neonatal epilepsy.
C1 PUCRS, Hosp Sao Lucas, Sch Med, Neurol Serv,Clin Neurophysiol Lab, BR-90610000 Porto Alegre, RS, Brazil.
   PUCRS, Sch Med, Div Neurol, BR-90610000 Porto Alegre, RS, Brazil.
RP Nunes, ML (corresponding author), PUCRS, Hosp Sao Lucas, Sch Med, Neurol Serv,Clin Neurophysiol Lab, Avenida Ipiranga 6690-220, BR-90610000 Porto Alegre, RS, Brazil.
EM nunes@pucrs.b
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR AICARDI J, 1978, REV EEG NEUROPHYSIOL, V8, P99, DOI 10.1016/S0370-4475(78)80124-5
   ASO K, 1989, J CLIN NEUROPHYSIOL, V6, P103, DOI 10.1097/00004691-198904000-00001
   BIAGIONI E, 1994, ELECTROEN CLIN NEURO, V91, P154, DOI 10.1016/0013-4694(94)90065-5
   Bye AME, 1997, PEDIATR NEUROL, V16, P225, DOI 10.1016/S0887-8994(97)00019-2
   CLANCY RR, 1991, EPILEPSIA, V32, P69, DOI 10.1111/j.1528-1157.1991.tb05614.x
   CURZI L, 1996, MANUEL TECHNIQUES EN
   DASILVA LFG, 2004, PEDIAT NEUROL, V30
   Douglass LM, 2002, J CHILD NEUROL, V17, P403, DOI 10.1177/088307380201700601
   ELLENBERG JH, 1984, ANN NEUROL, V15, P127, DOI 10.1002/ana.410150204
   FRANKENBURG WK, 1992, PEDIATRICS, V89, P91
   GRIGGDAMBERGER MM, 1989, PEDIATR NEUROL, V5, P84, DOI 10.1016/0887-8994(89)90032-5
   HOLMES GL, 1993, J CLIN NEUROPHYSIOL, V10, P323, DOI 10.1097/00004691-199307000-00008
   HOLMES GL, 1983, AM J DIS CHILD, V137, P21
   LANSKA MJ, 1995, NEUROLOGY, V45, P724, DOI 10.1212/WNL.45.4.724
   LEGIDO A, 1991, PEDIATRICS, V88, P583
   Lombroso C T, 1983, Adv Neurol, V34, P101
   Lombroso CT, 1996, BRAIN DEV-JPN, V18, P1, DOI 10.1016/S0387-7604(96)90001-7
   McBride MC, 2000, NEUROLOGY, V55, P506, DOI 10.1212/WNL.55.4.506
   Menache CC, 2002, PEDIATR NEUROL, V27, P93, DOI 10.1016/S0887-8994(02)00396-X
   MONOD N, 1972, ELECTROEN CLIN NEURO, V32, P529, DOI 10.1016/0013-4694(72)90063-6
   NUNES ML, 1995, ARQ NEURO-PSIQUIAT, V53, P625, DOI 10.1590/S0004-282X1995000400013
   NUNES ML, 1994, JLBE, V7, P27
   Ohtahara S, 1976, NO TO HATTATSU TOKYO, V8, P270, DOI [10.11251/ojjscn1969.8.270, DOI 10.11251/OJJSCN1969.8.270]
   Oliveira AJ, 2000, CLIN NEUROPHYSIOL, V111, P1646, DOI 10.1016/S1388-2457(00)00380-1
   Ortibus EL, 1996, ELECTROEN CLIN NEURO, V98, P175, DOI 10.1016/0013-4694(95)00245-6
   PEZZANI C, 1986, NEUROPEDIATRICS, V17, P11, DOI 10.1055/s-2008-1052492
   RONEN GM, 1995, ANN NEUROL, V38, P518
   Saliba Rima M., 1996, Epilepsia, V37, P13
   SCHER MS, 1993, PEDIATRICS, V91, P128
   SPREAFICO R, 1993, EPILEPSIA, V34, P800, DOI 10.1111/j.1528-1157.1993.tb02093.x
NR 30
TC 14
Z9 15
U1 0
U2 2
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD MAR
PY 2005
VL 63
IS 1
BP 14
EP 19
DI 10.1590/S0004-282X2005000100003
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 912TV
UT WOS:000228103700003
PM 15830058
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Portuguez, MW
   Fontoura, DR
   Anes, M
   Branco, DM
   Da Costa, JC
AF Portuguez, MW
   Fontoura, DR
   Anes, M
   Branco, DM
   Da Costa, JC
TI Language brain dominance in patients with refractory temporal lobe
   epilepsy: A comparative study between functional magnetic resonance
   imaging and dichotic listening test
SO EPILEPSIA
LA English
DT Meeting Abstract
CT 26th International Epilepsy Congress
CY AUG 28-SEP 01, 2005
CL Paris, FRANCE
SP Int League Against Epilepsy, Int Bureau Epilepsy
C1 Hosp Sao Lucas PUCRS, Epilepsy Surg Program, Porto Alegre, RS, Brazil.
RI DaCosta, Jaderson/C-4968-2015; Portuguez, Mirna/A-9362-2018
OI DaCosta, Jaderson/0000-0001-6776-1515; Portuguez,
   Mirna/0000-0003-4068-6249
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PY 2005
VL 46
SU 6
BP 154
EP 154
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 964MN
UT WOS:000231885300559
DA 2020-12-08
ER

PT J
AU Paglioli, E
   Palmini, A
   Paglioli, E
   da Costa, JC
   Portuguez, M
   Martinez, JV
   Calcagnotto, ME
   Hoefel, JR
   Raupp, S
   Barbosa-Coutinho, L
AF Paglioli, E
   Palmini, A
   Paglioli, E
   da Costa, JC
   Portuguez, M
   Martinez, JV
   Calcagnotto, ME
   Hoefel, JR
   Raupp, S
   Barbosa-Coutinho, L
TI Survival analysis of the surgical outcome of temporal lobe epilepsy due
   to hippocampal sclerosis
SO EPILEPSIA
LA English
DT Article
DE temporal lobe epilepsy; hippocampal sclerosis; epilepsy surgery;
   long-term outcome
ID RESECTIVE SURGERY; PARTIAL SEIZURES; FOLLOW-UP; LOBECTOMY;
   AMYGDALOHIPPOCAMPECTOMY; PREDICTION; PATHOLOGY; HISTORY; AURAS
AB Purpose: Surgical results in patients with mesial temporal lobe epilepsy due to hippocampal sclerosis (MTLE/HS) are often reported in conjunction with other etiologies of TLE.
   Methods: We prospectively collected surgical outcome data for 2 to I I years for 134 consecutive patients who specifically had MTLE and unilateral HS, according to magnetic resonance imaging (MRI) and confirmed by histopathology. Sixty-five had postoperative neuropsychological testing. Outcome was analyzed by using Engel's classification (a) through Kaplan-Meier estimated survival curves (as a function of the time to seizure recurrence), (b) as percentage of patients in each outcome class on a yearly basis, and (c) at the last updated follow-up.
   Results: Kaplan-Meier estimates of complete seizure freedom (Engel's class IA) for years 1, 2, 5, and 10 were 85%, 77%, 74%, and 66%, and of Engel's class I were 89%, 86%, 83%, and 81 %. Only nine (6.7%) patients had outcome classes III or IV at any point during follow-up. Of the patients tested, 26% of those operated on the left side and 22% of those operated on the right had postoperative decline of > ISD in verbal or visual memory, respectively.
   Conclusions: High rates of seizure freedom can be obtained and remain stable over the years in patients operated on for unilateral MTLE/HS, even in countries with limited resources.
C1 Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Porto Alegre Epilepsy Surg Program, Porto Alegre, RS, Brazil.
RP Paglioli, E (corresponding author), Hosp Sao Lucas, PU CRS, Porto Alegre Epilepsy Surg Program, Room 220,Avenida Ipiranga 6690, Porto Alegre, RS, Brazil.
EM epaglioli@hotmail.com
RI DaCosta, Jaderson/C-4968-2015; calcagnotto, maria elisa/B-1645-2013;
   CALCAGNOTTO, MARIA ELISA/AAU-7718-2020; Portuguez, Mirna/A-9362-2018
OI DaCosta, Jaderson/0000-0001-6776-1515; calcagnotto, maria
   elisa/0000-0001-8196-0596; CALCAGNOTTO, MARIA ELISA/0000-0001-8196-0596;
   Portuguez, Mirna/0000-0003-4068-6249
CR Arruda F, 1996, ANN NEUROL, V40, P446, DOI 10.1002/ana.410400314
   Barbosa-Coutinho LM, 1999, ARQ NEURO-PSIQUIAT, V57, P405, DOI 10.1590/S0004-282X1999000300011
   Berg AT, 1998, EPILEPSY RES, V29, P185
   BERG AT, 1997, EPILEPSY COMPREHENSI, P1891
   BERKOVIC SF, 1995, NEUROLOGY, V45, P1358, DOI 10.1212/WNL.45.7.1358
   Briellmann RS, 2002, NEUROLOGY, V58, P265, DOI 10.1212/WNL.58.2.265
   Doherty CP, 2002, NEW ENGL J MED, V346, P293
   Eliashiv SD, 1997, NEUROLOGY, V48, P1383, DOI 10.1212/WNL.48.5.1383
   ELWES RDC, 1991, J NEUROL NEUROSUR PS, V54, P949, DOI 10.1136/jnnp.54.11.949
   Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008
   Engel Jerome Jr., 1993, P609
   Engel Jerome Jr., 1993, P23
   Foldvary N, 2000, NEUROLOGY, V54, P630, DOI 10.1212/WNL.54.3.630
   FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604
   FRIED I, 1995, J NEUROSURG, V83, P60, DOI 10.3171/jns.1995.83.1.0060
   Gleissner U, 2002, EPILEPSIA, V43, P87, DOI 10.1046/j.1528-1157.2002.24101.x
   Jones-Gotman M, 1987, SURGICAL TREATMENT E, P203
   Kilpatrick C, 1999, EPILEPSIA, V40, P899, DOI 10.1111/j.1528-1157.1999.tb00796.x
   Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503
   Lezak M. D., 1983, NEUROPSYCHOLOGICAL A
   Mackenzie RA, 1997, J CLIN NEUROSCI, V4, P152, DOI 10.1016/S0967-5868(97)90064-3
   Marks WJ, 1998, EPILEPSIA, V39, P721, DOI 10.1111/j.1528-1157.1998.tb01157.x
   MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105
   McIntosh AM, 2001, EPILEPSIA, V42, P1288, DOI 10.1046/j.1528-1157.2001.02001.x
   Mohamed A, 2001, NEUROLOGY, V56, P1643, DOI 10.1212/WNL.56.12.1643
   MURRO AM, 1993, NEUROLOGY, V43, P2531, DOI 10.1212/WNL.43.12.2531
   Niemeyer P., 1958, TEMPORAL LOBE EPILEP, P461
   PALMINI A, 1992, NEUROLOGY, V42, P801, DOI 10.1212/WNL.42.4.801
   PALMINI A, 2000, EPILEPSY SURG, P675
   Polkey C E, 1993, J Neurosurg Sci, V37, P141
   Radhakrishnan K, 1998, NEUROLOGY, V51, P465, DOI 10.1212/WNL.51.2.465
   SALANOVA V, 1994, ARCH NEUROL-CHICAGO, V51, P1008, DOI 10.1001/archneur.1994.00540220054014
   Sawrie SM, 1998, EPILEPSIA, V39, P319, DOI 10.1111/j.1528-1157.1998.tb01380.x
   SPENCER DD, 1992, EPILEPSY SURGERY, P533
   Spencer SS, 2003, NEUROLOGY, V61, P1680, DOI 10.1212/01.WNL.0000098937.35486.A3
   Sperling MR, 1996, JAMA-J AM MED ASSOC, V276, P470, DOI 10.1001/jama.276.6.470
   SPERLING MR, 1995, NEUROLOGY, V45, P970, DOI 10.1212/WNL.45.5.970
   SPERLING MR, 1994, NEUROLOGY, V44, P2325, DOI 10.1212/WNL.44.12.2325
   St George EJ, 2002, NEW ENGL J MED, V346, P292
   Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501
   Wieser HG, 2003, J NEUROSURG, V98, P751, DOI 10.3171/jns.2003.98.4.0751
   WILLIAMSON PD, 1993, ANN NEUROL, V34, P781, DOI 10.1002/ana.410340605
   WINGKUN EC, 1991, EPILEPSIA, V32, P851, DOI 10.1111/j.1528-1157.1991.tb05541.x
   WYLER AR, 1995, NEUROSURGERY, V37, P982, DOI 10.1227/00006123-199511000-00019
   Yoon HH, 2003, NEUROLOGY, V61, P445, DOI 10.1212/01.WNL.0000081226.51886.5B
NR 45
TC 70
Z9 76
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD NOV
PY 2004
VL 45
IS 11
BP 1383
EP 1391
DI 10.1111/j.0013-9580.2004.22204.x
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 868JA
UT WOS:000224908700011
PM 15509239
DA 2020-12-08
ER

PT J
AU Oliveira, AJ
   Nunes, ML
   Fojo-Olmos, A
   Reis, FM
   da Costa, JC
AF Oliveira, AJ
   Nunes, ML
   Fojo-Olmos, A
   Reis, FM
   da Costa, JC
TI Clinical correlates of periodic breathing in neonatal polysomnography
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE periodic breathing; neonatal EEG; polysomnography; respiratory distress
   syndrome; hypoxia
ID INFANT DEATH SYNDROME; SLEEP-APNEA PROFILE; FULL-TERM NEWBORNS; PRETERM
   INFANTS; MATURATION; MISS
AB Objective: Periodic breathing is a respiratory pattern typical of preterm infants, but its clinical significance has not been clarified yet. The present study was designed to investigate whether the presence of periodic breathing is specifically associated to low post-conceptional ages, preterm birth, or common clinical disorders related to preterm birth.
   Methods: The study included 271 consecutive infants submitted to neonatal polysomnography, of whom 138 were born before 37 complete gestational weeks (preterm) and 133 were full-term. The main outcome measure was periodic breathing. A multivariate analysis was performed to test the specific impact of preterm birth, respiratory distress syndrome and hypoxic-ischemic encephalopathy on the occurrence of periodic breathing, with adjustment for potential confounding factors such as the post-conceptional age by the time of the polysomnography.
   Results: Periodic breathing was twice more frequent in infants born before term (83/138 [60%]) than in full-term babies (41/133 [31%], chi(2) = 22.1 P < 0.0001). The presence of periodic breathing was not significantly associated to either hypoxic-ischemic encephalopathy or respiratory distress syndrome. After a multivariate analysis, only preterm birth remained in the regression model as a specific risk factor for periodic breathing (adjusted odds ratio = 5.62, P < 0.0001).
   Conclusions: Periodic breathing is a respiratory pattern independently associated with preterm birth, and this association cannot be imputed to the coexistence of either respiratory distress syndrome or hypoxic-ischemic encephalopathy among preterm infants.
   Significance: The finding of periodic breathing in neonatal polysomnography correlates with preterm birth but not with its associated clinical disorders. (C) 2004 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
C1 Pontificia Univ Catolica Rio Grande Sul, Sao Lucas Univ Hosp, Div Neurol, BR-90610000 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande Sul, Sao Lucas Univ Hosp, Clin Neurophysiol Lab, BR-90610000 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande Sul, Sao Lucas Univ Hosp, Dept Internal Med, BR-90610000 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande Sul, Sao Lucas Univ Hosp, Dept Pediat, BR-90610000 Porto Alegre, RS, Brazil.
   UFMG, Dept Obstet & Gynecol, Belo Horizonte, MG, Brazil.
RP Nunes, ML (corresponding author), Pontificia Univ Catolica Rio Grande Sul, Sao Lucas Univ Hosp, Div Neurol, BR-90610000 Porto Alegre, RS, Brazil.
EM nunes@pucrs.br
RI DaCosta, Jaderson/C-4968-2015; Reis, Fernando M./E-5930-2013
OI DaCosta, Jaderson/0000-0001-6776-1515; Reis, Fernando
   M./0000-0002-9258-7472
CR ALBANI M, 1985, EUR J PEDIATR, V143, P261, DOI 10.1007/BF00442298
   Anders T, 1971, MANUAL STANDARDIZED
   AVERY ME, 1974, LUNG ITS DISORDERS N
   BENTELE KHP, 1985, ARCH DIS CHILD, V60, P547, DOI 10.1136/adc.60.6.547
   BOOTH CL, 1983, DEV MED CHILD NEUROL, V25, P283
   CURZIDASCALOVA L, 1983, BIOL NEONATE, V44, P325
   Gaultier C, 1991, SLEEP HLTH RISK, P399
   Greenough A, 1999, TXB NEONATOLOGY, P481
   GUILLEMINAULT C, 1979, PEDIATRICS, V64, P882
   KELLY DH, 1979, PEDIATRICS, V63, P355
   KHOO MCK, 1982, J APPL PHYSIOL, V53, P644
   Nunes ML, 1997, ELECTROEN CLIN NEURO, V102, P186, DOI 10.1016/S0013-4694(96)95191-7
   PARMELEE AH, 1972, NEUROPADIATRIE, V3, P294, DOI 10.1055/s-0028-1091768
   RIGATTO H, 1972, PEDIATRICS, V50, P202
NR 14
TC 12
Z9 12
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1388-2457
EI 1872-8952
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD OCT
PY 2004
VL 115
IS 10
BP 2247
EP 2251
DI 10.1016/j.clinph.2004.05.007
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 856KV
UT WOS:000224045000005
PM 15351365
DA 2020-12-08
ER

PT J
AU Da Silva, LFG
   Nunes, ML
   Da Costa, JC
AF Da Silva, LFG
   Nunes, ML
   Da Costa, JC
TI Risk factors for developing epilepsy after neonatal seizures
SO PEDIATRIC NEUROLOGY
LA English
DT Article
ID CEREBRAL-PALSY; FOLLOW-UP; EEG; CLASSIFICATION; CONTROVERSIES;
   EPIDEMIOLOGY; CONVULSIONS; INFANTS; TERM
AB The objective of this study was to determine clinical and polysomnographic risk factors that might be early predictors for the development of postnatal epilepsy in a cohort of infants with seizures. The study sample included 158 infants who presented two or more clinically proven seizures. Gestational, perinatal, and polysomnographic data were obtained retrospectively. A questionnaire designed to detect patients with epilepsy in the community was prospectively given to all families, and the positive cases were reassessed for confirmation of epilepsy. Epilepsy rate after neonatal seizures was 22% within 12 months of follow-up and 33.8% within 48 months. Transient electrolytic imbalance and perinatal asphyxia were the most frequent etiologic factors associated with neonatal seizures. More than one seizure type was detected in 17.3% (n = 22) of cases and strongly associated with central nervous system infection (relative risk [RR] = 3.02, 95% confidence interval [CI] = 1.24-7.40, P = 0.02). Focal symptomatic epilepsy (P = 0.01) and syndromes not determined as focal or generalized (P = 0.04) were also associated with central nervous system infection. Abnormal polysomnographic recordings (P = 0.09) and abnormal neurologic examination on discharge (P < 0.01) were correlated with postnatal epilepsy. No differences were observed between premature and term infants concerning outcome. Neonatal seizures were associated with a high incidence of postnatal epilepsy in the cohort, including epileptic syndromes with catastrophic evolution. Abnormal neurologic examination on discharge was a good predictor of an unfavorable outcome and abnormal polysomnographic recording a moderate predictor. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Div Neurol & Clin Neurophysiol, Sch Med, BR-90610000 Porto Alegre, RS, Brazil.
RP Da Silva, LFG (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Div Neurol, Sch Med, Av Ipiranga 6690,Cj 220, BR-90610000 Porto Alegre, RS, Brazil.
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR ANNEGERS JF, 1988, NEUROLOGY, V38, P1407, DOI 10.1212/WNL.38.9.1407
   [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x
   Arpino C, 2001, J CHILD NEUROL, V16, P651, DOI 10.1177/088307380101600905
   BERGMAN I, 1983, ANN NEUROL, V14, P642, DOI 10.1002/ana.410140607
   BERNES SM, 1994, PEDIATR CLIN N AM, V41, P1069
   CATLIN EA, 1986, J PEDIATR-US, V109, P865, DOI 10.1016/S0022-3476(86)80715-6
   CLANCY RR, 1991, EPILEPSIA, V32, P69, DOI 10.1111/j.1528-1157.1991.tb05614.x
   CURATOLO P, 1995, DEV MED CHILD NEUROL, V37, P776
   DENNIS J, 1978, DEV MED CHILD NEUROL, V20, P143
   DREYFUSBRISSAC C, 1975, EVOLUTION EEG BIRTH, P6
   ERIKSSON M, 1979, ACTA PAEDIATR SCAND, V68, P807
   FERNANDES JG, 1993, THESIS PORTO ALEGRE
   HAUSER WA, 1993, TXB EPILEPSY, P23
   Holmes GL, 1998, ANN NEUROL, V44, P845, DOI 10.1002/ana.410440602
   KEEN JH, 1973, ARCH DIS CHILD, V48, P542, DOI 10.1136/adc.48.7.542
   Lanska MJ, 1996, PEDIATR NEUROL, V15, P120, DOI 10.1016/0887-8994(96)00155-5
   LANSKA MJ, 1995, NEUROLOGY, V45, P724, DOI 10.1212/WNL.45.4.724
   LEGIDO A, 1991, PEDIATRICS, V88, P583
   LOMBROSCO CT, 1998, FUNDAMENTOS NEUROBIO, P163
   Lombroso C T, 1983, Adv Neurol, V34, P101
   Lombroso CT, 1996, EPILEPSIA, V37, P5, DOI 10.1111/j.1528-1157.1996.tb01814.x
   LOMBROSO CT, 1990, J CLIN NEUROPHYSIOL, V7, P380, DOI 10.1097/00004691-199007000-00005
   Lombroso CT, 1993, ELECTROENCEPHALOGRAP, P803
   MELLITS ED, 1982, PEDIATRICS, V70, P177
   MIZRAHI EM, 1987, NEUROLOGY, V37, P1837, DOI 10.1212/WNL.37.12.1837
   NELSON KB, 1979, PEDIATRICS, V64, P225
   NUNES ML, 1995, ARQ NEURO-PSIQUIAT, V53, P625, DOI 10.1590/S0004-282X1995000400013
   Oliveira AJ, 2000, CLIN NEUROPHYSIOL, V111, pS74, DOI 10.1016/S1388-2457(00)00405-3
   Oliveira AJ, 2000, CLIN NEUROPHYSIOL, V111, P1646, DOI 10.1016/S1388-2457(00)00380-1
   Ronen GM, 1999, J PEDIATR-US, V134, P71, DOI 10.1016/S0022-3476(99)70374-4
   ROSE AL, 1970, PEDIATRICS, V45, P404
   ROWE JC, 1985, ELECTROEN CLIN NEURO, V60, P183, DOI 10.1016/0013-4694(85)90030-6
   Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433
   SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829
   SCHER MS, 1989, PEDIATR CLIN N AM, V36, P281
   Scher MS, 1997, CLIN PERINATOL, V24, P735
   SILVA EA, 1993, ELECTROENCEPHALOGR C, V87, P106
   Volpe JJ, 2001, NEUROLOGY NEWBORN, P331
   WATANABE K, 1982, ADV EPILEPTOL, P77
NR 39
TC 37
Z9 39
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0887-8994
EI 1873-5150
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD APR
PY 2004
VL 30
IS 4
BP 271
EP 277
DI 10.1016/j.pediatrneurol.2003.09.015
PG 7
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 816VZ
UT WOS:000221138700008
PM 15087106
DA 2020-12-08
ER

PT J
AU Becker, J
   Gomes, I
   Ghisolfi, ES
   Schuch, A
   Ramos, FLP
   Ehlers, JA
   Nora, DB
   Lara, DR
   da Costa, JC
AF Becker, J
   Gomes, I
   Ghisolfi, ES
   Schuch, A
   Ramos, FLP
   Ehlers, JA
   Nora, DB
   Lara, DR
   da Costa, JC
TI Clozapine, but not typical antipsychotics, correct P50 suppression
   deficit in patients with schizophrenia
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE evoked potentials; P50; schizophrenia; antipsychotics; clozapine
ID SENSORY GATING DEFICITS; AUDITORY P50; TEMPORAL VARIABILITY;
   DESENSITIZATION; COMPONENT
AB Objective: To find out if there is a difference in P50 suppression between patients using typical antipsychotic drugs and those using clozapine, as well as to confirm the findings of abnormal P50 suppression in patients with schizophrenia, when compared to healthy volunteers.
   Methods: Fifty patients with schizophrenia and 25 healthy volunteers were divided into 3 groups: group 1 - patients using typical antipsychotics; group 2 - patients using clozapine; group 3 - controls. Before the examination, all patients were interviewed by a psychiatrist using the Brief Psychiatry Rating Scale (BPRS).
   Results: The average S2/S1 ratio was 0.82 +/- 0.45 in group 1, 0.57 +/- 0.41 in group 2, and 0.44 +/- 0.27 in group 3 (P = 0.003). Statistical analysis showed a significant difference when the results of group 1 were compared to those of groups 2 (P = 0.045) and 3 (P = 0.001). There was no significant difference between groups 2 and 3 (P = 0.182). There was a significant difference in the S1 - S2 difference only between groups 1 and 3 (P = 0.007), but a non-significant trend towards a similar difference was found between groups I and 2 (P = 0.067). There was no correlation between the BPRS values and any P50 parameter.
   Conclusions: The suppression of P50 among patients using clozapine was significantly greater than that obtained in patients using typical antipsychotics.
   Significance: This study confirms, in a more evident way, the improvement of the suppression of P50 potential in schizophrenics using clozapine. Additionally, it discusses the physiopathological mechanism involved. (C) 2003 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
C1 Pontificia Univ Catolica Rio Grande do Sul, Neurol Serv, Hosp Sao Lucas, Porto Alegre, RS, Brazil.
   Univ Fed Rio Grande do Sul, Neurol Serv, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Fac Biociencias, Dept Physiol Sci, Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Psychiat Serv, Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Fac Med, Dept Internal Med, Porto Alegre, RS, Brazil.
RP Becker, J (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Neurol Serv, Hosp Sao Lucas, Porto Alegre, RS, Brazil.
EM parg_neuro@hotmail.com
RI DaCosta, Jaderson/C-4968-2015; Becker, Jefferson/G-6417-2012
OI DaCosta, Jaderson/0000-0001-6776-1515; 
CR Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI 10.1093/oxfordjournals.schbul.a033320
   ADLER LE, 1993, AM J PSYCHIAT, V150, P1856
   Adler LE, 2000, BIOL PSYCHIAT, V47, p35S
   ADLER LE, 1990, SCHIZOPHR RES, V3, P131, DOI 10.1016/0920-9964(90)90046-A
   Arciniegas DB, 2001, J NEUROPSYCH CLIN N, V13, P213, DOI 10.1176/appi.neuropsych.13.2.213
   BOUTROS N, 1993, PSYCHIAT RES, V47, P243, DOI 10.1016/0165-1781(93)90082-R
   Boutros NN, 2002, BIOL PSYCHIAT, V51, P683, DOI 10.1016/S0006-3223(01)01237-9
   Buchanan R. W., 2000, COMPREHENSIVE TXB PS, P1096
   Clementz BA, 1998, AM J PSYCHIAT, V155, P1691, DOI 10.1176/ajp.155.12.1691
   Clementz BA, 1997, BIOL PSYCHIAT, V41, P1035, DOI 10.1016/S0006-3223(96)00208-9
   COON H, 1993, AM J HUM GENET, V52, P327
   Croft RJ, 2001, BIOL PSYCHIAT, V50, P441, DOI 10.1016/S0006-3223(01)01082-4
   CULLUM CM, 1993, SCHIZOPHR RES, V10, P131, DOI 10.1016/0920-9964(93)90048-N
   Flach KA, 1996, BIOL PSYCHIAT, V40, P1230, DOI 10.1016/0006-3223(95)00624-9
   Ghisolfi ES, 2002, NEUROPSYCHOPHARMACOL, V27, P629
   Griffith JM, 1998, BIOL PSYCHIAT, V44, P98, DOI 10.1016/S0006-3223(97)00362-4
   Jin Y, 1997, PSYCHIAT RES, V70, P71, DOI 10.1016/S0165-1781(97)03091-6
   Jin Y, 1998, BIOL PSYCHIAT, V43, P873, DOI 10.1016/S0006-3223(98)00115-2
   JUDD LL, 1992, AM J PSYCHIAT, V149, P488
   KANE JM, 1995, LANCET, V346, P820, DOI 10.1016/S0140-6736(95)91630-X
   Lara DR, 2000, MED HYPOTHESES, V54, P157, DOI 10.1054/mehy.1999.0003
   Light GA, 2000, AM J PSYCHIAT, V157, P767, DOI 10.1176/appi.ajp.157.5.767
   MITCHELL JB, 1993, J NEUROSCI, V13, P3439
   Nagamoto HT, 1999, NEUROPSYCHOBIOLOGY, V39, P10, DOI 10.1159/000026553
   Nagamoto HT, 1996, BIOL PSYCHIAT, V40, P181, DOI 10.1016/0006-3223(95)00371-1
   NAGAMOTO HT, 1991, SCHIZOPHR RES, V4, P31, DOI 10.1016/0920-9964(91)90007-E
   Patterson JV, 2000, ARCH GEN PSYCHIAT, V57, P57, DOI 10.1001/archpsyc.57.1.57
   Ross RG, 1999, AM J MED GENET, V88, P188, DOI 10.1002/(SICI)1096-8628(19990416)88:2<188::AID-AJMG17>3.3.CO;2-5
   Simosky JK, 2003, PSYCHOPHARMACOLOGY, V165, P386, DOI 10.1007/s00213-002-1285-x
   Waldo M, 1995, AM J MED GENET, V60, P506, DOI 10.1002/ajmg.1320600605
   WALDO M, 1992, PSYCHIAT RES, V44, P21, DOI 10.1016/0165-1781(92)90066-C
   Ward PB, 1996, PSYCHIAT RES, V64, P121, DOI 10.1016/0165-1781(96)02876-4
   Yee CM, 1998, J ABNORM PSYCHOL, V107, P691, DOI 10.1037/0021-843X.107.4.691
   Zouridakis G, 1997, PSYCHIAT RES, V69, P169, DOI 10.1016/S0165-1781(96)02979-4
NR 34
TC 47
Z9 49
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1388-2457
EI 1872-8952
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD FEB
PY 2004
VL 115
IS 2
BP 396
EP 401
DI 10.1016/j.clinph.2003.09.018
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 774KL
UT WOS:000188978600018
PM 14744582
DA 2020-12-08
ER

PT J
AU de Castro Ribeiro, M
   Barbosa-Coutinho, L
   Mugnol, F
   Hilbig, A
   Palmini, A
   da Costa, JC
   Neto, EP
   Paglioli, E
AF de Castro Ribeiro, M
   Barbosa-Coutinho, L
   Mugnol, F
   Hilbig, A
   Palmini, A
   da Costa, JC
   Neto, EP
   Paglioli, E
TI Corpora amylacea in temporal lobe epilepsy associated with hippocampal
   sclerosis
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE hippocampal sclerosis; corpora amylacea; temporal lobe epilepsy
AB Hippocampal sclerosis (HS) is the commonest pathology in epileptic patients undergoing temporal lobe epilepsy surgery. Beside, there are an increased density of corpora amylacea (CA) founded in 6 to 63% of those cases. Objective: verify the presence of CA and the clinical correlates of their occurrence in a consective series of patients undergoing temporal surgery with diagnosis of HS. Method: We reviewed 72 hippocampus specimens from January 1997 to July 2000. Student's t test for independent, samples, ANOVA and Tukey test were performed for statistical analysis. Results: CA were found in 35 patients (49%), whose mean epilepsy duration (28.7 years) was significantly longer than that group of patients without CA (19.5 years, p= 0.001). Besides, when CA were found, duration was also significantly correlated with distribution within hippocampus: 28.7 years with diffuse distribution of CA, 15.4 with exclusively subpial and 17.4 years with distribution subpial plus perivascular (p= 0.001). Conclusion: Our findings corroborate the presence of CA in patients with HS and suggest that a longer duration of epilepsy correlate with a more distribution of CA in hippocampus.
C1 PUC, Hosp Sao Lucas, Porto Alegre Epilepsy Surg Program, Porto Alegre, RS, Brazil.
RP Hilbig, A (corresponding author), PUC, Hosp Sao Lucas, Porto Alegre Epilepsy Surg Program, Porto Alegre, RS, Brazil.
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR BABB TL, 1986, PATHOLOGICAL FINDING, P511
   Barbosa-Coutinho LM, 1999, ARQ NEURO-PSIQUIAT, V57, P405, DOI 10.1590/S0004-282X1999000300011
   Botez G, 2001, NEUROPATH APPL NEURO, V27, P474, DOI 10.1046/j.1365-2990.2001.00362.x
   Cavanagh JB, 1999, BRAIN RES REV, V29, P265, DOI 10.1016/S0165-0173(99)00003-X
   Chung MH, 1996, J NEUROPATH EXP NEUR, V55, P403, DOI 10.1097/00005072-199604000-00002
   Erdamar S, 2000, J NEUROPATH EXP NEUR, V59, P698, DOI 10.1093/jnen/59.8.698
   Gati Istvan, 2001, Pathology and Oncology Research, V7, P140
   GRAHAM D, 1997, GREENFIELDS NEUROPAT, V1, P124
   Hoyaux D, 2000, BRAIN RES, V867, P280, DOI 10.1016/S0006-8993(00)02393-3
   LOISEAU H, 1992, J NEUROL NEUROSUR PS, V55, P1092, DOI 10.1136/jnnp.55.11.1092
   Nishio S, 2001, EPILEPSIA, V42, P960, DOI 10.1046/j.1528-1157.2001.01601.x
   OSSYL L, 1998, J NEUROL NEUROSUR PS, V65, P614
   PALMINI A, 2000, EPILEPSY SURG, P675
   RADHAKRISHNAN VV, 1999, NEUROL INDIA, V47, P1150
   SHINGHRAO SK, 1994, NEUROPATHOL APPL NEU, V20, P66
   SHINGHRAO SK, 1993, NEUROPATHOL APPL NEU, V19, P269
   SHINGRAO KSK, 1995, NEURODEGENERATION, V4, P335
   VanPaesschen W, 1997, J NEUROL NEUROSUR PS, V63, P513, DOI 10.1136/jnnp.63.4.513
NR 18
TC 1
Z9 1
U1 0
U2 1
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD DEC
PY 2003
VL 61
IS 4
BP 942
EP 945
DI 10.1590/S0004-282X2003000600010
PG 4
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 751JP
UT WOS:000187063500010
PM 14762595
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Nunes, ML
   Ferri, R
   Arzimanoglou, A
   Curzi, L
   Appel, CC
   da Costa, JC
AF Nunes, ML
   Ferri, R
   Arzimanoglou, A
   Curzi, L
   Appel, CC
   da Costa, JC
TI Sleep organization in children with partial refractory epilepsy
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
ID DEATH
AB Although it is currently known that sleep can influence epilepsy and epilepsy can influence sleep organization, few data have been published on this mutual interaction concerning the pediatric population. The objective of this study was to verify the eventual presence of sleep alterations in children with partial refractory epilepsy. Seventeen patients with partial refractory epilepsy were submitted to whole-night polysomnography as part of their epilepsy investigation. Polysomnographic recordings were performed on a digital video-electroencephalography (EEG) system and consisted of the registration of EEG (24 channels), electro-oculogram, electromyogram, electrocardiogram, and nasal airflow and abdominal respiratory movements. Sleep stages were visually scored following standard criteria, and ictal events were classified according to the international classification of seizures. The patients were also subdivided into two subgroups based on the presence or absence of ictal episodes during the recording night. The results concerning sleep organization were compared with those obtained from a normal control group. The analysis of the sleep parameters showed a reduction of total time in bed and total sleep time in both subgroups of epileptic children; there was a higher number of stage shifts per hour in the control group than in both epileptic subgroups. The percentage of stage 2 shifts is significantly reduced in patients with epilepsy and seizures during the night and the percentage of stage 3 to 4 shifts is increased. Nonsignificant differences are evident for the number of awakenings per hour and the percentage of stage 1 shifts. The percentage of rapid eye movement (REM) sleep is reduced, and first REM latency is increased in both epileptic subgroups, compared with normal controls, without statistical significance. Nine of 17 patients had seizures during the polysomnographic recording; nocturnal ictal events occurred mostly during non-REM sleep stage 2. Our results show that patients with partial refractory epilepsies have only mild sleep structure abnormalities, and this can be considered as an effect of the epileptic syndrome per se or as a result of the chronic antiepilepsy drug treatment.
C1 Hosp Sao Lucas, Div Neurol, PUCRS, Sch Med, BR-90610000 Porto Alegre, RS, Brazil.
   Oasi Inst Mental Retardat & Brain Aging, Sleep Res Ctr, Dept Neurol, Troina, Italy.
   Hop Robert Debre, Lab Physiol EF, F-75019 Paris, France.
   Hop Robert Debre, Serv Neuropediat, F-75019 Paris, France.
RP Nunes, ML (corresponding author), Hosp Sao Lucas, Div Neurol, PUCRS, Sch Med, Av Ipiranga6690-220, BR-90610000 Porto Alegre, RS, Brazil.
EM nunes@pucrs.br
RI DaCosta, Jaderson/C-4968-2015; Ferri, Raffaele/B-5439-2013
OI DaCosta, Jaderson/0000-0001-6776-1515; Ferri,
   Raffaele/0000-0001-6937-3065
CR Anders TF, 1995, PRINCIPLES PRACTICE, P7
   [Anonymous], 1981, Epilepsia, V22, P489
   [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x
   DALLABERNARDINA B, 1976, EPILEPSIA, V17, P161, DOI 10.1111/j.1528-1157.1976.tb03393.x
   Donner EJ, 2001, NEUROLOGY, V57, P430, DOI 10.1212/WNL.57.3.430
   Ferri R, 2002, J SLEEP RES, V11, P153, DOI 10.1046/j.1365-2869.2002.00283.x
   HRACHOVY RA, 1981, NEUROLOGY, V31, P688, DOI 10.1212/WNL.31.6.688
   Mendez M, 2001, J CLIN NEUROPHYSIOL, V18, P106
   Ohtahara S, 1976, Folia Psychiatr Neurol Jpn, V30, P275
   Rechtschaffen A, 1968, NIH PUBLICATION
   Sammaritano M, 2000, NEUROLOGY, V54, pS16
   Shorvon S, 1997, EPILEPSIA, V38, pS20, DOI 10.1111/j.1528-1157.1997.tb06118.x
   Shouse MN, 1996, J CLIN NEUROPHYSIOL, V13, P32, DOI 10.1097/00004691-199601000-00004
   TERZANO MG, 1992, EPILEPSIA, V33, P317, DOI 10.1111/j.1528-1157.1992.tb02322.x
   Touchon J, 1991, Epilepsy Res Suppl, V2, P73
NR 15
TC 48
Z9 52
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD NOV
PY 2003
VL 18
IS 11
BP 763
EP 766
PG 4
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 755XU
UT WOS:000187437400005
PM 14696903
DA 2020-12-08
ER

PT J
AU da Costa, JC
   Palmini, A
AF da Costa, JC
   Palmini, A
TI Epilepsia partialis continua due to malformations of cortical
   development
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
ID NEURONAL MIGRATION; DYSPLASTIC CORTEX; MOTOR EPILEPSY; GENE; DISCHARGES;
   MECHANISMS; MYOCLONUS; FEATURES; SPECTRUM; PROTEIN
C1 Hosp Sao Lucas PUCRS, Neurol Serv, BR-90610000 Porto Alegre, RS, Brazil.
   Hosp Sao Lucas PUCRS, Disciplina Neurol, BR-90610000 Porto Alegre, RS, Brazil.
RP da Costa, JC (corresponding author), Hosp Sao Lucas PUCRS, Neurol Serv, Avenida Ipiranga 6690, BR-90610000 Porto Alegre, RS, Brazil.
EM jcc@pucrs.br
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR Avoli M, 1999, ANN NEUROL, V46, P816, DOI 10.1002/1531-8249(199912)46:6<816::AID-ANA3>3.0.CO;2-O
   Babb TL, 1998, EPILEPSY RES, V32, P24, DOI 10.1016/S0920-1211(98)00037-0
   BANCAUD J, 1982, REV NEUROL, V138, P802
   Bancaud Jean, 1992, P363
   BARKOVICH AJ, 1992, AM J NEURORADIOL, V13, P95
   BARKOVICH AJ, 1992, AM J NEURORADIOL, V13, P85
   BIRABEN A, 1997, EPILEPSY COMPREHENSI
   Chauvel P, 1992, Adv Neurol, V57, P185
   Cockerell OC, 1996, BRAIN, V119, P393, DOI 10.1093/brain/119.2.393
   COWAN JMA, 1986, J NEUROL NEUROSUR PS, V49, P796, DOI 10.1136/jnnp.49.7.796
   DACOSTA JC, 1996, EPILIPSIA, V37, P37
   des Portes V, 1998, CELL, V92, P51
   DULAC O, 1983, ARCH FR PEDIATR, V40, P689
   DUONG T, 1992, ACTA NEUROPATHOL, V84, P250
   FERRER I, 1992, ACTA NEUROPATHOL, V83, P647, DOI 10.1007/BF00299415
   FERRER I, 1994, J NEUROL SCI, V123, P18, DOI 10.1016/0022-510X(94)90198-8
   Gambardella A, 1996, ELECTROEN CLIN NEURO, V98, P243, DOI 10.1016/0013-4694(95)00266-9
   Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5
   Jacobs KM, 1999, EPILEPSY RES, V36, P165, DOI 10.1016/S0920-1211(99)00050-9
   JUULJENSEN P, 1966, ARCH NEUROL-CHICAGO, V15, P563, DOI 10.1001/archneur.1966.00470180003001
   KIMBERLE MJ, 1999, J NEUROPHYSIOL, V81, P159
   KOZHEVNIKOV AY, 1991, CHRONIC ENCEPHALITIS, P245
   KUGELBERG E, 1954, ELECTROEN CLIN NEURO, V6, P503, DOI 10.1016/0013-4694(54)90068-1
   KUZNIECKY R, 1994, NEUROLOGY, V44, P379, DOI 10.1212/WNL.44.3_Part_1.379
   LAMARCHE M, 1978, ELECTORENCEPHALOGR C, V45, P3237
   LOHLER J, 1974, FORTSCHR NEUROL PSYC, V42, P185
   MISCHEL PS, 1995, J NEUROPATH EXP NEUR, V54, P137, DOI 10.1097/00005072-199503000-00001
   Najm Imad M., 2000, Epilepsia, V41, P68
   OBESO JA, 1985, BRAIN, V108, P193, DOI 10.1093/brain/108.1.193
   Oguni H, 1991, CHRONIC ENCEPHALITIS, P7
   OMOROKOV LI, CHRONIC ENCEPHALITIS, P263
   PALMINI A, 1991, ANN NEUROL, V30, P741, DOI 10.1002/ana.410300602
   PALMINI A, 1995, ANN NEUROL, V37, P476, DOI 10.1002/ana.410370410
   PALMINI A, 1994, EPILIPSIA, V36, P15
   REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0
   ROBAIN O, 1988, NEUROPATH APPL NEURO, V14, P125, DOI 10.1111/j.1365-2990.1988.tb00875.x
   Robain O, 1996, DYSPLASIAS OF CEREBRAL CORTEX AND EPILEPSY, P1
   Robain O, 1996, DYSPLASIAS OF CEREBRAL CORTEX AND EPILEPSY, P89
   SHOMER DL, 1993, EPILEPSIA S1, V34, pS29
   SHORVON SD, 1994, STATUS EPILEPTICUS I, P84
   Spreafico R, 1998, EPILEPSY RES, V32, P34, DOI 10.1016/S0920-1211(98)00038-2
   Spreafico R, 1998, NEUROLOGY, V50, P27, DOI 10.1212/WNL.50.1.27
   TAYLOR DC, 1971, J NEUROL NEUROSUR PS, V34, P369, DOI 10.1136/jnnp.34.4.369
   THOMAS JE, 1977, ARCH NEUROL-CHICAGO, V34, P266, DOI 10.1001/archneur.1977.00500170020003
   WIESER HG, 1978, ELECTROEN CLIN NEURO, V44, P14, DOI 10.1016/0013-4694(78)90101-3
   WOLPERT SM, 1994, AM J NEURORADIOL, V15, P1479
   YAKOVLEV PI, 1946, J NEUROPATH EXP NEUR, V5, P116, DOI 10.1097/00005072-194604000-00003
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD SEP
PY 2003
VL 61
SU 1
BP 54
EP 58
PG 5
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 769LD
UT WOS:000188650800009
PM 15104391
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Nunes, ML
   Gameleira, FT
   Oliveira, AJ
   da Costa, JC
AF Nunes, ML
   Gameleira, FT
   Oliveira, AJ
   da Costa, JC
TI Developmental characteristics of temporal sharp transients in the EEG of
   normal preterm and term newborns
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE neonatal EEG; temporal sharp waves; preterm newborn; sleep ontogenesis
ID MATCHED CONCEPTIONAL AGES; FULL-TERM; PREMATURE-INFANTS;
   GESTATIONAL-AGE; HEALTHY PRETERM; MATURATION; RECORDINGS
AB Objective: To describe developmental characteristics, morphological aspects and incidence of temporal sharp transients (TST) in normal preterm and term newborns at matched conceptional ages (CA). Method: Neonatal EEGs from two groups of normal newborns were evaluated in order to identify and characterize TST. Group I (n=40) consisted of newborns from 34 to 40 weeks of gestational age (GA) that were submitted to a single EEG between 24 and 48 hours of life. Group II consisted of 10 preterm newborns with GA between 30-32 weeks, followed with a weekly EEG until they reached term. Morphology of TST was divided in 3 groups (temporal sawtooth, isolated transients or repetitive transients). TST index, density and total number were calculated in each polysomnography and related to sleep stages and CA. Laterality (right/left) was also evaluated. The groups were compared at 34, 36, 38 and 40 weeks of CA. Results: TST index and density decreased with the increase of CA in both groups (p<0.0001). The temporal sawtooth feature was registered in both groups only at 34 weeks. Although rare, repetitive and isolated TST were the most prevalent morphology between 36 - 40 weeks CA. Significant intragroup difference was observed in the comparison of TST density in REM and transitional sleep in GI. Moreover, isolated TST morphology was significant higher in GI at 34 weeks when compared to the others CA. No intragroup differences were observed on GII. No significant differences between the groups were observed considering TST number, index, density, morphology or laterality, at the matched CA. Conclusion: TST are normal features of neonatal EEG, as they are registered in normal newborns. its incidence varies accordingly to morphology and they tend to disappear following the increase of CA. Temporal sawtooth appears more often in preterm newborns. Our results suggest that TST index, density and morphology variability may be a function of CA.
C1 Sao Lucas Hosp, Neurol Serv, BR-90610000 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande Sul, Fac Med, Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande Sul, Neurol & Nurofisiol Clin, Ex Aluno Curso Especializacao Neurociencias, EEG Neonatol Serv Neurol HSL, Porto Alegre, RS, Brazil.
RP Nunes, ML (corresponding author), Sao Lucas Hosp, Neurol Serv, Av Ipiranga 6690 Sala 220, BR-90610000 Porto Alegre, RS, Brazil.
RI DaCosta, Jaderson/C-4968-2015; beumer, rijkelt/C-3600-2008; Rombouts,
   Frans/F-9882-2011
OI DaCosta, Jaderson/0000-0001-6776-1515; 
CR Anders T, 1971, MANUAL STANDARDIZED
   BIAGIONI E, 1994, ELECTROEN CLIN NEURO, V91, P154, DOI 10.1016/0013-4694(94)90065-5
   Borsini W, 1990, Riv Neurol, V60, P234
   CAPURRO H, 1978, J PEDIATR-US, V93, P120, DOI 10.1016/S0022-3476(78)80621-0
   DACOSTA J, 1980, ELECTROENCEPHALOGR C, V50, P183
   DASCALOVA LC, 1996, MANUAL METHODS RECOR
   DREYFUS-BRISAC C, 1962, World Neurol, V3, P5
   DREYFUSBRISAC C, 1962, BIOL NEONATORUM, V4, P154
   DUFFY FH, 1990, CHILD DEV, V61, P1271, DOI 10.2307/1130893
   FERRARI F, 1992, EARLY HUM DEV, V28, P37, DOI 10.1016/0378-3782(92)90006-3
   FRANKENBURG WK, 1992, PEDIATRICS, V89, P91
   HUGHES JR, 1987, ELECTROEN CLIN NEURO, V67, P7, DOI 10.1016/0013-4694(87)90156-8
   HUGHES JR, 1989, CLIN ELECTROENCEPHAL, V20, P228, DOI 10.1177/155005948902000410
   Lamblin MD, 1999, NEUROPHYSIOL CLIN, V29, P123, DOI 10.1016/S0987-7053(99)80051-3
   LOMBROSO CT, 1985, J CLIN NEUROPHYSIOL, V2, P105, DOI 10.1097/00004691-198504000-00002
   Lombroso CT, 1993, ELECTROENCEPHALOGRAP, P803
   Nunes ML, 1997, ELECTROEN CLIN NEURO, V102, P186, DOI 10.1016/S0013-4694(96)95191-7
   Nunes ML, 2000, CLIN NEUROPHYSIOL, V111, P305, DOI 10.1016/S1388-2457(99)00234-5
   SCHER MS, 1994, ELECTROEN CLIN NEURO, V90, P173, DOI 10.1016/0013-4694(94)90088-4
   SCHER MS, 1992, SLEEP, V15, P442, DOI 10.1093/sleep/15.5.442
   SCHER MS, 1994, ELECTROEN CLIN NEURO, V90, P179, DOI 10.1016/0013-4694(94)90089-2
   Stockard-Pope J E, 1992, ATLAS NEONATAL ELECT
   TORRES F, 1985, J CLIN NEUROPHYSIOL, V2, P89, DOI 10.1097/00004691-198504000-00001
   Werner SS, 1977, ATLAS NEONATAL ELECT
NR 24
TC 4
Z9 5
U1 0
U2 1
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD SEP
PY 2003
VL 61
IS 3A
BP 574
EP 579
DI 10.1590/S0004-282X2003000400009
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 736RE
UT WOS:000186186300009
PM 14513160
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Branco, DM
   Coelho, TM
   Branco, BM
   Schmidt, L
   Calcagnotto, ME
   Portuguez, M
   Neto, EP
   Paglioli, E
   Palmini, A
   Lima, JV
   Da Costa, JC
AF Branco, DM
   Coelho, TM
   Branco, BM
   Schmidt, L
   Calcagnotto, ME
   Portuguez, M
   Neto, EP
   Paglioli, E
   Palmini, A
   Lima, JV
   Da Costa, JC
TI Functional variability of the human cortical motor map: Electrical
   stimulation findings in perirolandic epilepsy surgery
SO JOURNAL OF CLINICAL NEUROPHYSIOLOGY
LA English
DT Article; Proceedings Paper
CT 2nd Latin American Congress of Epilepsy
CY MAY 29-JUN 01, 2002
CL FOZ DO IGUACU, BRAZIL
DE brain mapping; motor cortex; motor homunculus; somatotopy
ID CORTEX HAND AREA; CEREBRAL BLOOD-FLOW; REPRESENTATION; REORGANIZATION;
   MOVEMENTS; MONKEYS; HOMUNCULUS; OWL
AB The purpose of this study was to assess the cortical representation of sensorimotor functions in patients undergoing perirolandic epilepsy surgery, focusing on somatotopy, mosaicism, and variability of function in relation to the classic motor homunculus. The authors studied 36 patients in whom intraoperative or extraoperative electrical cortical stimulation to map motor functions was performed. A computer program was devised to register electrode number, stimulation parameters, and response to each stimulus. Electrode position was represented graphically whenever a stimulus was delivered. A total of 43 maps from 36 patients were analyzed. The authors found variations in the organization of M1 (primary motor cortex) in seven patients (19.4%). Four patients (11.1%) presented mosaicism (overlapping of functional areas), two (5.6%) presented variability (inverted disposition of M1 functional areas), and one (2.8%) had both. The results of this study challenge the notion of orderly topographic relationships between the human sensorimotor functions and their representation in the primary motor cortex. These results confirm those of other studies with animals and humans using novel imaging techniques, suggesting that the motor homunculus may not always be considered a definite and absolute representation of M1.
C1 Pontificia Univ Catolica Rio Grande do Sul, Serv Neurol, Hosp Sao Lucas, Sch Med, BR-90610000 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Neurosurg Serv, Hosp Sao Lucas, Dept Surg,Sch Med, BR-90610000 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Hosp Sao Lucas, Dept Internal Med,Div Neurol, BR-90610000 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Hosp Sao Lucas, Porto Alegre Epilepsy Surg Program, BR-90610000 Porto Alegre, RS, Brazil.
   Univ Fed Rio Grande Sul, Inst Informat, Porto Alegre, RS, Brazil.
RP Da Costa, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Serv Neurol, Hosp Sao Lucas, Sch Med, Av Iprianga 6690,Sala 220, BR-90610000 Porto Alegre, RS, Brazil.
RI CALCAGNOTTO, MARIA ELISA/AAU-7718-2020; calcagnotto, maria
   elisa/B-1645-2013; DaCosta, Jaderson/C-4968-2015; Portuguez,
   Mirna/A-9362-2018
OI CALCAGNOTTO, MARIA ELISA/0000-0001-8196-0596; calcagnotto, maria
   elisa/0000-0001-8196-0596; DaCosta, Jaderson/0000-0001-6776-1515;
   Portuguez, Mirna/0000-0003-4068-6249
CR BARINAGA M, 1995, SCIENCE, V268, P1696, DOI 10.1126/science.7792588
   BRANCO DM, 1996, BRAZ J NEUROL PSYCHI, P29
   COHEN LG, 1991, BRAIN, V114, P615, DOI 10.1093/brain/114.1.615
   COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392
   DACOSTA JC, 1998, FUNDAMENTOS NEUROBIO, V2, P1009
   DACOSTA JC, 2000, EPILEPSIA, P395
   DONOGHUE JP, 1992, EXP BRAIN RES, V89, P1
   ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305
   Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117
   GRAFTON ST, 1991, J NEUROPHYSIOL, V66, P735
   Hedstrom A., 1992, Epilepsia, V33, P56
   Jones EG, 1998, SCIENCE, V282, P1121, DOI 10.1126/science.282.5391.1121
   Kandel E, 2000, PRINCIPLES NEUROSCIE
   KIM SG, 1993, J NEUROPHYSIOL, V69, P297
   Kleinschmidt A, 1997, EUR J NEUROSCI, V9, P2178, DOI 10.1111/j.1460-9568.1997.tb01384.x
   LUKASHIN AV, 1994, P NATL ACAD SCI USA, V91, P8651, DOI 10.1073/pnas.91.18.8651
   MERZENICH MM, 1983, NEUROSCIENCE, V10, P639, DOI 10.1016/0306-4522(83)90208-7
   Morris K, 2002, LANCET NEUROL, V1, P402, DOI 10.1016/S1474-4422(02)00213-2
   OJEMANN GA, 1996, TREATMENT EPILEPSY, P752
   Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389
   Penfield W, 1954, EPILEPSY FUNCTIONAL
   Penfield W., 1952, CEREBRAL CORTEX MAN
   PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843
   RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826
   RAO SM, 1995, NEUROLOGY, V45, P919, DOI 10.1212/WNL.45.5.919
   RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1031
   SANES JN, 1995, SCIENCE, V268, P1775, DOI 10.1126/science.7792606
   SCHIEBER MH, 1993, SCIENCE, V261, P489, DOI 10.1126/science.8332915
   Schieber MH, 1998, J NEUROSCI, V18, P9038
   SCHOTT GD, 1993, J NEUROL NEUROSUR PS, V56, P329, DOI 10.1136/jnnp.56.4.329
NR 30
TC 51
Z9 53
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0736-0258
J9 J CLIN NEUROPHYSIOL
JI J. Clin. Neurophysiol.
PD FEB
PY 2003
VL 20
IS 1
BP 17
EP 25
DI 10.1097/00004691-200302000-00002
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 668MP
UT WOS:000182298000002
PM 12684554
DA 2020-12-08
ER

PT J
AU Nunes, ML
   Appel, CC
   da Costa, JC
AF Nunes, ML
   Appel, CC
   da Costa, JC
TI Apparent life-threatening episodes as the first manifestation of
   epilepsy
SO CLINICAL PEDIATRICS
LA English
DT Article
ID APNEA; SEIZURES; EVENTS
AB Apparent life-threatening episodes (ALTE) can be the first manifestation of an epileptic seizure in children. However, the diagnosis of ALTE is generally delayed because the interictal EEG often appears normal and the presence of gastroesophageal reflux may mislead the diagnosis of the epileptic manifestation. We report 6 children with epilepsy who presented an ALTE as their first seizure manifestation. The retrospective analysis of our cases demonstrated that ictal EEGs, when available, appeared to be the most helpful test to confirm the diagnosis, although an abnormal-appearing cerebral imaging was also contributive in the patients when only interictal EEGs were available.
C1 Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Div Neurol, Hosp Sao Lucas, BR-90610000 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Div Pediat, Hosp Sao Lucas, BR-90610000 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Div Neurophysiol, Hosp Sao Lucas, BR-90610000 Porto Alegre, RS, Brazil.
RP Nunes, ML (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Div Neurol, Hosp Sao Lucas, Av Ipiranga 6690-220, BR-90610000 Porto Alegre, RS, Brazil.
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR BROOKS JG, 1992, CLIN PERINATOL, V19, P809
   DAVIS JM, 1986, ARCH DIS CHILD, V61, P791, DOI 10.1136/adc.61.8.791
   Heissessen L, 2000, ARCH PEDIATRIE, V7, P955, DOI 10.1016/S0929-693X(00)90010-1
   HEWERTSON J, 1994, PEDIATRICS, V94, P148
   MONOD N, 1988, ANN NY ACAD SCI, V533, P411, DOI 10.1111/j.1749-6632.1988.tb37268.x
   Nunes M L, 1999, J Pediatr (Rio J), V75, P55
   RIVAROLA MR, 1995, ARCH ARGENT PEDIATR, V93, P85
   SINGH B, 1993, EPILEPSIA, V34, P901, DOI 10.1111/j.1528-1157.1993.tb02109.x
   *US DEP HHS, 1986, US DEP HHS PUBL
   WATANABE K, 1982, PEDIATRICS, V70, P87
NR 10
TC 10
Z9 12
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0009-9228
EI 1938-2707
J9 CLIN PEDIATR
JI Clin. Pediatr.
PD JAN-FEB
PY 2003
VL 42
IS 1
BP 19
EP 22
DI 10.1177/000992280304200103
PG 4
WC Pediatrics
SC Pediatrics
GA 642HT
UT WOS:000180798700003
PM 12635977
DA 2020-12-08
ER

PT J
AU D'Agostino, MD
   Bernasconi, A
   Das, S
   Bastos, A
   Valerio, RM
   Palmini, A
   da Costa, JC
   Scheffer, IE
   Berkovic, S
   Guerrini, R
   Dravet, C
   Ono, J
   Gigli, G
   Federico, A
   Booth, F
   Bernardi, B
   Volpi, L
   Tassinari, CA
   Guggenheim, MA
   Ledbetter, DH
   Gleeson, JG
   Lopes-Cendes, I
   Vossler, DG
   Malaspina, E
   Franzoni, E
   Sartori, RJ
   Mitchell, MH
   Mercho, S
   Dubeau, F
   Andermann, F
   Dobyns, WB
   Andermann, E
AF D'Agostino, MD
   Bernasconi, A
   Das, S
   Bastos, A
   Valerio, RM
   Palmini, A
   da Costa, JC
   Scheffer, IE
   Berkovic, S
   Guerrini, R
   Dravet, C
   Ono, J
   Gigli, G
   Federico, A
   Booth, F
   Bernardi, B
   Volpi, L
   Tassinari, CA
   Guggenheim, MA
   Ledbetter, DH
   Gleeson, JG
   Lopes-Cendes, I
   Vossler, DG
   Malaspina, E
   Franzoni, E
   Sartori, RJ
   Mitchell, MH
   Mercho, S
   Dubeau, F
   Andermann, F
   Dobyns, WB
   Andermann, E
TI Subcortical band heterotopia (SBH) in males: clinical, imaging and
   genetic findings in comparison with females
SO BRAIN
LA English
DT Article
DE DCX; double cortex; LIS1; male; subcortical band heterotopia
ID DOUBLE CORTEX SYNDROME; DIFFUSE CORTICAL DYSPLASIA; DIEKER LISSENCEPHALY
   GENE; NEURONAL MIGRATION; LAMINAR HETEROTOPIA; CORPUS CALLOSOTOMY;
   SOMATIC MOSAICISM; DOUBLECORTIN GENE; MUTATIONS; LIS1
AB Subcortical band heterotopia (SBH) or double cortex syndrome is a neuronal migration disorder, which occurs very rarely in males: to date, at least 110 females but only 11 in males have been reported. The syndrome is usually associated with mutations in the doublecortin (DCX) (Xq22.3-q23) gene, and much less frequently in the LIS1 (17p13.3) gene. To determine whether the phenotypic spectrum, the genetic basis and genotype-phenotype correlations of SBH in males are similar to those in females, we compared the clinical, imaging and molecular features in 30 personally evaluated males and 60 previously reported females with SBH. Based on the MRI findings, we defined the following band subtypes: partial, involving one or two cerebral lobes; intermediate, involving two lobes and a portion of a third; diffuse, with substantial involvement of three or more lobes; and pachygyria-SBH, in which posterior SBH merges with anterior pachygyria. Karyo typing and mutation analysis of DCX and/or LIS1 were performed in 23 and 24 patients, respectively. The range of clinical phenotypes in males with SBH greatly overlapped that in females. MRI studies revealed that some anatomical subtypes of SBH, such as partial and intermediate posterior, pachygyria-SBH and diffuse bands with posterior predominance, were more frequently or exclusively present in males. Conversely, classical diffuse SBH and diffuse bands with anterior predominance were more frequent in females. Males had either mild or the most severe band subtypes, and these correlated with the over-representation of normal/borderline intelligence and severe mental retardation, respectively. Conversely, females who had predominantly diffuse bands exhibited mostly mild or moderate mental retardation. Seven patients (29%) had missense mutations in DCX; in four, these were germline mutations, whereas in three there was evidence for somatic mosaicism. A germline missense mutation of LIS1 and a partial trisomy of chromosome 9p were identified in one patient (4%) each. One male each had a possible pathogenic intronic base change in both DCX and LIS1 genes. Our study shows that SBH in males is a clinically heterogeneous syndrome, mostly occurring sporadically. The clinical spectrum is similar to that of females with SBH. However, the greater cognitive and neuroradiological heterogeneity and the small number of mutations identified to date in the coding sequences of the DCX and LIS1 genes in males differ from the findings in females. This suggests other genetic mechanisms such as mutations in the non-coding regions of the DCX or LIS1 genes, gonadal or somatic mosaicism, and finally mutations of other genes.
C1 McGill Univ, Montreal Neurol Hosp & Inst, Dept Human Genet, Neurogenet Unit, Montreal, PQ H3A 2B4, Canada.
   McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada.
   McGill Univ, Montreal Neurol Hosp & Inst, Dept Pediat, Montreal, PQ H3A 2B4, Canada.
   Hlth Sci Ctr, Winnipeg, MB, Canada.
   Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
   Shodair Childrens Hosp, Pediat Neurol Serv, Helena, MT USA.
   Univ Calif San Diego, Dept Neurosci, Div Pediat Neurol, San Diego, CA 92103 USA.
   Swedish Med Ctr, Epilepsy Ctr, Seattle, WA USA.
   Walter Reed Army Med Ctr, Dept Neurol, Washington, DC 20307 USA.
   Univ Sao Paulo, Clin Hosp, Sao Paulo, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Porto Alegre Epilepsy Surg Program, Porto Alegre, RS, Brazil.
   Univ Estadual Campinas, Dept Med Genet, Campinas, SP, Brazil.
   Univ Melbourne, Austin & Repatriat Med Ctr, Dept Neurol, Melbourne, Vic, Australia.
   Royal Childrens Hosp, Melbourne, Vic, Australia.
   Inst Child Hlth, Neurosci Unit, London, England.
   UCL, Great Ormond St Hosp Children, London, England.
   Ctr St Paul, Marseille, France.
   Toyonaka City Hosp, Div Pediat, Toyonaka, Osaka, Japan.
   Santa Maria della Misericordia Hosp, Dept Neurosci, Udine, Italy.
   Assoc Anni Verdi, Rome, Italy.
   Univ Siena, Inst Neurol Sci, Neurometab Unit, I-53100 Siena, Italy.
   Osped Bellaria CA Pizzardi, Bologna, Italy.
   Univ Bologna, Ctr Pediat Neurol, Bologna, Italy.
RP Andermann, E (corresponding author), McGill Univ, Montreal Neurol Hosp & Inst, Dept Human Genet, Neurogenet Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.
EM mida@musica.mcgill.ca
RI Lopes-Cendes, Iscia/B-9416-2013; Scheffer, Ingrid E/G-1668-2013;
   DaCosta, Jaderson/C-4968-2015; Dobyns, William/AAI-2768-2020
OI Lopes-Cendes, Iscia/0000-0002-6221-6822; Scheffer, Ingrid
   E/0000-0002-2311-2174; DaCosta, Jaderson/0000-0001-6776-1515; Dobyns,
   William/0000-0002-7681-2844; GIGLI, Gian Luigi/0000-0003-3526-1414;
   Vossler, David/0000-0003-4823-0537; Tassinari, Carlo
   Alberto/0000-0002-4183-5165; federico, antonio/0000-0002-5246-1621;
   FRANZONI, EMILIO/0000-0001-8913-3800; Berkovic,
   Samuel/0000-0003-4580-841X
CR Andermann E, 1996, DYSPLASIAS OF CEREBRAL CORTEX AND EPILEPSY, P11
   Anton ES, 1999, NEURON, V22, P277, DOI 10.1016/S0896-6273(00)81089-2
   Anton ES, 1997, DEVELOPMENT, V124, P3501
   BANCAUD J, 1981, EPILEPSIA, V22, P489, DOI 10.1111/j.1528-1157.1981.tb06159.x
   BARKOVICH AJ, 1994, ANN NEUROL, V36, P609, DOI 10.1002/ana.410360409
   BARKOVICH AJ, 1989, RADIOLOGY, V171, P455, DOI 10.1148/radiology.171.2.2468173
   Berg MJ, 1998, NEUROLOGY, V50, P1143, DOI 10.1212/WNL.50.4.1143
   Cardoso C, 2002, HUM MUTAT, V19, P4, DOI 10.1002/humu.10028
   Cardoso C, 2000, HUM MOL GENET, V9, P3019, DOI 10.1093/hmg/9.20.3019
   *CCTILAE, 1989, EPILEPSIA, V30, P389
   Chong SS, 1997, HUM MOL GENET, V6, P147, DOI 10.1093/hmg/6.2.147
   DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0
   des Portes V, 1998, HUM MOL GENET, V7, P1063, DOI 10.1093/hmg/7.7.1063
   des Portes V, 1998, CELL, V92, P51
   desPortes V, 1997, J MED GENET, V34, P177, DOI 10.1136/jmg.34.3.177
   DEVOLDER AG, 1994, PEDIATR NEUROL, V11, P290, DOI 10.1016/0887-8994(94)90003-5
   DOBYNS WB, 1991, AM J HUM GENET, V48, P584
   Dobyns WB, 1999, NEUROLOGY, V53, P270, DOI 10.1212/WNL.53.2.270
   Dobyns WB, 1996, NEUROLOGY, V47, P331, DOI 10.1212/WNL.47.2.331
   DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838
   Federico A, 1999, NEUROLOGY, V53, P430, DOI 10.1212/WNL.53.2.430
   Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0
   FRANZONI E, 1995, NEUROPEDIATRICS, V26, P37, DOI 10.1055/s-2007-979717
   GALLUCCI M, 1991, AM J NEURORADIOL, V12, P701
   GIGLI GL, 1996, B LEGA ITAL EPIL, V95, P399
   Gleeson JG, 2000, AM J HUM GENET, V67, P574, DOI 10.1086/303043
   Gleeson JG, 1999, ANN NEUROL, V45, P146, DOI 10.1002/1531-8249(199902)45:2<146::AID-ANA3>3.0.CO;2-N
   Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5
   Gleeson JG, 2000, ANN NEUROL, V47, P265, DOI 10.1002/1531-8249(200002)47:2<265::AID-ANA22>3.0.CO;2-N
   Gonzalez JL, 1997, J NEUROSCI, V17, P9204
   Guerrini R, 2001, AM J MED GENET, V106, P160, DOI 10.1002/ajmg.1569
   Harding B, 1996, DYSPLASIAS OF CEREBRAL CORTEX AND EPILEPSY, P81
   HASHIMOTO R, 1993, BRAIN DEV-JPN, V15, P57, DOI 10.1016/0387-7604(93)90007-U
   HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0
   Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599
   IANNETTI P, 1993, ACTA PAEDIATR, V82, P501
   Jacob H, 1938, Z GESAMTE NEUROL PSY, V160, P615, DOI 10.1007/BF02877999
   Jacob H, 1936, Z GESAMTE NEUROL PSY, V155, P1, DOI 10.1007/BF02865566
   Kato M, 2001, ANN NEUROL, V50, P547, DOI 10.1002/ana.1231
   KETONEN L, 1994, J CHILD NEUROL, V9, P384, DOI 10.1177/088307389400900409
   LANDY HJ, 1993, EPILEPSIA, V34, P79, DOI 10.1111/j.1528-1157.1993.tb02379.x
   LEDBETTER SA, 1992, AM J HUM GENET, V50, P182
   LoNigro C, 1997, HUM MOL GENET, V6, P157, DOI 10.1093/hmg/6.2.157
   Luria AR, 1973, WORKING BRAIN INTRO
   Matell M, 1893, ARCH PSYCHIAT NERVEN, V25, P124
   Matsumoto N, 2001, EUR J HUM GENET, V9, P5, DOI 10.1038/sj.ejhg.5200548
   MIURA K, 1993, BRAIN DEV-JPN, V15, P288, DOI 10.1016/0387-7604(93)90025-4
   OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1
   Ono J, 1997, NEUROLOGY, V48, P1701, DOI 10.1212/WNL.48.6.1701
   PALMINI A, 1991, NEUROLOGY, V41, P1656, DOI 10.1212/WNL.41.10.1656
   PALMINI A, 1993, DEV MED CHILD NEUROL, V35, P331
   PARMEGGIANI A, 1994, BRAIN DEV-JPN, V16, P320, DOI 10.1016/0387-7604(94)90031-0
   Pilz D, 2002, J NEUROPATH EXP NEUR, V61, P1
   Pilz DT, 1999, HUM MOL GENET, V8, P1757, DOI 10.1093/hmg/8.9.1757
   Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029
   PINARD JM, 1994, J NEUROL NEUROSUR PS, V57, P914, DOI 10.1136/jnnp.57.8.914
   Pinard JM, 2000, NEUROLOGY, V54, P1531, DOI 10.1212/WNL.54.7.1531
   Poolos NP, 2002, NEUROLOGY, V58, P1559, DOI 10.1212/WNL.58.10.1559
   RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9
   REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0
   RICCI S, 1992, ARCH NEUROL-CHICAGO, V49, P61, DOI 10.1001/archneur.1992.00530250065017
   Rice DS, 1998, DEVELOPMENT, V125, P3719
   Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3
   Ross ME, 1997, HUM MOL GENET, V6, P555, DOI 10.1093/hmg/6.4.555
   Saneto RP, 1998, AM J MED GENET, V80, P42, DOI 10.1002/(SICI)1096-8628(19981102)80:1<42::AID-AJMG7>3.0.CO;2-S
   Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977
   SCHEFFER IE, 1994, ANN NEUROL, V36, P511
   Sossey-Alaoui K, 1998, HUM MOL GENET, V7, P1327, DOI 10.1093/hmg/7.8.1327
   SOUCEK D, 1992, WIEN KLIN WOCHENSCHR, V104, P607
   Stern JM, 1996, NEUROLOGY, V47, P821, DOI 10.1212/WNL.47.3.821
   TOHYAMA J, 1993, BRAIN DEV-JPN, V15, P83, DOI 10.1016/0387-7604(93)90012-W
   Vossler DG, 1999, J CHILD NEUROL, V14, P282, DOI 10.1177/088307389901400503
   WIEST W D, 1958, Dtsch Z Nervenheilkd, V178, P224
   WILSON GN, 1985, AM J MED GENET, V20, P277, DOI 10.1002/ajmg.1320200211
   Yoneshima H, 1997, NEUROSCI RES, V29, P217, DOI 10.1016/S0168-0102(97)00088-6
NR 75
TC 65
Z9 68
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD NOV
PY 2002
VL 125
BP 2507
EP 2522
DI 10.1093/brain/awf248
PN 11
PG 16
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 608FH
UT WOS:000178834400012
PM 12390976
OA Bronze
DA 2020-12-08
ER

PT J
AU Palmini, A
   Chandler, C
   Andermann, F
   da Costa, JC
   Paglioli-Neto, E
   Polkey, C
   Rosenblatt, B
   Montes, J
   Martinez, JV
   Farmer, JP
   Sinclair, B
   Aronyk, K
   Paglioli, E
   Coutinho, L
   Raupp, S
   Portuguez, M
AF Palmini, A
   Chandler, C
   Andermann, F
   da Costa, JC
   Paglioli-Neto, E
   Polkey, C
   Rosenblatt, B
   Montes, J
   Martinez, JV
   Farmer, JP
   Sinclair, B
   Aronyk, K
   Paglioli, E
   Coutinho, L
   Raupp, S
   Portuguez, M
TI Resection of the lesion in patients with hypothalamic hamartomas and
   catastrophic epilepsy
SO NEUROLOGY
LA English
DT Article
ID GELASTIC SEIZURES; PRECOCIOUS PUBERTY; ICTAL LAUGHTER; DROP ATTACKS;
   EVOLUTION
AB Background: Patients with hypothalamic hamartomas (HH) often have severe refractory epilepsy, incapacitating behavioral abnormalities, and cognitive decline. Attempts to control the seizure disorder by resection of apparently epileptogenic mesial temporal or other cortical structures have failed consistently. Objective: To report a series of 13 patients in whom the hamartoma itself was resected. Methods: All patients underwent preoperative evaluation between ages 2 and 33 years and had subtotal or complete resection of the hamartoma. Follow-up ranged from 1 to 5.5 years (mean: 2.8 y). Results: Preoperatively, all patients had variable combinations of gelastic, complex partial, and generalized seizures. Eight had drop attacks. In addition, all had marked behavior abnormalities and cognitive impairment. Postoperatively, two patients are completely seizure-free and 11 are either seizure-free or have achieved a greater than 90% reduction of drop attacks and generalized tonic-clonic seizures. However, minor gelastic, complex partial, and atypical absence seizures have persisted in 11 patients, although at significantly reduced rates. In addition, there has been a dramatic improvement in behavior and cognition. Three patients had an anterior thalamic and one a capsular infarct, which left only minimal long-term deficits. Exact location of the lesion in relation to the interpeduncular fossa and the walls of the third ventricle correlated with extent of excision, seizure control, and complication rate. Conclusion: Resection can alleviate both the seizures and the behavioral and cognitive abnormalities of hypothalamic hamartomas, but complications are frequent.
C1 Hosp Sao Lucas, PUCRS, Serv Neurol, Porto Alegre Epilepsy Surg Program, BR-90610000 Porto Alegre, RS, Brazil.
   McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Inst, Montreal, PQ H3A 2T5, Canada.
   Kings Coll Hosp London, Dept Neurosurg, London, England.
   McGill Univ, Montreal Childrens Hosp, Dept Neurol & Neurosurg, Montreal, PQ H3A 2T5, Canada.
   Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada.
RP Palmini, A (corresponding author), Hosp Sao Lucas, PUCRS, Serv Neurol, Porto Alegre Epilepsy Surg Program, Avenida Ipiranga 6690 220, BR-90610000 Porto Alegre, RS, Brazil.
EM apalmini@conex.com.br
RI Portuguez, Mirna/A-9362-2018; DaCosta, Jaderson/C-4968-2015
OI Portuguez, Mirna/0000-0003-4068-6249; DaCosta,
   Jaderson/0000-0001-6776-1515
CR ALBRIGHT AL, 1993, J NEUROSURG, V78, P77, DOI 10.3171/jns.1993.78.1.0077
   Alpers BJ, 1939, RES PUBL ASSOC RES N, V20, P725
   ARROYO S, 1993, BRAIN, V116, P757, DOI 10.1093/brain/116.4.757
   Arroyo S, 1997, EPILEPSIA, V38, P114, DOI 10.1111/j.1528-1157.1997.tb01085.x
   Berkovic SF, 1997, EPILEPSIA, V38, P1
   BERKOVIC SF, 1988, ANN NEUROL, V23, P429, DOI 10.1002/ana.410230502
   BRENINGSTALL GN, 1985, NEUROLOGY, V35, P1180, DOI 10.1212/WNL.35.8.1180
   Bronstein IP, 1942, AM J DIS CHILD, V64, P211
   CASCINO GD, 1993, NEUROLOGY, V43, P747, DOI 10.1212/WNL.43.4.747
   CHUGANI HT, 1990, ANN NEUROL, V27, P406, DOI 10.1002/ana.410270408
   Delalande Olivier R., 1998, Epilepsia, V39, P90
   DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279
   DRIGGS M, 1939, ARCH PATH ANAT, V305, P567
   Flynn F G, 1988, Behav Neurol, V1, P49, DOI 10.3233/BEN-1988-1107
   Fukuda M, 1999, NEUROSURGERY, V44, P1347, DOI 10.1097/00006123-199906000-00115
   GAMBARDELLA A, 1994, NEUROLOGY, V44, P1074, DOI 10.1212/WNL.44.6.1074
   GASCON GG, 1971, EPILEPSIA, V12, P63, DOI 10.1111/j.1528-1157.1971.tb03916.x
   GLOOR P, 1996, TEMPORAL LOBE LIMBIC
   Kuzniecky R, 1997, ANN NEUROL, V42, P60, DOI 10.1002/ana.410420111
   LIST CF, 1958, NEUROLOGY, V8, P164, DOI 10.1212/WNL.8.3.164
   MACHADO HR, 1991, CHILD NERV SYST, V7, P462, DOI 10.1007/BF00263190
   Mendez MF, 1999, J NEUROPSYCH CLIN N, V11, P253
   MEYER JE, 1948, ARCH PSYCHIAT, V179, P378
   MIZUTANI T, 1981, ARCH NEUROL-CHICAGO, V38, P379, DOI 10.1001/archneur.1981.00510060081017
   MUNARI C, 1995, ELECTROEN CLIN NEURO, V95, P154, DOI 10.1016/0013-4694(95)00063-5
   Murphy JV, 2000, PEDIATR NEUROL, V23, P167, DOI 10.1016/S0887-8994(00)00170-3
   NGUYEN JP, 1991, ENCY MED CHIR NEUROL, pS10
   NISHIO S, 1994, EPILEPSIA, V35, P514, DOI 10.1111/j.1528-1157.1994.tb02470.x
   PAILLAS JE, 1969, REV NEUROL-FRANCE, V120, P177
   Parrent AG, 1999, J NEUROSURG, V91, P881, DOI 10.3171/jns.1999.91.5.0881
   PAZZAGLIA P, 1985, NEUROLOGY, V35, P1725, DOI 10.1212/WNL.35.12.1725
   Plouin P, 1983, Rev Electroencephalogr Neurophysiol Clin, V13, P312, DOI 10.1016/S0370-4475(83)80044-6
   PONSOT G, 1983, ARCH FR PEDIATR, V40, P757
   REEVES AG, 1969, ARCH NEUROL-CHICAGO, V20, P616, DOI 10.1001/archneur.1969.00480120062005
   Regis J, 2000, NEUROSURGERY, V47, P1343
   Rosenfeld JV, 2001, NEUROSURGERY, V48, P108, DOI 10.1097/00006123-200101000-00019
   SECKEL HPG, 1949, AM J DIS CHILD, V78, P484
   STOTIJN CPJ, 1950, J NERV MENT DIS, V111, P207, DOI 10.1097/00005053-195011130-00002
   Sturm JW, 2000, NEUROLOGY, V54, P971, DOI 10.1212/WNL.54.4.971
   STUTTE H, 1950, Dtsch Z Nervenheilkd, V164, P157, DOI 10.1007/BF00216980
   TASSINARI CA, 1997, EPILEPSY COMPREHENSI, P605
   VALDUEZA JM, 1994, NEUROSURGERY, V34, P949, DOI 10.1227/00006123-199406000-00001
NR 42
TC 110
Z9 118
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAY 14
PY 2002
VL 58
IS 9
BP 1338
EP 1347
DI 10.1212/WNL.58.9.1338
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 550WT
UT WOS:000175528300006
PM 12011278
DA 2020-12-08
ER

PT J
AU Bernasconi, A
   Martinez, V
   Rosa-Neto, P
   D'Agostino, D
   Bernasconi, N
   Berkovic, S
   MacKay, M
   Harvey, AS
   Palmini, A
   da Costa, JC
   Paglioli, E
   Kim, HI
   Connolly, M
   Olivier, A
   Dubeau, F
   Andermann, E
   Guerrini, R
   Whisler, W
   de Toledo-Morrell, L
   Morrell, F
   Andermann, F
AF Bernasconi, A
   Martinez, V
   Rosa-Neto, P
   D'Agostino, D
   Bernasconi, N
   Berkovic, S
   MacKay, M
   Harvey, AS
   Palmini, A
   da Costa, JC
   Paglioli, E
   Kim, HI
   Connolly, M
   Olivier, A
   Dubeau, F
   Andermann, E
   Guerrini, R
   Whisler, W
   de Toledo-Morrell, L
   Morrell, F
   Andermann, F
TI Surgical resection for intractable epilepsy in "double cortex" syndrome
   yields inadequate results
SO EPILEPSIA
LA English
DT Article
DE subcortical band heterotopia; double cortex; surgery; intractable
   epilepsy; MRI
ID NEURONAL MIGRATION; CORTICAL DYSPLASIA; CORPUS CALLOSOTOMY; BAND
   HETEROTOPIA; SEIZURES; EEG; BRAIN
AB Purpose: To analyze the results of surgical treatment of intractable epilepsy in patients with subcortical band heterotopia, or double cortex syndrome, a diffuse neuronal migration disorder.
   Methods: We studied eight patients (five women) with double cortex syndrome and intractable epilepsy. All had a comprehensive presurgical evaluation including prolonged video-EEG recordings and magnetic resonance imaging (MRI).
   Results: All patients had partial seizures, with secondary generalization in six of them. Neurologic examination was normal in all. Three were of normal intelligence, and five were mildly retarded. Six patients underwent invasive EEG recordings, three of them with subdural grids and three with stereotactic implanted depth electrodes (SEEG). Although EEG recordings showed multilobar epileptic abnormalities in most patients, regional or focal seizure onset was recorded in all. MRI showed bilateral subcortical band heterotopia, asymmetric in thickness in three. An additional area of cortical thickening in the left frontal lobe was found in one patient. Surgical procedures included multiple subpial transections in two patients, frontal lesionectomy in one, temporal lobectomy with amygdalohippocampectomy in five, and an additional anterior callosotomy in one. Five patients had no significant improvement, two had some improvement, and one was greatly improved.
   Conclusion: Our results do not support focal surgical removal of epileptogenic tissue in patients with double cortex syndrome, even in the presence of a relatively localized epileptogenic area.
C1 McGill Univ, Montreal Neurol Hosp & Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada.
   Pontificia Univ Catolica RS, Hosp Sao Lucas, Porto Alegre, RS, Brazil.
   Chonbuk Natl Univ, Sch Med, Dept Neurosurg, Chonju, South Korea.
   UCL, Great Ormond St Hosp Children NHS Trust, London, England.
   Rush Presbyterian St Lukes Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA.
   Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
RP Bernasconi, A (corresponding author), McGill Univ, Montreal Neurol Hosp & Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.
EM andrea@bic.mni.mcgill.ca
RI Rosa-Neto, Pedro/C-3494-2011; DaCosta, Jaderson/C-4968-2015; ROSA-NETO,
   PEDRO/F-5077-2015
OI DaCosta, Jaderson/0000-0001-6776-1515; ROSA-NETO,
   PEDRO/0000-0001-9116-1376; Berkovic, Samuel/0000-0003-4580-841X; Mackay,
   Mark/0000-0002-3787-1112; Connolly, Mary/0000-0002-7784-942X; Kim,
   Hyoung-Ihl/0000-0001-7914-3968
CR BARKOVICH AJ, 1994, ANN NEUROL, V36, P609, DOI 10.1002/ana.410360409
   BARKOVICH AJ, 1989, RADIOLOGY, V171, P455, DOI 10.1148/radiology.171.2.2468173
   CASCINO GD, 1993, NEUROLOGY, V43, P747, DOI 10.1212/WNL.43.4.747
   Dobyns WB, 1996, NEUROLOGY, V47, P331, DOI 10.1212/WNL.47.2.331
   Engel Jerome Jr., 1993, P609
   Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5
   Gleeson JG, 2000, ANN NEUROL, V47, P265, DOI 10.1002/1531-8249(200002)47:2<265::AID-ANA22>3.0.CO;2-N
   GRANATA T, 1994, ITAL J NEUROL SCI, V15, P15, DOI 10.1007/BF02343493
   Harding B, 1996, DYSPLASIAS OF CEREBRAL CORTEX AND EPILEPSY, P81
   LANDY HJ, 1993, EPILEPSIA, V34, P79, DOI 10.1111/j.1528-1157.1993.tb02379.x
   Li LM, 1997, ANN NEUROL, V41, P662, DOI 10.1002/ana.410410516
   MARCHAL G, 1989, ARCH NEUROL-CHICAGO, V46, P430, DOI 10.1001/archneur.1989.00520400090025
   MORRELL F, 1989, J NEUROSURG, V70, P231, DOI 10.3171/jns.1989.70.2.0231
   PALMINI A, 1991, CAN J NEUROL SCI, V18, P580, DOI 10.1017/S0317167100032753
   PALMINI A, 1991, NEUROLOGY, V41, P1656, DOI 10.1212/WNL.41.10.1656
   PARMEGGIANI A, 1994, BRAIN DEV-JPN, V16, P320, DOI 10.1016/0387-7604(94)90031-0
   RAYMOND AA, 1995, BRAIN, V118, P629, DOI 10.1093/brain/118.3.629
   RICCI S, 1992, ARCH NEUROL-CHICAGO, V49, P61, DOI 10.1001/archneur.1992.00530250065017
   Ross ME, 1997, HUM MOL GENET, V6, P555, DOI 10.1093/hmg/6.4.555
   Vossler DG, 1999, J CHILD NEUROL, V14, P282, DOI 10.1177/088307389901400503
NR 20
TC 47
Z9 49
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD SEP
PY 2001
VL 42
IS 9
BP 1124
EP 1129
DI 10.1046/j.1528-1157.2001.39900.x
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 479TC
UT WOS:000171418800003
PM 11580758
DA 2020-12-08
ER

PT J
AU Oliveira, AJ
   Nunes, ML
   Haertel, LM
   Reis, FM
   da Costa, JC
AF Oliveira, AJ
   Nunes, ML
   Haertel, LM
   Reis, FM
   da Costa, JC
TI Duration of rhythmic EEG patterns in neonates: new evidence for clinical
   and prognostic significance of brief rhythmic discharges
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE newborn; neonatal EEG; neonatal seizures; asphyxia; outcome
ID HEALTHY NEWBORNS; FULL-TERM; SEIZURES; QUANTIFICATION; CONTROVERSIES;
   EPILEPSY; PRETERM
AB Objective: This study aimed at identifying the characteristics - especially the duration - of rhythmic discharges in neonatal EEG, and their association with clinical neonatal problems. Specifically, we aimed at testing the diagnostic and prognostic validity of using 10 s as minimal duration for defining electroencephalographic seizures.
   Design and methods: The polysomnographies of 340 neonates were reviewed, and episodes of rhythmic discharges were identified, analyzed, and quantified. The study sample was divided into 3 groups: one in which the maximal duration of rhythmic discharges was shorter than 10 s (brief rhythmic discharges, BRD), a second one in which there were rhythmic discharges longer than 10 s (long rhythmic discharges, LRD), and finally a group in which no rhythmic discharge was found (No-RD). These 3 groups of subjects were compared for the baseline and outcome clinical data.
   Results: From the 340 neonates studied, 210 did not present any form of rhythmic discharge, 67 (19.7%) had only BRD episodes, and 63 (18.5%) had at least one LRD episode. Prevalence of rhythmic discharges was low among healthy full term newborns, and was significantly higher among preterm and high-risk newborns, Electrophysiological characteristics of rhythmic discharges did not differ between healthy neonates and high-risk ones. Accompanying clinical manifestations were present in 26.3% of the LRD group, but also in 15.9% of the BRD group. The presence of BRD was significantly associated with leukomalacia and with hypoglycemia in the cross-sectional analysis of baseline data, and with an increased risk for abnormal neurodevelopmental outcome after a mean follow-up period of 47 months (adjusted relative risk = 4.90, P < 0.01).
   Conclusions: The present data demonstrate an association between BRD and clinical history of hypoxic-ischemic encephalopathy, especially when complicated by leukomalacia, and also with a prognosis of increased risk for abnormal neurodevelopmental outcome. The clinical and prognostic significance of isolated BRD justifies the need to include these brief episodes in future studies of neonatal seizures. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
C1 Pontificia Univ Catolica Rio Grande Sul, Hosp Sao Lucas, Serv Neurol, Dept Internal Med,Div Neurol, BR-90610000 Porto Alegre, RS, Brazil.
   Univ Fed Rio Grande Sul, ICBS, Dept Physiol, Porto Alegre, RS, Brazil.
RP Nunes, ML (corresponding author), Pontificia Univ Catolica Rio Grande Sul, Hosp Sao Lucas, Serv Neurol, Dept Internal Med,Div Neurol, Av Ipiranga 6690,Sala 322, BR-90610000 Porto Alegre, RS, Brazil.
RI Reis, Fernando M./E-5930-2013; DaCosta, Jaderson/C-4968-2015
OI Reis, Fernando M./0000-0002-9258-7472; DaCosta,
   Jaderson/0000-0001-6776-1515
CR ARFEL G, 1977, REV EEG NEUROPHYSIOL, V7, P351, DOI 10.1016/S0370-4475(77)80014-2
   BYE AME, 1995, EPILEPSIA, V36, P1009, DOI 10.1111/j.1528-1157.1995.tb00960.x
   CLANCY RR, 1991, EPILEPSIA, V32, P69, DOI 10.1111/j.1528-1157.1991.tb05614.x
   CLANCY RR, 1987, EPILEPSIA, V28, P537, DOI 10.1111/j.1528-1157.1987.tb03685.x
   CLANCY RR, 1988, EPILEPSIA, V29, P256, DOI 10.1111/j.1528-1157.1988.tb03715.x
   DACOSTA JC, 1992, PEDIATR NEUROL, V8, P382
   DREYFUSBRISAC C, 1972, HDB ELECTROENCEPHALO, P38
   ENGEL JJ, 1992, EPILEPSY RES S, V9
   Engel R., 1975, ABNORMAL ELECTROENCE
   HAYAKAWA F, 1987, ELECTROEN CLIN NEURO, V67, P27, DOI 10.1016/0013-4694(87)90158-1
   HOLMES GL, 1988, INT PEDIAT, V3, P158
   HRACHOVY RA, 1990, CURRENT PRACTICE CLI, P201
   HUGHES JR, 1987, ELECTROEN CLIN NEURO, V67, P7, DOI 10.1016/0013-4694(87)90156-8
   J Aicardi, 1986, EPILEPSY CHILDREN, P183
   JOHNSTON MV, 1993, PEDIAT EPILEPSY DIAG, P27
   Kellaway P, 1983, Adv Neurol, V34, P93
   Lombroso C., 1974, HDB CLIN NEUROLOGY, P189
   LOMBROSO CT, 1979, ELECTROEN CLIN NEURO, V46, P460, DOI 10.1016/0013-4694(79)90147-0
   Lombroso CT, 1996, EPILEPSIA, V37, P5, DOI 10.1111/j.1528-1157.1996.tb01814.x
   Lombroso CT, 1993, ELECTROENCEPHALOGRAP, P803
   LOMBROSO CT, 1983, EPILEPSY DIAGNOSIS M, P297
   LOMBROSO CT, 1965, 11 INT C PED P, P38
   LOMBROSO CT, 1981, CURRENT CLIN NEUROPH, P83
   LOMBROSO CT, 1998, FUNDAMENTOS NEUROBIO
   LOU HC, 1979, ACTA PAEDIATR SCAND, V68, P803
   MIZRAHI EM, 1989, CLIN PERINATOL, V16, P485
   MONOD N, 1972, ELECTROEN CLIN NEURO, V32, P529, DOI 10.1016/0013-4694(72)90063-6
   NUNES ML, 1995, ARQ NEURO-PSIQUIAT, V53, P625, DOI 10.1590/S0004-282X1995000400013
   Nunes ML, 1997, ELECTROEN CLIN NEURO, V102, P186, DOI 10.1016/S0013-4694(96)95191-7
   Ortibus EL, 1996, ELECTROEN CLIN NEURO, V98, P175, DOI 10.1016/0013-4694(95)00245-6
   RADVANYBOUVET MF, 1985, NEUROPEDIATRICS, V16, P143, DOI 10.1055/s-2008-1052559
   SCHER MS, 1989, PEDIATR CLIN N AM, V36, P281
   SCHER MS, 1986, EPILEPSIA, V27, P609
   SCHER MS, 1989, J CHILD NEUROL, V4, P175, DOI 10.1177/088307388900400303
   SCHER MS, 1989, PEDIATR NEUROL, V5, P17, DOI 10.1016/0887-8994(89)90004-0
   SHEWMON DA, 1990, J CLIN NEUROPHYSIOL, V7, P315, DOI 10.1097/00004691-199007000-00003
   TORRES F, 1985, J CLIN NEUROPHYSIOL, V2, P89, DOI 10.1097/00004691-198504000-00001
   Volpe JJ, 1987, NEUROLOGY NEWBORN
   WASTERLAIN CG, 1976, ARCH NEUROL-CHICAGO, V33, P831
   WATANABE K, 1972, DEV MED CHILD NEUROL, V14, P373
   WEINER SP, 1991, PEDIATR NEUROL, V7, P363, DOI 10.1016/0887-8994(91)90067-U
   ZARET BS, 1991, CLIN ELECTROENCEPHAL, V22, P13, DOI 10.1177/155005949102200106
NR 42
TC 41
Z9 42
U1 0
U2 0
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 1388-2457
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD SEP
PY 2000
VL 111
IS 9
BP 1646
EP 1653
DI 10.1016/S1388-2457(00)00380-1
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 350MT
UT WOS:000089106000018
PM 10964078
DA 2020-12-08
ER

PT J
AU Oliveira, AJ
   Nunes, ML
   da Costa, JC
AF Oliveira, AJ
   Nunes, ML
   da Costa, JC
TI Polysomnography in neonatal seizures
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE newborn; neonatal EEG; polysomnography; neonatal seizures
ID PREMATURE-INFANTS; SHARP WAVES; FULL-TERM; HEALTHY NEWBORNS; PROGNOSTIC
   VALUE; EEG ACTIVITY; ELECTROENCEPHALOGRAM; EPILEPSY; CLASSIFICATION;
   MATURATION
AB Seizures are one of the most frequent problems in the neonatal period, and are frequently associated with high mortality and morbidity rates. On the other hand, neonatal seizures may represent a first or even the only sign of central nervous system dysfunction. However, establishing the diagnosis of neonatal seizures poses several problems, and clinical observation is not sufficient in many cases. Neonatal polysomnography is a valuable tool both in the diagnostic and in the prognostic assessment of neonatal seizures. The present text reviews some technical aspects related to neonatal polysomnographies, and its usefulness in the area of suspected neonatal seizures. Moreover, some questions are raised regarding rhythmic discharges and their significance as a possible ictal and interictal epileptic pattern in the neonate. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
C1 Pontificia Univ Catolica Rio de Janeiro, Sao Lucas Univ Hosp, Dept Internal Med, Div Neurol, Porto Alegre, RS, Brazil.
   Univ Fed Rio Grande do Sul, ICBS, Dept Physiol, Porto Alegre, RS, Brazil.
RP da Costa, JC (corresponding author), PUC RS, Hosp Sao Lucas, Serv Neurol, Av Ipirangn 6690,Sala 322, BR-90610000 Porto Alegre, RS, Brazil.
EM jdacosta@plug-in.com.br
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR ARFEL G, 1977, REV EEG NEUROPHYSIOL, V7, P351, DOI 10.1016/S0370-4475(77)80014-2
   ASO K, 1989, J CLIN NEUROPHYSIOL, V6, P103, DOI 10.1097/00004691-198904000-00001
   BIAGIONI E, 1994, ELECTROEN CLIN NEURO, V91, P154, DOI 10.1016/0013-4694(94)90065-5
   BYE AME, 1995, EPILEPSIA, V36, P1009, DOI 10.1111/j.1528-1157.1995.tb00960.x
   CHUNG HJ, 1991, ELECTROEN CLIN NEURO, V79, P256
   CLANCY RR, 1991, EPILEPSIA, V32, P69, DOI 10.1111/j.1528-1157.1991.tb05614.x
   CLANCY RR, 1987, EPILEPSIA, V28, P537, DOI 10.1111/j.1528-1157.1987.tb03685.x
   CLANCY RR, 1988, EPILEPSIA, V29, P256, DOI 10.1111/j.1528-1157.1988.tb03715.x
   Cukier F, 1972, Rev Electroencephalogr Neurophysiol Clin, V2, P318, DOI 10.1016/S0370-4475(72)80037-6
   DACOSTA JC, 1980, ELECTROEN CLIN NEURO, V50, pP183
   DACOSTA JC, 1992, PEDIATR NEUROL, V8, P382
   DREYFUSBRISAC C, 1972, HDB ELECTROENCEPHALO, P38
   Engel R., 1975, ABNORMAL ELECTROENCE
   GOLDBERG RN, 1982, PEDIATRICS, V69, P583
   GOTO K, 1992, ELECTROEN CLIN NEURO, V82, P197, DOI 10.1016/0013-4694(92)90167-G
   HAHN JS, 1989, ELECTROEN CLIN NEURO, V73, P410, DOI 10.1016/0013-4694(89)90090-4
   HAUSER WA, 1994, EPILEPSIA, V35, pS1, DOI 10.1111/j.1528-1157.1994.tb05932.x
   HAYAKAWA F, 1987, ELECTROEN CLIN NEURO, V67, P27, DOI 10.1016/0013-4694(87)90158-1
   HOLMES GL, 1986, J CLIN NEUROPHYSIOL, V3, P209, DOI 10.1097/00004691-198607000-00002
   HRACHOVY RA, 1990, CURRENT PRACTICE CLI, P201
   HUGHES JR, 1994, CLIN ELECTROENCEPHAL, V25, P127, DOI 10.1177/155005949402500404
   HUGHES JR, 1987, ELECTROEN CLIN NEURO, V67, P7, DOI 10.1016/0013-4694(87)90156-8
   J Aicardi, 1986, EPILEPSY CHILDREN, P183
   Kellaway P, 1987, EPILEPSY ELECTROCLIN, P13
   KELLAWAY P, 1990, NEONATAL SEIZURES, P1
   Lombroso C., 1974, HDB CLIN NEUROLOGY, P189
   LOMBROSO CT, 1985, PEDIATRICS, V76, P52
   LOMBROSO CT, 1979, ELECTROEN CLIN NEURO, V46, P460, DOI 10.1016/0013-4694(79)90147-0
   LOMBROSO CT, 1985, J CLIN NEUROPHYSIOL, V2, P105, DOI 10.1097/00004691-198504000-00002
   Lombroso CT, 1993, ELECTROENCEPHALOGRAP, P803
   LOMBROSO CT, 1983, EPILEPSY DIAGNOSIS M, P297
   LOMBROSO CT, 1982, ELECTROENCEPHALOGRAP, P599
   LOMBROSO CT, 1998, FUNDAMENTOS NEUROBIO, P173
   LOU HC, 1979, ACTA PAEDIATR SCAND, V68, P803
   MCMENAMIN JB, 1984, ANN NEUROL, V15, P285, DOI 10.1002/ana.410150315
   MIZRAHI EM, 1987, NEUROLOGY, V37, P1837, DOI 10.1212/WNL.37.12.1837
   MONOD N, 1972, ELECTROEN CLIN NEURO, V32, P529, DOI 10.1016/0013-4694(72)90063-6
   NOVOTNY EJ, 1987, NEUROLOGY, V37, P1481, DOI 10.1212/WNL.37.9.1481
   Nunes ML, 2000, CLIN NEUROPHYSIOL, V111, P305, DOI 10.1016/S1388-2457(99)00234-5
   OLIVEIRA AJ, 2000, IN PRESS CLIN NEUROP
   Ortibus EL, 1996, ELECTROEN CLIN NEURO, V98, P175, DOI 10.1016/0013-4694(95)00245-6
   RADVANYBOUVET MF, 1985, NEUROPEDIATRICS, V16, P143, DOI 10.1055/s-2008-1052559
   Sarnat HB, 1984, TOPICS NEONATAL NEUR, P1
   SCHER MS, 1988, J CHILD NEUROL, V3, P135, DOI 10.1177/088307388800300212
   SCHER MS, 1989, J CHILD NEUROL, V4, P175, DOI 10.1177/088307388900400303
   SCHER MS, 1989, PEDIATR NEUROL, V5, P17, DOI 10.1016/0887-8994(89)90004-0
   SCHER MS, 1994, ELECTROEN CLIN NEURO, V90, P179, DOI 10.1016/0013-4694(94)90089-2
   SHEWMON DA, 1990, J CLIN NEUROPHYSIOL, V7, P315, DOI 10.1097/00004691-199007000-00003
   SHORVON SD, 1990, LANCET, V336, P93, DOI 10.1016/0140-6736(90)91603-8
   THARP BR, 1983, CRIT CARE MED, V11, P926, DOI 10.1097/00003246-198312000-00004
   THARP BR, 1990, J CLIN NEUROPHYSIOL, V7, P302, DOI 10.1097/00004691-199007000-00002
   THARP BR, 1981, ELECTROEN CLIN NEURO, V51, P219, DOI 10.1016/0013-4694(81)90136-X
   VOLPE JJ, 1990, NEONATAL SEIZURES, P27
   WEINER SP, 1991, PEDIATR NEUROL, V7, P363, DOI 10.1016/0887-8994(91)90067-U
   ZARET BS, 1991, CLIN ELECTROENCEPHAL, V22, P13, DOI 10.1177/155005949102200106
NR 55
TC 12
Z9 12
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1388-2457
EI 1872-8952
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD SEP
PY 2000
VL 111
SU 2
BP S74
EP S80
DI 10.1016/S1388-2457(00)00405-3
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 363QZ
UT WOS:000089847200011
PM 10996558
DA 2020-12-08
ER

PT J
AU Nunes, ML
   Penela, MM
   da Costa, JC
AF Nunes, ML
   Penela, MM
   da Costa, JC
TI Differences in the dynamics of frontal sharp transients in normal and
   hypoglycemic newborns
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE frontal sharp transients; neonatal EEG; hypoglycemia; small for
   gestational age newborns
ID FULL-TERM; PRETERM; EEG
AB Objective: This study focuses on the characteristics of frontal sharp transients (FST), a normal variant of neonatal EEG, in newborns with hypoglycemia.
   Methods: The EEG from 20 newborns with symptomatic hypoglycemia were compared with a control group of normal newborns matched by conceptional age. The dynamics of these transients were evaluated concerning sleep stages. The density, type and bilateral synchrony of FST were also calculated. The results were compared in the two groups by Student's t test.
   Results: When compared with controls, hypoglycemic newborns have increased density of frontal sharp transients in all sleep stages but less bilateral synchrony (P < 0.05). FST density was even higher in small for gestational age newborns.
   Conclusions: The data suggests that normal patterns of neonatal EEG as FST can be influenced by systemic disturbances. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
C1 Pontificia Univ Catolica Rio Grande Sul, Sch Med, Hosp Sao Lucas, Div Neurol, Porto Alegre, RS, Brazil.
   Hosp Clin, Inst Neurol, Montevideo, Uruguay.
RP Nunes, ML (corresponding author), Pontificia Univ Catolica Rio Grande Sul, Sch Med, Hosp Sao Lucas, Div Neurol, Porto Alegre, RS, Brazil.
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR Anders T, 1971, MANUAL STANDARDIZED
   ARFEL G, 1977, REV EEG NEUROPHYSIOL, V7, P351, DOI 10.1016/S0370-4475(77)80014-2
   BHATIA VP, 1980, ARCH DIS CHILD, V55, P134, DOI 10.1136/adc.55.2.134
   CURZIDASCALOVA L, 1989, BRAIN DYSFUNCT, V2, P245
   DASCALOVA LC, 1996, MANUAL METHODS RECOR
   ELLINGSON RJ, 1980, ELECTROEN CLIN NEURO, V50, P457
   LEVITTKATZ L, 1996, INTENSIVE CARE FETUS, P201
   LOMBROSO CT, 1985, J CLIN NEUROPHYSIOL, V2, P105, DOI 10.1097/00004691-198504000-00002
   Lombroso CT, 1993, ELECTROENCEPHALOGRAP, P803
   MONOD N, 1960, Rev Neurol (Paris), V102, P375
   NUNES ML, 1995, ARQ NEURO-PSIQUIAT, V53, P625, DOI 10.1590/S0004-282X1995000400013
   Nunes ML, 1997, ELECTROEN CLIN NEURO, V102, P186, DOI 10.1016/S0013-4694(96)95191-7
   NUNES ML, 1995, ELECTROEN CLIN NEURO, V95, P12
   NUNES ML, 1998, BRAZIL J ELECTROENCE, V4, P7
   NUNES ML, 1994, THESIS U CAMPINAS SA
   SCHER MS, 1994, ELECTROEN CLIN NEURO, V90, P179, DOI 10.1016/0013-4694(94)90089-2
   Stockard-Pope J E, 1992, ATLAS NEONATAL ELECT
   TORRES F, 1985, J CLIN NEUROPHYSIOL, V2, P89, DOI 10.1097/00004691-198504000-00001
   Volpe J., 1995, NEUROLOGY NEWBORN
NR 19
TC 11
Z9 12
U1 0
U2 1
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 1388-2457
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD FEB
PY 2000
VL 111
IS 2
BP 305
EP 310
DI 10.1016/S1388-2457(99)00234-5
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 278UU
UT WOS:000085008000014
PM 10680566
DA 2020-12-08
ER

PT J
AU Nunes, ML
   Da Costa, JC
   Stancher, VM
   Diament, A
   Arita, F
   Rosemberg, S
   Dyken, P
AF Nunes, ML
   Da Costa, JC
   Stancher, VM
   Diament, A
   Arita, F
   Rosemberg, S
   Dyken, P
TI Subacute sclerosing panencephalitis - Clinical aspects and prognosis -
   The Brazilian registry
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE immunization; measles; seizures; subacute sclerosing panencephalitis
AB Subacute sclerosing panencephalitis (SSPE) is an inflammatory neurodegenerative disease related to the persistence of measles virus. Although its frequency is declining because of measles eradication, we still have some cases being diagnosed. With the aim to describe epidemiological as peels of SS PB in Brazil, we sent a protocol to Child Neurologists around the country, 48 patients were registered, 27 (56%) were from the southeast region, 34 (71%) were male and 35 (73%) white, 27 (56%) had measles, 9 (19%) had measles and were also immunized, 7 (14%) received only immunization, 1 patient had a probable neonatal form. Mean time between first symptoms and diagnosis was 12 months (22 started with myoclonus or tonic-clonic seizures, 7 (14%) with behavioral disturbances); 36 patients (75%) had EEG with pseudoperiodic complexes. Follow up, performed in 28 (58%) patients showed: 12 died, 2 had compete remission and the others had variable neurological disability Our data shows endemic regions in the country, a high incidence of post-immunization SSPE and a delay between first symptoms and diagnosis.
C1 PUCRS, Hosp Sao Lucas, Serv Neurol, BR-90610000 Porto Alegre, RS, Brazil.
   Univ Fed Rio de Janeiro, Inst Neurol Deolindo Couto, Rio De Janeiro, Brazil.
   USP, Hosp Clin, BR-09500900 Sao Paulo, Brazil.
   IRCND, Mobile, AL USA.
RI Rosemberg, Sergio/F-4464-2012; DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR CANELAS HORACIO M., 1967, ARQ NEURO PSIQUIAT, V25, P255
   DACOSTA JC, 1991, JLBE, V4, P17
   DYKEN P, 1996, CHILD NEUROLOGY, P859
   Dyken P R, 1987, Neurology, V37, P1883
   DYKEN PR, 1985, NEUROL CLIN, V3, P179, DOI 10.1016/S0733-8619(18)31062-4
   DYKEN PR, 1989, PEDIATR NEUROL, V5, P339, DOI 10.1016/0887-8994(89)90045-3
   GASCON GG, 1996, INT SSPE CONS GUID J
   *MIN SAUD BRAS FUN, 1991, B EP MIN SAUD BRAS
   MODLIN JF, 1979, J PEDIATR-US, V94, P231, DOI 10.1016/S0022-3476(79)80829-X
   NUNES ML, 1995, PEDIATR NEUROL, V13, P153, DOI 10.1016/0887-8994(95)00145-6
   OKUNO Y, 1989, INT J EPIDEMIOL, V18, P684, DOI 10.1093/ije/18.3.684
   TAYLOR WJ, 1984, DRUG INTELL CLIN PHA, V18, P377
   Thiel A, 1996, NEUROLOGY, V47, P1604, DOI 10.1212/WNL.47.6.1604
   YALAZ K, 1992, NEUROLOGY, V42, P488, DOI 10.1212/WNL.42.3.488
NR 14
TC 9
Z9 11
U1 0
U2 0
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 1999
VL 57
IS 2A
BP 176
EP 181
DI 10.1590/S0004-282X1999000200002
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 199VR
UT WOS:000080505200002
PM 10412514
OA Other Gold
DA 2020-12-08
ER

PT J
AU Barbosa-Coutinho, LM
   Hilbig, A
   Calcagnotto, ME
   Paglioli, E
   Paglioli-Neto, E
   Da Costa, JC
   Palmini, A
   De Paula, EC
AF Barbosa-Coutinho, LM
   Hilbig, A
   Calcagnotto, ME
   Paglioli, E
   Paglioli-Neto, E
   Da Costa, JC
   Palmini, A
   De Paula, EC
TI Neuropathology of epilepsy: experience with 300 cases
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA Portuguese
DT Article
DE epilepsy; surgery; neuropathology; hippocampal sclerosis; ganglioglioma;
   DNT
ID TEMPORAL-LOBE EPILEPSY; DISORDERS
AB We report histopathological findings in 300 consecutive surgical specimens fi om epilepsy surgery during 6 years. Our material was mainly from temporal lobe epilepsy (70.33%). In 44% the diagnosis was hippocampal sclerosis. There were tumors in 15% of cases and neuronal migration disorders in 10%. The most common tumors were gangliogliomas (42.22%) and dysembryoplastic neuroepithelial tumors (20%). We review the more frequent diagnosis in epilepsy surgery based on this series and comparing with literature.
C1 Fundacao Fac Fed Ciencias Med, Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande de Sul, Programa Cirurgia Epilepsia, Porto Alegre, RS, Brazil.
   Lab CAPC, Goiania, Go, Brazil.
RI CALCAGNOTTO, MARIA ELISA/AAU-7718-2020; calcagnotto, maria
   elisa/B-1645-2013; DaCosta, Jaderson/C-4968-2015
OI CALCAGNOTTO, MARIA ELISA/0000-0001-8196-0596; calcagnotto, maria
   elisa/0000-0001-8196-0596; DaCosta, Jaderson/0000-0001-6776-1515
CR ARMSTRONG DD, 1993, J NEUROPATH EXP NEUR, V52, P433, DOI 10.1097/00005072-199309000-00001
   Babb T. L., 1987, SURGICAL TREATMENT E, P511
   BARBOSACOUTINHO LM, 1993, JLBE, V6, P127
   BARBOSACOUTINHO LM, 1991, REV PESQUISA MED POR, V25, P61
   BRUTON CJ, 1988, MANDSLEY MONOGRAPH, V31
   DATTMASDUPORT C, 1993, BRAIN PATHOL, V3, P283
   FALCONER J, 1990, CAN J NEUROL SCI, V17, P35, DOI 10.1017/S0317167100029991
   Falconer M.A., 1953, P ROY SOC MED, V46, P971
   FERSZT R, 1989, KLIN NEUROPATHOLOGIE, P112
   Friede R. L., 1989, DEV NEUROPATHOLOGY, P330
   HARDING B, 1997, GREENFIELDS NEUROPAT, P397
   HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x
   HIRSCH LJ, 1991, ANN NEUROL, V30, P347, DOI 10.1002/ana.410300306
   Honavar M., 1997, GREENFIELDS NEUROPAT, P931
   JACKSON H, 1931, SELECTED WRITINGS J, P458
   JACKSON H, 1889, BRAIN, V12, P346
   KLEIHUES P, 1993, HISTOLOGICAL TYPING
   KUZNIECKY R, 1993, NEUROLOGY, V43, P681, DOI 10.1212/WNL.43.4.681
   Kuzniecky Ruben I., 1993, P197
   LEBLANC FE, 1974, HDB CLIN NEUROLOGY, V15, P292
   MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499
   MEENCKE KJ, 1991, EPILEPSY SURG, P705
   PALMINI A, 1991, CAN J NEUROL SCI, V18, P580, DOI 10.1017/S0317167100032753
   PALMINI A, 1995, ANN NEUROL, V37, P476, DOI 10.1002/ana.410370410
   PALMINI A, 1991, JLBE, V4, P11
   PEIFFER J, 1963, MORPHOLOGISCHE ASPEK
   PENFIELD W, 1950, AMA ARCH NEUROL PSY, V64, P491, DOI 10.1001/archneurpsyc.1950.02310280003001
   PEROT P, 1966, ARCH NEUROL-CHICAGO, V15, P498, DOI 10.1001/archneur.1966.00470170052005
   RASMUSSEN T, 1958, NEUROLOGY, V8, P435, DOI 10.1212/WNL.8.6.435
   ROBAIN O, 1988, NEUROPATH APPL NEURO, V14, P125, DOI 10.1111/j.1365-2990.1988.tb00875.x
   ROBITAILLE Y, 1991, CHRONIC ENCEPHALITIS, P7
   SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309
   SCHOLZ W, 1959, EPILEPSIA, V1, P36, DOI 10.1111/j.1528-1157.1959.tb04248.x
   SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604
   Sommer W., 1880, ARCH PSYCHIAT NERVEN, V10, P631, DOI DOI 10.1007/BF02224538
   STAUDER KH, 1935, ARCH PSYCHIAT NERVEN, V104, P181
   Vinters Harry V., 1993, P593
   WOLF HK, 1993, BRAIN PATHOL, V3, P371, DOI 10.1111/j.1750-3639.1993.tb00765.x
   YAKOVLEV PI, 1946, J NEUROPATH EXP NEUR, V5, P116, DOI 10.1097/00005072-194604000-00003
   YAKOVLEV PI, 1946, NEUROPATHOL EXP NEUR, V5, P169
   1839, HIPPOCRATES OEUVRES
NR 41
TC 7
Z9 7
U1 0
U2 1
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 1999
VL 57
IS 2B
BP 405
EP 414
DI 10.1590/S0004-282X1999000300011
PG 10
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 207LB
UT WOS:000080937400011
PM 10450347
OA Other Gold
DA 2020-12-08
ER

PT J
AU Oliveira, AJ
   da Costa, JC
   Hilario, LN
   Anselmi, OE
   Palmini, A
AF Oliveira, AJ
   da Costa, JC
   Hilario, LN
   Anselmi, OE
   Palmini, A
TI Localization of the epileptogenic zone by ictal and interictal SPECT
   with Tc-99m-ethyl cysteinate dimer in patients with medically refractory
   epilepsy
SO EPILEPSIA
LA English
DT Article
DE epilepsy; single photon emission computed tomography; ethyl cysteinate
   dimer; seizures; epilepsy surgery
ID TEMPORAL-LOBE EPILEPSY; EMISSION COMPUTED-TOMOGRAPHY; BRAIN SPECT;
   BLOOD-FLOW; NORMAL CT; MRI; TECHNETIUM-99M-HMPAO; LATERALIZATION;
   HYPOPERFUSION; LOBECTOMY
AB Purpose: To evaluate the accuracy, feasibility and clinical value of both ictal and interictal Tc-99m-ethyl cysteinate dimer (ECD) single photon emission computed tomography (SPECT) in patients with medically refractory epilepsy.
   Methods: The study included 75 consecutive patients, 48 with temporal lobe epilepsy (TLE group), and 27 with extratemporal epilepsy (ExT group). The accuracy of SPECT was analyzed considering the final diagnosis reached by convergence of clinical, electrophysiologic, structural, pathologic and outcome data.
   Results: Ictal. SPECT correctly identified the epileptogenic zone in 21 (91.3%) of 23 patients, whereas interictal SPECTs could correctly identify the epileptogenic zone in only 41 (62.1%) of 66 patients (chi(2) = 5.56, df = 1, p < 0.05). Results were similar when the two study groups were analyzed separately. Moreover, ictal studies had significantly higher specificity (91.3 vs. 60.6%) and positive predictive value (91.3 vs. 66.2%) than interictal studies for the whole series of patients. Considering all tools used in the preoperative workup of these patients, ictal SPECT significantly contributed to the final topographic diagnosis in seven of 14 patients from TLE group and in six of nine patients from the ExT group. In these patients, ictal SPECT either obviated the need for invasive EEG or helped to define where to concentrate the efforts of invasive investigation.
   Conclusions: These data demonstrate that ictal SPECT can be easily achieved by using Tc-99m-ECD and can accurately localize the epileptogenic zone in both temporal and extratemporal epilepsies. Ictal ECD SPECT proved to be significantly more sensitive and specific than interictal ECD SPECT, and clinically useful in the definition of the epileptogenic zone.
C1 Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Serv Neurol,Porto Alegre Epilepsy Surg Program, Div Neurol,Dept Internal Med, BR-90610000 Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Nucl Med Serv, Porto Alegre, RS, Brazil.
RP da Costa, JC (corresponding author), Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Serv Neurol,Porto Alegre Epilepsy Surg Program, Div Neurol,Dept Internal Med, Av Ipiranga 6690,Sala 322, BR-90610000 Porto Alegre, RS, Brazil.
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR AHMANN P, 1997, EPILEPSIA S3, V38, P10
   Alksne John F., 1993, Epilepsia, V34, P139
   Arroyo Santiago, 1993, P377
   Carrilho P G, 1994, Arq Neuropsiquiatr, V52, P149
   CENDES F, 1993, NEUROLOGY, V43, P719, DOI 10.1212/WNL.43.4.719
   DEVOUS MD, 1994, J NUCL MED, V35, P1094
   Duncan JS, 1997, BRAIN, V120, P339, DOI 10.1093/brain/120.2.339
   Duncan R, 1996, EPILEPSIA, V37, P134, DOI 10.1111/j.1528-1157.1996.tb00004.x
   Engel Jerome Jr., 1993, P609
   Fletcher RH, 1996, CLIN EPIDEMIOLOGY ES
   GRUNWALD F, 1994, J NUCL MED, V35, P1896
   HARVEY AS, 1993, EPILEPSIA, V34, P869, DOI 10.1111/j.1528-1157.1993.tb02104.x
   HARVEY AS, 1993, NEUROLOGY, V43, P1966, DOI 10.1212/WNL.43.10.1966
   HIRSCH LJ, 1991, ANN NEUROL, V30, P347, DOI 10.1002/ana.410300306
   HO SS, 1995, ANN NEUROL, V37, P738, DOI 10.1002/ana.410370607
   HO SS, 1994, NEUROLOGY, V44, P2277, DOI 10.1212/WNL.44.12.2277
   HOLMAN BL, 1992, J NUCL MED, V33, P1888
   Jack CR, 1996, MAYO CLIN PROC, V71, P695
   JACK CR, 1994, NEUROLOGY, V44, P829, DOI 10.1212/WNL.44.5.829
   KUZNIECKY R, 1993, ANN NEUROL, V34, P627, DOI 10.1002/ana.410340421
   Lancman ME, 1997, EPILEPSIA, V38, P466, DOI 10.1111/j.1528-1157.1997.tb01737.x
   LAUNES J, 1992, ACTA NEUROL SCAND, V86, P558, DOI 10.1111/j.1600-0404.1992.tb05486.x
   LEVEILLE J, 1992, J NUCL MED, V33, P480
   LUDERS HO, 1991, EPILEPSY SURG, P51
   MANGERA KO, 1995, EUR J NUCL MED, V22, P1163, DOI 10.1007/BF00800599
   MARKAND ON, 1994, ACTA NEUROL SCAND, V89, P137, DOI 10.1111/j.1600-0404.1994.tb05206.x
   MARKS DA, 1992, ANN NEUROL, V31, P250, DOI 10.1002/ana.410310304
   MATSUDA H, 1993, CLIN NUCL MED, V18, P754, DOI 10.1097/00003072-199309000-00005
   Menzel C, 1995, Ann Nucl Med, V9, P215
   NEWTON MR, 1992, NEUROLOGY, V42, P371, DOI 10.1212/WNL.42.2.371
   NEWTON MR, 1993, J NUCL MED, V34, P666
   Packard AB, 1996, J NUCL MED, V37, P1101
   PALMINI A, 1996, TREATMENT EPILEPSY P, P1006
   ROWE CC, 1991, J NUCL MED, V32, P1688
   RYVLIN P, 1992, EPILEPSIA, V33, P28, DOI 10.1111/j.1528-1157.1992.tb02279.x
   SAMMARITANO M, 1987, ANN NEUROL, V21, P361, DOI 10.1002/ana.410210408
   Sirven JI, 1997, ANN NEUROL, V42, P873, DOI 10.1002/ana.410420608
   SPENCER SS, 1994, EPILEPSIA, V35, pS72, DOI 10.1111/j.1528-1157.1994.tb05990.x
   Spencer Susan S., 1993, P359
   Sperling MR, 1996, JAMA-J AM MED ASSOC, V276, P470, DOI 10.1001/jama.276.6.470
   STEFAN H, 1990, ANN NEUROL, V27, P162, DOI 10.1002/ana.410270211
   TSUCHIDA T, 1994, J NUCL MED, V35, P27
   Vattimo A, 1996, NUCL MED COMMUN, V17, P48, DOI 10.1097/00006231-199601000-00009
   WALOVITCH RC, 1989, J NUCL MED, V30, P1892
   WEIS M, 1994, ACTA NEUROL SCAND, V89, P145, DOI 10.1111/j.1600-0404.1994.tb05207.x
   WILLIAMSON PD, 1992, ANN NEUROL, V31, P193, DOI 10.1002/ana.410310210
NR 46
TC 34
Z9 41
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD JUN
PY 1999
VL 40
IS 6
BP 693
EP 702
DI 10.1111/j.1528-1157.1999.tb00765.x
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 203DK
UT WOS:000080692200003
PM 10368065
DA 2020-12-08
ER

PT J
AU Lopes-Cendes, I
   Teive, HGA
   Cardoso, F
   Viana, EM
   Calcagnotto, ME
   da Costa, JC
   Trevisol-Bittencourt, PC
   Maciel, JA
   Rousseau, M
   Santos, AS
   Araujo, AQC
   Rouleau, GA
AF Lopes-Cendes, I
   Teive, HGA
   Cardoso, F
   Viana, EM
   Calcagnotto, ME
   da Costa, JC
   Trevisol-Bittencourt, PC
   Maciel, JA
   Rousseau, M
   Santos, AS
   Araujo, AQC
   Rouleau, GA
TI Molecular characteristics of Machado-Joseph disease mutation in 25 newly
   described Brazilian families
SO BRAZILIAN JOURNAL OF GENETICS
LA English
DT Article
ID SPINOCEREBELLAR ATAXIA TYPE-1; TRINUCLEOTIDE CAG REPEAT;
   CLINICAL-FEATURES; EXPANSION; LOCUS; GENE; ATROPHY; DOMINANT; MAPS;
   CHROMOSOME-14Q
AB Machado-Joseph disease (MJD) is a form of autosomal dominant spinocerebellar ataxia first described in North-American patients originating from the Portuguese islands of the Azores. Clinically this disorder is characterized by late onset progressive ataxia with associated features, such as: ophthalmoplegia, pyramidal and extrapyramidal signs and distal muscular atrophies. The causative mutation is an expansion of a CAG repeat in the coding region of the MIDI gene.
   We have identified 25 unrelated families segregating the MJD mutation during a large collaborative study of spinocerebellar ataxias in Brazil. In the present study a total of 62 family members were genotyped for the CAG repeat in the MJD1 gene, as well as 63 non-MJD individuals (126 normal chromosomes), used as normal controls. We observed a wide gap between the size range of the normal and expanded CAG repeats: the normal allele had from 12 to 33 CAGs (mean = 23 CAGs), whereas the expanded alleles ranged from 66 to 78 CAGs (mean = 71.5 CAGs). There were no differences in CAG tract length according to gender of affected individuals or transmitting parent. We observed a significant negative correlation between age at onset of the disease and length of the CAG tract in the expended allele (r = -0.6, P = 0.00006); however, the size of the expanded CAG repeat could explain only about 40% of the variability in age at onset (r(2) = 0.4).
C1 McGill Univ, Ctr Res Neurosci, Montreal, PQ H3A 2T5, Canada.
RP Lopes-Cendes, I (corresponding author), Univ Estadual Campinas, Fac Ciencias Med, Dept Med Genet, Cidade Univ Zeferino Vaz, Caixa Postal 6111,Distrito de Barao Geraldo, BR-13083970 Campinas, SP, Brazil.
RI calcagnotto, maria elisa/B-1645-2013; de Queiroz-Campos Araujo,
   Abelardo/N-3637-2013; DaCosta, Jaderson/C-4968-2015; Cardoso,
   Francisco/R-8542-2019; Lopes-Cendes, Iscia/B-9416-2013; CALCAGNOTTO,
   MARIA ELISA/AAU-7718-2020
OI calcagnotto, maria elisa/0000-0001-8196-0596; de Queiroz-Campos Araujo,
   Abelardo/0000-0001-7694-7223; DaCosta, Jaderson/0000-0001-6776-1515;
   Lopes-Cendes, Iscia/0000-0002-6221-6822; CALCAGNOTTO, MARIA
   ELISA/0000-0001-8196-0596
CR ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398
   BELL J, 1942, ANN EUGEN, V11, P272
   BRUNT ERP, 1996, NEUROLOGY, V46, P197
   Burt T, 1996, NEUROLOGY, V46, P1118, DOI 10.1212/WNL.46.4.1118
   Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423
   CANCEL G, 1995, AM J HUM GENET, V57, P809
   CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758
   CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254
   COUTINHO P, 1978, NEUROLOGY, V28, P703, DOI 10.1212/WNL.28.7.703
   COUTINHO P, 1994, DOENCA MACHADO JOSEP
   Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285
   Iughetti P, 1996, J MED GENET, V33, P439, DOI 10.1136/jmg.33.5.439
   KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221
   KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9
   LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0
   LIMA L, 1980, NEUROLOGY, V30, P319, DOI 10.1212/WNL.30.3.319
   LopesCendes I, 1996, ARCH NEUROL-CHICAGO, V53, P1168, DOI 10.1001/archneur.1996.00550110120020
   LopesCendes I, 1996, ANN NEUROL, V40, P199, DOI 10.1002/ana.410400211
   LOPESCENDES I, IN PRESS ARQ NEUROPS
   MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E
   MACIEL P, 1995, AM J HUM GENET, V57, P54
   NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14
   NAKANO KK, 1972, NEUROLOGY, V22, P49, DOI 10.1212/WNL.22.1.49
   ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221
   PENROSE LS, 1948, ANN EUGENIC, V14, P125
   Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269
   RANUM LPW, 1995, AM J HUM GENET, V57, P603
   RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S
   ROMANUL FCA, 1977, NEW ENGL J MED, V296, P1505, DOI 10.1056/NEJM197706302962606
   ROSENBERG RN, 1976, T AM NEUROL ASSOC, V101, P1
   ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8
   Sambrook J, 1989, MOL CLONING LAB MANU
   SAMPEI K, 1996, NAT GENET, V14, P277
   SCHOLS L, 1995, HUM MOL GENET, V4, P1001, DOI 10.1093/hmg/4.6.1001
   SEQUEIROS J, 1994, GENOMICS, V21, P645, DOI 10.1006/geno.1994.1327
   SEQUEIROS J, 1981, GENETIC ASPECTS MACH, V2, P137
   Silveira I, 1996, NEUROLOGY, V46, P214, DOI 10.1212/WNL.46.1.214
   STEVANIN G, 1994, AM J HUM GENET, V54, P11
   STEVANIN G, 1995, J MED GENET, V32, P827, DOI 10.1136/jmg.32.10.827
   STRACHAN T, 1996, HUM MOL GENET, P401
   SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636
   TAKIYAMA Y, 1993, NAT GENET, V4, P300, DOI 10.1038/ng0793-300
   TEIVE H A G, 1991, Arquivos de Neuro-Psiquiatria, V49, P172
   TWIST EC, 1995, J MED GENET, V32, P25, DOI 10.1136/jmg.32.1.25
   Zhou YX, 1997, NEUROLOGY, V48, P482, DOI 10.1212/WNL.48.2.482
   Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62
   Zoghbi HY, 1996, NAT GENET, V14, P237, DOI 10.1038/ng1196-237
NR 47
TC 10
Z9 11
U1 0
U2 1
PU SOC BRASIL GENETICA
PI RIBEIRAO PRET
PA RUA CAP ADELMIO NORBET DA SILVA, 736, ALTO DA BOA VISTA, 14025-670
   RIBEIRAO PRET, BRAZIL
SN 0100-8455
J9 BRAZ J GENET
JI Braz. J. Genet.
PD DEC
PY 1997
VL 20
IS 4
BP 717
EP 724
DI 10.1590/S0100-84551997000400026
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA YM555
UT WOS:000071076500026
OA Bronze
DA 2020-12-08
ER

PT J
AU Gherpelli, JLD
   Guerreiro, MM
   daCosta, JC
   Rotta, NT
   Manreza, MLG
   Reed, UC
   Diament, A
   Silva, EA
   Guerreiro, CAM
   Nunes, ML
   Palmini, A
   VegaGutierrez, L
   Vizioli, J
   Pedroso, F
   Chiste, MA
AF Gherpelli, JLD
   Guerreiro, MM
   daCosta, JC
   Rotta, NT
   Manreza, MLG
   Reed, UC
   Diament, A
   Silva, EA
   Guerreiro, CAM
   Nunes, ML
   Palmini, A
   VegaGutierrez, L
   Vizioli, J
   Pedroso, F
   Chiste, MA
TI Vigabatrin in refractory childhood epilepsy. The Brazilian multicenter
   study
SO EPILEPSY RESEARCH
LA English
DT Article
DE antiepileptic drugs; childhood epilepsy; refractory epilepsy; vigabatrin
ID GAMMA-VINYL-GABA; BLIND
AB Children, 47, with various types of severe drug-resistant epilepsy were entered into a prospective, add-on, open trial with vigabatrin. Patients with West syndrome and idiopathic generalized epilepsies were excluded. Seven children had the drug withdrawn, five because of increase in seizure frequency and two because of adverse effects. Drug efficacy, measured according to seizure type, showed a 100% decrease in seizure frequency in 18.6% of partial seizures and 17.3% of the generalized seizures. There was a higher than 500% decrease in 39.5% of partial and 60.8% of generalized seizures, and less than 50% decrease or increase in seizure frequency in 41.8% and 21.8% of partial and generalized seizures, respectively. Vigabatrin mean dosage during phase 3 was 63.6 mg/kg per day (S.D. = 30.5), ranging from 19.3 to 110.5 mg/kg per day. Parametric statistical analysis (Student's t-test) of seizure frequency between phases 1 and 3 showed a significant decrease in seizure frequency for partial (P = 0.022), and generalized seizures (P < 0.0001). Drug-related adverse effects were observed in 18/47 cases (38.3%), consisting mainly of irritability, hyperactivity, dizziness, somnolence and gastrointestinal symptoms. (C) 1997 Elsevier Science B.V.
C1 UNIV CAMPINAS,FAC MED SCI,DEPT NEUROL,CAMPINAS,SP,BRAZIL.
   CATHOLIC UNIV RIO GRANDE SUL,ST LUCAS HOSP,DEPT INTERNAL MED,DIV NEUROL,PORTO ALEGRE,RS,BRAZIL.
   UNIV FED RIO GRANDE SUL,DEPT CHILD NEUROL,PORTO ALEGRE,RS,BRAZIL.
RP Gherpelli, JLD (corresponding author), UNIV SAO PAULO,FAC MED,HOSP CLIN,DIV CLIN NEUROL,AV ENEAS CARVALHO AGUIAR 255,BR-05403000 SAO PAULO,BRAZIL.
RI DaCosta, Jaderson/C-4968-2015; Gherpelli, Jose Luiz/I-4141-2012
OI DaCosta, Jaderson/0000-0001-6776-1515; Gherpelli, Jose
   Luiz/0000-0002-0589-0917
CR APPLETON RE, 1993, NEUROLOGY, V43, pS21
   DULAC O, 1991, J CHILD NEUROL S2, V6, pS30
   FOIS A, 1994, CHILD NERV SYST, V10, P244, DOI 10.1007/BF00301162
   GIBBS JM, 1992, PEDIATR NEUROL, V8, P338, DOI 10.1016/0887-8994(92)90086-E
   GRAM L, 1983, ACTA NEUROL SCAND, V68, P34, DOI 10.1111/j.1600-0404.1983.tb04812.x
   HERRANZ JL, 1991, J CHILD NEUROL, V6, pS45
   LIVINGSTON JH, 1989, BRIT J CLIN PHARMACO, V27, pS109, DOI 10.1111/j.1365-2125.1989.tb03470.x
   LUNA D, 1989, EPILEPSIA, V30, P430, DOI 10.1111/j.1528-1157.1989.tb05322.x
   MATILAINEN R, 1988, NEUROLOGY, V38, P743, DOI 10.1212/WNL.38.5.743
   PITKANEN A, 1993, ARCH NEUROL-CHICAGO, V50, P224
   REYNOLDS EH, 1991, EPILEPSIA, V32, P530, DOI 10.1111/j.1528-1157.1991.tb04688.x
   RIEKKINEN PJ, 1989, EPILEPSIA, V30, pS18, DOI 10.1111/j.1528-1157.1989.tb05828.x
   SCHECHTER PJ, 1984, NEUROPHARMACOLOGY, V23, P865, DOI 10.1016/0028-3908(84)90285-5
   SIVENIUS J, 1991, NEUROLOGY, V41, P562, DOI 10.1212/WNL.41.4.562
   ULDALL P, 1991, J CHILD NEUROL, V6, pS38
   VLES JSH, 1993, NEUROPEDIATRICS, V24, P230, DOI 10.1055/s-2008-1071546
NR 16
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-1211
J9 EPILEPSY RES
JI Epilepsy Res.
PD DEC
PY 1997
VL 29
IS 1
BP 1
EP 6
DI 10.1016/S0920-1211(97)00052-1
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA YJ781
UT WOS:A1997YJ78100001
PM 9416454
DA 2020-12-08
ER

PT J
AU LopesCendes, I
   Teive, HGA
   Calcagnotto, ME
   DaCosta, JC
   Cardoso, F
   Viana, E
   Maciel, JA
   Radvany, J
   Arruda, WO
   TrevisolBittencourt, PC
   Neto, PR
   Silveira, I
   Steiner, CE
   Pinto, W
   Santos, AS
   Neto, YC
   Werneck, LC
   Araujo, AQC
   Carakushansky, G
   Mello, LR
   Jardim, LB
   Rouleau, GA
AF LopesCendes, I
   Teive, HGA
   Calcagnotto, ME
   DaCosta, JC
   Cardoso, F
   Viana, E
   Maciel, JA
   Radvany, J
   Arruda, WO
   TrevisolBittencourt, PC
   Neto, PR
   Silveira, I
   Steiner, CE
   Pinto, W
   Santos, AS
   Neto, YC
   Werneck, LC
   Araujo, AQC
   Carakushansky, G
   Mello, LR
   Jardim, LB
   Rouleau, GA
TI Frequency of the different mutations causing spinocerebellar ataxia
   (SCA1, SCA2, MJD/SCA3 and DRPLA) in a large group of Brazilian patients
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE neurodegenerative disease; spinocerebellar ataxia type 1;
   spinocerebellar ataxia type 2; spinocerebellar ataxia type 3;
   Machado-Joseph disease; dentatorubropallidoluysian atrophy;
   trinucleotide repeat expansion
ID MACHADO-JOSEPH-DISEASE; DOMINANT CEREBELLAR-ATAXIA;
   DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; CAG REPEAT;
   DENTATORUBROPALLIDOLUYSIAN ATROPHY; TRINUCLEOTIDE REPEAT; HEREDITARY
   ATAXIA; GENE; LOCUS; EXPANSION
AB Spinocerebellar ataxia type 1 (SCA1), spinocerebellar ataxia type 2 (SCA2) and Machado-Joseph disease or spinocerebellar ataxia type 3 (MJD/SCA3) are three distinctive forms of autosomal dominant spinocerebellar ataxia (SCA) caused by expansions of an unstable CAG repeat localized in the coding region of the causative genes. Another related disease, dentatorubropallidoluysian atrophy (DRPLA) is also caused by an unstable triplet repeat and can present as SCA in late onset patients. We investigated the frequency of the SCA1, SCA2, MJD/SCA3 and DRPLA mutations in 328 Brazilian patients with SCA, belonging to 90 unrelated families with various patterns of inheritance and originating in different geographic regions of Brazil. We found mutations in 35 families (39%), 32 of them with a clear autosomal dominant inheritance. The frequency of the SCA1 mutation was 3% of all patients; and 6% in the dominantly inherited SCAs. We identified the SCA2 mutation in 6% of all families and in 9% of the families with autosomal dominant inheritance. The MJD/SCA3 mutation was detected in 30% of all patients; and in the 44% of the dominantly inherited cases. We found no DRPLA mutation. In addition, we observed variability in the frequency of the different mutations according to geographic origin of the patients, which is probably related to the distinct colonization of different parts of Brazil. These results suggest that SCA may be occasionally caused by the SCA1 and SCA2 mutations in the Brazilian population, and that the MJD/SCA3 mutation is the most common cause of dominantly inherited SCA in Brazil.
C1 MCGILL UNIV,CTR RES NEUROSCI,MONTREAL,PQ H3A 2T5,CANADA.
   MCGILL UNIV,MONTREAL GEN HOSP,MONTREAL,PQ H3A 2T5,CANADA.
   UNIV FED PARANA,HOSP CLIN,SERV NEUROL,BR-80060000 CURITIBA,PARANA,BRAZIL.
   PONTIFICIA UNIV CATOLICA RIO GRANDE SUL,HOSP SAO LUCAS,DEPT NEUROL,PORTO ALEGRE,RS,BRAZIL.
   UNIV FED MINAS GERAIS,DEPT NEUROL,BELO HORIZONT,MG,BRAZIL.
   UNICAMP,FAC CIENCIAS MED,DEPT NEUROL,CAMPINAS,SP,BRAZIL.
   ALBERT EINSTEIN COLL MED HOSP,SAO PAULO,SP,BRAZIL.
   HOSP UNIV FED SANTA CATARINA,SERV NEUROL,FLORIANOPOLIS,SC,BRAZIL.
   DONGKWANGJU HOSP,DEPT NEUROL,KWANGJU,SOUTH KOREA.
   UNICAMP,FCM,DEPT MED GENET,CAMPINAS,SP,BRAZIL.
   HOSP CARIDADE,FLORIANOPOLIS,SC,BRAZIL.
   UNIV FED RIO DE JANEIRO,DEPT NEUROL,RIO JANEIRO,RJ,BRAZIL.
   UNIV FED RIO DE JANEIRO,DEPT MED GENET,RIO JANEIRO,RJ,BRAZIL.
   UNIV REG BLUMENAU,SERV NEUROCIRURGIA,BLUMENAU,SC,BRAZIL.
   UNIV FED RIO GRANDE SUL,HOSP CLIN PORTO ALEGRE,UNIDADE GENET MED,PORTO ALEGRE,RS,BRAZIL.
RI Steiner, Carlos E/B-9319-2014; Silveira, Isabel/D-6881-2012; Arruda,
   Walter Oleschko/AAJ-8256-2020; Rosa-Neto, Pedro/C-3494-2011; Jardim,
   Laura B/B-6149-2013; Lopes-Cendes, Iscia/B-9416-2013; Werneck,
   Lineu/Y-4038-2019; de Queiroz-Campos Araujo, Abelardo/N-3637-2013;
   Cardoso, Francisco/R-8542-2019; calcagnotto, maria elisa/B-1645-2013;
   Cardoso, Francisco EC/A-2285-2014; CALCAGNOTTO, MARIA
   ELISA/AAU-7718-2020; DaCosta, Jaderson/C-4968-2015; ROSA-NETO,
   PEDRO/F-5077-2015
OI Steiner, Carlos E/0000-0001-5148-3063; Silveira,
   Isabel/0000-0002-2610-5260; Lopes-Cendes, Iscia/0000-0002-6221-6822; de
   Queiroz-Campos Araujo, Abelardo/0000-0001-7694-7223; calcagnotto, maria
   elisa/0000-0001-8196-0596; Cardoso, Francisco EC/0000-0003-0808-0116;
   CALCAGNOTTO, MARIA ELISA/0000-0001-8196-0596; DaCosta,
   Jaderson/0000-0001-6776-1515; ROSA-NETO, PEDRO/0000-0001-9116-1376
FU NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [NS 31687] Funding Source: Medline; NATIONAL
   INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Neurological Disorders & Stroke (NINDS)
   [R01NS031687, R01NS031687, R01NS031687] Funding Source: NIH RePORTER
CR ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856
   BELAL S, 1994, NEUROLOGY, V44, P1423, DOI 10.1212/WNL.44.8.1423
   BENHAMIDA C, 1993, NAT GENET, V5, P195
   BENOMAR A, 1995, NAT GENET, V10, P84, DOI 10.1038/ng0595-84
   BRUNT ERP, 1996, NEUROLOGY, V46, P197
   BURKE JR, 1994, NAT GENET, V7, P521, DOI 10.1038/ng0894-521
   Burt T, 1996, NEUROLOGY, V46, P1118, DOI 10.1212/WNL.46.4.1118
   Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423
   CHAMBERLAIN S, 1988, NATURE, V334, P248, DOI 10.1038/334248a0
   COUTINHO P, 1978, NEUROLOGY, V28, P703, DOI 10.1212/WNL.28.7.703
   COUTINHO P, 1994, DOENCA MACHADO JOSEP
   Flanigan K, 1996, AM J HUM GENET, V59, P392
   Gaspar C, 1996, HUM GENET, V98, P620, DOI 10.1007/s004390050270
   GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295
   GIUNTI P, 1994, BRAIN, V117, P645, DOI 10.1093/brain/117.4.645
   GOUW LG, 1995, NAT GENET, V10, P89, DOI 10.1038/ng0595-89
   Greenfield JG, 1954, SPINO CEREBELLAR DEG
   GUDMUNDSSON KR, 1969, ACTA NEUROL SCAND, V45, P114
   HARDING AE, 1984, HEREDITARY ATAXIAS R
   Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285
   INGHETTI P, 1996, J MED GENET, V33, P439
   JACKSON JF, 1977, NEW ENGL J MED, V296, P1138, DOI 10.1056/NEJM197705192962003
   JODICE C, 1993, HUM MOL GENET, V2, P1383, DOI 10.1093/hmg/2.9.1383
   KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221
   KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9
   LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0
   LISBOA MFS, 1984, ARQ NEUROPSIQUIATR S, P45
   LopesCendes I, 1996, ARCH NEUROL-CHICAGO, V53, P1168, DOI 10.1001/archneur.1996.00550110120020
   LOPESCENDES I, 1994, AM J HUM GENET, V54, P774
   LopesCendes I, 1996, ARQ NEURO-PSIQUIAT, V54, P412, DOI 10.1590/S0004-282X1996000300009
   LOPESCENDES I, 1994, GENOMICS, V21, P270, DOI 10.1006/geno.1994.1257
   LOPESCENDES I, 1997, INT AT M MONTR CAN
   MACIEL P, 1995, AM J HUM GENET, V57, P54
   Marie P., 1893, SEM MED PARIS, V13, P444
   NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14
   NAITO H, 1982, NEUROLOGY, V32, P798, DOI 10.1212/WNL.32.8.798
   NAKANO KK, 1972, NEUROLOGY, V22, P49, DOI 10.1212/WNL.22.1.49
   Nechiporuk A, 1996, NEUROLOGY, V46, P1731, DOI 10.1212/WNL.46.6.1731
   ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221
   OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141
   PIAZZA Walter. F., 1983, SANTA CATARINA SUA H
   Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269
   Radvany J, 1993, Arq Neuropsiquiatr, V51, P21
   RADVANY J, 1988, ARQ NEUROPSIQUIATR S, pB46
   RANUM LPW, 1994, AM J HUM GENET, V55, P244
   RANUM LPW, 1995, AM J HUM GENET, V57, P603
   RANUM LPW, 1994, NAT GENET, V8, P280, DOI 10.1038/ng1194-280
   ROMANUL FCA, 1977, NEW ENGL J MED, V296, P1505, DOI 10.1056/NEJM197706302962606
   ROSENBERG RN, 1976, T AM NEUROL ASSOC, V101, P1
   Sambrook J, 1989, MOL CLONING LAB MANU
   SAMPEI K, 1996, NAT GENET, V14, P277
   SCHOLS L, 1995, HUM MOL GENET, V4, P1001, DOI 10.1093/hmg/4.6.1001
   SCHUT JW, 1950, ARCH NEURO PSYCHIATR, V63, P535, DOI 10.1001/archneurpsyc.1950.02310220002001
   SEQUEIROS J, 1994, GENOMICS, V21, P645, DOI 10.1006/geno.1994.1327
   Silveira I, 1996, NEUROLOGY, V46, P214, DOI 10.1212/WNL.46.1.214
   SKRE H, 1978, SPINOCEREBELLAR DEGE, P103
   Smith JK, 1975, HDB CLIN NEUROLOGY, V21, P519
   STEVANIN G, 1994, AM J HUM GENET, V54, P11
   STEVANIN G, 1995, J MED GENET, V32, P827, DOI 10.1136/jmg.32.10.827
   TAKIYAMA Y, 1993, NAT GENET, V4, P300, DOI 10.1038/ng0793-300
   TEIVE H A G, 1991, Arquivos de Neuro-Psiquiatria, V49, P172
   TWELLS R, 1994, HUM MOL GENET, V3, P177, DOI 10.1093/hmg/3.1.177
   TWIST EC, 1995, J MED GENET, V32, P25, DOI 10.1136/jmg.32.1.25
   WARNER TT, 1995, ANN NEUROL, V37, P452, DOI 10.1002/ana.410370407
   WOODS BT, 1972, J NEUROL SCI, V17, P149, DOI 10.1016/0022-510X(72)90137-2
   YAKURA H, 1974, NEW ENGL J MED, V291, P154
   Zhou YX, 1997, NEUROLOGY, V48, P482, DOI 10.1212/WNL.48.2.482
   Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62
   ZOGHBI HY, 1988, ANN NEUROL, V23, P580, DOI 10.1002/ana.410230609
   1993, CELL, V72, P971
NR 70
TC 25
Z9 27
U1 0
U2 3
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA C/O DR OSWALDO LANGE, CAIXA POSTAL 8877, 01065-970 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD SEP
PY 1997
VL 55
IS 3B
BP 519
EP 529
DI 10.1590/S0004-282X1997000400001
PG 11
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA XZ273
UT WOS:A1997XZ27300001
PM 9629399
OA Other Gold
DA 2020-12-08
ER

PT J
AU Velluti, JC
   daCosta, JC
   Russo, RE
AF Velluti, JC
   daCosta, JC
   Russo, RE
TI The cerebral hemisphere of the turtle in vitro. An experimental model
   with spontaneous interictal-like spikes for the study of epilepsy
SO EPILEPSY RESEARCH
LA English
DT Article
DE epilepsy; in vitro hemispheric brain; turtle medial cortex; interictal
   spike; paroxysmal depolarization shift; seizure-like activity
ID NEOCORTICAL NEURONS; INVITRO; CORTEX; ELECTROPHYSIOLOGY; HIPPOCAMPAL
AB Slice in vitro preparations have been useful to study the cellular basis of some epilepsy related phenomena, However, the cellular mechanisms that generate ictal activity remain poorly understood. Therefore, an experimental in vitro model capable of generating seizure-like activity might contribute to the study of the cellular basis of seizures. The outstanding resistance to hypoxia of turtles enabled us to develop an in vitro preparation that keeps all the cortical neural circuitry intact. A whole cerebral hemisphere of the turtle Chrysemys d'orbigny was isolated (n = 45) and simultaneous electrographic and intracellular recordings were performed in the medial cortex. The electrographic activity was composed by a non-rhythmic, low-voltage (10-20 mu V) activity interrupted by spontaneous large (50-700 mu V) sharp waves (LSWs). The cellular counterpart of the LSWs was often a burst of action potentials that resembled the paroxysmal depolarisation shift (PDS). Bicuculline (20-40 mu M, n = 20) increased the interictal-like activity and in some preparations (3 out of 20) provoked seizure-like events. Complex bursting activity and a slow afterhyperpolarisation were cellular events observed during seizures, We propose that this model might be a Valuable tool for the study the cellular mechanisms involved in the transition from the interictal to the ictal activities. (C) 1997 Elsevier Science B.V.
C1 FAC MED,DEPT FISIOL,MONTEVIDEO 11800,URUGUAY.
RP Velluti, JC (corresponding author), FAC CIENCIAS,UNIDAD ASOCIADA NEUROFISIOL,INST INVEST BIOL CLEMENTE ESTABLE,AVDA ITALIA 3318,MONTEVIDEO 11600,URUGUAY.
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR AVOLI M, 1988, NEUROTRANSMITTERS CO, P187
   AYALA GF, 1970, J NEUROPHYSIOL, V33, P73
   BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7
   BULLOCK TH, 1984, PERSPECT BIOL MED, V27, P510
   Connors B. W., 1993, EPILEPSY MODELS MECH, P388
   CONNORS BW, 1982, J NEUROPHYSIOL, V48, P1302
   CONNORS BW, 1986, J NEUROSCI, V6, P164
   DONDAY M, 1995, HDB ELECTROENCEPHALO, P55
   ENGLE J, 1980, BRAIN RES, V190, P543
   GASTAUT H, 1959, HANDB PHYSIOL, V1, P329
   GAZTELU JM, 1991, BRAIN BEHAV EVOLUT, V37, P144, DOI 10.1159/000114354
   HUONSGAARD J, 1990, PREPARATION VERTEBRA, P155
   HWA GGC, 1991, EXP BRAIN RES, V83, P329
   Johnston D., 1984, ELECTROPHYSIOLOGY EP, P277
   LARSONPRIOR LJ, 1988, BRAIN RES, V460, P369, DOI 10.1016/0006-8993(88)90384-8
   MATSUMOTO H, 1964, EXP NEUROL, V9, P286, DOI 10.1016/0014-4886(64)90025-1
   MATSUMOTO H, 1964, EXP NEUROL, V9, P305, DOI 10.1016/0014-4886(64)90026-3
   MORI K, 1980, J PHYSIOL-LONDON, V314, P281
   NORTCUTT RG, 1970, BIOL MONOGR, V43, P113
   PRINCE DA, 1967, ARCH NEUROL-CHICAGO, V16, P194, DOI 10.1001/archneur.1967.00470200082007
   PRINCE DA, 1985, EPILEPSIA, V26, pS3, DOI 10.1111/j.1528-1157.1985.tb05721.x
   ROMER AS, 1972, VERTEBRATE BODY, P627
   RUSSO RE, 1992, EXP BRAIN RES, V92, P85
   SCHWARTZKROIN PA, 1994, EPILEPSY RES, V17, P185, DOI 10.1016/0920-1211(94)90049-3
   SCHWARTZKROIN PA, 1986, EPILEPSIA, V27, P523, DOI 10.1111/j.1528-1157.1986.tb03578.x
   SHEN JM, 1986, J NEUROPHYSIOL, V56, P1626
   SWARTZWELDER HS, 1987, BRAIN RES, V410, P362
   TASKER JG, 1991, NEUROCHEM RES, V16, P251, DOI 10.1007/BF00966088
   ULTSCH GR, 1982, J EXP BIOL, V96, P11
   VELLUTI JC, 1991, BRAIN BEHAV EVOLUT, V38, P7, DOI 10.1159/000114376
   WONG RKS, 1984, ELECTROPHYSIOLOGY EP, P253
NR 31
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-1211
J9 EPILEPSY RES
JI Epilepsy Res.
PD JUL
PY 1997
VL 28
IS 1
BP 29
EP 37
DI 10.1016/S0920-1211(97)00028-4
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA XL612
UT WOS:A1997XL61200004
PM 9255597
DA 2020-12-08
ER

PT J
AU Nunes, ML
   DaCosta, JC
   Taufer, L
AF Nunes, ML
   DaCosta, JC
   Taufer, L
TI The relationship of apnea and phasic activity of REM sleep in newborns
   and infants that presented an apparent life-threatening event
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA Spanish
DT Article
DE apnea; polysomnography; sudden infant death syndrome
ID DEATH SYNDROME; PRETERM INFANTS; MUSCLE-ACTIVITY; RAPID EYE; SUDDEN;
   PARAMETERS; MATURATION; MOVEMENTS
AB When the apnea hypothesis turned to be an explanation Tol sudden infant death syndrome (SIDS) many authors tried to find if near-miss or apparent life-threatening events (ALTE) could be markers of SIDS. It was suggested that phasic REM activity is associated with increased respiratory neuron activity anti prevents prolonged apnea in near-miss SIDS. In a previous retrospective study with newborns Lye did not confirm these results, nevertheless we had several babies with serious neurological disturbances. The aim of this study was to verify the relationship of phasic activity (rapid eyes movement and sucking bursts) with both apneic and non-apneic epochs during REM sleep. We studied 86 children refered for evaluation because they presented an ALTE during sleep or apneas. The subjects were divided in three groups by age (newborns, n=31; 1-6 months, n=48; and >6<12 months, n=7). They were all submitted to a clinical and neurological evaluation in order to detect possible etiological factors to the apneic episode. The polysomnograms (PS) consisted of EEG, submental EMG, electro-oculogram and cardiorespiratory monitoring. The records were made between 11 am and 15 pm for 2 or 3 hours. The electrodes were disposed in the 10-20 system. During one five-minutes epoch of REM sleep we verified the incidence of phasic activity (rapid eyes movement or sucking bursts) time locked to apneic episodes and compared with a similar duration non-apneic epoch. To evaluate the relationship of phasic activity with apneic and non-apneic epochs we compared the incidence of rapid eyes movements and sucking bursts in each group. Our results showed that phasic activity of REM sleep (sucking bursts) seems to be more frequent in non-apneic epochs (p < 0.05). Between 1-6 months the number of rapid eyes movements were more frequent in non-apneic epochs (p=0.001). In conclusion our findings suggest that phasic activity of REM sleep seems to be more evident in non-apneic epochs during the first six months of life. Although central apneas may have their origin in an intrinsic disturb of the respiratory control center they may be influenced by the phasic activity of REM sleep. The rapid eyes movements and sucking bursts may have a protection effect against apneas at least in the first 6 months of life, which is the predominant period for SIDS. We suggest that the excitatory driving related to generation of phasic activity in REM sleep may block or atenuate tonic inhibition of respiratory motoneuron and avoid apnea. It is still open fbr discussion the possible relation between failure of this protective mechanism and SIDS.
C1 PUC RS, HOSP SAO LUCAS, NEUROL SERV, LAB NEUROFISIOL CLIN, BR-90610000 PORTO ALEGRE, RS, BRAZIL.
   PONTIFICIA UNIV CATOLICA RIO GRANDE DO SUL, FAC MED, PORTO ALEGRE, RS, BRAZIL.
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR Anders T, 1971, MANUAL STANDARDIZED
   BROOKS JG, 1992, APENA SIDS, P809
   da Costa JC, 1990, SONO ASPECTOS ATUAIS, P133
   DACOSTA JC, 1992, PEDIATR NEUROL, V8, P382
   DACOSTA JC, 1980, ELECTROEN CLIN NEURO, V75, P531
   FLORESGUEVARA R, 1982, NEUROPEDIATRICS, V13, P21, DOI 10.1055/s-2008-1059630
   GUILLEMINAULT C, 1981, PEDIATRICS, V68, P354
   GUILLENINAUT C, 1986, DISORDERS NERVOUS SY, P867
   HOFFMAN HJ, 1992, APNEA SIDS, P717
   KELLY DH, 1979, PEDIATRICS, V63, P355
   KOHYAMA J, 1989, BRAIN DEV-JPN, V11, P186, DOI 10.1016/S0387-7604(89)80096-8
   KOHYAMA J, 1993, J SLEEP RES, V2, P241, DOI 10.1111/j.1365-2869.1993.tb00095.x
   KOHYAMA J, 1994, BRAIN DEV-JPN, V16, P81, DOI 10.1016/0387-7604(94)90040-X
   KOHYAMA J, 1995, EXP BRAIN RES, V107, P137
   KOHYAMA J, 1990, ELECTROEN CLIN NEURO, V76, P325, DOI 10.1016/0013-4694(90)90033-G
   KOHYAMA J, 1991, ELECTROEN CLIN NEURO, V79, P277, DOI 10.1016/0013-4694(91)90123-L
   LEE D, 1987, PEDIATR RES, V22, P344, DOI 10.1203/00006450-198709000-00021
   NIEDERMEYER E, 1987, ELECTROENCEPHALOGRAP, P133
   NUNES ML, 1996, BJECN, V2, P27
   Reimao R, 1986, Arq Neuropsiquiatr, V44, P219
   RIGATTO H, 1972, PEDIATRICS, V50, P202
   Sakai K., 1980, RETICULAR FORMATION, P427
   STEINSCHNEIDER A, 1972, PEDIATRICS, V50, P646
   WATANABE K, 1983, EUR J PEDIATR, V140, P289, DOI 10.1007/BF00442665
NR 24
TC 0
Z9 1
U1 0
U2 0
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA C/O DR OSWALDO LANGE, CAIXA POSTAL 8877, 01065-970 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD JUN
PY 1997
VL 55
IS 2
BP 213
EP 219
DI 10.1590/S0004-282X1997000200008
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA XB390
UT WOS:A1997XB39000008
PM 9629380
OA Other Gold, Bronze
DA 2020-12-08
ER

PT J
AU Nunes, ML
   DaCosta, JC
   MouraRibeiro, MVL
AF Nunes, ML
   DaCosta, JC
   MouraRibeiro, MVL
TI Polysomnographic quantification of bioelectrical maturation in preterm
   and fullterm newborns at matched conceptional ages
SO ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE newborn; preterm; polysomnography; neonatal EEG
ID GESTATIONAL-AGE; PREMATURE-INFANTS; BRAIN MATURATION; HEALTHY PRETERM;
   EEG RECORDINGS; TERM INFANTS; SLEEP; CONTINUITY; PATTERN
AB We analyzed the relationship between normal neonatal EEG features and gestational age and conceptional age, and evaluated the normal aspects of EEG maturation in preterm babies compared to term babies. We report 46 newborns, divided into two groups. Group I consisted of 11 newborns with gestational age between 30 and 32 weeks, followed with weekly polysomnograms until they reach 42 weeks' conceptional age. Group II (control) consisted of 35 newborns with gestational ages of 34 weeks (n = 5), 36 weeks (n = 10), 38 weeks (n = 10) and 40 weeks (n = 10) evaluated with one polysomnogram in their first 24-48 h of life. In each examination one 5 min epoch in REM and NREM sleep was analyzed to quantify the number of delta brushes, the presence of frontal and temporal sharp transients, the presence of delta frontal rhythmic activity, the grade of concordance between EEG patterns and sleep stages, the percent of interhemispheric synchrony and the duration of interburst interval. The age dependent variability of the EEG patterns was evaluated during the subsequent weeks with group comparisons at weeks 34, 36, 38 and 40. Our results show that the number of delta brushes and the duration of the interburst interval decrease as gestational and conceptional age increase. The percent of interhemispheric synchrony increases with gestational and conceptional age. The presence of frontal sharp transients and delta frontal rhythmic activity suggest that the newborn is fullterm. The presence of temporal sharp transients suggest a preterm newborn. The degree of concordance between behavioral sleep patterns and EEG was more helpful in recognizing sleep stages than in estimating gestational or conceptional age. Although the EEG patterns were comparable between the groups at the same age, analyses of the behavioral patterns of concordance in NREM sleep showed that newborns in Group I had a more immature behavior than newborns in Group II. Our results also suggest that extrauterine life of preterm babies does not seem to accelerate EEG maturation but may influence the acquisition of behavioral patterns during NREM sleep. (C) 1997 Elsevier Science Ireland Ltd.
C1 UNIV CAMPINAS,SAO PAULO,BRAZIL.
RP Nunes, ML (corresponding author), PUCRS,SAO LUCAS HOSP,DIV NEUROL,AV IPIRANGA 6690,ROOM 322,BR-90610000 PORTO ALEGRE,RS,BRAZIL.
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR ANDERS T, 1971, UCLA BRAIN INFORMATI
   ARFEL G, 1977, REV EEG NEUROPHYSIOL, V7, P351, DOI 10.1016/S0370-4475(77)80014-2
   BELL AH, 1991, J CLIN NEUROPHYSIOL, V8, P312, DOI 10.1097/00004691-199107010-00007
   BIAGIONI E, 1994, ELECTROEN CLIN NEURO, V91, P154, DOI 10.1016/0013-4694(94)90065-5
   Borsini W, 1990, Riv Neurol, V60, P234
   CAPURRO H, 1978, J PEDIATR-US, V93, P120, DOI 10.1016/S0022-3476(78)80621-0
   DACOSTA JC, 1991, SONO ASPECTOS ATUAIS, P133
   DREYFUS-BRISAC C, 1962, World Neurol, V3, P5
   DREYFUSBRISAC C, 1962, BIOL NEONATORUM, V4, P154
   DUFFY FH, 1990, CHILD DEV, V61, P1271, DOI 10.2307/1130893
   EYRE JA, 1988, DEV MED CHILD NEUROL, V30, P599
   FERRARI F, 1992, EARLY HUM DEV, V28, P37, DOI 10.1016/0378-3782(92)90006-3
   GOLDIE L, 1971, DEV MED CHILD NEUROL, V13, P40
   GOTO K, 1992, ELECTROEN CLIN NEURO, V82, P197, DOI 10.1016/0013-4694(92)90167-G
   HAHN JS, 1989, ELECTROEN CLIN NEURO, V73, P410, DOI 10.1016/0013-4694(89)90090-4
   HUGHES JR, 1987, ELECTROEN CLIN NEURO, V67, P7, DOI 10.1016/0013-4694(87)90156-8
   LOMBROSO CT, 1985, PEDIATRICS, V76, P52
   LOMBROSO CT, 1979, ELECTROEN CLIN NEURO, V46, P460, DOI 10.1016/0013-4694(79)90147-0
   Lombroso CT, 1993, ELECTROENCEPHALOGRAP, P803
   MONOD N, 1960, Rev Neurol (Paris), V102, P375
   NOLTE R, 1978, DEV MED CHILD NEUROL, V20, P167
   NUNES ML, 1992, PEDIATR NEUROL, V8, P385
   NUNES ML, 1994, PEDIATR NEUROL, V11, P129
   NUNES ML, 1994, THESIS U CAMPINAS SP
   PARMELEE AH, 1968, ELECTROEN CLIN NEURO, V24, P319, DOI 10.1016/0013-4694(68)90193-4
   SAMSONDOLFUS D, 1984, NEUROLOGICAL ELECTRO, P1
   Sarnat HB, 1984, TOPICS NEONATAL NEUR, P1
   SCHER MS, 1987, PEDIATR NEUROL, V3, P256, DOI 10.1016/0887-8994(87)90064-6
   SCHER MS, 1994, ELECTROEN CLIN NEURO, V90, P173, DOI 10.1016/0013-4694(94)90088-4
   SCHER MS, 1992, SLEEP, V15, P442, DOI 10.1093/sleep/15.5.442
   SCHER MS, 1994, ELECTROEN CLIN NEURO, V90, P179, DOI 10.1016/0013-4694(94)90089-2
   SCHER MS, 1994, PEDIATR RES, V36, P732, DOI 10.1203/00006450-199412000-00008
   Stockard-Pope J E, 1992, ATLAS NEONATAL ELECT
   THORNBERG E, 1990, ACTA PAEDIATR SCAND, V79, P20, DOI 10.1111/j.1651-2227.1990.tb11324.x
   TORRES F, 1985, J CLIN NEUROPHYSIOL, V2, P89, DOI 10.1097/00004691-198504000-00001
NR 35
TC 40
Z9 42
U1 0
U2 1
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0013-4694
J9 ELECTROEN CLIN NEURO
JI Electroencephalogr. Clin. Neurophysiol.
PD MAR
PY 1997
VL 102
IS 3
BP 186
EP 191
DI 10.1016/S0013-4694(96)95191-7
PG 6
WC Engineering, Biomedical; Clinical Neurology
SC Engineering; Neurosciences & Neurology
GA WR224
UT WOS:A1997WR22400005
PM 9129574
DA 2020-12-08
ER

PT J
AU Gambardella, A
   Palmini, A
   Andermann, F
   Dubeau, F
   DaCosta, JC
   Quesney, LF
   Andermann, E
   Olivier, A
AF Gambardella, A
   Palmini, A
   Andermann, F
   Dubeau, F
   DaCosta, JC
   Quesney, LF
   Andermann, E
   Olivier, A
TI Usefulness of focal rhythmic discharges on scalp EEG of patients with
   focal cortical dysplasia and intractable epilepsy
SO ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE intractable partial epilepsy; cortical dysplastic lesions; scalp EEG
ID NEURONAL MIGRATION DISORDERS; ANOMALIES; CORTEX
AB We examined the significance and frequency of occurrence of rhythmic epileptiform discharges (REDs) on the scalp EEGs of 74 patients with intractable partial epilepsy. We also analyzed the relationship of this abnormality to the continuous epileptiform discharges (CEDs) recorded on ECoG. Both REDs and CEDs had been found to be highly specific and sensitive indicators of focal cortical dysplastic lesions. Thirty-four patients (group I) had focal cortical dysplastic lesions (FCDLs) and 40 (group II) had non-dysplastic structural lesions. REDs were observed in 15 (44%) of the 34 patients of group I and in none of group II. REDs did not occur in isolation, were associated with more intermittent interictal spikes involving other regions, but had a greater (P < 0.05) significance for the localization of the epileptogenic area. A strong relationship was observed between the presence of REDs on scalp EEG and the occurrence of CEDs on ECoG recordings. Twelve (80%) of 15 patients with REDs had CEDs. Focal cortical dysplastic lesions are likely to be present when rhythmic epileptiform discharges are found.
C1 MONTREAL NEUROL HOSP & INST,MONTREAL,PQ H3A 2B4,CANADA.
   MCGILL UNIV,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA.
   PUCRS,HOSP SAO LUCAS,NEUROL & NEUROSURG SERV,PORTO ALEGRE EPILEPSY SURG PROGRAM,PORTO ALEGRE,RS,BRAZIL.
RI Gambardella, Antonio/F-5295-2012; DaCosta, Jaderson/C-4968-2015
OI Gambardella, Antonio/0000-0001-7384-3074; DaCosta,
   Jaderson/0000-0001-6776-1515
CR AjmoneMarsan C, 1980, ELECTRODIAGNOSIS CLI, P167
   BARKOVICH AJ, 1987, AM J NEURORADIOL, V8, P1009
   BOON PA, 1991, EPILEPSIA, V32, P467, DOI 10.1111/j.1528-1157.1991.tb04679.x
   DESBIENS R, 1993, ARCH NEUROL-CHICAGO, V50, P695, DOI 10.1001/archneur.1993.00540070015007
   FERRER I, 1992, ACTA NEUROPATHOL, V83, P647, DOI 10.1007/BF00299415
   Gloor P, 1977, CURRENT CONCEPTS CLI, P9
   GUERRINI R, 1992, DEV MED CHILD NEUROL, V34, P706
   HAGLUND MM, 1992, J NEUROSURG, V77, P209, DOI 10.3171/jns.1992.77.2.0209
   HIRABAYASHI S, 1993, J NEUROL NEUROSUR PS, V56, P765, DOI 10.1136/jnnp.56.7.765
   KUZNIECKY R, 1988, ANN NEUROL, V23, P317, DOI 10.1002/ana.410230402
   MATTIA D, 1995, NEUROLOGY, V45, P1391, DOI 10.1212/WNL.45.7.1391
   PALMINI A, 1991, CAN J NEUROL SCI, V18, P580, DOI 10.1017/S0317167100032753
   PALMINI A, 1994, EPILEPSIA, V35, pS57, DOI 10.1111/j.1528-1157.1994.tb05989.x
   PALMINI A, 1991, ANN NEUROL, V30, P741, DOI 10.1002/ana.410300602
   PALMINI A, 1995, ANN NEUROL, V37, P476, DOI 10.1002/ana.410370410
   PFURTSCHELLER G, 1975, ELECTROEN CLIN NEURO, V38, P93, DOI 10.1016/0013-4694(75)90215-1
   QUIRK JA, 1993, NEUROPEDIATRICS, V24, P193, DOI 10.1055/s-2008-1071538
   RAYMOND AA, 1995, ELECTROEN CLIN NEURO, V94, P389, DOI 10.1016/0013-4694(94)00335-I
   VANNESS PC, 1990, ANN NEUROL, V28, P263
   WESTMORELAND BF, 1990, J CLIN NEUROPHYSIOL, V7, P209, DOI 10.1097/00004691-199004000-00005
NR 20
TC 135
Z9 140
U1 0
U2 0
PU ELSEVIER SCI IRELAND LTD
PI CLARE
PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND
SN 0013-4694
J9 ELECTROEN CLIN NEURO
JI Electroencephalogr. Clin. Neurophysiol.
PD APR
PY 1996
VL 98
IS 4
BP 243
EP 249
DI 10.1016/0013-4694(95)00266-9
PG 7
WC Engineering, Biomedical; Clinical Neurology
SC Engineering; Neurosciences & Neurology
GA UN725
UT WOS:A1996UN72500003
PM 8641147
DA 2020-12-08
ER

PT J
AU NUNES, ML
   DACOSTA, JC
   TAUFER, L
   DASILVEIRA, CMD
AF NUNES, ML
   DACOSTA, JC
   TAUFER, L
   DASILVEIRA, CMD
TI RELATIONSHIP OF EEG, NEUROLOGICAL DISEASES AND FOLLOW-UP IN PRETERM
   NEWBORNS
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA Portuguese
DT Article
DE NEWBORN; PREMATURE; EEG; POLYSOMNOGRAPHY
ID PREMATURE-INFANTS; PROGNOSTIC VALUE; FULL-TERM
AB The importance of the EEG for the investigation of neurological diseases in the neonatal period has been largely discussed, since it is often the only way to approach cerebral function in newborns with severe pathologies or under drug effect. The present study was carried out with 85 newborns (NB) who presented perinatal dysfuntions and were submitted to neurological and electroencephalogram (EEG) or polysomnography (PS) evaluation. EEG/PS alterations, pathologies and prognosis were reported. The EEG were classified according to basal activity alterations, presence of paroxysmal activity and sleep stages organization and maturity. The most frequent pathology was perinatal asphyxia (40%) followed by intraventricular hemorrhage (HIV, 16%). The most frequent complaint for exam indication was apnea (71%) followed by convulsion (19%). Fifty-five percent of the exams exclusively required because apnea complaint were considered normal and out of all exams required because seizures only 31% were normal. The EEG alteration most frequently related to perinatal asphyxia, HIV and intrauterine growth delay was immaturity and in the NE with seizures immature EEG and abnormal paroxysms. Many different alterations were registered in the NE with nervous system infection. The EEG findings more correlated with unfavorable prognosis were isoelectricity and abnormal paroxysmal activity including positive sharp waves (100%).
C1 PONTIFICA UNIV CATOLICA RIO GRANDE SUL,HOSP SAO LUCAS,SERV NEUROL,BR-90610000 PORTO ALEGRE,RS,BRAZIL.
   PONTIFICA UNIV CATOLICA RIO GRANDE SUL,HOSP SAO LUCAS,NEUROFISIOL CLIN LAB,BR-90610000 PORTO ALEGRE,RS,BRAZIL.
   PONTIFICA UNIV CATOLICA RIO GRANDE SUL,FAC MED,BR-90610000 PORTO ALEGRE,RS,BRAZIL.
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR ASO K, 1989, J CLIN NEUROPHYSIOL, V6, P103, DOI 10.1097/00004691-198904000-00001
   DACOSTA JC, SONO ASPECTOS ATUAIS, P133
   FRANKENBURG WK, 1967, J PEDIATR, P181
   LOMBROSO CT, 1985, J CLIN NEUROPHYSIOL, V2, P105, DOI 10.1097/00004691-198504000-00002
   LOMBROSO CT, 1994, ELECTROENCEPHALOGRAP, P803
   MONOD N, 1972, ELECTROEN CLIN NEURO, V32, P529, DOI 10.1016/0013-4694(72)90063-6
   NUNES ML, 1992, PEDIATR NEUROL, V8, P385
   NUNES ML, 1994, THESIS U ESTADUAL CA
   NUNES ML, 1994, JLBE, V7, P27
   SILVA EA, 1993, ELECTROENCEPH CLIN S, V2
   THARP BR, 1989, NEUROPEDIATRICS, V20, P64, DOI 10.1055/s-2008-1071267
   THARP BR, 1981, ELECTROEN CLIN NEURO, V51, P219, DOI 10.1016/0013-4694(81)90136-X
NR 12
TC 8
Z9 9
U1 0
U2 1
PU ASSOC ARQUIVOS DE NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA C/O DR OSWALDO LANGE, CAIXA POSTAL 8877, 01065-970 SAO PAULO SP, BRAZIL
SN 0004-282X
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD SEP
PY 1995
VL 53
IS 3B
BP 625
EP 630
DI 10.1590/S0004-282X1995000400013
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA TB699
UT WOS:A1995TB69900013
PM 8585821
OA Other Gold
DA 2020-12-08
ER

PT J
AU NUNES, ML
   DACOSTA, JC
   DASILVA, LFG
AF NUNES, ML
   DACOSTA, JC
   DASILVA, LFG
TI TRIHEXYPHENIDYL AND ISOPRINOSINE IN THE TREATMENT OF SUBACUTE SCLEROSING
   PANENCEPHALITIS
SO PEDIATRIC NEUROLOGY
LA English
DT Article
ID INTERFERON THERAPY; MEASLES-VIRUS
AB Six cases of subacute sclerosing panencephalitis (1 stage I, 3 stage II, 2 stage III) were diagnosed at our institution in the last 10 years. Five patients were treated with isoprinosine and the antiepileptic drug valproic acid. Three patients presented with myoclonic seizures refractory to valproic acid and the usual antiepileptic therapy. They received trihexyphenidyl with good results. We suggest the use of trihexyphenidyl in combination with isoprinosine in patients with subacute sclerosing panencephalitis with myoclonic seizures refractory to valproic acid.
C1 PUCRS,SCH MED,PORTO ALEGRE,RS,BRAZIL.
RP NUNES, ML (corresponding author), SAO LUCAS HOSP,DIV NEUROL,AV IPIRANGA 6690,322,BR-90610000 PORTO ALEGRE,RS,BRAZIL.
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR Anderson J R, 1988, Curr Top Pathol, V76, P23
   Brimani D J, 1986, Rev Electroencephalogr Neurophysiol Clin, V16, P433, DOI 10.1016/S0370-4475(86)80033-8
   CATTANEO R, 1988, J VIROL, V62, P1388, DOI 10.1128/JVI.62.4.1388-1397.1988
   DACOSTA JC, 1991, JLBE, V4, P17
   DHIBJALBUT S, 1988, J VIROL, V62, P2483, DOI 10.1128/JVI.62.7.2483-2489.1988
   DHIBJALBUT S, 1994, HDB NEUROVIROLOGY, P539
   DUNCALF CM, 1989, BRIT J PSYCHIAT, V155, P557, DOI 10.1192/bjp.155.4.557
   DYKEN PR, 1981, ANN NEUROL, V11, P359
   GASCON G, 1993, BRAIN DEV-JPN, V15, P346, DOI 10.1016/0387-7604(93)90120-W
   GASCON GG, 1995, GUIDELINES SSPE CONS, P1
   GELLIN BG, 1994, J INFECT DIS, V170, pS3, DOI 10.1093/infdis/170.Supplement_1.S3
   GRAVES MC, 1984, NEUROL CLIN, V2, P267, DOI 10.1016/S0733-8619(18)31103-4
   HATANAKA T, 1989, EUR NEUROL, V29, P6, DOI 10.1159/000116367
   JABBARI B, 1989, Epilepsia, V30, P725
   JONES CE, 1982, LANCET, V8, P1034
   JUNES ML, 1992, J LIGA BRASILEIRA EP, V5, P23
   LOMBROSO CT, 1968, NEUROLOGY, V18, P69, DOI 10.1212/WNL.18.1_Part_2.069
   MAIMONE D, 1988, ACTA NEUROL SCAND, V78, P161, DOI 10.1111/j.1600-0404.1988.tb03639.x
   MODLIN JF, 1971, PEDIATRICS, V94, P231
   SALIB EA, 1988, BRIT J PSYCHIAT, V152, P709, DOI 10.1192/bjp.152.5.709
   SULTANT TB, 1992, PEDIATR NEUROL, V8, P38
   YALAZ K, 1992, NEUROLOGY, V42, P488, DOI 10.1212/WNL.42.3.488
NR 22
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE PUBL CO INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0887-8994
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD SEP
PY 1995
VL 13
IS 2
BP 153
EP 156
DI 10.1016/0887-8994(95)00145-6
PG 4
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA RW569
UT WOS:A1995RW56900009
PM 8534281
DA 2020-12-08
ER

PT J
AU NUNES, ML
   DACOSTA, JC
   SEVERINI, MH
AF NUNES, ML
   DACOSTA, JC
   SEVERINI, MH
TI EARLY-ONSET BILATERAL CALCIFICATIONS AND EPILEPSY
SO PEDIATRIC NEUROLOGY
LA English
DT Note
AB Bilateral occipital calcifications associated with epilepsy and sometimes with celiac disease have been described previously, A boy with bilateral frontal and occipital diffuse calcifications accompanied by failure to thrive, nephrogenic diabetes insipidus, developmental delay and seizures, but without celiac disease is presented, Follow-up at 3 years of age disclosed neurodevelopmental delay, height and weight less than expected for age, and seizures controlled with carbamazepine, The uncommon association of these features and the early onset of symptoms is discussed. Although bilateral occipital calcifications share some clinical features with bilateral fronto-occipital calcifications, it is arguable whether the two are on a spectrum of a single disease or represent separate entities.
C1 PUC RS,SCH MED,BR-90610000 PORTO ALEGRE,RS,BRAZIL.
   PUC RS,HOSP SAO LUCAS,DEPT PEDIAT,PORTO ALEGRE,RS,BRAZIL.
   PUC RS,HOSP SAO LUCAS,INTENS CARE UNIT,PORTO ALEGRE,RS,BRAZIL.
RP NUNES, ML (corresponding author), PUC RS,SAO LUCAS HOSP,DIV NEUROL,AV IPIRANGA 6690,ROOM 322,BR-90610000 PORTO ALEGRE,RS,BRAZIL.
RI DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515
CR ARROYO H, 1992, PEDIATR NEUROL, V8, P389
   CACERES LP, 1992, PEDIATR NEUROL, V8, P401
   GOBBI G, 1992, LANCET, V340, P439
   GOBBI G, 1992, PEDIATR NEUROL, V8, P369
   JOHNSEN SD, 1982, PRACTICE PEDIATRIC N, P632
   MAGAUDDA A, 1991, Epilepsia, V32, P119
   MAGAUDDA A, 1992, PEDIATR NEUROL, V8, P371
   Marsilli E, 1992, Radiol Med, V83, P114
   NUNES ML, 1993, EPILEPSIA, V34, P177
   ROSARIO AM, 1992, PEDIATR NEUROL, V8, P392
   SCHOFER O, 1990, ARCH DIS CHILD, V65, P885, DOI 10.1136/adc.65.8.885
NR 11
TC 3
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE PUBL CO INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0887-8994
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD JUL
PY 1995
VL 13
IS 1
BP 80
EP 82
DI 10.1016/0887-8994(95)00085-T
PG 3
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA RM038
UT WOS:A1995RM03800016
PM 7575857
DA 2020-12-08
ER

PT J
AU PALMINI, A
   GAMBARDELLA, A
   ANDERMANN, F
   DUBEAU, F
   DACOSTA, JC
   OLIVIER, A
   TAMPIERI, D
   GLOOR, P
   QUESNEY, F
   ANDERMANN, E
   PAGLIOLI, E
   PAGLIOLINETO, E
   COUTINHO, L
   LEBLANC, R
   KIM, HI
AF PALMINI, A
   GAMBARDELLA, A
   ANDERMANN, F
   DUBEAU, F
   DACOSTA, JC
   OLIVIER, A
   TAMPIERI, D
   GLOOR, P
   QUESNEY, F
   ANDERMANN, E
   PAGLIOLI, E
   PAGLIOLINETO, E
   COUTINHO, L
   LEBLANC, R
   KIM, HI
TI INTRINSIC EPILEPTOGENICITY OF HUMAN DYSPLASTIC CORTEX AS SUGGESTED BY
   CORTICOGRAPHY AND SURGICAL RESULTS
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID NEURONAL MIGRATION DISORDERS; INTRACTABLE PARTIAL EPILEPSY; CORTICAL
   DYSPLASIA; INFANTILE SPASMS; RESECTION; ANOMALIES; LESIONS; TOMOGRAPHY;
   MRI
AB Cortical dysplastic lesions (CDyLs) are often associated with severe partial epilepsies. We describe the electrographic counterpart of this high degree of epileptogenicity, manifested by continuous or frequent rhythmic epileptogenic discharges recorded directly from CDyLs during intraoperative electrocorticography (ECoG). These ictal or continuous epileptogenic discharges (I/CEDs) assumed one of the following three patterns: (1) repetitive electrographic seizures, (2) repetitive bursting discharges, or (3) continuous or quasicontinuous rhythmic spiking. One or more of these patterns were present in 23 of 34 patients (67%) with intractable partial epilepsy associated with CDyLs, and in only 1 of 40 patients (2.5%) with intractable partial epilepsy associated with other types of structural lesions. I/CEDs were usually spatially restricted, thus contrasting with the more widespread interictal ECoG epileptic activity, and tended to colocalize with the magnetic resonance imaging-defined lesion. Completeness of excision of cortical tissue displaying I/CEDs correlated positively with surgical outcome in patients with medically intractable seizures; i.e., three-fourths of the patients in whom it was entirely excised had favorable surgical outcome; in contrast, uniformly poor outcome was observed in those patients in whom areas containing I/CEDs remained in situ. We conclude that CDyLs are highly and intrinsically epileptogenic, and that intraoperative ECoG identification of this intrinsically epileptogenic dysplastic cortical tissue is crucial to decide the extent of excision for best seizure control.
C1 PUCRS,HOSP SAO LUCAS,NEUROSURG SERV,BR-90610000 PORTO ALEGRE,RS,BRAZIL.
   MCGILL UNIV,DEPT NEUROL & NEUROSURG,MONTREAL,PQ,CANADA.
   MONTREAL NEUROL HOSP & INST,MONTREAL,PQ,CANADA.
   CHONBUK NATL UNIV HOSP,DEPT NEUROSURG,CHONJU,SOUTH KOREA.
RP PALMINI, A (corresponding author), PUCRS,HOSP SAO LUCAS,SERV NEUROL,PORTO ALEGRE EPILEPSY SURG PROGRAM,AV IPIRANGA 6690,BR-90610000 PORTO ALEGRE,RS,BRAZIL.
RI DaCosta, Jaderson/C-4968-2015; Gambardella, Antonio/F-5295-2012
OI DaCosta, Jaderson/0000-0001-6776-1515; Gambardella,
   Antonio/0000-0001-7384-3074; Kim, Hyoung-Ihl/0000-0001-7914-3968
CR Andermann F, 1987, ADV EPILEPTOL, V16, P35
   AWAD IA, 1991, EPILEPSIA, V32, P179, DOI 10.1111/j.1528-1157.1991.tb05242.x
   BARKOVICH AJ, 1987, AM J NEURORADIOL, V8, P1009
   BOON PA, 1991, EPILEPSIA, V32, P467, DOI 10.1111/j.1528-1157.1991.tb04679.x
   BRODTKORB E, 1992, ACTA NEUROL SCAND, V86, P24, DOI 10.1111/j.1600-0404.1992.tb08049.x
   CASCINO GD, 1990, MAYO CLIN PROC, V65, P1053, DOI 10.1016/S0025-6196(12)62716-5
   CHUGANI HT, 1993, PEDIATR NEUROL, V9, P10, DOI 10.1016/0887-8994(93)90003-U
   CHUGANI HT, 1990, ANN NEUROL, V27, P406, DOI 10.1002/ana.410270408
   CHUGANI HT, 1993, EPILEPSIA, V34, P764, DOI 10.1111/j.1528-1157.1993.tb00459.x
   DACOSTA JC, 1992, EPILEPSIA, V33, P37
   DEROSA MJ, 1992, ACTA NEUROPATHOL, V84, P250, DOI 10.1007/BF00227817
   DESBIENS R, 1993, ARCH NEUROL-CHICAGO, V50, P695, DOI 10.1001/archneur.1993.00540070015007
   Douglas R, 1990, SYNAPTIC ORG BRAIN, P389
   ENGEL J, 1989, SEIZURES EPILEPSY
   FERRER I, 1992, ACTA NEUROPATHOL, V83, P647, DOI 10.1007/BF00299415
   FISH D, 1991, NEUROLOGY, V41, P1481
   GALE K, 1988, EPILEPSIA, V29, pS15, DOI 10.1111/j.1528-1157.1988.tb05795.x
   Gambardella Antonio, 1993, Epilepsia, V34, P127
   GUERRINI R, 1992, DEV MED CHILD NEUROL, V34, P706
   HABLITZ JJ, 1987, J NEUROPHYSIOL, V58, P1052
   HAGLUND MM, 1992, J NEUROSURG, V77, P209, DOI 10.3171/jns.1992.77.2.0209
   HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762
   JENSEN MS, 1988, ANN NEUROL, V24, P591, DOI 10.1002/ana.410240502
   Jones-Gotman M, 1987, SURGICAL TREATMENT E, P203
   KITASATO H, 1975, J THEOR BIOL, V51, P181, DOI 10.1016/0022-5193(75)90147-2
   KUZNIECKY R, 1988, ANN NEUROL, V23, P317, DOI 10.1002/ana.410230402
   KUZNIECKY R, 1993, ANN NEUROL, V34, P627, DOI 10.1002/ana.410340421
   LEE N, 1994, ANN NEUROL, V35, P290, DOI 10.1002/ana.410350308
   LEPPIK IE, 1986, EPILEPSY, P633
   Milner B, 1975, NEUROSURGICAL MANAGE, P299
   OLSON DM, 1990, EPILEPSIA, V31, P731, DOI 10.1111/j.1528-1157.1990.tb05514.x
   PALMINI A, 1991, ANN NEUROL, V30, P750, DOI 10.1002/ana.410300603
   PALMINI A, 1991, CAN J NEUROL SCI, V18, P580, DOI 10.1017/S0317167100032753
   PALMINI A, 1994, EPILEPSIA, V35, pS57, DOI 10.1111/j.1528-1157.1994.tb05989.x
   PALMINI A, 1991, ANN NEUROL, V30, P741, DOI 10.1002/ana.410300602
   Palmini Andre, 1992, Epilepsia, V33, P75
   PEROT P, 1966, ARCH NEUROL-CHICAGO, V15, P498, DOI 10.1001/archneur.1966.00470170052005
   PILCHER WH, 1993, J NEUROSURG, V78, P891, DOI 10.3171/jns.1993.78.6.0891
   PRINCE DA, 1985, EPILEPSIA, V26, pS3, DOI 10.1111/j.1528-1157.1985.tb05721.x
   ROBITAILLE Y, 1992, FRONTAL LOBE SEIZURE, P499
   SARNAT HB, 1992, CEREBRAL DYSGENESIS
   SPENCER DD, 1984, NEUROLOGY, V34, P432, DOI 10.1212/WNL.34.4.432
   TAYLOR DC, 1971, J NEUROL NEUROSUR PS, V34, P339
NR 43
TC 562
Z9 575
U1 0
U2 9
PU LITTLE BROWN CO
PI BOSTON
PA 34 BEACON STREET, BOSTON, MA 02108-1493
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD APR
PY 1995
VL 37
IS 4
BP 476
EP 487
DI 10.1002/ana.410370410
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA RD290
UT WOS:A1995RD29000009
PM 7717684
DA 2020-12-08
ER

PT J
AU BITTENCOURT, PRM
   ANTONIUK, SA
   BIGARELLA, MM
   DACOSTA, JC
   DORO, MP
   FERREIRA, AS
   FONSECA, LC
   GORZ, AM
   SILVA, GEGE
   MARCOURAKIS, T
   TEDROS, GMAS
AF BITTENCOURT, PRM
   ANTONIUK, SA
   BIGARELLA, MM
   DACOSTA, JC
   DORO, MP
   FERREIRA, AS
   FONSECA, LC
   GORZ, AM
   SILVA, GEGE
   MARCOURAKIS, T
   TEDROS, GMAS
TI CARBAMAZEPINE AND PHENYTOIN IN EPILEPSIES REFRACTORY TO BARBITURATES -
   EFFICACY, TOXICITY AND MENTAL FUNCTION, (VOL 16, PG 147, 1993)
SO EPILEPSY RESEARCH
LA English
DT Correction, Addition
C1 CATHOLIC UNIV PORTO ALEGRE,PORTO ALEGRE,BRAZIL.
   CATHOLIC UNIV CAMPINAS,CAMPINAS,BRAZIL.
   UNIV SAO PAULO,CTR INVEST NEUROL,SAO PAULO,BRAZIL.
   UNIV FED PERNAMBUCO,BR-50000 RECIFE,PE,BRAZIL.
RP BITTENCOURT, PRM (corresponding author), HOSP NOSSA SENHORA GRACAS,UNIDADE NEUROL CLIN,RUA ALCIDES MUNHOZ 433,BR-80810 CURITIBA,BRAZIL.
RI Marcourakis, Tania/D-6667-2012; DaCosta, Jaderson/C-4968-2015
OI DaCosta, Jaderson/0000-0001-6776-1515; Ferreira,
   Zulma/0000-0001-6571-837X
CR BITTENCOURT PRM, 1993, EPILEPSY RES, V16, P147, DOI 10.1016/0920-1211(93)90029-7
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-1211
J9 EPILEPSY RES
JI Epilepsy Res.
PD MAR
PY 1994
VL 17
IS 3
BP 271
EP 271
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA ND554
UT WOS:A1994ND55400009
DA 2020-12-08
ER

PT J
AU PALMINI, A
   GAMBARDELLA, A
   ANDERMANN, F
   DUBEAU, F
   DACOSTA, JC
   OLIVIER, A
   TAMPIERI, D
   ROBITAILLE, Y
   PAGLIOLI, E
   NETO, EP
   COUTINHO, L
   KIM, HI
AF PALMINI, A
   GAMBARDELLA, A
   ANDERMANN, F
   DUBEAU, F
   DACOSTA, JC
   OLIVIER, A
   TAMPIERI, D
   ROBITAILLE, Y
   PAGLIOLI, E
   NETO, EP
   COUTINHO, L
   KIM, HI
TI OPERATIVE STRATEGIES FOR PATIENTS WITH CORTICAL DYSPLASTIC LESIONS AND
   INTRACTABLE EPILEPSY
SO EPILEPSIA
LA English
DT Article; Proceedings Paper
CT 1993 Annual Course at the American-Epilepsy-Society Meeting -
   Neuroimaging and Epilepsy: The Role of New Techniques
CY DEC   05, 1993
CL MIAMI, FL
SP AMER EPILEPSY SOC
ID NEURONAL MIGRATION DISORDERS; TEMPORAL-LOBE EPILEPSY;
   SURGICAL-TREATMENT; CHILDHOOD EPILEPSY; STRUCTURAL LESIONS; PARTIALIS
   CONTINUA; STATUS EPILEPTICUS; INFANTILE SPASMS; FOLLOW-UP; SEIZURES
AB Cortical dysplastic lesions (CDLs) are usually identified by magnetic resonance imaging (MRI). Clinical, electrographic and histologic findings suggest that focal CDLs (FCDLs) are highly epileptogenic, often involve the rolandic cortex, and can present variable degrees of histopathologic abnormalities. An ictal or ''ictal-like'' bursting pattern of electrographic activity was recorded over dysplastic cortex in 65% of our patients. Resective surgery can eliminate or significantly reduce seizure frequency in many medically intractable patients, depending on lesion location, degree, and extent of histopathologic abnormalities. Best results are achieved when complete or major excision of both the MRI-visible lesion and the cortical areas displaying ictal electrographic activity can be performed. This is more likely when the degree of histopathologic abnormality is mild to moderate or when the lesion is in a temporal lobe. More severe histopathologic abnormalities and central insular or multilobar lesions usually lead to less favorable results: either major excision of the visualized lesion is impractical or the lesion is microscopically more extensive than shown by MRI. Multilobar resection or hemispherectomy for patients with infantile spasms associated with CDLs and for patients with hemimegalencephaly are often associated with dramatic improvement in seizure control. Callosotomy can be performed in selected patients with diffuse CDLs who have intractable drop attacks.
C1 PUCRS,HOSP SAO LUCAS,NEUROSURG SERV,PORTO ALEGRE EPILEPSY SURG PROGRAM,BR-90610000 PORTO ALEGRE,RS,BRAZIL.
   MCGILL UNIV,DEPT NEUROL & NEUROSURG,MONTREAL,PQ,CANADA.
   MONTREAL NEUROL HOSP & INST,MONTREAL H3A 2B4,PQ,CANADA.
   UNIV MONTREAL,DEPT NEUROPATHOL,MONTREAL,PQ,CANADA.
   FAC CIENCIAS MED PORTO ALEGRE,DEPT PATHOL,PORTO ALEGRE,RS,BRAZIL.
   CHONBUK NATL UNIV,DEPT NEUROSURG,CHONJU,SOUTH KOREA.
RP PALMINI, A (corresponding author), PUCRS,HOSP SAO LUCAS,NEUROL SERV,PORTO ALEGRE EPILEPSY SURG PROGRAM,AVE IPIRANGA 6690,BR-90610000 PORTO ALEGRE,RS,BRAZIL.
RI Gambardella, Antonio/F-5295-2012; DaCosta, Jaderson/C-4968-2015
OI Gambardella, Antonio/0000-0001-7384-3074; DaCosta,
   Jaderson/0000-0001-6776-1515
CR ALRODHAN NRF, 1992, STEREOT FUNCT NEUROS, V58, P172, DOI 10.1159/000098992
   AMBROSETTO G, 1992, EPILEPSIA, V33, P499, DOI 10.1111/j.1528-1157.1992.tb01699.x
   ANDERMANN F, 1992, EPILEPSY SURGERY, P203
   AWAD IA, 1991, EPILEPSIA, V32, P179, DOI 10.1111/j.1528-1157.1991.tb05242.x
   BARKOVICH AJ, 1987, AM J NEURORADIOL, V8, P1009
   BARKOVICH AJ, 1992, AM J NEURORADIOL, V13, P95
   BARKOVICH AJ, 1989, RADIOLOGY, V171, P455, DOI 10.1148/radiology.171.2.2468173
   BEBIN EM, 1993, EPILEPSIA, V34, P651, DOI 10.1111/j.1528-1157.1993.tb00442.x
   BERKOVIC SF, 1991, ANN NEUROL, V29, P175, DOI 10.1002/ana.410290210
   BOON PA, 1991, EPILEPSIA, V32, P467, DOI 10.1111/j.1528-1157.1991.tb04679.x
   BRANNSTROM T, 1993, EPILEPSIA, V34, P71
   CASCINO GD, 1992, EPILEPSIA, V33, P639, DOI 10.1111/j.1528-1157.1992.tb02340.x
   Cascino Gregory D., 1993, P77
   Cendes F., 1993, Epilepsia, V34, P126
   CHUGANI HT, 1990, ANN NEUROL, V27, P406, DOI 10.1002/ana.410270408
   CHUGANI HT, 1993, EPILEPSIA, V34, P764, DOI 10.1111/j.1528-1157.1993.tb00459.x
   DEROSA MJ, 1992, NEUROPATH APPL NEURO, V18, P566, DOI 10.1111/j.1365-2990.1992.tb00827.x
   DEROSA MJ, 1992, ACTA NEUROPATHOL, V84, P250, DOI 10.1007/BF00227817
   DESBIENS R, 1993, ARCH NEUROL-CHICAGO, V50, P695, DOI 10.1001/archneur.1993.00540070015007
   Engel Jerome Jr., 1993, P609
   Engel Jerome Jr., 1993, P23
   FERRER I, 1992, ACTA NEUROPATHOL, V83, P647, DOI 10.1007/BF00299415
   FISH D, 1991, NEUROLOGY, V41, P1781, DOI 10.1212/WNL.41.11.1781
   FRIED I, 1992, J NEUROSURG, V76, P735, DOI 10.3171/jns.1992.76.5.0735
   Fried I, 1993, EPILEPSIA, V34, P78
   Fried Itzhak, 1993, P501
   Friede R. L., 1989, DEV NEUROPATHOLOGY, P330
   FUSCO L, 1992, BRAIN DEV-JPN, V14, P323, DOI 10.1016/S0387-7604(12)80152-5
   Goldring S, 1986, Clin Neurosurg, V33, P15
   Gomez MR, 1988, TUBEROUS SCLEROSIS, P21
   GUERRINI R, 1992, DEV MED CHILD NEUROL, V34, P706
   HAGLUND MM, 1992, J NEUROSURG, V77, P209, DOI 10.3171/jns.1992.77.2.0209
   Hauser W, 1991, EPILEPSY SURG, P133
   JAY V, 1993, J NEUROSURG, V79, P53, DOI 10.3171/jns.1993.79.1.0053
   KIM HI, 1992, STEREOT FUNCT NEUROS, V58, P162, DOI 10.1159/000098990
   KUZNIECKY R, 1988, ANN NEUROL, V23, P317, DOI 10.1002/ana.410230402
   KUZNIECKY R, 1993, LANCET, V341, P608, DOI 10.1016/0140-6736(93)90363-L
   KUZNIECKY R, 1993, NEUROLOGY, V43, P681, DOI 10.1212/WNL.43.4.681
   KUZNIECKY R, 1991, ANN NEUROL, V29, P293, DOI 10.1002/ana.410290311
   KUZNIECKY RI, 1994, EPILEPSIA, V35, pS44, DOI 10.1111/j.1528-1157.1994.tb05988.x
   Kuzniecky Ruben I., 1993, P197
   LANDY HJ, 1993, EPILEPSIA, V34, P79, DOI 10.1111/j.1528-1157.1993.tb02379.x
   Lee Namsoo, 1992, Epilepsia, V33, P76
   LEPPIK IE, 1986, NEUROL CLIN, V4, P633, DOI 10.1016/S0733-8619(18)30967-8
   LEVESQUE MF, 1991, J NEUROSURG, V75, P364, DOI 10.3171/jns.1991.75.3.0364
   LINDSAY J, 1979, DEV MED CHILD NEUROL, V21, P285
   LUDERS HO, 1991, EPILEPSY SURG, P51
   MEENCKE HJ, 1992, MOL NEUROBIOLOGY EPI, P31
   MORREL F, 1993, NEUROSURGEONS, V12, P101
   PALMINI A, 1991, ANN NEUROL, V30, P750, DOI 10.1002/ana.410300603
   PALMINI A, 1991, CAN J NEUROL SCI, V18, P580, DOI 10.1017/S0317167100032753
   PALMINI A, 1993, EPILEPSIA, V34, P84, DOI 10.1111/j.1528-1157.1993.tb02380.x
   PALMINI A, 1991, NEUROLOGY, V41, P1656, DOI 10.1212/WNL.41.10.1656
   PALMINI A, 1993, DEV MED CHILD NEUROL, V35, P331
   PALMINI A, 1991, ANN NEUROL, V30, P741, DOI 10.1002/ana.410300602
   PALMINI A, 1992, MOL NEUROBIOLOGY EPI, P19
   Palmini Andre, 1992, Epilepsia, V33, P75
   PEROT P, 1966, ARCH NEUROL-CHICAGO, V15, P498, DOI 10.1001/archneur.1966.00470170052005
   PILCHER WH, 1993, J NEUROSURG, V78, P891, DOI 10.3171/jns.1993.78.6.0891
   PRAYSON RA, 1993, EPILEPSIA, V34, P609, DOI 10.1111/j.1528-1157.1993.tb00436.x
   RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116
   RASMUSSEN T, 1963, EPILEPSIA, V4, P181, DOI 10.1111/j.1528-1157.1963.tb05220.x
   RASMUSSEN T, 1991, EPILEPSY SURG, P173
   RICHMAN DP, 1975, SCIENCE, V189, P18
   ROBAIN O, 1988, NEUROPATH APPL NEURO, V14, P125, DOI 10.1111/j.1365-2990.1988.tb00875.x
   SARNAT HB, 1992, CEREBRAL DYSGENESIS
   SILLANPAA M, 1993, EPILEPSIA S2, V34, P147
   SPENCER DD, 1984, NEUROLOGY, V34, P432, DOI 10.1212/WNL.34.4.432
   SPERLING MR, 1989, EPILEPSIA, V30, P559, DOI 10.1111/j.1528-1157.1989.tb05471.x
   SWAHNEY IMS, 1993, EPILEPSIA S2, V34, P110
   TAYLOR DC, 1971, J NEUROL NEUROSUR PS, V34, P369, DOI 10.1136/jnnp.34.4.369
   TOWNSEND JJ, 1975, NEUROLOGY, V25, P448, DOI 10.1212/WNL.25.5.448
   VANNESS PC, 1990, ANN NEUROL, V28, P263
   VIGEVANO F, 1989, EPILEPSIA, V30, P833, DOI 10.1111/j.1528-1157.1989.tb05347.x
   VIGEVANO F, 1991, B LEGA IT EPIL, V74, P157
   WIESER HG, 1988, EPILEPSIA, V29, pS100, DOI 10.1111/j.1528-1157.1988.tb05793.x
   YEH HS, 1990, J NEUROSURG, V72, P216, DOI 10.3171/jns.1990.72.2.0216
NR 77
TC 142
Z9 145
U1 0
U2 1
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PY 1994
VL 35
SU 6
BP S57
EP S71
DI 10.1111/j.1528-1157.1994.tb05989.x
PG 15
WC Clinical Neurology
SC Neurosciences & Neurology
GA NV614
UT WOS:A1994NV61400007
PM 8206015
DA 2020-12-08
ER

PT J
AU BITTENCOURT, PRM
   ANTONIUK, SA
   BIGARELLA, MM
   DACOSTA, JC
   DORO, MP
   FERREIRA, AS
   FONSECA, LC
   GORZ, AM
   SILVA, GEG
   MARCOURAKIS, T
   TEDROS, GMAS
AF BITTENCOURT, PRM
   ANTONIUK, SA
   BIGARELLA, MM
   DACOSTA, JC
   DORO, MP
   FERREIRA, AS
   FONSECA, LC
   GORZ, AM
   SILVA, GEG
   MARCOURAKIS, T
   TEDROS, GMAS
TI CARBAMAZEPINE AND PHENYTOIN IN EPILEPSIES REFRACTORY TO BARBITURATES -
   EFFICACY, TOXICITY AND MENTAL FUNCTION
SO EPILEPSY RESEARCH
LA English
DT Article
DE ANTIEPILEPTIC DRUGS; CONTROLLED TRIAL; BARBITURATES; PHENYTOIN;
   CARBAMAZEPINE; PARTIAL SEIZURES; COGNITIVE FUNCTION; PSYCHOPATHOLOGY
AB A group of 51 patients with chronic cryptogenic or symptomatic localized epilepsy refractory lo therapy with barbiturates underwent progressive substitution with phenytoin or carbamazepine, in standardized and randomized fashion. After drug changes were completed two thirds of the patients remained seizure free during a period of 6 months. A clearer effect of phenytoin and carbamazepine was seen on secondary generalized than on partial seizures. The frequency of severe side effects decreased after the change to phenytoin and carbamazepine. The group on carbamazepine improved in immediate and late recall, and in immediate and late recognition of pictures. The group on phenytoin improved significantly in the Stroop test. Patients changed to phenytoin, but not those changed to carbamazepine, became significantly more aggressive, anxious and depressive than when on phenobarbital, as measured by subjective scales. The results indicate that patients should not be considered refractory to antiepileptic drug therapy while on barbiturates. Cognitive dysfunction and mood changes observed in epilepsy may be temporary and dependent on the presence of seizures and/or on use of barbiturates.
C1 CATHOLIC UNIV CAMPINAS,CAMPINAS,SP,BRAZIL.
   UNIV SAO PAULO,CTR INVEST NEUROL,SAO PAULO,SP,BRAZIL.
   FED UNIV PERNAMBUCO,RECIFE,PE,BRAZIL.
   CATHOLIC UNIV PORTO ALEGRE,PORTO ALEGRE,RS,BRAZIL.
RP BITTENCOURT, PRM (corresponding author), HOSP NOSSA SENHORA GRACAS,UNIDADE NEUROL CLIN,RUA ALCIDES MUNHOZ 433,BR-80810 CURITIBA,PARANA,BRAZIL.
RI DaCosta, Jaderson/C-4968-2015; Marcourakis, Tania/D-6667-2012
OI DaCosta, Jaderson/0000-0001-6776-1515; Ferreira,
   Zulma/0000-0001-6571-837X
CR [Anonymous], 1989, EPILEPSIA, V30, P389
   BARZAGHI N, 1989, THER DRUG MONIT, V11, P661, DOI 10.1097/00007691-198911000-00009
   BIGARELLA M M, 1991, Arquivos de Neuro-Psiquiatria, V49, P136
   Bittencourt P R, 1992, Arq Neuropsiquiatr, V50, P24
   BITTENCOURT PRM, 1987, EPILEPSIA, V28, P582
   BITTENCOURT PRM, 1990, INT EPILEPTOLOGY, P807
   BITTENCOURT PRM, 1988, TXB EPILEPSY, P518
   GALLASSI R, 1987, ACTA NEUROL SCAND, V75, P258, DOI 10.1111/j.1600-0404.1987.tb07930.x
   Gorz A M, 1986, Arq Neuropsiquiatr, V44, P225
   Griffits RR, 1987, PSYCHOPHARMACOLOGY 3, P1535
   LEPPIK IE, 1989, ANTIEPILEPTIC DRUGS, P439
   LOISEAU P, 1989, ANTIEPILEPTIC DRUGS, P533
   MATTSON R, 1985, NEW ENGL J MED, V313, P1837
   MATTSON RH, 1989, ANTIEPILEPTIC DRUGS, P341
   MEADOR K J, 1991, Neurology, V41, P384
   MEINARDI H, 1988, TXB EPILEPSY, P528
   MUSICCO M, 1989, Neurology, V39, P148
   PAINTER MJ, 1989, ANTIEPILEPTIC DRUGS, P329
   RIMMER EM, 1988, TXB EPILEPSY, P421
   SERIKAWA T, 1990, EPILEPSIA, V319, P9
   SMITH DB, 1989, ANTIEPILEPTIC DRUGS, P423
   TABAKOFF B, 1987, PSYCHOPHARMACOLOGY 3, P1521
   THOMPSON P, 1981, BRIT J CLIN PSYCHOL, V20, P155, DOI 10.1111/j.2044-8260.1981.tb00513.x
   ZIELINSKI JJ, 1988, TXB EPILEPSY, P21
   1981, EPILEPSIA, V22, P480
NR 25
TC 18
Z9 18
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-1211
J9 EPILEPSY RES
JI Epilepsy Res.
PD OCT
PY 1993
VL 16
IS 2
BP 147
EP 155
DI 10.1016/0920-1211(93)90029-7
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA ME571
UT WOS:A1993ME57100007
PM 8269913
DA 2020-12-08
ER

EF